<SEC-DOCUMENT>0001299130-22-000030.txt : 20220228
<SEC-HEADER>0001299130-22-000030.hdr.sgml : 20220228
<ACCEPTANCE-DATETIME>20220228161234
ACCESSION NUMBER:		0001299130-22-000030
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220228
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
		CENTRAL INDEX KEY:			0001299130
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				161590339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34899
		FILM NUMBER:		22689634

	BUSINESS ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-521-8000

	MAIL ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIFIC BIOSCIENCES OF CALIFORNIA INC
		DATE OF NAME CHANGE:	20050829

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOFLUIDICS INC
		DATE OF NAME CHANGE:	20040729
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pacb-20211231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Inline XBRL document created by Certent Disclosure Management 1.0.0.0-->
<!--Created on: 02/28/2022 20:56:06 PM-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:pacb="http://www.pacificbiosciences.com/20211231" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <head>
    <title>pacb-20211231x10k</title>
    <meta http-equiv="Content-Type" content="text/html" /></head>
  <body xml:lang="en-US">
    <div style="display:none"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="ct-nonNumeric-eca2eb9e-c1c6-4865-9be8-5ac88411ec9d" contextRef="Duration_1_1_2021_To_12_31_2021" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="ct-nonNumeric-5e1d2db1-c833-458d-8dc8-1749fb810bc9" contextRef="Duration_1_1_2021_To_12_31_2021">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="ct-nonNumeric-41696a35-e0f7-4da9-9d8d-f13c283818b7" contextRef="Duration_1_1_2021_To_12_31_2021">0001299130</ix:nonNumeric><ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="ct-nonNumeric-79396175-d825-42a4-aae0-e7ec43a3819e" contextRef="Duration_1_1_2021_To_12_31_2021">Yes</ix:nonNumeric><ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="ct-nonNumeric-68c96891-44c6-44c0-87ea-784654e81cf5" contextRef="Duration_1_1_2021_To_12_31_2021">Yes</ix:nonNumeric><ix:nonNumeric name="dei:EntityVoluntaryFilers" id="ct-nonNumeric-840695b2-f4d5-4538-8f01-50526802d26c" contextRef="Duration_1_1_2021_To_12_31_2021">No</ix:nonNumeric><ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" id="ct-nonNumeric-3538407f-725e-45e3-b430-f7eb8eb2549c" contextRef="Duration_1_1_2021_To_12_31_2021">Yes</ix:nonNumeric><ix:nonFraction id="ct-nonFraction-91c7be65-3a9c-4f3f-baf5-bb6c340382ae" name="us-gaap:CommitmentsAndContingencies" contextRef="As_Of_12_31_2020" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-272c0ad2-cbce-4b43-8c6a-5f3a931cfd02" name="us-gaap:CommitmentsAndContingencies" contextRef="As_Of_12_31_2021" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-f6bf32a1-eba1-44b5-9c64-71c3bce57c57" name="us-gaap:DeferredTaxLiabilities" contextRef="As_Of_12_31_2020" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-369660c8-8827-4509-8766-859d252aae68" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit15" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-0217e24c-f3e2-41a5-a3e4-da83db5c7554" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-32b2087d-0dc9-4882-923e-433e378fe9f9" name="us-gaap:PreferredStockValue" contextRef="As_Of_12_31_2020" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-d2485028-363e-4392-a795-dcac64f2aaa6" name="us-gaap:PreferredStockValue" contextRef="As_Of_12_31_2021" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-157432ee-ccb2-4053-b0e5-c7935377bc43" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember" unitRef="Unit1" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-ea27d075-ab14-46bd-a50a-ca1f6250a2fa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember" unitRef="Unit13" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-e9acf03d-13df-451d-9874-2f208766a4f5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember" unitRef="Unit1" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-1d49af19-806d-4049-a513-6d773e6a0680" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember" unitRef="Unit13" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-30bbf7d7-4b14-4f75-9fd7-3cbfdadeb778" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember" unitRef="Unit1" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-1ab6d777-8192-4d46-8320-5a5063ac3e21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember" unitRef="Unit13" xsi:nil="true"></ix:nonFraction><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-8beefc21-f615-4705-ab86-3b5ae2a9a9cc" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember">P0Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-6736a5db-23ed-4317-8508-2a31e2442346" contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember">P0Y</ix:nonNumeric><ix:nonFraction id="ct-nonFraction-a1755a45-08c0-4740-a627-f6abb27a4908" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit13" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-01e6ae09-6c26-4e08-8828-7a21518d3f2e" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="pacb-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_RestatementAxis_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201904Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201904Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_RestatementAxis_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201904Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201904Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementScenarioAxis_pacb_UnderwrittenPublicEquityOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:UnderwrittenPublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourteenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeElevenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeAcqusitionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeThirteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourteenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeElevenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeThirteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeAcqusitionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeAcqusitionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeAcqusitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_TwoThousandTenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:TwoThousandTenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_InducementEquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:InducementEquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_2_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_InducementEquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:InducementEquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_22_2021_To_11_22_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_InducementEquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:InducementEquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-22</xbrli:startDate><xbrli:endDate>2021-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_21_2021_To_4_21_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_InducementEquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:InducementEquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-21</xbrli:startDate><xbrli:endDate>2021-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:PerformanceBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:PerformanceBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:PerformanceBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_VestingAxis_pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">pacb:ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_NorthAmericaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_EuropeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_AsiaPacificMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_pacb_InstrumentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_pacb_ConsumableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_srt_NorthAmericaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_srt_EuropeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_srt_AsiaPacificMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_pacb_InstrumentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_pacb_ConsumableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_StatementGeographicalAxis_srt_NorthAmericaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_StatementGeographicalAxis_srt_EuropeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_StatementGeographicalAxis_srt_AsiaPacificMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_pacb_InstrumentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_pacb_ConsumableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2015_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_SecurityDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">pacb:SecurityDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_SecurityDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">pacb:SecurityDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_SecurityDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">pacb:SecurityDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_CustomerDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">pacb:CustomerDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pacb:ObrienLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pacb:ObrienLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2015_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pacb:ObrienLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pacb_LaboratoryEquipmentAndMachineryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pacb:LaboratoryEquipmentAndMachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pacb_LaboratoryEquipmentAndMachineryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pacb:LaboratoryEquipmentAndMachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2021_To_9_20_2021_us-gaap_StatementEquityComponentsAxis_pacb_PrivatePlacementOfCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pacb:PrivatePlacementOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-20</xbrli:startDate><xbrli:endDate>2021-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_20_2021_To_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:CirculomicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-20</xbrli:startDate><xbrli:endDate>2021-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_12_31_2020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_pacb_IlluminaFcOpsCorpMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pacb:IlluminaFcOpsCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_dei_LegalEntityAxis_pacb_IlluminaFcOpsCorpMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pacb:IlluminaFcOpsCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementScenarioAxis_pacb_WithExpirationMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:WithExpirationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_pacb_ContingentConsiderationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pacb:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_pacb_ContingentConsiderationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pacb:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pacb:InProcessResearchAndDevelopmentIndefiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_20_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_20_2021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2021_To_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_9_2021_To_2_9_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-09</xbrli:startDate><xbrli:endDate>2021-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_9_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_pacb_ServiceContractMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pacb:ServiceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_MajorCustomersAxis_pacb_InvitaeCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:InvitaeCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ServiceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_pacb_DomesticCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_pacb_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_pacb_DomesticCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_pacb_CustomerDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_pacb_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_MajorCustomersAxis_pacb_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_MajorCustomersAxis_pacb_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2021_us-gaap_StatementEquityComponentsAxis_pacb_PrivatePlacementOfCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pacb:PrivatePlacementOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2010-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_pacb_CashAndMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_pacb_CashAndMoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_pacb_CashAndMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_pacb_CashAndMoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:CirculomicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_ContingentConsiderationByTypeAxis_pacb_AchievementOfMilestoneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">pacb:AchievementOfMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_ContingentConsiderationByTypeAxis_pacb_AchievementOfMilestoneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">pacb:AchievementOfMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-20</xbrli:startDate><xbrli:endDate>2021-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_ShortTermRestrictedCashMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:ShortTermRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_LongTermRestrictedCashMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:LongTermRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_CashAndMoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_ShortTermRestrictedCashMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:ShortTermRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_LongTermRestrictedCashMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:LongTermRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_CashAndMoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:SharesIssuableUponConversionOfConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_OptionsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:PerformanceBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_OptionsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:PerformanceBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_OptionsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_pacb_StockBasedCompensationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_pacb_MergerRelatedExpensesStockSettledMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesStockSettledMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_pacb_MergerRelatedExpensesMilestoneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_pacb_MergerRelatedExpensesCashSettledMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesCashSettledMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_pacb_StockBasedCompensationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_pacb_StockBasedCompensationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_MajorCustomersAxis_pacb_TenPercentOrGreaterBalanceAccountsReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:TenPercentOrGreaterBalanceAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:CirculomicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_dei_LegalEntityAxis_pacb_IlluminaFcOpsCorpMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pacb:IlluminaFcOpsCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_12_31_2019_dei_LegalEntityAxis_pacb_IlluminaFcOpsCorpMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pacb:IlluminaFcOpsCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2020_To_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_20_2020_To_4_20_2020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-20</xbrli:startDate><xbrli:endDate>2020-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_pacb_UnderwrittenPublicEquityOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:UnderwrittenPublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2021_To_9_20_2021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-20</xbrli:startDate><xbrli:endDate>2021-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2021_To_9_20_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-20</xbrli:startDate><xbrli:endDate>2021-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_16_2021_To_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_16_2021_To_2_16_2021_srt_StatementScenarioAxis_pacb_OneHundredAndEightyFirstDayTo360thDayMember_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:OneHundredAndEightyFirstDayTo360thDayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_16_2021_To_2_16_2021_srt_StatementScenarioAxis_pacb_EachDayDuringFirst180DaysMember_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:EachDayDuringFirst180DaysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2021_To_9_20_2021_us-gaap_AwardTypeAxis_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OmniomeStockAwardsRelatedToAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-20</xbrli:startDate><xbrli:endDate>2021-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-20</xbrli:startDate><xbrli:endDate>2021-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashCashEquivalentsAndInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashCashEquivalentsAndInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pacb:ObrienLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit16"><xbrli:measure>pacb:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit15"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit14"><xbrli:measure>pacb:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit13"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit12"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit1"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
    <div class="headerContainer"></div>
    <div><div style="border-bottom: none;border-left: none;border-right: none;border-top: solid #000000 1.0pt;padding-top: 0;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 4pt;line-height: 1.0pt;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 1pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 4pt;line-height: 1.0pt;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 1pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></div><div style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-top: 1.0pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 4pt;line-height: 1.0pt;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 1pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 16pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 3pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 16pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">UNITED STATES </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 16pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 16pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">SECURITIES AND EXCHANGE COMMISSION </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Washington,&#160;D.C. 20549 </span></p><div style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;margin-left: 3.14in;margin-right: 3.14in;padding-bottom: 1.0pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 1.0pt;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 18pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 18pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Form&#160;</span><ix:nonNumeric name="dei:DocumentType" id="ct-nonNumeric-f78b3ec5-f592-4d1c-9fa1-d2a3948e7de4" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 18pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">10-K</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 18pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p><div style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;margin-left: 3.14in;margin-right: 3.14in;padding-bottom: 1.0pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 1.0pt;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(Mark One)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.34in;margin-right: 0;margin-top: 0;text-align: center;text-indent: -0.34in;"><span style="white-space:pre-wrap; display: inline-block;text-indent: 0;width: 0.340in;"><ix:nonNumeric name="dei:DocumentAnnualReport" id="ct-nonNumeric-5cf6a085-c25b-490a-97d8-4962159b6465" contextRef="Duration_1_1_2021_To_12_31_2021" format="ixt:booleantrue"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">x</span></span></ix:nonNumeric></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">For the fiscal year ended </span><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="ct-nonNumeric-00eeec03-31d3-4a13-a0c0-5838d70fb068" contextRef="Duration_1_1_2021_To_12_31_2021" format="ixt:datemonthdayen"><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="ct-nonNumeric-ad907059-4858-4959-8047-e22cea9a6165" contextRef="Duration_1_1_2021_To_12_31_2021" format="ixt:datemonthdayyearen" continuedAt="ct-nonNumeric-ad907059-4858-4959-8047-e22cea9a6165-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31</span></ix:nonNumeric></ix:nonNumeric><ix:continuation id="ct-nonNumeric-ad907059-4858-4959-8047-e22cea9a6165-continuation-0" continuedAt="ct-nonNumeric-ad907059-4858-4959-8047-e22cea9a6165-continuation-1"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">, </span></ix:continuation><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="ct-nonNumeric-c657aa9d-aa9b-466e-8aed-dbc0250c2601" contextRef="Duration_1_1_2021_To_12_31_2021"><ix:continuation id="ct-nonNumeric-ad907059-4858-4959-8047-e22cea9a6165-continuation-1"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></ix:continuation></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Or</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.34in;margin-right: 0;margin-top: 2.25pt;text-align: center;text-indent: -0.34in;"><span style="white-space:pre-wrap; display: inline-block;text-indent: 0;width: 0.340in;"><ix:nonNumeric name="dei:DocumentTransitionReport" id="ct-nonNumeric-3f7a22f4-43e1-4084-996e-e740839708e7" contextRef="Duration_1_1_2021_To_12_31_2021" format="ixt:booleanfalse"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span></ix:nonNumeric></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Commission File Number </span><ix:nonNumeric name="dei:EntityFileNumber" id="ct-nonNumeric-7e41b509-9c45-4fb2-990b-a07bb9de80e9" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">001-34899</span></ix:nonNumeric></p><div style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;margin-left: 3.14in;margin-right: 3.14in;padding-bottom: 1.0pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 1.0pt;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 1.0pt;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 1.0pt;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 24pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 15pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 24pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><img src="pacb-20211231x10kg001.jpg" style="width: 2.554594in; height: 0.5558115in" alt="Graphic 3" /></span></p><p dir="ltr" style="font-family: Roboto;font-size: 12pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 15pt;text-align: center;"><ix:nonNumeric name="dei:EntityRegistrantName" id="ct-nonNumeric-8849fb0d-1b5e-4e57-bff6-e1054007812b" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Pacific Biosciences of California, Inc.</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(Exact name of registrant as specified in its charter) </span></p><div style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;margin-left: 3.14in;margin-right: 3.14in;padding-bottom: 1.0pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 1.0pt;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 2.5pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 2.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="ct-nonNumeric-8f893a01-ccf6-4177-9e92-0f5d5bfa3940" contextRef="Duration_1_1_2021_To_12_31_2021" format="ixt-sec:stateprovnameen"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Delaware</span></ix:nonNumeric></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="ct-nonNumeric-ef8f88c1-a62e-4dc1-ae48-e70f9dc6c0f5" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">16-1590339</span></ix:nonNumeric></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7.5pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 7.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(State or other jurisdiction of</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7.5pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 7.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">incorporation or organization)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 50.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7.5pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 7.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(I.R.S. Employer</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7.5pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 7.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Identification No.)</span></p></td></tr><tr style="height: 0.08in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 50.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 50.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="ct-nonNumeric-3037c611-eeb9-4033-85b1-070d52bf6516" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">1305 O&#8217;Brien Drive</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="ct-nonNumeric-832f8ecb-450f-4c06-bf18-615cd6cbea1f" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Menlo Park</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">, </span><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="ct-nonNumeric-9fcd8178-c13a-4dc6-8a85-82b82ec53134" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CA</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="ct-nonNumeric-ba192e1b-35ef-473f-a153-ea3cb2f422e6" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">94025</span></ix:nonNumeric></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 50.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="ct-nonNumeric-904c5db5-486b-469e-be55-8a31fdd81fd4" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">94025</span></ix:nonNumeric></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 7.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(Address of principal executive offices)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 7.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(Zip Code)</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7.5pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 7.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(Registrant&#8217;s telephone number, including area code) </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(</span><ix:nonNumeric name="dei:CityAreaCode" id="ct-nonNumeric-2afa2f03-946d-428b-85e2-88688d046950" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">650</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">)&#160;</span><ix:nonNumeric name="dei:LocalPhoneNumber" id="ct-nonNumeric-84fde0d5-e188-4bf4-9002-42094e91897e" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">521-8000</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Securities registered pursuant to Section&#160;12(b) of the Act:</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 39.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 30.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 30.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 39.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 30.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 30.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 39.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7.5pt;line-height: 106.7%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 7.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Title of each class</span></p><div style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;margin-left: 1.47in;margin-right: 1.48in;padding-top: 1.0pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 4pt;line-height: 1.0pt;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 30.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7.5pt;line-height: 106.7%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 7.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Trading Symbol(s)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 30.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7.5pt;line-height: 106.7%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 7.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Name of each exchange on which registered</span></p><div style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;margin-left: 0.83in;margin-right: 0.83in;padding-top: 1.0pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 4pt;line-height: 1.0pt;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 39.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 106.7%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="ct-nonNumeric-fce5e74f-4b3e-45c5-9339-31c8e22f9d48" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 30.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="ct-nonNumeric-85ec7f48-9766-4e13-874f-9900d3e4e936" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PACB</span></ix:nonNumeric></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 30.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="ct-nonNumeric-b72087f6-16a0-4e6f-bc4b-c9bacb05d62e" contextRef="Duration_1_1_2021_To_12_31_2021" format="ixt-sec:exchnameen"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">The NASDAQ Stock Market LLC</span></ix:nonNumeric></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 2.5pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 2.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Securities registered pursuant to Section&#160;12(g) of the Act: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">None </span></p><div style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;margin-left: 3.14in;margin-right: 3.14in;padding-bottom: 1.0pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 1.0pt;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-3538407f-725e-45e3-b430-f7eb8eb2549c;">x</span></span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;No </span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">o</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">o</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;No&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-840695b2-f4d5-4538-8f01-50526802d26c;">x</span></span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;Yes&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-79396175-d825-42a4-aae0-e7ec43a3819e;">x</span></span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;No&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">o</span></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-68c96891-44c6-44c0-87ea-784654e81cf5;">x</span></span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">No&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">o</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one): </span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 58.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 23.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="dei:EntityFilerCategory" id="ct-nonNumeric-e9f341c3-a130-47e1-b331-03eebb6c5a1f" contextRef="Duration_1_1_2021_To_12_31_2021" format="ixt-sec:entityfilercategoryen"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Large accelerated filer</span></ix:nonNumeric></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 58.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">x</span></span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#61472;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 23.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accelerated&#160;filer</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">o</span></span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Non-accelerated filer</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 58.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">o</span></span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#61472;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 23.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Smaller&#160;reporting&#160;company</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="dei:EntitySmallBusiness" id="ct-nonNumeric-d0f8c658-7b70-4a9e-b6c6-25da9ea2f02c" contextRef="Duration_1_1_2021_To_12_31_2021" format="ixt:booleanfalse"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">o</span></span></ix:nonNumeric></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 58.0%;"><p dir="ltr" style="text-align:left; font-family: Wingdings;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 23.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Emerging growth company</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Wingdings;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="ct-nonNumeric-fb902d1e-0309-4fa7-b943-8385356ab2d8" contextRef="Duration_1_1_2021_To_12_31_2021" format="ixt:booleanfalse"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">o</span></span></ix:nonNumeric></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 2.5pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 2.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">o</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes&#160;</span><ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" id="ct-nonNumeric-06271725-bd27-4606-ab11-64a66d5345df" contextRef="Duration_1_1_2021_To_12_31_2021" format="ixt:booleantrue"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">x</span></span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;No&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">o</span></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">o</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">No&#160;</span><ix:nonNumeric name="dei:EntityShellCompany" id="ct-nonNumeric-d751ce2d-a144-432d-86c5-396c2addfbbb" contextRef="Duration_1_1_2021_To_12_31_2021" format="ixt:booleanfalse"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">x</span></span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Aggregate market value of registrant&#8217;s common stock held by non-affiliates of the registrant on June 30, 2021, based upon the closing price of Common Stock on such date as reported by NASDAQ Global Select Market, was approximately $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9b0beadb-c1c4-410a-b698-0eab20b8189c" name="dei:EntityPublicFloat" contextRef="As_Of_6_30_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">6,791,088,144</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.  Shares of voting stock held by each officer and director have been excluded in that such persons may be deemed to be affiliates. This assumption regarding affiliate status is not necessarily a conclusive determination for other purposes. </span></p></div>
    <div><div class="footerContainer"></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Number of shares outstanding of the issuer&#8217;s common stock as of January 31, 2022: </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3c1bdb9b-2255-4985-9017-4ed427d0d595" name="dei:EntityCommonStockSharesOutstanding" contextRef="As_Of_1_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">221,182,457</ix:nonFraction></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 2.25pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">DOCUMENTS INCORPORATED BY REFERENCE: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><ix:nonNumeric name="dei:DocumentsIncorporatedByReferenceTextBlock" id="ct-nonNumeric-9399595d-34a1-42d5-9ac9-bb85b3fc2d00" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Portions of the registrant&#8217;s definitive Proxy Statement relating to its 2022 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K where indicated. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="border-bottom: none;border-left: none;border-right: none;border-top: solid #000000 1.0pt;padding-top: 0;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 2pt;line-height: 1.0pt;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 2pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Pacific Biosciences of California, Inc.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Annual </span><span id="TOC" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Report</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> on Form 10-K </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">For the Fiscal Year Ended December 31, 2021</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Table of Contents</span></p><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 0.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 0.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 0.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 0.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 0.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 0.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 7.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 7.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Page</span></p><div style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-top: 1.0pt;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></div></td></tr><tr><td style="background: white;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">PART&#160;I</span></p></td><td style="background: white;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: white;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item&#160;1.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item1" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Business</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item&#160;1A.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item1A" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Risk Factors</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item&#160;1B.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item1B" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Unresolved Staff Comments</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 2.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item2" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Properties</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 3.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item3" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Legal Proceedings</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 4.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item4" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Mine Safety Disclosures</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">PART II</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 5.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item5" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">49</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 6.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item6" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">[Reserved]</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 7.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item7" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">51</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item&#160;7A.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item7A" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Quantitative and Qualitative Disclosures about Market Risk</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">63</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 8.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#FinancialStatements" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Financial Statements and Supplementary Data</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">65</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item&#160;9.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item9" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">105</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item&#160;9A.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item9A" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Controls and Procedures</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">105</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item&#160;9B.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item9B" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Other Information</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">108</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item&#160;9C</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item9C" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">108</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-indent: -0.17in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-indent: -0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">PART III</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item&#160;10.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item10" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">109</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item&#160;11.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item11" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Executive Compensation</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">109</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item&#160;12.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item12" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">109</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item&#160;13.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item13" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">109</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item&#160;14.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item14" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Principal Accountant Fees and Services</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">109</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-indent: -0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">PART&#160;IV</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item&#160;15.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item15" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Exhibits, Financial Statement Schedules</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">110</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item&#160;16.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item16" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Form 10-K Summary</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">113</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Signatures" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Signatures</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 66.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">114</span></p></td></tr></table></div><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This Annual Report on Form 10-K, including the sections titled &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contain or may contain forward-looking statements that are based on the beliefs and assumptions of the management of Pacific Biosciences of California, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) and on information currently available to our management. The statements contained in this Annual Report on Form 10-K that are not purely historical are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and include, but are not limited to:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the attributes and sequencing advantages of SMRT</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>&#174;</sup></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> technology; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our current and future products; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">market opportunities, strategic and commercial plans, including strategy for our business and related financing; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">expectations regarding the conversion of backlog to revenue and the pricing and gross margin for products;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">manufacturing plans including developing and scaling of manufacturing and delivery of our products; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">research and development plans; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">product development including, among other things, statements relating to future uses, quality or performance of, or benefits of using, products or technologies, updates or improvements of our products; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">intentions regarding seeking regulatory approval for our products; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">competition; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">expectations regarding unrecognized income tax benefits; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">expectations regarding the impact of an increase in market rates on the value of our investment portfolio; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the sufficiency of cash, cash equivalents and investments to fund projected operating requirements;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the effects of recent accounting pronouncements on our financial statements; and </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">other future events. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Forward-looking statements can be identified by words such as: &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or similar expressions and the negatives of those terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading &#8220;Risk Factors&#8221; in this report and in other documents we file with the Securities and Exchange Commission (&#8220;SEC&#8221;). Given these risks and uncertainties, you should not place undue reliance on forward-looking statements. Also, forward-looking statements represent management&#8217;s beliefs and assumptions as of the date of this report. Except as required by law, we assume no obligation to update forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business, and the markets for our products, including data regarding the estimated size and estimated growth for those markets. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span id="Item1_Business" style="text-decoration: none;"></span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">ITEM 1.  </span><span id="Item1" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">BUSINESS </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Overview </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems.  Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing technology and our emerging short read Sequencing by Binding (SBB</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #333333;font-family: 'Arial', 'sans-serif';font-size: 8.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>&#174;</sup></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">) technology. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our products address solutions across a broad set of applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our focus is on providing our customers with advanced sequencing technologies with higher throughput and improved workflows that we believe will enable dramatic advancements in routine healthcare. </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies and agricultural companies.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Our Mission and Impact</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our mission is to enable the promise of genomics to better human health. Genomics is core to all biological processes, and our </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">advanced genomics</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> tools provide scientists and clinical researchers the insights to better understand biology and health.  The &#8220;promise of genomics&#8221; postulates that medicine, agriculture, public health, drug development, and other disciplines will be </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">fundamentally </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">transformed with the incorporation of routine genomic information over the coming decades</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  We see early progress toward this transformation in the applied use of genomics in areas </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">such as</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> genetic disease, oncology, and sustainable food production.  However, legacy genomics technologies have fundamental limitations in progressing these fields toward the promise of genomics.  We believe that unleashing the full potential of genomics will require a level of accuracy and completeness that is inaccessible to legacy technologies.  Accuracy and completeness are central to our product development strategy, and thus we have created some of the most innovative, high-quality, genomics solutions on the market.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">The Underlying Science</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Genetic inheritance in living systems is conveyed through a naturally occurring information storage system known as deoxyribonucleic acid, or DNA. DNA stores information in linear chains of the chemical bases adenine, cytosine, guanine and thymine, represented by the symbols A, C, G and T respectively.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In humans, the genome is comprised of approximately three billion DNA base-pairs, which are divided into 23 chromosomes ranging in size from 50&#160;million to 250&#160;million bases. There are approximately 23,000 smaller regions within these chromosomes, called genes, which contain the blueprints for protein production. The proteins synthesized from these blueprints essentially underlie the operation of all biological systems. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Genome sequencing reads the bases of long fragments of nucleic acids. Initial genome sequencing studies have shown that mutations in these DNA base pairs play a critical role in human disease, contributing to the burgeoning field of genomics. Since then, recent discoveries have highlighted additional complexities of DNA and ribonucleic acid, or RNA. These include the presence of modified bases such as methylation, and post-translational modification or the processing of RNA molecules after they are transcribed from the genome, both of which can affect protein synthesis. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Our Principal Markets </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Researchers utilize our solutions in human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Human Germline Sequencing: Improving rare disease research and understanding</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">According to a World Health Organization publication, it is estimated that 400 million people worldwide are affected by up to 8,000 distinct rare diseases, with 80% of these believed to be genetic in nature. Other sequencing technologies applied </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">2</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to rare disease diagnosis are technologically limited to interrogating small variants, representing only a subset of possible genomic variation. Consequently, most genetic disease cases are undiagnosed, leaving families on multi-year diagnostic odysseys. &#160;Sequencing the human genome with long and accurate reads enables the potential detection of all known classes of disease-causing variation. In addition, the ability of PacBio&#8217;s long-read sequencing technology to detect 5-Methylcytosine, an epigenetic factor shown to alter gene behavior, may enable further advances in research and development in genetic disease diagnosis. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Infectious Disease and Microbiology: Understanding and tracking microbes and pathogens in support of global public health</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our technology has increased the scientific community&#8217;s understanding of microorganism and viruses and their malignancy, transmission, and potential resistance to antibiotics or vaccines.  Our sequencing technology delivers some of the most comprehensive and complete genomes available, enabling federal agencies, public health organizations, and healthcare providers the ability to conduct wide-ranging research and surveillance activities to:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Generate high quality, complete genome assemblies, revealing variants of all known types, to gain a deeper understanding of community-acquired and hospital-associated infections and transmissions;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Identify and characterize pathogens to inform regional, national and global public health agencies for preparation and response to rapidly evolving microorganism; and</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0.50in;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Characterize complex microbial communities to understand their role in human, animal, and environmental health.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Oncology: Enable the discoveries of underlying causes of cancer, progression and relapse</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Understanding the cellular and molecular complexity of tumor cells is critical in developing more effective targeted cancer therapies. Advancements in single-cell analyses have previously been recognized by </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Nature Methods </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">magazine as the &#8220;method of the year&#8221; in 2019.&#160;Single-cell transcriptomics is particularly impactful in defining cellular identity and function; however, other technologies only sequence a portion of RNAs, missing critical information.&#160; Our long-read RNA sequencing method, single-cell Iso-Seq (scIso-Seq), accurately detects molecular events such as RNA isoforms and expressed mutations and provides gene expression information at the single-cell level.&#160; We believe scIso-Seq is uniquely positioned to enable discoveries by researchers of the underlying causes of cancer initiation, progression, and relapse, as well as the discovery by researchers of novel diagnostic, prognostic and predictive biomarkers that may inform future clinical tests. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As novel discoveries continue to be made using our long sequencing technology, we believe our SBB short-read sequencing technology will enable us to meet the demands of customers in the expanding non-invasive testing market in oncology. Due to the small amounts of circulating tumor DNA (ctDNA) present in the blood of early-stage cancer patients and those with minimal residual disease (MRD), the presence of cancer often goes undetected and a more sensitive assay will be required. Based on internal testing, we believe our SBB technology has the potential to offer higher accuracy than competitor sequencing technologies, which may in the future support our customers&#8217; development of more sensitive tests for the purpose of earlier detection and more robust monitoring of cancer.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Plant and Animal Sciences: Helping scientists answer biological questions across a broad range of plant and animal sciences</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There are hundreds of thousands of distinct plant and animal species. Our technology is used to build de novo reference genomes for these organisms across several global initiatives which are dedicated to preserving, monitoring and cataloging biodiversity with actionable and accurate genomic data. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Our Technology, Products and Solutions</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have developed HiFi long-read sequencing combined with highly accurate Single Molecule Real-Time (SMRT) technology, which enables single-molecule, real-time </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">detection</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> of nucleic acid sequences for long-read applications. We are also expanding our genomic solutions with our short read Sequencing by Binding (SBB</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #333333;font-family: 'Arial', 'sans-serif';font-size: 8.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>&#174;</sup></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">) chemistry which offers sensitive sequencing for short read applications. Upon launch of the SBB platform, we believe we will be the only company offering both native long read and native short read technologies into the market.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> sales consist of sales of instruments, chips and reagents based on our SMRT technology as well as services we perform for customers and we are developing products based on our nanobind technology. </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">3</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">HiFi Long-</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">read</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> Sequencing</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our HiFi long-read sequencing protocol was built upon our</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> HiFi sequencing systems, including consumables and software, and offers customized end-to-end workflows for different SMRT sequencing applications. Highly accurate, long sequence reads simplify and accelerate data analysis algorithms, reducing the needs for error correction steps and/or assembly aspects, depending on the application.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Customers use our HiFi long read sequencing platforms in a wide range of sequencing applications, including whole genome sequencing and </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">de novo</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> genome assembly, long-range phasing, targeted sequencing, full-length RNA and single-cell sequencing, characterization of metagenomic communities and other mixed DNA samples, viral genome sequencing, and others.  Our technology is also capable of detecting epigenetic markers simultaneously by analyzing the kinetics of DNA polymerization which is affected, and thereby detectable, by epigenetic markers such as 5-methylcytosine or N</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>6</sup></span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-methyladenine, and we anticipate such capability to become commercially available in April 2022. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">SMRT Technology</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our proprietary SMRT Technology enables the observation of DNA synthesis as it occurs in real time by harnessing the natural process of DNA replication, which in nature is a highly efficient and accurate process actuated by DNA polymerases.  DNA polymerases attach to a strand of DNA to be replicated, examine the individual base at the point it is attached, and then determine which of the four building blocks, or nucleotides (A, C, G, or T), is required to complement that individual base.  After determining which nucleotide is required, the polymerases incorporate that nucleotide into the growing strand being produced.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">SMRT Sequencing is based on following the activity of DNA polymerase on individual DNA molecules in real time which occurs on our SMRT cells that are monitored and analyzed within our Sequel I, II, and IIe systems. Carried out on SMRTbell templates, which attach hairpin adapters to the ends of double-stranded DNA molecules to be sequenced, SMRT sequencing allows for the successive sequencing of both the forward and reverse strands of the individual DNA molecule occurring multiple times, thereby allowing for the same base of the same molecule to be sequenced more than once in a sequencing run. According to research we performed in collaboration with other researchers subsequently published in Nature Biotechnology in 2019, the base calls from the resulting subreads can be processed to generate the final base call in an analytical procedure called circular consensus sequencing, leading to what we have defined as our HiFi sequence reads which have high accuracy typically being defined as having greater than 99% read accuracy, but often exceeding greater than 99.9% accuracy according to research we performed in collaboration with other researchers, subsequently published in Nature Biotechnology in 2019. While HiFi reads have been utilized routinely for DNA inserts in the kilobase (1000 bases) range for applications such as full-length RNA sequencing or amplicon sequencing, advancements made a few years ago to increase the number of bases covered by the polymerase to greater than ~50,000 bases has allowed us to routinely increase the size of DNA fragments that can be subjected to HiFi sequencing, ranging currently to up to 25 kilobases in size providing sufficient read length with our accuracy to support a multitude of applications across human health, plant and animal, and microbiology, according to research we performed in collaboration with other researchers, subsequently published by Scientific Data in 2020. The ability to generate single-DNA molecule sequence reads that are both long and highly accurate allows researchers to obtain more contiguous, complete and accurate genomic data, thereby allowing for greater insights into the complexity of biological systems.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Sequel, Sequel II and Sequel IIe Instruments </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single molecule biochemical reactions in real time. The instruments use extremely sensitive imaging systems to collect the light pulses emitted by fluorescent reagents allowing the observation of biological processes. Computer algorithms are used to translate the information that is captured by the optics system. Using the recorded information, light pulses are converted into either an A, C, G or T base call with associated quality metrics. Once sequencing is started, the real-time data is delivered to the system&#8217;s primary analysis pipeline, which outputs base identity and quality values.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">4</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Consumables</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Customers purchase proprietary consumable products to run their PacBio systems. Our consumable products include our proprietary SMRT Cells and reagent kits. One SMRT Cell is consumed per sequencing reaction, and scientists can choose the number of SMRT Cells they use per experiment.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We offer several reagent kits, each designed to address a specific step in the core sequencing workflow. A template preparation kit is used to convert DNA into SMRTbell</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>&#174;</sup></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> double-stranded DNA library formats and includes typical molecular biology reagents, such as ligase, buffers and exonucleases. Our binding kits include our modified DNA polymerase, and are used to bind SMRTbell libraries to the polymerase in preparation for sequencing. Our core sequencing kits contain reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, we offer HiFiViral for SARS-CoV-2, our first fit-for-purpose, end-to-end solution for COVID-19 genome sequencing.  This solution uses a differentiated molecular inversion probe (MIPs) design which is robust to the emergence of new variants in the COVID-19 genome and allows for detection of all known classes of variation across the entire viral genome. Both of these characteristics are required for efficient and effective public health surveillance programs battling the COVID-19 pandemic. The solution also includes fit-for-purpose software that enables automated variant calling and preparation of files for submission into public databases tracking the evolution of the COVID-19 genome.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">S</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">BB Short-read Sequencing</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In contrast to SMRT sequencing, Sequencing by Binding (SBB&#174;) reads short fragments of DNA (hundreds of bases instead of kilobases) in a massively parallel manner, thereby achieving higher throughput and lower price per datapoint relative to long read solutions. Current short-read next generation sequencing technologies available in the market incur various rates of errors in results.  Researchers deploy multiple tactics to try to mitigate these effects, including oversampling or implementing complex library preparation methods, yet still face challenges, including missing rare variants.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> believe our proprietary SBB approach will enable researchers to address the gap in detecting rare variants, especially in complex heterogenous samples. Employing a two-phase sequencing chemistry, the SBB approach binds a dye-labeled nucleotide without incorporation into the DNA chain, then removes that base, then blocks and extends with a terminated nucleotide.  Using nucleotides with single modifications, we incorporate more native bases, avoiding potential scarring due to fluorescent linker presence. This design helps avoid raw errors and we believe can help us develop a product with substantially greater accuracy than currently marketed short read sequencing products. SBB enables simplified upfront library preparation, redefines coverage requirements and reduces bioinformatic workload for downstream analysis. The accuracy of our novel sequencing approach has the potential to advance translational cancer research, drive higher fidelity single-cell applications, and broadly enable clinical sequencing&#8212;even in regions of the genome prone to sequencing errors with other short-read sequencing technologies.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">5</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Our Strategy for Growth</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To enable the promise of genomics, our strategy includes the following key elements:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Continue to drive commercial adoption and utilization of our current generation Sequel II/IIe platform</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Drive clinical utility of HiFi long-read sequencing by completing development of our next generation higher throughput HiFi long-read sequencing platform</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Complete development of our SBB short-read sequencing platform</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Develop applications that expand existing applications for our sequencing solutions</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Create an ecosystem of customers, partners and collaborators whose expertise and offerings complement and enhance the capabilities and utility of our technology and increase genomic data available on our platforms</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Marketing, Sales, Service and Support </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We market our products through a direct sales force in North America and parts of Europe and through distribution partners in Asia, certain other parts of Europe, the Middle East and Africa, and Latin America. We plan to continue to invest in growing our marketing, sales, service and support resources as we drive continued adoption of products, launch new products and expand our customer base.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our business is subject to seasonal trends.  See the </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Risk Fact</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">ors</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> section, specifically the risk factor titled </span><a href="#RiskFactors_Seasonalitymaycause" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Seasonality may cause fluctuations in our revenue and results of operations</span></a><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for additional information.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Customers </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies and agricultural companies. In general, our customers will isolate, prepare and analyze genetic samples using PacBio sequencing systems in their own laboratories, or they will send their genetic samples to third party service providers who in turn will sequence the samples with PacBio systems and provide the sequence data back to the customer for further analysis. For example, customers in academic research institutions may have bacteria, animal, or human DNA samples isolated from various sources while agricultural biology companies may have DNA samples isolated from different strains of rice, corn or other crops. For the years ended December 31, 2021, 2020 and 2019, one customer, Gene Company Limited, our primary distributor for China and Hong Kong, accounted for approximately 13%, 14% and 17% of our total revenue, respectively. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe that the majority of our current customers are early adopters of sequencing technology. By focusing our efforts on high-value applications, and developing whole product solutions around these applications, we seek to drive the adoption of our products across a broader customer base and into numerous large-scale projects. In general, the broader adoption of new technologies by mainstream customers can take a number of years. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Backlog </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2021, our instrument backlog was approximately $2.0 million, compared to $10.1 million as of December 31, 2020. We define backlog as purchase orders or signed contracts from our customers which we believe are firm and for which we have not yet recognized revenue. We expect to convert this backlog to revenue during 2022; however, our ability to do so is subject to customers who may seek to cancel or delay their orders even if we are prepared to fulfill them. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Manufacturing </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We manufacture sequencing instruments, SMRT cells and reagents. Our key manufacturing and service facility in Menlo Park, California has received ISO 13485 and ISO 9001 certifications for the design, development, manufacture, distribution, installation, and servicing of its nucleic acid sequencing platforms.  We utilize subcontract manufacturers for components of the manufacturing process.  We purchase both custom and off-the-shelf components from a large number of suppliers and subject them to significant quality specifications. We periodically conduct quality audits of most critical suppliers and </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">6</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">have established a&#160;supplier certification program.  Some of the components required in our products are currently either sole sourced or single sourced. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Research and Development </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have historically made and plan to continue to make significant investments in research and development.  Our research and development efforts focus on programs to develop new and existing platforms, as well as increase throughput and decrease costs on behalf of our customers. We are currently developing higher throughput platforms that encompass our HiFI long read sequencing. We also have a mid-throughput short read Sequencing by Binding platform that is currently under development. In addition to platform development, we also innovate across end-to-end workflows to </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">improve usability, as well as develop new applications for the advancement of human health. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk534891425" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Intellectual Property </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Developing and maintaining a strong intellectual property position is an important element of our business. We have sought, and will continue to seek, patent protection for our SMRT technology, for improvements to our SMRT technology, as well as for any of our other technologies where we believe such protection will be advantageous. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our current patent portfolio, including patents exclusively licensed to us, is directed to various technologies, including SMRT nucleic acid sequencing and other methods for analyzing biological samples, ZMW arrays, surface treatments, phospholinked nucleotides and other reagents for use in nucleic acid sequencing, optical components and systems, processes for identifying nucleotides within nucleic acid sequences and processes for analysis and comparison of nucleic acid sequence data. With the acquisition of Omniome and Circulomics, we have further obtained patent applications related to short read nucleic acid sequencing and nucleic acid preparation and purification. Some of the patents and applications that we own, as well as some of the patents and applications that we have licensed from other parties, are subject to U.S. government march-in rights, whereby the U.S. government may disregard our exclusive patent rights on its own behalf or on behalf of third parties by imposing licenses in certain circumstances, such as if we fail to achieve practical application of the U.S. government funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, U.S. government funded inventions must be reported to the government and U.S. government funding must be disclosed in any resulting patent applications. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2021, we own or hold exclusive licenses to 392 issued U.S. patents, 107 pending U.S. patent applications, 343 granted foreign patents and 150 pending foreign patent applications, including foreign counterparts of U.S. patent and patent applications. The full term of the issued U.S. patents will expire between 2022 and 2040.&#160; We also have non-exclusive patent licenses with various third parties to supplement our own large and robust patent portfolio.&#160; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Of our exclusively licensed patent applications, 6 issued U.S. patents are licensed to us by the Cornell Research Foundation, which manages technology transfers on behalf of Cornell University. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Other Sequencing Solutions </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There are a significant number of companies offering nucleic acid sequencing equipment or consumables. These include, but are not limited to, Illumina, Inc. (&#8220;Illumina&#8221;), BGI Genomics, Thermo Fisher Scientific Inc. (&#8220;Thermo&#8221;), </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Oxford Nanopore Technologies Ltd. (&#8220;ONT Ltd.&#8221;)</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, Roche, Qiagen N.V. (&#8220;Qiagen&#8221;), Element Biosciences, Inc. (&#8220;Element&#8221;), Bionano Genomics, Inc. (&#8220;Bionano&#8221;), and Singular Genomics Systems, Inc. (&#8220;Singular&#8221;). These companies may have different levels of financial, technical, manufacturing, administrative and support resources available to them. We expect the competition to intensify within the overall nucleic acid sequencing market as there are also several companies developing new sequencing technologies, products and/or services.  Increased competition may result in pricing pressures, which could harm our sales, profitability or share of supply.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In order for us to maintain and increase our sales, we will need to demonstrate that our products deliver superior performance and value as a result of our key differentiators.  Our HiFi long-read sequencing will need to continue to deliver very high consensus accuracy and long read lengths and include single molecule, real-time resolution, with the ability to detect real-time kinetic information, fast time to result and flexibility, as well as support the breadth and depth of current and future applications. </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">7</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Government Regulation</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The development, testing, manufacturing, marketing, postmarket surveillance, distribution, advertising and labeling of certain medical devices, including in vitro diagnostic products and laboratory-developed tests, are subject to regulation in the United States by the Center for Devices and Radiological Health of the U.S. Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (FDCA) and comparable state and foreign regulatory agencies. FDA defines a medical device as an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent or other similar or related article, including any component part or accessory, which is (i) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or (ii) intended to affect the structure or any function of the body of man or other animals and which does not achieve any of its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes. Medical devices to be commercially distributed in the United States must receive from the FDA either clearance of a premarket notification, known as 510(k), or premarket approval pursuant to the FDC Act prior to marketing, unless subject to an exemption.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We intend to label and sell our products for research use only (&#8220;RUO&#8221;) and expect to sell them to research customers in various settings, including academic institutions, life sciences and research laboratories that conduct research, and biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Our current RUO products are not intended or promoted for use in clinical practice in the diagnosis of disease or other conditions, and they are labeled for research use only, not for use in diagnostic procedures. Accordingly, we believe our products, as we intend to market them, are not subject to regulation by FDA. Rather, while FDA regulations require that RUO products be labeled for research use only and to market and distribute RUO products in accordance with the FDA RUO guidance, the regulations do not subject RUO products to the FDA&#8217;s jurisdiction or the broader pre- and postmarket controls for medical devices</span><span id="_cp_text_1_81" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. However, in the future, certain of our products or related applications</span><span id="_cp_text_4_82" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, such as </span><span id="_cp_text_1_83" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">those that may be developed for clinical uses, could be subject to FDA regulation, </span><span id="_cp_text_4_84" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">or the </span><span id="_cp_text_1_85" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FDA&#8217;s regulatory jurisdiction could be expanded to include our products. If we wish to label and expand product lines to address the diagnosis of disease, </span><span id="_cp_text_1_86" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">regulation by governmental authorities in the United States and other countries will become an increasingly significant factor in development, testing, production, and marketing. In the future, products that we may develop in the molecular diagnostic markets, depending on their intended use, may be regulated as medical devices or in vitro diagnostic products (&#8220;IVDs&#8221;) by the FDA and comparable agencies in other countries. In the U.S., if we market our products for use in performing clinical diagnostics, such products would be subject to regulation by the FDA under premarket and postmarket control as medical devices, unless an exemption applies, and we would be required to obtain either prior 510(k) clearance or prior premarket approval from the FDA before commercializing the product. Obtaining the requisite regulatory approvals can be expensive and may involve considerable delay. Some countries have regulatory review processes that are substantially longer than U.S. processes. Failure to obtain regulatory approval in a timely manner and meet all of the local regulatory requirements including language and specific safety standards in any foreign country </span><span id="_cp_text_4_87" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">in which we </span><span id="_cp_text_4_88" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">plan to </span><span id="_cp_text_1_89" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">market our products could prevent us from marketing products in such countries or subject us to sanctions and fines. Changes to the current regulatory framework, including the imposition of additional or new regulations, could arise at any time during the development or marketing of our products. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_cp_text_1_90" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In November 2013, the FDA issued a final guidance on products labeled RUO, which, among other things, reaffirmed that a company may not make any clinical or diagnostic claims about an RUO product, stating that merely including a labeling statement that the product is for research purposes only will not necessarily render the device exempt from the FDA&#8217;s clearance, approval, or other regulatory requirements if the totality of circumstances surrounding the distribution of the product indicates that the manufacturer knows its product is being used by customers for diagnostic uses or the manufacturer intends such a use. These circumstances may include, among other things, written or verbal marketing claims regarding a product&#8217;s performance in clinical diagnostic applications and a manufacturer&#8217;s provision of technical support for such activities. If FDA were to determine, based on the totality of circumstances, that our products labeled and marketed for RUO are intended for diagnostic purposes, they would be considered medical devices that will require clearance or approval prior to commercialization. Further, sales of devices for diagnostic purposes may subject us to additional healthcare regulation. We continue to monitor the changing legal and regulatory landscape to ensure our compliance with any applicable rules, laws and regulations. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA classifies medical devices into one of three classes. Devices deemed to pose lower risk to the patient are placed in either class I or II, which, unless an exemption applies, requires the manufacturer to submit a premarket notification requesting FDA clearance for commercial distribution pursuant to Section 510(k) of the FDCA. This process, known as </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">8</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">510(k) clearance, requires that the manufacturer demonstrate that the device is substantially equivalent to a previously cleared and legally marketed 510(k) device or a &#8220;pre-amendment&#8221; class III device for which premarket approval applications (&#8220;PMAs&#8221;) have not been required by the FDA. This FDA review process typically takes from four to twelve months, although it can take longer. Most Class I devices are exempted from this 510(k) premarket submission requirement. If no legally marketed predicate can be identified for a new device to enable the use of the 510(k) pathway, the device is automatically classified under the FDCA as Class III, which generally requires premarket approval, or PMA approval. However, FDA can reclassify or use &#8220;de novo classification&#8221; for a device that meets the FDCA standards for a Class II device, permitting the device to be marketed without a PMA approval. To grant such a reclassification, FDA must determine that the FDCA&#8217;s general controls alone, or general controls and special controls together, are sufficient to provide a reasonable assurance of the device&#8217;s safety and effectiveness. The de novo classification route is generally less burdensome than the PMA approval process.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting, or implantable devices, or those deemed not substantially equivalent to a legally marketed predicate device, are placed in class III. Class III devices typically require PMA approval. To obtain PMA approval, an applicant must demonstrate the reasonable safety and effectiveness of the device based, in part, on data obtained in clinical studies. All clinical studies of investigational medical devices to determine safety and effectiveness must be conducted in accordance with FDA&#8217;s investigational device exemption (&#8220;IDE&#8221;) regulations, including the requirement for the study sponsor to submit an IDE application to FDA, unless exempt, which must become effective prior to commencing human clinical studies. PMA reviews generally last between one and two years, although they can take longer. Both the 510(k) and the PMA processes can be expensive and lengthy and may not result in clearance or approval. If we are required to submit our products for premarket review by the FDA, we may be required to delay marketing and commercialization while we obtain premarket clearance or approval from the FDA. There would be no assurance that we could ever obtain such clearance or approval.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All medical devices, including IVDs, that are regulated by the FDA are also subject to the quality system regulation. Obtaining the requisite regulatory approvals, including the FDA quality system inspections that are required for PMA approval, can be expensive and may involve considerable delay. The regulatory approval process for such products may be significantly delayed, may be significantly more expensive than anticipated, and may conclude without such products being approved by the FDA. Without timely regulatory approval, we will not be able to launch or successfully commercialize such diagnostic products. Changes to the current regulatory framework, including the imposition of additional or new regulations, could arise at any time during the development or marketing of our products. This may negatively affect our ability to obtain or maintain FDA or comparable regulatory clearance or approval of our products in the future. In addition, regulatory agencies may introduce new requirements that may change the regulatory requirements for us or our customers, or both.</span><span id="_cp_text_1_92" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_cp_text_1_93" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As noted above, although our products are currently labeled and sold for research purposes only, the regulatory requirements related to marketing, selling, and supporting such products could be uncertain and depend on the totality of circumstances. This uncertainty exists even if such use by our customers occurs without our consent. If the FDA or other regulatory authorities assert that any of our RUO products are subject to regulatory clearance or approval, </span><span id="_cp_text_4_91" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our business, financial condition</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, or results of operations could be adversely affected.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_cp_text_1_94" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For example, in some cases, our customers, including laboratories that offer services as part of our certified service provider program, may use our RUO products in their own laboratory-developed tests (&#8220;LDTs&#8221;) or in other FDA-regulated products for clinical diagnostic use. The FDA has historically exercised enforcement discretion in not enforcing the medical device regulations against LDTs and LDT manufacturers. However, on October 3, 2014, the FDA issued two draft guidance documents that set forth the FDA&#8217;s proposed risk-based framework for regulating LDTs, which are designed, manufactured, and used within a single laboratory. In January 2017, the FDA announced that it would not issue final guidance on the oversight of LDTs and LDT manufacturers, but would seek further public discussion on an appropriate oversight approach and give Congress an opportunity to develop a legislative solution. More recently, the FDA has issued warning letters to genomics labs for illegally marketing genetic tests that claim to predict patients&#8217; responses to specific medications, noting that the FDA has not created a legal &#8220;carve-out&#8221; for LDTs and retains discretion to take action when appropriate, such as when certain genomic tests raise significant public health concerns. As laboratories and manufacturers develop more complex genetic tests and diagnostic software, FDA may increase its regulation of LDTs. Any future legislative or administrative rule making or oversight of LDTs and LDT manufacturers, if and when finalized, may impact the sales of our products and how customers use our products, and may require us to change our business model in order to maintain compliance with these laws. We would become subject to additional FDA requirements if our products are determined to </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">9</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">be medical devices or if we elect to seek 510(k) clearance or premarket approval. If our products become subject to FDA regulation as medical devices, we would need to invest significant time and resources to ensure ongoing compliance with FDA quality system regulations and other postmarket regulatory requirements.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If our products become subject to FDA regulation as medical devices, the regulatory clearance or approval and the maintenance of continued and postmarket regulatory compliance for such products will be expensive, time-consuming, and uncertain both in timing and in outcome. Commercialization of such regulated medical devices can increase our exposure under additional laws. For example, medical device companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business and may constrain the financial arrangements and relationships through which we research, as well as sell, market and distribute any medical products for which we obtain marketing authorization. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, data privacy and security, and transparency laws and regulations related to payments and other transfers of value made to physicians and other healthcare providers. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and imprisonment. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the future, to the extent we develop any clinical diagnostic assays, we may pursue payment for such products through a diverse and broad range of channels and seek coverage and reimbursement by government health insurance programs and commercial third-party payors for such products. In the United States, there is no uniform coverage for clinical laboratory tests. The extent of coverage and rate of payment for covered services or items vary from payor to payor. Obtaining coverage and reimbursement for such products can be uncertain, time-consuming, and expensive, and, even if favorable coverage and reimbursement status were attained for our tests, to the extent applicable, less favorable coverage policies and reimbursement rates may be implemented in the future. Changes in healthcare regulatory policies could also increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our products, decrease our revenue and adversely impact sales of, and pricing of and reimbursement for, our products.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">International sales of medical devices are subject to foreign government regulations, which vary substantially from country to country. In the future, if we decide to distribute or market our diagnostic products as IVDs in Europe, such products will be subject to regulation under the European Union (&#8220;EU&#8221;) IVD Medical Device Regulation (&#8220;IVDR&#8221;) EU 2017/746. Outside of the EU, regulatory approval needs to be sought on a country-by-country basis in order to market medical devices. Although there is a trend towards harmonization of a quality system, standards and regulations in each country may vary substantially which can affect timelines of introduction.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are committed to the protection of our employees and the environment. Our operations require the use of hazardous materials that subject us to various federal, state, and local environmental and safety laws and regulations. We believe that we are in material compliance with current applicable laws and regulations. However, we could be held liable for damages and fines should contamination of the environment or individual exposures to hazardous substances occur. In addition, we cannot predict how changes in these laws and regulations, or the development of new laws and regulations, will affect our business operations or the cost of compliance.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additionally, we must comply with complex foreign and U.S. laws and regulations, such as the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, and other local laws prohibiting corrupt payments to governmental officials, anti-competition regulations and sanctions imposed by the U.S. Office of Foreign Assets Control and other similar laws and regulations. Violations of these laws and regulations could result in fines and penalties, criminal sanctions, restrictions on our business conduct and on our ability to offer our products in one or more countries, and could also materially affect our brand, our ability to attract and retain employees, our international operations, our business and our operating results. Although we have implemented policies and procedures designed to ensure compliance with these laws and regulations, there can be no assurance that our employees, contractors, or agents will not violate our policies.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As we continue to expand our business into multiple international markets, our success will depend, in large part, on our ability to anticipate and effectively manage these and other risks associated with our international operations. Any of these risks could harm our international operations and negatively impact our sales, adversely affecting our business, results of operations, financial condition and growth prospects.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">10</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Human Capital </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2021, we had 728 full-time employees. Of these employees, 342 were in research and development, 101 were in operations and service, 178 were in marketing, sales and customer support, and 107 were in general and administration. With the exception of our field-based sales, marketing and service teams, the majority of our employees are in California. None of our employees are represented by labor unions or are covered by a collective bargaining agreement with respect to their employment. We have not experienced any work stoppages, and we consider our relationship with our employees to be good. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Talent Acquisition and Retention</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We recognize that our employees largely contribute to our success. To this end, we support business growth by seeking to attract and retain best-in-class talent. Our talent acquisition team uses internal and external resources to recruit highly skilled candidates globally. In 2021, we were successful in hiring key positions throughout the organization that will help advance our growth. This includes an appointment of a new Chief Commercial Officer, Chief Operating Officer, and Chief Accounting Officer. We continue to attract and retain superior talent as measured by our minimal turnover rate and high employee service tenure.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Total Rewards</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our total rewards philosophy has been to invest in our workforce by offering competitive and fair compensation and benefits packages. We provide employees with compensation packages that include base salary, short-term incentives such as annual bonuses and commissions, and long-term equity awards. We also offer comprehensive employee benefits, which vary by country and region, such as life, disability, and health insurance, health savings and flexible spending accounts, paid time off, paid parental leave, Employee Stock Purchase Program, and a 401(k) plan.  It is our expressed intent to be an employer of choice in our industry by providing market-competitive compensation and benefits packages.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Health, Safety, and Wellness</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The health, safety, and wellness of our employees is a priority in which we have always invested and will continue to do so. We provide our employees and their families with access to a variety of innovative, flexible, and convenient health and wellness programs. Program benefits are intended to provide protection and security, so employees can have peace of mind concerning events that may require time away from work or that may impact their financial well-being. These programs are highlighted regularly in our monthly human resources newsletters.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We continue our investments in and the prioritization of employee health, safety, and wellness in light of the COVID-19 pandemic. To protect and support our essential team members, we have implemented health and safety measures that included a mandatory vaccination policy for our U.S.-based employees, maximizing personal workspaces, changing shift schedules, providing personal protective equipment (PPE), instituting mandatory screening before accessing buildings and performing asymptomatic COVID-19 testing regularly for employees who work on site. We have also supported access to testing by holding on-site testing clinics available to employees and their family members. We continue to monitor this evolving situation and will continue to seek programs to educate and assist employees whenever possible.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Diversity, Equity, and Inclusion</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe a diverse workforce is critical to our success. Our mission is to value differences in races, ethnicities, religions, nationalities, genders, ages, sexual orientations, as well as education, skill sets and experience. We offer training programs on diversity awareness to help employees understand, recognize, respond, and prevent bias throughout the employee lifecycle.   We are focused on inclusive hiring practices, fair and equitable treatment, organizational flexibility, and training and resources.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Training and Development</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe in encouraging employees in becoming lifelong learners by providing ongoing learning and leadership training opportunities. We provide a scaled learning platform of on-demand and virtual classroom learning focused on personal and </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">11</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">professional development. While we strive to provide real-time recognition of employee performance, we have a formal annual review process not only to determine pay and equity adjustments tied to individual contributions, but to identify areas where training and development may be needed.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk31803430" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Available Information </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our website is located at </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">www.pacb.com</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The information posted on </span><span id="_cp_text_1_113" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">or that can be accessed through </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our website is not incorporated </span><span id="_cp_text_1_114" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">by reference </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">into this Annual Report on Form 10-K</span><span id="_cp_text_1_115" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, and the inclusion of our website address is an inactive textual reference only</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 10-K and amendments to reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge through the &#8220;Investors&#8221; section of our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The SEC also maintains a website that contains our SEC filings. The address of the site is </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">www.sec.gov</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additionally, we use our website (including the blog section of our website) as well as our Twitter account (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">@pacbio</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">) as a channel of distribution for important company information and to comply with our disclosure obligations under Regulation FD. Important information, including press releases, analyst presentations and financial information regarding us, as well as corporate governance information, is routinely posted and accessible on the &#8220;Investor Relations&#8221; section of the website, which is accessible by clicking on the tab labeled &#8220;About Us - Investors&#8221; on our website home page. In addition, important information is routinely posted and accessible on the blog section of our website, which is accessible through our website at </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">www.pacb.com/blog</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, as well as our Twitter account (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">@pacbio</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">).  The contents of our website and our Twitter account are not incorporated by reference into this Annual Report on Form 10-K or in any other report or document we file with the SEC, and any references to our website or Twitter account are intended to be inactive textual references only.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.77in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.77in;"><span style="white-space:pre-wrap; display: inline-block;text-indent: 0;width: 0.770in;"><span id="Item1A" style="text-decoration: none;"></span></span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">12</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.77in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.77in;"><span style="white-space:pre-wrap; display: inline-block;text-indent: 0;width: 0.770in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">ITEM&#160;1A.</span></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">RISK FACTORS</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">You should consider carefully the risks and uncertainties described below, together with all of the other information in our public filings with the Securities and Exchange Commission, which could materially affect our business, financial condition, results of operations and prospects. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially affect our business, financial condition, results of operations and prospects.</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">In addition, the impact of the COVID-19 pandemic and any worsening of the economic environment may exacerbate the risks described below, any of which could have a material impact on us. This situation is changing rapidly and additional impacts may arise that we are not aware of currently.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Summary Risk Factors</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following is a summary of the principal risks that could adversely affect our business, operations and financial results. Such risks are discussed more fully below and include, but are not limited to, risks related to:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The potential adverse impact of health epidemics, including the ongoing COVID-19 pandemic;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our ability to successfully market, commercialize, and sell current and future products and related maintenance services; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our ability to achieve profitability for our business;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our ability to</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> successfully leverage and integrate our acquisitions and future acquisitions;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our ability to successfully research, develop and timely manufacture our current and future products;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Management of new product introductions and transitions, resultant costs, and ability of new products to generate promised performance;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Recent significant changes to our leadership team and resultant disruptions to our business;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Retention, recruitment, and training of senior management, key personnel, scientists and engineers;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our ability to further penetrate nucleic acid sequencing applications, as well as grow product demand;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our reliance on outsourcing to other companies for manufacturing certain components and sub-assemblies, some of which are sole-sourced;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our ability to consistently manufacture our instruments and consumables to meet customers&#8217; specifications, quantity, cost, or performance requirements;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The high amount of competition we face in our industry;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our ability to attract customers and increase sales of current and future products;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Reliance on a limited number of customers for a significant portion of our revenues, including academic, research and government institutions;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The complexity of our products giving rise to defects or errors;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our unpredictable and lengthy sales cycle;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our business, financial condition and results of operations could be adversely affected by the political and economic tensions between the United States and other countries, including China;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Securing and maintaining patent or other intellectual property protection for our products and related improvements;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Current and future legal proceedings filed against us claiming intellectual property infringement;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Governmental regulations that burden operations or narrow the market for our products;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">13</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Evolving ethical, legal, privacy, social, and regulatory concerns regarding genetic testing;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Volatility of the price of our common stock; and</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our stock price falling as a result of future offerings or sales.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to Our Business</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our business may be adversely affected by health epidemics, including the </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">ongoing COVID-19 pandemic.</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044022" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our business could be adversely impacted by the effects of COVID-19 or other epidemics or pandemics.  As a result of the ongoing COVID-19 pandemic, our financial results continue to be impacted negatively as our customers in multiple regions around the world suspended or curtailed their normal operations in efforts to curb the spread of COVID-19. While a significant number of our customer sites that shut down due to COVID-19 have re-opened, a significant number of our customers had delayed purchases of capital assets due to the negative impact of the pandemic on their businesses. This dynamic continues to negatively impact the recognition of revenue related to the sale of our Sequel and Sequel II/IIe instruments and the associated consumables and software. The inability to receive or accept shipments of orders for our products on a timely basis, or at all, the delay or possible cancellation of orders for our products or related maintenance and support services, and the reduced utilization of our products has negatively affected and may negatively affect in the future our operations and revenues. In response to local stay-at-home orders and in alignment with CDC recommendations, we limited our manufacturing and commercial operations based in Menlo Park, California. We will, however, continue to provide consumables and support to scientists at government, academic, and commercial labs that remain open. To aid in containing the spread of COVID-19, we have implemented remote-work options and are limiting employee travel. We are continuing to monitor this evolving situation.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044041" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our manufacturing partners and suppliers have been and could continue to be disrupted by conditions related to COVID-19 or other epidemics or pandemics, possibly resulting </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">in disruption to the production of our products. </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If our manufacturing partners or suppliers are unable or fail to fulfill their obligations to us for any reason, we may not be able to manufacture our products and satisfy customer demand or our obligations under sales agreements in a timely manner, and our business could be harmed as a result. There is significant uncertainty relating to the long-term effect of COVID-19 on our business. Infections may resurge or become more widespread and the limitation on our ability to travel and timely sell and distribute our products, as well as any closures or supply disruptions, may be extended for longer periods of time, which could have a negative impact on our business, financial condition and operating results. For example, because our semiconductor manufacturers are located in a region where immunization rates in certain communities may be low, the Omicron variant of COVID-19, as well as any future variants that evolve, could impact workforce availability at those locations and disrupt supply.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Even after the COVID-19 pandemic has subsided, we may continue to experience an adverse impact to our business as a result of its global economic impact, including any recession that has occurred or may occur in the future. Specifically, difficult macroeconomic conditions, such as decreases in discretionary capital expenditure spending, changes to the government funding environment, increased and prolonged unemployment or a decline in consumer confidence as a result of the COVID-19 pandemic, as well as limited or significantly reduced points of access of our products, could have a continuing adverse effect on the demand for some of our products and, consequently, related maintenance and support services. The degree of impact of COVID-19 on our business will depend on several factors, such as the duration and the extent of the pandemic, as well as actions taken by governments, businesses and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The commercialization and sales of our current or future products may be unsuccessful</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">or less successful than anticipated. While we plan to continue pursuing new products and expand into adjacent markets, we have limited experience in managing and selling multiple products and, as a result, may face challenges selling in new markets and fail to successfully carry out these initiatives, which may adversely impact our business, financial condition or results of operation.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In September 2015, we launched the&#160;PacBio Sequel</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>&#174;</sup></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> System, and concurrently began phasing out production of PacBio RS II instruments, and, in April 2019 we announced the commercial launch of the </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Sequel II System</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. In October 2020, we </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">14</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">launched the Sequel IIe System, which has increased computational capacity, and is designed to enable customers to generate PacBio HiFi reads more efficiently.  In April 2021, we released a new HiFi sequencing workflow allowing for more accurate HiFi reads with limited sample quantities. We placed 374 Sequel II/IIe systems during the year ended December 31, 2021, and we expect the number of Sequel II/IIe placements to continue to grow during 2022. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have made and expect to continue making substantial investments to develop new products and enhance our existing products through our acquisitions and research and development efforts.  For example, we are developing a SBB short read sequencing platform. However, due to challenges we may experience in developing and marketing our existing products and launching new products, we may not be able to effectively:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">manage the timeliness of our new product introductions and the rate at which sales of our new products may cannibalize sales of our older products or manage sales and marketing of multiple sequencing platforms;&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">drive adoption of our current and future products, including the Sequel II/IIe Systems and products under development related to our emerging SBB technology;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">maintain our competitive position by continuing to attract and retain customers for our products;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">provide appropriate levels of customer training and support for our products;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">implement an effective marketing strategy to promote awareness of our products;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">develop and implement an effective sales and distribution strategy for our current and future products;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">develop, manufacture and commercialize new products or achieve an acceptable return on our manufacturing or research and development efforts and expenses;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">comply with regulatory requirements applicable to our products;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">anticipate and adapt to changes in our market;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">accommodate customer expectations and demands with respect to our products, increase product adoption by our existing customers or develop new customer relationships;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">deliver our future products in a timely manner to our customers;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">grow our share by marketing and selling our products for new and additional applications; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">manage the significant burdens that expanding our existing or future products into current and new markets may impose on marketing, compliance, and other administrative and managerial resources;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">maintain and develop strategic relationships with vendors, manufacturers and other industry partners to acquire necessary materials for the production of, and to develop, manufacture and commercialize, our existing or future products;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">adapt or scale our manufacturing activities to meet performance specifications and potential demand at a reasonable cost;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">avoid infringement and misappropriation of third-party intellectual property;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">obtain and maintain any necessary licenses to third-party intellectual property on commercially reasonable terms;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">obtain valid and enforceable patents that give us a competitive advantage or enforce existing patents;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">protect our proprietary technology; and</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">attract, retain and motivate qualified personn</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">el.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044071" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The risks noted above, especially with respect to the marketing, sales, and commercialization of our products, may be heightened by the impact of the COVID-19 pandemic.&#160;In addition, a high percentage of our expenses is and will continue to be fixed. Accordingly, if we do not generate revenue as and when anticipated, we could suffer a material adverse effect on our business, financial conditions, results of operations and prospects.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">15</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We have incurred losses to date, and we expect to continue to incur significant losses as we develop our business and may never achieve profitability.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044102" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Except for the quarters ended September 30, 2015 (as a result of a one-time gain on lease amendments), March 31, 2020 (as a result of the recognition of a gain relating to the Continuation Advances), </span><span id="_cp_text_1_168" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">December 31, 2020 (as a result of recognition of gain relating to the Reverse Termination Fee), September 30, 2021 (as a result of the recognition of a one-time income tax benefit from business acquisitions),</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and the year ended December 31, 2020 (as a result of recognition of gain relating to the Reverse Termination Fee and gain relating to the Continuation Advances), we have incurred net losses since inception and we cannot be certain if or when we will produce sufficient revenue from our operations to support our costs. Even if profitability is achieved in the future, we may not be able to sustain profitability on a consistent basis. We expect to continue to incur substantial losses and negative cash flow from operations for the foreseeable future.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our net losses since inception and our expectation of incurring substantial losses and negative cash flow for the foreseeable future could:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">make it more difficult for us to satisfy our obligations;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">increase our vulnerability to general adverse economic and industry conditions;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">limit our ability to fund future working capital, capital expenditures, research and development and other business opportunities;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">increase the volatility of the price of our common stock;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">limit our flexibility to react to changes in our business and the industry in which we operate;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">place us at a disadvantage to other companies that offer nucleic acid sequencing equipment or consumables; and</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">limit our ability to borrow additional funds.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Any or all of the foregoing may have a material adverse effect on our business, operations, financial condition, and prospects.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We are not cash flow positive and may not have sufficient cash to make required payments under the terms of our debt or fund our long term planned operations. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044126" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our operations have consumed substantial amounts of cash since inception, and we expect to continue to incur substantial losses and negative cash flow from operations for the foreseeable future. Additional funds may not be available on terms acceptable to us or at all. We have incurred and may further incur additional debt, including the debt incurred through issuance of $900.0 million in aggregate principal amount of 1.50% Convertible Senior Notes due 2028. We may not have sufficient cash to make required payments under the terms of this debt, and, should this occur, debt holders have rights senior to common stockholders to make claims on our assets. We may not be able to issue equity securities due to unacceptable terms and conditions to us in the capital markets. To the extent that we intend to raise additional funds through the sale of our common stock, downward fluctuations in our stock price could adversely affect such fundraising efforts. Furthermore, equity financings normally involve shares sold at a discount to the current market price and fundraising through sales of additional shares of common stock or other equity securities will have a dilutive effect on our existing investors. The shares may also be sold at a time when the market price for our common stock is low because we are in need of the funds, which will further dilute existing holders more than if the market price for our common stock was higher.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe that our growth will depend, in part, on our ability to fund our commercialization efforts and our efforts to develop new products, including any improvements to the SMRT Cell 8M and Sequel II/IIe Systems and our planned development of a SBB short read sequencing platform. To the extent our existing resources are not sufficient, it may require us to delay, or even not allow us to conduct any or all of these activities that we believe would be beneficial for our future growth. We may need to raise additional funds through public or private debt or equity financing or alternative financing arrangements, which may include collaborations or licensing arrangements. If we are unable to raise funds on favorable terms, or at all, we may have to reduce our cash burn rate and may not be able to support our commercialization efforts and launching of new products, operations or to increase or maintain the level of our research and development activities. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.47in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">16</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If we are unable to generate sufficient cash flows or to raise adequate funds to finance our forecasted expenditures, we may have to make significant changes to our operations, including delaying or reducing the scope of, or eliminating some or all of, our development programs. We also may have to reduce sales, marketing, engineering, customer support or other resources devoted to our existing or new products, or we may need to cease operations. Any of these actions could materially impede our ability to achieve our business objectives and could materially harm our operating results. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If our cash, cash equivalents and investments are insufficient to fund our projected operating requirements and we are unable to raise capital, it could have a material adverse effect on our business, financial condition and results of operations and prospects. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We have made acquisitions and, in the future, may continue to acquire businesses, technologies or assets, form joint ventures or make other strategic investments with companies that could harm our operating results, dilute our stockholders&#8217; ownership, or cause us to incur debt or significant expense.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As part of our business strategy, we have acquired and expect to continue to pursue acquisitions of complementary businesses, technologies or assets. We may also pursue technology license arrangements, strategic alliances or investments that complement our business. For example, we entered into a multi-year Development and Commercialization Agreement with Invitae, whereby Invitae provides us with funding to develop certain products relating to production-scale high-throughput sequencing. In July 2021, we acquired Circulomics and in September 2021, we acquired Omniome. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Acquisitions involve numerous risks, any of which could harm our business and negatively affect our financial condition and results of operations, including:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">i</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ntense competition for suitable acquisition targets, which could increase prices and adversely affect our ability to consummate deals on favorable or acceptable terms;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">failure or material delay in closing a transaction;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">transaction-related lawsuits or claims;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">difficulties in integrating the technologies, operations, existing contracts, and personnel of an acquired company;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">difficulties in retaining key employees or business partners of an acquired company;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">difficulties in retaining suppliers, partners or customers of an acquired company;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">challenges with integrating the brand identity of an acquired company with our own;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">diversion of financial and management resources from existing operations or alternative acquisition opportunities;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">failure to realize the anticipated benefits or synergies of a transaction;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">difficulties in developing technology post-acquisition;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">failure to identify the problems, liabilities, or other shortcomings or challenges of an acquired company or technology, including issues related to intellectual property, regulatory compliance practices, litigation, revenue recognition or other accounting practices, or employee or user issues;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">risks that regulatory bodies may enact new laws or promulgate new regulations that are adverse to an acquired company or business;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">risks that regulatory bodies do not approve our acquisitions or business combinations or delay such approvals;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">theft of our trade secrets or confidential information that we share with potential acquisition candidates;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">risk that an acquired company or investment in new services cannibalizes a portion of our existing business; and</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">adverse m</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">arket reaction to an acquisition.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To finance any acquisitions or other strategic investments, we may raise additional funds, which could adversely affect our existing stockholders and our business. If the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. In addition, our stockholders may experience substantial dilution as a result of additional securities we may issue for acquisitions. Open market sales of substantial amounts of our common stock issued to </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">17</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">stockholders of companies we acquire could also depress our stock price. Additional funds may not be available on terms that are favorable to us, or at all.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If we fail to address the foregoing risks or other problems encountered in connection with past or future acquisitions of businesses, new technologies, services, and other assets and strategic investments, or if we fail to successfully integrate such acquisitions or investments, our business, financial condition, and results of operations could be adversely affected.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we are unable to successfully develop and timely manufacture our current and future products, including with respect to SMRT Cell Sequel II/IIe Systems, the SBB products under development, and related products, our business may be adversely affected.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044157" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In light of the highly complex technologies involved in our products, there can be no assurance that we will be able to manufacture and commercialize our current and future products on a timely basis or continue providing adequate support for our existing products. The commercial success of our products, including the Sequel and Sequel II/IIe Systems, depends on a number of factors, including performance and reliability of the system, our anticipating and effectively addressing customer preferences and demands, the success of our sales and marketing efforts, effective forecasting and management of product demand, purchase commitments and inventory levels, effective management of manufacturing and supply costs, and the quality of our products, including consumables such as SMRT Cells and reagents. Should we face delays in or discover unexpected defects during the further development or manufacturing process of instruments or consumables related to our products, including with respect to SMRT Cells, reagents, Sequel II/IIe Systems, </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">SBB products under development,</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and including any delays or defects in software development or product functionality, the timing and success of the&#160;continued&#160;rollout and scaling of our products may be significantly impacted, which may materially and negatively impact our revenue and gross margin. The ability of our customers to successfully utilize our products will also depend on our ability to deliver high quality SMRT Cells and reagents, including with respect to the SMRT Cell 8M. We have designed SMRT Cells and other consumables specifically for the Sequel and Sequel II/IIe Systems,&#160;and may need to develop in the future, other customized SMRT Cells and consumables for our future products. Our production of the SMRT Cells for the Sequel and Sequel II/IIe Systems has been and may in the future be below desired levels and yields, and we have experienced and may experience in the future manufacturing delays, product or quality defects, SMRT Cell variability, and other issues. For example, the COVID&#8211;19 pandemic outbreak has impacted and could result in more pronounced impacts to our manufacturing and our ability to supply products. The performance of our consumables is critical to our customers&#8217; successful utilization of our products, and any defects or performance issues with our consumables would adversely affect our business. All of the foregoing could materially negatively impact our ability to sell our products or result in other material adverse effects on our business, operations, financial condition, operations and prospects. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044180" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The development of our products is complex and costly. Problems in the design or quality of our products may have a material and adverse effect on our brand, business, financial condition, and operating results, and could result in us losing our certifications from the International Organization for Standardization (&#8220;ISO&#8221;). If we were to lose ISO certification, then our customers might choose not to purchase products from us and this could adversely impact our ability to develop products approved for clinical uses. Unanticipated problems with our products could divert substantial resources, which may impair our ability to support our new and existing products, and could substantially increase our costs. If we encounter development challenges or discover errors in our products late in our development cycle, we may be forced to delay product shipments or the scaling of manufacturing or supply. In particular, if the continued rollout of our current and future products, including with respect to the SMRT Cell 8M and Sequel II/IIe Systems, is delayed or is not successful or less successful than anticipated, then we may not be able to achieve an acceptable return, if any, on our substantial research and development efforts, and our business may be materially and adversely affected. The expenses or losses associated with delayed or unsuccessful product development or lack of market acceptance of our existing and new products, including the SMRT Cell 8M and Sequel II/IIe Systems, could materially and adversely affect our business, operations, financial condition, and prospects.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">18</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our research and development efforts may not result in the benefits that we anticipate, and our failure to successfully market, sell, and commercialize our current and future products could have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have dedicated significant resources to developing our current products, including sequencing systems and consumables based on our proprietary SMRT sequencing technology and our Sequel and Sequel II/IIe Systems. We are also engaged in substantial and complex research and development efforts, which, if successful, may result in the introduction of new products in the future, including in connection with the SMRT Cell 8M and the Sequel II/IIe Systems. Our research and development efforts are complex and require us to incur substantial expenses. We may not be able to develop, manufacture and commercialize new products, obtain regulatory approval if necessary, or achieve an acceptable return, if any, on our research and development efforts and expenses or joint research and development efforts with partners. Our joint research and development efforts with partners require significant management attention and operational resources. If we are unable to successfully manage such joint research and development efforts, our future results may be adversely impacted. In January 2021, we entered into a multi-year collaboration with Invitae to begin development of a production-scale high-throughput sequencing platform; in certain termination circumstances of this collaboration, we may be obligated to refund all or a portion of the development funds advanced by Invitae and/or we may owe Invitae a share of the revenue generated from the sale of the program products. Furthermore, we need to continue to expand our internal capabilities or seek new partnerships or collaborations, or both, in order to successfully develop, market, sell and commercialize our products for and in the markets we seek to reach. If </span><span id="_cp_text_1_172" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">are unable to do so or are delayed, then this could materially and adversely affect our business, operations, financial condition and prospects.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We must successfully manage new product introductions and transitions, including with respect to the SMRT Cell 8M and </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Sequel II/IIe Systems</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">, and the development of our proposed SBB short read sequencing platform, and we may incur significant costs during these transitions and development, and these efforts may not result in the benefits we anticipate.</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044204" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If our products and services fail to deliver the performance, scalability or results expected by our current and future customers, or are not delivered on a timely basis, our reputation and credibility may suffer, our current and future sales and revenue may be materially harmed and our business may not succeed. For instance, if we are not able to realize the benefits we anticipate from the development and commercialization of the SMRT Cell 8M and Sequel II/IIe Systems, our proposed SBB short read sequencing platform, and any future products that may be developed for medical and clinical uses, it could have a material adverse effect on our business, financial condition and results of operations. In addition, the introduction of future products, including with respect to future long-read and short-read products, and related consumables, has and may in the future lead to our limiting or ceasing development of further enhancements to our existing products as we focus our resources on new products, and has resulted and could in the future result in reduced marketplace acceptance and loss of sales of our existing products, materially adversely affecting our revenue and operating results. The introduction of new products has had and may in the future also have a negative impact on our revenue in the near-term as our current and future customers have delayed or cancelled and may in the future delay or cancel orders of existing products in anticipation of new products and we may also be pressured to decrease prices for our existing products. Further, we have experienced, and&#160;may&#160;in the future experience, difficulty in managing or forecasting customer reactions, purchasing decisions or transition requirements with respect to newly launched products. We have incurred and may continue to incur significant costs in completing these transitions,&#160;including costs of write-downs of our products, as current or future customers transition to new products. If we do not successfully manage these product transitions, including with respect to the SMRT Cell 8M and Sequel II/IIe System, our business, operations, financial condition, and prospects may be materially and adversely affected.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Significant changes to our leadership team and the resulting management transitions might harm our future operating results.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have experienced significant changes to our leadership team.  Our President and Chief Executive Officer Christian O. Henry was appointed effective September 14, 2020, succeeding Dr. Michael Hunkapiller who retired on December 31, 2020. Our Chief Financial Officer Susan G. Kim was appointed effective September 28, 2020, succeeding Susan K. Barnes who retired on August 7, 2020.  Our Chief Operating Officer, Mark Van Oene, and our Chief Commercial Officer, Peter Fromen, were each appointed effective January 8, 2021.  Also, our Vice President and Chief Accounting Officer Michele Farmer was appointed effective May 17, 2021, and our Chairman of the Board Dr. John F. Milligan was appointed effective September 14, 2020.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044235" style="text-decoration: none;"></span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">19</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Although we believe these leadership transitions are in the best interest of our stakeholders, these transitions may result in the loss of personnel with deep institutional or technical knowledge. Further, the transition could potentially disrupt our operations and relationships with employees, suppliers, partners and customers due to added costs, operational inefficiencies, decreased employee morale and productivity and increased turnover. We must successfully recruit and integrate our new leadership team members within our organization to achieve our operating objectives; as such, the leadership </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">transition</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> may temporarily affect our business performance and results of operations while the new members of our leadership team become familiar with our business. In addition, our competitors may seek to use this transition and the related potential disruptions to gain a competitive advantage over us. Furthermore, these changes increase our dependency on the other members of our leadership team that remain with us, who are not contractually obligated to remain employed with us and may leave at any time. Any such departure could be particularly disruptive given that we are already experiencing leadership transitions and, to the extent we experience additional management turnover, competition for top management is high such that it may take some time to find a candidate that meets our requirements. Our future operating results depend substantially upon the continued service of our key personnel and in significant part upon our ability to attract and retain qualified management personnel.&#160; If we are unable to mitigate these or other similar risks, our business, results of operations and financial condition may be materially and adversely affected.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We depend on the continuing efforts of our senior management team and other key personnel. If we lose members of our senior management team or other key personnel or are unable to successfully retain, recruit and train qualified scientists, engineers, sales personnel and other employees, our ability to maintain, develop and commercialize our products could be harmed and we may be unable to achieve our goals.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044267" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our success depends upon the continuing services of members of our senior management team and scientific and engineering personnel. In particular, our scientists and engineers are critical to our technological and product innovations and we will need to hire additional qualified personnel. Our industry, particularly in the San Francisco Bay Area, is characterized by high demand and intense competition for talent, and the turnover rate can be high. We compete for qualified management and scientific personnel with other life science companies, academic institutions and research institutions, particularly those focusing on genomics. In addition, we will need to continue to recruit, hire and retain sales personnel to support the commercialization of our products. Our employees could leave our company with little or no prior notice and would be free to work for a competitor.&#160;In addition, changes to&#160;U.S.&#160;immigration policies, particularly to H-1B and other visa programs, could restrain the flow of technical and professional talent into the U.S. and may inhibit our ability to hire qualified personnel.&#160;If one or more of our senior executives or other key personnel were unable or unwilling to continue in their present positions, we may not be able to replace them easily or at all, and other senior management may be required to divert attention from other aspects of the business. In addition, we do not have &#8220;key person&#8221; life insurance policies covering any member of our management team or other key personnel. Further, our vaccination and return to office protocols related to COVID-19 may also impact the recruitment and retention of key employees. The loss of any of these individuals or any inability to attract or retain qualified personnel, including scientists, engineers, sales personnel and others, could prevent us from pursuing collaborations and materially and adversely affect our support of existing products, product development and introductions, business growth prospects, results of operations and financial condition.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our success is highly dependent on our ability to further penetrate nucleic acid sequencing applications as well as on the growth and expansion of the demand for our products.  If our products fail to achieve and sustain sufficient market acceptance, we will not generate expected revenue and our business may not succeed.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Although nucleic acid sequencing technology is well-established, our SMRT Sequencing technology is relatively new and evolving. We cannot be sure that our current or future products will gain acceptance in the marketplace at levels sufficient to support our costs. Our success depends, in part, on our ability to expand overall demand for nucleic acid sequencing to include new applications that are not practicable with other current technologies and to introduce new products that capture a larger share of growing overall demand for sequencing. To accomplish this, we must successfully commercialize, and continue development of, our proprietary SMRT Sequencing technology for use in a variety of life science and other research applications, including uses by academic, government and clinical laboratories, as well as pharmaceutical, diagnostic, biotechnology and agriculture companies, among others. However, we may be unsuccessful in these efforts and the sale and commercialization of the SMRT Cell 8M and Sequel II/IIe Systems, and related products may not grow sufficiently to cover our costs.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044306" style="text-decoration: none;"></span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">20</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There can be no assurance that we will be successful in adding new products or securing additional customers for our current and future products, including with respect to the SMRT Cell 8M and Sequel II/IIe Systems and products related to our recent Circulomics and Omniome acquisitions.  If we are unable to develop SBB technology and sell acquired technology product, we may fail to achieve our strategic commercial initiatives in connection with the planned release of new products and anticipated entry into new markets. Our ability to further penetrate existing applications and any new applications depends on a number of factors, including the cost, performance and perceived value associated with our products, as well as customers&#8217; willingness to adopt a different approach to nucleic acid sequencing. Potential customers may have already made significant investments in other sequencing technologies and may be unwilling to invest in new technologies.&#160;We are experiencing pricing pressures caused by industry competition and increased demand for lower-priced instruments and lower operational costs. We have limited experience commercializing and selling products outside of the academic and research settings, and we cannot guarantee success in acquiring additional customers. Furthermore, we cannot guarantee that our products will be satisfactory to potential customers or that our products will perform in accordance with customer expectations. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Nucleic acid sequencing applications are new and dynamic, and there can be no assurance that they will develop as quickly as we anticipate, that they will reach their full potential or that our products will be appropriate competitive for these applications. As a result, we may be required to refocus our marketing efforts, and we may have to make changes to the specifications of our products to enhance our ability to enter particular applications more quickly. We may also need to delay full-scale commercial deployment of new products as we develop them in order to perform quality control and early access user testing. Even if we are able to implement our technology successfully, we and/or our sales and distribution partners may fail to achieve or sustain market acceptance of our current or future products across the full range of our intended life science and other applications. We need to continue to expand and update our internal capabilities or to collaborate with other partners, or both, in order to successfully expand sales of our products in the applications that we seek to reach, which we may be unable to do at the scale required to support our business.&#160;&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If the demand for our products grows more slowly than anticipated, if we are unable to successfully scale or otherwise ensure sufficient manufacturing capacity for new products to meet demand, if we are not able to successfully market and sell our products, if competitors develop better or more cost-effective products, if our product launches and commercialization are not successful, or if we are unable to further grow our customer base or do not realize the growth with existing customers that we are expecting, our current and future sales and revenue may be materially and adversely harmed and our business may not succeed.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We rely on other companies for the manufacture of certain components and sub-assemblies and intend to outsource additional sub-assemblies in the future, some of which are sole sources. We may not be able to successfully scale the manufacturing process necessary to build and test multiple products on a full commercial basis, which could materially harm our business.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044338" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our products are complex and involve a large number of unique components, many of which require precise manufacturing. The nature of our products requires customized components that are currently available only from a limited number of sources, and in some cases, single sources. We have chosen to source certain critical components from a single source, including suppliers for our SMRT Cells, reagents and instruments. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We cannot assure you that product supplies will not be limited or interrupted, especially with respect to our sole source third-party manufacturing and supply collaborators, or that product supplies will be of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. We may be unable to negotiate binding agreements with our current and future sole source third-party manufacturing and supply collaborators or, in the event that such collaborators&#8217; services become interrupted for any reason, find replacement manufacturers to support our development and commercial activities at commercially reasonable terms. We do not always have arrangements in place for a redundant or second-source supply for our sole source vendors in the event they cease to provide their products or services to us or fail to provide sufficient quantities in a timely manner. </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> If we are required to purchase these components from alternative sources, it could take several months or longer to qualify the alternative sources. If we are unable to secure a sufficient supply of these product components on a timely basis, or if these components do not meet our expectations or specifications for quality and functionality, our operations and manufacturing would be materially and adversely affected, we could be unable to meet customer demand and our business and results of operations may be materially and adversely affected.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">21</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The operations of our third-party manufacturing partners and suppliers have been and could continue to be disrupted by conditions unrelated to our business or operations or that are beyond our control, including but not limited to international trade restrictions, inflation, supply chain disruptions, and conditions related to COVID-19 or other epidemics. If our manufacturing partners or suppliers are unable or fail to fulfill their obligations to us for any reason, we may not be able to manufacture our products and satisfy customer demand or our obligations under sales agreements in a timely manner, and our business could be harmed as a result. For example, the global shortage of semiconductors, which has been reported since early 2021, has caused challenges for us in our supply chain and resulted in some cost increases that have and may continue to adversely impact margins. During these periods of shortages or delays, the price of components may increase, or the components may not be available at all. We may not be able to secure enough components at reasonable prices or of acceptable quality to build new products in a timely manner in the quantities or configurations needed. Accordingly, our revenue and gross margins could suffer until other sources can be developed. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, because our semiconductor suppliers are in regions that may have communities with low vaccination rates, the Omicron variant of COVID-19, or any variants that evolve in the future, could lead to increased infections among workers that could further disrupt the supply chain. Our current manufacturing process is characterized by long lead times between the placement of orders for and delivery of our products. If we do not accurately anticipate our needs or if we receive insufficient components to manufacture our products on a timely basis to meet customer demand, our sales and our gross margin may be adversely affected and our business could be materially harmed. If we are unable to reduce our manufacturing costs and establish and maintain reliable, high-volume manufacturing suppliers as we scale our operations, our business, operations, financial condition, and prospects could be materially and adversely harmed.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may be unable to consistently manufacture our instruments and consumables, including SMRT Cells and reagents, to the necessary specifications or in quantities necessary to meet demand at an acceptable cost or at an acceptable performance level.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044377" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In order to successfully generate revenue from our products, we need to supply our customers with products that meet their expectations for quality and functionality in accordance with established specifications. Our customers have experienced variability in the performance of our products. We have experienced and may continue to experience delays, quality issues or other difficulties leading to customer dissatisfaction with our products.&#160;Our production of SMRT Cells and reagents involves a long and complex manufacturing process, and has been and may in the future be below desired yields and resulting output levels. We have experienced and may experience in the future manufacturing delays, product defects, variability in the performance of SMRT Cells and other products, inadequate reserves for inventory, or other issues.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There is no assurance that we will be able to manufacture our products so that they consistently achieve the product specifications and quality that our customers expect, including any products developed for clinical uses. Problems in the design or quality of our products, including low manufacturing yields of SMRT Cells, or sub-performing reagent lots may have a material adverse </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">effect</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> on our brand, business, financial condition, and operating results, and could result in us losing our ISO certifications. If we were to lose our ISO certifications, then our customers might choose not to purchase products from us. There is also no assurance that we will be able to increase manufacturing yields and decrease costs, or that we will be successful in forecasting customer demand or manufacturing and supply costs, or that product supplies, including reagents or integrated chips, will not be limited or interrupted, or will be of satisfactory quality or continue to be available at acceptable prices. Furthermore, while we are undertaking efforts to increase our manufacturing scale and capability, we may not be able to increase manufacturing to meet anticipated demand or may experience downtime in our manufacturing facilities, including, for example, if we experience increased cases of COVID-19 among our employees, or if our suppliers are unable to meet our increased demand at a time when the supply chain is under duress due to potential dislocations and disruptions in product and employee availability due to COVID-19. An inability to manufacture products and components that consistently meet specifications, in necessary quantities and at commercially acceptable costs, will have a negative impact, and may have a material adverse effect on our business, product development timelines, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Rapidly changing technology in life sciences and research diagnostics could make our products obsolete unless we continue to develop, manufacture and commercialize new and improved products and pursue new opportunities.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our industry is characterized by rapid and significant technological changes, frequent new product introductions and enhancements and evolving industry standards. Our future success depends on our ability to continually improve our products, to develop and introduce new products that address the evolving needs of our customers on a timely and cost-</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">22</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">effective basis and to pursue new opportunities. These new opportunities may be outside the scope of our proven expertise or in areas where demand is unproven, and new products and services developed by us may not gain market acceptance or may not adequately perform in order to capture market share. Our inability to develop and introduce new products and to gain market acceptance of our existing and new products could harm our future operating results. Unanticipated difficulties or delays in replacing existing products with new products or in commercializing our existing or new products in sufficient quantities and of acceptable quality to meet customer demand, including with respect to the SMRT Cell 8M and Sequel II/IIe Systems, could diminish future demand for our products and may materially and adversely harm our future operating results.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Increased market adoption of our products by customers may depend on the availability of sample preparation and informatics tools, some of which may be developed by third parties.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our commercial success may depend in part upon the development of sample preparation and software and informatics tools by third parties for use with our products. We cannot guarantee that product supplies, including reagents, will not be limited or interrupted, or will be of satisfactory quality or continue to be available at acceptable prices, or that third parties will develop tools that our current and future customers will find useful with our products, or that customers will adopt such third-party tools on a timely basis or at all. A lack of complementary sample preparation and informatics tools, or delayed updates of such tools, may impede the adoption of our products and may materially and adversely impact our business.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We operate in a highly competitive industry and if we are not able to compete effectively, our business and operating results will likely be harmed.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044414" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There are a significant number of companies offering nucleic acid sequencing products and/or services, including Illumina, BGI Genomics, Thermo, Oxford Nanopore Technologies Ltd. (&#8220;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ONT Ltd.&#8221;), Roche, and Qiagen. </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Many of these companies currently have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater financial, technical, research and/or other resources, more experience in new product development, larger and more established manufacturing capabilities and marketing, sales and support functions, and/or more established distribution channels to deliver products to customers than we do. These companies may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards or customer requirements. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There are also several companies that are in the process of developing or have already developed and commercialized new, competing or potentially competing technologies, products and/or services,&#160;including&#160;ONT Ltd. and its subsidiaries, against whom we have filed complaints for patent infringement in the U.S. District Court for the District of Delaware and, previously, with the U.S. International Trade Commission, in the High Court of England and Wales and in the District Court of Mannheim, Germany. ONT Ltd.&#160;previously filed claims against us in the High Court of England and Wales and the District Court of Mannheim, Germany, also for patent infringement, and its subsidiary, Oxford Nanopore Technologies, Inc. (&#8220;ONT Inc.&#8221;)</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, filed counterclaims against us in the U.S. District Court for the District of Delaware seeking declaratory judgements of non-infringement, invalidity and unenforceability of the asserted patents, as well as antitrust, false advertising and unfair competition counterclaims that were subsequently dismissed by that court</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. Roche is developing potentially competing sequencing products. Increased competition may result in pricing pressures, which could harm our sales, profitability or market share. Our failure to further enhance our existing products and to introduce new products to compete effectively could materially and adversely affect our business, operations, financial condition and prospects.&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may be unable to successfully increase sales of our current products or market and sell our future products.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our ability to achieve profitability depends on our ability to attract customers for our current and future products, and we may be unable to effectively market or sell our products, or find appropriate partners to do so. To perform sales, marketing, distribution and customer support functions successfully, we face a number of risks, including:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our ability to attract, retain and manage qualified sales, marketing and service personnel necessary to expand market acceptance for our technologies;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the performance and commercial availability expectations of our existing and potential customers with respect to new and existing products;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">23</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">availability of potential sales and distribution partners to sell our technologies, and our ability to attract and retain such sales and distribution partners;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the time and cost of maintaining and growing a specialized sales, marketing and service force for a particular application, which may be difficult to justify in light of the revenue generated; and</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our sales, marketing and service force may be unable to execute successful commercial activities.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044446" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have enlisted and may continue to enlist third parties to assist with sales, distribution and customer support. There is no guarantee that we will be successful in attracting desirable sales and distribution partners, that we will be able to enter into arrangements with such partners on terms favorable to us or that we will be able to retain such partners on a going-forward basis. If our sales and marketing efforts, or those of any of our third-party sales and distribution partners, are not successful, or our products do not perform in accordance with customer expectations, our technologies and products may not gain market acceptance, which could materially and adversely impact our business, operations, financial condition and prospects.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Large purchases by a limited number of customers represent a significant portion of our revenue, and any loss or delay of expected purchases has resulted, and in the future could result, in material quarter-to-quarter fluctuations of our revenue or otherwise adversely affect our results of operations.&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We receive a significant portion of our revenue from a limited number of customers. For example,</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for the fiscal years ended December 31, 2021, 2020 and 2019, one of our customers, Gene Company Limited, accounted for approximately 13%, 14% and 17% of our total revenue, respectively.</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Gene Company Limited is our primary distributor in China. Many of these customers make large purchases on a purchase-order basis rather than pursuant to long-term contracts. As a consequence of the concentrated nature of our customer base and their purchasing behavior, our quarterly revenue and results of operations have fluctuated, and may fluctuate in the future, from quarter to quarter and are difficult to forecast. For example, the cancellation of orders or acceleration or delay in anticipated product purchases or the acceptance of shipped products by our larger customers has materially affected, and in the future could materially affect, our revenue and results of operations in any quarterly period. We have been, and may be in the future be, unable to sustain or increase our revenue from our larger customers, or offset any discontinuation or decrease of purchases by our larger customers with purchases by new or other existing customers. To the extent one or more of our larger customers experience significant financial difficulty, bankruptcy or insolvency, this could have a material adverse effect on our sales and our ability to collect on receivables, which could materially and adversely harm our financial condition and results of operations. &#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, many of our customers, including some of our larger customers, have negotiated, or may in the future negotiate, volume-based discounts or other more favorable terms from us or our sales and distribution partners, which can and have had a negative effect on our gross margins or revenue. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We expect that such concentrated purchases will continue to contribute materially to our revenue for the foreseeable future and that our results of operations may fluctuate materially as a result of such larger customers&#8217; buying patterns. In addition, we may see consolidation of our customer base. The loss of one of our larger customers, a significant delay or reduction in its purchases, or any volume-based discount or other more favorable terms that we or our sales and distribution partner(s) may agree to provide, in light of the aggregated purchase volume or buying power resulting from such consolidation, has harmed, and in the future could harm, our business, financial condition, results of operations and prospects.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our products are highly complex, have recurring support requirements and could have unknown defects or errors, which may give rise to claims against us or divert application of our resources from other purposes.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Products using our SMRT sequencing technology are highly complex and may develop or contain undetected defects or errors. Our customers have experienced and may continue to experience reliability issues with our existing and future products, including the Sequel System and the Sequel II/IIe Systems. Despite testing, defects or errors may arise in our products, which could result in a failure to obtain, maintain or increase market acceptance of our products, diversion of development resources, injury to our reputation and increased warranty, service and maintenance costs. New products, including the SMRT Cell 8M and Sequel II/IIe Systems, or enhancements to our existing products in particular may contain undetected errors or performance problems that are discovered only after delivery to customers. If our products have </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">24</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">reliability or other quality issues or require unexpected levels of support in the future, the market acceptance and utilization of our products may not grow to levels sufficient to support our costs and our reputation and business could be harmed. Low utilization rates of our products could cause our revenue and gross margins to be adversely affected. We generally ship our sequencing instruments with one year of service included in the purchase price with an option to purchase one or more additional years of service. We also provide a warranty for our consumables, which is generally limited to replacing, or at our option, giving credit for any consumable with defects in material or workmanship. Defects or errors in our products may also discourage customers from purchasing our products. The costs incurred in correcting any defects or errors may be substantial and could materially and adversely affect our operating margins. If our service and support costs increase, our business and operations may be materially and adversely affected.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044534" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, such defects or errors could lead to the filing of product liability claims against us or against third parties who we may have an obligation to indemnify against such claims, which could be costly and time-consuming to defend and result in substantial damages. Although we have product liability insurance, any product liability insurance that we have or procure in the future may not protect our business from the financial impact of a product liability claim. Moreover, we may not be able to obtain adequate insurance coverage on acceptable terms. Any insurance that we have or obtain will be subject to deductibles and coverage limits. A product liability claim could have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">A significant portion of our sales depends on customers&#8217; spending budgets that may be subject to significant and unexpected variation which could have a negative effect on the demand for our products.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our instruments represent significant capital expenditures for our customers in research applications. Current and potential customers for our current or future products include academic and government institutions, genome centers, medical research institutions, clinical laboratories, pharmaceutical, agricultural, biotechnology, diagnostic and chemical companies. Their spending budgets can have a significant effect on the demand for our products. Spending budgets are based on a wide variety of factors, including the allocation of available resources to make purchases, funding from government sources which is highly uncertain and subject to change, the spending priorities among various types of research equipment, policies regarding capital expenditures during economically uncertain periods and the impact of COVID-19. Any decrease in capital spending or change in spending priorities of our current and potential customers could significantly reduce the demand for our products. Any delay or reduction in purchases by current or potential customers or our inability to forecast fluctuations in demand could materially and adversely harm our future operating results.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may not be able to convert our orders in backlog into revenue.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our backlog represents product orders from our customers that we have confirmed but have not been able to fulfill, and, accordingly, for which we have not yet recognized revenue. We may not receive revenue from these orders, and&#160;any&#160;order backlog we report may not be indicative of our future revenue.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Many events can cause an order to be delayed or not completed at all, some of which may be out of our control, including the potential impacts from COVID-19 and our suppliers, especially our sole source suppliers, not being able to provide us with products or components. If we delay fulfilling customer orders or if customers reconsider their orders, those customers may seek to cancel or modify their orders with us. Customers may otherwise seek to cancel or delay their orders even if we are prepared to fulfill them. If our orders in backlog do not result in sales, our operating results may suffer.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our sales cycle is unpredictable and lengthy, which makes it difficult to forecast revenue and may increase the magnitude of quarterly or annual fluctuations in our operating results.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The sales cycle for our sequencing instruments is lengthy because they represent a major capital expenditure and generally require the approval of our customers&#8217; senior management. This may contribute to substantial fluctuations in our quarterly or annual operating results, particularly during the periods in which our sales volume is low. Factors that may cause fluctuations in our quarterly or operating results include, without limitation, market acceptance for our products; our ability to attract new customers; publications of studies by us, competitors or third parties; the timing and success of new product introductions by us or our competitors or other changes in the competitive dynamics of our industry, such as consolidation; the amount and timing of our costs and expenses; changes in our pricing policies or those of our competitors; general economic, industry and market conditions; the effects of seasonality; the regulatory environment; expenses associated </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">25</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">with warranty costs or unforeseen product quality issues; the hiring, training and retention of key employees, including our ability to grow our sales organization; litigation or other claims against us for intellectual property infringement or otherwise; our ability to obtain additional financing as necessary; changes or trends in new technologies and industry standards; and the impact of COVID-19. Because of these fluctuations, it is likely that in some future quarters our operating results will fall below the expectations of securities analysts or investors. If that happens, the market price of our stock would likely decrease. Past fluctuations in our quarterly and annual operating results have resulted in decreases in our stock price. Such fluctuations also mean that investors may not be able to rely on our operating results in any particular period as an indication of future performance. Sales to existing customers and the establishment of a business relationship with other potential customers is a lengthy process, generally taking several months and sometimes longer. Following the establishment of the relationship, the negotiation of purchase terms can be time-consuming, and a potential customer may require an extended evaluation and testing period. In anticipation of product orders, we may incur substantial costs before the sales cycle is complete and before we receive any customer payments. As a result, in the event that a sale is not completed or is canceled or delayed, we may have incurred substantial expenses, making it more difficult for us to become profitable or otherwise negatively impacting our financial results. Furthermore, because of our lengthy sales cycle, the realization of revenue from our selling efforts may be substantially delayed, our ability to forecast our future revenue may be more limited and our revenue may fluctuate significantly from quarter to quarter.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Because some of our customers and suppliers are based in China, our business, financial condition and results of operations could be adversely affected by the political and economic tensions between the United States and China.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are subject to risks associated with political conflicts between the U.S. and China. A significant portion of our revenue is generated from China. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For example, for the fiscal years ended December 31, 2021, 2020 and 2019, Gene Company Limited, our primary distributor in China, accounted for approximately 13%, 14% and 17% of our total revenue, respectively. In addition, certain c</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">omponents, some of which are critical components, of our products are manufactured in China. These components are either sourced directly from companies in China or indirectly from third parties that source from companies in China.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The imposition of tariffs or other trade barriers between the U.S. and China, including the tariffs previously implemented and additional tariffs that have been proposed by the U.S. government on various imports from China and by the Chinese government on certain U.S. goods, the scope and duration of which, if implemented, remain uncertain. Beginning in September 2018, the U.S. Trade Representative (the &#8220;USTR&#8221;) enacted various tariffs of 7.5%, 10%, 15% and 25% on the import of Chinese products, including non-U.S. components and materials that may be used in our products. These tariffs could raise our costs. Additionally, in November 2018, the U.S. Commerce Department&#8217;s Bureau of Industry and Security (&#8220;BIS&#8221;) released an advance notice of proposed rulemaking to control the export of emerging technologies.&#160; This notice included &#8220;[b]iotechnology, including nanobiology; synthetic biology; genomic and genetic engineering; or neurotech&#8221; as possible areas of increased export controls.&#160;Therefore, it is possible that our ability to export our products to China may be restricted in the future. China also has imposed tariffs on imports into China from the United States. Given the relatively fluid regulatory environment in China and the United States and uncertainty how the U.S. or foreign governments will act with respect to tariffs, international trade agreements and policies, there could be additional tax or other regulatory changes in the future. Any such changes could directly and adversely impact our financial results and results of operations. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other risks could include:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">interruptions to operations in China as a result of the COVID-19 pandemic or other disease outbreaks and natural catastrophic events, which have in the past and can result in the future in business closures, transportation restrictions, import and export complications and cause shortages in the supply of raw materials or disruptions in manufacturing;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">product supply disruptions and increased costs as a result of heightened exposure to changes in the policies of the Chinese government, political unrest or unstable economic conditions in China; and</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the nationalization or other expropriation of private enterprises or intellectual property by the Chinese governm</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ent.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Difficulties in this relationship may require us to take actions adverse to our business to comply with governmental restrictions on business and&#160;trade&#160;with&#160;China.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">26</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, our consumable chips are partly manufactured by a company based in Taiwan. Accordingly, there is a risk that current political tensions between China and Taiwan may lead to circumstances that negatively affect the availability of such consumable chips to us, which could lead to an increase in our supply costs if we cannot find a similar cost alternative supplier, resulting in an adverse impact to our financial results and results of operations.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="RiskFactors_Seasonalitymaycause" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Seasonality may cause fluctuations in our revenue and results of operations. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We operate on a December&#160;31st year-end and believe that there are significant seasonal factors which may cause sales of our products, and particularly our sequencing instruments, to vary on a quarterly or yearly basis, contribute to the lengthy sales cycle for our sequencing instruments, and increase the magnitude of quarterly or annual fluctuations in our operating results. We believe that this seasonality results from a number of factors, including the procurement and budgeting cycles of many of our customers, especially government-funded customers, which often coincide with government fiscal year ends. For example, the U.S. government&#8217;s fiscal year-end occurs in our third quarter and may result in increased sales of our products during this quarter if government-funded customers have unused funds that may be forfeited, or future budgets that may be reduced if funds remain unspent at fiscal year-end. Furthermore, Lunar New Year celebrations, which occur during our first quarter, and may last for a week or longer, resulting in closure of many of our customers&#8217; offices in China and across the Asia-Pacific region have caused, and may in the future cause, decreased sales of our consumables during our first quarter. These factors have contributed, and may contribute in the future, to substantial fluctuations in our quarterly operating results. Because of these fluctuations, it is possible that in some quarters our operating results will fall below the expectations of securities analysts or investors. If that happens, the market price of our stock would likely decrease. These fluctuations, among other factors, also mean that our operating results in any particular period may not be relied upon as an indication of future performance. Seasonal or cyclical variations in our sales have in the past, and may in the future, become more or less pronounced over time, and have in the past materially affected, and may in the future materially affect, our business, financial condition, results of operations and prospects.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our ability to use net operating losses to offset future taxable income may be subject to substantial limitations, and changes to U.S. tax laws may cause us to make adjustments to our financial statements.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Under Section&#160;382 of the Internal Revenue Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating losses (&#8220;NOLs&#8221;) to offset future taxable income. We believe that we have had one or more ownership changes, as a result of which our existing NOLs are currently subject to limitation. Future changes in our stock ownership could result in additional ownership changes under Section&#160;382. We may not be able to utilize a material portion of our NOLs even if we attain profitability.  Furthermore, the changes to deductions, credits and expense recognition resulting from the Tax Cuts and Jobs Act of 2018 enacted on December 22, 2017, have materially impacted the value of our deferred tax assets and liabilities, and could adversely affect our future taxable income and effective tax rate. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our facilities in California are located near earthquake faults, and the occurrence of an earthquake or other catastrophic disaster could cause damage to our facilities and equipment, which could require us to cease or curtail operations.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our facilities in the San Francisco Bay Area are located near earthquake fault zones and are vulnerable to damage from earthquakes. We are also vulnerable to damage from other types of disasters, including fire, floods, power loss, communications failures and similar events. If any disaster were to occur, our ability to operate our business at our facilities would be seriously, or potentially completely, impaired. In addition, the nature of our activities could cause significant delays in our research programs and commercial activities and make it difficult for us to recover from a disaster. The insurance we maintain may not be adequate to cover our losses resulting from disasters or other business interruptions. Accordingly, an earthquake or other disaster could materially and adversely harm our ability to conduct business.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">27</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to Our Intellectual Property</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Failure to secure patent or other intellectual property protection for our products and improvements to our products may reduce our ability to maintain any technological or competitive advantage over our current and potential competitors.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our ability to protect and enforce our intellectual property rights is uncertain and depends on complex legal and factual questions. Our ability to establish or maintain a technological or competitive advantage over our competitors may be diminished because of these uncertainties. For example:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we or our licensors might not have been the first to make the inventions covered by each of our pending patent applications or issued patents;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we or our licensors might not have been the first to file patent applications for these inventions;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">it is possible that neither our pending patent applications nor the pending patent applications of our licensors will result in issued patents;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the scope of the patent protection we or our licensors obtain may not be sufficiently broad to prevent others from practicing our technologies, developing competing products, designing around our patented technologies or independently developing similar or alternative technologies;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our and our licensors&#8217; patent applications or patents have been, are and may in the future be, subject to interference, opposition or similar administrative proceedings, which could result in those patent applications failing to issue as patents, those patents being held invalid or the scope of those patents being substantially reduced;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our enforcement of patents and proprietary rights in other countries may be problematic or unpredictable;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions;&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we or our partners may not adequately protect our trade secrets;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we may not develop additional proprietary technologies that are patentable; or</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the patents of others may limit our freedom to operate and prevent us from commercializing our technology in accordance with our plans.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The occurrence of any of these events could impair our ability to operate without infringing upon the proprietary rights of others or prevent us from establishing or maintaining a competitive advantage over our competitors.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Variability in intellectual property laws may adversely affect our intellectual property position.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intellectual property laws, and patent laws and regulations in particular, have been subject to significant variability either through administrative or legislative changes to such laws or regulations or changes or differences in judicial interpretation, and it is expected that such variability will continue to occur. Additionally, intellectual property laws and regulations differ by country. Variations in the patent laws and regulations or in interpretations of patent laws and regulations in the United States and other countries may diminish the value of our intellectual property and may change the impact of third-party intellectual property on us. Accordingly, we cannot predict the scope of the patents that may be granted to us with certainty, the extent to which we will be able to enforce our patents against third parties or the extent to which third parties may be able to enforce their patents against us.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Some of the intellectual property that is important to our business is owned by other companies or institutions and licensed to us, and changes to the rights we have licensed may adversely impact our business.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044577" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We license from third parties some of the intellectual property that is important to our business. If the third parties who license intellectual property to us fail to maintain the intellectual property that we have licensed, or lose rights to that intellectual property, the rights we have licensed may be reduced or eliminated, which would eliminate barriers against our competition. Termination of these licenses or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, or could subject us to claims of intellectual property </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">28</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">infringement or contract breach in litigation or other administrative proceedings that could result in damage awards against us and injunctions that could prohibit us from selling our products. In addition, some of our licenses from third parties limit the field in which we can use the licensed technology. Therefore, in order for us to use such licensed technology in potential future applications that are outside the licensed field of use, we may be required to negotiate new licenses with our licensors or expand our rights under our existing licenses. We cannot be certain that we will be able to obtain such licenses or expanded rights on reasonable terms or at all. In the event a dispute with our licensors were to occur, our licensors may seek to renegotiate the terms of our licenses, increase the royalty rates that we pay to obtain and maintain those licenses, limit the field or scope of the licenses, or terminate the license agreements. In addition, we have limited rights to participate in the prosecution and enforcement of the patents and patent applications that we have licensed. If we fail to meet our obligations under these licenses, or if we have a dispute regarding the terms of the licenses, these third parties could terminate the licenses, which could subject us to claims of intellectual property infringement. As a result, we cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business. Further, because of the rapid pace of technological change in our industry, we may need to rely on key technologies developed or licensed by third parties, and we may not be able to obtain licenses and technologies from these third parties at all or on reasonable terms. The occurrence of these events may have a material adverse effect on our business, financial condition or results of operations.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The measures that we use to protect the security of and enforce our intellectual property and other proprietary rights may not be adequate, which could result in the loss of legal protection for, and thereby diminish the value of, such intellectual property and other rights.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition to patents, we also rely upon trademarks, trade secrets, copyrights and unfair competition laws, as well as license agreements and other contractual provisions, to protect our intellectual property and other proprietary rights. Despite these measures, any of our intellectual property rights could be challenged, invalidated, circumvented or misappropriated. In addition, we attempt to protect our intellectual property and proprietary information by requiring our employees and consultants to enter into confidentiality and assignment of inventions agreements, and by entering into confidentiality agreements with our third-party development, manufacturing, sales and distribution partners, who may also acquire, develop and/or commercialize alternative or competing products or provide services to our competitors. For example, Roche had certain access to our trade secrets and other proprietary information pursuant&#160;to&#160;our agreement with them, subject to the confidentiality provisions thereof&#160;(certain of&#160;which provisions survive the termination of the agreement); however, Roche is developing potentially competing sequencing products. There can be no assurance that our measures have provided or will provide adequate protection for our intellectual property and proprietary information. These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets and other proprietary information may be disclosed to others, or others may gain access to or disclose our trade secrets and other proprietary information. Enforcing a claim that a third party illegally obtained and is using our trade secrets is expensive and time consuming, and the outcome is unpredictable. Additionally, others may independently develop proprietary information and techniques that are substantially equivalent to ours. The occurrence of these events may have a material adverse effect on our business, financial condition or results of operations.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our intellectual property may be subject to challenges in the United States or foreign jurisdictions that could adversely affect our intellectual property position.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044623" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our pending, issued and granted U.S. and foreign patents and patent applications have been, are and may in the future be, subject to challenges by ONT Ltd., ONT Inc. and Metrichor, Ltd. (&#8220;Metrichor&#8221; and, together with ONT Ltd. and ONT Inc., &#8220;ONT&#8221;) in addition to other parties asserting prior invention by others or invalidity on various grounds, through proceedings, such as </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">interferences</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, reexaminations or opposition proceedings. Addressing these challenges to our intellectual property has been, and any future challenges can be, costly and distract management&#8217;s attention and resources. For example, we previously incurred significant legal expenses to litigate and settle a complaint seeking review of a patent interference decision of the U.S. Patent and Trademark Office. Additionally, ONT previously requested that the U.S. Patent and Trademark Office institute </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">inter partes</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> reviews of certain patents that we have asserted against ONT Inc. and ONT Ltd. in litigation proceedings for patent infringement. While none of the </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">inter partes</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> reviews requested by ONT were instituted by the U.S. Patent and Trademark Office, challenges of this nature in the future could result in determinations that our patents or pending patent applications are unpatentable to us, or are invalidated or unenforceable in whole or in part and could require us to expend significant time, funds, and other resources in litigating such challenges. Accordingly, adverse rulings </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">29</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">in such proceedings could negatively impact the scope of our intellectual property protection for our products and technology, and could materially and adversely affect our business.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Some of our technology is subject to &#8220;march-in&#8221; rights by the U.S. government.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Some of our patented technology was developed with U.S. federal government funding. When new technologies are </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">developed</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> with U.S. government funding, the government obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise &#8220;march-in&#8221; rights to use or allow third parties to use our patented technology. The government can exercise its march-in rights if it determines that such action is necessary to (i) achieve practical application of the U.S. government-funded technology, (ii) alleviate health or safety needs, (iii) meet requirements of federal regulations, or (iv)&#160;give preference to U.S. industry. In addition, U.S. government-funded inventions must be reported to the government and such government funding must be disclosed in any resulting patent applications. Furthermore, our rights in such inventions are subject to government license rights and foreign manufacturing restrictions. The U.S. government has generally denied requests to exercise its march-in rights, even to provide access to potentially life-saving medications; however, if the U.S. government were to exercise its march-in rights to our patent technologies funded by the U.S. government, particularly for the benefit of one of more of our competitors, that may have a material adverse effect on our business.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We are involved in legal proceedings to enforce our intellectual property rights.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk64044650" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our intellectual property rights involve complex factual, scientific and legal questions. We operate in an industry characterized by significant intellectual property litigation. Even though we may believe that we have a valid patent on a particular technology, other companies have from time to time taken, and may in the future take, actions that we believe violate our patent rights. For example, we are involved in legal proceedings for patent infringement and related matters in the United States with PGI, and we were previously involved in other legal proceedings with ONT and Harvard University in several United States and European jurisdictions. We have in the past received adverse rulings against us with respect to our complaint with the United States International Trade Commission for one of these proceedings. Legal actions to enforce our patent rights have been, and will continue to be, expensive, and may divert significant management time and resources. Adverse parties from previous legal actions have brought, and they and others may in the future bring, claims against us and/or our intellectual property. Litigation is a significant ongoing expense, recognized in sales, general and administrative expense, with an uncertain outcome, and has been, and may in the future be, a material expense for us. Our enforcement actions may not be successful, have given rise to legal claims against us and could result in some of our intellectual property rights being determined to be invalid or not enforceable. Furthermore, an adverse determination or judgement could lead to an award of damages against us, or the issuance of an injunction against us or our products that could prevent us from selling any products found to be infringing the intellectual property rights of another party.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">30</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We have been, are currently, and could in the future be, subject to legal proceedings with third parties who may claim that our products infringe or misappropriate their intellectual property rights.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our products are based on complex, rapidly developing technologies. We may not be aware of issued or previously filed patent applications that belong to third parties that mature into issued patents that cover some aspect of our products or their use. In addition, because patent litigation is complex and the outcome inherently uncertain, our belief that our products do not </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">infringe</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> third-party patents of which we are aware or that such third-party patents are invalid and unenforceable may be determined to be incorrect. As a result, third parties have claimed, and may in the future claim, that we infringe their patent rights and have filed, and may in the future file lawsuits or engage in other proceedings against us to enforce their patent rights. For example, ONT Ltd. and Harvard University have, in the past, filed claims against us in the High Court of England and Wales and the District Court of Mannheim, Germany for patent infringement, and Personal Genomics of Taiwan, Inc. (&#8220;PGI&#8221;) has filed claims against us in the U.S. District Court for the District of Delaware and </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">in </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the Wuhan People&#8217;s Court in China. We are aware of other issued patents and patent applications owned by third parties that could be construed to read on our products, and related maintenance and support services. Although we do not believe that our products or services infringe any valid issued patents, the third-party owners of these patents and applications may in the future claim that we infringe their patent rights and file lawsuits against us. In addition, as we enter new markets, our competitors and other third parties may claim that our products infringe their intellectual property rights as part of a business strategy to impede our successful entry into those markets. Furthermore, parties making claims against us may be able to obtain injunctive or other relief, which effectively could block our ability to further develop or commercialize products or services, and could result in the award of substantial damages against us. Patent litigation between competitors in our industry is common. Additionally, we have certain obligations to many of our customers and suppliers to indemnify and defend them against claims by third parties that our products or their use infringe any intellectual property of these third parties. In defending ourselves against any of these claims, we have in the past incurred, and could in the future incur, to defend ourselves or our customers, substantial costs, and the attention of our management and technical personnel could be diverted. For example, we previously incurred significant legal expenses to litigate and settle a complaint alleging patent infringement. Even if we have an agreement that indemnifies us against such costs, the indemnifying party may be unable to uphold its contractual obligations. To avoid or settle legal claims, it may be necessary or desirable in the future to obtain licenses relating to one or more products or relating to current or future technologies, which could negatively affect our gross margins. We may not be able to obtain these licenses on commercially reasonable terms, or at all. We may be unable to modify our products so that they do not infringe the intellectual property rights of third parties. In some situations, the results of litigation or settlement of claims may require us to cease allegedly infringing activities which could prevent us from selling some or all of our products. The occurrence of these events may have a material adverse effect on our business, financial condition or results of operations.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, in the course of our business, we may from time to time have access or be alleged to have access to confidential or proprietary information of others, which, though not patented, may be protected as trade secrets. Others could bring claims against us asserting that we improperly used their confidential or proprietary information, or that we misappropriated their technologies and incorporated those technologies into our products. A determination that we illegally used the confidential or proprietary information or misappropriated technologies of others in our products could result in us paying substantial damage awards or being prevented from further developing or selling some or all of our products, which could materially and adversely affect our business.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We have not yet registered some of our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Some of our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. In addition, in the U.S. Patent and Trademark Office and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our use of &#8220;open source&#8221; software could adversely affect our ability to sell our products and subject us to possible litigation.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A portion of the products or technologies developed and/or distributed by us incorporate &#8220;open source&#8221; software, and we may incorporate open source software into other products or technologies in the future. Some open source software </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">31</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">licenses require that we disclose the source code for any modifications to such open source software that we make and distribute to one or more third parties, and that we license the source code for such modifications to third parties, including our competitors, at no cost. We monitor the use of open source software in our products to avoid uses in a manner that would require us to disclose or grant licenses under our source code that we wish to maintain as proprietary; however, there can be no assurance that such efforts have been or will be successful. In some circumstances, distribution of our software that includes or is linked with open source software could require that we disclose and license some or all of our proprietary source code in that software, which could include permitting the use of such software and source code at no cost to the user. Open source license terms are often ambiguous and there is little legal precedent governing the interpretation of these licenses. Successful claims made by the licensors of open source software that we have violated the terms of these licenses could result in unanticipated obligations, including being subject to significant damages, being enjoined from distributing products that incorporate open source software and being required to make available our proprietary source code pursuant to an open source license, which could substantially help our competitors develop products that are similar to or better than ours or otherwise materially and adversely affect our business.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">32</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to Regulation </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We are, and may become, subject to governmental regulations that may impose burdens on our operations, and the markets for our products may be narrowed.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are subject, both directly and indirectly, to the adverse impact of government regulation of our operations and markets. For example, export of our instruments may be subject to strict regulatory control in a number of jurisdictions.&#160;We have expanded and are continuing to expand the international jurisdictions into which we supply products, which increase the risks surrounding governmental regulations relating to our business.&#160;The failure to satisfy export control criteria or to obtain necessary clearances could delay or prevent shipment of products, which could materially and adversely affect our revenue and profitability. Moreover, the life sciences industry, which is expected to continue to be one of the primary markets for our technology, has historically been heavily regulated. There are, for example, laws in several jurisdictions restricting research in genetic engineering, which may narrow our markets. Given the evolving nature of this industry, legislative bodies or regulatory authorities may adopt additional regulations that may adversely affect our market opportunities. Additionally, if ethical and other concerns surrounding the use of genetic information, diagnostics or therapies become widespread, there may be less demand for our products.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our business is also directly affected by a wide variety of government regulations applicable to business enterprises generally and to companies operating in the life science industry in particular. Failure to comply with government regulations or obtain or maintain necessary permits and licenses could result in a variety of fines or other censures or an interruption in our business operations which may have a negative impact on our ability to generate revenue and the cost of operating our business.&#160;&#160;In addition, changes to laws and government regulations could cause a material adverse effect on our business as we will need to adapt our business to comply with such changes. For example, a governmental prohibition on the use of human&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">in vitro</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;diagnostics or other regulations that negatively impact the research and development activities of our customers would adversely impact our commercialization of products on which we have expended significant research and development resources, which would in turn have a material adverse impact on our business and prospects.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our products could become subject to </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">government regulation as medical devices</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> by the U.S. Food and Drug Administration or other domestic and international regulatory agencies </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">even if we do not elect to seek regulatory clearance or approval to market our products for diagnostic purposes</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">, which could increase our costs and impede or delay our commercialization efforts, thereby materially and adversely affecting our business and results of operations.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our products are currently labeled and promoted as research use only (&#8220;RUO&#8221;) products, and are not currently designed, or intended to be used, for clinical diagnostic tests or as medical devices. However, in the future, certain of our products or related applications, such as those that may be developed for clinical uses, could be subject  regulation by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), or the FDA&#8217;s regulatory jurisdiction could be expanded to include our products.  Also, even if our products are labeled, promoted, and intended as RUO, the FDA or comparable agencies of other countries could disagree with our conclusion that our products are intended for research use only or deem our sales, marketing and promotional efforts as being inconsistent with the FDA&#8217;s guidance on RUO products. For example, our customers may independently elect to use our RUO labeled products in their own laboratory developed tests (&#8220;LDTs&#8221;) for clinical diagnostic use, which could subject our products to government regulation, and the regulatory clearance or approval and maintenance process for such products may be uncertain, expensive, and time-consuming. Regulatory requirements related to marketing, selling, and distribution of RUO products could change or be uncertain, even if clinical uses of our RUO products by our customers were done without our consent. If the FDA or other regulatory authorities assert that any of our RUO products are subject to regulatory clearance or approval, our business, financial condition, or results of operations could be adversely affected. In the event that we fail to obtain and maintain necessary regulatory clearances or approvals for products that we develop for clinical uses, or if clearances or approvals for future products and indications are delayed or not issued, our commercial operations may be materially harmed. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the product, which may limit the market for the product. We do not have experience in obtaining FDA approvals and no assurance can be given that we will be able to obtain or to maintain such approvals. Furthermore, any approvals that we may obtain can be revoked if safety or efficacy problems develop.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">33</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA has historically exercised enforcement discretion in not enforcing the medical device regulations against laboratories developing and offering LDTs. However, on October 3, 2014, the FDA issued two draft guidance documents that set forth the FDA&#8217;s proposed risk-based framework for regulating LDTs, which are designed, manufactured, and used within a single laboratory. The draft guidance documents provide the anticipated details through which the FDA would propose to establish an LDT oversight framework, including premarket review for higher-risk LDTs, such as those that have the same intended use as FDA-approved or cleared companion diagnostic tests currently on the market. In January 2017, the FDA announced that it would not issue final guidance on the oversight of LDTs and manufacturers of products used for LDTs, but would seek further public discussion on an appropriate oversight approach, and give Congress an opportunity to develop a legislative solution. More recently, the FDA has issued warning letters to certain genomics labs for illegally marketing genetic tests that claim to predict patients&#8217; responses to specific medications, noting that the FDA has not created a legal &#8220;carve-out&#8221; for LDTs and retains discretion to take action when appropriate, such as when certain genomic tests raise significant public health concerns. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As manufacturers develop more complex diagnostic tests and diagnostic software, the FDA may increase its regulation of LDTs. Any future legislative or administrative rule making or oversight of LDTs, if and when finalized, may impact the sales of our products and how customers use our products, and may require us to change our business model in order to maintain compliance with these laws. We cannot predict how these various efforts will be resolved, how Congress or the FDA will regulate LDTs in the future, or how that regulatory system will impact our business. Changes to the current regulatory framework, including the imposition of additional or new regulations, including regulation of our products, could arise at any time during the development or marketing of our products, which may negatively affect our ability to obtain or maintain FDA or comparable regulatory approval of our products, if required. Further, sales of devices for diagnostic purposes may subject us to additional healthcare regulation and enforcement by the applicable government agencies. Such laws include, without limitation, state and federal anti-kickback or anti-referral laws, healthcare fraud and abuse laws, false claims laws, privacy and security laws, Physician Payments Sunshine Act and related transparency and manufacturer reporting laws, and other laws and regulations applicable to medical device manufacturers. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additionally, on November 25, 2013, the FDA issued Final Guidance &#8220;Distribution of In Vitro Diagnostic Products Labeled for Research Use Only.&#8221; The guidance emphasizes that the FDA will review the totality of the circumstances when it comes to evaluating whether equipment and testing components are properly labeled as RUO. The final guidance states that merely including a labeling statement that the product is for research purposes only will not necessarily render the device exempt from the FDA&#8217;s clearance, approval, and other regulatory requirements if the circumstances surrounding the distribution, marketing and promotional practices indicate that the manufacturer knows its products are, or intends for its products to be, used for clinical diagnostic purposes. These circumstances may include written or verbal sales and marketing claims or links to articles regarding a product&#8217;s performance in clinical applications and a manufacturer&#8217;s provision of technical support for clinical applications. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As part of the Trump Administration&#8217;s efforts to combat COVID-19 and consistent with Executive Orders 13771 and 13924, the Department of Health and Human Services (&#8220;HHS&#8221;) announced rescission of guidance and other informal issuances of the FDA regarding premarket review of LDT absent notice-and-comment rulemaking, stating that, absent notice-and-comment rulemaking, those seeking approval or clearance of, or an emergency use authorization (&#8220;EUA&#8221;), for an LDT may nonetheless voluntarily submit a premarket approval application (&#8220;PMA&#8221;), premarket notification or an Emergency Use Authorization request, respectively, but are not required to do so. However, laboratories opting to use LDTs without FDA premarket review or authorization would not be eligible for liability protection under the Public Readiness and Emergency Preparedness Act. In November 2021, HHS under the Biden Administration issued a statement that withdrew the 2020 policy announcement issued under the Trump Administration, stating that HHS does not have a policy on LDTs that is separate from FDA&#8217;s longstanding approach. The FDA also issued a revised version of its COVID-19 test policy that states the FDA expects newly offered COVID-19 tests, including LDTs, to have an EUA, or traditional marketing authorization such as a granted De Novo or cleared 510(k), prior to clinical use. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Further, in June 2021, Congress introduced an updated legislation called the Verifying Accurate, Leading-edge IVCT Development Act (VALID Act), which, if enacted, will establish a new risk-based regulatory framework for in vitro clinical tests (IVCTs), which include IVDs, LDTs, collection devices, and instruments used with such tests, and a technology certification program, among other proposals. The adoption of new restrictions on IVDs, LDTs, or RUOs, whether by the FDA or Congress, could adversely affect our ability to commercialize our products and the demand for our specialized reagents </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">34</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and instruments. Further, we could be required to obtain premarket clearance or approval from the FDA before we can sell our products to certain customers.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If the FDA determines our products or related applications should be subject to additional regulation as in vitro diagnostic devices based upon customers&#8217; use of our products for clinical diagnostic or therapeutic decision-making purposes, our ability to market and sell our products could be impeded and our business, prospects, results of operations and financial condition may be adversely affected. In addition, the FDA could consider our products to be misbranded or adulterated under the Federal Food, Drug, and Cosmetic Act and subject to recall and/or other enforcement action.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">To the extent we elect to label and promote any of our products as medical devices, we would be required to obtain prior approval or clearance by the FDA or comparable foreign regulatory authority, which could take significant time and expense and could fail to result in a marketing authorization for the intended uses we believe are commercially attractive. Obtaining marketing authorization in one jurisdiction does not mean that we will be successful in obtaining marketing authorization in other jurisdictions where we conduct business.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If we elect to label and market our products for use as, or in the performance of, clinical diagnostics in the United States, thereby subjecting them to FDA regulation as medical devices, we would be required to obtain premarket 510(k) clearance or premarket approval from the FDA, unless an exception applies. It is possible, in the event we elect to submit 510(k) applications for certain of our products, that the FDA would take the position that a more burdensome premarket application, such as a PMA or a </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">de novo</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> application is required for some of our products. If such applications were required, greater time and investment would be required to obtain FDA approval. Even if the FDA agreed that a 510(k) was appropriate, FDA clearance can be expensive and time consuming. It generally takes a significant amount of time to prepare a 510(k), including conducting appropriate testing on our products, and several months to years for the FDA to review a submission. Notwithstanding the effort and expense, FDA clearance or approval could be denied for some or all of our products for which we choose to market as a medical device or a clinical diagnostic device. Even if we were to seek and obtain regulatory approval or clearance, it may not be for the intended uses we request or that we believe are important or commercially attractive. There can be no assurance that future products for which we may seek premarket clearance or approval will be approved or cleared by FDA or a comparable foreign regulatory authority on a timely basis, if at all, nor can there be assurance that labeling claims will be consistent with our anticipated claims or adequate to support continued adoption of such products. Compliance with FDA or comparable foreign regulatory authority regulations will require substantial costs, and subject us to heightened scrutiny by regulators and substantial penalties for failure to comply with such requirements or the inability to market our products. The lengthy and unpredictable premarket clearance or approval process, as well as the unpredictability of the results of any required clinical studies, may result in our failing to obtain regulatory clearance or approval to market such products, which would significantly harm our business, results of operations, reputation, and prospects.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If we sought and received regulatory clearance or approval for certain of our products, we would be subject to ongoing FDA obligations and continued regulatory oversight and review, including the general controls listed above and the FDA&#8217;s QSRs for our development and manufacturing operations. In addition, we would be required to obtain a new 510(k) clearance before we could introduce subsequent material modifications or improvements to such products. We could also be subject to additional FDA post-marketing obligations for such products, any or all of which would increase our costs and divert resources away from other projects. If we sought and received regulatory clearance or approval and are not able to maintain regulatory compliance with applicable laws, we could be prohibited from marketing our products for use as, or in the performance of, clinical diagnostics and/or could be subject to enforcement actions, including warning letters and adverse publicity, fines, injunctions, and civil penalties; recall or seizure of products; operating restrictions; and criminal prosecution.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Further, if we decide to seek regulatory clearance or approval for certain of our products in countries outside of the United States or if a foreign regulatory authority determines that our products are regulated as medical devices, we would be subject to extensive medical device laws and regulations outside of the United States. Sales of such products outside the United States will likely be subject to foreign regulatory requirements, which can vary greatly from country to country. As a result, the time required to obtain clearances or approvals outside the United States may differ from that required to obtain FDA clearance or approval and we may not be able to obtain foreign regulatory approvals on a timely basis or at all. In Europe, we would need to comply with the new Medical Device Regulation 2017/745 and In Vitro Diagnostic Regulation 2017/746, which became effective May 26, 2017, with application dates of May 26, 2021 (postponed from 2020) and May 26, 2022, respectively. This will increase the difficulty of regulatory approvals in Europe in the future. In addition, the FDA </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">35</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">regulates exports of medical devices. </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The number and scope of these requirements are increasing. Unlike many of the other companies offering nucleic acid sequencing equipment or consumables, this is an area where we do not have expertise. We, or our other third-party sales and distribution partners, may not be able to obtain regulatory approvals in such countries or may incur significant costs in obtaining or maintaining our foreign regulatory approvals. In addition, the export by us of certain of our products, which have not yet been cleared for domestic commercial distribution, may be subject to FDA or other export restrictions.</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Failure to comply with these regulatory requirements or obtain and maintain required approvals, clearances and certifications could impair our ability to commercialize our products for diagnostic use outside of the United States.</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Any action brought against us for violations of these laws or regulations, even if successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Enhanced trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers may materially harm our business. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are continuing to expand our international operations as part of our growth strategy and have experienced an increasing concentration of sales in certain regions outside the United States, especially the Asia-Pacific region. There is currently significant uncertainty about the future relationship between the United States and various other countries, most significantly China, with respect to trade policies, treaties, government regulations and tariffs. Starting in </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">September 2018, the U.S. Trade Representative (the &#8220;USTR&#8221;) enacted various tariffs of 7.5%, 10%, 15% and 25% on the import of Chinese products, including </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">non-U.S. components and materials that may be used in our products. Additionally, China also has imposed tariffs on imports into China from the United States. These tariffs could raise our costs. Furthermore, tariffs, trade restrictions, or trade barriers that have been, and may in the future be, placed on products such as ours by foreign governments, especially China, have raised, and could further raise, amounts paid for some or all of our products, which may result in the loss of customers and our business, and our financial condition and results of operations may be harmed. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">F</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">urther tariffs may be imposed that could cover imports of components and materials used in our products, or our business may be adversely impacted by retaliatory trade measures taken by China or other countries, including restricted access to components or materials used in our products or increased amounts that must be paid for our products, which could materially harm our business, financial condition and results of operations.  Further, the continued threats of tariffs, trade restrictions and trade barriers could have a generally disruptive impact on the global economy and, therefore, negatively impact our sales. Given the relatively fluid regulatory environment in China and the United States and uncertainty how the U.S. or foreign governments will act with respect to tariffs, international trade agreements and policies, there could be additional tax or other regulatory changes in the future. Any such changes could directly and adversely impact our financial results and results of operations.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additionally, in November 2018, the U.S. Commerce Department&#8217;s Bureau of Industry and Security (&#8220;BIS&#8221;) released an advance notice of proposed rulemaking to control the export of emerging technologies.&#160; This notice included &#8220;[b]iotechnology, including nanobiology; synthetic biology; genomic and genetic engineering; or neurotech&#8221; as possible areas of increased export controls.&#160; BIS has implemented export controls on some items described in this notice, and we understand that BIS plans to continue to issue controls on additional emerging technologies. Therefore, it is possible that our ability to export our products may be restricted in the future, most notably China.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our international business could expose us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Engaging in international business inherently involves a number of difficulties and risks, including:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">r</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">equired compliance with existing and changing foreign regulatory requirements and laws that are or may be applicable to our business in the future, such as the European Union&#8217;s General Data Protection Regulation (&#8220;GDPR&#8221;) and other data privacy requirements, labor and employment regulations, anti-competition regulations, the U.K. Bribery Act of 2010 and other anti-corruption laws, regulations relating to the use of certain hazardous substances or chemicals in commercial products, and require the collection, reuse, and recycling of waste from products we manufacture;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">required compliance with U.S. laws such as the Foreign Corrupt Practices Act, and other U.S. federal laws and regulations established by the Office of Foreign Asset Control;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">export requirements and import or trade restrictions;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">36</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">laws and business practices favoring local companies;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">foreign currency exchange, longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">changes in social, economic, and political conditions or in laws, regulations and policies governing foreign trade, manufacturing, research and development, and investment both domestically as well as in the other countries and jurisdictions in which we operate and into which we may sell our products including as a result of the separation of the United Kingdom from the European Union (&#8220;Brexit&#8221;);</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements, and other trade barriers;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">difficulties and costs of staffing and managing foreign operations; and</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">difficulties protecting, maintaining, enforcing or procuring intellectual property rights and defending against intellectual property claims under the law and judicial systems of other countries.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If one or more of these risks occurs, it could require us to dedicate significant resources to remedy such occurrence, and if we are unsuccessful in finding a solution, our financial results will suffer.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our operations involve the use of hazardous materials, and we must comply with environmental, health and safety laws, which can be expensive and may adversely affect our business, operating results and financial condition.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our research and development and manufacturing activities involve the use of hazardous materials, including chemicals and biological materials, and some of our products include hazardous materials. Accordingly, we are subject to federal, state, local and foreign laws, regulations and permits relating to environmental, health and safety matters, including, among others, those governing the use, storage, handling, exposure to and disposal of hazardous materials and wastes, the health and safety of our employees, and the shipment, labeling, collection, recycling, treatment and disposal of products containing hazardous materials. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence. For example, under certain circumstances and under certain environmental laws, we could be held liable for costs relating to contamination at our or our predecessors&#8217; past or present facilities and at third-party waste disposal sites. We could also be held liable for damages arising out of human exposure to hazardous materials. There can be no assurance that violations of environmental, health and safety laws will not occur as a result of human error, accident, equipment failure or other causes. The failure to comply with past, present or future laws could result in the imposition of substantial fines and penalties, remediation costs, property damage and personal injury claims, investigations, the suspension of production or product sales, loss of permits or a cessation of operations. Any of these events could harm our business, operating results and financial condition. We also expect that our operations will be affected by new environmental, health and safety laws and regulations on an ongoing basis, or more stringent enforcement of existing laws and regulations. New laws or changes to existing laws may result in additional costs and may increase penalties associated with violations or require us to change the content of our products or how we manufacture them, which could have a material adverse effect on our business, operating results and financial condition.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Ethical, legal, privacy, data protection and social concerns or governmental restrictions surrounding the use of genetic information could reduce demand for our technology.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our products may be used to provide genetic information about humans, agricultural crops and other living organisms. The information obtained from our products could be used in a variety of applications which may have underlying ethical, legal, privacy, data protection and social concerns, including the genetic engineering or modification of agricultural products or testing for genetic predisposition for certain medical conditions. Governmental authorities could, for safety, social or other purposes, call for limits on or regulation of the use of genetic testing, and may consider or adopt such regulations or other restrictions. Such concerns or governmental restrictions could limit the use of our products or be costly and burdensome to comply with, and actual or perceived violations of any such restrictions may lead to the imposition of substantial fines and penalties, remediation costs, claims and litigation, regulatory investigations and proceedings, and other liability, and of which could have a material adverse effect on our business, financial condition and results of operations.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">37</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Regulations related to conflict minerals has caused us to incur, and will continue to cause us to incur, additional expenses and could limit the supply and increase the costs of certain materials used in the manufacture of our products.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are subject to requirements under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 that require us to conduct diligence and report on whether or not our products contain conflict minerals. The implementation of these requirements could adversely affect the sourcing, availability and pricing of the materials used in the manufacture of components used in our products. Furthermore, the complex nature of our products requires components and materials that may be available only from a limited number of sources and, in some cases, from only a single source. We have incurred, and will continue to incur, additional costs to comply with the disclosure requirements, including costs related to conducting diligence procedures to determine the sources of conflict minerals that may be used or necessary to the production of our products and, if applicable, potential changes to components, processes or sources of supply as a consequence of such verification activities. We may face reputational harm if we determine that certain of our products contain minerals that are not determined to be conflict free or if we are unable to alter our processes or sources of supply to avoid using such materials. In such circumstances, the reputational harm could materially and adversely affect our business, financial condition or results of operations.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">38</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to Owning Our Common Stock</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The price of our common stock has been, is, and may continue to be, highly volatile, and you may be unable to sell your shares at or above the price you paid to acquire them.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The market price of our common stock is highly volatile, and we expect it to continue to be volatile for the foreseeable future in response to many risk factors listed in this section, and others beyond our control, including:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">actual or anticipated fluctuations in our financial condition and operating results;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">announcements of new products, technological innovations or strategic partnerships by us or our competitors;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">announcements by us, our customers, partners or suppliers relating directly or indirectly to our products, services or technologies;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">overall conditions in our industry and market;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">addition or loss of significant customers;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">changes in laws or regulations applicable to our products;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">actual or anticipated changes in our growth rate relative to our competitors;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, capital commitments or achievement of significant milestones;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">additions or departures of key personnel;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">competition from existing products or new products that may emerge;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">issuance of new or updated research or reports by securities analysts;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">disputes or other developments related to proprietary rights, including patents, litigation matters or our ability to obtain intellectual property protection for our technologies;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">announcement or expectation of additional financing efforts;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">sales of our common stock by us or our stockholders;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">stock price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">reports, guidance and ratings issued by securities or industry analysts; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">operating results below the expectations of securities analysts or investors; and </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">general economic and market conditions, which could be impacted by various events including COVID-19 or interest rate fluctuations.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If any of the forgoing occurs, it would cause our stock price or trading volume to decline. Stock markets in general and the market for companies in our industry in particular have experienced price and volume fluctuations, which have been exacerbated by the COVID-19 pandemic, that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market price of our common stock. You may not realize any return on your investment in us and may lose some or all of your investment. In the past, companies that </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">have</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> experienced volatility in the market price of their stock have been subject to securities class action litigation. We have been a party to this type of litigation in the past and may be the target of this type of litigation again in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">39</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could reduce the market price that our common stock might otherwise attain and may dilute your voting power and your ownership interest in us.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales could occur, could adversely affect the market price of our common stock and may make it more difficult for existing stockholders to sell their common stock at a time and price that they deem appropriate and may dilute their voting power and ownership interest in us.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, if our existing stockholders sell, or indicate an intent to sell, a large number of shares of our common stock in the public market, it could cause our stock price to fall. </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may also issue shares of common stock or securities convertible into our common stock in connection with a financing, acquisition, our equity incentive plans, or otherwise. Any such issuances would result in dilution to our existing stockholders and the market price of our common stock may be adversely affected.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On September 20, 2021, in connection with the closing of the Omniome Merger, we completed a Private Placement for the sale of an aggregate of 11,214,953 shares of our common stock, at a price of $26.75 per share, for aggregate gross proceeds of approximately $300&#160;million. In connection with the Private Placement, we entered into a Registration Rights Agreement with the Private Placement investors, providing them, among other things, certain registration rights, including our obligation to register the Private Placement shares for resale within 30 days following the closing of the Private Placement.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Concentration of ownership by our principal stockholders may result in control by such stockholders of the composition of our board of directors.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our existing&#160;principal stockholders, executive officers, directors and their affiliates beneficially own a significant number of our outstanding shares of common stock. In addition, such parties may acquire additional control by purchasing stock that we issue in connection with our future fundraising efforts. Also, SB Northstar LP, a subsidiary of SoftBank Group Corp., purchased $900 million in aggregate principal amount of our 1.50% Convertible Senior Notes due 2028, convertible at the option of the holders at any time into shares of our common stock based on an initial conversion rate of 22.9885 shares of common stock per $1,000 principal amount of the Notes (which is equal to an initial conversion price of $43.50 per share). In addition, </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">on September 20, 2021 in connection with the closing of the Omniome Merger, we completed a Private Placement for the sale of an aggregate of 11,214,953 shares of our common stock, at a price of $26.75 per share, for aggregate gross proceeds of approximately $300 million with certain qualified institutional buyers and institutional accredited investors, including approximately $60 million to SB Northstar LP. </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As a result, these current and future stockholders may now and in the future be able to exercise a significant level of control over all matters requiring stockholder approval, including the election of directors. This control could have the effect of delaying or preventing a change of control of our company or changes in management and will make the approval of certain transactions difficult or impossible without the support of these stockholders.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management and limit the market price of our common stock.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Provisions in our certificate of incorporation and bylaws, as amended and restated, may have the effect of delaying or preventing a change of control or changes in our management. Our amended and restated certificate of incorporation and bylaws include provisions that:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">authorize our board of directors to issue, without further action by the stockholders, up to 50,000,000 shares of undesignated preferred stock and up to approximately 1,000,000,000 shares of authorized but unissued shares of common stock;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">specify that special meetings of our stockholders can be called only by our board of directors, the Chairman of the Board, the Chief Executive Officer or the President;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">40</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered terms;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">provide that our directors may be removed only for cause; and</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furthermore, our amended and restated bylaws provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (i) any derivative action or proceeding brought on our behalf</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Cambria', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#894;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (ii) any action asserting a breach of fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Cambria', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#894;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law; (iv) any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Cambria', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#894;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> or (v) any action asserting a claim against us that is governed by the internal affairs doctrine, subject to the court having personal jurisdiction over the indispensable parties named as defendants therein. This provision is not intended to apply to actions arising under the Securities Act or the Exchange Act, or any claim for which the federal courts have exclusive jurisdiction. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to this provision. This exclusive-forum provision may discourage lawsuits against us or our directors, officers, and employees. </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our large number of authorized but unissued shares of common stock may potentially dilute existing stockholders&#8217; stockholdings.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have a significant number of authorized but unissued shares of common stock. Our board of directors may issue shares of common stock from this authorized but unissued pool from time to time without stockholder approval, resulting in the dilution of our existing stockholders.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We do not intend to pay dividends for the foreseeable future.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have never declared or paid any dividends on our common stock and do not intend to pay any dividends in the foreseeable future. We anticipate that we will retain all of our future earnings for use in the operation of our business and for general corporate purposes. Any determination to pay dividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">41</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to Our Notes</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may not have the ability to raise the funds necessary to settle conversions of the Notes in cash or to repurchase the Notes upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the Notes.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In February 2021, we issued $900.0 million in aggregate principal amount of 1.50% Convertible Senior Notes due 2028, which we refer to as the Notes, The Notes will mature on February 15, 2028, subject to earlier conversion, redemption or repurchase, including upon a fundamental change.  </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Holders of the Notes will have the right to require us to repurchase all or a portion of their Notes upon the occurrence of a fundamental change before the maturity date at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus unpaid interest to, but excluding, the maturity date. In addition, upon conversion of the Notes, unless we elect to deliver solely shares of our common stock to settle such conversion (other than paying cash in lieu of delivering any fractional share), we will be required to settle a portion or all of our conversion obligation in cash in respect of the Notes being converted. Moreover, we will be required to repay the Notes in cash at their maturity unless earlier converted, redeemed or repurchased. However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of Notes surrendered therefor or pay cash with respect to Notes being converted or at their maturity.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, our ability to repurchase Notes or to pay cash upon conversions of Notes or at their maturity may be limited by law, regulatory authority or agreements governing our future indebtedness. Our failure to repurchase Notes at a time when the repurchase is required by the indenture or to pay cash upon conversions of Notes or at their maturity as required by the indenture would constitute a default under the indenture. A default under the indenture or the fundamental change itself could also lead to a default under agreements governing our future indebtedness. Moreover, the occurrence of a fundamental change under the indenture could constitute an event of default under any such agreement. If the payment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness or to pay cash amounts due upon conversion, upon required repurchase or at maturity of the Notes. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If the Notes are converted, it may adversely affect our financial condition and operating results.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Holders of the Notes are entitled to convert their Notes at any time at their option. If one or more holders elect to convert their Notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation in cash, which could adversely affect our liquidity. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">42</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">General Risk Factors </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">General conditions in the global economy and in the global financial markets could adversely affect our results of operations, including the potential effects from the COVID-19 pandemic as discussed above, and the overall demand for nucleic acid sequencing products may be particularly vulnerable to unfavorable economic conditions. A global financial crisis, inflation or a global or regional political disruption could cause extreme volatility in the capital and credit markets. A severe or prolonged economic downturn or political disruption could result in a variety of risks to our business, including weakened demand for our products and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our product and services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Delivery of our products could be delayed or disrupted by factors beyond our control, and we could lose customers as a result.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We rely on third-party carriers for the timely delivery of our products. As a result, we are subject to carrier disruptions and increased costs that are beyond our control. Any failure to deliver products to our customers in a safe and timely manner may damage our reputation and brand and could cause us to lose customers. If our relationship with any of these third-party carriers is terminated or impaired or if any of these carriers are unable to deliver our products, the delivery and acceptance of our products by our customers may be delayed, which could harm our business and financial results. The failure to deliver our products in a safe and timely manner may harm our relationship with our customers, increase our costs and otherwise disrupt our operations.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Doing business internationally creates operational and financial risks for our business.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We currently conduct operations in various countries and jurisdictions, and continue to expand to new international jurisdictions as part of our growth strategy and have experienced an increasing concentration of sales in certain regions outside the U.S. We sell directly and through distribution partners throughout Europe, the Asia-Pacific region, Mexico, Brazil, and South Africa and have a significant portion of our sales and customer support personnel in Europe and the Asia-Pacific region. As a result,&#160;we or our distribution partners may be subject to additional regulations and increased diversion of management time and efforts. Conducting and launching operations on an international scale requires close coordination of activities across multiple jurisdictions and time zones and consumes significant management resources.&#160;If we fail to coordinate and manage these activities effectively, our business, financial condition or results of operations could be materially and adversely affected and failure to comply with laws and regulations applicable to business operations in foreign jurisdictions may also subject us to significant liabilities and other penalties.&#160;&#160;International operations entail a variety of other risks, including, without limitation:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">limits to travel as a result of the COVID-19 pandemic;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">challenges in staffing and managing foreign operations;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">potentially longer sales cycles and more time required to engage and educate customers on the benefits of our platform outside of the United States;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the potential need for localized software and documentation;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">reduced protection for intellectual property rights in some countries and practical difficulties of enforcing intellectual property and contract rights abroad;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">defending against intellectual property claims in other countries;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">restriction on cross-border investment, including enhanced oversight by the Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;) and substantial restrictions on investment from China;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. and foreign government trade restrictions, including those which may impose restrictions on the importation, exportation, re-exportation, sale, shipment or other transfer of programming, technology, components, and/or services to foreign persons;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">43</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">changes in diplomatic and trade relationships, including new tariffs, trade protection measures, import or export licensing requirements, trade embargoes, sanctions and other trade barriers;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">tariffs imposed by the U.S. on goods from other countries and tariffs imposed by other countries on U.S. goods, including the tariffs by the U.S. government on various imports from China, Canada, Mexico and the EU and by the governments of these jurisdictions on certain U.S. goods, and any other possible tariffs that may be imposed on products such as ours, the scope and duration of which, if implemented, remains uncertain;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">deterioration of political relations between the U.S. and China, Canada, Russia, the United Kingdom (&#8220;U.K.&#8221;) and the European Union (&#8220;EU&#8221;), which could have a material adverse effect on our sales and operations in these countries;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">changes in social, political and economic conditions or in laws, regulations and policies governing foreign trade, manufacturing, development and investment both domestically as well as in the other countries and jurisdictions into which we sell our products, including as a result of the withdrawal of the U.K. from the EU;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">difficulties in obtaining export licenses or in overcoming other trade barriers and restrictions resulting in delivery delays;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">fluctuations in currency exchange rates and the related effect on our results of operations;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">increased financial accounting and reporting burdens and complexities;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">disruptions to global trade due to disease outbreaks or conflicts;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">potential increases on tariffs or restrictions on trade generally; and</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.84in;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">significant taxes or other burdens of complying with a variety of foreign laws and regulations, including laws and regulations relating to privacy and data protection such as the EU General Data Protection Regulation which took effect in the EU in 2018.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In conducting our international operations, we are subject to U.S. laws relating to our international activities, such as the Foreign Corrupt Practices Act of 1977, as well as foreign laws relating to our activities in other countries, such as the United Kingdom Bribery Act of 2010. Additionally, the inclusion of one of our foreign customers on any U.S. Government sanctioned persons list, including but not limited to the U.S. Department of Commerce&#8217;s List of Denied Persons and the U.S. Department of Treasury&#8217;s List of Specially Designated Nationals and Blocked Persons List, could be material to our earnings. Failure to comply with these laws may subject us to claims or financial and/or other penalties in the United States and/or foreign countries that could materially and adversely impact our operations or financial condition.&#160;&#160;These risks have become increasingly prevalent as we have expanded our sales into countries that are generally recognized as having a higher risk of corruption.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We face risks related to the current global economic environment, which could delay or prevent our customers from purchasing our products, which could in turn harm our business, financial condition and results of operations.&#160;The state of the global economy continues to be uncertain. The current global economic conditions and uncertain credit markets and concerns regarding the availability of credit pose a risk that could impact customer demand for our products, as well as our ability to manage normal commercial relationships with our customers, suppliers and creditors, including financial institutions. If the current global economic environment deteriorates, our business could be negatively affected.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Moreover, changes in the value of the relevant currencies may affect the cost of certain items required in our operations. Changes in currency exchange rates may also affect the relative prices at which we are able sell products in the same market. Our revenue from international customers may be negatively impacted as increases in the U.S. dollar relative to our international customers&#8217; local currencies could make our products more expensive, impacting our ability to compete&#160;or as a result of financial or other instability in such locations which could result in decreased sales of our products. Our costs of materials from international suppliers may also increase as the value of the U.S. dollar decreases relative to their local currency. Foreign policies and actions regarding currency valuation could result in actions by the United States and other countries to offset the effects of such fluctuations. Such actions may materially and adversely impact our financial condition and results of operations.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">44</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Violations of complex foreign and U.S. laws and regulations could result in fines and penalties, criminal sanctions against us, our officers, or our employees, prohibitions on the conduct of our business and on our ability to offer our products and services in one or more countries, and could also materially affect our brand, our international growth efforts, our ability to attract and retain employees, our business, and our operating results. Even if we implement policies or procedures designed to ensure compliance with these laws and regulations, there can be no assurance that our distribution partners, our employees, contractors, or agents will not violate our policies and subject us to potential claims or penalties.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, which would adversely affect our business and our stock price.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Ensuring that we have adequate internal financial and accounting controls and procedures in place to produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be evaluated frequently. We may in the future discover areas of our internal financial and accounting controls and procedures that need improvement. Operating as a public company requires sufficient resources within the accounting and finance functions in order to produce timely financial information, ensure the level of segregation of duties, and maintain adequate internal control over financial reporting customary for a U.S. public company.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with&#160;U.S. GAAP. Our management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within our company will have been detected.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pursuant to Section&#160;404 of the Sarbanes-Oxley Act, we perform periodic evaluations of our internal control over financial reporting. While we have in the past performed this evaluation and concluded that our internal control over financial reporting was operating effectively, there can be no assurance that in the future material weaknesses or significant deficiencies will not exist or otherwise be discovered. In addition, if we are unable to produce accurate financial statements on a timely basis, investors could lose confidence in the reliability of our financial statements, which could cause the market price of our common stock to decline and make it more difficult for us to finance our operations and growth.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our business could be negatively impacted by changes in the United States political environment.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There is significant ongoing uncertainty with respect to potential legislation, regulation and government policy at the federal level, as well as the state and local levels. Any such changes could significantly impact our business as well as the markets in which we compete. Specific legislative and regulatory proposals discussed during election campaigns and more recently that might materially impact us include, but are not limited to, changes to spending priorities and potential reductions in research funding. Uncertainty about U.S. government funding has posed, and may continue to pose, a risk as customers may choose to postpone or reduce spending in response to actual or anticipated restraints on funding. To the extent changes in the political environment have a negative impact on us or on our markets, our business, results of operation and financial condition could be materially and adversely impacted in the future</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Disruption of critical information technology systems or material breaches in the security of our systems could harm our business, customer relations and financial condition.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Information technology (&#8220;IT&#8221;) helps us to operate efficiently, interface with customers, maintain financial accuracy and efficiently and accurately produce our financial statements. IT systems are used extensively in virtually all aspects of our business, including sales forecast, order fulfillment and billing, customer service, logistics, and management of data from running samples on our products. Our success depends, in part, on the continued and uninterrupted performance of our IT systems. IT systems may be vulnerable to damage from a variety of sources, including telecommunications or network failures, power loss, natural disasters, human acts, computer viruses, ransomware, computer denial-of-service attacks, unauthorized access to customer or employee data or company trade secrets, and other attempts to harm our systems. Certain of our systems are not redundant, and our disaster recovery planning is not sufficient for every eventuality. Despite </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">45</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">any precautions we may take, such problems could result in, among other consequences, disruption of our operations, which could harm our reputation and financial results.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If we do not allocate and effectively manage the resources necessary to build and sustain the proper IT infrastructure, we could be subject to transaction errors, processing inefficiencies, loss of customers, business disruptions or loss of or damage to intellectual property through security breach. If our data management systems do not effectively collect, store, process and report relevant data for the operation of our business, whether due to equipment malfunction or constraints, software deficiencies or human error, our ability to effectively plan, forecast and execute our business plan and comply with applicable laws and regulations will be impaired, perhaps materially. Any such impairment could materially and adversely affect our reputation, financial condition, results of operations, cash flows and the timeliness with which we report our internal and external operating results.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, our proprietary business information and that of our customers, suppliers and business partners, and personally identifiable information of our customers and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our IT infrastructure may be vulnerable to attacks by hackers, computer viruses, malicious codes, ransomware, unauthorized access attempts, and cyber- or phishing-attacks, or breached or otherwise disrupted due to employee error, malfeasance, faulty password management or other disruptions. Third parties may attempt to fraudulently induce employees or other persons into disclosing usernames, passwords or other sensitive information, which may in turn be used to access our IT systems, commit identity theft or carry out other unauthorized or illegal activities. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. We engage third-party vendors and service providers to store and otherwise process some of our data, including sensitive and personal information. Our vendors and service providers may also be the targets of the risks described above, including cyberattacks, malicious software, ransomware, phishing schemes, and fraud. Our ability to monitor our vendors and service providers&#8217; data security is limited, and, in any event, third parties may be able to circumvent those security measures, resulting in the unauthorized access to, misuse, disclosure, loss or destruction of our data, including sensitive and personal information, and disruption of our or third-party service providers&#8217; systems. We and our third-party service providers may face difficulties in identifying, or promptly responding to, potential security breaches and other instances of unauthorized access to, or disclosure or other loss of, information. Any hacking or other attack on our or our third-party service providers&#8217; or vendors&#8217; systems, and any unauthorized access to, or disclosure or other loss of, information suffered by us or our third-party service providers or vendors, or the perception that any of these have occurred, could result in legal claims or proceedings, loss of intellectual property, liability under laws that protect the privacy of personal information, negative publicity, disruption of our operations and damage to our reputation, which could divert our management&#8217;s attention from the operation of our business and materially and adversely affect our business, revenues and competitive position. Moreover, we may need to increase our efforts to train our personnel to detect and defend against cyber- or phishing-attacks, which are becoming more sophisticated and frequent, and we may need to implement additional protective measures to reduce the risk of potential security breaches, which could cause us to incur significant additional expenses.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, our insurance may be insufficient to cover our losses resulting from cyber-attacks, breaches, or other interruptions, and any incidents may result in loss of, or increased costs of, such insurance. The successful assertion of one or more large claims against us that exceed available insurance coverage, the occurrence of changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, or denials of coverage, could have a material adverse effect on our business, including our financial condition, results of operations and reputation.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">46</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We are currently subject to, and may in the future become subject to additional, U.S. federal and state laws and regulations imposing obligations on how we collect, store and process personal information. Our actual or perceived failure to comply with such obligations could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our future customer base, and thereby decrease our revenue.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the ordinary course of our business, we currently, and in the future will, collect, store, transfer, use or process sensitive data, including personally identifiable information of employees, and intellectual property and proprietary business information owned or </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">controlled</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> by ourselves and other parties. The secure processing, storage, maintenance, and transmission of this critical information are vital to our operations and business strategy. We are, and may increasingly become, subject to various laws and regulations, as well as contractual obligations, relating to data privacy and security in the jurisdictions in which we operate. The regulatory environment related to data privacy and security is increasingly rigorous, with new and constantly changing requirements applicable to our business, and enforcement practices are likely to remain uncertain for the </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">foreseeable</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> future. These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible that they will be interpreted and applied in ways that may have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the United States, various federal and state regulators, including governmental agencies like the Consumer Financial Protection </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Bureau</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and the </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Federal</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Trade Commission, have adopted, or are considering adopting, laws and regulations concerning personal information and data security. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to personal information than federal, international or other state laws, and such laws may differ from each other, all of which may complicate compliance efforts. For example, the California Consumer Privacy Act (&#8220;CCPA&#8221;), which increases privacy rights for California residents and imposes obligations on companies that process their personal information, came into effect on January 1, 2020. Among other things, the CCPA requires covered companies to provide new disclosures to California consumers and provide such consumers new data protection and privacy rights, including the ability to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches that result in the loss of personal information. This private right of action may increase the likelihood of, and risks associated with, data breach litigation. In November 2020, California also passed the California Privacy Rights Act, or (&#8220;CPRA&#8221;), which significantly expands the CCPA, including by introducing additional obligations such as data minimization and storage limitations and granting additional rights to consumers, among others. In addition, laws in all 50 U.S. states require businesses to provide notice to consumers whose personal information has been disclosed as a result of a data breach. State laws are changing rapidly and there is discussion in the U.S. Congress of a new comprehensive federal data privacy law to which we would become subject if it is enacted. These and future laws and regulations may increase our compliance costs and potential liability. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furthermore, regulations promulgated pursuant to the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), establish privacy and security standards that limit the use and disclosure of individually identifiable health information (known as &#8220;protected health information&#8221;) and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can require complex factual and statistical analyses and may be subject to changing interpretation. Although we take measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, manipulated, publicly disclosed, lost or stolen. Any such access, breach or other loss of information could result in legal claims or proceedings, and liability under federal or state laws that protect the privacy of personal information, such as the HIPAA, the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and regulatory penalties. Notice of breaches must be made to affected individuals, the Secretary of the Department of Health and Human Services, and for extensive breaches, notice may need to be made to the media or State Attorneys General. Such a notice could harm our reputation and our ability to compete.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are in the process of evaluating compliance needs, but do not currently have in place formal policies and procedures related to the storage, collection and processing of information, and have not conducted any internal or external data privacy audits, to ensure our compliance with all applicable data protection laws and regulations. Additionally, we do not currently have policies and procedures in place for assessing our third-party vendors&#8217; compliance with applicable data </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">47</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">protection laws and regulations. All of these evolving compliance and operational requirements impose significant costs, such as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants, which are likely to increase over time. In addition, such requirements may require us to modify our data processing practices and policies, distract management or divert resources from other initiatives and projects, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Any failure or perceived failure by us or our third-party vendors, collaborators, contractors and consultants to comply with any applicable federal, state or similar foreign laws and regulations relating to data privacy and security, or could result in damage to our reputation, as well as proceedings or litigation by governmental agencies or other third parties, including class action privacy litigation in certain jurisdictions, which would subject us to significant fines, sanctions, awards, penalties or judgments, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Increased scrutiny of our environmental, social or governance responsibilities may result in additional costs and risks, and may adversely impact our reputation, employee retention, and willingness of customers and suppliers to do business with us.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Investor advocacy groups, institutional investors, investment funds, proxy advisory services, stockholders, and customers are increasingly focused on environmental, social and governance (&#8220;ESG&#8221;) practices of companies. Additionally, public interest and legislative pressure related to public companies&#8217; ESG practices continues to grow. If our ESG practices fail to meet regulatory requirements or investor or other industry stakeholders&apos; evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, support for local communities, Board of Director and employee diversity, human capital management, employee health and safety practices, product quality, supply chain management, corporate governance and transparency and employing ESG strategies in our operations, our brand, reputation and employee retention may be negatively impacted and customers and suppliers may be unwilling to do business with us. In addition, as we work to align our ESG practices with industry standards, we will likely continue to expand our disclosures in these areas and doing so may result in additional costs and require additional resources to monitor, report, and comply with our various ESG practices. If we fail to adopt ESG standards or practices as quickly as stakeholders desire, report on our ESG efforts or practices accurately, or satisfy the expectations of stakeholders, our reputation, business, financial performance and growth may be adversely impacted.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.77in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.77in;"><span style="white-space:pre-wrap; display: inline-block;text-indent: 0;width: 0.770in;"><span id="Item1B" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">ITEM 1B.</span></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">UNRESOLVED STAFF COMMENTS</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">None.</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">       </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.77in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.77in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-indent: 0;width: 0.770in;">ITEM&#160;2.</span><span id="Item2" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PROPERTIES</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our corporate headquarters, research and development facilities, manufacturing and distribution centers are located in Menlo Park, California. We lease approximately 180,000 square feet under a lease expiring on October 31, 2027.</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> We operate additional research, development and support functions in San Diego, where we lease approximately 73,500 square feet under a lease expiring on September 30, 2027, which was acquired in connection with the acquisition of Omniome.  Including these leases, we lease approximately 278,000 square feet globally. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe that our existing facilities, together with suitable additional or alternative space available on commercially reasonable terms, will be sufficient to meet our needs. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.76in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.77in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-indent: 0;width: 0.765in;">ITEM&#160;3.</span><span id="Item3" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">LEGAL</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> PROCEEDINGS  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Please see </span><a href="#Note8_Commitments_Contingencies" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Note 8. Commitments and Contingencies</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, subsection titled </span><a href="#Note8_subsection_LegalProceedings" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Legal Proceedings</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, in Part II, Item 8 of this Annual Report on Form 10-K.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.76in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.77in;"><span id="Item4" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">ITEM 4.      MINE SAFETY DISCLOSURES</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.76in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.77in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Not applicable.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">48</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 13.5pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PART II</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 13.5pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.76in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.77in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-indent: 0;width: 0.765in;">ITEM 5.</span><span id="Item5" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">MARKET</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our common stock is traded on The Nasdaq Global Select Market under the symbol &#8220;PACB.&#8221; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Holders of Record </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of January 31, 2022, there were approximately 59 stockholders of record of our common stock, although we believe that there are a significantly larger number of beneficial owners of our common stock. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Dividend Policy </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have never declared or paid any cash dividend on our common stock and have no present plans to do so. We intend to retain earnings for use in the operation and expansion of our business.</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">49</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 13.5pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Performance Graph </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The performance graph included in this Annual Report on Form 10-K shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference into any filing of Pacific Biosciences under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following graph shows a comparison from December 31, 2016 through December&#160;31, 2021 of the cumulative total return for our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index. Such returns are based on historical results and are not intended to suggest future performance. Data for The Nasdaq Composite Index and the Nasdaq Biotechnology Index assume reinvestment of dividends. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-align: center;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><img src="pacb-20211231x10kg002.jpg" style="width: 6.400646in; height: 5.421663in" alt="Chart, line chart&#xA;&#xA;Description automatically generated" /></span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 13.5pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Recent Sales of Unregistered Securities </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Not applicable.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">IT</span><span id="Item6" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">EM 6. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">       [Reserved]</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 9pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">50</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.76in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.77in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-indent: 0;width: 0.765in;">ITEM&#160;7. </span><span id="Item7" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">MANAGEMENT&#8217;S</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_cp_text_2_1303" style="text-decoration: none;"></span><span id="_cp_text_2_93" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">You should read the following discussion and analysis of our financial condition </span><span id="_cp_text_5_1304" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">and results of operations </span><span id="_cp_text_2_1305" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">together with our consolidated financial statements and the related notes included in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and </span><span id="_cp_text_5_1306" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">strategy for our business and related financing, </span><span id="_cp_text_2_1307" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">includes forward-looking statements that involve risks and uncertainties. You should read the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 13.5pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our Management&#8217;s Discussion and Analysis (MD&amp;A) is organized in the following sections: </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.53in;margin-right: 0;margin-top: 13.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Overview and Outlook </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.53in;margin-right: 0;margin-top: 13.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Results of Operations </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.53in;margin-right: 0;margin-top: 13.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Liquidity and Capital Resources </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.53in;margin-right: 0;margin-top: 13.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Critical Accounting Policies and Estimates</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.53in;margin-right: 0;margin-top: 13.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Quantitative and Qualitative Disclosure of Market Risk</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.53in;margin-right: 0;margin-top: 13.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Recent Accounting Pronouncements</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.53in;margin-right: 0;margin-top: 13.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Contractual Obligations</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.53in;margin-right: 0;margin-top: 13.5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Off Balance Sheet Arrangements</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 13.5pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Overview and Outlook</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 13.5pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">About PacBio</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems.&#160; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing and our emerging SBB short read sequencing technologies. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.&#160; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our focus is on providing our customers with advanced sequencing technologies with higher throughput and improved workflows that we believe will enable dramatic advancements in routine healthcare.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies and agricultural companies. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2021, our commercial team is comprised of over 178 employees, including 48 commissionable employees, many with advanced degrees in biology and significant experience in the genomics industry.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In 2021, we grew revenues by 65% as compared to December 31, 2020, driven by increased sales of our sequencing platforms and newly developed products as well as through strategic business acquisitions. We have added to our leadership team, expanded our critical commercial and research and development capabilities, and achieved development milestones toward commercialization of new and enhanced technologies. These achievements in 2021 focused on building a foundation for growth, that we will leverage to continue to focus on strategic, future-oriented execution as an organization, with our products and for our customers.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">51</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;vertical-align: baseline;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022 Strategic Objectives</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2021</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> was a productive year for us as we set out to transform the company, scale the business and drive adoption for our advanced sequencing technologies.</span></p><p dir="ltr" style="font-family: 'Segoe UI', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our 2022 strategic objectives include:&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;vertical-align: baseline;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61607;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Execution &#8211; leveraging commercial investment to drive continued HiFi and Sequel II/IIe adoption;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;vertical-align: baseline;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61607;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Progress our product pipeline &#8211; continue developing our future higher throughput HiFi sequencing platform and differentiated short-read technology; and</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;vertical-align: baseline;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61607;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Delight our customers &#8211; deepening our customer relationships and expanding customer collaborations across existing and rapidly expanding new applications for our technology.</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Segoe UI', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.03in;vertical-align: baseline;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We will continue to leverage our commercial organization and make significant improvements in efficiency and usability of our Sequel II/IIe to seek to reach a broader customer base. We believe the commercial investments we have made in 2021 and will continue to make in 2022 will further help drive growth in our business.&#160; We employed 48 quota-carrying field sales personnel as of December 31, 2021, and we expect to continue to grow the number of quota-carrying field sales personnel throughout 2022.&#160; In 2021, we sought to increase the awareness of our products and the number of potential customers. In 2022, we expect to continue to expand our sales, general and administrative departments to invest in our growth.&#160;&#160;&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Segoe UI', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To increase the adoption of HiFi sequencing, we have various development programs in progress to expand our product portfolio as well as increase the throughput and improve the usability of our existing sequencing technologies. Our focus for 2022 will be to progress these programs to accelerate new platform launches in the near to mid-term as well as increase application for our technologies. In an effort to address the oncology markets with a highly differentiated alternative, we are also progressing our short read platform development with a goal of launching our SBB short read sequencing platform in the first half of 2023.&#160; As a result, we expect our research and development expense to increase significantly in 2022 as compared to 2021.</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We continue to believe that with the capabilities of our HiFi chemistry and SMRT technology, we can be a market leader in whole-genome clinical sequencing. Leading institutions have adopted our products to study rare and inherited disease. We believe the market opportunity for clinical sequencing is significant and could drive substantial revenue growth for the company. We plan to pursue an expanding pipeline of other potential customer collaborations where the technologies being developed or applications being considered extend beyond whole-genome clinical sequencing. Collaborative arrangements will likely increase through 2022, ultimately adding to the awareness of our products and service offerings and driving new applications for use of our technology.&#160;&#160;&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Financial Overview</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The COVID-19 pandemic and efforts to control its spread have significantly curtailed the movement of people, goods, and services worldwide, including in the regions in which we sell our products and services and conduct our business operations. Due to the </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">uncertain</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> scope and duration of the pandemic, we cannot reasonably estimate the future impact to our operations and financial results.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In response to local stay-at-home orders and in alignment with CDC recommendations, we have limited our manufacturing and commercial operations. We have and will continue to provide consumables, instruments, and support to scientists at government, </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">academic</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, and commercial labs that remain open. To aid in containing the spread of COVID-19, we have implemented remote-work options and are limiting employee travel. We are monitoring this rapidly evolving situation.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Even after the COVID-19 pandemic has subsided, we may continue to experience an adverse impact to our business as a result of its global economic impact, including any recession that has occurred or may occur in the future. Specifically, difficult macroeconomic conditions, decreases in discretionary capital spending, increased and prolonged unemployment or a decline in consumer confidence as a result of the COVID-19 pandemic could have a continuing adverse effect on the demand for some of our products. Such economic disruption could have a material adverse effect on our business, results of operations and liquidity. The degree of impact of COVID-19 on our business will depend on several factors, such as the </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">52</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">duration and the extent of the pandemic, as well as actions taken by governments, businesses and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">See the</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span><a href="#Item1A" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Risk Factors</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> section for further discussion of the possible impact of the COVID-19 pandemic on our business.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Key highlights of our </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2021</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> consolidated financial results include the following: </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Revenue increased $51.6 million, or 65%, to $130.5 million for the year ended December 31, 2021, as compared to $78.9 million for the year ended December 31, 2020, driven primarily by an increase in instrument and consumable revenue. We expect revenue to grow in 2022 compared to 2021 and 2020. However, our future revenues largely depend on the rate of sales of our sequencing instruments, which are a leading indicator of future sales of consumables.  We expect instrument placements to continue to grow as we expand our sales globally through our expanded sales force, through application of technology in new markets and through offering new features and solutions.  In turn, we expect that this will continue to increase our sales of consumables and related services.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Gross profit as a percentage of revenue (gross margin) was 45.1% in 2021 compared to 41.3% for the year ended December 31, 2020. </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The improved gross margin percentage was primarily due to higher sales volumes and increased utilization of our products during the year ended December 31, 2021, compared to 2020. Our gross margin in future periods will depend on several factors, including: strategic product pricing; </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">product mix; sales of higher-margin consumables; supply chain constraints increasing the cost of raw materials; manufacturing capacity and production volumes impacting the cost of inventory; freight costs; warranty costs; and excess or obsolete inventories.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Loss from operations increased $105.8 million or 101%, to $210.2 million for the year ended December 31, 2021, as compared to $104.4 million for the year ended December 31, 2020, driven primarily by an increase of $132.1 million of operating expenses, including $31.1 million of merger-related expenses incurred in connection with the acquisitions of Omniome, Inc. and Circulomics, Inc. in 2021.  We expect the loss from operations to continue to grow due to continued increases in operating expenses, as we further invest in product commercialization, product development efforts and incur a full year of operating expenses associated with the acquisition of Omniome. See </span><a href="#Note2_BusinessAcquisitions" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Note 2. Business Acquisitions</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for further details. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash, cash equivalents and short-term investments were $1.04 billion at December 31, 2021, which represents an increase of 228% compared to the balance at December 31, 2020.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> detailed discussion of our comparison between 2021 and 2020 is presented below. A discussion of the changes in our results of operations between the years ended December 31, 2020 and December 31, 2019, has been omitted from this Annual Report on Form 10-K but may be found in </span><a href="#Item7" style="text-decoration: none;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 7.&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#160;</span></a><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">of our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on February 26, 2021, which is incorporated herein by reference, and which is available free of charge on the SEC&#8217;s website at </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">www.sec.gov</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and our corporate website (</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">www.pacb.com</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">).</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">53</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span id="Results_of_Operations" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Results of Operations </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Comparison of the Years Ended December&#160;31, 2021 and 2020 </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 24.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">$ Change</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">% Change</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Revenue:</span></p></td><td colspan="10" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 50.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands, except percentages)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Product revenue </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 113,505</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 65,424</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 48,081</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">73%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Service and other revenue </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 17,008</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 13,469</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 3,539</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">26%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.58in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total revenue </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 130,513</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 78,893</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 51,620</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">65%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cost of Revenue:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cost of product revenue </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 56,358</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 35,424</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 20,934</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">59%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cost of service and other revenue </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 14,989</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 10,903</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 4,086</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">37%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization of intangible assets</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 306</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 306</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.58in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total cost of revenue </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 71,653</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 46,327</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 25,326</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.92in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Gross profit </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 58,860</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 32,566</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 26,294</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">81%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating Expense:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 112,899</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 64,152</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 48,747</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">76%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Sales, general and administrative </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 124,124</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 72,799</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 51,325</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">71%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Merger-related expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 31,129</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 31,129</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Change in fair value of contingent consideration</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 1,143</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 1,143</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.58in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total operating expense </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 269,295</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 136,951</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 132,344</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">97%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating loss </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (210,435)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (104,385)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (106,050)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(102%)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Gain from reverse termination fee from Illumina</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 98,000</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (98,000)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(Loss)/Gain from continuation advances from Illumina</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (52,000)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 34,000</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (86,000)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(253%)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Interest expense </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (12,530)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (267)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (12,263)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(4593%)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other income, net </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 93</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 2,055</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (1,962)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(95%)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net (loss) income</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (274,872)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 29,403</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (304,275)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(1035%)</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Revenue </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Revenue increased $51.6 million, or 65%, to $130.5 million for the year ended December 31, 2021, as compared to $78.9 million for the year ended December 31, 2020, driven primarily by an increase in instrument and consumable revenue. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Instrument revenue increased $27.0 million, or 79%, to $61.3 million for the year ended December 31, 2021, as compared to the year ended December 31, 2020, primarily due to an increase in instruments sold. During the year ended December 31, 2021, our installed base was 374 Sequel II and Sequel IIe systems compared to the 203 systems in the year ended December 31, 2020. We expect the number of Sequel II/IIe placements to continue to grow during 2022, reflecting our increased commercial presence and customer demand. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Consumables revenue increased $21.0 million, or 68%, to $52.2 million for the year ended December 31, 2021, as compared to the year ended December 31, 2020. The increase in consumable sales was primarily attributable to higher Sequel II/IIe consumables sales from growth of the installed base.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Service and other revenue increased $3.5 million, or 26%, to $17.0 million for the year ended December 31, 2021, primarily due to product services contracts sold on the growing installed base.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">54</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Cost of revenue, gross profit and gross margin</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cost of product revenue increased by $20.9 million, or 59%, to $56.4 million for the year ended December 31, 2021, compared to $35.4 million for the year ended December 31, 2020. The increase in cost of product revenue was primarily due to higher sales.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cost of service and other revenue increased by $4.1 million, or 37%, to $15.0 million for the year ended December 31, 2021, compared to $10.9 million for the year ended December 31, 2020, primarily due to higher service volumes from our growing installed base and increased stock-based compensation expense.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Gross profit increased $26.3 million, or 81%, to $58.9 million for the year ended December 31, 2021, compared to the year ended December 31, 2020. Gross margin was 45.1%, for the year ended December 31, 2021, compared to gross margin of 41.3% for the year ended December 31, 2020. The improved gross margin percentage was primarily due to higher sales volumes and increased factory utilization during the year ended December 31, 2021, compared to 2020, which was more adversely impacted by the impact of the COVID-19 pandemic.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The global shortage of semiconductors, which has been reported since early 2021, has caused challenges for us in our supply chain and resulted in some cost increases that have and may continue to adversely impact margins. During these periods of shortages or delays, the price of components may increase, or the components may not be available at all. We may not be able to secure enough components at reasonable prices or of acceptable quality to build new products in a timely manner in the quantities or configurations needed. Accordingly, our revenue and gross margins could suffer until other sources can be developed.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Research and Development Expense</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development expense increased by $48.7 million, or 76%, to $112.9 million for the year ended December 31, 2021, compared to the year ended December 31, 2020. This change was primarily driven by an increase of $29.0 million in personnel expenses, due to an increase in headcount, including the acquired workforce from the Omniome acquisition, and an increase of $14.3 million of product development costs. Research and development expense included stock-based compensation expense of $20.3 million and $7.1 million during the twelve months ended December 31, 2021 and 2020, respectively. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We will continue to focus a significant portion of our resources on developing new products and solutions, including improving the efficiency and usability of existing products, developing new solutions, software, workflows and applications leveraging our core technologies. We have and expect to continue to collaborate with strategic partners to develop sequencing solutions and expand the application of our technology. We intend to continue to significantly invest in research and development efforts into the foreseeable future. </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We expect research and development expenses to increase significantly in 2022, due to continued product development, research collaboration efforts, the acquisition of Omniome and our intent to continue to hire additional personnel in research and development. We also expect to continue to incur costs associated with products being developed in connection with the Invitae collaboration.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk95776079" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Sales, General and Administrative Expense</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Sales, general and administrative expense increased by $51.3 million, or 71%, to $124.1 million for the year ended December 31, 2021, compared to the year ended December 31, 2020. This change was primarily driven by an increase of $53.6 million in salaries and related expense due to increased headcount, which included quota-carrying sales representatives and executive hires, which was partially offset by a decrease of $6.6 million in consulting and professional services fees.  Sales, general and administrative expense included stock-based compensation expense of $35.4 million and $8.2 million during the twelve months ended December 31, 2021 and 2020, respectively.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Sales, general and administrative expense is planned to increase significantly in 2022 as we expect to increase quota-carrying sales representatives, increase headcount as part of our business expansion and incur incremental costs in connection with the acquisition of Omniome. </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">55</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Merger-related expenses</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Merger-related expenses of $31.1 million during the year ended December 31, 2021, consist of $12.2 million of transaction costs arising from the acquisitions of Omniome and Circulomics and $18.9 million of stock-based compensation expense resulting from the acceleration of certain equity awards in connection with the Omniome merger. We recognized $18.9 million of stock-based compensation expense for the acceleration that was not attributable to pre-combination services, consisting of $6.3 million that was settled in shares of our common stock, $7.4 million that was settled in cash and $5.2 million related to contingent consideration.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Change in fair value of contingent consideration</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Change in fair value of contingent consideration of $1.1 million during the year ended December 31, 2021, represents the remeasurement impact of the </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">contingent consideration of $200 million (composed of $100 million in cash and $100 million in shares of our common stock) that is due upon the achievement of a milestone, defined as the first commercial shipment to a customer of a nucleotide sequencing platform, utilizing SBB technology.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Gain from Reverse Termination Fee from Illumina </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As part of the Termination Agreement, Illumina paid us a Reverse Termination Fee of $98.0 million in the first quarter of 2020. Pursuant to the Termination Agreement, in the event that, on or prior to September 30, 2020, we entered into a definitive agreement providing for, or consummated, a Change of Control Transaction, then we may have been required to repay the Reverse Termination Fee (without interest) to Illumina in connection with the consummation of such Change of Control Transaction. We deferred the gain from the Reverse Termination Fee from Illumina until the date when the associated contingency was resolved. On October 1, 2020, the contingency clauses lapsed and we recorded the $98.0 million as a part of other income.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">(Loss) Gain from Continuation Advances from Illumina </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As part of the Termination Agreement, Illumina paid us Continuation Advances of $18.0 million during the fourth quarter of 2019 and $34.0 million during the first quarter of 2020. We recorded the $34.0 million as part of other income in the year ended December 31, 2020. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Up to the full $52.0 million of Continuation Advances paid to us were repayable without interest to Illumina if, within two years of March 31, 2020, we entered into, or consummated a Change of Control Transaction or raised at least $100 million in a single equity or debt financing (that may have multiple closings), with the amount repayable dependent on the amount raised by us. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Resulting from the issuance and sale of $900 million of 1.50% Convertible Senior Notes due February 15, 2028, $52.0 million of Continuation Advances were paid without interest to Illumina in February 2021 and recorded as other expense in the year ended December 31, 2021. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Interest Expense</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Interest expense for the year ended December 31, 2021, was $12.5 million compared to $0.3 million for the year ended December 31, 2020, primarily due to the interest incurred on the $900 million of 1.50% Convertible Senior Notes due February 15, 2028 that we issued on February 16, 2021.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Other Income, Net</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The decrease in Other income, net was primarily driven by a $0.8 million foreign exchange loss for the year ended December 31, 2021, compared to a $1.0 million foreign exchange gain recognized for the year ended December 31, 2020. </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">56</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Benefit from Income Taxes</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A deferred income tax benefit of $93.6 million for the year ended December 31, 2021, is related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Omniome and Circulomics acquisitions. We maintain a full valuation allowance on the net deferred tax assets of our U.S. entities as we have concluded that it is more likely than not that we will not realize our deferred tax assets. Accordingly, this benefit from income taxes is reflected on our </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Consolidated Statements of Operations and Comprehensive (Loss) Income</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for the year ended December 31, 2021.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Liquidity and Capital Resources </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our primary sources of liquidity, other than our holdings of cash, cash equivalents, and investments, has primarily been through the issuance of debt or equity securities, together with cash flow from operating activities.  We have historically incurred, and expect to continue to incur, operating losses and generate negative cash flows from operations on an annual basis due to the investments we intend to make as described in </span><a href="#Results_of_Operations" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Results of Operations</span></a><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> above, and as a result, we may require additional capital resources to execute our strategic initiatives to grow our business.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Cash, cash equivalents and investments </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2021, we had $1.04 billion in cash, cash equivalents and investments, compared to $318.8 million at December 31, 2020. The increase was attributable to the net proceeds from our issuance of $900 million of 1.50% Convertible Senior Notes on February 16, 2021, and $300 million of common stock in a private placement on September 20, 2021. This increase was partially offset by the payment of $319.8 million, net of cash acquired, in the acquisitions of Omniome and Circulomics in the third quarter of 2021, repayment of $52 million of Continuation Advances to Illumina in the first quarter of 2021 and $111.2 million cash used in operating activities for the twelve months ended December 31, 2021. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Convertible Senior Notes</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">At December 31, 2021, we had $900 million of principal Convertible Senior Notes outstanding which mature on February 15, 2028, subject to earlier conversion, redemption or repurchase. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On February 9, 2021, we issued convertible notes due 2028 (Notes) with an aggregate principal of $900 million.  The net proceeds from the issuance, after deducting offering expenses, were $895.6 million. The Notes are governed by an indenture (the &#8220;Indenture&#8221;) between the Company and U.S. Bank National Association, as trustee. The Notes bear interest at a rate of 1.50% per annum. Interest on the Notes is payable semi-annually in arrears on February 15 and August 15 commencing on August 15, 2021. The Notes will mature on February 15, 2028, subject to earlier conversion, redemption or repurchase.  The proceeds from the issuance of the convertible notes will be used to fund operations, strategic investments and capital requirements.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The Notes are convertible into shares of our common stock based on an initial conversion rate of 22.9885 shares of common stock per $1,000 principal amount of the Notes (which is equal to an initial conversion price of $43.50 per share), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the Notes, we may elect to settle such conversion obligation in shares, cash or a combination of shares and cash. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">With certain exceptions, upon a change of control of the Company or the failure of our common stock to be listed on certain stock exchanges, the holders of the Notes may require that we repurchase all or part of the principal amount of the Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">57</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the Notes under the Indenture. The Indenture also includes customary covenants for convertible notes of this type.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">See </span><a href="#Note7_ConvertibleDebt" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Note 7. Convertible Senior Notes</span></a><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for further details.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Acquisitions</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On September 20, 2021, we acquired Omniome, a </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">San Diego-based company developing a highly differentiated, proprietary short-read DNA sequencing platform capable of delivering high accuracy results, for total consideration of $714.8 million, consisting of $315.7 million in cash, $249.4 million in shares of PacBio common stock, and contingent consideration with a fair value of $168.6 million. Out of the total payment, approximately $18.9 million, comprised of $7.4 million of cash, 226,811 shares of PacBio common stock with a fair value of $6.3 million and $5.2 million of contingent consideration, was accounted for as a one-time post acquisition stock-based compensation expense. See </span><a href="#Note2_BusinessAcquisitions" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Note 2. Business Acquisitions</span></a><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for further details.&#160; </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">With regards to the contingent consideration with a fair value of $168.6 million, we are required to pay Omniome stockholders an additional payment of $200 million, composed of $100 million in cash and $100 million in shares of our common stock, upon the achievement of a milestone, defined as the first commercial shipment to a customer of a nucleotide sequencing platform, comprising both an instrument and related consumables, that utilizes SBB technology.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Private Placement of Common Stock</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On July&#160;19, 2021, we entered into a purchase agreement with certain qualified institutional buyers and institutional accredited investors, pursuant to which we agreed to sell an aggregate of 11,214,953 shares of common stock, at a price of $26.75 per share, for aggregate gross proceeds of approximately $300&#160;million. The transaction closed on September 20, 2021. We registered the private placement shares for resale following the closing of the merger.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Invitae Collaboration Arrangement</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On January 12, 2021, we entered into a multi-year Development and Commercialization Agreement with Invitae Corporation (&#8220;Invitae&#8221;). Pursuant to the Development Agreement, Invitae is providing certain funding to us to develop products relating to production-scale high-throughput sequencing (&#8220;Program Products&#8221;). If Program Products become commercially available, Invitae may purchase the Program Products. In addition to selling the Program Products to Invitae, we will have the right to broadly commercialize Program Products for sale to other customers.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Under the Development Agreement, we are conducting a program to develop and will subsequently manufacture the Program Products. Invitae is funding certain development costs we incur in connection with the Program Products (&#8220;Program Development Costs&#8221;) and will receive preferred pricing on the Program Products as further described in </span><a href="#Note3_InvitaeCollab" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Note 3. Invitae Collaboration Arrangement</span></a><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In certain termination circumstances, (i) we will be obligated to refund all or a portion of the development costs advanced by Invitae and/or (ii) we will owe Invitae a share of the revenue that may be generated from the sale of the Program Products to third parties if and when they are commercialized, until such time as Invitae has recouped the amounts paid to us, and in certain circumstances, a mutually agreed return.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have incurred and expect to incur significant development costs over the duration of the Development Agreement. There can be no assurances that the development program will be successful or that the Program Products will become ready for commercial sale.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All amounts received from Invitae are initially deferred and accumulated in deferred revenue, non-current. As of December 31, 2021, we have recognized payments received from Invitae of $23.5 million in deferred revenue, non-current, on the Consolidated Balance Sheet.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">58</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Additional Capital Requirements </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We anticipate that our existing cash, cash equivalents and investments will be sufficient to fund our projected operating and capital requirements for at least the next 12 months from the date of filing of this Annual Report on Form 10-K for the year ended December 31, 2021. Operating needs include planned costs to operate our business, including costs to fund working capital and capital expenditures.&#160; Recent and expected working and other capital requirements, in addition to the above matters, include: </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0.50in;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our purchase orders and contractual obligations of approximately $68.7 million as of December 31, 2021, which consist of open purchase orders and contractual obligations in the ordinary course of business, including commitments with contract manufacturers and suppliers for which we have not received the goods or services. A majority of these purchase obligations are due within a year. Although open purchase orders are considered enforceable and legally binding, the terms generally allow us the option to cancel, reschedule and adjust our requirements based on our business needs prior to the delivery of goods or performance of services.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our research and development expenditures were $112.9 million in 2021 and $64.2 million in 2020, and we expect to increase our investment in research and development in 2022, including enhancements of our existing products, continued development of a commercial product leveraging our acquired SBB technology, continued development of products in connection with our Invitae collaboration and new technology and products. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash outflows for capital expenditures were $5.9 million in 2021 and $1.0 million in 2020.&#160; We expect capital expenditures to increase in fiscal 2022 to support the increase in manufacturing and expansion of our business. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amounts related to future lease payments for operating lease obligations at December 31, 2021, totaled $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">57.7 million, with $11.3 million expected to be paid within the next 12 months.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amounts due under the term loan </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">acquired in connection with Omniome at December 31, 2021, totaled $3.9 million, with $1.6 million expected to be paid within the next 12 months. Please see </span><a href="#Note6_BalSheetCompon" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Note 6. Balance Sheet Components</span></a><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for additional information.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Payments made to 3rd party collaborators to help advance our technologies and the capabilities of our products.  We may also choose to drive investments to help create an ecosystem of customers, partners and collaborators whose expertise and offerings complement and enhance the capabilities and utility of our technology and increase genomic data available on our platforms.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Payments related to licensing and other arrangements are cancelable license agreements with third parties for certain patent rights and technology. Under the terms of these agreements, we may be obligated to pay royalties based on revenue from the sales of licensed products, or minimum royalties, whichever is greater, and license maintenance fees. The future license maintenance fees and minimum royalty payments under the license agreements are not deemed to be material. At this time, obligations for future royalties under our license agreements are not estimable or probable.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our capital needs may be impacted by the pace of adoption of our products, which affects the sales of our products and services; our ability to obtain new collaboration and customer arrangements; the progress of our research and development programs; initiation or expansion of research programs and collaborations; the purchase of patent licenses; manufacturing costs; service costs; the impact of product quality; litigation costs, including the costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; costs of developing new and enhanced products; acquisitions of complementary businesses, technologies or assets; macroeconomic impacts of COVID-19; and other factors. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If economic, financial, business or other factors adversely affect our ability to fund our projected operating cash requirements, we may be required to obtain funding through traditional or alternative sources of financing.&#160; We cannot be certain that funds will be available on favorable terms, or at all. If we are required and unable to raise additional capital when desired, our business, operating results and financial condition may be adversely affected.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">59</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Cash Flow Summary</span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 67.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 67.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 31.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 67.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 15.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 67.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash (used in) provided by operating activities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (111,180)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 19,503&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 67.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash used in investing activities </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (678,531)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (219,322)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 67.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash provided by financing activities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 1,169,581&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 251,839&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 67.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net increase in cash, cash equivalents and restricted cash</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 379,870&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 52,020&#160;</span></p></td></tr></table></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk54598465" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Operating Activities</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our primary uses of cash in operating activities are for the development of future products and product enhancements, manufacturing, and support functions related to our sales, general and administrative activities. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We used $111.2 million of cash in operating activities for the year ended December 31, 2021, compared to cash provided by operating activities of $19.5 million for the year ended December 31, 2020.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash used in operating activities for the year ended December 31, 2021, of $111.2 million was due primarily to a $181.0 million net loss, which includes a $93.6 million deferred income tax benefit, that was partially offset by a loss of $52.0 million from Continuation Advances repaid to Illumina that is considered a financing activity, non-cash items such as stock-based compensation of $73.4 million, depreciation of $7.2 million, amortization of right-of-use assets of $4.0 million and a net cash inflow from changes in operating assets and liabilities of $20.7 million. The change in net operating assets and liabilities was primarily attributable to increases of $25.7 million in deferred revenue, an increase of $15.1 million in accrued expenses and an increase of $6.4 million in accounts payable partially offset by an increase of $12.4 million in inventory, an increase of $7.2 million in accounts receivable, an increase of $1.0 million in prepaid expenses and other assets and a decrease of $5.0 million in operating lease liabilities.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash provided by operating activities for the year ended December 31, 2020, was $19.5 million, reflecting net income of $29.4 million which included a gain from the Reverse Termination Fee received from Illumina of $98.0 million and a gain from the Continuation Advances from Illumina of $34.0 million. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">However, the Continuation Advances are considered a financing activity and therefore an associated $34.0 million adjustment has been reflected to cash provided by operating activities. The net income of $29.4 million included </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">non-cash expense items such as stock-based compensation of $17.5 million and depreciation of $6.4 million. The change in net operating assets and liabilities was primarily attributed to an increase of $4.1 million in accrued expenses and an increase of $5.0 million in other liabilities, partially offset by a decrease of $5.1 million in accounts payable. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Investing Activities </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our investing activities consist primarily of business acquisitions, capital expenditures and investment purchases, sales and maturities. We used </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$678.5</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of cash for investing activities for the year ended December 31, 2021, compared to $219.3 million for the same period in 2020. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash used in investing activities for the year ended December 31, 2021, was due primarily to net purchases of investments of $352.8 million, cash paid, net of cash acquired, of $319.8 million for the acquisitions of Omniome and Circulomics and purchases of property and equipment of $5.9 million.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash used in investing activities for the year ended December 31, 2020, was due primarily to net purchases of investments of $218.3 million and purchases of property and equipment of $1.0 million.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Financing Activities </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash provided by financing activities was $1.17 billion and $251.8 million for the year ended December 31, 2021 and 2020, respectively. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash provided by financing activities during the year ended December 31, 2021, resulted from net proceeds of $895.5 million from our February 2021 issuance of $900 million of 1.50% Convertible Senior Notes after deducting debt issuance costs, net proceeds of $294.8 million from our September 2021 private placement of common stock after deducting issuance </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">60</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">costs and proceeds of $31.8 million from the issuance of common stock through our equity compensation plans, partially offset by $52.0 million of Continuation Advances repaid to Illumina. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash provided by financing activities during the year ended December 31, 2020, resulted from net proceeds of $187.5 million from our August 2020 and November 2020 underwritten public equity offerings after deducting underwriter commissions and paid offering expenses, $34.0 million of Continuation Advances from Illumina and proceeds of $46.4 million from the issuance of common stock through our equity compensation plans, partially offset by $16.0 million we repaid for the remaining outstanding principal to Deerfield upon the maturity of the Facility Agreement.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Off-Balance Sheet Arrangements</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2021, we did not have any off-balance sheet arrangements.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the ordinary course of business, we enter into standard indemnification arrangements. Pursuant to these arrangements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology, or from claims relating to our performance or non-performance under a contract, any defective products supplied by us, or any acts or omissions, or willful misconduct, committed by us or any of our employees, agents or representatives. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments we could be required to make under these agreements is not determinable because it involves claims that may be made against us in future periods but have not yet been made. To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between us and such third parties in connection with such fundraising efforts. To the extent that such indemnification obligations apply to the lawsuits described in&#160;</span><a href="#Note8_Commitments_Contingencies" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Note&#160;8. Commitments and&#160;Contingencies</span></a><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> of this Form 10-K, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification agreements has been recorded as of December 31, 2021.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Critical Accounting Policies and Estimates </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based upon our Consolidated Financial Statements, which we have prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, cost of revenue, and operating expenses, and related disclosure of contingent assets and liabilities. Management based its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Revenue Recognition </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables; Service and other revenue consist primarily of revenue earned from product maintenance agreements.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">61</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods or services is transferred to our customers or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our instrument sales are generally sold in a bundled arrangement and commonly include the instrument, instrument </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">accessories, installation, training, and consumables. Additionally, our </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">instrument sale arrangements generally include a&#160;one year period of service. For such bundled arrangements, we account for individual products and services separately if they are distinct, that is, if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. Our </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">customers cannot benefit from our instrument systems without installation, and installation can only be performed by us or qualified distributors. As a result, the system and installation are considered to be a single performance obligation recognized after installation is completed except for sales to qualified distributors, in which case the system is distinct and recognized when control has transferred to the distributor which typically occurs upon shipment.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The consideration for bundled arrangements is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using average selling prices over a 12-month period combined with an assessment of current market conditions. If the standalone selling price is not directly observable, we rely on estimates</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices and other observable inputs. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts, distributor commissions, and sales taxes collected on behalf of governmental authorities.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Inventories </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inventories are stated at the lower of cost or net realizable value on a first-in, first-out (&#8220;FIFO&#8221;) basis. The cost basis of our inventory is reduced for any products that are considered excessive or obsolete based upon assumptions about future demand, market conditions and the release of new products that may supersede old ones. If actual future demand or market conditions are less favorable than those projected by management, additional inventory write-downs may be required, which could have a material adverse effect on the results of our operations.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Goodwill and Intangible Assets </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We make assumptions and estimates in determining the fair value of assets acquired and liabilities assumed in a business combination. The determination of fair value of intangible assets, which represents </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">a significant portion of the purchase price in most acquisitions, requires the use of significant judgment relating to the fair value, whether the asset should be amortized, and if so, the period and method by which the intangible asset should be amortized. The Company estimates the fair value of the acquisition-related intangible assets primarily using the income approach, which discounts expected future cash flows to present value at the dates of the acquisition.</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Expected future cash flows utilize significant assumptions such as assumed revenue growth, discount rate and obsolescence factors</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Finite-lived intangible assets, our developed technology and customer relationships, are capitalized and amortized over the lesser of the terms of the agreement or estimated useful life. We regularly review the carrying amount of our finite-lived intangible assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. We make judgements about the recoverability of finite-lived assets when events or changes in circumstances indicate that an impairment may exist.  An impairment loss would be recognized when the sum of the expected future undiscounted net cash flows is less than the carrying amount of the asset. Should impairment exist, the impairment loss would be measured based on the excess of the carrying amount of the asset over the asset&#8217;s fair value.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">62</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Goodwill is evaluated for impairment annually in the </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">second quarter of each year, and when events occur, or circumstances change that would more likely than not reduce the fair value of the asset below its carrying value.  </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Qualitative factors that might require an interim evaluation include unexpected adverse business conditions, economic factors, unanticipated technological changes or competitive activities, loss of key personnel and acts by governments or courts.  </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">When impairment seems more likely than not during our qualitative assessment, we perform the quantitative assessment where we compare the fair value of the reporting unit with the carrying values, including goodwill. If the carrying amounts of the reporting units exceed the fair values, we will record an impairment loss based on the difference. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indefinite-lived intangible assets, our In-Process Research and Development (IPR&amp;D), is not subject to amortization and is assessed for impairment on, at least, an annual basis in the second quarter of each year. We review indefinite-lived intangible assets for impairment using a qualitative assessment. When impairment seems more likely than not during our qualitative assessment, we will proceed with a quantitative assessment where we estimate the fair value. Recoverability of indefinite-lived intangible assets is measured by comparing the carrying amount of the asset to its fair value. We make judgements about the recoverability of indefinite-lived assets when events or changes in circumstances indicate that an impairment may exist. Upon the commercialization of an IPR&amp;D asset, it is reclassified to developed technology, which is a finite-lived intangible asset, and amortized over its estimated useful life. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Estimates of discounted future cash flows require assumptions related to revenue and operating income growth rates, discount rates and other factors. We consider peer revenues and earnings trading multiples from companies that have operational and financial characteristics that are similar to the asset under measurement and estimated weighted average costs of capital. Different assumptions from those made in our analysis could materially affect projected cash flows and the evaluation of assets for impairment.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We acquired $11.4 million of finite-lived intangible assets, $400.0 million of IPR&amp;D and $410.0 million of goodwill in connection with the acquisitions of Omniome and Circulomics in the third quarter of 2021.  We will perform the first annual quantitative goodwill and IPR&amp;D impairment test in the second quarter of 2022. Through the review of qualitative factors in the fourth quarter of 2021, we noted no indications of impairment. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Contingent Consideration</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In connection with the acquisition of Omniome in the third quarter of 2021, we entered into an arrangement where we are obligated to pay $200 million in cash and equity dependent upon the achievement of a milestone event upon the first commercial shipment of products developed from our acquired sequencing technology. See </span><a href="#Note2_BusinessAcquisitions" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Note 2. Business Acquisitions</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for further information. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The contingent consideration liability was measured at fair value as of the acquisition date and is remeasured periodically at each reporting date, with changes in fair value recorded as change in fair value of contingent consideration in the statement of operations. The initial measurement and post-acquisition remeasurement require estimates and assumptions using a scenario-based method that considers a range of potential outcomes and assigned probabilities of occurrence for each outcome. Outcomes are discounted to present value, which is then weighted by the probability of each scenario to determine the total fair value of the contingent consideration payment as of each reporting period. Refer to </span><a href="#Note5_FinancialInstruments" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Note 5. Financial Instruments</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for further discussion on valuation assumptions.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Recent Accounting Pronouncements</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Please see </span><a href="#Note1_OrgandAccountingPolicies" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Note 1. Organization and Significant Accounting Policies</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, subsection titled &#8220;Recent Accounting Pronouncements&#8221;, in Part II, Item 8 of this Annual Report on Form 10-K for information regarding applicable recent accounting pronouncements.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.77in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.77in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-indent: 0;width: 0.770in;">ITEM&#160;7A. </span><span id="Item7A" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-transform: uppercase;">Quantitative</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-transform: uppercase;"> and Qualitative Disclosures About Market Risk</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Interest Rate and Market Risk</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our investment portfolio is exposed to market risk from changes in interest rates. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and cash equivalents and investments. </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">63</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we maintain a portfolio of cash equivalents and investments in a variety of securities of high credit quality. The securities in our investment portfolio are not leveraged, are classified as available for sale and are, due to their short-term nature, subject to minimal interest rate risk. We currently do not hedge interest rate exposure. Due to the short-term maturities of our investments, we do not believe that a hypothetical 10% adverse move in interest rates would have any material negative impact on the value of our investment portfolio. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We carry our convertible senior notes at the principal amount, less unamortized debt issuance costs, on our Consolidated Balance Sheets.  Because the notes have a fixed annual interest rate of 1.50%, we do not have any economic interest rate exposure or financial statement risk associated with changes in interest rates. The fair value of the notes, however, may fluctuate when interest rates and the market price of our stock changes. See </span><a href="#Note7_ConvertibleDebt" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Note 7. Convertible Senior Notes</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in Part II, Item 8 of this Annual Form 10-K for additional information. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 1pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Foreign Exchange Risk</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our revenue, expense, and capital purchasing activities are primarily transacted in U.S. dollars; however, a portion of our operations is conducted in foreign currencies. As a result, we have foreign exchange exposures relating to non-U.S. dollar denominated cash flows and monetary assets and liabilities that are denominated in currencies other than U.S. dollars. The value of the amounts is exposed to changes in currency exchange rates from the time the transactions are originated, until the time the cash settlement is converted into U.S. dollars. Our foreign currency exposure is primarily concentrated in the Euro. A 10% strengthening of the U.S. dollar exchange rate against all currencies with which we have exposure, after taking into account offsetting positions at December 31, 2021 would have resulted in a $2.7 million decrease in the carrying amounts of those net assets. Actual gains and losses in the future may differ materially from these hypothetical gains and losses based on changes in the timing and amount of foreign currency exchange rate movements and our actual exposure. Our international operations are subject to risks typical of international operations, including, but not limited to, differing economic conditions, changes in political climate, differing tax structures, other regulations and restrictions and foreign exchange rate volatility.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">64</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-indent: 0;width: 0.500in;">ITEM&#160;8. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">FINANCIAL STATEMENTS AND SUPPLEMENTAL DATA </span><span id="FinancialStatements" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 9pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PACIFIC BIOSCIENCES OF CALIFORNIA, INC. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Index to Consolidated Financial Statements </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 90.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 90.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 9.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 90.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Page(s)</span></p><div style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-top: 1.0pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 90.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-indent: -0.17in;"><a href="#Auditors_opinion" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Report of Independent Registered Public Accounting Firm</span><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;"> (PCAOB ID: </span></a><ix:nonNumeric name="dei:AuditorFirmId" id="ct-nonNumeric-31de3ef3-92ae-4fa9-a379-d1e96bd177dd" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">42</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">66</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 90.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-indent: -0.17in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Consolidated Financial Statements</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 90.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-indent: -0.17in;"><a href="#BS" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Consolidated Balance Sheets</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">69</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 90.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-indent: -0.17in;"><a href="#IS" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Consolidated Statements of Operations and Comprehensive (Loss) Income</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">70</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 90.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-indent: -0.17in;"><a href="#SE" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">71</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 90.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-indent: -0.17in;"><a href="#CF" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Consolidated Statements of Cash Flows</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">72</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 90.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-indent: -0.17in;"><a href="#Notes" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Notes to Consolidated Financial Statements</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">73</span></p></td></tr></table></div><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">65</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </span><span id="Auditors_opinion" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To the Stockholders and the Board of Directors of Pacific Biosciences of California, Inc.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Opinion on the Financial Statements</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have audited the accompanying consolidated balance sheets of Pacific Biosciences of California, Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive (loss) income</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">,</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&apos;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control&#8211;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 28, 2022 expressed an unqualified opinion thereon.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Basis for Opinion</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">These financial statements are the responsibility of the Company&apos;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Critical Audit Matters</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><sup> </sup></span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">consolidated</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">66</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;"><tr style="height: 0.01in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 116.25pt;"><span style="white-space:pre-wrap; "></span><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 351.75pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 116.25pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 351.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Business combinations - Valuation of intangible assets</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 116.25pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 351.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 116.25pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Description of the Matter</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 351.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As described in Note 2 to the consolidated financial statements, the Company completed its acquisitions of Omniome, Inc. and Circulomics, Inc. during 2021. The transactions were accounted for as business combinations. As a result of the acquisitions, the Company recorded goodwill of $410.0 million and intangible assets of $411.4 million. </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Auditing the Company&#8217;s accounting for the acquisitions was challenging because the determination of the fair value of the identified intangible assets, which principally consisted of in-process research and development (IPR&amp;D), required management to make subjective estimates and assumptions. The Company used an income approach to measure the intangible assets. The valuation of the intangible assets is subject to higher estimation uncertainty due to management&#8217;s judgments in determining significant assumptions that included assumed revenue growth and obsolescence factors. Changes in these significant assumptions could have a significant effect on the fair value of the intangible assets.</span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 116.25pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">How We Addressed the Matter in Our Audit</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 351.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls addressing the identified audit risks. For example, we tested controls over management&#8217;s review of the significant assumptions used to develop the fair value estimates of the intangible assets. We also tested management&#8217;s controls to validate that data used in the fair value estimates were complete and accurate. </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To test the estimated fair value of the intangible assets, we performed audit procedures that included, among others, evaluating the Company&#8217;s valuation models with the assistance of valuation specialists, performing sensitivity analyses to determine which assumptions had the greatest impact on the overall determination of value, and testing the completeness and accuracy of the underlying data used to develop the assumptions. We also evaluated the assumptions by comparing them to market and economic trends, historical results of the Company&#8217;s business and other guideline companies within the same industry.</span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">67</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 116.25pt;"><span style="white-space:pre-wrap; "></span><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 351.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Revenue recognition - Estimation of standalone selling price</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 116.25pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 351.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 116.25pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Description of the Matter</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 351.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As described in Note 1 to the consolidated financial statements, the Company&apos;s instrument is generally sold in a bundled arrangement and commonly includes the instrument, instrument accessories, installation, one-year period of service, training, and consumables. The consideration for bundled arrangements is allocated between separate performance obligations based on their individual standalone selling price.  The Company estimates the standalone selling price of each performance obligation using average selling prices over a 12-month period combined with an assessment of current market conditions. If the standalone selling price is not directly observable, then the Company estimates the standalone selling price by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices and other observable inputs. </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Auditing the Company&apos;s estimated standalone selling price is complex and required a higher level of judgment due to the level of estimation and subjectivity in establishing the standard selling price for products that are not sold separately. </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 116.25pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">How We Addressed the Matter in Our Audit</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 351.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls addressing the identified audit risks. For example, we tested controls over the process to determine the standalone selling price of each performance obligation. We also tested management&#8217;s controls to validate that data used were complete and accurate.</span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We tested management&#8217;s calculation of the standalone selling price by evaluating the completeness and accuracy of the underlying data used in management&apos;s calculation by agreeing the data to historical transactions and contract pricing for backlog orders. We also performed sensitivity analyses of significant assumptions to evaluate the changes in revenue recognized for the period under audit that would result from changes in the Company&apos;s estimated standalone selling price for the performance obligations.</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 36pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 36pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ </span><ix:nonNumeric name="dei:AuditorName" id="ct-nonNumeric-f72f7870-5e2a-4f8e-9821-ce9940605ba4" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Ernst &amp; Young LLP</span></ix:nonNumeric></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have served as the Company&#8217;s auditor since 2011.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="dei:AuditorLocation" id="ct-nonNumeric-94636b27-6333-4811-b529-c191adebe36c" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Redwood City, California</span></ix:nonNumeric></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2022</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">68</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span id="Consolidated_BalanceSheet" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Consolidated </span><span id="BS" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balance</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> Sheets</span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 30.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands, except per share amounts)</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Assets</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Current assets </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d5c2e910-3685-4f73-9136-07df07162169" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">460,725</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-aa283256-2652-4460-ae81-c43e9840e966" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">81,611</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Investments </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9b9963e7-99b4-416b-85bd-e6a967548973" name="us-gaap:ShortTermInvestments" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">583,675</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cd98a3ed-ae6d-4a6b-8d51-7a2286988855" name="us-gaap:ShortTermInvestments" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">237,203</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accounts receivable, net</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-163cc2ae-7709-4daf-af26-20c5773c8d43" name="us-gaap:AccountsReceivableNetCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">24,241</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bb008d58-4453-487a-8fc3-eec1f4d9eb88" name="us-gaap:AccountsReceivableNetCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">16,837</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inventory</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-54eb918b-e15c-4841-8543-8fc6c7ef93e2" name="us-gaap:InventoryNet" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">24,599</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c9c2054f-be7e-4d9d-9f27-676a4942a9e3" name="us-gaap:InventoryNet" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">14,230</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid expenses and other current assets </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4787d6b2-3ae8-435c-b2cf-a3e1135a091a" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,394</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dfd2f86a-4cf6-458f-b4d5-5874985a0a10" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,870</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Short-term restricted cash</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fcf0c16f-5d40-428f-81ba-dafaf867a4fa" name="us-gaap:RestrictedCashCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">500</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-06f465d7-e5a7-4f9f-841a-278c71651a7d" name="us-gaap:RestrictedCashCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">836</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total current assets </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6adaf220-2866-4b91-ae74-e3bbb2e53a05" name="us-gaap:AssetsCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,101,134</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a0a02f68-ba27-4bd3-9dd9-e35dedccdc53" name="us-gaap:AssetsCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">355,587</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment, net </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bc414ce4-5681-435b-940c-90f3bc746058" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">32,504</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b330fa70-21da-461f-ac1f-568703e5feb7" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">24,899</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease right-of-use assets, net </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6d378aa8-5ff9-4859-8f3e-daef16828beb" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">46,617</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4a476362-86dd-4e24-929d-79a63122fa30" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">29,951</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Long-term restricted cash</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-02679caa-f657-495b-8b9a-95d14bf1f561" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,592</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c21c788b-6620-4be1-a124-8001f2ab260e" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,500</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intangible assets, net</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c3df477e-aa74-4410-b3b7-b01c63b4d1a5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">410,979</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Goodwill</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bd8e0b25-8e98-42ee-a345-4cf6902bdae0" name="us-gaap:Goodwill" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">409,974</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other long-term assets </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-47ebf613-9cbd-4389-b081-9f79db477757" name="us-gaap:OtherAssetsNoncurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,170</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c69aa942-eef6-4214-9bcf-9985c0e1a1e9" name="us-gaap:OtherAssetsNoncurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">43</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total assets </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-da51de65-352c-475a-9f7f-b4662d01492a" name="us-gaap:Assets" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,006,970</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f791b945-4245-412c-ad48-a83fdb8c1211" name="us-gaap:Assets" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">413,980</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Liabilities and Stockholders&#8217; Equity </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Current liabilities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accounts payable </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2355c66b-d54a-4805-ad3c-2c789ddab419" name="us-gaap:AccountsPayableCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">11,002</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-14afaa21-e678-4f51-a0e0-9de966a241d6" name="us-gaap:AccountsPayableCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,579</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued expenses </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-090d5190-6d91-4b50-a96f-46d70c2fe830" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">36,261</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-83d5bbc0-e855-479d-9056-00a76f296034" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,350</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred revenue, current </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-80c285f7-bfca-440c-ba93-41f9f26c2101" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10,977</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fe1e1929-eb69-45e2-b519-2d5312523aea" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8,722</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liabilities, current</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cc03452f-de2e-4638-b948-02e6abb3c2ad" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,710</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ada47c97-117a-4b53-a56b-cba95504f5af" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,332</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other liabilities, current </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-647d3423-c39a-447a-9dcc-89c6158f5b59" name="us-gaap:OtherLiabilitiesCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,759</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-aaa5e04b-428b-4c3c-8034-9b135ceee99d" name="us-gaap:OtherLiabilitiesCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,519</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total current liabilities </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1f5bf8f7-6842-498a-bc56-8daaf1df4674" name="us-gaap:LiabilitiesCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">71,709</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-90491f07-8bbc-42c4-aa5f-783bd8077bda" name="us-gaap:LiabilitiesCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">38,502</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred revenue, non-current </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b6d12111-e024-491d-a49d-e010c57d0297" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">25,049</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-33e4d20e-b3d5-4824-8511-a2cec55d09bc" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,568</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Contingent consideration liability, non-current</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-56cbb077-cb54-4c01-aa82-695d6dcef92f" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">169,717</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liabilities, non-current </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cd4cd0a4-db3c-4a83-8987-fbe06b3c70e2" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">49,970</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a6cf280c-7534-415b-99b6-ba435e084063" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">37,667</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Convertible senior notes, net, non-current</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7aa35061-0bf1-4b0d-8568-77117cfce1a5" name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">896,067</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other liabilities, non-current </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1a10d532-e0d8-49b4-8684-b1210d9b98b8" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,471</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7548881a-fa72-44d6-8408-6b0cd149205d" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">752</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total liabilities </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-20a8acb8-ce5d-40ea-b78a-df983de746c8" name="us-gaap:Liabilities" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,215,983</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-56ab023e-1ec8-4a6d-9538-9f12ac3b7b7f" name="us-gaap:Liabilities" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">78,489</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commitments and contingencies </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-272c0ad2-cbce-4b43-8c6a-5f3a931cfd02;">&#160;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-91c7be65-3a9c-4f3f-baf5-bb6c340382ae;">&#160;</span></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stockholders&#8217; equity</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Preferred stock, $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0e8d609c-dbfa-4ba5-9465-c6372418a8e4" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="As_Of_12_31_2020" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-6e70a175-b3c8-4f8f-8ab0-603e71b87c37" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="As_Of_12_31_2021" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> par value:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Authorized </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-839205ba-e092-40b7-9c2b-79aec13846b1" name="us-gaap:PreferredStockSharesAuthorized" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3"><ix:nonFraction id="ct-nonFraction-ebc2c3c9-85d3-415c-b880-4358e64ba44a" name="us-gaap:PreferredStockSharesAuthorized" contextRef="As_Of_12_31_2021" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">50,000</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares; </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-567af0dd-6806-4538-a7db-624c8d6d2e31" name="us-gaap:PreferredStockSharesIssued" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-ad00071b-6c8e-4013-83dc-8018fa965501" name="us-gaap:PreferredStockSharesIssued" contextRef="As_Of_12_31_2021" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-7414eb41-c3f6-465b-bd03-771b139ec0ee" name="us-gaap:PreferredStockSharesOutstanding" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-db062ac3-daf7-4255-a69d-559438e3e7f3" name="us-gaap:PreferredStockSharesOutstanding" contextRef="As_Of_12_31_2021" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares issued or outstanding </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-d2485028-363e-4392-a795-dcac64f2aaa6;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-32b2087d-0dc9-4882-923e-433e378fe9f9;">&#8212;</span></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common stock, $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e7db06b8-57ea-4e14-878c-a42cbbbefe69" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="As_Of_12_31_2020" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-2433308d-b8a7-46fe-a605-d84abd7f8e47" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="As_Of_12_31_2021" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> par value:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Authorized </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2ceccb10-affc-42eb-a900-8b72a900867b" name="us-gaap:CommonStockSharesAuthorized" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3"><ix:nonFraction id="ct-nonFraction-d311accb-9075-453a-a03c-f0bf54b3de58" name="us-gaap:CommonStockSharesAuthorized" contextRef="As_Of_12_31_2021" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">1,000,000</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares; issued and outstanding </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-daf434d1-2218-43a4-9f15-d69d1f0c4609" name="us-gaap:CommonStockSharesIssued" contextRef="As_Of_12_31_2021" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3"><ix:nonFraction id="ct-nonFraction-95cc0506-dbbf-4a67-b29d-960b5ad232a7" name="us-gaap:CommonStockSharesOutstanding" contextRef="As_Of_12_31_2021" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">220,978</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-24e15aa4-6497-4c82-9a2d-117bd9fec7f3" name="us-gaap:CommonStockSharesIssued" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3"><ix:nonFraction id="ct-nonFraction-d290c820-bf64-49e4-bdeb-f3530f50619d" name="us-gaap:CommonStockSharesOutstanding" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">192,294</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares at December 31, 2021 and December 31, 2020, respectively </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-74f0dde5-8886-4d07-9a33-90bc224b18ca" name="us-gaap:CommonStockValue" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">221</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ccf72dd3-e3bf-4919-a82f-333cb0c2bc30" name="us-gaap:CommonStockValue" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">192</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additional paid-in capital </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0a4517c7-b633-4852-bdc1-e2a42ecb840d" name="us-gaap:AdditionalPaidInCapital" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,009,945</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a4218f14-fa19-4f34-999b-1738637079a5" name="us-gaap:AdditionalPaidInCapital" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,372,083</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated other comprehensive (loss) income </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e74690b9-303d-4928-959f-4afea9a4c5fd" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">1,087</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e8879b85-3eb6-462c-b004-236b14639553" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">85</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated deficit </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3eec3ea6-940d-4fab-8b91-c61f5d2c21e1" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">1,218,092</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d334d431-0822-4bdd-9b0f-4d00fc014989" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">1,036,869</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total stockholders&#8217; equity </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-650c4763-49a9-4393-9d98-876c20ba459f" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">790,987</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-39360d4e-229f-4ad0-9a9b-a5050c18f07a" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">335,491</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 69.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total liabilities and stockholders&#8217; equity </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-093bc273-decf-4a6f-8d4f-f67c84a8b4b8" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,006,970</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d0ed45e4-5a16-4e06-a8ca-4619518c9414" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">413,980</ix:nonFraction></span></p></td></tr></table></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">See accompanying </span><a href="#Notes" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">notes</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to the consolidated financial statements. </span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">69</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span id="Consolidated_ProfitLoss" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Consolidated Statements of </span><span id="IS" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Operations</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> and Comprehensive (Loss) Income</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 43.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands, except per share amounts)</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2019</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Revenue:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Product revenue </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2e94d8f3-c5b3-4520-b8b7-7a49360a94b0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">113,505</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e75e3d75-448b-4780-b236-58c96caec32f" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">65,424</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bf4a035c-cb15-4422-8e3c-ca4d9c0a49ee" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">77,742</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Service and other revenue </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-32131022-14b0-41d6-bb17-fe678a2b3f77" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,008</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c276da63-fe5b-4dd5-a876-d5a81c571cb8" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">13,469</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5fd5cd2b-f05e-407d-953d-eb0a9c1fd4c2" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">13,149</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.58in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total revenue </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-234521a3-ef62-4613-bf2d-d963edc970a4" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">130,513</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.58in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-eabc7729-9651-48d0-b805-c0c20234e3d1" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">78,893</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.58in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3381eb9a-bfaa-4ce1-8928-d693eb71a207" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">90,891</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cost of Revenue:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cost of product revenue </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-77063e35-fb51-4c42-b8c1-d946f500350b" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">56,358</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d5cd058a-e9d6-46f8-be07-e84347e5183d" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">35,424</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-12706945-c6d1-4b30-a8ef-254515643fd1" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">44,771</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cost of service and other revenue </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-81fb636a-02e9-4f59-8f22-0d32dd0e24c7" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">14,989</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-59143282-90be-450e-9b8c-a02a455451b7" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10,903</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-98a51f76-a7a0-44a2-b218-fe508c26d95d" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">11,544</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization of intangible assets</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ff8f8dcd-5384-40ac-a4b1-99ddfd1a076c" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">306</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.58in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total cost of revenue </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a18b513a-3f9e-4f2b-bbea-98d20793665a" name="us-gaap:CostOfRevenue" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">71,653</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.58in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4af6f348-5b1c-4cb8-8fd2-26d1dcc858c0" name="us-gaap:CostOfRevenue" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">46,327</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.58in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-288f20b3-1860-4eb9-b938-f3745316ee71" name="us-gaap:CostOfRevenue" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">56,315</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.92in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Gross profit </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 1.00in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-620ee34d-5920-4bb0-ac28-c532eb8c9780" name="us-gaap:GrossProfit" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">58,860</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.92in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 1.00in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-574e33e6-6bab-40b6-89b9-73890d906913" name="us-gaap:GrossProfit" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">32,566</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.92in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 1.00in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3851b177-0cf6-4aaf-a6d4-bd09dff401bc" name="us-gaap:GrossProfit" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">34,576</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating Expense:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c1b3f7af-81eb-46ed-9934-66b0b3001c72" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">112,899</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-db6a6d4c-7a4f-4569-8c7b-97d8133b5e0f" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">64,152</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f64ad57f-2c41-49fc-a56d-dab5142a0641" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">59,630</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Sales, general and administrative </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-341edae7-d737-4e89-818e-fd22f2bc2eb2" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">124,124</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a294ed95-b752-43be-81db-c7601e501d70" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">72,799</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3eb2e8c8-31a3-44a6-b96f-6541db593f13" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">75,491</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Merger-related expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-060c7ac2-12d1-41b1-a851-a42cc757ac01" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">31,129</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Change in fair value of contingent consideration</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8bc19d83-993b-4e38-935d-4483a232d4b3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,143</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.58in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total operating expense </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3cd449d9-83ad-4e5d-a91c-4c3fb493b431" name="us-gaap:OperatingExpenses" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">269,295</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.58in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c6139f6e-1d5b-4237-857c-742160179eb7" name="us-gaap:OperatingExpenses" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">136,951</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.58in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.67in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f94a5264-6c38-4d26-8941-4768f717345d" name="us-gaap:OperatingExpenses" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">135,121</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating loss </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e181c5f0-ff1e-4d4e-b28f-cb6294701d58" name="us-gaap:OperatingIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">210,435</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b0bec31b-1cea-4fe6-9e00-c9070d45caec" name="us-gaap:OperatingIncomeLoss" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">104,385</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-38df6862-2fbd-44d2-9c57-0c33106d7cd1" name="us-gaap:OperatingIncomeLoss" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">100,545</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Gain from Reverse Termination Fee from Illumina</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-234f126b-19f3-4354-be80-3295d577c947" name="pacb:GainLossOnReverseTerminationFee" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">98,000</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(Loss)/Gain from Continuation Advances from Illumina</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0568c9e9-6717-4f8f-8ec6-8b8d2bf2276d" name="us-gaap:GainLossOnContractTermination" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">52,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f68074f0-8209-49ce-a5fa-96d1b37b27ed" name="us-gaap:GainLossOnContractTermination" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">34,000</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8e8fdc76-776d-4d7a-b5c0-7002aff91457" name="us-gaap:GainLossOnContractTermination" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">18,000</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Interest expense </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-995f4e52-84d0-4afc-a92f-a3e350a27d26" name="us-gaap:InterestExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">12,530</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c42af5fb-54ef-4155-9a98-a383d372622f" name="us-gaap:InterestExpense" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">267</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0a93b37f-1d54-4eaa-8e17-9b0bc549b2ad" name="us-gaap:InterestExpense" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,611</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other income, net </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5c8202e0-f6cb-4b31-9ad7-815b322c0d71" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">93</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6ca132de-1444-4553-ad8c-920ac5bb5645" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,055</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bcfbb0e8-14b2-49cd-9173-9307c943eaf5" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,022</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(Loss) income before benefit from income taxes</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-88d8ef40-df4a-4aa7-8d1b-16635df61371" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">274,872</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c231b71a-b996-4238-b794-f24de08591e6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">29,403</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ea7b3384-b650-4885-b598-dbb320deb7c8" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">84,134</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Benefit from income taxes</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-126312a8-959d-4e91-9c2b-c7332949b140" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">93,649</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net (loss) income</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a41c134a-fd79-4d79-ac0f-690c26e8f49b" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">181,223</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5a769d77-28dc-4f60-af4a-6f60a4d99d73" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">29,403</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3ebea204-9ff6-46e2-b351-10d6a141a80c" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">84,134</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other comprehensive (loss) income:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Unrealized (loss) gain on investments </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-002a13ff-34d1-41ad-9040-1333c88cc5b2" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">1,172</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a11ad2b2-2a3b-4ae2-89a7-99ffd1bed5d3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">80</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8c4d614e-3795-447e-b446-dcd133f6252e" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">41</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Comprehensive (loss) income</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fb3c14e2-a6f4-40c8-b640-5f4502d68d15" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">182,395</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bb37ceee-be98-481c-b5bb-cb66cc5e1c2e" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">29,483</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-93959884-dc7a-470f-a785-bf6e243e5e90" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">84,093</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net (loss) income per share:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Basic </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-814c604d-7f90-457c-bc99-040abfb7c166" name="us-gaap:EarningsPerShareBasic" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" sign="-">0.89</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8db2e302-114b-4160-9674-1867750d3a46" name="us-gaap:EarningsPerShareBasic" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">0.18</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-03ab7caa-b795-46f7-89b8-c01302c01bc3" name="us-gaap:EarningsPerShareBasic" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" sign="-">0.55</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Diluted </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f4ddecfa-2086-4e89-b006-ece379b6487c" name="us-gaap:EarningsPerShareDiluted" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" sign="-">0.89</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-74d37f14-8353-4d34-8f85-a0cddc785511" name="us-gaap:EarningsPerShareDiluted" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">0.17</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-36e217e6-1807-4f53-b388-36ca3d2215a7" name="us-gaap:EarningsPerShareDiluted" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" sign="-">0.55</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Weighted average shares outstanding used in calculating net (loss) income per share</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Basic </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2fe115e8-aea4-49f2-89c7-8bc4cbec4710" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">204,136</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3216134b-9673-4e5d-8941-83ab4ab20a33" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">165,187</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5a7cdc85-4e56-48a9-8079-01a43616f07d" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">152,527</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 56.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Diluted </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-148905bf-920b-4664-8c2c-01d277f13b2f" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">204,136</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1dca59b4-5904-4145-b0a1-b99baf3062a6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">174,970</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4920865d-f196-4679-81ab-e2ead3eb329b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">152,527</ix:nonFraction></span></p></td></tr></table></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">See accompanying </span><a href="#Notes" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">notes</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to the consolidated financial statements.</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">70</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PACIFIC BIOSCIENCES OF CALIFORNIA, INC. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span id="Consolidated_StockholdersEquity" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Consolidated Statements of </span><span id="SE" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stockholders</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#8217; Equity</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Accumulated</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Additional </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Other</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Total</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="4" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Common Stock </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Paid-in</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Comprehensive </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Accumulated </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stockholders&apos;</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Shares</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amount</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Capital</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(Loss) Income</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Deficit</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Equity</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balance at December 31, 2018</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c06ebfc1-0dc7-41a2-96f5-1803c4737d76" name="us-gaap:CommonStockSharesOutstanding" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">150,244</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a40aeaf2-5e76-433a-8ea1-6688c805c8d5" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">150</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f0e93292-4de8-45f0-a4f7-99c3503960c7" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,096,053</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2bbdd5ed-ef32-4c27-b30b-d460d8603107" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">36</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-19891ae8-f854-41fa-b1c3-ba925927f386" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">982,106</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0efce515-7a2d-4fe9-a694-87904866f98b" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">114,061</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-848bded8-01c4-465d-ad35-bf185334a5d8" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">84,134</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8d6f46d5-827b-4e5d-9199-984f52dd87f4" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">84,134</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other comprehensive gain</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7c30e17f-b872-496b-ad73-30cc4a4a358f" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">41</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-be363dbe-59e0-4448-b486-252820123fc5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">41</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock in conjunction with equity plans</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-84a7e3ca-f8dd-4181-9487-ba1a262a2a3a" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">2,875</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f39749b2-f555-43b4-b37d-68cc659eb5e4" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5cf95d35-e805-4fb8-9704-f3837260e9d5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8,545</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e349c695-3e22-4377-a3c3-30609e9d1cb5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8,548</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation expense</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6e5aa3f0-41b9-4885-83fb-f1fb5fe22661" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">16,401</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8612c3cc-997f-48de-ad0c-5a636e4284e6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">16,401</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balance at December 31, 2019</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4abfcf62-ed90-4f7d-bd48-17b9b72401d9" name="us-gaap:CommonStockSharesOutstanding" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">153,119</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5879f360-83fc-40f9-859b-057084f30844" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">153</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-42f85971-354b-4c26-abcc-9dbaac46d39c" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,120,999</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-520a68fd-5837-43e1-b670-f7123cd89f80" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f51b1af7-5ae7-41f8-8b2f-6331b9e3f3b4" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">1,066,240</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d1b6c9ee-8e3d-4796-ab6c-9f64d46214cd" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">54,917</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net income</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4857c16e-4c44-4629-90eb-75cf542d69a6" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">29,403</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b5775874-ae34-48a1-af64-ace025d37282" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">29,403</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other comprehensive gain</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-98d0708b-ed82-4bee-b964-638f721e1308" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">80</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9f46e95b-5247-44dd-b15e-d8277a785284" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">80</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ASC326 adoption effect</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1bc08bba-6140-4f7e-8064-60802fdd3864" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2020_srt_RestatementAxis_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201904Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">32</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-774fbd7c-3b77-4ef6-b686-efc9fcc88f0f" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2020_srt_RestatementAxis_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201904Member" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">32</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock in conjunction with equity plans</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-97577e23-3273-4e74-afca-2f66314b0604" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">9,819</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bd580523-d45b-4e07-aa81-1095df41ccae" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7871755e-7616-4ebb-bb97-01f7e46a5579" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">46,350</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-48d8d27b-0bbe-44b7-9343-ef48ee017ae4" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">46,360</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock from Underwritten Public Equity Offerings, net of issuance costs</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ab291aa9-49c7-41a7-9a6a-fbf0924f968d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">29,356</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-66b16c27-f890-4fb3-b242-1ffc3eda1cc0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">29</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-99d3dc88-d949-4141-ac88-9230d01c9606" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">187,201</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ee004ff2-167e-4f2e-97a5-f0d2b17f5ca2" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">187,230</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation expense</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dfde40a8-fc4f-415f-9c5b-9d8b036c8b7a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,533</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c4fcf05e-d8c0-424e-9a08-9e1f634eafa7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,533</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balance at December 31, 2020</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7f275066-212f-4ec3-a6bc-ab425fc3ee13" name="us-gaap:CommonStockSharesOutstanding" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">192,294</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4f4ef83c-2fe6-4b9b-a988-7ca74e390680" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">192</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-36c4e9ed-5286-4bb1-8558-a8284e034d84" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,372,083</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4b84a06a-0f63-4736-8bf9-16289b8b83be" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">85</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-739680a8-d6bb-47ad-a17c-2616ac85a87a" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">1,036,869</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-949eb8e1-4636-4053-b5f5-2ed183f53d5d" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">335,491</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ab6b6cdd-2441-4290-9849-e7039bf911e8" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">181,223</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-44d33126-a098-481b-821e-4a86cc87013b" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">181,223</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other comprehensive loss</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8dd80f50-34a2-4fbd-9c16-b5a168f88a3a" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">1,172</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c703cd7c-05af-4236-924f-538bafc9eaf7" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">1,172</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock in conjunction with equity plans</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5a53ccea-0309-4116-aad3-9cc40e422e66" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">8,557</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-01d2f7f4-f2b5-4e46-9c16-96c7ec87a667" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-169b2c7f-3c84-4bfe-8512-99296c9be24a" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">31,797</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a89c6b01-e640-416a-a2c9-cddaa4b0391c" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">31,806</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock in Private Placement, net of issuance costs</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d8ebc3ce-94b7-457d-bfef-2d6936e5aebd" name="pacb:IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">11,215</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-20478285-4a26-4215-b84f-0111d6d6017d" name="pacb:StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">11</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-04079d83-417e-4d9f-9f2a-19002a37fb73" name="pacb:StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">294,834</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-08a1d3d6-fd86-4b44-8335-383e1fb6dc07" name="pacb:StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">294,845</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock in acquisition of Omniome</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-487574a3-3726-48cf-8b67-ca8c38fdd0a7" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">8,912</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fe92d27d-5f75-4421-a8da-e7cc4c401031" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a6e0ccd7-a3ef-49c3-8c6f-6c10e4426ff6" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">237,876</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bbcb4411-9c3a-4df8-a1f9-f93e8afd464d" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">237,885</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation expense</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4cbfccdd-604c-4837-aa25-f25d40b29fc1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">73,355</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f4cfc0cd-d528-4dbc-ad96-aea22f056b01" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">73,355</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balance at December 31, 2021</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-37a3d983-6780-4d97-91e2-d5274956e4b2" name="us-gaap:CommonStockSharesOutstanding" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">220,978</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fc28d275-a551-4280-8c33-80f19db1a7e2" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">221</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7b23897c-77f4-4fdb-92bd-a3f08430876a" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,009,945</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b10b2e16-102e-489c-8c0f-7042f929c7e1" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">1,087</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-526657c1-3b35-475b-a2f9-607d04565bdc" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">1,218,092</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0702cbb2-83cc-44be-a688-f83ad778cb0e" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">790,987</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr></table></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 9pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">See accompanying </span><a href="#Notes" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">notes</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to the consolidated financial statements.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">71</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span id="Consolidated_CashFlowStmt" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Consolidated Statements of </span><span id="CF" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> Flows</span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.6pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.1pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.6pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.1pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2019</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash flows from operating activities</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.1pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net (loss) income</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-36ca32c5-0728-4bb5-b7cc-b5b4981ca170" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">181,223</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7744681c-e5ba-4730-ab81-fc174716872c" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">29,403</ix:nonFraction></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7d091be2-d905-4b95-901f-df8467a79887" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">84,134</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Adjustments to reconcile net loss to net cash used in operating activities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Loss (gain) from Continuation Advances </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1894aa79-143c-40bb-837e-e14dfd85cf26" name="us-gaap:GainLossOnContractTermination" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">52,000</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a584a6bd-9f8b-45fb-abc4-1ca21b7ea2e8" name="us-gaap:GainLossOnContractTermination" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">34,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-64ef155f-54ad-4133-8e6b-1bf73ccc8a8d" name="us-gaap:GainLossOnContractTermination" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">18,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Depreciation </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1f89ee5d-45b5-4fed-9405-9eefab78c04d" name="us-gaap:Depreciation" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,199</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cf3cb136-f46e-4200-9c57-9817ceb48324" name="us-gaap:Depreciation" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,428</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-12953702-3709-4d18-87f9-722470ad5197" name="us-gaap:Depreciation" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,265</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization of intangibles</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1ebb746b-c5ad-44a2-845d-e66eae7b94a3" name="pacb:AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">381</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization of right-of-use assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-620b764c-5301-41e0-8559-3097e12044a7" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,005</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dcd658d2-50f3-4501-8743-7b5abc7ccd15" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,876</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0d081f88-7f3c-4a6a-8838-564a07b3a0ca" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,683</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization of debt discount and financing costs</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-39697cd8-30e7-46c2-a2be-fc34b88d47c7" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">539</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3e7064ff-4bfa-4736-8a1c-dea29a2751b8" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">129</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-abc91cdc-c9e9-4bf4-9571-b9f256ef3f86" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,212</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d07f19f4-ce64-4462-886e-50e0ec818be3" name="us-gaap:ShareBasedCompensation" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">73,355</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-177095d3-3ae7-43d8-bf58-dcfaed662e96" name="us-gaap:ShareBasedCompensation" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,533</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f936cca9-32fc-4edc-a6d7-689e67d2b724" name="us-gaap:ShareBasedCompensation" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">16,401</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Loss from derivative</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-35376783-df52-4a37-bbf4-ba3294073a75" name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">16</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization (accretion) from investment premium (discount)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cdbdd1e4-3074-439c-8e19-20eaeade34b6" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">4,011</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-794e4f02-8a71-4bce-889b-d541c590588c" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">107</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-af9b7f96-7adf-4b45-ad58-ab415aee937c" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">913</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Change in the estimated fair value of contingent consideration</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-221e47fa-0767-4e9a-9001-51ca10cd148c" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,143</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Loss on disposition of equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-342dd1b8-6d7a-4002-be69-3a3cb5ffe86a" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">54</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a57022b6-b4fb-4917-a4f6-27673f46b975" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">194</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred income taxes</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1cf085a5-9335-48af-806c-db4c267eaa88" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">93,649</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Changes in assets and liabilities </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.6pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.1pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accounts receivable </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c2e6dd2d-64ab-4d6a-9f38-51a172ee048d" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,166</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4696d09c-7b8c-4d61-b9c7-d5035afcd00f" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,603</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d2d89753-1a00-440d-b4f8-baa4807ed38e" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,671</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inventory </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-45608407-3331-4f40-b612-27e9d7ce538b" name="us-gaap:IncreaseDecreaseInInventories" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">12,431</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0fe76a92-a8b4-446a-9101-a79195db3651" name="us-gaap:IncreaseDecreaseInInventories" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,096</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-60f702fa-ee4d-48f2-85f7-489390ccb62b" name="us-gaap:IncreaseDecreaseInInventories" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">3,915</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid expenses and other assets </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-98ff2d4a-054b-42fd-a076-ac535b776bdd" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,024</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1663d0f3-8985-476c-92d5-f740611a71f5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,063</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3229ada8-43ca-4028-89d2-4f06bec82929" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">523</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accounts payable </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-940311e6-dcef-4b32-8bc1-e01757ec5fc2" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,363</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1cc0773e-ff4b-4309-bf51-68b070edb851" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">5,072</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5e7d0548-47c8-421b-8c30-e1674e40e5a7" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,713</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued expenses  </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-936fbccb-39dd-4488-8f2b-0eadada45ca9" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">15,320</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0edacfa7-306c-437e-b9ff-fb5145fdc7ec" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,102</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b9a632de-3d38-42af-93c2-08fbbb96a6b2" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,333</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred revenue </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-21b86b7e-7694-4ff6-85b2-64890aa9e998" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">25,736</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fd61088e-8c38-4ecd-91da-c03c4442da51" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">729</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-53167d06-6cb9-4369-ab2d-1b93776bfab3" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">2,134</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liabilities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-12fbac7b-0a7a-4d3b-8921-d02cb661dc58" name="us-gaap:OperatingLeasePayments" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,990</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ca3770c4-75bf-4cde-88c1-6794fabeb76f" name="us-gaap:OperatingLeasePayments" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,802</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e7f1d412-0787-4c59-a2ef-52bd64762221" name="us-gaap:OperatingLeasePayments" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,428</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other liabilities </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cae0163e-2c1e-4c4b-a110-2a318d01891f" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">803</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4cd3679c-3092-4a65-b6f9-400544e853b1" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,046</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3f62bf7e-7d86-413f-a2d8-f4f2660364df" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">2,477</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.75in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash (used in) provided by operating activities </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a0ed39e9-a452-44b5-9cc9-d894da4aeae5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">111,180</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.75in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-57a0fa91-fe68-4e47-811b-2b3fbf8644a8" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">19,503</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.75in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-25a1787c-7519-4187-b43f-055af4c9dc94" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">78,312</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash flows from investing activities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.6pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.1pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Purchase of property and equipment </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-12ef068b-8b0e-47a7-99b9-ec44d8c855bd" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,931</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3d18cf89-f602-43eb-92bf-94f41a28dd6e" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,039</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4ad246d3-84a6-498f-94f9-a05fbe4a5425" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,836</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash paid for purchase of Circulomics, net of cash acquired</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-aeaa15fc-9af5-4b04-952b-96bebabb786e" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">28,560</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash paid for purchase of Omniome, net of cash acquired</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3c31b26d-2c4e-4331-994a-b423babc9cce" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">291,233</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Purchase of investments </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cf027acb-29cf-490a-90b7-59b76e414567" name="us-gaap:PaymentsToAcquireInvestments" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">988,046</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3fe7a01d-c77b-44d0-ab93-405417036120" name="us-gaap:PaymentsToAcquireInvestments" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">373,283</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e9d6c88a-3646-4b3e-ae22-263cc7baf266" name="us-gaap:PaymentsToAcquireInvestments" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">57,727</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Sales of investments </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9f15382d-a2ad-4f71-b0fe-b6acb4914389" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">212,734</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-62db91e6-af6a-4117-a6e4-647f485c7a39" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,400</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-398f97ff-0bed-4fdd-b691-ad976124b73b" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,500</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Maturities of investments </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b640867d-5b20-45a6-9662-3f92d9b7d945" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">422,505</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-09c5a1ed-fb9b-4ac4-a235-6a80b033bf61" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">153,600</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8ce243c9-f48a-496c-9c8f-ff4fd1bcae80" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">121,110</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.75in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash (used in) provided by in investing activities </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-76952398-447c-45a9-9a2f-155d30da87f8" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">678,531</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.75in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9c0e1d6b-040d-481d-bfe8-ff1eb7038b95" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">219,322</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.75in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0d39c0e9-06fd-46b1-91ab-816e54498810" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">62,047</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash flows from financing activities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Continuation Advances</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-97b7ca78-01e0-4e99-b25c-a4aa904d59e4" name="pacb:ProceedsFromRepaymentsOfContractTermination" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">52,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ccf287aa-b25e-40e8-a68e-e162f36eb149" name="pacb:ProceedsFromRepaymentsOfContractTermination" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">34,000</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f6f453c5-286f-48cd-8112-e9328379347c" name="pacb:ProceedsFromRepaymentsOfContractTermination" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">18,000</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proceeds from issuance of Convertible Senior Notes, net of issuance costs</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-007c342c-86bb-4364-812f-14aafdf12299" name="us-gaap:ProceedsFromConvertibleDebt" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">895,536</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proceeds from issuance of common stock under equity offerings, net of issuance costs</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d74b4a5e-29ab-4a77-8337-30cc5f024ef5" name="pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">294,845</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4ff4237c-add1-4932-a2ee-158250882646" name="pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">187,479</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proceeds from issuance of common stock from equity plans</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dc9f16af-6f32-468a-8922-bce6e1098931" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">31,806</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8845eeb5-1c16-4a54-b117-744c519ffdec" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">46,360</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-495e3c55-f855-4d37-b360-3808f0119583" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8,548</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Notes payable principal payoff </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ff0a80e2-d4cd-4f52-907b-53715d7a01e9" name="us-gaap:RepaymentsOfNotesPayable" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">361</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-53b9f35c-5e79-4830-969d-0f6e3092966c" name="us-gaap:RepaymentsOfNotesPayable" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">16,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a2b0b68a-071d-4b8f-a158-9b02d95efb07" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">245</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.75in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash provided by financing activities </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0a130728-3d70-4bb8-bd5f-f4833c7def87" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,169,581</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.75in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0bd14ef3-c908-4bed-8fb3-fb27f3a297b8" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">251,839</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.75in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0b5ff76f-986c-43f2-aa5d-ad52f0378b5b" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">26,548</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net increase in cash and cash equivalents and restricted cash</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-67fd90b9-b502-4eda-af32-6edac5e13e3f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">379,870</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.75in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2137f2c6-85c0-484e-a09e-8247119ddac2" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">52,020</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.75in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-01bfd42e-ef67-4950-bf0c-f9c948906279" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10,283</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents and restricted cash at beginning of period </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2a501384-b962-4e01-b9bd-decda3e12271" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">85,947</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-28974f1d-bd96-4598-ab55-e7d2d09f4457" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">33,927</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-69a6a5e8-6e4b-410f-b975-7a2e6fa65e98" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">23,644</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents and restricted cash at end of period </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-89b88439-3acc-4781-a8b3-f9f4ffbb2c8e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">465,817</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8e0ab16b-d178-407e-b80d-c22c2c8cd803" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">85,947</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1ec234b3-17bf-4fa3-922b-eb0a904c662f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">33,927</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents at end of period </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7d7a2bfa-057c-43d8-a082-8e118cfe8e30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">460,725</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-06cb146c-2857-4396-9e42-d4cf4e2ad33d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">81,611</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bd2d7b83-e4a7-4b82-bc2a-53a74a0dde7a" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">29,627</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Restricted cash at end of period </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c8a49315-4532-47ba-a8a5-eb63122af2ba" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,092</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3d5279bc-9caa-4bc2-ba47-340e6322bd4c" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,336</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2617fd80-e69d-4212-b400-10dfe45d7989" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,300</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents and restricted cash at end of period </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7666d46f-1fb3-42bf-8a8b-e1526cc00af8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">465,817</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-79bf65fb-b63e-4866-a8ad-1ca0316f2778" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">85,947</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-409134e3-e172-4bbf-8ed8-57656c583cb0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">33,927</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.75pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Supplemental disclosure of cash flow information</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.6pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.1pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Interest paid</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7877ac50-827c-420f-945d-632e4d2dfc49" name="us-gaap:InterestPaidNet" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,928</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3c5d0d92-16a3-4222-a04b-ab1090d66727" name="us-gaap:InterestPaidNet" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">491</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d8f1c225-aaff-4b34-a3b1-c69710857ca2" name="us-gaap:InterestPaidNet" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,400</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Supplemental disclosure of non-cash investing and financing activities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.65pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.75pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inventory transferred to property and equipment </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6e7745ed-e7aa-4b7e-a060-b065b6c54ffd" name="pacb:InventoryTransferredToFromPropertyAndEquipment" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,586</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9bd77e73-4650-4a48-8d33-6a3365d3bd17" name="pacb:InventoryTransferredToFromPropertyAndEquipment" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,097</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-58f81175-d831-486d-b25b-970bcede660b" name="pacb:InventoryTransferredToFromPropertyAndEquipment" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,062</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment transferred to inventory</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-abab3cae-e78c-41f4-9daa-6cbb2efd6c5e" name="pacb:InventoryTransferredFromPropertyAndEquipment" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">383</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0f7aa8af-81af-4916-9150-b60c7d11506e" name="pacb:InventoryTransferredFromPropertyAndEquipment" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">919</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8f7aac32-9a1d-476a-93b7-e68e8b553923" name="pacb:InventoryTransferredFromPropertyAndEquipment" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,536</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Right-of-use asset and liability additions and modifications</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c1ade6e5-b63d-407a-a5ad-4ef6f2943be6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,576</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> -</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> -</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 344.2pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock in acquisition of Omniome</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.6pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f48d25e7-9e58-4712-bed0-a84d1d06894f" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">237,885</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.65pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> -</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.1pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> -</span></p></td></tr></table></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">See accompanying </span><a href="#Notes" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">notes</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to the consolidated financial statements. </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">72</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PACIFIC BIOSCIENCES OF CALIFORNIA, INC. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span id="Notes" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Notes to Consolidated Financial Statements </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="Note1_OrgandAccountingPolicies" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb-continuation-0" continuedAt="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb-continuation-1"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Business Overview</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems.  Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing technology and our emerging short read Sequencing by Binding (SBB</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #333333;font-family: 'Arial', 'sans-serif';font-size: 8.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>&#174;</sup></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">) technology. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our products address solutions across a broad set of applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our focus is on providing our customers with advanced sequencing technologies with higher throughput and improved workflows that we believe will enable dramatic advancements in routine healthcare. </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies and agricultural companies.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">References in this report to &#8220;PacBio,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; and &#8220;our&#8221; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:nonNumeric name="us-gaap:BasisOfAccounting" id="ct-nonNumeric-25e7d500-8739-4bae-ac1f-efdd4738640d" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-25e7d500-8739-4bae-ac1f-efdd4738640d-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Basis of Presentation </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-25e7d500-8739-4bae-ac1f-efdd4738640d-continuation-0"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. </span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:nonNumeric name="us-gaap:UseOfEstimates" id="ct-nonNumeric-e873fc7d-431a-408d-a44a-ebc8d8e08efb" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-e873fc7d-431a-408d-a44a-ebc8d8e08efb-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Use of Estimates </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-e873fc7d-431a-408d-a44a-ebc8d8e08efb-continuation-0"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates including, but not limited to, the valuation of inventory, the determination of stand-alone selling prices for revenue recognition, the fair value of contingent consideration, the valuation of acquired intangible assets, the fair value of certain equity awards, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, the borrowing rate used in calculating the operating lease right-of-use assets and operating lease liabilities, the probability associated with variable payments under partnership development agreements, and the valuations related to our convertible senior notes. While the extent of the impact of the COVID-19 pandemic on our business is highly uncertain, we considered the impact on our assumptions and estimates used to determine the results reported and asset valuations as of December 31, 2021. Actual results could differ materially from these estimates. </span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><ix:nonNumeric name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ct-nonNumeric-ccd307b7-89a3-48c8-98e6-1fddef07aedf" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-ccd307b7-89a3-48c8-98e6-1fddef07aedf-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Functional Currency</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-ccd307b7-89a3-48c8-98e6-1fddef07aedf-continuation-0"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The U.S. dollar is the functional currency of our international operations.  We remeasure foreign subsidiaries monetary assets and liabilities to the U.S. dollar and record net gains or losses from remeasurement in other income, net, in the consolidated statement of operations and comprehensive (loss) income.</span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ct-nonNumeric-9d749fcc-f437-4dc2-a33a-9465d0eb811b" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-9d749fcc-f437-4dc2-a33a-9465d0eb811b-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash, Cash Equivalents, and Investments </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-9d749fcc-f437-4dc2-a33a-9465d0eb811b-continuation-0" continuedAt="ct-nonNumeric-9d749fcc-f437-4dc2-a33a-9465d0eb811b-continuation-1"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We classify our investments in debt securities as available-for sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-</span></p></ix:continuation></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">73</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb-continuation-1" continuedAt="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb-continuation-2"><div><ix:continuation id="ct-nonNumeric-9d749fcc-f437-4dc2-a33a-9465d0eb811b-continuation-1"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">related.  Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive (loss) income in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and US government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.</span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" id="ct-nonNumeric-280d9f4f-b16b-48b0-9741-f1041184212f" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-280d9f4f-b16b-48b0-9741-f1041184212f-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Concentration and Credit Risks </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-280d9f4f-b16b-48b0-9741-f1041184212f-continuation-0" continuedAt="ct-nonNumeric-280d9f4f-b16b-48b0-9741-f1041184212f-continuation-1"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments that potentially subject us to credit risk consist principally of interest-bearing investments and trade receivables. We maintain cash, cash equivalents and investments with various major financial institutions. The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities and government agencies of high credit standing. At December 31, 2021, most of our cash was deposited with U.S. financial institutions.  Our investment policy generally restricts the amount of credit exposure to any one issuer. There is no limit to the percentage of the portfolio that may be maintained in securities issued by the U.S. Treasury and U.S. Government Agencies, or other securities fully backed by US Treasury or Government agencies. We have not experienced significant credit losses from financial institutions.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our trade receivables are derived from net revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers&#8217; financial condition and, generally, require no collateral from our customers. The allowance for doubtful accounts is based on our assessment of the collectability of customer accounts. We regularly review our trade receivable including consideration of factors such as historical experience, the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. We have not experienced any significant credit losses to date. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For the years ended December 31, 2021, 2020 and 2019, one customer, Gene Company Limited, accounted for approximately </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dfafaf69-b089-4857-ad1a-29e143e13415" name="us-gaap:ConcentrationRiskPercentage1" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_pacb_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">13</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cd5b7ce0-7913-4dc6-92b6-206de2980504" name="us-gaap:ConcentrationRiskPercentage1" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_pacb_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">14</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% and </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-68a53b09-5d3f-405e-b932-8beaf3d2eba2" name="us-gaap:ConcentrationRiskPercentage1" contextRef="Duration_1_1_2019_To_12_31_2019_srt_MajorCustomersAxis_pacb_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">17</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% our total revenue, respectively. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2021 and 2020, </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3d28c7a1-5b95-4941-86bb-33a3cecb9ff0" name="us-gaap:ConcentrationRiskPercentage1" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_pacb_DomesticCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">53</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% and </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-41e7eb0c-9e5c-44eb-9870-c70c18b972a3" name="us-gaap:ConcentrationRiskPercentage1" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_pacb_DomesticCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">43</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of our accounts receivable were from domestic customers, respectively. As of December 31, 2021, </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7eb8b5fe-8ed1-4006-8c11-e39f58b066e8" name="us-gaap:AccountsAndNotesReceivableNet" contextRef="As_Of_12_31_2021_srt_MajorCustomersAxis_pacb_TenPercentOrGreaterBalanceAccountsReceivableMember" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> customer represented 10% of greater of our net accounts receivable. As of December 31, 2020, two customers, Berry Genomics Co., Ltd and Gene Company Limited, represented approximately </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a75dabd6-a5b2-412d-bc0c-0e295b6916be" name="us-gaap:ConcentrationRiskPercentage1" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_pacb_CustomerDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">15</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% and </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-498deb68-a347-4101-9abd-fd2a5220c5e3" name="us-gaap:ConcentrationRiskPercentage1" contextRef="Duration_1_1_2019_To_12_31_2019_srt_MajorCustomersAxis_pacb_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">12</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of our net accounts receivable, respectively. </span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:continuation id="ct-nonNumeric-280d9f4f-b16b-48b0-9741-f1041184212f-continuation-1"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We currently purchase several key parts and components used in the manufacture of our products from a limited number of suppliers. Generally, we have been able to obtain an adequate supply of such parts and components but in certain instances have incurred additional costs to secure supply constrained materials. An extended interruption in the supply of parts and components currently obtained from our suppliers could adversely affect our business and consolidated financial statements. </span></ix:continuation></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" id="ct-nonNumeric-04672a80-35cc-4e24-a1a5-34a1b947e90f" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-04672a80-35cc-4e24-a1a5-34a1b947e90f-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Inventory </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-04672a80-35cc-4e24-a1a5-34a1b947e90f-continuation-0" continuedAt="ct-nonNumeric-04672a80-35cc-4e24-a1a5-34a1b947e90f-continuation-1"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inventories are stated at the lower of average cost or net realizable value. Cost is determined using the first-in, first-out (&#8220;FIFO&#8221;) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs while determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories. &#160; </span></p></ix:continuation></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">74</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb-continuation-2" continuedAt="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb-continuation-3"><div><ix:continuation id="ct-nonNumeric-04672a80-35cc-4e24-a1a5-34a1b947e90f-continuation-1" continuedAt="ct-nonNumeric-04672a80-35cc-4e24-a1a5-34a1b947e90f-continuation-2"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><ix:continuation id="ct-nonNumeric-04672a80-35cc-4e24-a1a5-34a1b947e90f-continuation-2"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.</span></ix:continuation></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ct-nonNumeric-9be23bb0-ca4d-42f7-8933-6981e59d4908" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-9be23bb0-ca4d-42f7-8933-6981e59d4908-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Property and Equipment, Net </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-9be23bb0-ca4d-42f7-8933-6981e59d4908-continuation-0"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment are stated at cost, reviewed regularly for impairment charges, and depreciated over the estimated useful lives of the assets, using the straight-line method.  Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Estimated useful lives of the major classes of property and equipment are as follows:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="pacb:EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock" id="ct-nonNumeric-849d340d-e5b7-4613-bc43-d8803c48ff56" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.8%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.8%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 15.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 44.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Estimated Useful Lives</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Leasehold improvements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 15.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 44.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ct-nonNumeric-ec0412c0-ac62-41c0-adfd-01be459fe548" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to </span><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ct-nonNumeric-d98c87c4-9364-4112-80b0-194237897ea4" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lab equipment</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 15.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 44.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ct-nonNumeric-89a56f48-3918-4a7b-b791-899751316220" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to </span><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ct-nonNumeric-afdfb85f-9357-4edb-a69b-9d207e1c81cd" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Computer equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 15.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 44.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ct-nonNumeric-ef2fe2e1-aca3-4720-8c63-732fe4f22d53" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to </span><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ct-nonNumeric-a9fe764e-dce4-4f3b-98fb-851c9f2e4ddd" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Computer software</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 15.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 44.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ct-nonNumeric-e4a8504c-fe26-4aa5-9d8f-8a9219d8584e" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furniture and fixtures</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 15.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 44.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ct-nonNumeric-b10e388b-b221-4b1c-b2a1-1765bdac5b1b" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to </span><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ct-nonNumeric-a813a487-0d17-4b1d-bb6d-d40badf08956" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years</span></p></td></tr></table></div></ix:nonNumeric></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ct-nonNumeric-ae87abb3-eb14-4da4-b151-b1a33ed0c2e5" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-ae87abb3-eb14-4da4-b151-b1a33ed0c2e5-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Impairment of Tangible Long-Lived Assets </span></ix:nonNumeric></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><ix:continuation id="ct-nonNumeric-ae87abb3-eb14-4da4-b151-b1a33ed0c2e5-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset is impaired or the estimated useful lives are no longer appropriate. Fair value is estimated based on discounted future cash flows. If indicators of impairment exist and the undiscounted projected cash flows associated with such assets are less than the carrying amount of the asset, an impairment loss is recorded to write the asset down to its estimated fair value. To date, we have not recorded any impairment charges.</span></ix:continuation></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" id="ct-nonNumeric-2353071e-1770-4bf1-8193-d23f4953e552" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-2353071e-1770-4bf1-8193-d23f4953e552-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Operating Leases </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-2353071e-1770-4bf1-8193-d23f4953e552-continuation-0"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We record operating lease right-of-use assets and liabilities on our Consolidated Balance Sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. Operating lease expense is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period incurred. </span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="ct-nonNumeric-7bd3870f-1ae1-43a9-8ddd-72f5b37c245a" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-7bd3870f-1ae1-43a9-8ddd-72f5b37c245a-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Goodwill and Intangible Assets</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-7bd3870f-1ae1-43a9-8ddd-72f5b37c245a-continuation-0"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We perform annual impairment testing of goodwill and in-process research and development project (&#8220;IPR&amp;D&#8221;) in the second quarter of each year, or more frequently if indicators of potential impairment exist.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We capitalize IPR&amp;D </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">assets and will begin to amortize the asset over the life of the product upon commercialization or record an impairment charge if the project is abandoned. We also capitalize finite-lived intangibles assets and amortize them on a straight-line basis over the estimated useful lives.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Finite-lived intangibles assets include our acquired developed technology and customer relationships. We regularly review the carrying amount and useful lives of our finite-lived assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives.&#160;</span></p></ix:continuation></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">75</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb-continuation-3" continuedAt="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb-continuation-4"><div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:nonNumeric name="pacb:ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock" id="ct-nonNumeric-543e4754-2f48-417a-89a9-64fba227d727" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-543e4754-2f48-417a-89a9-64fba227d727-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Short-term Restricted Cash </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-543e4754-2f48-417a-89a9-64fba227d727-continuation-0"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">At December 31, 2021, the short-term restricted cash balance of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-554dafcd-195c-4d38-af45-e2d185f01204" name="us-gaap:RestrictedCashEquivalentsCurrent" contextRef="As_Of_12_31_2021_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_SecurityDepositMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million consisted of </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">security deposits for employee credit cards</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:nonNumeric name="pacb:LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock" id="ct-nonNumeric-3e261846-f4ab-4d7f-ac30-fd8a0edfb973" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-3e261846-f4ab-4d7f-ac30-fd8a0edfb973-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Long-term Restricted Cash </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-3e261846-f4ab-4d7f-ac30-fd8a0edfb973-continuation-0"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Under the lease agreement for our corporate offices, we</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> were required to establish a letter of credit for the benefits of the landlord and to submit $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-55fcc704-2473-4971-b5d2-aba85e9fffc5" name="us-gaap:RestrictedCashEquivalentsNoncurrent" contextRef="As_Of_10_31_2015_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">4.5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million as a deposit for the letter of credit in October 2015. Subsequently pursuant to the terms of the O&#8217;Brien Lease, beginning on May 1, 2019, the amount of the letter of credit was reduced by $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-56dd3074-0643-4a00-b288-1e662c6b8cd6" name="pacb:AnnualReductionInNonCurrentRestrictedCash" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million each year thereafter on May 1. As such, $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-807629d9-497f-4773-bbe0-dcbde140a9ea" name="us-gaap:RestrictedCashEquivalentsNoncurrent" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">3.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b82ab556-fc16-4be8-94aa-680674d34639" name="us-gaap:RestrictedCashEquivalentsNoncurrent" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">3.5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million was recorded in long-term restricted cash related to the O&#8217;Brien Lease in the Consolidated Balance Sheets as of December 31, 2021 and December 31, 2020, respectively.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In connection with the acquisition of Omniome in September 2021, we acquired $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8737e76c-d88d-4de5-9fa8-92dca60ffbc2" name="us-gaap:RestrictedCashEquivalentsNoncurrent" contextRef="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">1.6</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of long-term restricted cash related to a letter of credit established for a facility lease.</span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" id="ct-nonNumeric-94e8be2a-b97a-4223-9696-ca9973e637db" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-94e8be2a-b97a-4223-9696-ca9973e637db-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Revenue Recognition </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-94e8be2a-b97a-4223-9696-ca9973e637db-continuation-0" continuedAt="ct-nonNumeric-94e8be2a-b97a-4223-9696-ca9973e637db-continuation-1"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables. Service and other revenue consists primarily of revenue earned from product maintenance agreements. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods or services is transferred to our customers or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our instrument sales are generally sold in a bundled arrangement and commonly include the instrument, instrument </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">accessories, installation, training, and consumables. Additionally, our </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">instrument sale arrangements generally include a&#160;one-year period of service. For such bundled arrangements, we account for individual products and services separately if they are distinct, that is, if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. Our </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">customers cannot benefit from our instrument systems without installation, and installation can only be performed by us or qualified distributors. As a result, the system and installation are considered to be a single performance obligation recognized after installation is completed except for sales to qualified distributors, in which case the system is distinct and recognized when control has transferred to the distributor which typically occurs upon shipment.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The consideration for bundled arrangements is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using average selling prices over a 12-month period combined with an assessment of current market conditions. If the standalone selling price is not directly observable, then we will estimate the SSP</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices and other observable inputs. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts, distributor commissions, and sales taxes collected on behalf of governmental authorities.  </span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><ix:continuation id="ct-nonNumeric-94e8be2a-b97a-4223-9696-ca9973e637db-continuation-1"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We record deferred revenues when cash payments are received or due in advance of our performance. Deferred revenue for instrument service contracts is recognized over the related performance period, generally one year to five years, on a straight-line basis as we are standing ready to provide services and a time-based measure of progress best reflects the satisfaction of the performance obligation. </span></ix:continuation></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">76</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb-continuation-4" continuedAt="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb-continuation-5"><div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:nonNumeric name="us-gaap:CostOfSalesPolicyTextBlock" id="ct-nonNumeric-82bfa7a2-e864-4795-8e9a-0f9241f55214" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-82bfa7a2-e864-4795-8e9a-0f9241f55214-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cost of Revenue</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-82bfa7a2-e864-4795-8e9a-0f9241f55214-continuation-0"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cost of revenue reflects the direct cost of product components, third-party manufacturing services and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain and support our instruments, consumables, and services. There are no incremental costs associated with our contractual revenue; all product development costs are reflected in research and development expense.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Manufacturing overhead is predominantly comprised of labor and facility costs. We determine and capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support our installed customer base. </span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ct-nonNumeric-36111a4c-dda1-4067-9aac-42015eb7961d" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-36111a4c-dda1-4067-9aac-42015eb7961d-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Research and Development </span></ix:nonNumeric></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:continuation id="ct-nonNumeric-36111a4c-dda1-4067-9aac-42015eb7961d-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development expense consists primarily of expenses for personnel engaged in the development of our core technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, partner development costs, facilities costs and other related overhead. We expense research and development costs during the period in which the costs are incurred. However, we defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered. </span></ix:continuation></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:nonNumeric name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" id="ct-nonNumeric-85301920-8f02-40c8-82d3-7a73a45acdc1" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-85301920-8f02-40c8-82d3-7a73a45acdc1-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Credit Losses</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-85301920-8f02-40c8-82d3-7a73a45acdc1-continuation-0"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We adopted Topic 326 on January 1, 2020. The adoption of Topic 326 did not have a material impact on our financial statements and our bad debt expense was immaterial as of the years ended December 31, 2020 and 2021. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Trade accounts receivable</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - The allowance for doubtful accounts is based on our assessment of the collectability of customer accounts. We regularly review the allowance by considering factors such as the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Available-for-sale debt securities</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and US government and agency securities. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as significance of loss, historical experience, market data, issuer-specific factors, and current economic conditions and concluded that an allowance for credit losses was immaterial as of December 31, 2021. The unrealized losses on our investments are</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">mainly attributable to government securities, including U.S. government and U.S. agency bond securities, impacted by movements in market rates and not due to issuer credit ratings. We have the ability to hold and do not intend to sell the investments in unrealized loss positions before the recovery of their amortized cost bases.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruptions associated with the evolution of the COVID-19 pandemic, or other customer-specific factors. </span></p></ix:continuation></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">77</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb-continuation-5" continuedAt="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb-continuation-6"><div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" id="ct-nonNumeric-c700afa5-bce9-4340-8c94-4312405ff2ff" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-c700afa5-bce9-4340-8c94-4312405ff2ff-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Income Taxes </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-c700afa5-bce9-4340-8c94-4312405ff2ff-continuation-0"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. The effect of a change in tax rates on the deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We regularly review our positions taken relative to income taxes. To the extent our tax positions are more likely than not going to result in additional taxes, we accrue the estimated amount of tax related to such uncertain positions. </span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ct-nonNumeric-1b801c94-a29e-4e84-bd0a-56a776358240" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-1b801c94-a29e-4e84-bd0a-56a776358240-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Stock-based Compensation </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-1b801c94-a29e-4e84-bd0a-56a776358240-continuation-0"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We account for share-based payments using a fair-value based method for costs related to all share-based payments, including stock options, restricted stock units, and stock issued under our employee stock purchase plan (&#8220;ESPP&#8221;). We estimate the fair value of share-based payment awards that are stock options and issued under our ESPP on the date of grant using an option-pricing model. See </span><a href="#Note10_StockholdersEquity" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Note 10. Stockholders&#8217; Equity</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for further information regarding stock-based compensation.</span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:nonNumeric name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="ct-nonNumeric-64ac521c-6b02-47ea-be05-fbe99dee97e7" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-64ac521c-6b02-47ea-be05-fbe99dee97e7-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Other Comprehensive (Loss) Income</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-64ac521c-6b02-47ea-be05-fbe99dee97e7-continuation-0"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other comprehensive (loss) income is comprised of unrealized gains (losses) on our investment securities. </span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:nonNumeric name="us-gaap:ShippingAndHandlingCostPolicyTextBlock" id="ct-nonNumeric-09580229-680f-4d90-b5be-88fad2acd497" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-09580229-680f-4d90-b5be-88fad2acd497-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Shipping and Handling</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-09580229-680f-4d90-b5be-88fad2acd497-continuation-0"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Costs related to shipping and handling are included in cost of revenues for all periods presented.</span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Recent Accounting Pronouncements </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Recently Adopted Accounting Standards</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In August 2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2020-06,&#160;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity.</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> This guidance simplifies the accounting for convertible instruments primarily by eliminating the existing cash conversion and beneficial conversion models within Subtopic 470-20, which will result in fewer embedded conversion options being accounted for separately from the debt host. The guidance also amends and simplifies the calculation of earnings per share relating to convertible instruments. This guidance is effective for annual periods beginning after December 15, 2021, including interim periods within that reporting period, excluding smaller reporting companies. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within that reporting period, using either a full or modified retrospective approach. We adopted ASU 2020-06 on January 1, 2021. Because we had no convertible instruments within the scope of ASU 2020-06 at the time of adoption, there was no impact of adoption on our consolidated financial statements. In February 2021, we issued $900 million of 1.50% Convertible Senior Notes due February 15, 2028, as described in </span><a href="#Note7_ConvertibleDebt" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Note 7.</span><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;"> Convertible Senior Notes</span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">,</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> which are accounted for under ASU 2020-06.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #212529;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In&#160;December 2019,&#160;the FASB issued ASU&#160;No.&#160;2019-12,&#160;</span><span style="white-space:pre-wrap; color: #212529;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Income Taxes (Topic&#160;</span><span style="white-space:pre-wrap; color: #212529;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">740</span><span style="white-space:pre-wrap; color: #212529;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">): Simplifying the Accounting for Income Taxes</span><span style="white-space:pre-wrap; color: #212529;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. This ASU simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step up in the tax basis of goodwill, and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The standard is effective for our annual reporting periods beginning after December 15, 2020, including interim reporting periods within those fiscal years. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not&#160;have a material impact on our consolidated financial statements.</span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">78</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb-continuation-6" continuedAt="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb-continuation-7"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Accounting Pronouncements Pending Adoption</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In October 2021, the FASB issued ASU No. 2021-08, </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Business Combinations (Topic 805):</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This ASU provides specific guidance on how to recognize contract assets and contract liabilities related to revenue contracts with customers acquired in a business combination. This amendment improves comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. This authoritative guidance will be effective for us in the first quarter of 2023, with early adoption permitted. We are currently evaluating the effect of this new guidance on our consolidated financial statements.</span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.34in;"><ix:continuation id="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb-continuation-7"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span id="Note2_BusinessAcquisitions" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:BusinessCombinationDisclosureTextBlock" id="ct-nonNumeric-ccd3e286-0983-49a8-8f67-f3f85b7168bf" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-ccd3e286-0983-49a8-8f67-f3f85b7168bf-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">NOTE 2. BUSINESS ACQUISITIONS</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-ccd3e286-0983-49a8-8f67-f3f85b7168bf-continuation-0" continuedAt="ct-nonNumeric-ccd3e286-0983-49a8-8f67-f3f85b7168bf-continuation-1"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Omniome, Inc.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On September 20, 2021, we completed our acquisition of Omniome, Inc. (&#8220;Omniome&#8221;), a San Diego-based company developing a highly differentiated, proprietary short-read DNA sequencing platform capable of delivering high accuracy. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In connection with the acquisition, all outstanding equity securities of Omniome were cancelled in exchange for approximately $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cffb3bc3-9440-4551-8da2-af67e0590627" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">315.7</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in cash, </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0f42e2c2-7280-4867-bb78-679df44bf032" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">8,911,580</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of our common stock with a fair value of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e91a9e64-6737-4e2f-ba1e-d170a8d2a756" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">249.4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and contingent consideration with a fair value of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0d0e760e-1aba-44aa-b4e2-892caca7d946" name="pacb:ContingentConsiderationIncurredDuringPeriod" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">168.6</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million. The fair value of the </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5023feb1-c92d-42e3-850e-2654c3fa4c91" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">8,911,580</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> common shares issued was determined based on the closing market price of PacBio&#8217;s common shares on the acquisition date.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, approximately $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9f7d0397-039b-42df-925d-0679006f55ae" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_AwardTypeAxis_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">18.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, comprised of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c8ca8ea2-0317-4e89-8727-76ffef2607ad" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_AwardTypeAxis_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">7.4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of cash, </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-db84688c-df4f-49f0-bedd-e952763e2a89" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_AwardTypeAxis_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">226,811</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of our common stock with a fair value of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bb171b94-0fd7-4e08-ad38-92e865ff7743" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_AwardTypeAxis_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">6.3</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, and $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3d065c8f-fadc-41ce-90bc-65c37bd123f6" name="pacb:ContingentConsiderationIncurredDuringPeriod" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_AwardTypeAxis_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">5.2</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million related to contingent consideration, was accounted for as a one-time post acquisition stock-based compensation expense. This stock-based compensation expense was due to accelerated vesting of Omniome stock awards in connection with the acquisition.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total consideration transferred for the acquisition is as follows (in thousands):</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="pacb:ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock" id="ct-nonNumeric-d42b6fbf-ef03-414a-9dd9-ea0821842b13" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total cash paid</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b29ee0ae-098d-4951-b427-aa8a88e6ed92" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">315,703</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Fair value of share consideration</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e884bcb5-b7b0-49ea-b195-69cf7d3def8d" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">249,435</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Fair value of contingent consideration</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4cf05aa0-f4cf-4655-8d92-c7828164ea98" name="pacb:ContingentConsiderationIncurredDuringPeriod" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">168,574</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less: Stock-based compensation expense excluded from consideration transferred</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a335bb5e-728a-46af-9730-d097f1fadf39" name="pacb:StockBasedCompensationExpenseExcludedFromConsiderationTransferred" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">18,923</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total consideration transferred</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1997c203-a5e5-4edd-81e2-f9a814961130" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">714,789</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The contingent consideration of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9d182fea-8ec1-49aa-a836-d36e03d19695" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_ContingentConsiderationByTypeAxis_pacb_AchievementOfMilestoneMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">200</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million (composed of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fcf61d6c-96cb-4357-b4aa-ab1752ea1f2f" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_ContingentConsiderationByTypeAxis_pacb_AchievementOfMilestoneMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">100</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in cash and $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5d049a13-b97a-46b5-a3bf-338e5cda47f5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_ContingentConsiderationByTypeAxis_pacb_AchievementOfMilestoneMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">100</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in shares of our common stock) is due upon the achievement of a milestone, defined as the first commercial shipment to a customer of a nucleotide sequencing platform, comprising both an instrument and related consumables, that utilizes </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">SBB </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">technology. The number of shares of stock to be issued will be determined using the volume-weighted average of the trading prices of our common stock for the twenty trading days ending with and including the trading day that is two days immediately prior to the achievement of the milestone. Of the $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8f7aa6d5-0f0e-4f8e-9039-d2721666c1c7" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_ContingentConsiderationByTypeAxis_pacb_AchievementOfMilestoneMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">100</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in shares of our common stock to be issued as part of the milestone, $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0da89a07-b183-4e82-aa06-8ff6c20ddd8c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_ContingentConsiderationByTypeAxis_pacb_AchievementOfMilestoneMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">4.1</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million is attributable to stock options issued by PacBio in replacement of Omniome&#8217;s unvested options as part of the transaction.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized in our Consolidated Statements of Operations and Comprehensive (Loss) Income. The fair value of the contingent consideration liability, with the assistance from a third-party valuation firm, is based on a scenario-based method which considers a range of possible outcomes and their assigned probabilities of occurrence. The potential outcomes are discounted to present value at a discount rate equal to the sum of the term-matched risk-free-interest rate plus PacBio&#8217;s credit spread. </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">79</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-ccd3e286-0983-49a8-8f67-f3f85b7168bf-continuation-1" continuedAt="ct-nonNumeric-ccd3e286-0983-49a8-8f67-f3f85b7168bf-continuation-2"><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The acquisition was accounted for as a business combination and, accordingly, the total fair value of the consideration transferred was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values on the acquisition date. The major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):</span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.38in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="ct-nonNumeric-316cbe3a-fbcc-46fd-bb8a-9a8cd0c9ed9c" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-31891769-df44-49cf-9af5-ae1a34019d89" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">15,338</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment, net </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-703a9b89-008c-4cf0-8b4f-afd42512460e" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,123</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease right-of-use assets, net </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-20d2affb-0076-4db5-87b3-b2f50c23304c" name="pacb:BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">18,095</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In-process research and development (&quot;IPR&amp;D&quot;)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-53b52366-70e1-4fff-97f9-38140a92f370" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">400,000</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Goodwill</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-001ac643-cf4a-4aa8-9d8a-b960653c581c" name="us-gaap:Goodwill" contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">390,665</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other assets</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d068b696-1ac7-405b-b07c-6bc903464cfd" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,203</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred income tax liability</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-39e44d25-3a7e-4ff7-ab9b-2944fda73e2e" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">91,814</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Liabilities assumed</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dfd3eeab-e777-4c9f-951c-67129ccd391f" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">26,821</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total consideration transferred</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7ef0eafb-5611-4c1b-9ab7-719e7de3f737" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">714,789</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The purchase price allocation is preliminary. We continue to collect information regarding certain estimates and assumptions, including potential liabilities and contingencies. We will recognize adjustments to the preliminary amounts with a corresponding adjustment to goodwill in the reporting period in which the adjustments to the preliminary amounts are determined over a period not to exceed twelve months.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the year ended December 31, 2021, we recorded a measurement period adjustment of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7136bf13-27d1-47b3-b1bc-367adb5b62d2" name="us-gaap:Goodwill" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6" sign="-">1.6</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million to decrease goodwill and a corresponding $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-758b9ba1-d0e5-49f4-a52d-3c344ff0b457" name="us-gaap:DeferredTaxLiabilitiesDeferredExpense" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6" sign="-">0.4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million to decrease the deferred tax liability on the Consolidated Balance Sheet, and a $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a1dfdfea-73dd-49a7-ae0f-781700e0f312" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6" sign="-">1.2</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million decrease to our benefit from income taxes on the Consolidated Statements of Operations and Comprehensive (Loss) Income. The measurement period adjustment was due to new information that became available to us upon the completion of the IRC Section 382 Tax Study, where we identified additional net operating losses that are available to us from acquired assets. Refer to </span><a href="#Note9_IncomeTaxes" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Note 9. Income Taxes</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for more information.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The goodwill recognized was primarily attributable to the assembled workforce and synergies that are expected to occur from the integration of Omniome and is not deductible for income tax purposes. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We allocated $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-88e20336-be6e-4dad-8347-e24441081ae1" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">400</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of the purchase price to acquired in-process research and development.  The fair value of the IPR&amp;D was determined, with the assistance of a third-party valuation firm, using an income approach based on a forecast of expected future cash flows. Expected future cash flows utilize significant assumptions such as assumed revenue growth, discount rate and obsolescence factors. The IPR&amp;D will remain on our consolidated balance sheet as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development activities. During the development period following the acquisition, IPR&amp;D will not be amortized, but instead will be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We incurred costs related to the Omniome acquisition of approximately $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-49966522-88d1-4a7d-aeff-7b0ae834c7a0" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">12.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million during the twelve months ended December 31, 2021, which are included in merger-related costs on the Consolidated Statement of Operations and Comprehensive (Loss) Income.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span id="_Hlk85563457" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Separately, in connection with the Omniome acquisition, on September 20, 2021, we issued and sold </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5a4474a3-bbf5-4aea-8d7c-5dab44cc0cd7" name="pacb:IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares" contextRef="Duration_9_20_2021_To_9_20_2021" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">11,214,953</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock in a private placement transaction at a price of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d828971a-3110-4c82-8481-293e7732f79b" name="us-gaap:SaleOfStockPricePerShare" contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">26.75</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share, for aggregate proceeds of approximately $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6712a9a6-7bff-4614-a010-3de224e9b7c1" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">294.8</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, net of issuance costs of approximately $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1eb38d0d-4361-4879-b0d2-cbe19519f963" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">5.2</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million.  We were also required to register the private placement shares for resale following the closing of the merger. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following unaudited pro forma financial information presents combined results of operations for each of the periods presented as if Omniome had been acquired as of the beginning of the comparable fiscal year prior to the year of acquisition, giving effect on a pro forma basis to the purchase accounting adjustments such as $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b123d31b-2da1-42f3-9f85-837b5a8041d9" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">12.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of PacBio acquisition-related costs, $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-82a7b72d-0add-4c8f-835d-fb5fea1dbb2c" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">18.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of stock-based compensation expense related to acceleration of certain Omniome stock options not attributable to pre-combination service, and a $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1afdf8aa-3c7c-4241-a444-06630a6bacd5" name="pacb:IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">91.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million one-time income tax benefit from the reduction of our deferred tax asset valuation allowance resulting from the Omniome acquisition, as well as a pro forma adjustment to reflect $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3abcae01-5ee9-4e94-9d6d-862d78e8d59e" name="pacb:ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">16.7</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of Omniome&#8217;s acquisition-related costs. The unaudited pro forma information presented below is for </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">80</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-ccd3e286-0983-49a8-8f67-f3f85b7168bf-continuation-2" continuedAt="ct-nonNumeric-ccd3e286-0983-49a8-8f67-f3f85b7168bf-continuation-3"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">informational purposes only and is not necessarily indicative of the consolidated results of the combined business had the acquisition actually occurred at the beginning of the fiscal year 2020 or the results of future operations of the combined business.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table summarizes the unaudited pro forma financial information:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.38in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.38in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="ct-nonNumeric-88e6b057-e395-4442-8471-6d6b9e055b33" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 59.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 59.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 59.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;">(in thousands, except per share amounts)</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 59.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 59.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pro forma total revenue</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-34b50231-a774-4967-9c62-40d1733f76a6" name="us-gaap:BusinessAcquisitionsProFormaRevenue" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">130,513</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7ee23b2f-03a6-4b6a-bb00-1352c6e4df56" name="us-gaap:BusinessAcquisitionsProFormaRevenue" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">78,893</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 59.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pro forma net (loss) income</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-eabfd9f5-7023-4f5b-a108-ba7a4b4c7c97" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">278,451</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-730f93c1-2c06-4ad5-85be-5027a3e72f74" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,510</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 59.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pro forma net (loss) income per share - basic and diluted</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b241fdd6-f692-47d6-9565-986181b79508" name="pacb:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" sign="-">1.27</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-711f5a92-2346-4d78-ab0a-b9679135af6b" name="pacb:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">0.09</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our consolidated financial statements include the results of operations for Omniome beginning September 20, 2021. Since the date of acquisition, revenues of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-19882983-1f15-4316-b810-1eae1210038d" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and a net loss of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5dcf0d2e-4cbd-4ea2-a1d7-760c517dca8c" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">15.6</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million from the acquired Omniome business have been included in our Consolidated Statement of Operations and Comprehensive (Loss) Income for the twelve months ended December 31, 2021.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Circulomics, Inc.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On July 20, 2021, we acquired Circulomics Inc. (&#8220;Circulomics&#8221;), a Maryland-based biotechnology company focused on delivering highly differentiated sample preparation products that enable genomic workflows.  </span></p><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We paid $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-265d895c-d67a-4adb-a1e2-f96775e07fa4" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="Duration_7_20_2021_To_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">29.5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in cash in exchange for all outstanding shares of common stock of Circulomics. We allocated the consideration transferred to the identifiable assets acquired and liabilities assumed based on their respective fair values at the date of the completion of the acquisition. The major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):</span></p><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.38in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="pacb:ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock" id="ct-nonNumeric-bc7d2377-69a8-463d-9695-db3a74d09fd0" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 74.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 74.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8a74f0e9-1552-458e-a294-8688ec4a299d" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">987</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 74.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment, net </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fdf7c051-4a1b-4cb4-a5e9-ef73d83f9df1" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">214</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 74.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intangible assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-67530150-4f02-4acc-ad69-71de9a4065c3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">11,360</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 74.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Goodwill</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6c3f664e-f6a3-4179-8290-010c7b5d6316" name="us-gaap:Goodwill" contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">19,309</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 74.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5e9e59cc-e9bd-4fa8-ad2f-3940e5f1389c" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">467</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 74.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred income tax liability</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-50c8daec-27f3-4a05-aaf0-50efe75642c8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,672</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 74.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Liabilities assumed</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8049f47c-08e8-424c-9507-4c9cadc92ff3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">118</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 74.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total consideration transferred</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8e4f5e39-a96b-4f25-ad76-c1b74a0c2bfb" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">29,547</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The excess of the value of consideration paid over the aggregate fair value of those net assets has been recorded as goodwill. We recognized goodwill of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cd4c5b1d-1431-420a-88b6-369c5d757961" name="us-gaap:Goodwill" contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">19.3</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, which is primarily attributable to the synergies expected from capabilities in extraction and sample preparation and is not deductible for income tax purposes.  </span></p><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We recorded $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-12c33e59-4edf-4e3b-88ca-5f5bbea5b712" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_7_20_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">11.4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million for the fair value of acquired intangible assets, of which $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8751b82c-2d58-433b-ae15-e1ef91f15f73" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_7_20_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">11.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million consists of developed technology. The fair value of the developed technology was determined, with the assistance from a third-party valuation firm, using an income approach based on a forecast of expected future cash flows. The purchase price allocation is preliminary as we continue to collect information with regard to certain estimates and assumptions. We will record adjustments to the fair value of the assets acquired, liabilities assumed and goodwill within the twelve-month measurement period, if necessary.</span></p></ix:continuation><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:continuation id="ct-nonNumeric-ccd3e286-0983-49a8-8f67-f3f85b7168bf-continuation-3"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="Note3_InvitaeCollab" style="text-decoration: none;"></span><ix:nonNumeric name="pacb:DevelopmentAndCommercializationAgreementDisclosureTextBlock" id="ct-nonNumeric-180acdbf-64b6-4ac1-a426-4a257e8fba71" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-180acdbf-64b6-4ac1-a426-4a257e8fba71-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">NOTE 3. INVITAE COLLABORATION ARRANGEMENT</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-180acdbf-64b6-4ac1-a426-4a257e8fba71-continuation-0" continuedAt="ct-nonNumeric-180acdbf-64b6-4ac1-a426-4a257e8fba71-continuation-1"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On January 12, 2021 we entered into a multi-year Development and Commercialization Agreement (the &#8220;Development Agreement&#8221;) with Invitae Corporation (&#8220;Invitae&#8221;). Pursuant to the Development Agreement, Invitae is providing certain funding to us to develop products relating to production-scale high-throughput sequencing (&#8220;Program Products&#8221;). If Program Products become commercially available, Invitae may purchase the Program Products. In addition to selling the Program Products to Invitae, we will have the right to broadly commercialize Program Products for sale to other customers.</span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">81</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-180acdbf-64b6-4ac1-a426-4a257e8fba71-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Under the Development Agreement, Invitae is funding certain development costs we incur in connection with the Program Products (&#8220;Program Development Costs&#8221;). Under the Development Agreement, we will be responsible for conducting a program to develop Program Products, and subsequently for manufacturing the Program Product. We jointly make general decisions regarding the development program with Invitae but we are responsible for research and development activities. The development program is expected to last approximately sixty months but may be shorter or longer.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The primary benefit of the arrangement to Invitae is preferred pricing on the Program Products. Each Program Product will have a preferential pricing period, which will not exceed four years from the date of the first delivery of that Program Product (&#8220;Preferential Pricing Period&#8221;). During the Preferential Pricing Period for each Program Product, we are obligated to sell the Program Product at a substantial discount to Invitae until a multiple of the contribution received from Invitae is repaid. For a specified period after the end of the Preferential Pricing Period, we have arranged to sell the Program Product to Invitae at a higher price, as determined by a formula, than the price during the Preferential Pricing Period (&#8220;Extended Pricing Period&#8221;).  The Extended Pricing Periods will terminate early if Invitae does not meet certain volume minimums.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We and Invitae may terminate the Development Agreement if the other party remains in material breach of the Development Agreement following a cure period to remedy the material breach and certain other circumstances by each party, including circumstances where Invitae may terminate for delays, intellectual property concerns, our change in control, or without cause. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In certain termination circumstances, (i) we will be obligated to refund all or a portion of the development costs advanced by Invitae and/or (ii) we will owe Invitae a share of the revenue that may be generated from the sale of the Program Products to third parties if and when they are commercialized, until such time as Invitae has recouped the amounts paid to us, and in certain circumstances, a mutually agreed return.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have incurred and expect to incur significant development costs over the duration of the Development Agreement. There can be no assurances that the development program will be successful or that the Program Products will become ready for commercial sale.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The contract is accounted for in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Revenue from Contracts with Customers </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">as</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> the primary benefit from the arrangement to Invitae is the ability to procure the Program Products during the Preferential Pricing Period at substantial discounts. Invitae is not expected to substantially benefit from the intellectual property developed under the arrangement, or benefit from other goods or services during the development period. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We will recognize </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">proportionate amounts of t</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">he material right in revenue as the performance obligations are satisfied, which is </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">when Invitae places purchase orders for Program Products and the associated goods or services are delivered. Discounts that are not expected to be used will be recognized consistent with the guidance in Topic 606 relating to breakage, in proportion to the expected purchases by Invitae. Any remaining unused discounts will be recognized when they expire. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All amounts received from Invitae are initially deferred and accumulated in deferred revenue, non-current. As of December 31, 2021, we have recognized payments received from Invitae of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d9adb758-5dda-418e-b015-702270e5fb73" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="As_Of_12_31_2021_srt_MajorCustomersAxis_pacb_InvitaeCorporationMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">23.5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in deferred revenue, non-current, on the Consolidated Balance Sheet. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Costs incurred to develop the Program Products are research and development costs and are expensed as incurred. There were no capitalized origination or fulfilment costs related to the arrangement with Invitae that are eligible to be capitalized.</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span id="Note4_TermofMergerwithIllumina" style="text-decoration: none;"></span><ix:nonNumeric name="pacb:MergerTermination" id="ct-nonNumeric-af7590ab-fb86-4d4f-b6c7-8b3eb47d7790" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-af7590ab-fb86-4d4f-b6c7-8b3eb47d7790-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">NOTE 4. TERMINATION OF MERGER WITH ILLUMINA</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-af7590ab-fb86-4d4f-b6c7-8b3eb47d7790-continuation-0" continuedAt="ct-nonNumeric-af7590ab-fb86-4d4f-b6c7-8b3eb47d7790-continuation-1"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November 1, 2018, we entered into an Agreement and Plan of Merger (as amended, the &#8220;Illumina Merger Agreement&#8221;) with Illumina, Inc. (&#8220;Illumina&#8221;) and FC Ops Corp., a wholly owned subsidiary of Illumina (&#8220;Illumina Merger Sub&#8221;). On January 2, 2020, we, Illumina and Illumina </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Merger Sub,</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> entered into an agreement to terminate the Merger Agreement (the &#8220;Termination Agreement&#8221;). </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">82</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-af7590ab-fb86-4d4f-b6c7-8b3eb47d7790-continuation-1" continuedAt="ct-nonNumeric-af7590ab-fb86-4d4f-b6c7-8b3eb47d7790-continuation-2"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Continuation Advances from Illumina</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As part of the Termination Agreement, Illumina paid us cash payments (&#8220;Continuation Advances&#8221;) of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2a3c34f4-0cec-4d35-8f7c-142c60356485" name="pacb:ProceedsFromContractTermination" contextRef="Duration_10_1_2019_To_12_31_2019_dei_LegalEntityAxis_pacb_IlluminaFcOpsCorpMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">18.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million during the fourth quarter of 2019 and $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e83c2576-1f90-4330-b624-9ad35c72c1fd" name="pacb:ProceedsFromContractTermination" contextRef="Duration_1_1_2020_To_3_31_2020_dei_LegalEntityAxis_pacb_IlluminaFcOpsCorpMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">34.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million during the first quarter of 2020. We recorded the $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-075847f3-35bf-45f8-b7c1-190d2d0bab19" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_pacb_IlluminaFcOpsCorpMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">34.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-99210e34-7166-431f-b961-53a61d00b868" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Duration_1_1_2019_To_12_31_2019_dei_LegalEntityAxis_pacb_IlluminaFcOpsCorpMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">18.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million as non-operating income in the Consolidated Statements of Operations and Comprehensive (Loss) Income for the years ended December 31, 2020 and 2019, respectively. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Up to the full $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c0fbb82d-8546-45bd-8506-e967ebf00f88" name="pacb:ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace" contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">52.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of Continuation Advances paid to us were repayable without interest to Illumina if, within two years of March 31, 2020, we entered into, or consummated a Change of Control Transaction or raised at least $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8fdea957-1aea-41fb-af95-9704275c59ea" name="pacb:MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">100</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in a single equity or debt financing </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(that may have multiple closings),</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> with the amount repayable dependent on the amount raised by us. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Resulting from the issuance and sale of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9199911e-08ec-45d3-b0d0-1d716fbd8e41" name="us-gaap:DebtInstrumentFaceAmount" contextRef="As_Of_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">900</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-78cbe027-ca29-4d52-b969-2f1ca7b03ae3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="As_Of_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">1.50</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% Convertible Senior Notes due </span><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="ct-nonNumeric-b5002bc6-986f-4d3f-b768-d6ecdf7594f6" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" format="ixt:datemonthdayyearen"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 15, 2028</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-702d1b36-baf9-419c-b7e9-a4a8ba833ed7" name="us-gaap:GainLossOnContractTermination" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6" sign="-">52.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of Continuation Advances were paid without interest to Illumina in February 2021 and recorded a non-operating expense in the Consolidated Statements of Operations and Comprehensive (Loss) Income for the year ended December 31, 2021. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Please refer to </span><a href="#Note1_OrgandAccountingPolicies" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Note 1. Organization and Significant Accounting Policies</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for the accounting treatment of the Continuation Advances.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Reverse Termination Fee from Illumina</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As part of the Termination Agreement, Illumina paid us a $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-86dd5204-25b2-498a-b59d-6295ad270faa" name="us-gaap:ProceedsFromFeesReceived" contextRef="Duration_4_20_2020_To_4_20_2020" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">98.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million termination fee (the &#8220;Reverse Termination Fee&#8221;), from which we paid our financial advisor associated fees of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8628e126-3117-46c6-8c82-7b1d78b189f0" name="pacb:PaymentsForAdvisorFees" contextRef="Duration_4_20_2020_To_4_20_2020" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">6.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in April 2020. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pursuant to the Termination Agreement, in the event that, on or prior to September 30, 2020, we entered into a definitive agreement providing for, or consummated, a Change of Control Transaction, then we may have been required to repay the Reverse Termination Fee (without interest) to Illumina in connection with the consummation of such Change of Control Transaction. As indicated in ASC 450, </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Contingencies</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a gain contingency usually is not recognized in the financial statements until the period in which all contingencies are resolved and the gain is realizable. As such, we deferred the gain from the Reverse Termination Fee from Illumina until the date when the associated contingency lapsed. On October 1, 2020, the contingency clauses lapsed and we recorded the $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cec500bb-e33c-4b07-ba7d-56fc8df1b3b1" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Duration_10_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">98.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million as a part of non-operating income in the fourth quarter of 2020.</span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:continuation id="ct-nonNumeric-af7590ab-fb86-4d4f-b6c7-8b3eb47d7790-continuation-2"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Note5_FinancialInstruments" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="ct-nonNumeric-8d344414-e3d7-43e3-9ad1-cadaaf8b8321" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-8d344414-e3d7-43e3-9ad1-cadaaf8b8321-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">NOTE 5. FINANCIAL INSTRUMENTS</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-8d344414-e3d7-43e3-9ad1-cadaaf8b8321-continuation-0" continuedAt="ct-nonNumeric-8d344414-e3d7-43e3-9ad1-cadaaf8b8321-continuation-1"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Fair Value of Financial Instruments</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The fair value hierarchy established under GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level&#160;1: quoted prices in active markets for identical assets or liabilities;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level&#160;2: inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.84in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level&#160;3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">83</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-8d344414-e3d7-43e3-9ad1-cadaaf8b8321-continuation-1" continuedAt="ct-nonNumeric-8d344414-e3d7-43e3-9ad1-cadaaf8b8321-continuation-2"><div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">time or among market makers.&#160;Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of&#160;December 31, 2021 and December 31, 2020 respectively:</span></p><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="ct-nonNumeric-26b872e4-38c5-49b2-a318-00eef67f5d56" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 1</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level&#160;2</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 3</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Total</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 1</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level&#160;2</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 3</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Total</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Assets</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Cash and cash equivalents:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and money market funds </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-13555178-5c54-4cad-8234-5beed65e16a0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_pacb_CashAndMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">327,315</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0d98a7c4-29c1-49d4-a923-590f3ee249fe" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_pacb_CashAndMoneyMarketFundsMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">327,315</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-de52e5a4-42a5-4a44-b5a2-fd312e7448d9" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_pacb_CashAndMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">43,040</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b9388566-8f77-40e7-a0c6-7ea5ac3280f4" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_pacb_CashAndMoneyMarketFundsMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">43,040</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fd84f0d7-4737-4e8a-bea6-fa03c322a110" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">133,185</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5be579d8-93ad-404a-8a48-a3083443c013" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">133,185</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d8829c55-d74c-4209-aa3d-f4b392a1a265" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">32,537</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8b58e6b5-cc3c-4db0-a03b-dbdbe0a89658" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">32,537</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government &amp; agency securities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-98f750be-17bb-49af-a644-748d54025c3f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">225</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-af096940-2a4a-41cb-9117-59b36c2b5cc2" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">225</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-df9f7ddb-7562-400e-a166-f3b45b540f76" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">170</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c5391703-1076-4ce0-a4a4-b10eb63da9af" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">170</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. Treasury security</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2a20278e-8f47-41ba-a760-1b0ce33a1e1c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">5,864</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-603f4183-c2be-4b81-93c2-0e22ee175832" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">5,864</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total cash and cash equivalents </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-38a1a0ed-0d8e-4ea6-8e0f-7e309f528dd4" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">327,315</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6b6d03da-d1db-4b7f-b31d-6797275ffa59" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">133,410</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d358b00f-ac16-4173-8228-1b9ab092f8f9" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">460,725</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-62361fd4-591a-4fd5-89ff-d2d54c7987b2" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">43,040</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-75867037-8337-491c-9f91-d1700d2157eb" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">38,571</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-afd070c5-6a66-4d79-80aa-320b381400b6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">81,611</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Investments:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5475ca3a-0672-42f5-a772-eca472cbb794" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">187,632</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7920cd52-645a-4e49-b594-2ffd8b664597" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">187,632</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a6689625-7d44-4fbb-baa6-3764aa19d668" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">112,644</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c4ca05a9-d9ee-4942-a373-0da46c1a7d02" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">112,644</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate debt securities </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e11fc3a0-5467-496f-9494-dccdaecffc2a" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">8,968</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1bfaf7c2-7b50-471c-addf-da37375db928" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">8,968</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7bfd2fb5-0acf-4cdd-90ba-7472843552e0" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">17,456</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-17ee24c8-41d3-4866-9260-337154f83d67" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">17,456</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government &amp; agency securities</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1241f6bf-605f-4810-9bfe-995b6e3e1596" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">387,075</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c70d47d8-2388-4057-b56d-f0177bd8e04b" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">387,075</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fb374935-c44e-49b0-8e88-a47c6e10e384" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">107,103</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-769c2a65-6f8e-452e-9ce7-f6034ec8d61f" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">107,103</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total investments </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2c4bcd16-76a9-4e98-9b1a-9bb6bc886dc6" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">583,675</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-84b6dbec-06af-47c8-ae52-350e47a82037" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">583,675</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c328bea8-3619-46fc-ad51-20c04ea7c933" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">237,203</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-93c91dd0-6d7f-4e69-8206-dc00aba842f6" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">237,203</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Short-term restricted cash:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-aedfe7c9-fa7b-446c-a688-9527396ebd20" name="pacb:ShortTermRestrictedCashFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">500</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c397831a-f1ed-4f58-9744-e2071201eb04" name="pacb:ShortTermRestrictedCashFairValueDisclosure" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">500</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cb202487-05f5-4035-96ed-c2b193a9058e" name="pacb:ShortTermRestrictedCashFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">836</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7adce2eb-edbd-492f-ba88-91089ef397fb" name="pacb:ShortTermRestrictedCashFairValueDisclosure" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">836</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Long-term restricted cash:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c4f9471f-e882-463a-984f-0b0b911b9e50" name="pacb:LongTermRestrictedCashFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">4,592</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-65cd1cdd-f842-4820-92dc-e66d43caedc6" name="pacb:LongTermRestrictedCashFairValueDisclosure" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">4,592</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e7873aca-9779-42b5-b07e-ecd5eb7d002e" name="pacb:LongTermRestrictedCashFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">3,500</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a0309296-bfff-40c2-a226-d513c44f7708" name="pacb:LongTermRestrictedCashFairValueDisclosure" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">3,500</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total assets measured at fair value </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-65b114ac-3ffa-4c6a-8e4a-046e64a84795" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">332,407</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c8d3bd24-b83f-4f44-bc39-60e66644f6e8" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">717,085</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-205673a8-b457-433c-803d-3e4b840b890c" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">1,049,492</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-81b5143d-216b-42c5-aa73-b794632501a8" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">47,376</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-95494094-9d99-43f4-ada8-c4f62918d642" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">275,774</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-04064e33-d41a-40bb-93d6-40d6dc8eeae2" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">323,150</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Liabilities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Continuation advances </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Contingent consideration</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-49b303b9-28df-4662-8515-e76684ea13a5" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_pacb_ContingentConsiderationMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">169,717</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-db8d1800-dec6-4c54-8262-68fe02b81f01" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_pacb_ContingentConsiderationMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">169,717</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total liabilities measured at fair value </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6da24c07-9492-4b1a-9f29-f9f0c1397a91" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">169,717</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-11cdd45e-09aa-4710-be48-622e761210f5" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">169,717</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We classify contingent consideration, which was incurred in connection with the acquisition of Omniome, within Level 3 as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value. </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">84</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-8d344414-e3d7-43e3-9ad1-cadaaf8b8321-continuation-2" continuedAt="ct-nonNumeric-8d344414-e3d7-43e3-9ad1-cadaaf8b8321-continuation-3"><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On a quarterly basis, we estimate the fair value of the contingent consideration liability by discounting the probability-weighted outcomes to present value using an estimate of our borrowing rate and the risk-free rate.</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The potential outcomes of milestone achievement dates are within the period from December 31, 2022 to June 30, 2025. A decrease in the probability of an earlier scenario within this range would result in a decrease in the fair value of the liability.  The discount rates used are the sum of the U.S. risk-free rate and the estimated subordinated credit spread for B- and B credit rating, which ranges from </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1526ffeb-e8a5-4d87-a5a3-fbca973dd5a5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">4.8</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7fb0c10d-01b4-47b4-b7d9-ced8bd482710" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">5.5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%. Changes in our estimated subordinated credit spread can result in changes in the fair value of the contingent consideration liability, where a lower credit spread may result in an increased liability valuation.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Changes in the estimated fair value of the contingent consideration liability for the year ended December 31, 2021 were as follows:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="pacb:ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock" id="ct-nonNumeric-85b67614-a8e7-48a7-a70d-797798a73608" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 76.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 76.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(in thousands)</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 3</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 76.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Beginning balance as of January 1, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> -</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 76.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Acquisition of Omniome</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e10eff03-4817-4d56-962c-cf6f48b28e57" name="pacb:ContingentConsiderationIncurredDuringPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">168,574</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 76.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Change in estimated fair value</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fcb34a18-2197-4d0d-92e3-f07b36d3c5dd" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,143</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 76.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Ending balance as of December 31, 2021</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 23.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bfdb8209-7c54-4227-9637-9ac4405e0bb1" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">169,717</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Changes to the fair value are recorded as the Change in fair value of contingent consideration in the Consolidated Statement of Operations and Comprehensive (Loss) Income.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2020, we classified the Continuation Advances, which were incurred in connection with the Illumina Merger Agreement and were subject to repayment under certain circumstances, as a financial liability and were reported at fair value. The estimated fair value of the liability related to the Continuation Advances was determined using Level 3 inputs, or significant unobservable inputs. Management assessed the fair value of this financial instrument to be </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-462006af-548a-4d3c-895a-46cb6728f374" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> at December 31, 2020.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We were first approached by </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">SB Northstar LP during the quarter ended March 31, 2021 regarding a potential convertible debt transaction.  As discussed further below in </span><a href="#Note7_ConvertibleDebt" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Note 7. Convertible Senior Notes</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, in February 2021, we entered into an investment agreement with SB Northstar LP for </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the issuance and sale of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d5c7d230-5648-4894-b61a-5c44e628ea16" name="us-gaap:DebtInstrumentFaceAmount" contextRef="As_Of_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">900</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1f78a9c3-17b0-4093-8108-0f75fa505229" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="As_Of_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">1.50</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% Convertible Senior Notes due </span><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="ct-nonNumeric-5a1d3761-ee1e-4042-af45-a657a7030db6" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" format="ixt:datemonthdayyearen"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 15, 2028</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. As a result, $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2004abc7-b0cf-4d2b-ac32-d258da17e4f4" name="pacb:RepaymentsOfContractTermination" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">52.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of Continuation Advances were repaid without interest to Illumina in February 2021 and recorded as a non-operating expense in the Consolidated Statements of Operations and Comprehensive (Loss) Income for the year ended December 31, 2021. There was </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ae420a81-f0f8-4c42-95fd-40fed86b2fe2" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-6" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> further liability exposure for Continuation Advances as of December 31, 2021.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For the year ended December 31, 2021, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and our valuation techniques did not change compared to the prior year. As discussed above, we recorded a contingent consideration liability in connection with our acquisition of Omniome during the year ended December 31, 2021.</span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">85</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-8d344414-e3d7-43e3-9ad1-cadaaf8b8321-continuation-3" continuedAt="ct-nonNumeric-8d344414-e3d7-43e3-9ad1-cadaaf8b8321-continuation-4"><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 14.4pt;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Cash, Cash Equivalents and Investments</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table summarizes our cash, cash equivalents and investments as of December&#160;31, 2021 and 2020:</span></p><ix:nonNumeric name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="ct-nonNumeric-708f53be-f812-412d-b986-90e83692d0d6" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">As of December 31, 2021</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Gross</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Gross</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amortized</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">unrealized</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">unrealized</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> Cost </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">gains </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">losses </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Value </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash and cash equivalents:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and money market funds</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ffcfc8f5-9bb1-4007-a2b9-08f6497d7bf9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_CashAndMoneyMarketFundsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">327,316</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d134e253-6ecd-40c5-a6c9-ef88e9944f9a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_CashAndMoneyMarketFundsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">327,316</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-472f2b82-e22f-439f-882e-fe3c9006d526" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">133,190</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-04a29bfe-85a8-42d7-8c5c-59a5dc00c582" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3579f72f-4d6d-49b5-b27e-d6478a56d37f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">133,185</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government &amp; agency securities</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-984bb4ba-f804-43ad-93e6-b4ee2df7a3c4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">225</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-666c6d6e-927f-44d8-bf66-67534bba1f31" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">224</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total cash and cash equivalents </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a84708ed-411d-4d22-ad20-3b616f09c1fb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">460,731</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-363e9bbe-edcb-4526-a0a3-33127395b39b" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ad90aaf3-b639-4103-b69b-ebb2172ab5f5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">460,725</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Investments:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-556cea28-88d9-4e83-8e1b-f4526737245d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">187,705</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8da127f4-9fa2-4490-9aed-63045a6b0b39" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">73</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a1e6198c-3817-424a-9eb3-a7490c98f2cf" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">187,632</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate debt securities </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-31cafb06-ef3b-42cc-a6df-c9be78cd211d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8,964</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7e5d7a56-7693-47a8-8e44-387c725c067b" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a0604df3-22eb-4718-88a0-ffa0931f9104" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bec372df-c76a-4b10-9c50-98c678c25fc7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8,968</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government &amp; agency securities</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-905a888e-aace-4753-a41f-ddf96d44cd78" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">388,088</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3e4e8c47-9455-4af3-8483-3b7745116f4d" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-940dcd40-409b-4da2-ba36-558f3f86a0d0" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,014</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-04af086a-5b0b-4c55-b977-75c3675fe6e3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">387,075</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total investments </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-778a2ffd-18ad-4c92-a8cf-3bcf4b2485a3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">584,757</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-02159222-34e9-458b-ac18-81e06724d806" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-51d58577-b82e-4dfd-ba10-26f577cd31de" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,092</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-158ab14d-dded-48da-8763-e2548fcf7273" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">583,675</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total cash, cash equivalents and investments </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-61a68c74-142b-4c7d-9593-df949fb5f5d1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,045,488</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ed9c51a3-cbfa-4ad4-b415-da654348de73" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9be1953b-d09f-4289-8621-4639635f81ba" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,097</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2ff8ce93-685d-44f8-8981-0294ee499058" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,044,400</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Short-term restricted cash:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-70c2252d-dfb3-47b1-8d3c-d823661d7512" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_ShortTermRestrictedCashMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">500</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d6c0bc55-f675-46e6-ae34-e740fc9a1c48" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_ShortTermRestrictedCashMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">500</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Long-term restricted cash:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0b7bf337-febc-4e6e-9a18-94c6417aed38" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_LongTermRestrictedCashMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,592</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c898c1b9-dad2-4a0d-967b-b152898d46bf" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_LongTermRestrictedCashMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,592</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="11" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">As of December 31, 2020</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Gross</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Gross</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amortized</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">unrealized</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">unrealized</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> Cost </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">gains </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">losses </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Value </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash and cash equivalents:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and money market funds</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1ad8ba1b-588b-44df-91fb-b6b279b67d01" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_CashAndMoneyMarketFundsMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">43,040</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-569db562-90c3-484b-aed6-2d104c2853f8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_CashAndMoneyMarketFundsMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">43,040</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a7aee793-0374-4ecf-83df-f6b6f81a1731" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">32,538</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-375d05d8-4ba8-45c4-bcc1-54f7015ae98e" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">1</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-80781391-3ac4-4bf0-9cd9-862c5e618823" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">32,537</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government &amp; agency securities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5820220f-5bc8-4011-aade-be550bb5a2f7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">170</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ad1b4c71-8fc1-4b74-8985-bf56b7dc779d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">170</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. Treasury security</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-95e37052-9668-4fe1-a6c0-f8deb5d008e8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,864</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-da196f34-aa43-44bf-a729-68122dc44e33" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,864</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total cash and cash equivalents </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-67708776-01ef-436e-bd68-74d4da98b353" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">81,612</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-131cfc73-fe85-4747-bca2-410ef84ca0b6" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-edbc89ea-9697-41df-b73a-65292e072a76" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">81,611</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Investments:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-401f9ca8-e7e9-452f-9d48-245838789d6a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">112,648</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8c949558-746a-4492-94f7-8723a4036480" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-654083b5-8d03-4727-a99d-49b6dbca8df3" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8d1642e1-9967-4f8b-8739-521f199dec52" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">112,644</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate debt securities </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c3ae5997-20f5-4cc0-ab75-ce8a8edabafa" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,360</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-189b50a9-ba67-48c8-accb-7f89ab8e55f6" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">96</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-97f9d490-4ca7-464e-8555-c3e9622f1eae" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,456</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government &amp; agency securities</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b23ae31a-9c6a-4ecb-81dc-b02505ca78ac" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">107,109</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-29c715eb-6a73-4564-891f-819d2457e680" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b0c04e18-2920-4a16-9bc5-8eb45b93f1f1" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">12</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e0eb57a3-f5d1-4101-9e0c-7de38b7e581e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">107,103</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total investments </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-42a4ca02-2f9a-48c1-88ae-f05a24065f0e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">237,117</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ba7d92c0-60c2-44c2-ac9f-5ed435b9158b" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">106</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-53c38b5a-ac7d-4066-813e-74a873265914" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">20</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ff6e24c9-4304-4d0c-b276-d099c108bee4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">237,203</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total cash, cash equivalents and investments </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d0329ac1-27ad-4ef4-823a-e30454c2e1ac" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">318,729</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a7c0ae25-26ea-4aca-b00c-78fe0f788402" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">106</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-798f2330-a2b8-42d8-80a6-1822d9c78022" name="pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">21</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9fb3a5ae-ce7e-4ab1-a85e-e9b62935bb68" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">318,814</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Short-term restricted cash:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-967d9af1-e263-4fd9-b1ed-f74b7f6332b6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_ShortTermRestrictedCashMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">836</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d0dba90b-93d8-4e7c-a4bd-5df0b316fa9e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_ShortTermRestrictedCashMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">836</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Long-term restricted cash:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5d9f3ee5-9f4c-4307-b49e-d6f048d5d168" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_LongTermRestrictedCashMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,500</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-aa84dea2-72e0-4450-8daa-00bb5193f8b7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_LongTermRestrictedCashMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,500</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of December 31, 2021:</span></p><ix:nonNumeric name="us-gaap:MarketableSecuritiesTextBlock" id="ct-nonNumeric-d7dd34d4-dde5-49e4-8b1c-76bd20917ac3" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-d7dd34d4-dde5-49e4-8b1c-76bd20917ac3-continuation-0"><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair Value</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 78.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Due in one year or less </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8b534ce6-5580-4038-b44a-7ea92e59fce3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">595,063</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 78.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Due after one year through 5 years </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0d8b7eea-6cf0-45d7-92e0-fb05c587210c" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">122,022</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 78.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total investments </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-186d140c-8bb0-4266-9284-245378ffe806" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">717,085</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">86</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-8d344414-e3d7-43e3-9ad1-cadaaf8b8321-continuation-4" continuedAt="ct-nonNumeric-8d344414-e3d7-43e3-9ad1-cadaaf8b8321-continuation-5"><ix:continuation id="ct-nonNumeric-d7dd34d4-dde5-49e4-8b1c-76bd20917ac3-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.</span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:continuation id="ct-nonNumeric-8d344414-e3d7-43e3-9ad1-cadaaf8b8321-continuation-5"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span id="Note6_BalSheetCompon" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="ct-nonNumeric-38b9391e-3aa5-46bd-a952-e7f7dac1fa47" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-38b9391e-3aa5-46bd-a952-e7f7dac1fa47-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">NOTE 6. BALANCE SHEET COMPONENTS</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-38b9391e-3aa5-46bd-a952-e7f7dac1fa47-continuation-0" continuedAt="ct-nonNumeric-38b9391e-3aa5-46bd-a952-e7f7dac1fa47-continuation-1"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Short-term restricted cash </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2021, the short-term restricted cash balance of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-34a4d4bb-c252-4452-be75-c0b122fd834a" name="us-gaap:RestrictedCashCurrent" contextRef="As_Of_12_31_2021_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_SecurityDepositMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million was comprised of security deposits for the credit cards of employees. As of December 31, 2020, the short-term restricted cash balance of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-22363acd-b9ec-4b58-ad95-a4c4e9fb3d25" name="us-gaap:RestrictedCashCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.8</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million was comprised of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0f93f500-99cb-4971-abcf-136d733a5b90" name="us-gaap:RestrictedCashCurrent" contextRef="As_Of_12_31_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_CustomerDepositMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million for a customer deposit and $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cead3ba3-eacf-4070-b69e-b2f4c23bc71e" name="us-gaap:RestrictedCashCurrent" contextRef="As_Of_12_31_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_SecurityDepositMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.3</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million for a security deposit for the credit cards of employees. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In connection with the acquisition of Omniome in September 2021, we acquired $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f3798d15-507f-4528-9430-264a1ea27c3b" name="us-gaap:RestrictedCashCurrent" contextRef="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_SecurityDepositMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.2</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of short-term restricted cash consisting of a security deposit for credit cards of Omniome employees.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Inventory</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2021 and 2020, our inventory consisted of the following components: </span></p><ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="ct-nonNumeric-a71f30fd-fae9-4c9e-bfca-7a41fe427119" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 46.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 46.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 46.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 46.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 46.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Purchased materials</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b73b23eb-ddd4-48df-8030-f71d78f72838" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,993</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7e5a93dc-c584-4ba6-8167-11ec7ddf93e0" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,531</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 46.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Work in process</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0a73602c-14c5-4461-8899-fea8e906f2e9" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8,611</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a52b39e2-e8cc-4cdd-b934-e408ff908930" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,651</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 46.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Finished goods</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-417bfc01-eeef-4853-ac89-8eb2181c8afc" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,995</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e7cba006-2581-4636-aeae-fde894cd476c" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,048</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 46.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inventory</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ac5867b5-b578-4a67-8c20-e4597a8d0c51" name="us-gaap:InventoryNet" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">24,599</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dd061eb2-b98d-41d0-a3c3-0d76495bcd69" name="us-gaap:InventoryNet" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">14,230</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Property and Equipment, Net</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2021 and 2020, our property and equipment, net, consisted of the following components: </span></p><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ct-nonNumeric-9894f5a7-fb5d-40ca-84b1-1ba1ec68c9fb" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 47.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 47.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 25.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 47.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Laboratory equipment and machinery </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-448e3467-8f6f-40c9-b22b-68f205667538" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pacb_LaboratoryEquipmentAndMachineryMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">31,534</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-edb71b5f-3f72-4b75-acf4-4c72eb27989b" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pacb_LaboratoryEquipmentAndMachineryMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">24,948</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 47.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Leasehold improvements</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-60f657e6-fbf4-41be-8213-d896d69495a3" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">31,114</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1a502da3-65ce-4e34-9339-3899f163559e" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">29,931</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 47.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Computer equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-57e411f4-9f10-4049-b886-0849485f2f26" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">15,059</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-887fa72a-8844-42de-8a63-fe563bf4d837" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">12,400</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 47.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Software</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a9738a66-d6fd-4462-a53e-c753eb4070af" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,578</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-85532f47-4b4b-4982-873b-e238b4ab989c" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,940</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 47.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furniture and fixtures</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-eee6488e-5434-4dc1-a1ae-a4b8f9767dc2" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,202</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-253aa0dc-fbaf-40ba-9e6b-379ad3296bae" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,434</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 47.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Construction in progress</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2361ce3d-deea-459f-8719-1a8b748bae55" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,303</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f65ad122-eeca-4fc4-a285-227927d2297e" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">137</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 47.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a321fff7-ade0-456f-aeec-ac95fd90be35" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">88,790</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ebda8369-6359-4480-b2f9-93420adfbb53" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">74,790</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 47.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less: Accumulated depreciation </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-da9be31b-e529-47f9-8b06-d2ce57e611e3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">56,286</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d887749c-5c96-4e64-a5bd-0959a4de8c5e" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">49,891</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 47.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment, net </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5b925ec8-2e9c-499e-8a71-4224b193f9a7" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">32,504</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8fe56ac3-983f-49fb-8476-ea9b2774b7b6" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">24,899</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Depreciation expense during the years ended December 31, 2021, 2020 and 2019 was $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b8c4fd5c-010c-4e36-9e94-f4722fbb934b" name="us-gaap:Depreciation" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">7.2</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0cf38f41-3fc3-456e-9254-1c77c6852cff" name="us-gaap:Depreciation" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">6.4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d2a78bca-b2f6-47f7-b5e2-cd504cf3a2fe" name="us-gaap:Depreciation" contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">7.3</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, respectively. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Long-term restricted cash </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For our facility located at 1305 O&#8217;Brien Drive, Menlo Park, California (the &#8220;O&#8217;Brien Lease&#8221;), we were required to establish a letter of credit for the benefit of the landlord and to submit $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cfac663f-1fd8-4749-9011-0b6e1ee56a27" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="As_Of_10_31_2015_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">4.5</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million as a deposit for the letter of credit in October 2015. Subsequently, pursuant to the terms of the O&#8217;Brien Lease, beginning on May 1, 2019, the amount of the letter of credit was reduced by $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5dfadd5d-29c5-452b-b800-bc844df722d6" name="pacb:AnnualDecreaseInLongTermRestrictedCash" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.5</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million each year thereafter on May 1. As such, $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f0e2cc29-09ee-4729-a355-4c7666cc54ff" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">3.0</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e3925746-e02c-4d5f-9dc7-4bf77e3c02c1" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">3.5</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million was recorded in long-term restricted cash related to the O&#8217;Brien Lease in the Consolidated Balance Sheets as of December 31, 2021 and December 31, 2020, respectively. </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">87</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-38b9391e-3aa5-46bd-a952-e7f7dac1fa47-continuation-1" continuedAt="ct-nonNumeric-38b9391e-3aa5-46bd-a952-e7f7dac1fa47-continuation-2"><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In connection with the acquisition of Omniome in September 2021, we acquired $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a6824c35-3f5d-4e04-87ad-bdfb3b2d712d" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">1.6</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of long-term restricted cash related to a letter of credit established for a facility lease.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Goodwill and intangible assets</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Goodwill</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Goodwill arises from business combinations and represents the excess of the purchase price over the fair value of the net assets and other identifiable intangible assets acquired. The fair values of net tangible assets and intangible assets acquired are based upon preliminary valuations and our estimates and assumptions are subject to change within the measurement period (potentially up to one year from the acquisition date).</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table presents the changes in the carrying amount of goodwill for the periods indicated (in thousands):</span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 1pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Wa</span></p><ix:nonNumeric name="us-gaap:ScheduleOfGoodwillTextBlock" id="ct-nonNumeric-04efb01a-12b6-4812-901a-3392cade9bb1" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 76.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 76.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Balance as of December 31, 2020</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> -</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 76.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Acquisition of Omniome</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c2f7b681-d4be-4aa7-914d-a25897851a39" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">390,665</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 76.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Acquisition of Circulomics</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f7faf70b-20f0-4fea-a738-53128bf234e5" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">19,309</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 76.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Balance as of December 31, 2021</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5602d843-089f-4939-8274-79f0121fb201" name="us-gaap:Goodwill" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">409,974</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Acquired Intangible Assets</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intangible assets include acquired in-process research and development (IPR&amp;D) of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-22ef98ec-62bd-4ef4-827a-2a92573741af" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">400</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million as a result of the Omniome acquisition in September 2021. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition to IPR&amp;D, we had the following acquired definite-lived intangible assets as of December 31, 2021 (in thousands, except years):</span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="ct-nonNumeric-0a550bff-2f87-4033-8095-1e1e29bb098d" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Estimated </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Gross</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Net</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Useful Life</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Carrying</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Accumulated</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Carrying</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in years)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amount</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amortization</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amount</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Developed technology</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ct-nonNumeric-83993b2e-6414-4e78-b8f6-aa1695ca7973" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c3f519e8-c92e-4632-bc4b-3f04337799f0" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">11,000</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-057ba42e-a4a9-4d70-946b-1b8390eb4346" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">306</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ca2bdbf0-c01d-440e-87e7-746b60e7ed0e" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">10,694</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Customer relationships</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ct-nonNumeric-aeeedadc-04f3-48cb-bf62-06e91ed59942" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2</span></ix:nonNumeric></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b355d29f-2049-4e75-9dda-35a111c18847" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">360</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-af927be1-dd12-4c62-8fbc-2b23bed9f64e" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">75</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-63ddbb0d-2d4e-4d8f-a35c-7e781d9fb077" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">285</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f70f8200-09cd-43fd-a473-1a27dfbe2dc6" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">11,360</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1f8af2f9-9718-4310-89a6-b2fd4e6f5be0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">381</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a1f8b0a4-5b61-4408-a22b-e4cf5ed89f1d" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">10,979</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.58in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization expense of intangibles was $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b72ad955-a509-4538-9f1e-5b8d5a75dfe1" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.4</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million for the year ended December 31, 2021. We had </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-792894a6-179e-4229-8f27-e2d2bc7765d3" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-74c5a63d-034d-4f0d-8455-144b8e5b0d96" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> amortization expense of intangibles for the years ended December 31, 2020 and 2019.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The estimated future amortization expense of acquisition-related intangible assets with definite lives is estimated as follows (in thousands):</span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="ct-nonNumeric-21e700d8-47c3-4ad5-8d82-a40927adc47e" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-21e700d8-47c3-4ad5-8d82-a40927adc47e-continuation-0"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.06in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 40.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 40.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 40.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ad42d1b1-7bed-495a-b8a6-d89989ef8300" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">913</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 40.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-114d44d9-6b1f-402b-9c73-9bb4d4e2899a" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">838</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 40.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8eeefe31-2129-4860-8b01-420d7385875c" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">733</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2025</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 40.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-25997480-411c-4145-9796-f87a8b20d1f6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">733</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2026</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 40.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5c4097d2-67d0-495e-9b75-04af1741276d" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">733</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2027 and thereafter</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 40.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ed7361cc-2f93-4ff2-b2d1-cc951570867c" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">7,029</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 40.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d78d9e5f-78d0-400d-bff5-e733548bf3a1" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">10,979</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 40.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">88</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-38b9391e-3aa5-46bd-a952-e7f7dac1fa47-continuation-2" continuedAt="ct-nonNumeric-38b9391e-3aa5-46bd-a952-e7f7dac1fa47-continuation-3"><div><ix:continuation id="ct-nonNumeric-21e700d8-47c3-4ad5-8d82-a40927adc47e-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Accrued Expenses</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2021 and 2020, our accrued expenses consisted of the following components: </span></p><ix:nonNumeric name="pacb:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" id="ct-nonNumeric-3827c5cb-fa17-4ea3-9904-99424ccdfbf4" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 47.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 23.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="3" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 21.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Salaries and benefits</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8dcbbba7-23f7-4684-8e64-18bf536e096a" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">25,282</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-219a4684-88e9-454a-a3e4-31796741ec88" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">15,261</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued product development costs</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-37223fb2-e047-4e50-bc2e-e4bab88b5a27" name="pacb:AccruedProductDevelopmentCostsCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,936</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-96523f6d-af90-4d6c-8b8f-5e1ac5871a7f" name="pacb:AccruedProductDevelopmentCostsCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">415</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued interest payable</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2d6f3963-c79f-4be0-a59c-ff783d5477ea" name="pacb:AccruedTenantImprovementsCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,100</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inventory accrual</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-89cffa0f-a431-47bd-9bfa-13caf89042f1" name="us-gaap:ProductLiabilityContingencyAccrualPresentValue" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">108</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-56c61898-0594-45de-b80f-7b70be47a7f1" name="us-gaap:ProductLiabilityContingencyAccrualPresentValue" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">218</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Warranty</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6834fb00-7e1c-4962-a8b5-660f10a58eeb" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">594</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-65a9a010-ddae-43c9-a509-8938f5130b98" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">161</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued professional services and legal fees</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4175eef9-257f-41f1-931b-c9a8652bc1bb" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,640</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dcc44095-8f09-4461-8ae2-9a5d41b6fd6c" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">726</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f7783830-9707-485a-a5f7-630cde685c85" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,601</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-24339c11-12de-4527-8755-106ac2e7b3ab" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">569</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued expenses </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-463ed506-49a6-4610-8f73-d19eb95cd5a8" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">36,261</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td colspan="2" style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9d21ca3d-129d-45e3-be91-784329c04232" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,350</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Deferred Revenue</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2021, we had a total of $ </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ad793e25-5209-4dcc-a905-1003a3393c9e" name="us-gaap:ContractWithCustomerLiability" contextRef="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ServiceMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">36.0</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of deferred revenue, $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2e0c1d5e-9755-4119-b206-f71c61377eb6" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ServiceMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">11.0</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of which was recorded as deferred revenue, current and primarily relates to deferred service contract revenues to be recognized over the next year and the remaining $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-af1da831-6bc4-4da0-a725-b4abea11f3de" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ServiceMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">25.0</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million was recorded as deferred revenue, non-current. Of the deferred revenue, non-current balance, $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-aa47eb0a-05eb-4b3f-b913-634564173fb7" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="As_Of_12_31_2021_srt_MajorCustomersAxis_pacb_InvitaeCorporationMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">23.5</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million relates to payments received under the Invitae collaboration and $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d6691c45-9e4a-48b0-be8e-5b56dcec3e38" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_pacb_ServiceContractMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">1.5</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million primarily relates to deferred service contract revenues and is scheduled to be recognized in the next </span><ix:nonNumeric name="pacb:ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" id="ct-nonNumeric-6cb64c39-71e9-47b4-a62e-fa9f9d19c076" contextRef="Duration_1_1_2021_To_12_31_2021" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years. Revenue recorded in the year ended&#160;December 31, 2021 includes&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-359d7975-2c51-4634-925f-9cfdf4af889e" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">8.6</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of previously deferred revenue that was included in &#8220;Deferred revenue, current&#8221; as of&#160;December&#160;31, 2020. Contract assets as of&#160;December 31, 2021 and December 31, 2020 were not material.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2021, we had a total of $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-905a8087-e6b9-4b8a-87ca-6e8749610266" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ServiceMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.7</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of deferred commissions included in &#8220;Prepaid expenses and other current assets&#8221; which is recognized as the related revenue is recognized. Additionally, as a practical expedient, we expense costs to obtain a contract as incurred if the amortization period would ha</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ve been a year or less.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Term Loans</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In connection with the acquisition of Omniome, we acquired $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d17b9c0d-1d9a-4eec-b936-d4161735be4a" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" contextRef="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">1.3</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in short-term debt and $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5dd642fb-c99c-4909-8b8e-d6ee82f1b047" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" contextRef="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">3.0</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in long-term debt relating to a term loan facility that Omniome obtained in April 2020. Borrowings on the term loan facility were used to fund Omniome&#8217;s purchases of equipment, which serves as collateral. Each term loan has a term of </span><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="ct-nonNumeric-8e604603-edff-44f7-93a9-d823cefe9f79" contextRef="Duration_9_1_2021_To_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" format="ixt-sec:durmonth"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">43</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> months and bears a fixed interest rate of approximately </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5897ac90-db1f-4138-b38f-61598d9a7ccb" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">17</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% annually. The fee for the elective option to prepay all, but not less than all, of the borrowed amounts at any time after the 24</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>th</sup></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> month and before the 43</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>rd</sup></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> month after the commencement date, is </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-eb53f2ef-a92c-4dc0-80f2-33a3fd0d77ea" name="pacb:PercentageOfFeeToPrepayDebt" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="0" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the outstanding loan balance. Payments are made in equal monthly installments including principal and interest. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2021, the carrying value of term loans outstanding was $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c96915c0-edda-4497-9217-52b6b167459a" name="us-gaap:NotesPayable" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">3.9</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million. The related long-term portion of $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b4848321-e12b-44da-a0d4-66fdf39f90fd" name="us-gaap:LongTermNotesPayable" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">2.3</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million was recorded as part of &#8220;Other liabilities, non-current&#8221; and the short-term portion of $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c1beffca-42dd-40ce-bb20-10c1e07c70d2" name="us-gaap:NotesPayableCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">1.6</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million was recorded as part of &#8220;Other liabilities, current&#8221; on the Consolidated Balance Sheet. The interest expense was $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6bbf7e21-8bac-4723-94da-20a00a46100a" name="us-gaap:InterestExpenseBorrowings" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.2</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million for the year ended December 31, 2021, which was included as part of interest expense in the Consolidated Statement of Operations and Comprehensive (Loss) Income.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2021, the future principal payments remaining on term loans was the following:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="ct-nonNumeric-479350d6-eec8-4d68-8d07-3fec328ba8a7" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-479350d6-eec8-4d68-8d07-3fec328ba8a7-continuation-0"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 40.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 40.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 40.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-909f9653-a65d-4aeb-a55f-1d9265f24a8d" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">1,608</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 40.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-db7edeea-32fa-4f9d-aa38-3871e65b2211" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">1,842</ix:nonFraction></span></p></td></tr><tr style="height: 0.22in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 40.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9729f52e-1fd0-4c3a-8459-e7066cce43db" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">490</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 40.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1ddaca2e-01ba-4ab0-81fe-370a56804b05" name="us-gaap:LongTermDebt" contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">3,940</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">89</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-38b9391e-3aa5-46bd-a952-e7f7dac1fa47-continuation-3" continuedAt="ct-nonNumeric-38b9391e-3aa5-46bd-a952-e7f7dac1fa47-continuation-4"><ix:continuation id="ct-nonNumeric-479350d6-eec8-4d68-8d07-3fec328ba8a7-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Other liabilities, current</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2021 and 2020, our Other liabilities, current consisted of the following components: </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="ct-nonNumeric-50f2f3af-cad4-4cd4-b98c-786e6bf4878e" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued ESPP</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0c000925-50f4-4611-8590-8bc456a703fa" name="pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,598</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4725200e-e587-4f71-8e9c-5bcc9bd29d28" name="pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,037</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ea8dd885-237d-4758-8f5f-e4b4f381cec0" name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,161</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cfe91bcb-f4d0-4159-8856-0ec195e468b0" name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,482</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other liabilities, current</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5836b02a-410d-47fd-9e8f-37d54ff9af1d" name="us-gaap:OtherLiabilitiesCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,759</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6b80ba23-d73f-4023-8721-d76d8fb0b6f1" name="us-gaap:OtherLiabilitiesCurrent" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,519</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><ix:continuation id="ct-nonNumeric-38b9391e-3aa5-46bd-a952-e7f7dac1fa47-continuation-4"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span id="Note7_ConvertibleDebt" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" id="ct-nonNumeric-3bc7bf1e-1a97-4d36-b215-e75968b89835" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-3bc7bf1e-1a97-4d36-b215-e75968b89835-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">NOTE 7. CONVERTIBLE SENIOR NOTES</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-3bc7bf1e-1a97-4d36-b215-e75968b89835-continuation-0" continuedAt="ct-nonNumeric-3bc7bf1e-1a97-4d36-b215-e75968b89835-continuation-1"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On February&#160;9, 2021, we entered into an investment agreement (the &#8220;Investment Agreement&#8221;) with SB Northstar LP (the &#8220;Purchaser&#8221;), a subsidiary of SoftBank Group Corp., relating to the issuance and sale to the Purchaser of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8a365df5-8d69-4bb8-9a49-88aa727ae358" name="us-gaap:DebtInstrumentFaceAmount" contextRef="As_Of_2_9_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">900</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in aggregate principal amount of our </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4bb0888a-2851-48ed-9ce7-4337c19e071f" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="As_Of_2_9_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">1.50</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% Convertible Senior Notes (the &#8220;Notes&#8221;). The Notes were issued on </span><ix:nonNumeric name="us-gaap:DebtInstrumentIssuanceDate1" id="ct-nonNumeric-96148dcb-f7f0-4bb7-8053-ee12d769bfa4" contextRef="Duration_2_16_2021_To_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" format="ixt:datemonthdayyearen"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 16, 2021</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Notes are governed by an indenture (the &#8220;Indenture&#8221;) between the Company and U.S. Bank National Association, as trustee. The Notes bear interest at a rate of </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b1df45ce-ae2a-4e2b-a111-8e248643aaa5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="As_Of_2_9_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">1.50</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% per annum. Interest on the Notes is payable semi-annually in arrears on February&#160;15 and August&#160;15 and commenced on August&#160;15, 2021. The Notes will mature on </span><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="ct-nonNumeric-128e88e7-990c-4456-b630-c6bdb38d9ac9" contextRef="Duration_2_9_2021_To_2_9_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" format="ixt:datemonthdayyearen"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February&#160;15, 2028</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, subject to earlier conversion, redemption or repurchase.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The Notes are convertible into shares of our common stock based on an initial conversion rate of </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ad5c32a5-3d27-493b-8696-b38a93f15f6f" name="pacb:DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount" contextRef="Duration_2_16_2021_To_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">22.9885</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock per $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ae7fc92a-8555-4a2a-9845-e0334a346eaf" name="pacb:DebtInstrumentStatedPrincipalAmountForConversionRate" contextRef="Duration_2_16_2021_To_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">1,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> principal amount of the Notes (which is equal to an initial conversion price of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-360ebf4e-ede6-4cdf-b87b-e9975ee2409e" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="As_Of_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">43.50</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the Notes, we may elect to settle such conversion obligation in shares, cash or a combination of shares and cash.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On or after February&#160;20, 2026, the Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8bd53313-825a-4429-b9e4-fd9b17c42ede" name="pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice" contextRef="Duration_2_16_2021_To_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">150</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the conversion price then in effect for at least </span><ix:nonNumeric name="pacb:DebtInstrumentRedemptionPriceTradingDays" id="ct-nonNumeric-14d82926-b234-4432-a79d-6d06f21baf4a" contextRef="Duration_2_16_2021_To_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" format="ixt-sec:durday"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> trading days (whether or not consecutive) during any </span><ix:nonNumeric name="pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays" id="ct-nonNumeric-57862226-41d8-417a-9cc6-e6978f3203c7" contextRef="Duration_2_16_2021_To_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" format="ixt-sec:durday"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">30</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-613b9045-945f-4518-8050-0f8a36d83cfd" name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="Duration_2_16_2021_To_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">100</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the principal amount of such Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">With certain exceptions, upon a change of control of the Company or the failure of our common stock to be listed on certain stock exchanges (a &#8220;Fundamental Change&#8221;), the holders of the Notes may require that we repurchase all or part of the principal amount of the Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the Notes under the Indenture. The Indenture also includes customary covenants for convertible notes of this type.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the Notes at a rate equal to (i)&#160;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-aa985380-8659-4606-8337-12552f9118f2" name="pacb:DebtInstrumentAdditionalInterestInEventOfDefault" contextRef="Duration_2_16_2021_To_2_16_2021_srt_StatementScenarioAxis_pacb_EachDayDuringFirst180DaysMember_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit15" decimals="5" format="ixt:numdotdecimal" scale="-2">0.25</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% per annum of the principal amount of the Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8f7636f3-bbc0-4d60-82a5-5a374db93d48" name="pacb:DebtInstrumentAdditionalInterestInEventOfDefault" contextRef="Duration_2_16_2021_To_2_16_2021_srt_StatementScenarioAxis_pacb_OneHundredAndEightyFirstDayTo360thDayMember_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit15" decimals="4" format="ixt:numdotdecimal" scale="-2">0.50</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% per annum of the principal amount of the Notes outstanding for each day from, and including, the 181st calendar day to, and including, the 360th calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the Indenture). On the 361st day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361st day), the Notes shall be subject to acceleration as provided for in the Indenture.</span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">90</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-3bc7bf1e-1a97-4d36-b215-e75968b89835-continuation-1" continuedAt="ct-nonNumeric-3bc7bf1e-1a97-4d36-b215-e75968b89835-continuation-2"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the Notes were not issued at a premium; therefore, the Notes are accounted for in their entirety as a liability.  Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The requirement to repurchase the Notes including unpaid interest to the maturity date in the event of a Fundamental Change is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Derivatives and Hedging.</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> However, given the low probability of a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We incurred issuance costs related to the Notes of approximately $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-436d722f-853e-4204-9b2f-3fb256d64288" name="us-gaap:DeferredFinanceCostsGross" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">4.5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, which were recorded as debt issuance cost and are presented as a reduction to the Notes on our Consolidated Balance Sheets and are amortized to interest expense using the effective interest method over the term of the Notes, resulting in an effective interest rate of </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8272a82b-c898-4515-813c-c69748805183" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">1.6</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2021, the net carrying amount of the liability for the Notes is recorded as convertible senior notes, net in the Consolidated Balance Sheets as follows (in thousands):</span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="ct-nonNumeric-efe198bc-9069-4ece-b2e0-4068147d2d50" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Principal amount</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a499866a-5297-4fb4-8910-5e561d3b5258" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">900,000</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Unamortized debt issuance costs</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cf991059-3052-4be1-901f-e42d166fa0a4" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">3,933</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net carrying amount</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-32d15380-4b09-4558-be66-85b8da97ff12" name="us-gaap:LongTermDebt" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">896,067</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For the year ended December 31, 2021, interest expense for the Notes was as follows (in thousands):</span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="pacb:ScheduleOfInterestExpenseTableTextBlock" id="ct-nonNumeric-ecaa0a63-c2c7-4aba-9747-3c749fa398ee" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Contractual interest expense</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-caef0b14-176b-4e22-a068-ee0495517730" name="pacb:ContractualInterestExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">11,812</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization of debt issuance costs</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-264f7e0e-f1f7-4483-bd1e-f908fa89cfc5" name="us-gaap:AmortizationOfFinancingCosts" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">532</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total interest expense</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b528f5ec-3bc7-4245-be9c-1ce9a3fce110" name="us-gaap:InterestExpenseDebt" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">12,344</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2021, the estimated fair value (Level 2) of the Notes was $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b9752710-42d5-4fcc-9039-07921afaca59" name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">787.5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million. The fair value of the Notes is estimated using a pricing model that is primarily affected by the trading price of our common stock and market interest rates.</span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><ix:continuation id="ct-nonNumeric-3bc7bf1e-1a97-4d36-b215-e75968b89835-continuation-2"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="Note8_Commitments_Contingencies" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:LossContingencyDisclosures" id="ct-nonNumeric-b6d4a54a-c9cb-49ca-9916-feb50846770f" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-b6d4a54a-c9cb-49ca-9916-feb50846770f-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">NOTE 8. COMMITMENTS AND CONTINGENCIES </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-b6d4a54a-c9cb-49ca-9916-feb50846770f-continuation-0" continuedAt="ct-nonNumeric-b6d4a54a-c9cb-49ca-9916-feb50846770f-continuation-1"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Leases</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We record operating lease right-of-use assets and liabilities on our Consolidated Balance Sheets for all leases with a term of more than 12 months. In connection with the acquisition of Omniome, we acquired $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-20dc595a-fa29-4928-a6eb-ef4c7f3691b4" name="us-gaap:OperatingLeaseLiability" contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6"><ix:nonFraction id="ct-nonFraction-7257a4bd-e1d7-47f9-9bc0-e5620171d1e5" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">18.1</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in right-of-use assets and liabilities on our Consolidated Balance Sheets. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. All of our leases are operating leases. Lease payments comprise the base rent per the term of the Lease. Lease expense for these leases is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period those payments are incurred.</span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">91</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-b6d4a54a-c9cb-49ca-9916-feb50846770f-continuation-1" continuedAt="ct-nonNumeric-b6d4a54a-c9cb-49ca-9916-feb50846770f-continuation-2"><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We often have options to renew lease terms for buildings. For the O&#8217;Brien Lease, the renewal option is </span><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ct-nonNumeric-ec84200c-210e-412e-9f39-a9158d6ef137" contextRef="As_Of_12_31_2021" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5 years</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and the rent will be based on fair market value at the time of renewal and was not included in the lease term. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table presents information as to the amount and timing of cash flows arising from our operating leases as of </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">December 31</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2021:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="pacb:LesseeOperatingLeaseDescriptionTableTextBlock" id="ct-nonNumeric-93783207-5770-40a3-9025-12070a6bd490" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 25.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 25.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Maturity of Lease Liabilities</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 27.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amount </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years ending December 31,</span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 27.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 25.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a401c220-5c71-43ac-a63a-13c9098d9102" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">11,326</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 25.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-353ef3d7-3130-4749-9384-d64f429bc91c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">11,851</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 25.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fabf0c27-1613-4593-a41e-9df4a0c7cdfb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">12,040</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2025</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 25.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-109ce433-6a1b-48d0-900b-93e41ce929d3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">12,328</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2026</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 25.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6f1318f6-92a0-45cd-8891-30942d9f5be7" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">12,437</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Thereafter</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 25.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-50a71054-3efc-4432-9276-351c57dd666a" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9,930</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total undiscounted operating lease payments</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 25.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-25abf7e3-6e7a-4a54-b734-7855c834ae33" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">69,912</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less: imputed interest</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 25.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f7290562-ccf2-4de9-a9b0-85d6ddd54b3c" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">12,232</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Present value of operating lease liabilities </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 25.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-401984d4-922f-4bc8-a160-739f5a0f7baf" name="us-gaap:OperatingLeaseLiability" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">57,680</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 25.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balance Sheet Classification</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 25.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liabilities, current</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 25.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-49afa191-1630-4a4d-a6d5-f4c4d86e5993" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,710</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liabilities, non-current</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 25.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d389f540-b0ba-489a-9ad6-a3879678f23d" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">49,970</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Total operating lease liabilities</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 25.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-12878192-5353-41fb-83e8-3ef7a8e81658" name="us-gaap:OperatingLeaseLiability" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">57,680</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We use our incremental borrowing rate to determine the present value of lease payments, as the implicit rates in our leases are not readily determinable. The weighted average discount rate used to measure our operating lease liabilities was </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bd41d851-0f7f-46ca-a958-88874a315d34" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="As_Of_12_31_2021" unitRef="Unit15" decimals="4" format="ixt:numdotdecimal" scale="-2">6.7</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%. The weighted average remaining lease term for our operating leases as of December 31, 2021 was </span><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ct-nonNumeric-b9a00124-3e75-4aed-9cd8-a5c3f389bb29" contextRef="As_Of_12_31_2021" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.7</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Cash Flows</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash paid for amounts included in the present value of operating lease liabilities was $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e1ba8d8d-2a98-47ff-804b-44ffcc5cefac" name="us-gaap:PaymentsForRent" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">8.2</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9554f5ce-098c-49ce-9364-8e48561edd1c" name="us-gaap:PaymentsForRent" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">7.2</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million for the years ended December 31, 2021 and 2020, respectively and were included in operating cash flow. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Operating Lease Costs</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease costs were $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-af38aaef-1607-4136-a7a8-c0cc92c75af6" name="us-gaap:OperatingLeaseCost" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">7.2</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ca8cac21-fb12-4f4f-880c-89a8ea9761ca" name="us-gaap:OperatingLeaseCost" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">6.2</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million for the years ended December 31, 2021 and 2020, respectively. For both 2021 and 2020 the total lease costs primarily related to our operating leases, but also included immaterial amounts for variable leases.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Contingencies </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="Note8_subsection_LegalProceedings" style="text-decoration: none;"></span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">92</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-b6d4a54a-c9cb-49ca-9916-feb50846770f-continuation-2" continuedAt="ct-nonNumeric-b6d4a54a-c9cb-49ca-9916-feb50846770f-continuation-3"><div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Legal Proceedings</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">U.S. District Court Proceedings </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On September 26, 2019, Personal Genomics of Taiwan, Inc. (&#8220;PGI&#8221;) filed a complaint in the U.S. District Court for the District of Delaware against us for patent infringement (C.A. No. 19-cv-1810) (the &#8220;PGI District Court matter&#8221;). The matter from this complaint is based on PGI&#8217;s U.S. Patent No. 7,767,441 (the &#8220;&#8216;441 Patent&#8221;). We plan to vigorously defend in this matter. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November 20, 2019, we filed our answer to the complaint, denying infringement and seeking a declaratory judgement of invalidity of the &#8216;441 Patent. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span id="_Hlk93913409" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On June 22, 2020, we filed a petition requesting institution of an inter-partes review (IPR) to the Patent Trial and Appeals Board (the &#8220;Board&#8221;) at the United States Patent Office requesting the Board to find a set of claims in the &#8216;441 Patent invalid. On June 27, 2020, we filed a second petition requesting institution of an IPR requesting the Board to find another set of claims in the &#8216;441 Patent invalid. The two petitions (the &#8220;PacBio IPR Petitions&#8221;) requesting IPRs assert that all of the claims relevant to the PGI complaint are invalid. On January 19, 2021, the Board ordered that both PacBio IPR Petitions are instituted on all grounds presented. On January 18, 2022, the Board issued decisions on the two IPRs.  In one IPR, all challenged claims were found unpatentable including PGI&#8217;s core device claims. In the second IPR, the board did not find the disputed claims unpatentable. We are appealing the decision in the second IPR to the U.S. Court of Appeals for the Federal Circuit.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On August 19, 2020, the court ordered a stay of the PGI District Court matter based on a joint stipulation by the parties pending a final written decision on the IPRs. Following the final decision on the IPRs described above, on February 2, 2022, the judge ordered that the PGI District Court matter be reopened. We plan to vigorously defend against the remaining claims.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Proceedings in China</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On May 12, 2020, PGI filed a complaint in the Wuhan Intermediate People&#8217;s Court in China alleging infringement of one or more claims of China patent No. CN101743321B (the &#8220;CN321 Patent&#8221;), which is related to the &#8216;441 Patent.  We were served on January 20, 2021 and plan to vigorously defend in this matter.  On November 23, 2020 we filed an Invalidation Petition at the China National Intellectual Property Administration (CNIPA) demonstrating the invalidity of the claims in the CN321 Patent on grounds of insufficient disclosure, and the lack of support, essential technical features, clarity, novelty, and inventiveness. A hearing in the invalidation proceeding at the CNIPA was held on April 29, 2021. On September 2, 2021, the CNIPA issued its decision on the Invalidation Petition and determined that all claims (1-61) of the CN321 patent were invalid.  We have filed a petition with the Wuhan Intermediate People&#8217;s court requesting dismissal of the infringement action. On December 1, 2021, PGI filed an appeal with the Beijing IP Court, contesting the CNIPA decision.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Other Proceedings</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">From time to time, we may also be involved in a variety of other claims, lawsuits, investigations and proceedings relating to securities laws, product liability, patent infringement, contract disputes, employment and other matters that arise in the normal course of our business. In addition, third parties may, from time to time, assert claims against us in the form of letters and other communications. We record a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We currently do not believe that the ultimate outcome of any of the matters described above is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources and other factors.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Indemnification</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">93</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-b6d4a54a-c9cb-49ca-9916-feb50846770f-continuation-3" continuedAt="ct-nonNumeric-b6d4a54a-c9cb-49ca-9916-feb50846770f-continuation-4"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-564dd174-7f78-4668-9a46-232996964868" name="pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> additional liability associated with such indemnification obligations has been recorded as of December 31, 2021.</span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.34in;"><ix:continuation id="ct-nonNumeric-b6d4a54a-c9cb-49ca-9916-feb50846770f-continuation-4"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.00in;"><span id="Note9_IncomeTaxes" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" id="ct-nonNumeric-ea595284-4e87-4429-b51f-8e1ed490bf2e" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-ea595284-4e87-4429-b51f-8e1ed490bf2e-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">NOTE 9. INCOME TAXES</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-ea595284-4e87-4429-b51f-8e1ed490bf2e-continuation-0" continuedAt="ct-nonNumeric-ea595284-4e87-4429-b51f-8e1ed490bf2e-continuation-1"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are subject to income taxes in the United States and certain states in which we operate, and we use estimates in determining our provisions for income taxes. Significant management judgement is required in determining our provision for income taxes, deferred tax assets and liabilities and valuation allowances recorded against net deferred tax assets in accordance with U.S. GAAP. These estimates and judgements occur in the calculation of tax credits, benefits, and deductions, and in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes, as well as the interest and penalties related to uncertain tax positions. Significant changes to these estimates may result in an increase or decrease to our tax provision in the current or subsequent period.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether the factors underlying the sustainability assertion have changed and the amount of the recognized tax benefit is still appropriate.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We account for Global Intangible Low-taxed Income as a period cost.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the years ended December 31, 2021, 2020 and 2019 income (loss) before taxes from U.S. operations were ($</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bf150130-424b-4e05-b150-13bfeccf498a" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6" sign="-">275.4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">) million, $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-48fb23ef-7ccd-4ee7-8919-ad2ebe46d822" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">28.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and ($</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-aac5f284-c275-496f-b7fe-350393a64703" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6" sign="-">84.8</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">) million, respectively, and income before taxes from foreign operations was $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8cd35885-2767-4bdb-a8b5-a2b5c70b735c" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.8</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6c701ddf-8d33-41e9-8e9b-46a9ce421f15" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.6</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-61daa1e5-ecb0-402d-aae1-bb733f031602" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, respectively. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a8a6151b-e06c-4232-81fa-ddd96f33ea8e" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">21</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to pretax income or loss as follows: </span></p><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ct-nonNumeric-7651496e-7955-40e8-ac6f-4516c34562c9" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 46.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2019</span></p></td><td style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Statutory tax rate </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b6feeb3e-19c2-4769-9acc-7e77b4aa0837" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">21.0</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-18b547e1-e13f-4faf-8013-95ad43a72c3a" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">21.0</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-df80a677-e9ff-4494-93aa-d360b0f943a9" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">21.0</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">State tax rate, net of federal benefit</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-608ecd15-ea85-4ddf-9cdb-67f5eed6f17d" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">5.5</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a0d65d63-0f3a-4845-9b53-d0cb26d2855b" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2" sign="-">8.3</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-240f4ed1-745c-4550-9944-ae4dd432099b" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">4.9</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Change in valuation allowance </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-32a97d3b-892d-4cd0-9e5c-e956170b2dc0" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">4.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-743fded6-4dc1-41e5-be2e-3f3d3be46961" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2" sign="-">6.3</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f845801a-e82f-4f93-82f5-590de302d05b" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">27.5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tax credits</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-35feec1f-357d-4a43-836d-3e3daf39cb80" name="pacb:EffectiveIncomeTaxRateReconciliationTaxCredit" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">2.5</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-59f01227-ac5f-4917-b0cb-dd4ccfaf565d" name="pacb:EffectiveIncomeTaxRateReconciliationTaxCredit" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2" sign="-">3.6</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2ad8d9cd-5f1f-4279-9ec9-d732df977551" name="pacb:EffectiveIncomeTaxRateReconciliationTaxCredit" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">2.2</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5a6f1fcb-adb9-4045-a946-d049f9ad4737" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2" sign="-">10.9</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e5fca548-0249-4916-b4fd-51d1ed03f968" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">15.2</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f04876e7-0551-4bbc-9d7c-f9a3bfee87a7" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">0.8</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Merger Expenses</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fd7a0a0f-2793-485b-be23-bc33ce5c34f8" name="pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" sign="-">0.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> -</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> -</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2e801f0c-5612-412d-b739-ed9281cf6143" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2" sign="-">0.1</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f6434966-ee41-4445-b16c-00ff653b45e4" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2" sign="-">0.2</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ea949e34-ab6c-4474-a5fc-3ed633799615" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">0.2</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-57ca3a3f-ce26-41a9-93d3-c0f582d4ec15" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">34.0</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-0217e24c-f3e2-41a5-a3e4-da83db5c7554;">0.0</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 10.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-369660c8-8827-4509-8766-859d252aae68;">(0.0)</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">94</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-ea595284-4e87-4429-b51f-8e1ed490bf2e-continuation-1" continuedAt="ct-nonNumeric-ea595284-4e87-4429-b51f-8e1ed490bf2e-continuation-2"><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred income taxes reflect the net tax effects of loss and credit carry forwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands): </span></p><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ct-nonNumeric-84ad5964-850f-4dd9-9c4d-e63db367528e" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 47.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Deferred tax assets:</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 25.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net operating loss carryforwards</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-518f942b-0bb5-4e5b-b442-38bacefe414f" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">378,035</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9eaaa585-41af-4ad4-8320-3e63a87ee64a" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">233,225</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development credits </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b17c34e7-e64d-4e98-9acb-ee2868605502" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">60,672</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-466415fa-0054-4178-9f53-0785eb74a8ae" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">49,179</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accruals and reserves</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-71e6dc14-d8a1-4c55-b961-aaf86c99812c" name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10,822</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5d0dabc2-3bbd-42fd-a33c-fffe2a68d8f3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,337</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-26cde2c6-7a85-47bd-84ce-02a1f1b4bb07" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">12,838</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-eb69071d-78df-4858-91cc-8c4ec7c88ac6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9,717</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ASC 842 Operating lease liability</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f211d836-8a86-4333-af46-b6871ef18391" name="pacb:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">13,105</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b5c30ed1-b2d2-45dc-b03a-a94b583cdd78" name="pacb:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">9,870</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total deferred tax assets </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dda76bd0-d910-419a-a84c-8979e5865a34" name="us-gaap:DeferredTaxAssetsGross" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">475,472</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2ad8effd-192a-48e3-a732-122a372fe31c" name="us-gaap:DeferredTaxAssetsGross" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">308,328</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less: Valuation allowance</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6f64f83c-d5b7-4bcf-8f24-e56f850f2495" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">366,940</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-abe8fe9c-fba4-4345-9977-ac6fa476ab74" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">300,505</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Total deferred tax assets:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-639cce06-2eb8-4105-bf60-bc47437f9c39" name="us-gaap:DeferredTaxAssetsNet" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">108,532</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f69217f2-0b4a-4887-83ba-bbb3254cdc62" name="us-gaap:DeferredTaxAssetsNet" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,823</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intangibles</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a31a795a-c5ec-4544-86c7-42426534f89f" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">97,345</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Fixed assets</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b363ddb5-ddf9-4a46-9811-566f20ba5294" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,523</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-69082b4c-80dc-4757-a3af-003b12e06827" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">786</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ASC 842 Operating lease right-of-use assets</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-00f44bfe-e45e-4658-baf2-471bfffdf6e1" name="pacb:DeferredTaxLiabilitiesRightOfUseAssets" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10,502</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-904ac10c-0097-49d9-9e7d-b207b400e723" name="pacb:DeferredTaxLiabilitiesRightOfUseAssets" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,037</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Total deferred tax liabilities</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-33db6fef-4ff9-4837-a9ff-c3cf5d0e11f8" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">109,370</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3610b040-9393-4805-8981-3f36f801c95a" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,823</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Net deferred tax assets </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b1531f69-8a62-4549-a7fc-90c7be3461c5" name="us-gaap:DeferredTaxLiabilities" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">838</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 21.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-f6bf32a1-eba1-44b5-9c64-71c3bce57c57;">&#8212;</span></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">At December&#160;31, 2021, we maintained a full valuation allowance against all of our deferred tax assets which totaled $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d65754c5-ad33-433e-b9b5-564b9135277d" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">366.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, including net operating loss carryforwards and research and development credits of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bb8b076b-5cee-49e3-9d43-da52d7e49c15" name="us-gaap:OperatingLossCarryforwards" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">378.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bed229e7-42a5-420d-84f3-819ea47569f3" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">60.7</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, respectively.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. We regularly assess the need for a valuation allowance against our deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that our deferred income tax assets will be realized. In evaluating our ability to recover our deferred income tax assets within the jurisdiction from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. A deferred income tax benefit of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d2fec537-1c08-41eb-81f9-71b6682cc080" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6" sign="-">93.6</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million for the year ended December 31, 2021, is related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Omniome and Circulomics acquisitions. We maintain a valuation allowance on the net deferred tax assets of our U.S. entities as we have concluded that it is more likely than not that we will not realize our deferred tax assets. Accordingly, this benefit from income taxes is reflected on our Consolidated Statements of Operations and Comprehensive (Loss) Income for the year ended December 31, 2021. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For the year ended December 31, 2021, our valuation allowance increased to $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-010b4b78-ca75-4f3e-81f2-3f0f3bc0d9a5" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">366.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, primarily because of an increase in our net operating losses, credits and acquisition of deferred tax assets that were fully offset by a valuation allowance. For the year ended December 31, 2020, our valuation allowance increased to $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-37b4ef2c-0183-4834-9431-cab57e8ed902" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">300.5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, primarily because of an increase in our net operating losses and tax credits offset by a decrease to our stock-based compensation deferred tax asset. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2021, we had a net operating loss carryforward for federal income tax purposes of approximately $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3bfb09f2-45bb-49d8-a1ac-232309ed42b4" name="us-gaap:OperatingLossCarryforwards" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">1,491.3</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, of which $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7a318f34-67f6-47df-8c64-f2cefcedd726" name="us-gaap:OperatingLossCarryforwards" contextRef="As_Of_12_31_2021_srt_StatementScenarioAxis_pacb_WithExpirationMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">774.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million will begin to expire in </span><ix:nonNumeric name="pacb:OperatingLossCarryforwardsExpirationYear" id="ct-nonNumeric-77d49eae-de67-4c2b-a7de-8df2931fd891" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> if not utilized. We had a total state net operating loss carryforward of approximately $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dc97985d-6595-4e44-82e4-da67fbfc9d45" name="us-gaap:OperatingLossCarryforwards" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">997.4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, which are subject to annual expirations. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the &#8220;change of ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have federal credits of approximately $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-496ccb96-ecc4-483d-aa9e-f78fae0434c1" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">39.1</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, which will begin to expire in </span><ix:nonNumeric name="pacb:TaxCreditCarryforwardExpirationYear" id="ct-nonNumeric-9a9f782e-c59c-4b72-a02f-8fe0cff46d57" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> if not utilized and state research credits of approximately $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e6967d1a-0a15-42ad-9a4b-d1f57b2a8895" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">36.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million which have no expiration date. These tax credits are subject to the same limitations discussed above. </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">95</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-ea595284-4e87-4429-b51f-8e1ed490bf2e-continuation-2" continuedAt="ct-nonNumeric-ea595284-4e87-4429-b51f-8e1ed490bf2e-continuation-3"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2021, our total unrecognized tax benefit was $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b389d2e2-9d0b-4051-a069-d1d3a08eb963" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">8.3</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A reconciliation of the beginning and ending unrecognized tax benefit balance is as follows (in thousands): </span></p><ix:nonNumeric name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="ct-nonNumeric-726edfef-3c8e-45fa-afb2-38cec193d854" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Balance as of December 31, 2018</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-296cf037-6e2f-49e3-bef4-31de181a7076" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">20,447</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Decrease in balance related to tax positions taken in prior year </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-01e6ae09-6c26-4e08-8828-7a21518d3f2e;">&#8212;</span></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Increase in balance related to tax positions taken during current year </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bef74b6e-e786-475e-b3f5-3f2647ad75ae" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,532</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Balance as of December 31, 2019</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e51a8afc-5a4e-4443-9915-d5c9ffbeb995" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">21,979</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Decrease in balance related to tax positions taken in prior year </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bf119f64-c9f9-4855-ae69-dab9ea440b76" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,255</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Increase in balance related to tax positions taken during current year </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-08c91b9f-70c9-47be-908b-629862d727f9" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,230</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Balance as of December 31, 2020</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-612b9d41-9f30-482c-8489-b9fa081217da" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,954</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Increase in balance related to tax positions taken in prior year </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-19505527-bf44-452b-b021-4c0eadd1c3e9" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">189</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Increase in balance related to tax positions taken during current year </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-97db72ea-8036-4a8d-b451-69db936b30db" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,192</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Balance as of December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-686914ec-9e45-4c45-adcf-57465646b061" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8,335</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of both December&#160;31, 2021 and 2020, we had </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a7510685-8ef9-456a-a6d9-92f3b9652fc7" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-5" format="ixt-sec:numwordsen" scale="6"><ix:nonFraction id="ct-nonFraction-0f6e3ada-d88d-4d40-ab76-cab717e103b4" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> accrued interest or penalties due to our net operating losses available to offset any tax adjustment. If total unrecognized tax benefits were realized in the future, it would not result in any tax benefit as we currently have a full valuation allowance. We file U.S. federal and various state income tax returns. For U.S. federal and state income tax purposes, the statute of limitations currently remains open for the years ending December&#160;31, 2018 to present and December&#160;31, 2017 to present, respectively. In addition, all of the net operating losses and research and development credit carryforwards that may be utilized in future years may be subject to examination. We are not currently under examination by income tax authorities in any jurisdiction.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On December 27, 2020, the U.S. government enacted the Consolidated Appropriations Act, 2021, which enhances and expands certain provisions of the CARES Act. This legislative act did not have a material impact on the Company&#8217;s consolidated financial results.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On March 11, 2021, the American Rescue Plan Act of 2021 (&#8220;American Rescue Plan&#8221;) was signed into law to provide additional relief in connection with the ongoing COVID-19 pandemic. The American Rescue Plan includes, among other things, provisions relating to PPP loan expansion, defined pension contributions, excessive employee remuneration, and the repeal of the election to allocate interest expense on a worldwide basis. Under ASC 740, the effects of new legislation are recognized upon enactment. Accordingly, the American Rescue Plan is effective beginning in the quarter that includes March 11, 2021. These provisions did not have a material impact on the Company&#8217;s Consolidated Financial Statements.</span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.34in;"><ix:continuation id="ct-nonNumeric-ea595284-4e87-4429-b51f-8e1ed490bf2e-continuation-3"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.00in;"><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">NOTE 10. STOCKHOLDERS&#8217; EQUITY</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae-continuation-0" continuedAt="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae-continuation-1"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Preferred Stock </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our Certificate of Incorporation, as amended and restated in October 2010 in connection with the closing of our initial public offering, authorizes us to issue </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-96542b5e-e9b7-4b34-8f6e-58bf81424904" name="us-gaap:CommonStockSharesAuthorized" contextRef="As_Of_10_31_2010" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">1,000,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5e540e51-7e73-42ac-89d5-49bd4fb3dbea" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="As_Of_10_31_2010" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> par value common stock and </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-56d22280-d2e7-43e5-bc0d-834a9ee72990" name="us-gaap:PreferredStockSharesAuthorized" contextRef="As_Of_10_31_2010" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d063e17a-9c29-4447-aff5-2af6711b68a4" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="As_Of_10_31_2010" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> par value preferred stock. As of December&#160;31, 2021 and 2020, there were </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3eefa605-2348-4e9e-bdd6-dbf57db69207" name="us-gaap:PreferredStockSharesIssued" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-50ecd1f8-f0f2-4311-b41c-4b7c8a9b0fa1" name="us-gaap:PreferredStockSharesIssued" contextRef="As_Of_12_31_2021" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-a36203d4-7efe-4588-94cd-3f05c60875bd" name="us-gaap:PreferredStockSharesOutstanding" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-ae8b49ec-bbbc-4620-aced-de7e20ab0f33" name="us-gaap:PreferredStockSharesOutstanding" contextRef="As_Of_12_31_2021" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of preferred stock issued or outstanding. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Common Stock </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common stockholders are entitled to dividends when and if declared by our board of directors. There have been </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bd97a32a-672c-4035-8b1c-c0f1c14cfc56" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit13" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> dividends declared to date. The holder of each share of common stock is entitled to </span><ix:nonNumeric name="us-gaap:CommonStockVotingRights" id="ct-nonNumeric-1356ebf1-f440-422f-bca9-5b5f795fd2e7" contextRef="Duration_1_1_2021_To_12_31_2021"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-66fa351e-8852-4381-a2bb-aa03816c9796" name="pacb:CommonStockVotingRightsNumberOfVotesPerShareOwned" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit14" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> vote. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Underwritten Public Equity Offerings</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In August 2020, we entered into an underwriting agreement, relating to the public offering of </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5b1a3696-39ee-4e89-bf75-ee75ff7f06c3" name="pacb:PublicOfferingShares" contextRef="Duration_8_1_2020_To_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">19,430,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of our common stock, $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-186b023a-4071-426a-aadf-f2c9c7d2fdcb" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="As_Of_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> par value per share, at a price to the public of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f5a21929-aff9-407d-a1c3-dbb579e9b95d" name="pacb:OfferingShareAmountMaximum" contextRef="As_Of_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">4.47</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share. Under the terms of the underwriting agreement, we also granted the underwriters a </span><ix:nonNumeric name="pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod" id="ct-nonNumeric-92c6ce20-ff63-4eb2-bc7e-ef705461a5a6" contextRef="Duration_8_1_2020_To_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" format="ixt-sec:durday"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">30</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-day option to purchase up to an additional </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5ec9797e-26d8-435d-b63f-f8afa6a301d4" name="pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares" contextRef="Duration_8_1_2020_To_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,914,500</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of our common stock, which was subsequently exercised in full, and the offering including the sale of shares of common stock </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">96</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae-continuation-1" continuedAt="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae-continuation-2"><div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">subject to the underwriters&#8217; option, closed in August 2020.&#160;In total, we sold </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5fc4bcb5-19c0-4629-a12c-2bafa9379898" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="Duration_8_1_2020_To_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" unitRef="Unit1" decimals="-5" format="ixt:numdotdecimal" scale="6">22.3</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million shares of our common stock. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We paid a commission equal to </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d9d4cd71-db29-428e-af46-d4e0563a75e6" name="pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" contextRef="Duration_8_1_2020_To_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">6</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the gross proceeds from the sale of shares of our common stock. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The total net proceeds to us from the offering after deducting the underwriting discount were approximately $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0611f5a8-8d19-4f71-b264-1fe5472827bf" name="pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" contextRef="Duration_8_1_2020_To_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">93.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, excluding approximately $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ff8dd3ab-1fe8-44e9-b2e6-28769fc2e5ef" name="us-gaap:DeferredOfferingCosts" contextRef="As_Of_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.3</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of offering expenses. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In November 2020, we entered into an underwriting agreement, relating to the public offering of </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fc7c0c6e-3e3c-40c3-83cc-f802309004ad" name="pacb:PublicOfferingShares" contextRef="Duration_11_1_2020_To_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">6,096,112</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of our common stock, $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2ae7e250-2709-4632-ba82-13fbab03981c" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="As_Of_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> par value per share, at a price to the public of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a1bf90d2-3ba6-41a5-9686-efb7ad640959" name="pacb:OfferingShareAmountMaximum" contextRef="As_Of_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">14.25</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share. Under the terms of the underwriting agreement, we also granted the underwriters a </span><ix:nonNumeric name="pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod" id="ct-nonNumeric-7b664084-ab0e-47fa-9966-8b519194516e" contextRef="Duration_11_1_2020_To_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" format="ixt-sec:durday"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">30</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-day option to purchase up to an additional </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e384a21c-060c-48ac-a778-ca9e6f51b5cb" name="pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares" contextRef="Duration_11_1_2020_To_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">914,416</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of our common stock, which was subsequently exercised in full, and the offering including the sale of shares of common stock subject to the underwriters&#8217; option, closed in November 2020.&#160;In total, we sold </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fca2c2b6-b642-46a7-8e0e-5ae744ec18bc" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="Duration_11_1_2020_To_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" unitRef="Unit1" decimals="-5" format="ixt:numdotdecimal" scale="6">7.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million shares of our common stock. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We paid a commission equal to </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-05ebe1e9-e8a3-461a-9693-7eb1a26d0cfe" name="pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" contextRef="Duration_11_1_2020_To_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">6</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the gross proceeds from the sale of shares of our common stock. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The total net proceeds to us from the offering after deducting the underwriting discount were approximately $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7e32f61c-72da-414d-b15a-fc3a2a6f59e3" name="pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" contextRef="Duration_11_1_2020_To_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">93.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, excluding approximately $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-219e158b-2be0-4e74-a643-71395056c9f9" name="us-gaap:DeferredOfferingCosts" contextRef="As_Of_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.3</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of offering expenses.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In total, for the year ended December 31, 2020, we issued </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9d1140cb-12fb-4861-9f65-b77281c6a08f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_pacb_UnderwrittenPublicEquityOfferingMember" unitRef="Unit1" decimals="-5" format="ixt:numdotdecimal" scale="6">29.4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million shares of our common stock through our </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1ae30328-cbc5-4a6e-8860-279408b4f9ba" name="pacb:NumberOfOfferings" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_pacb_UnderwrittenPublicEquityOfferingMember" unitRef="Unit14" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> underwritten public offerings with an average offering price of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e55eb629-fcd1-4334-a992-a4ed631c99a4" name="us-gaap:SharesIssuedPricePerShare" contextRef="As_Of_12_31_2021_srt_StatementScenarioAxis_pacb_UnderwrittenPublicEquityOfferingMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">6.40</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The total net proceeds to us from the </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e264baee-2445-423a-819c-613ff840ffa4" name="pacb:NumberOfOfferings" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_pacb_UnderwrittenPublicEquityOfferingMember" unitRef="Unit14" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> offerings, after deducting the underwriting commission and offering expenses, were approximately $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-924cae20-5cb7-49fd-9e3c-1e68d6731f9b" name="pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_pacb_UnderwrittenPublicEquityOfferingMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">187.2</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Private Placement of Common Stock</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On July&#160;19, 2021, in connection with the Omniome acquisition, we entered into a purchase agreement with certain qualified institutional buyers and institutional accredited investors, pursuant to which we agreed to sell an aggregate of </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0ec15364-fa9c-4d9d-8c36-cbceaf18c41c" name="us-gaap:CommonStockSharesIssued" contextRef="As_Of_9_20_2021_us-gaap_StatementEquityComponentsAxis_pacb_PrivatePlacementOfCommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">11,214,953</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock, at a price of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8c457f30-590f-411c-827b-d160402b1473" name="us-gaap:SharesIssuedPricePerShare" contextRef="As_Of_9_20_2021_us-gaap_StatementEquityComponentsAxis_pacb_PrivatePlacementOfCommonStockMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">26.75</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share, for aggregate gross proceeds of approximately $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-423f7a88-c441-47f4-9cbc-76536684b76a" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_StatementEquityComponentsAxis_pacb_PrivatePlacementOfCommonStockMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">300</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million. The transaction closed on September 20, 2021. We registered the private placement shares for resale following the closing of the merger.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Equity Plans </span></p><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), the 2020 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;) and the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#8220;Omniome Plan&#8221;) allow for the issuance of stock options, restricted units and awards and performance-based awards.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On August 4, 2020, stockholders approved the 2020 Plan and reserved </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-74d35d38-907c-4741-b244-829fe8c860ef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="As_Of_8_4_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EquityIncentivePlan2020Member" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">11,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of our common stock for issuance pursuant to equity awards granted under the 2020 Plan.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On December 2, 2020, the Board of Directors (the &#8220;Board&#8221;) adopted the Inducement Plan and reserved&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-502ba08d-5989-4746-a51f-fdf14d16f9e3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="As_Of_12_2_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_InducementEquityIncentivePlan2020Member" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">2,500,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of our common stock for issuance pursuant to equity awards granted under the Inducement Plan. On April 18, 2021 and November 22, 2021, the Board amended the Inducement Plan to reserve an additional </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fbcc4a41-deba-46a8-a1f0-1c9b5d8e307b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="Duration_4_21_2021_To_4_21_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_InducementEquityIncentivePlan2020Member" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">750,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c3adacbd-7c59-4e4f-b6ea-1ddcd71a0151" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="Duration_11_22_2021_To_11_22_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_InducementEquityIncentivePlan2020Member" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">360,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares, respectively. </span></p><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On September 20, 2021, in connection with the acquisition of Omniome, we adopted the Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#8220;Omniome Plan&#8221;). Under the Omniome Merger Agreement, each unvested option to purchase Omniome common stock, granted under the Omniome Plan held by employees continuing with us, were assumed by PacBio and converted into an option to purchase shares of our common stock. The terms and conditions of the converted options are substantially the same (including vesting and exercisability), except that (A) the assumed options cover shares of PacBio&#8217;s common stock; (B) the number of shares of our common stock subject to the assumed option is equal to the product of (i) the number of shares of Omniome common stock subject to the corresponding unvested option, multiplied by (ii) the exchange ratio (as defined below), with any resulting fractional share rounded down to the nearest whole share; and (C) the exercise price per share of the assumed options is equal to the quotient of (i) the exercise price per share of the corresponding unvested option to purchase shares of Omniome common stock, divided by (ii) the exchange ratio (as defined below), with any resulting fractional cent rounded up to the nearest whole cent. The exchange ratio was equal to </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-320d54b5-c5b0-40c5-a305-36e383ebcd53" name="pacb:ExchangeRatio" contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember" unitRef="Unit14" decimals="INF" format="ixt:numdotdecimal">0.259204639</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. We reserved </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f7ca43fd-caf3-43da-ad34-dc2caf10adcf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="As_Of_9_20_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,494,128</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of our common stock for issuance pursuant to equity awards under the Omniome Plan. </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">97</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae-continuation-2" continuedAt="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae-continuation-3"><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">2020 Equity Incentive Plan </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Under the 2020 Plan, with the approval of the Board of Directors or the Compensation Committee of the Board of Directors, we may grant </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">equity-based awards, including non-statutory stock options, restricted stock units (&#8220;RSUs&#8221;), restricted stock, stock appreciation rights, performance shares and performance units. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock options granted under the 2020 Plan may be either incentive stock options </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(&#8220;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">I</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">SOs&#8221;) within the meaning of Internal Revenue code Section 422 or non-qualified stock options (&#8220;NSOs&#8221;). Stock options under the 2020 Plan may be granted with a term of up to ten years and at prices no less than the fair market value of our common stock on the date of grant. To date, stock options granted to existing employees generally vest over four years on a monthly basis and stock options granted to new employees vest at a rate of 25% upon the first anniversary of the vesting commencement date and 1/48th&#160;per month thereafter, in each case, subject to continued service with us through the applicable vesting dates.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">2020 Inducement Equity Incentive Plan</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Under the Inducement Plan, </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">with the approval of the Board of Directors or the Compensation Committee of the Board of Directors, we may grant </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">equity-based awards, including non-statutory stock options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance units. The terms of the Inducement Plan are substantially similar to the 2020&#160;Plan, including with respect to treatment of equity awards in the event of a &#8220;merger&#8221; or &#8220;change in control&#8221; as defined under the Inducement Plan, but with such other terms and conditions intended to comply with the NASDAQ Inducement Award exception. In accordance with Rule 5635(c)(4) of the NASDAQ Listing Rules, awards under the Inducement Plan may only be made to individuals not previously employees or non-employee directors of the Company (or following such individuals&#8217; bona fide period of non-employment with the Company), as an inducement material to the individuals&#8217; entry into employment with the Company or in connection with a merger or acquisition, to the extent permitted by Rule 5635(c)(3) of the NASDAQ Listing Rules.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2021, we had </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7abd6315-accf-429b-a040-dd29cd042b47" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="As_Of_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_InducementEquityIncentivePlan2020Member" unitRef="Unit1" decimals="-5" format="ixt:numdotdecimal" scale="6">8.1</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Omniome Plan.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Stock Options</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Time-based stock options</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table summarizes time-based stock option activity for all of our equity compensation plans for the year ended December 31, 2021 (in thousands, except per share amounts):</span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ct-nonNumeric-04441bd1-997f-4c72-a26b-5874a82d1f49" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionsMember"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="7" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stock Options Outstanding</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">average</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">of shares</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exercise price</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">exercise price</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding at December 31, 2020</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bd0a3235-9737-4452-8442-cb89fad1964e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">14,638</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-009aa21b-f8f9-4cb6-9df7-ee02c76df623" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">1.16</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8211; </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-13d0ddba-68c7-4921-8f8b-dd70779a40b9" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">20.90</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-820a24c3-e2e6-4ebe-b058-e00144055a36" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">5.53</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9d929e1b-b523-4d49-8a56-4ffbbc25fac9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTwoMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">2,489</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-92de6e4a-96ea-40a7-a8c3-450c6c86d4ce" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTwoMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">23.06</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8211; </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0dd53b58-0fa2-45af-aaac-aca5ec15b1ae" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTwoMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">46.37</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2ee5e7b3-4f8b-4e4a-932a-35611645394a" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTwoMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">33.78</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Assumed Omniome options</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0a6e3b54-0e68-4c88-96ad-146f4342d868" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">339</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-02bece14-5377-4333-b739-db7e1478d742" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">2.05</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8211; </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2580acbc-afe6-4219-b1ea-f5c987ac80c3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">4.90</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-be3623d7-b282-48dd-bdb6-969c6a681e3d" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">4.43</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Exercised </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a625d643-a65d-4856-a7a5-09c8609e562f" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThreeMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">4,766</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-17677cbc-96d8-45f9-9e6c-ff9a8030f65e" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThreeMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">1.16</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8211; </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-42cfc3b6-8489-4e95-b661-d77b2284c6e6" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThreeMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">15.98</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4888b02c-1490-48d3-bca8-a5e71257e688" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThreeMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">5.31</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Canceled </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-68a61345-0e42-44f9-bc48-6a9381b28307" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">541</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-552ce895-5b1d-4ef0-9aac-7b7c0ecf6a85" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">2.54</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8211; </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7ba04cb8-d3ca-4cfb-863c-0445287d5fa1" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">46.37</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-16ea7c44-e69a-4102-9a4b-c92c06e36a41" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">5.25</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 43.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding at December 31, 2021</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1ff0130c-b3f3-4747-9eff-be97a7c8d679" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFiveMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">12,159</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fcc9671b-de99-4bda-9d07-996b9c035c59" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFiveMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">1.16</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8211; </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a9c170a9-03b5-41ac-a268-784e042033a8" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFiveMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">46.37</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-35b06228-9146-461a-848d-976d91a574a4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFiveMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">11.38</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The expired options during the year ended December 31, 2021 totaled </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e681d321-01cb-44d7-9853-29740a89eb16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit1" decimals="-4" format="ixt:numdotdecimal" scale="6">0.02</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million with exercise prices ranging from $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d6780d00-a2b6-40e3-a64b-20b2c9bf5a86" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">2.54</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-657be5b8-8643-4fb5-94de-69d6ddec0c9f" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">46.37</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share and a weighted average exercise price per share of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3ea1ee24-b394-4b15-ac80-18d91462f7ca" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">9.80</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">98</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae-continuation-3" continuedAt="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae-continuation-4"><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Performance-based stock options</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table summarizes performance-based stock option activity for all of our equity compensation plans for the year ended December 31, 2021 (in thousands, except per share amounts):</span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ct-nonNumeric-7786e635-76dc-4381-b12e-444e3d8a0b13" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 15.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 15.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 15.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 15.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="7" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stock Options Outstanding</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 15.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 15.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 15.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 15.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">average</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">of shares</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exercise price</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">exercise price</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding at December 31, 2020</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Assumed Omniome options</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-207120a0-8164-4a92-9c22-3c0376e35f01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal" scale="3">304</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a3e5062c-d317-477b-a9cb-5762632873f3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">4.71</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-04d2e1cd-8c18-4b34-b212-634dbb03d3f4" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">4.90</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-64f9d9c5-b182-4ca6-acaf-cd95c8994bb5" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">4.71</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Exercised </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Canceled </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 39.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding at December 31, 2021</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6f8f98cc-80d8-4bf8-8ab5-93465eb52896" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal" scale="3">304</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-952d3d55-9400-432c-bbb8-72a8cedac1a5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">4.71</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1945d1e9-554b-479d-a71e-3e0c51092812" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">4.90</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b7c89c33-7097-4b1c-9eee-0b527d1abe5d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">4.71</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table summarizes information with respect to stock options outstanding and exercisable under our equity compensation plans at December&#160;31, 2021: </span></p><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="ct-nonNumeric-7ec79656-3b74-4e55-9372-8a57324f60e5" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="6" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 47.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Options Outstanding</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="4" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 35.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Options Exercisable</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted average</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">outstanding</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">remaining contractual</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted average </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">vested</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted average </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exercise price</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in 000s)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">life (Years)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">exercise price</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in 000s)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">exercise price</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6d3ccb66-6ea1-4996-a525-4a0314b48794" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">0.00</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a28b32b2-f5da-4845-8142-ceb05aafd4dc" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">4.64</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3b2a2cd6-1b3a-4222-9f22-4351aded3159" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">3,676</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-267c2923-40c7-4324-bb30-40bcedf63a7d" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.37</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5d648b1f-06b4-47fe-9656-252b4460f6c0" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">2.91</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0afae772-42bb-485b-852e-82a738bc579e" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">3,508</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5dc52550-6e86-4d44-9149-c9ab9702ecba" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">2.91</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b6bc4a85-36e7-4c1f-a83f-9c60698d426f" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">4.64</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-347854a2-0a05-436a-a79d-fcb347c3f935" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">9.27</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-334e0171-ad51-4732-bba2-b8fce81e5953" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">5,480</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-7560aca1-8b18-492a-b10d-d2eafe956b40" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.88</span></ix:nonNumeric></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-57d2a885-4be7-4b3a-adf1-b9d76e7ccd18" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">6.64</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-abea4916-6d2b-4925-9ede-ae065c3e9e64" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">4,010</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cccf8efa-c6bf-4b0c-a814-f3d1d6a65d30" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">6.68</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-441a6f52-0b3b-4a7d-9fac-0db8eea6fc7f" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">9.27</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5e9acfc3-6d41-4b36-b4f3-9b901e811fae" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">13.91</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ec777f85-1d94-43d5-8b91-827bb69c12b9" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">702</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-729e6ac6-8a3c-4b9b-a139-3d6f8cd71ba9" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.69</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a6d92eab-e5cd-4e64-809d-905c475893ff" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">9.81</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c5ca2927-3520-4070-bb0d-5421c3fea5b0" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">427</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b151738a-d4a4-4a43-9fb5-e227c4eabf37" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">9.94</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0ffb110b-d0ae-45ee-a3ec-1e39d5758880" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">13.91</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ddc4698d-4805-4a43-9cb9-bc3366d4a0fe" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">18.55</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c1ffd3d8-ea87-4c22-b418-99d52a1cea60" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">35</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-eb65caf3-7bf6-40b9-aaf8-f1b746cfb1bf" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8.79</span></ix:nonNumeric></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1c6e267d-e98b-4ea0-b2fc-ac7e04b19000" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">14.34</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fd7922d4-ffe4-4ec7-a1c3-cd393f1b998a" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7e07150b-f15b-46ac-9a31-59ffe8122569" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">14.34</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6209f12d-6bbb-47ff-9840-8df27210c2d4" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">18.55</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-64278d91-1fa9-4144-8145-7b653ffaaaab" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">23.19</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cde44e46-4905-4ed8-9ddf-7fffcc65b529" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">180</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-f754cd39-3b2c-4b66-960b-35f28021dc1d" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9.38</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c215b008-ece2-4247-9052-6a188cb76901" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">21.86</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d01dab73-3d7c-41ad-9c9c-febf4ff45155" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">25</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f2513e93-dfc3-4d5b-ae54-2e690b72cf64" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">20.90</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7bba64ec-96ae-4349-9710-6cf787b65c43" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeElevenMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">23.19</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fe688ab0-0ccb-42b6-b355-5f08d2083880" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeElevenMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">27.82</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a53a01bb-8e43-485c-98ab-ec620051ce6d" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeElevenMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">320</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-d0d47cff-5d41-4bec-9453-b983adfe023c" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeElevenMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9.50</span></ix:nonNumeric></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ed7623d5-d77f-4c33-bbf1-b18104d9095e" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeElevenMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">24.22</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3054b960-1053-45a2-a9ba-bf19c3e2ee21" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">27.82</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6cda0aca-39ac-4a1c-84e0-a2575444a000" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">32.46</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-816775b6-158b-4937-9d1c-383427abeeec" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">472</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-8838ab9e-c301-4817-b3e8-e0f67040428b" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9.43</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ef9c94cd-5992-4d70-b293-8f5f1414bf9a" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">28.77</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-20598e8d-bd90-4692-870a-3d96e944366b" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">52</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e4f63b7b-9da6-4a74-ba11-a77a1d4078cb" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">27.90</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-518d84a4-ca8a-4ac7-9ea7-58b9308c80f1" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourteenMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">32.46</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-aba41de2-c0f3-4305-9b74-0223a53a07ab" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourteenMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">37.10</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6c8af849-2f5c-49d9-8faf-852cf01aea4c" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourteenMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">1,380</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-84712b46-6ea4-4f6d-968e-75fd1a7d93b7" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourteenMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9.00</span></ix:nonNumeric></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6743c6ce-0dec-4f17-a6bc-d6209bacdd42" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourteenMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">36.18</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-16686fd2-4344-4834-8314-d4eaaf0d1e92" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">41.73</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-13ad147e-f247-4686-a792-1aa091376fd8" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">46.37</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e2b05ab9-b60e-40e2-9cb3-222e2178ded1" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">218</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-40ed5421-bd81-403f-9c0f-3009f660b84b" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9.13</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f2bd0996-ca28-4514-b9cb-605b40f4ebbc" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">46.37</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-99f93bd1-ec0c-4740-b0ca-34dcb93d006b" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-063cfae5-2ba8-4e5c-b822-1effef3197bc" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">46.37</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4885d3ad-0d31-4190-b4d3-9599c176f016" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">12,463</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-fc2fe679-f37a-427b-9cd2-fde365f885ee" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.47</span></ix:nonNumeric></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-72f98c10-eb75-479f-a35f-265b8d6aaa28" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">11.22</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b0c51488-cebf-4393-8e39-21cd6b52ebdb" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">8,081</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7d0fd138-f84e-4d3d-9b89-c3f42fb60cfa" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">5.63</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The aggregate intrinsic value of the outstanding and exercisable options presented in the table above totaled $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4b2f062d-df3e-4162-9aaa-01a032761234" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">147.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6511611a-1a11-46fa-b65b-c3593abe92cd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">121.4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, respectively. The aggregate intrinsic value represents the total pretax intrinsic value (i.e., the difference between $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d870224b-a895-494b-ac8a-672bb69396a9" name="us-gaap:SharePrice" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">20.46</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, our closing stock price on the last trading day of our fourth quarter of 2021 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2021. The aggregate intrinsic value changes at each reporting date based on the fair market value of our common stock. The weighted average remaining contractual life for exercisable options is </span><ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ct-nonNumeric-391ba3ba-6f74-4bd5-b81b-51e001b5484c" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.12</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The vested and expected to vest options as of December 31, 2021 totaled </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8bce952c-4a31-4c22-af61-5f657c6234e6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">11,535,217</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, with aggregate intrinsic value of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-05697323-8984-4a24-939e-1ec9a86a8fd7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">141.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, weighted average exercise price per share of $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-469f88cb-103e-4feb-aaa3-dc20a9b512cd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">10.46</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and weighted average remaining contractual life of </span><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ct-nonNumeric-325ecf7e-3921-43d4-a9d1-082e08e3d6b4" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.28</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The total intrinsic value of stock options exercised during the years ended December&#160;31, 2021, 2020 and 2019 was $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f8c8a2ac-0389-4916-bc4b-6dd9eb2d1d5f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">146.1</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-257d6fc7-6c62-4a2f-b746-f57bde63f072" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">63.1</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6e1190d0-2b79-4549-bb8a-d20bd387b94a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">2.6</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, respectively. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span id="_Hlk62660604" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The weighted-average grant-date fair value of all options granted with exercise prices equal to fair market value was $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2860afa6-2160-4830-9482-41da78b95ea9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">18.36</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in 2021 and $</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9c2884dd-d6ec-4bbe-a7fe-4fa703855426" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">4.14</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in 2020 determined by the Black-Scholes option valuation method. </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">No stock options were granted in 2019.</span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">99</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae-continuation-4" continuedAt="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae-continuation-5"><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Time-based RSUs&#160;</span></p><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Each RSU represents </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-00ca43e5-0815-46cf-a8ca-416088168b74" name="pacb:ShareInstrumentNumberOfSharesConversionRatio" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> equivalent share of our common stock to be issued after satisfying the applicable continued service-based vesting criteria over a specified period. These RSUs vest over </span><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ct-nonNumeric-e6b3aab0-7c22-4975-91bb-1cbef8f186bb" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">four years</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> at a rate of </span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-694f8b3f-ae72-4776-b776-a0774e1860ab" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_VestingAxis_pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">25</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% annually. The fair value for these RSUs is based on the closing price of our common stock on the date of grant. We measure compensation expense for these RSUs at fair value on the date of grant and recognize the expense over the expected vesting period on a straight-line basis. The RSUs do not entitle participants to the rights of holders of common stock, such as voting rights, until the shares are issued. RSUs that are expected to vest are net of estimated future forfeitures. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table summarizes the time-based RSUs activity for the year ended December 31, 2021 (in thousands, except per share amounts): </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="ct-nonNumeric-ee83c78b-7d2e-4acf-a04a-92d90a0c8423" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 20.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted average</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">grant date</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">of shares</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 24.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">fair value</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">RSUs outstanding at December 31, 2020</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ef155ab0-5c83-47a1-a666-b583c25eafa9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">5,919</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 20.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6fe753cf-7f14-4410-9e24-d9c3c938b3de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">5.25</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">RSUs granted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2517020a-31c2-4053-a8ae-1651d3c8dc02" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">3,744</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 20.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-baa6fdf5-78ea-4582-bae9-1ac6189d7e56" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">35.33</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">RSUs released</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-66653d9e-f780-4639-b6bc-79a63fdaf83b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">1,798</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 20.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7a1a00ec-9307-4051-b95b-6c8c4547e59a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">5.13</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">RSUs forfeited</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3efdb89f-2685-4fe5-b24d-229fa33b2b4c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">473</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 20.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-95cd3856-5b5f-4218-bd4b-5d5b7f5ff898" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">16.68</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 57.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Unvested RSUs outstanding at December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d3923107-9cb2-4263-a705-58bf0d64b355" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">7,392</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 20.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7735b3e3-79d9-4aca-a8ca-d9f7d8fd9ffc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">19.78</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Performance-based RSUs&#160;</span></p><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Compensation Committee of the Board of Directors approved awards of RSUs with performance-based vesting under the 2010 Plan to certain employees which expired on July 29, 2020. Performance-based RSUs are governed under the 2020 Plan.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table summarizes the performance-based RSUs activity for the year ended December 31, 2021 (in thousands, except per share amounts): </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="ct-nonNumeric-dff1dc09-6e4d-4543-aa0e-b56a23e9acc9" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 61.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 61.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted average</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 61.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">grant date</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 61.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">of shares</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">fair value</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 61.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">PSUs outstanding at December 31, 2020</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e4513b6b-f9da-445a-8bb7-40accb7b0897" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">94</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-071a014e-530e-481c-9591-43e6bb534ea0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">2.63</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 61.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">PSUs granted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-157432ee-ccb2-4053-b0e5-c7935377bc43;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 17.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-ea27d075-ab14-46bd-a50a-ca1f6250a2fa;">&#8212;</span></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 61.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">PSUs released</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-30bbf7d7-4b14-4f75-9fd7-3cbfdadeb778;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 17.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-1ab6d777-8192-4d46-8320-5a5063ac3e21;">&#8212;</span></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 61.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">PSUs forfeited</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-939c05c1-c68f-4924-a68b-2881ed015669" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">94</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8717c31b-cedd-49bb-ad3b-df09f92ded0a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">2.63</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 61.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Unvested PSUs outstanding at December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-e9acf03d-13df-451d-9874-2f208766a4f5;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 17.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.42in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-1d49af19-806d-4049-a513-6d773e6a0680;">&#8212;</span></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">2010 Employee Stock Purchase Plan </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2021, a total of </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7cd7c553-e0df-4c41-b0b9-077664fa950a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="As_Of_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_TwoThousandTenEquityIncentivePlanMember" unitRef="Unit1" decimals="-5" format="ixt:numdotdecimal" scale="6">21.5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million shares of our common stock have been reserved for issuance under our 2010 Employee Stock Purchase Plan (ESPP).  The ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Each offering period will generally consist of </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4315f005-1573-48e5-b36c-f1cb8be4b32b" name="pacb:NumberOfPurchasePeriods" contextRef="As_Of_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit14" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> purchase periods, each purchase period being approximately </span><ix:nonNumeric name="pacb:PurchasePeriodOfEmployeeStockPurchasePlan" id="ct-nonNumeric-3a5c2e66-67f9-4720-a041-10b0671dc1b9" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">six months</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The price at which the stock is purchased is equal to the lower of </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-548ca816-e2e3-41fd-9312-baf6f5cbe657" name="pacb:PercentageOfFairMarketValueAtWhichStockCanBePurchased" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">85</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period. Each offering period will generally end and the shares will be purchased twice yearly on March 1 and September 1. If the stock price at the end of the purchase period is lower than the stock price at the beginning of the offering period, that offering period will then be terminated and new offering period comes to place. The ESPP provides for an annual increase to the shares available for issuance at the beginning of each fiscal year equal to the lessor of </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a9c507f6-11aa-486b-8ea2-a7dcf61d423d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">2</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the common shares then outstanding, </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9bef6782-7f18-4776-bc34-64a4f77852e2" name="us-gaap:CommonStockSharesIssued" contextRef="As_Of_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">4,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares, or an amount determined by the ESPP&#8217;s administrator. </span></p><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pursuant to the terms of the then-in-process Merger Agreement with Illumina, offerings under our 2010 ESPP were suspended after the completion of the purchase period ended March 1, 2019. After the merger with Illumina was terminated in January 2020, we began offerings under the ESPP again starting with the offering period beginning March 1, 2020. </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">100</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae-continuation-5" continuedAt="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae-continuation-6"><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For the years ended December&#160;31, 2021, 2020 and 2019, </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9d90b554-10a0-4257-b766-74b8c13a889e" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">1,913,968</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares, </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-786dfe2d-b6da-4262-b266-120055d29215" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">834,677</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares and </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ff0cf5e9-610e-4f6f-bf3c-4f74d19261a5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">1,306,329</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock were purchased under the ESPP, respectively. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2021, </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ea9d4ab2-d036-47aa-a33e-8f6569e9f349" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="As_Of_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">7,810,673</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of our common stock remain available for issuance under our ESPP. </span></p><p dir="ltr" style="background: #FFFFFF;font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Stock-based Compensation </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total stock-based compensation expense consists of the following (in thousands): </span></p><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ct-nonNumeric-ce062468-1e8c-4ab5-8e4b-2bd30d0fb6d4" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 48.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years Ended December 31, </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2019</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cost of revenue</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-17e3be15-2033-42b8-8794-ab72903e91c9" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,126</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ef52399c-3894-41c3-83ad-05e4c05966a0" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,236</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-eb4ab13b-fc9b-4377-a8e0-16eb644b2373" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,857</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b93e7610-8a79-4ee5-81aa-f9f9a28360ab" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">20,275</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-110f1a26-d777-4624-961c-4ccce3c0db2f" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,061</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6e4850fd-6ba0-4f93-aef4-02a48c2ab420" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,699</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Sales, general and administrative</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-42cf26d8-17d0-44f8-b9b8-8989b05c82d9" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">35,403</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-56e40865-4347-443b-bc02-4b7e2e7abf0e" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8,236</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-37bf6527-1140-42cc-818a-46406491b2aa" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,845</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Merger-related expenses - stock-settled</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0f8fd475-6bfc-4da5-b298-d67bbac5bf3a" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_pacb_MergerRelatedExpensesStockSettledMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,349</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Merger-related expenses - milestone</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5abad583-a577-4ec1-a170-94e6d7461a17" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_pacb_MergerRelatedExpensesMilestoneMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,202</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cd9fab44-fe41-4a48-b00e-2c37c5650aa6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_pacb_StockBasedCompensationMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">73,355</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-341d7418-7ea3-4da4-af31-c021145ed352" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_pacb_StockBasedCompensationMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,533</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-10e9b3f5-15d2-4707-917b-4cbae82ee09d" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_pacb_StockBasedCompensationMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">16,401</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Merger-related expenses - cash-settled</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ca68c3c9-dc2e-4618-bf9f-1e4985017b5d" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_pacb_MergerRelatedExpensesCashSettledMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,373</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 51.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total stock-based compensation expense</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-07751413-df9d-4fb7-bb31-2095bc196b61" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">80,728</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d424eed9-8e93-4c84-8685-c20de0a4d31b" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,533</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-09053142-788c-4a9a-b8a8-bdf84bbc7047" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">16,401</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2021 and 2020, $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-97ef6cfd-f35f-42d6-bffc-b0218373a481" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3cf146db-133d-46d9-87c9-949c2cdf5364" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.3</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of stock-based compensation cost was capitalized in inventory on our consolidated balance sheets, respectively. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The tax benefit of stock-based compensation expense was immaterial for the years ended December 31, 2021, 2020 and 2019. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Determining Fair Value</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We estimate the fair value of share options granted using the Black-Scholes valuation method and a single option award approach. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSU awards granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting period. For shares purchased under our Employee Stock Purchase Plan, or ESPP, we estimate the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected Term - The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock options and vesting schedules.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected Volatility - The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected Dividend - We have never paid dividends on our shares and, accordingly, the dividend yield percentage is zero for all periods.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Risk-Free Interest Rate - The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Stock Options</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We estimated the fair value of employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. For the year ended December 31, 2019, we did </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d99e41dd-4e8a-4d02-994f-ef7808d0f0c9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">t grant any stock options. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference observable market prices of similar or identical instruments in active markets. </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">101</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae-continuation-6" continuedAt="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae-continuation-7"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For the years ended December 31, 2021, 2020 and 2019, the fair value of employee stock options was estimated using the following weighted average assumptions:</span></p><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ct-nonNumeric-ec15ea9e-2851-4c49-8f8a-0e8ecc157477" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 48.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 48.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 48.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years Ended December 31, </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 48.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 18.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 16.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2019</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 48.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected term in years</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-d544368e-c55e-4057-8c75-5bada83ea210" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.1</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-c29241b4-9425-44f4-9022-dac127b57eca" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.6</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-a910f758-df3e-4397-946e-b04613e006b4" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.0</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-8beefc21-f615-4705-ab86-3b5ae2a9a9cc;">&#8212;</span></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 48.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected volatility </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-78b1f4cd-028b-44f8-b286-1ba88f447e4c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">67</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-44b0249a-bb44-4a9b-be1c-58d93d8cbe9c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">80</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8e7af148-fee7-4994-9efa-d96c0db0e57c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2">70.7</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 48.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Risk-free interest rate </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5afe349d-7b3a-481c-b1fe-7c67ee322127" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit15" decimals="4" format="ixt:numdotdecimal" scale="-2">0.05</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% &#8211; </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ff069c6e-2b44-43e4-86e6-3750d8c53dc4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit15" decimals="4" format="ixt:numdotdecimal" scale="-2">1.10</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-02f389c5-a8a5-42be-88ae-1064d04f48bf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2">0.3</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 48.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Dividend yield </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 48.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Weighted average grant date fair value per share</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b3bcaf46-f52b-41fb-ae9a-cf6f6bcf884b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">15.53</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f91faecf-5b21-455b-a652-ed2b8af55580" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit13" decimals="1" format="ixt:numdotdecimal">7.20</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-a1755a45-08c0-4740-a627-f6abb27a4908;">&#8212;</span></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 48.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash received from option exercises for the years ended December&#160;31, 2021, 2020 and 2019 was $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5a5b9e23-a755-41db-a862-87867ce30347" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">25.4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5b3d2655-ed97-4da4-80fd-59bedf99ec4d" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">43.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4b79970b-8afe-4602-a063-99a9ed0550ab" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">5.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, respectively.  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">ESPP </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We estimate the fair value of shares to be issued under the ESPP using the Black-Scholes option pricing model. For the years ended December 31, 2021, 2020 and 2019, the fair value of shares to be issued under the ESPP was estimated using the following assumptions:</span></p><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="ct-nonNumeric-38d5b823-97d9-43c4-b58b-d6c3c2fc791a" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 48.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 48.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.0%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 48.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years Ended December 31, </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 48.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 16.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 16.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 15.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2019</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 48.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected term in years</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-bd0370ae-f1d9-49fa-83d8-57147b5191f8" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.5</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-7734cc86-ae4e-4c2d-85b5-686e415128f4" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.0</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-a99c74fb-ffcc-4bbf-ac86-2c57dd87ee88" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.5</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-3eb193ef-be81-4ae6-a751-f83a66f60b68" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.0</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-6736a5db-23ed-4317-8508-2a31e2442346;">&#8212;</span></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 48.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected volatility </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-adeffcd8-da4a-409f-9a49-7ad171835900" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">67</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-771e2a9e-9a20-4573-82f9-c03813b583e2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">68</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4b4e3f7a-d950-4c85-bbb0-2cb0bbf5ef16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">57</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-61cfd96c-25e7-4e35-83b4-418d7690c416" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">71</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 48.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Risk-free interest rate </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2064fcb9-4a42-4161-bbc2-22672131f36c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">0.1</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e73cb34b-a24e-497e-bee3-8b934b58a8b8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">0.2</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8e4b7f88-8ac1-4348-a7e6-3b3f7f52e685" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal" scale="-2">0.1</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%-</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e19054c0-6531-4914-a390-c69893f35483" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">1.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 48.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Dividend yield </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 48.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Weighted average grant date fair value per share</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5a905af3-d5b3-4575-b03c-6a7e81c99716" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">25.07</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.0%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1f1eae48-4eb4-4077-b996-ee2b3a6e3d66" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">1.87</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;&#160;</span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash received through the ESPP for the years ended December 31, 2021, 2020 and 2019 was $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ceb8ec41-252f-4205-b2ae-0c9c8e7e00d3" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">6.4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-26c8aca1-2287-4b4f-8bae-793b78aea799" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">2.4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ce811de1-8735-4999-8f53-5964ffd1f90d" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">2.7</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, respectively.</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2021, $</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9a9f4f7f-596c-4503-b3b8-fac5211d630e" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">122.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of total unrecognized compensation expense related to stock options, restricted stock and ESPP shares was expected to be recognized over a weighted-average period of </span><ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ct-nonNumeric-81ef5e87-f4d4-4dd7-b3f7-7a25bb2007dd" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.9</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><ix:continuation id="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae-continuation-7"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span id="Note11_EPS" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" id="ct-nonNumeric-668332c7-8032-4850-9dc2-997722b0a9d2" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-668332c7-8032-4850-9dc2-997722b0a9d2-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">NOTE 11. NET (LOSS) INCOME PER SHARE</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-668332c7-8032-4850-9dc2-997722b0a9d2-continuation-0" continuedAt="ct-nonNumeric-668332c7-8032-4850-9dc2-997722b0a9d2-continuation-1"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Basic net (loss) income per share and diluted net (loss) income per share are presented for the three years presented. Basic net (loss) income per share is computed by dividing net (loss) income by the weighted average number of shares of common stock outstanding during the period. Diluted net (loss) income per share is computed using the weighted average number of shares of common stock outstanding and potential shares assuming the dilutive effect of outstanding stock options, restricted stock units and common stock issuable pursuant to our ESPP, using the treasury stock method. </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">102</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-668332c7-8032-4850-9dc2-997722b0a9d2-continuation-1" continuedAt="ct-nonNumeric-668332c7-8032-4850-9dc2-997722b0a9d2-continuation-2"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table presents the calculation of weighted average shares of common stock used in the computations of basic and diluted net (loss) income per share amounts presented in the accompanying consolidated statements of operations and comprehensive (loss) income (in thousands, except per share amounts): </span></p><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ct-nonNumeric-e839daa0-bbab-49ad-a70f-af7cda91328c" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 36.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.2%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2019</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Numerator:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 23.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net (loss) income</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d9b0207d-9ca0-4d15-9adf-095cf4d59fb5" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">181,223</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2c580219-ed63-4e10-a8c0-657877e20ea0" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">29,403</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cc9d1ef5-9d16-4c0a-8be4-bd050971c3cf" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">84,134</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Denominator:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Basic</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Weighted average shares used in computing basic net income (loss) per share</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fce75830-07d7-47a9-8c02-800c696ee16a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">204,136</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a48b74dc-e871-4c84-bcbd-09a166305e35" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">165,187</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2c7455c4-969d-4ef9-8cd6-83f99cefd957" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">152,527</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Basic net (loss) income per share</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1402b19b-4dd2-494d-95e5-f9673dacab78" name="us-gaap:EarningsPerShareBasic" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" sign="-">0.89</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-139e0d38-e08c-4163-8ce7-ad377dd62a42" name="us-gaap:EarningsPerShareBasic" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">0.18</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bd49e345-6c30-4c23-ab4c-2ae276f2884d" name="us-gaap:EarningsPerShareBasic" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" sign="-">0.55</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Diluted</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Weighted average shares used in computing basic net (loss) income per share</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-67f9dcd5-3a36-47b7-baeb-20658ce044d5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">204,136</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-04c93e10-6e70-4b5e-853e-32680c58f136" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">165,187</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d6846bc5-81e1-4164-ae8c-0ca95c63212c" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">152,527</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Add: weighted average stock options</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d406b1b1-f990-4582-a8bf-9f66c7e5826d" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">6,092</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Add: weighted average restricted stock units</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9e48ffe7-f38d-4cfc-87dc-978a33bf3181" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">2,324</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Add: weighted average common stock issuable pursuant to our ESPP</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6b79c4fc-81b5-488a-9d48-286e7fc48d7a" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">1,367</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Weighted average shares used in computing diluted net (loss) income per share</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3863f49c-5d22-424e-a36d-5cbb03d9b462" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">204,136</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-97b93a56-0f56-4278-9ad3-4067a18f91ed" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">174,970</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-211adb0c-b8b2-46c9-9950-66bc922df58c" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">152,527</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Diluted net (loss) income per share</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c7edd9f4-c9b1-403b-a427-38762a22de25" name="us-gaap:EarningsPerShareDiluted" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" sign="-">0.89</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bc22b6a0-c101-48d5-8328-062a0dc50626" name="us-gaap:EarningsPerShareDiluted" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">0.17</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-50d9d73d-35ff-4483-aac8-f42948ba02f0" name="us-gaap:EarningsPerShareDiluted" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" sign="-">0.55</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following shares issuable upon conversion of convertible senior notes, options outstanding, time-based RSUs, performance-based RSUs and ESPP shares to purchase common stock were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive: </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ct-nonNumeric-0d232fd4-e3f5-4a66-b5a8-42c59b6b9fec" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 59.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 40.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 59.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2019</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 59.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shares issuable upon conversion of convertible senior notes</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b52fdabb-fd78-413e-b635-d83a0537bdd9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">18,026</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 59.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options to purchase common stock </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0f06716d-8669-467e-8cbf-f2c67cb9fda7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">12,463</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4b7be88a-1b49-4077-a17e-edf232056d98" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">4,908</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-257e81fc-4b2b-42c7-8bb3-f0b38cc28f3b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_OptionsToPurchaseCommonStockMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">22,697</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 59.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">RSUs with time-based vesting </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fe6c0063-ccbc-4fa8-b396-8d0527bb568a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">7,392</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-304409d9-b9af-4d5f-ac64-46ed1e4f7afe" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">100</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9027c6fe-282e-40be-96a9-db68c312323d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">1,086</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 59.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">RSUs with performance-based vesting </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-06c8af4b-190b-4102-966a-32cd32caf883" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">94</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-50cf0d8f-8b3a-4114-90ad-a7feb59165c2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">138</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 59.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ESPP shares</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-07f482cf-a5a0-4e82-96b5-38ccf1ca3a45" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">1,564</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c3389e97-0370-4cc5-ad81-260cbd6f4c74" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">2,890</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><ix:continuation id="ct-nonNumeric-668332c7-8032-4850-9dc2-997722b0a9d2-continuation-2"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span id="Note12_SegmentsandGeography" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" id="ct-nonNumeric-f5b2c1a1-bf86-4319-a602-2506161a7962" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-f5b2c1a1-bf86-4319-a602-2506161a7962-continuation-0"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">NOTE 12. SEGMENT AND GEOGRAPHIC INFORMATION</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-f5b2c1a1-bf86-4319-a602-2506161a7962-continuation-0" continuedAt="ct-nonNumeric-f5b2c1a1-bf86-4319-a602-2506161a7962-continuation-1"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are organized as, and operate in, </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b26d7e2b-7b4d-4c3d-8380-f88d8e9fe774" name="us-gaap:NumberOfReportableSegments" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit16" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> reportable segment: the development, manufacturing and marketing of an integrated platform for genetic analysis. Our chief operating decision-maker is our Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis for purposes of evaluating financial performance and allocating resources, accompanied by information about revenue by geographic regions. Our assets are primarily located in the United States of America and not allocated to any specific region and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue. Revenue by geographic region is based on the ship to address on the customer order.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A summary of our revenue by geographic location for the years ended December 31, 2021, 2020 and 2019 is as follows:</span></p><ix:nonNumeric name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="ct-nonNumeric-0f0ee084-c47d-441a-97c6-0ac26c2ebc97" contextRef="Duration_1_1_2021_To_12_31_2021" continuedAt="ct-nonNumeric-0f0ee084-c47d-441a-97c6-0ac26c2ebc97-continuation-0"><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 16.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2019</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">North America</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3b90dc40-14cb-44a4-a7ad-6758e73a3b67" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_NorthAmericaMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">64,521</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6bbd0015-c5da-4d06-bf90-9d2f8fa04ba1" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_srt_NorthAmericaMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">37,277</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-51b3a71e-eb8c-4b93-b623-8a73683cf57c" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2019_To_12_31_2019_srt_StatementGeographicalAxis_srt_NorthAmericaMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">44,681</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Europe (including the Middle East and Africa)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1149e714-9afc-4ec8-8dd8-0b31d1723bfe" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">30,271</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-eac3cd5f-b0f9-46f0-937a-9c70463a18d9" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">19,065</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0a57f599-1692-43e1-a36b-4ac1e3a0eebc" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2019_To_12_31_2019_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">19,600</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Asia Pacific</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d198dcda-e9ea-45a2-8e36-64282128920d" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_AsiaPacificMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">35,721</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0f8fccc3-6ebf-48a8-b44e-e790d38039e0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_srt_AsiaPacificMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">22,551</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c3c272cb-534c-4316-864e-d96e0c753bc2" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2019_To_12_31_2019_srt_StatementGeographicalAxis_srt_AsiaPacificMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">26,610</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dbc86676-68ad-43ab-8032-560ee4d310de" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">130,513</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9858561c-4db1-4b47-82c2-378575fa32de" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">78,893</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-38a4181c-3d45-4dbd-8677-eae50e21659d" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">90,891</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">103</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-f5b2c1a1-bf86-4319-a602-2506161a7962-continuation-1" continuedAt="ct-nonNumeric-f5b2c1a1-bf86-4319-a602-2506161a7962-continuation-2"><ix:continuation id="ct-nonNumeric-0f0ee084-c47d-441a-97c6-0ac26c2ebc97-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A summary of our revenue by category for the years ended December 31, 2021, 2020 and 2019 is as follows:</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="ct-nonNumeric-32bf20e5-fe9f-4119-83e3-74ed9ca6a2f2" contextRef="Duration_1_1_2021_To_12_31_2021"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.7%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.8%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 16.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2019</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Instrument revenue</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e0b5651a-af35-4213-ab4d-dc5546c06a0c" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_pacb_InstrumentMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">61,324</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a919ee37-117a-4f68-81f2-56cc34973dc2" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_pacb_InstrumentMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">34,282</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fbbcc11d-9bba-415b-8569-70bea6dc398e" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_pacb_InstrumentMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">45,126</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Consumable revenue</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1126fae9-bee4-4d00-934c-ced21d0f4ffb" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_pacb_ConsumableMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">52,181</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b5c43d49-d8e0-4d8b-9809-94f2a598be87" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_pacb_ConsumableMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">31,142</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e32a6591-234e-43c3-971b-04fbf86e5afa" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_pacb_ConsumableMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">32,616</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Product revenue</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-decabd30-8ba3-4ad4-8d82-3c1180fac294" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">113,505</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c5bfa427-25ba-4b5a-9ca2-7ebd244e5186" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">65,424</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-75b1ec28-1bdf-48bd-b038-ef75d290e6f1" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">77,742</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Service and other revenue</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-eac48340-b972-49d0-935b-480c74441ef2" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">17,008</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b3166d07-eb85-49ea-8dce-d5fd007a581e" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">13,469</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-17cb6c67-b1dc-4f83-ac70-a6b8831191b6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">13,149</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total revenue</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-084b6af6-bd21-405c-9296-8672e6ec9467" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">130,513</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-85134a94-ae0e-4a3e-99af-56ac11c8528c" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">78,893</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f6102fb3-01a2-48ac-8bb3-6d60adfdeb13" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal" scale="3">90,891</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 50.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.5%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.7%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><ix:continuation id="ct-nonNumeric-f5b2c1a1-bf86-4319-a602-2506161a7962-continuation-2"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 13.5pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; display: inline-block;text-indent: 0;width: 0.750in;"><span id="Item9" style="text-decoration: none;"></span></span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">104</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; display: inline-block;text-indent: 0;width: 0.750in;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">I</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">TEM 9.</span></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">None.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; display: inline-block;text-indent: 0;width: 0.750in;"><span id="Item9A" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">ITEM 9A.</span></span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CONTROLS AND PROCEDURES</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Evaluation of Disclosure Controls and Procedures </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our management, with the participation of our chief executive officer, our chief financial officer, and our principal accounting officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules&#160;13a&#8211;15(e) and 15d&#8211;15(e) of the Exchange Act) as of the end of the period covered by this Annual Report on Form 10&#8211;K. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgement in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our chief executive officer, chief fina</span><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ncial officer and our principal accounting officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Management&#8217;s Report on Internal Control Over Financial Reporting </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f). Pacific Biosciences of California, Inc&#8217;s internal control over financial reporting is designed to provide reasonable assurance to the Company&#8217;s management and board of directors regarding the preparation and fair presentation of published financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2021. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). Based on our assessment, we concluded that, as of December 31, 2021, the Company&#8217;s internal control over financial reporting was effective based on those criteria.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Management&#8217;s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of Omniome, Inc. and Circulomics, Inc., which are included in our 2021 consolidated financial statements and constituted 2% of total assets as of December 31, 2021 and approximately 1% of consolidated revenues for the year then ended. The Company&#8217;s internal control over financial reporting as of December 31, 2021 has been audited by Ernst &amp;Young LLP, the independent registered public accounting firm who also audited the Company&#8217;s financial statements. Ernst &amp;Young&#8217;s attestation report on the Company&#8217;s internal control over financial reporting appears on page </span><a href="#AuditorsICFR" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">106</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> hereof.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Changes in Internal Control Over Financial Reporting </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">An evaluation was performed under the supervision and with the participation of our management, including our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer to determine whether any change in our internal control over financial reporting occurred during the fiscal quarter ended December 31, 2021 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. There were no material changes in our internal control over financial reporting during the year ended December 31, 2021, that have materially affected, or were reasonably likely to materially affect, our internal control over financial reporting. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span id="AuditorsICFR" style="text-decoration: none;"></span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">105</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Report of Independent Registered Public Accounting Firm</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To the Stockholders and the Board of Directors of Pacific Biosciences of California, Inc.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Opinion on Internal Control over Financial Reporting</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have audited Pacific Biosciences of California, Inc.&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Pacific Biosciences of California, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As indicated in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting, management&#8217;s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of Omniome, Inc. and Circulomics, Inc., which are included in the 2021 consolidated financial statements of the Company and constituted 2% of total assets as of December 31, 2021 and 1% of revenues for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of Omniome, Inc. and Circulomics, Inc.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2021 consolidated financial statements of the Company and our report dated February 28, 2022 expressed an unqualified opinion thereon.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Basis for Opinion</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Definition and Limitations of Internal Control Over Financial Reporting</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">106</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Ernst &amp; Young LLP</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Redwood City, California </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2022&#8195;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; display: inline-block;text-indent: 0;width: 0.750in;"><span id="Item9B" style="text-decoration: none;"></span></span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">107</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; display: inline-block;text-indent: 0;width: 0.750in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">ITEM 9B.</span></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">OTHER INFORMATION</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">None.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-indent: 0;width: 0.750in;">ITEM 9C.</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">DISCLOSURE REGARDING FOREIGN JURISDICTIONS </span><span id="Item9C" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">THAT PREVENT INSPECTIONS</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Not applicable.</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">108</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PART III</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.77in;margin-right: 0;margin-top: 12pt;text-indent: -0.77in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-indent: 0;width: 0.770in;">ITEM 10.</span><span id="Item10" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">DIRECTORS</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Information responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days after the end of the fiscal year covered by this Annual Report on Form 10-K. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.77in;margin-right: 0;margin-top: 12pt;text-indent: -0.77in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-indent: 0;width: 0.770in;">ITEM 11.</span><span id="Item11" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">EXECUTIVE</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> COMPENSATION </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Information responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2022 Annual Meeting of Stockholder to be filed with the SEC within 120&#160;days after the end of the fiscal year covered by this Annual Report on Form 10-K. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.77in;margin-right: 0;margin-top: 12pt;text-indent: -0.77in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-indent: 0;width: 0.770in;">ITEM&#160;12.</span><span id="Item12" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">SECURITY</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Information responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days after the end of the fiscal year covered by this Annual Report on Form 10-K. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.77in;margin-right: 0;margin-top: 12pt;text-indent: -0.77in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-indent: 0;width: 0.770in;">ITEM&#160;13.</span><span id="Item13" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CERTAIN</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Information responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days after the end of the fiscal year covered by this Annual Report on Form 10-K. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.76in;margin-right: 0;margin-top: 12pt;text-indent: -0.77in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-indent: 0;width: 0.765in;">ITEM 14.</span><span id="Item14" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PRINCIPAL</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> ACCOUNTING FEES AND SERVICES </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 12pt;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Information responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days after the end of the fiscal year covered by this Annual Report on Form 10-K. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">109</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 13.5pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PART IV </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.77in;margin-right: 0;margin-top: 13.5pt;text-indent: -0.77in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-indent: 0;width: 0.770in;">ITEM 15.</span><span id="Item15" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">EXHIBITS</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">, FINANCIAL STATEMENT SCHEDULES. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.68in;margin-right: 0;margin-top: 4.5pt;text-indent: -0.34in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.340in;">(a)</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following documents are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K: </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.68in;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Financial Statements</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">: See Index to Consolidated Financial Statements under Item&#160;8 of this Annual Report on Form 10-K. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.68in;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Financial Statement Schedules</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">: All schedules are omitted because they are not required, are not applicable or the information is included in the consolidated financial statements or notes thereto. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.68in;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3. </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Exhibits</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">: We have filed or incorporated by reference into this Annual Report on Form 10-K, the exhibits listed on the accompanying Exhibit Index immediately below. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.68in;margin-right: 0;margin-top: 4.5pt;text-indent: -0.34in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.340in;">(b)</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial Statement Schedules: See Item&#160;15(a)(2), above. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.68in;margin-right: 0;margin-top: 4.5pt;text-indent: -0.34in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.340in;">(c)</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Exhibits: Refer to the </span><a href="#Index" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Exhibit Index</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> that follows. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">110</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exhibit Ind</span><span id="Index" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">ex</span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 27.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.01in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 27.5%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="4" style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 33.3%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Incorporated by reference herein</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.1%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 106.7%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exhibit</span><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number</span></p><div style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-top: 1.0pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 59.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 106.7%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Description</span></p><div style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-top: 1.0pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></div></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Form</span></p><div style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-top: 1.0pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exhibit&#160;No.</span></p><div style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-top: 1.0pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Filing Date</span></p><div style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-top: 1.0pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312511075269/dex31.htm"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">3.1</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span></a></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312511075269/dex31.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Amended and Restated Certificate of Incorporation</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.1</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March&#160;23,&#160;2011</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312518318421/d647083dex31.htm"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">3.2</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312518318421/d647083dex31.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Second Amended and Restated Bylaws of Pacific Biosciences of California, Inc.</span></a><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.1</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">November 5, 2018</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312510221497/dex41.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">4.1</span></a></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312510221497/dex41.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Specimen Common Stock Certificate</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1/A</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.1</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">October&#160;1,&#160;2010</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913020000008/pacb-20191231xex4_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">4.2</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913020000008/pacb-20191231xex4_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Description of Registrant&#8217;s securities registered under Section 12 of the Exchange Act</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.2</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2020</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913021000049/pacb-20210216xex4_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">4.3</span></a></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913021000049/pacb-20210216xex4_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Indenture, dated February 16, 2021, between Pacific Biosciences of California, Inc. and U.S. Bank National Association, as Trustee</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.1</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 17, 2021</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913021000049/pacb-20210216xex4_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">4.4</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913021000049/pacb-20210216xex4_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Form of 1.50% Convertible Senior Notes due 2028 (included in Exhibit 4.3)</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.1</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 17, 2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312510189512/dex101.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.1</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312510189512/dex101.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Form of Director and Executive Officer Indemnification Agreement</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">August 16, 2010</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000119312510189512/dex104.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.2</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000119312510189512/dex104.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">2010 Equity Incentive Plan</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.4</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">August 16, 2010</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913018000031/pacb-20180331xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.3</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913018000031/pacb-20180331xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">2010 Equity Incentive Plan forms of agreement</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">May 2, 2018</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312510189512/dex105.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.4</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312510189512/dex105.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">2010 Employee Stock Purchase Plan and forms of agreement thereunder</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.5</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">August 16, 2010</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312510189512/dex106.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.5</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312510189512/dex106.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">2010 Outside Director Equity Incentive Plan </span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.6</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">August 16, 2010</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913018000031/pacb-20180331xex10_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.6</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913018000031/pacb-20180331xex10_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">2010 Outside Director Equity Incentive Plan forms of agreement</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.2</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">May 2, 2018</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913020000116/pacb-20200805xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.7</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913020000116/pacb-20200805xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">2020 Equity Incentive Plan and related forms of agreement</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">August 5, 2020</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913020000157/pacb-20201204xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.8</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312521121215/d95363dex101.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Pacific Biosciences of California, Inc. 2020 Inducement Equity Incentive Plan, as amended, and forms of agreement thereunder</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">April 19, 2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913020000148/pacb-20200930xex10_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.12</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913020000148/pacb-20200930xex10_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Letter Relating to Employment Terms by and between the Registrant and Susan G. Kim effective September&#160;28, 2020</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.2</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">November 3, 2020</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913020000148/pacb-20200930xex10_3.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.13</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913020000148/pacb-20200930xex10_3.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Change in Control and Severance Agreement by and between the Registrant and Susan G. Kim effective September&#160;28, 2020</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.3</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">November 3, 2020</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_14.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.14</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_14.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Form of Change in Control and Severance Agreement for executive officers</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.14</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 26, 2021</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_15.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.15</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_15.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Letter Relating to Employment Terms by and between the Registrant and Christian O. Henry effective September&#160;14, 2020</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.15</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 26, 2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_16.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.16</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_16.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Change in Control and Severance Agreement by and between the Registrant and Christian O. Henry effective September&#160;14, 2020</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.16</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 26, 2021</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_17.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.17</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_17.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Amended Change in Control and Severance Agreement by and between the Registrant and Christian O. Henry dated February 3, 2021</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.17</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 26, 2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_18.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.18</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_18.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Letter Relating to Employment Terms by and between the Registrant and Mark Van Oene effective January 8, 2021</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.18</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 26, 2021</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_19.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.19</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_19.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Letter Relating to Employment Terms by and between the Registrant and Peter Fromen effective January 8, 2021</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.19</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 26, 2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913015000128/pacb-20150630ex1026040de.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.20</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913015000128/pacb-20150630ex1026040de.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Lease Agreement by and between the Registrant and Menlo Park Portfolio II, LLC, dated July&#160;22, 2015.</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.2</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">August 5, 2015</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913017000016/pacb-20161231xex10_50.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.21</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8224;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913017000016/pacb-20161231xex10_50.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">First Amendment to Lease Agreement by and between the Registrant and Menlo Park Portfolio II, LLC, dated December&#160;23, 2016.</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.50</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 6, 2017</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_23.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.22</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8224;&#8224;</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_23.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Development and Commercialization Agreement by and between the Registrant and Invitae Corporation dated January 12, 2021</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.23</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 26, 2021</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000192/pacb-20210630xex10_6.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.23</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8224;&#8224;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000192/pacb-20210630xex10_6.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Amendment to Development and Commercialization Agreement, dated as of June 3, 2021, by and between Pacific Biosciences of California, Inc. and Invitae Corporation</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.6</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">August 6, 2021</span></p></td></tr></table></div></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">111</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; "></span><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312521035435/d121704dex101.htm"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.24</span><span style="white-space:pre-wrap; color: #0000FF;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span></a></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312521035435/d121704dex101.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Investment Agreement, dated as of February 9, 2021, between Pacific Biosciences of California, Inc. and SB Northstar LP.</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 10, 2021</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312510234059/dex108.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.25</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8224;&#8224;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312510234059/dex108.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Exclusive License Agreement by and between the Registrant and Cornell Research Foundation, Inc., dated as of February 1, 2004</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1/A</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.8</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">October 22, 2010</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913021000192/pacb-20210630xex10_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.26</span></a><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000129913021000192/pacb-20210630xex10_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Letter Relating to Employment Terms by and between the Registrant and Michele Farmer effective May 17, 2021</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.2</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">August 6, 2021</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312521219136/d198514dex101.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.27</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312521219136/d198514dex101.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Agreement and Plan of Merger of Reorganization among Pacific Biosciences of California, Inc., Apollo Acquisition Corp., Apollo Acquisition Sub, LLC, Omniome, Inc. and Shareholder Representative Services, LLC, as securityholder representative, dated as of July 19, 2021</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">July 20, 201</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312521219136/d198514dex102.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.28</span></a></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312521219136/d198514dex102.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Securities Purchase Agreement, dated as of July 19, 2021, by and between Pacific Biosciences of California, Inc. and each of the Investors</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.2</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">July 20, 201</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312521219136/d198514dex103.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.29</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1299130/000119312521219136/d198514dex103.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Registration Rights Agreement, dated as of July 19, 2021, by and between Pacific Biosciences of California, Inc. and each of the Investors</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.3</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">July 20, 2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="pacb-20201231xex21_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">21.1</span></a></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="pacb-20211231xex21_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">List of Subsidiaries of the Registrant</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Filed herewith</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="pacb-20211231xex23_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">23.1</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="pacb-20211231xex23_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Consent of Independent Registered Public Accounting Firm</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Filed herewith</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="pacb-20211231xex31_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">31.1</span></a></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="pacb-20211231xex31_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Filed herewith</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="pacb-20211231xex31_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">31.2</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="pacb-20211231xex31_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Filed herewith</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="pacb-20211231xex32_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">32.1</span></a><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="pacb-20211231xex32_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160; </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furnished herewith</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="pacb-20211231xex32_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">32.2</span></a><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><a href="pacb-20211231xex32_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furnished herewith</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.INS</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Filed herewith</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.SCH</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Taxonomy Extension Schema Document</span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Filed herewith</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.CAL</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Filed herewith</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.DEF</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Filed herewith</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.LAB</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Taxonomy Extension Labels Linkbase Document</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Filed herewith</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.PRE</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Filed herewith</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.1%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">104</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 59.6%;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cover Page Interactive File (formatted as inline XBRL and contained in Exhibit 101) </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 5.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.6%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 17.9%;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Filed herewith</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: 0;margin-left: 0.68in;margin-right: 0;margin-top: 0;text-indent: -0.34in;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">_________________________</span></p><div style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;margin-left: 0;margin-right: 13.00in;padding-bottom: 1.0pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 6.0pt;margin-bottom: 3pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.34in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.34in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.340in;">+</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicates management contract or compensatory plan. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.34in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.34in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.340in;">&#8224;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Confidential treatment has been requested for portions of this exhibit. These portions have been omitted and have been filed separately with the Securities and Exchange Commission. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.34in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.34in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.340in;">&#8224;&#8224;</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Certain confidential information contained in this Exhibit was omitted by means of marking such portions with brackets because the identified confidential information (i) is not material and (ii) would be competitively harmful if publicly disclosed.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.34in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.34in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.340in;">*</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The certifications attached as Exhibit 32.1 and 32.2 that accompany this Annual Report on Form 10-K are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Pacific Biosciences of California, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;<span style="white-space:pre-wrap; margin: 0 0 0 0.00in;padding: 0 0 0 0;"></span></span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;"><span id="Item16" style="text-decoration: none;"></span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">112</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">ITEM 16. FORM 10-K SUMMARY</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.34in;margin-right: 0;margin-top: 12pt;text-align: justify;text-indent: -0.34in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">None.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">113</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Signatures</span><span id="Signatures" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 229.8pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.4pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 229.7pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 229.8pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.4pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 229.7pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 229.7pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Pacific Biosciences of California, Inc.</span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.4pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 229.7pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Date: February 28, 2022</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 16.4pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">By:</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 229.7pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/&#160;&#160;&#160;&#160; Christian O. Henry</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 7.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;&#160;&#160;</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 229.8pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 16.4pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 229.7pt;"><p dir="ltr" style="font-family: Roboto;font-size: 7.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 7.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Christian O. Henry</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 229.8pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 16.4pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 229.7pt;"><p dir="ltr" style="font-family: Roboto;font-size: 7.5pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 7.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Chief Executive Officer and President</span></p></td></tr></table></div><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 246.1pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.4pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 229.7pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Date: February 28, 2022</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 16.4pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">By:</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 229.7pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/&#160;&#160;&#160;&#160; S</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 7.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">USAN</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> G. Kim</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 7.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 229.8pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 16.4pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 229.7pt;"><p dir="ltr" style="font-family: Roboto;font-size: 7.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 7.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Susan G. Kim</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 229.8pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 16.4pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 229.7pt;"><p dir="ltr" style="font-family: Roboto;font-size: 7.5pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 7.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Chief Financial Officer </span></p></td></tr></table></div><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 229.8pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.4pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 229.7pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 229.8pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.4pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 229.7pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 229.7pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.4pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 229.7pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Date:  February 28, 2022</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 16.4pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">By:</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 229.7pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/&#160;&#160;&#160;&#160; Michele Farmer</span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 7.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;&#160;&#160;</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 229.8pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 16.4pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 229.7pt;"><p dir="ltr" style="font-family: Roboto;font-size: 7.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 7.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Michele Farmer</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 42.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 229.8pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 16.4pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 229.7pt;"><p dir="ltr" style="font-family: Roboto;font-size: 7.5pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 7.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Vice President and Chief Accounting Officer </span></p></td></tr></table></div><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 9pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">114</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 18pt;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">POWER OF ATTORNEY </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Christian O. Henry, Susan G. Kim, Brett Atkins and Michele Farmer, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for each individual in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or the individual&#8217;s substitute, may lawfully do or cause to be done by virtue hereof. </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;"><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 170.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 222.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 120.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 170.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 222.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 120.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 170.75pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 105.8%;margin-bottom: 1pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Signature</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 222.75pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 105.8%;margin-bottom: 1pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Title</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 8pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 120.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 8pt;line-height: 105.8%;margin-bottom: 1pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Roboto;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Date</span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 170.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 231.25pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 129.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 170.75pt;"><div style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ </span><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Christian O. Henry</span></p></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: 1pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Christian O. Henry</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 222.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director, Chief Executive Officer</span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: 1pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and President (Principal Executive Officer)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 120.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2022</span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 170.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 231.25pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 129.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 170.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 231.25pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 129.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 170.75pt;"><div style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Susan G. Kim</span></p></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: 1pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Susan G. Kim</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 222.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Chief Financial Officer </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: 1pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(Principal Financial Officer)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 120.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2022</span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 170.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 231.25pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 129.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 170.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 231.25pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 129.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 170.75pt;"><div style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Michele Farmer</span></p></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: 1pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Michele Farmer</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 222.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Vice President and Chief Accounting Officer (Principal Accounting Officer)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 120.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2022</span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 170.75pt;"><div style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ John F. Milligan</span></p></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: 1pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">John F. Milligan</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 222.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0.14in;margin-right: 0;margin-top: 0;text-indent: -0.14in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0.14in;margin-right: 0;margin-top: 0;text-indent: -0.14in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Chairman of the Board of Directors</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 120.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2022</span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 170.75pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 222.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0.14in;margin-right: 0;margin-top: 0;text-indent: -0.14in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 120.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 170.75pt;"><div style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ David Botstein</span></p></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: 1pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">David Botstein</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 222.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0.14in;margin-right: 0;margin-top: 0;text-indent: -0.14in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0.14in;margin-right: 0;margin-top: 0;text-indent: -0.14in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 120.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2022</span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 170.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 231.25pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 129.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 170.75pt;"><div style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ William W. Ericson</span></p></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: 1pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">William W. Ericson</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 222.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0.14in;margin-right: 0;margin-top: 0;text-indent: -0.14in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0.14in;margin-right: 0;margin-top: 0;text-indent: -0.14in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 120.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2022</span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 170.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 222.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 120.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 170.75pt;"><div style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Hannah A. Valantine</span></p></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Hannah A. Valantine</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 222.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 120.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2022</span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 170.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 222.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 120.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 170.75pt;"><div style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Randall S. Livingston</span></p></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: 1pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Randall S. Livingston</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 222.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0.14in;margin-right: 0;margin-top: 0;text-indent: -0.14in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 120.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2022</span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 170.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 231.25pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 129.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 170.75pt;"><div style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Marshall L. Mohr</span></p></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: 1pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Marshall L. Mohr</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 222.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0.14in;margin-right: 0;margin-top: 0;text-indent: -0.14in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0.14in;margin-right: 0;margin-top: 0;text-indent: -0.14in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 120.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2022</span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 170.75pt;"><p dir="ltr" style="font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: 1pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 222.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 120.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 170.75pt;"><div style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Kathy Ordo&#241;ez</span></p></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: 1pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Kathy Ordo&#241;ez</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 222.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0.14in;margin-right: 0;margin-top: 0;text-indent: -0.14in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 120.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2022</span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 170.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 231.25pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 129.35pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 1pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">115</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;"><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 170.75pt;"><div style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;"><span style="white-space:pre-wrap; "></span><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Lucy Shapiro</span></p></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: 1pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lucy Shapiro</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.5pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 222.75pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0.14in;margin-right: 0;margin-top: 0;text-indent: -0.14in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0.14in;margin-right: 0;margin-top: 0;text-indent: -0.14in;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 120.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Roboto;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2022</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9pt;"><p dir="ltr" style="text-align:left; font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 120.35pt;"><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 105.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: Roboto;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.34in;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: -0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">116</span></p></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>pacb-20211231xex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 22.1.0.2-->
<!--Created on: 2/28/2022 12:56:18 PM-->
<html>
	<head>
		<title>
			Exhibit 21.1_Taxonomy2021
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt;text-align:right;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Exhibit </font><font style="display: inline;font-weight:bold;font-size:10pt;">21.1</font><font style="display: inline;font-weight:bold;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">LIST OF SUBSIDIARIES</font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-indent:24.5pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-family:Calibri;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:30.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 8.6pt;height:1.00pt">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 8.6pt;height:1.00pt">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">Subsidiary name</font></p>
				</td>
				<td valign="bottom" style="width:30.00%;padding:0pt 0pt 0pt 8.6pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">Jurisdiction</font></p>
				</td>
				<td valign="bottom" style="width:16.00%;padding:0pt 0pt 0pt 8.6pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">Type</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:54.00%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:30.00%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:16.00%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Pacific Biosciences International LLC</font></p>
				</td>
				<td valign="top" style="width:30.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6.75pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Delaware</font></p>
				</td>
				<td valign="top" style="width:16.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Domestic</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:30.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6.75pt;line-height:115%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Pacific Biosciences Canada Limited</font></p>
				</td>
				<td valign="top" style="width:30.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6.75pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Canada (New Brunswick)</font></p>
				</td>
				<td valign="top" style="width:16.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Foreign</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:54.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:30.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6.75pt;line-height:115%;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:16.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Pacific Biosciences Germany GmbH</font></p>
				</td>
				<td valign="top" style="width:30.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6.75pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Germany (Munich)</font></p>
				</td>
				<td valign="top" style="width:16.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Foreign</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:30.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6.75pt;line-height:115%;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Pacific Biosciences Japan GK</font></p>
				</td>
				<td valign="top" style="width:30.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6.75pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Japan (Tokyo)</font></p>
				</td>
				<td valign="top" style="width:16.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Foreign</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:30.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6.75pt;line-height:115%;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Pacific Biosciences (Shanghai) Co., Ltd.</font></p>
				</td>
				<td valign="top" style="width:30.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6.75pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">China (Shanghai)</font></p>
				</td>
				<td valign="top" style="width:16.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Foreign</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:30.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6.75pt;line-height:115%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">PacBio Singapore PTE, Limited</font></p>
				</td>
				<td valign="top" style="width:30.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6.75pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Singapore</font></p>
				</td>
				<td valign="top" style="width:16.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Foreign</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:30.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6.75pt;line-height:115%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Pacific Biosciences UK Limited</font></p>
				</td>
				<td valign="top" style="width:30.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6.75pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">United Kingdom (London)</font></p>
				</td>
				<td valign="top" style="width:16.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Foreign</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:30.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6.75pt;line-height:115%;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Omniome, Inc.</font></p>
				</td>
				<td valign="top" style="width:30.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6.75pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Delaware</font></p>
				</td>
				<td valign="top" style="width:16.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Domestic</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:30.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6.75pt;line-height:115%;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30.3pt;line-height:115%;text-indent:30.3pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Circulomics, Inc.</font></p>
				</td>
				<td valign="top" style="width:30.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6.75pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Maryland</font></p>
				</td>
				<td valign="top" style="width:16.00%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 4.5pt;line-height:115%;text-indent:13pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Domestic</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:9pt 0pt 0pt -36pt;text-indent:24.5pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>pacb-20211231xex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 22.1.0.2-->
<!--Created on: 2/28/2022 12:56:26 PM-->
<html>
	<head>
		<title>
			Exhibit 23.1_Taxonomy2021
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:5pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Exhibit 23.1 </font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<a name="_Hlk95736678"></a><font style="display: inline;font-family:EYInterstate Light;font-weight:bold;color:#000000;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<a name="_Hlk1411284"></a><font style="display: inline;font-family:EYInterstate Light;color:#000000;font-size:10pt;">We consent to the incorporation by reference in the following Registration Statements:</font>
		</p>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:normal;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:EYInterstate Light;line-height:normal;border-bottom:1pt none #D9D9D9;color:#000000;font-size:10pt;;"> (1)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:normal;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-family:EYInterstate Light;color:#000000;font-size:10pt;">Registration Statements (Forms S-8 Nos. 333-170211, 333-179810, 333-186065, 333-193437, 333-201678, 333-209157, 333-215746, 333-222696, 333- 229368, 333-236061, 333-241687, 333-170211, 333-179810, 333-186065, 333-193437, 333-201678, 333-209157, 333-215746, 333-222696, 333-229368, 333-236061, 333-251153, 333-253669, 333-255342, 333-259671 and 333-261251) pertaining to the Pacific Biosciences of California, Inc. 2010 Equity Incentive Plan, the Pacific Biosciences of California, Inc. 2010 Employee Stock Purchase Plan, the Pacific Biosciences of California, Inc. 2010 Outside Director Equity Incentive Plan, the Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan, the Pacific Biosciences of California, Inc. 2020 Inducement Equity Incentive Plan, and the Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc., and</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:normal;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:normal;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:EYInterstate Light;line-height:normal;border-top:1pt none #D9D9D9;color:#000000;font-size:10pt;;"> (2)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:normal;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-family:EYInterstate Light;color:#000000;font-size:10pt;">Registration Statements (Forms S-3 Nos. 333-239071, 333-249999, 333-255324, 333-259670 and 333-259672) and related Prospectuses of Pacific Biosciences of California, Inc.;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:EYInterstate Light;color:#000000;font-size:10pt;">of our reports dated February 28, 2022, with respect to the consolidated financial statements of Pacific Biosciences of California, Inc. and the effectiveness of internal control over financial reporting of Pacific Biosciences of California, Inc. included in this Annual Report (Form 10-K) of Pacific Biosciences of California, Inc. for the year ended December 31, 2021.</font>
		</p>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:EYInterstate Light;color:#000000;font-size:10pt;">/s/ Ernst &amp; Young LLP</font>
		</p>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<a name="_Hlk95736684"></a><font style="display: inline;font-family:EYInterstate Light;color:#000000;font-size:10pt;">Redwood City, California</font>
		</p>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:EYInterstate Light;color:#000000;font-size:10pt;">February 28, 2022</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<br /><font style="display: inline;font-family:EYInterstate Light;font-size:10pt;color:#000000;"></font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:EYInterstate Light;font-weight:bold;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>pacb-20211231xex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 22.1.0.2-->
<!--Created on: 2/28/2022 12:56:33 PM-->
<html>
	<head>
		<title>
			Exhibit 31.1_Taxonomy2021
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Exhibit 31.1 </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">SECURITIES EXCHANGE ACT RULES&nbsp;13a-15(e), AS ADOPTED PURSUANT </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">TO SECTION&nbsp;302 OF THE SARBANES-OXLEY ACT OF 2002 </font>
		</p>
		<p style="margin:9pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">I, Christian Henry, certify that: </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">1.&nbsp;I have reviewed this annual report on Form&nbsp;10-K of Pacific Biosciences of California, Inc.; </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">2.&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">3.&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">4.&nbsp;The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">a)&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">c)&nbsp;Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;&nbsp;and </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">d)&nbsp;Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting;&nbsp;and </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">5.&nbsp;The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">a)&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information;&nbsp;and </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">b)&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Date: February 28, 2022</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="right" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td colspan="2" valign="middle" style="width:15.90pt;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 12pt">
						<font style="display: inline;">Christina </font></p>
				</td>
				<td colspan="2" valign="middle" style="width:200.10pt;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:15.90pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:200.10pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:15.90pt;padding:0pt;">
					<p style="margin:5pt 0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">By:</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:200.10pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">/s/ Christian Henry </font></p>
					<p style="margin:1pt 0pt 0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman;font-size: 4pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:08.55pt;padding:0pt 0pt 0pt 8.6pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman;font-size: 4pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:201.15pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Christian Henry</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:08.55pt;padding:0pt 0pt 0pt 8.6pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman;font-size: 4pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:201.15pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Chief Executive Officer and President </font></p>
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">(Principal Executive Officer)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:9pt 0pt 0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>pacb-20211231xex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--HTML document created with Certent Disclosure Management 22.1.0.2-->
<!--Created on: 2/28/2022 12:56:41 PM-->
<html>
	<head>
		<title>
			Exhibit 31.2_Taxonomy2021
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt;text-align:right;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Exhibit 31.2 </font>
		</p>
		<p style="margin:0pt;text-align:right;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">SECURITIES EXCHANGE ACT RULES&nbsp;13a-15(e), AS ADOPTED PURSUANT </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">TO SECTION&nbsp;302 OF THE SARBANES-OXLEY ACT OF 2002 </font>
		</p>
		<p style="margin:9pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">I, Susan Kim, certify that: </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">1.&nbsp;I have reviewed this annual report on Form&nbsp;10-K of Pacific Biosciences of California, Inc.; </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">2.&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">3.&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">4.&nbsp;The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">a)&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">c)&nbsp;Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;&nbsp;and </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">d)&nbsp;Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting;&nbsp;and </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">5.&nbsp;The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">a)&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information;&nbsp;and </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">b)&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Date: February 28, 2022</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="right" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td colspan="2" valign="middle" style="width:15.95pt;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">, &nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:200.05pt;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:15.95pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:200.05pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:15.95pt;padding:0pt;">
					<p style="margin:5pt 0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">By:</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:200.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 15.75pt;line-height:115%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">/s/ Susan Kim</font></p>
					<p style="margin:1pt 0pt 0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman;font-size: 4pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:08.20pt;padding:0pt 0pt 0pt 8.6pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman;font-size: 4pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:201.50pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Susan Kim</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:08.20pt;padding:0pt 0pt 0pt 8.6pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman;font-size: 4pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:201.50pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Chief Financial Officer </font></p>
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">(Principal Financial Officer)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>pacb-20211231xex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 22.1.0.2-->
<!--Created on: 2/28/2022 12:56:49 PM-->
<html>
	<head>
		<title>
			Exhibit 32.1_Taxonomy2021
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt;text-align:right;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;line-height:100%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Exhibit 32.1 </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;line-height:100%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Certification of CEO Furnished Pursuant to 18 U.S.C. Section&nbsp;1350, </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;line-height:100%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">As Adopted Pursuant To </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;line-height:100%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Section&nbsp;906 of The Sarbanes-Oxley Act of 2002 </font>
		</p>
		<p style="margin:9pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;line-height:100%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In connection with the Annual Report of Pacific Biosciences of California, Inc. (the &#x201C;Company&#x201D;) on Form 10-K for the period ended December&nbsp;31, 2021, as filed with the Securities and Exchange Commission on the date hereof, I, Christian Henry, Chief Executive Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge, </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;line-height:100%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">(i) the Annual Report of the Company on Form 10-K for the period ended December&nbsp;31, 2021 (the &#x201C;Report&#x201D;), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;line-height:100%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Calibri;line-height:100%;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:228.00pt;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">5</font></p>
				</td>
				<td valign="middle" style="width:228.00pt;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:228.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:228.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:228.15pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Date: February 28, 2022</font></p>
				</td>
				<td valign="bottom" style="width:239.85pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">/s/ Christian Henry</font></p>
					<p style="margin:1pt 0pt 0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:228.15pt;padding:0pt 0pt 0pt 8.6pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:239.85pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Christian Henry</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:228.15pt;padding:0pt 0pt 0pt 8.6pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:239.85pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Chief Executive Officer and President</font></p>
					<p style="margin:0pt 0pt 0.75pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">(Principal Executive Officer)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>pacb-20211231xex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--HTML document created with Certent Disclosure Management 22.1.0.2-->
<!--Created on: 2/28/2022 12:56:57 PM-->
<html>
	<head>
		<title>
			Exhibit 32.2_Taxonomy2021
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt;text-align:right;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;line-height:100%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Exhibit 32.2 </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;line-height:100%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;line-height:100%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Certification of CFO Furnished Pursuant to 18 U.S.C. Section&nbsp;1350, </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;line-height:100%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">As Adopted Pursuant To </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;line-height:100%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Section&nbsp;906 of The Sarbanes-Oxley Act of 2002 </font>
		</p>
		<p style="margin:9pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;line-height:100%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In connection with the Annual Report of Pacific Biosciences of California, Inc. (the &#x201C;Company&#x201D;) on Form 10-K for the period ended December&nbsp;31, 2021, as filed with the Securities and Exchange Commission on the date hereof, I, Susan Kim, Chief Financial Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge, </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;line-height:100%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">(i) the Annual Report of the Company on Form 10-K for the period ended December&nbsp;31, 2021 (the &#x201C;Report&#x201D;), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;line-height:100%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Calibri;line-height:100%;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:228.00pt;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:228.00pt;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:228.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:228.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:234.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Date: February 28, 2022</font></p>
				</td>
				<td valign="bottom" style="width:234.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">/s/ Susan Kim</font></p>
					<p style="margin:1pt 0pt 0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:234.00pt;padding:0pt 0pt 0pt 8.6pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:234.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Susan Kim</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:234.00pt;padding:0pt 0pt 0pt 8.6pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:234.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Chief Financial Officer </font></p>
					<p style="margin:0pt 0pt 0.75pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">(Principal Financial Officer)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>pacb-20211231x10kg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pacb-20211231x10kg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  T .\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P"S^TA^UU\7
M?!/QT\:Z%HGC.XL-)L-1>&VMEM+=A&@ P,M&2?Q->;?\-R?''_H?KG_P"M?_
M (U6/^UU_P G+?$7_L+2?R%?1?[%/[(OP\^.GPANO$7BFVU"74H]6FLU:UO&
MB7RUCB8< =<N>:^M:H4:,:DX+IT1_0\XY1EF5T<7BL/%IQCM"+=VO,\,_P"&
MY/CC_P!#]<_^ 5K_ /&JZGP7_P %%OC'X:U".75-4L?%-F&^>UU"QBBRO?#P
MJC ^A.?H1Q7V/_P[?^#/_/EK'_@R;_"OF']K_P#83M?@GX5;QGX-U"]U#P_!
M(D=_9:@5>:U#L%6174+N3<54@C(R#D@G&$*V"K2Y.5*_D>;A<TX9S.JL*L/&
M+EHKPBM>UUL_N/N+]G+]IKPQ^T?X;EO-(#Z;K-F%%_HUPX:6W)Z,K #?&3G#
M #IR >*]?K\._P!G[XL7OP5^+?A[Q3:S.EO;W"Q7T2GB>U<A9D([_+DC/1E4
M]0*_<,$, 0<BO*QN&6'FN79GY[Q1D<<FQ4?8_P .>J\K;KY77WBT5S7CCXE>
M%?AGIJW_ (J\0:?H-JV=C7TZQF0@9(13RY]E!->'WW_!0_X(V=XD$?B&^O8V
M.#<0:7.$7Z[E5OR!Z5R0HU*BO"+9\[A\MQN,CS8>C*2[I-K[SZ5HKS_P7\?O
MAY\1-#OM6\.^+=.U.SL+=KN[6-RLUO"HRTDD+ 2*H'<J*YH?MC?!=B /B%I1
M)_ZZ?_$TO95&VE%_<3'+\9*4H1HR;6ZY7IZZ:'LM%%(2%!).!61P"T5XI\0?
MVROA#\-;Z2QU3Q?;W6H1DJ]KI<;W;(PX*L8P54Y[$@UR_A__ (*%?!77;Q;>
M77[S2&8X634-/E5"<X^\@8#ZG KH6'K27,H.WH>Q#)\QJ4_:PP\W'ORO_(^D
MZ*S]!\0:7XJTFWU31M1M=6TVX7=#=V4RRQ2#V920:T*PVT9Y$HN+<9*S1^;/
MC[]J?XIZ/X[\1V%GXMGAM+74KF"&,6L!V(LK*HR8\G  ZU@_\-<?%S_H<I__
M  $M_P#XW7#_ !1_Y*9XN_["]Y_Z.>OJ?]FO]E?P)\4OA#IGB'7(+]M2N)9T
M=K>Z*+A)648&/0"OMZOU7#4HU*D%TZ(_JK'1R+)<OI8O&86#3Y5I3BW=J_EV
M/$/^&N/BY_T.4_\ X"6__P ;K<\-?MN?%/0[Q)+W5;77K<$9M[ZRB4$=_FB"
M-GZDU]0M^PE\+VZ1:NOTOO\ [&O"OVH?V1]+^%'A0>*_"U[>3:=#,D-Y9WS*
MYB#G:LB. .-VU2I!.6SG'%<M/$8"O)4U!:^2/#P><<(YM7C@HX:*E/17IQ6O
M176J;Z'U'\!?VBM!^.VFSBTB;3-<M$#W>ES.&*J3C?&W&],X&< @D @9&>Y^
M(/B"?PGX#\1ZW;1>=<Z;IUQ=Q1XR&:.-F (],BORZ^ OC"Z\#?&#PIJEM,T2
M_;XK>X )P\$C!)%([_*Q_$ ]J_6&>".ZADAFC66&12CQR*&5E(P00>H(KQ\?
MA8X6LN7X7_5C\TXMR*AP_F--T5>C/WDGTL]8W[=GOK\S\@;[XA>)]2\1-KT^
MOZBVLE_,%Z+EUE5LY&U@?E (& .F!7Z>_L]>,]3^('P9\+Z]K&#J5U;LLS@8
M\PQR/&)"/5@@8XXRU?+&K?"+]G&[\3O>Q?$:2PT]I=[Z7&^57GE%<IN"_7)]
MZ^U?"-OI%IX6TB+0$BCT-;2(V0@&$\DJ"A'U!!YYYKKS*M3J4X*,&GYJWR/H
M>.,TP>.P>'IT,/*$D]Y0<;*WPJ^_1Z::&O67XB\4:/X1TYK_ %O5+32;)3@S
MWDRQ)GTRQY/M7G7[0WQ^TWX%^%EG*1WVOWF5L-/9\;B.LCXY"+^IP!CJ/S9\
M>?$;Q%\3-<EU;Q'J<VHW+$[%=CY<*D_=C3HB^P_G7+@\OGBESR=H_F?/\-<&
MXG/H_6:LO9T>]KN7HNWG^>I^A^J_MH?"?2[AH5\037K*<%K6QF9?^^BH!_#-
M;OA3]J#X7^,KI;:P\76<-RV (M05[0DGHH,JJK'V!-?E?17LO)Z%K*3O\O\
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M>_;,U;QEXDU3P#X-OY-/\,6,KVM_>6[;9-0E4E74,#_J0<C ^]C)R,"ONO\
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MI[94XR.:^9]0_P""9_P]U;XA:IKL^K:E;:'=SFXAT#3T2".#/+(),,=F[.%
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M5JPC%-7:<FUZ>ZM>VIYE7ZO_ +.]Y<7_ ,#?!$UUDS?V5"F6.255=JG_ +Y
MK\V_@W\(=9^,OC*UT;3(9%M0RO>WVW]W:PYY8GIG&0!W/XU^K>B:/:^'M&L-
M+L8_*L[&".VA3^ZB*%4?D!73G-2-HTUON>WXF8ZA*%#!1=ZB;D_)6LK^OZ'X
MX7W_ !^W'_71OYFOUL^$L:S?"'P9&ZAT;0K)64]"#;ID5^2=]_Q^W'_71OYF
MOUN^$'_))?!/_8$L?_1"56<_PX'1XF?[GA?\3_)'Y:?%+P/<?#;XA:]X;N%<
M?8+IXXGD&#)"3F)_^!(5;\:Y6OT5_:W_ &:Y/BUIL7B+P[$I\5V$?EF#(47L
M().S)X#KDE2>N2#VQ^>%Y9W&GW<UK=026US"YCEAF0H\; X*LIY!![&O4P>*
MCB:2=]5N?>\,Y]1SS QJ*7[R*2FNJ??T>Z^[=$-%%%=Y]<%?8?\ P3U\"RS:
MWXD\7S1,MO! NFVTASAG=@\F/=0J?]]U\Z_"/X/^(/C)XGBTG1+9O)5E-W?.
M/W-K&3RS'UZX4<FOU%^'/@'2_ACX-TWPWI"%;.RCV^8P&^5R<M(V/XF))_3H
M*\+-,5&G3=&+]Y_D?DW'^?4<+@I9;2E>K4M?^['?7UV2[79\I_%_]B7P-X]^
M)GB'Q#J&J^(8;W4KHW$T=M<0+&K$#(4-"2!]2:]U_9C^$>C_  7^'MSX?T2Y
MOKJS?4)+HR:A(CR;F2,$91%&/E';UHHKQ\1*3PZ3?8_-,WK59Y13A*3:]W2_
MD>N4445XY^;!1110!X%^T-^R)\./C';:AK^JZ9-IGB"*!Y6U32'6":<HN0)0
M597Z ;F4M@8!%?E/KG@NRTWQ[)HD4MPUHK[0[LI?[V.NW'Z445]-ELI2IM-G
M[GP57JU,'*,YMI;7;T].Q^E/P%_8E^&&B^"?[3>PO-4U;5M/> WVH3+*]JLL
M95C"NP(K ,<,5+#UZYSH_P#@F#\*(W5AK/BW*G(_TVV_^1Z**YHU)^TG[S/#
MI8[%?6\3^]ENNK_S/KVL_7_#^F>*M&N])UBPM]3TR[3RY[2ZC$D<B^A4\'G!
M^HHHKP]M4?E,9.+4HNS1^?7[77[&/P\^&.BQ>(/#0U736N964V'VL26\>,?=
MWH7[]W->&_LT_ 'P[\8/'MKH^MW6I06CR$,;*6-&(&>,LC>E%%?649R>'YF]
M3^A\LQ->ID_M9S;E;>[O]Y^I?PG^!_@KX)Z0;#PCH<&F^8 )[LC?<W&.1YDI
M^9N2<#.!G@"N\HHKY6<G*3<G<_G_ !%6I6JRG5DY-O=N[/G37OV%?A_XBUS4
M=5N=2\0I<7US)=2+%=0A SL6(4&$G&3QDFJ'_#OSX<_]!7Q+_P"!<'_QBBBO
MI(U:G*O>?WG[A1S#&*E%*M+9?:?^8?\ #OSX<_\ 05\2_P#@7!_\8K0T?]@_
MX8Z;<)+<#6=553GR;R] 4_7RT0_K1145:U50;4G]YS8[,\=##3E&O-.W\S_S
M/<?"?@W0_ ND1Z7X?TNUTFP3D0VL84,<8W,>K-Q]XDD^M;-%%?.-N3NS\4J5
M)U9.=1MM[MZL^:)?V /AU-*\C:IXD!9BQQ=P=_\ MA7T-X;T.#POX=TO1K5Y
M)+73K6*TB>8@NR1H$4L0 "< 9P!117JXV<I1CS.Y^A<48FO7HTE5FY6;W;?3
MS-&O./BC^SYX'^+Q\[7]) U$ *-2LV\FY  P 6'W@.P8$"BBO/HRE":<78^+
MRW$5L-BJ<Z$W%W6J;3_ _.WXT?#73/ASXHETW39[N>!)S$&NG5FP#_LJHS^%
M>U?LY?LP>#?B(UQ=ZX^I7*6Z(XMDN%CC?/4-M4-^3"BBOM,1.4</S)ZV/ZAS
MC$UZ63.K3FU+EW3:?WGVQX6\(Z-X)T>'2M!TVWTO3X?NP6Z;1GU)ZL?4G)-:
5]%%?#-N3NS^3YU)U).<W=O=O<__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>pacb-20211231x10kg002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pacb-20211231x10kg002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S/$.MVWAOP_?:S
M=AC!9Q&1E7JWHH]R<#\: -.BO-(/$OQ,0:=JMSX9TJXTJ]F4?8+.23[9!&_W
M6=F.SCC)X'KMY(N:QXN\1ZAXPNO#/@RRTV2XTZ-)+^\U-G\F,N,K& G)8C!S
MTZC'% '?T5Y?+\2=;T_P]XH@U73;.V\3:#&LI1"SVUS&Q&V1.0VW!Z$Y&1T.
M0*4?Q9U1OA/+KYLK/_A(([\:>+4(_E&4L"!MW;O]6?[W4?A0!Z[17CMK\2?&
M&LVG@R'2;;0EU'7XKMY#=QS"%#"S8QM8D953Z\^E;FA>/M7MM7\2:1XO@TQ+
MK1;07S3Z:[F)HRH;:0^6#<CKC.>G0D ]&HKSCX:^/M8\47UWI_B&RM+2\%I!
M?V@ME8++;R#.?F8\C*_G[5GZ7XL^)'B,ZW<Z-%X4CLM-U">R O1<+(WEX.?E
M8KT(YR.<]* /5Z*\PLOB??ZEHO@G4(+*WB.N7YL[M) S;-I*L8R",9(R,YQG
M'-1^(/B%XF7QCK.B^&['29CH\,<LMK>-)]JO=R[V%NJ]<+['J#WQ0!ZG17!:
M_P".M4C;0-)T#2 WB'6X!<+!J&Y$LHP 6,P&&X^88&#D'O@%NE>+_$>G>*(O
M#?C&QTV.[O89)M/N]-9S!+L7+1D/\P8#)SQV'O0!W]%>0^$/C!=^(? WB&_N
M;>SAUS2[26[CA17$4T84[6P6S@,-IP?3IFO1?#6KR:OX/TO6;P11R75E'<S"
M,$(I9 QQDDX_$T ;-%>767C'Q_XJLKC7?"NCZ*-#5W6UCOY)/M-VJ$@LNTA5
MR00 W0CJ>M-U#XFZKJ6B^%;KPO:V$=WK=R]K+#J8=E@D4<J2A!X.><<C' H
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MPE<C('7_ &>2-3QYXD\6Z+H[^(O#G]@3Z'%9I._VQ9C.Y)ZH%(7;M*=2#UH
M[^BO+KOQCXWT?PG%J&IP^'9=1U6>TM]'@M!-M9Y22WFACGA<8VGKGVK0TOQ_
M?:A\)M1\3-;6\6KZ?%.MQ;%6\M)XL_*1G.,;3C/?K0!Z#167X:U*;6?"ND:I
M<+&L][90W$BQ@A0SH&(&23C)]37/?$/Q/K?AT:%;Z#%I[WFJ:@MF#?*YC7<.
M#\A!'./7Z4 =K17G6G>+/%VF>.]*\-^++;0W&JQ2M;RZ2TN8S&I8[Q)S@@8X
M'X\&LSPWXG^)_BW3'U/2XO"$=J)Y(56Z6Y#_ "''.TD?K0!ZQ17!>--8\=>'
M] &KZ>GAQX;.Q$NH+<"<L90/F\H CY?3<<UBP>-_'-FOA:YUB#PZ;37[VVBB
M%FD^](Y!N;=N; ;!7&,CK0!ZO17)ZOXGO;#XC^'?#L45N;/4H;B29V5O,4QJ
M2-IS@>^0:XO2_&GQ+UOPU?>(;&'PDEA:M/E+@7"R$19S_%M[=R!]* /8**\?
MUGXS7.F6_@W4QIT(T[6(WEOD8,TD*JP#%"" <98\CD#M73R^-KX^/[S1;."T
MNK"+0?[5@=1(7E?> !E Y*D'HJ,>F,]* .YHKG/"6M:QK%K,=:T@Z=<1D$*5
M<;E8L5ZC'";,X8G<6!5, 'HZ "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "N<\>>'YO%/@?5=%MY%2>YB'E%NF]6#*#Z E0,^]='10!YA9>.O%;6VEZ+9
M^ ]535XY(X+R6]C\NS5$XD9)@2#D#@XQSQNX#)=?VOX"^(NN:XF@ZCK.C:\L
M!8Z9$)IK>6-2,%,@E3R<\#D#K7J%% 'B&K:+X@\2:3XW\57&B7EF^H6266FZ
M<T9-R\2."6=!DAB1]WKU[8)HIX-US_A.H8/L%W_8IL$U1AY#;!=+:F(+G&-^
M_G;UKWVB@#Y]T;P-<:Q!\-=,U[0;]M/A@U 7\<D4L0A)+L@=A@IDA<9(S74^
M-/ ]IHGA!?#7@O1);=]>OHH+NXACDF\J+(W-(Y)(08'!('+>IKUFB@#QR7PK
MXK\)^./#&O3ZM/XAA5AI<ZVVE+$8+9@<%A'G**?FR>F!US6%#\(1XH\/^+;J
M?3[BR\0_VU<O833AXQ+$-K*NUL*48E@' Z]R!BO:9?$=E#XGAT!EF^U30^:L
M@4>6/O$(3G[Q".P&.BD^F5E\4^'H)9HIM>TN.2$,TJ/>1@QA6V,6!/&&!4YZ
M'B@#S.0:GKMA\.IQX9O-.EL=55;VU2Q>)+?:!EPN,+&>H/3G&<@U4^)%B^I:
MQJT&N^ ]0U*98#_8FJZ);N6Y7@3D-U5@.H..2%YY]=GUW1[5;-KC5;&%;['V
M0R7"*+C.,;,GYL[ATSU'K1_;VC_VF-,_M:Q_M!F*BU^TIYI(&2-F<Y YZ=*
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M:7-J5G'J$R[H[1YU$KCGD(3DC@]!V-5[GQ'I-NUW$E_:SW-F%,]M'<Q"2/)
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M<T.*!'M4@9I#&\(5U*@9R" ,8XR:] N/&6FV_A7_ (2 174L&[R_L\<7[_S
MVQH]A(^92&R,_P )JUJ'B&ULDLA!!<:A<7RE[6VM I>5  6?+,JA0",EF Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6P5VL-QP>:G;P38*TDEI=WME<&]^VQ3P,FZ%_)6$JH92I4H@!#!NN?3'2T4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0V@M8O,F1"DTB0 @D-C"$L,@XQ73C0-2U#YM;URX93UM=.)M8@/3<#YC?7>
M?05':> ?#]C';Q6\>H+!;RI-% VJW31*Z.'4^69"IPP!P1U%=-0!@Q^"O#$;
M;VT&PFD_YZW$ F?_ +Z?)_6GR^#O#$PQ)X=TEL=,V4>1^E;=% '/?\(A:6_S
M:3?:CI;CI]GN6:/_ +]2;D_)12&?Q/I7S7$%MK5L.K6J^1< >NQF*/\ @R^P
MKHJ* ,W2]>TW6&>.TN/](B'[VVE4QS1?[T;88?7&#VK2K.U70[#6%C-U$1/$
M<PW,3%)83ZJXY'TZ'N#65]NUCPX%750^J::./M\$?[^(>LT:\,/]I!]5 YH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO+KT:8Y\E/PPTA]"(_6NCH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!>L'_H4M %^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM/L[>"VUV^6"&.)6MX681J%!):7DX[T :=%%% !1110 4444 %%%% !1110
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M>-8HU]% P* +-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !117+>)O'%IX;UC3]*_L^^O
M[N[5I3%:1[FCB!P7QU8Y/W5R>#[9 .IHKG)_&=C::[_9EY9ZA:HWF".]GA"0
M2F.,2/MYWX"D_,5"DJ0"35*#XBZ9-9F4V&HQW+&V^SV<B1B:X%Q_JF3Y]N#A
MOO,I7:=V* .PJA%_R'[S_KU@_P#0I:31-8MM>TJ._M5D1'9D:.4 /&ZL59&
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MQI':,-Q & 7@9L!0JC)/ %:FA:1'H&B6NE0W$]Q%;+L22?;OVY) ^55& #@
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M9Z .@HKG_P#A--%7_6M?V_\ U\:9<Q?^A1BC_A.?"@XD\1:9"?2:Y2,_DQ%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)765U+0$DE>",<D\CGWJMI/@_1=$%L+&&Y"6IS;QS7L\R0_*R_(KN0ORNPX
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ME9(S+_J]SA2J@^I./6IE\7Z$^M'2%OLW8F-O_J7\LS!=QC$NW87"G.W=GVH
MVZ*YI/'_ (7>&[F&JJ(K6-Y7D:&15=%?8S1$KB4!OERF[D@=Q6IH^N:?KMO-
M-I\SN(93#*DD+Q/&XQE61P&4\CJ.] &C17/:]XKAT#7=(L+B#,%_'=2R7&\_
MN%@C\PG: 2V1]/QJ.W\?^&+FTNKI-3V06UJE[(\\$D7[E_NNN]1O!(Q\N>>.
MO% '2T5G:3KNGZXD[6$SLUO)Y<T4L+PR1-@'#(X#+D$$9'-:- !1110 4444
M %%%% !1110 4444 %%9-OXCT^Y\276@QN_VRVB$C$CY3T+*#GEE#QDCL)%]
M>-:@ HHKSF[^+5I:R>+K=M._TSP_\R0FXQ]K3(4L#M^7!(R,'J/7@ ]&HKC_
M !3X^@\,:GH]I)9-.MZ0]S*LFT6<)=(Q*PP<C?(H[4[Q%XTETGQ/9^'[#3H+
MV_N+5KI8Y[P6WF ,%"1$J0\A^8[25&%Z^@!UU%<==>+]8/B#5]*TO0+>Z;2[
M6*XE,]^8G?S%8A%41."WRD<L!TYJ#Q#\2K/2/".E^(+&PFU!=2'F16P<1R"(
M1M)(QX(^15.1^M '<45SVK^*!:/I-MI=LNH7VKY:S0S>5&8U4,\C/AB%"D=%
M))(&.:DT'Q"^J7VHZ9>V8LM4TYD\^%)?-C9'!*.C[5W*0#U4$$$8[D W:*Y3
M2?%6J:XEOJ.G:"DVAW$YCCN/MH6<Q@E?-\HJ%V;A_P ]-Q7G&>*T#XNT(:S_
M &4;[_2O/^S9\I_*\[;N\KS<;/,QSLW;O:@#;HKD(OB?X1N(HI(=1GD2:)YH
MBFGW!\U$.'*?N_FV_P 0&2 "3@ U;O/'WAJR,0EU!W\VR&H)Y%K--FW/_+3Y
M%.%]<].] '245@77C7P[9W$<,VII\Z12&2.-WBC64XC:2104C#'H6(SVJ2\\
M7Z%8:TND7-Z4O&:-"!#(R(TF?+5I NQ6;!P&()H VZ*XN'XC6,G_  CR_9Y)
MFUJXFAC>TCFEB01EP3N,:L3E0"-HQDG.T9.UI/BW0]<O9+33K[SIE5F7,3HL
MJJQ1FC9@%D4,,%D)'3GD4 ;5%%% !1110 4444 %%%% !1110 445BZIXGT_
M2KPV<B7=Q<+%Y\D=I;/,8H\D!FV@X!P<#J<' .* -JBH;2[M[^SAO+299K>=
M!)%(AR&4C((J:@ HKC[[X@6FG?$%?"=S;%'ELOM,%R9?E=_F_=D8X)"$@YYZ
M8JG??$G[)\.],\41:0T]UJ(7R=.6XY)PS-\^WLJL?N]J .\HKDM>\=V>E:7H
M=[;+;S+K,B);275Q]GA4,A<,\@5MO&!T/)IESXMUF/4M#TJ/P]#'J6I6LMQ+
M#=ZAL6W,>W<N^..0/][@C''IT !V%%<>_CR./P;J&MOI["]L+AK*6P\WDW0<
M((U?'(+,N&QT(.*>GCRV?P+9^(TLI9)KMD@BL$<;VNF?R_)W' X?().. 3CM
M0!UM%<[8>([O_A(4T+6M.ALKR>W:XMGMKDSQ3*I <;BB$,,@XVXP1SUK&U+Q
M[J5I+XFDM]$M);+P^1]HDEU%HY)!Y8D.Q!$PS@XP6&30!W=%<TWC;2X+JZ6\
MGBMX(+."Z.\R&;$I(52@3!)(P K,Q/&!QFOJ_P 0M'TWPZ^L0K=7:+=+9M"E
MM(LD<I8#;(A7='US\P!.1@'(R =;16$OC+0&U0:<;_9<;MA\R&1$5]F_RRY4
M*'V\["=WM6;>_$;1$T+5-0TV0WLUA9F\%NZ20>?'D@.C.GSID$;EW#IZB@#K
MZ*Y>#X@^')--DO9;UX%A:%)XY;:57C:7_5_*4#%6[,!@XZU<B\8:%+HUUJPO
MBEI:S&WG,L$D<B2C'[LQLH??R,+C)R,#F@#<HKE)_'FG&ZTB.Q4W"7U\]E,9
M-T#VKJC.=\;J&!XZ$+P0>E:&E^+]"UFXD@L;\.Z1&8>9$\:R1@D&2-G $B C
M[RDCISR* -NBN3'Q+\)$,3JCJ%A%QE[.=0T1=8Q(I*?,A9@-PR.IS@'&_:ZM
M8WVHW]A;3>9<V#(MRNQ@$+KN4;B,$XP>"<9YQ0!=HHHH **** "BBB@ HHHH
M **** (YX(;JWEM[B*.:"5"DD<BAE=2,$$'@@CM6'_P@GA#_ *%30_\ P71?
M_$UT%% '#ZM\--'N-1M+S2M*\.6?DQ2Q20W.BI/'+O,9#;5=,,NP@$YX=JDT
M7X;:#9"]?5-'\/WT]S<>:OE:0D4<*^6B;$5BY RA8\]7/%=I10!S_P#P@GA#
M_H5-#_\ !=%_\357Q?X4;7M#TS2]/\BU@M+ZVF**[0A(8VY6,H,J<<#&,>HK
MJJ* .(USP+_Q+XH- 5/WE\MSJ,-[>S?\3",(5,<LIWN5Z?*<KQ@BLG1/ .O:
M!:Z!<VQTJ6_TJ:^W6WFR10/%<'(VL$)4J0O&T@C(ST->FT4 >::AX#\0ZI8^
M,/M=UI9O=>L[.)#%YB1I)$&WY!#$+SQR2>^.E2:EX!U>?Q5>:]:SV1D6[TZ[
MM899'42&".2.17(4[<B4E6 ;D<BO1Z* ,;[+K%_X9OK74S8I?W,4T:K;%_*C
M# A 6;EB 1EMHSV45Q7AWX>ZEI<WAO\ XEVAZ6^E[?M=_ILS&>^ C*E''DI\
MK-ACEFZ?C7IU% 'E>C?#SQ%X?LD-E-I<]W-IUQI]PLTTBQQA[B26.1"$); E
M(92%SCAAUI?^%8:E8:QI<^D7-K:O9Q6D#:I#<317$D,0 >*6'#1RJVU2.4Q@
M Y"\^IT4 <AH>A>(-!U2]M[9],?2;O5)K]YY6D,X23YC&(P N0_\9<\?PYKC
M+3X2ZO9VD,;2V-T9;.:SNHFO[J"-0UQ)*K8BVF8;92#&VT9'#<FO8J* /-M:
M^'FIWJ^*4LY[*--433$M0SN-@MF!?=P<9 XP3[XK8T;P_K^BZA?VD$FFOH][
MJ4]])/(\AN DHW&,( %!#YP^\\?PYKL:* /);/X4WT.C/IUU!I-Z+:TDMK62
M[O+R59@T@(S'O5;<%5&=F[#8(^[@[>@Z/XF\(Z7%:0/'<17&K1+'9O/+=K8V
M1 #(DK*APH!(W    ?,3SW]% ''>,_"E_P"(M5TNZM);9$M+6^AD$S,"3/#Y
M:8P#P#U]NF:YV[^&.KW=C#!]NLXVA\.66FJ=SL#<V\PE!(P/W9*@9Z\GBO4Z
M* ,W23K3BX?68]/A+./(ALW>38F!G=(P7<2<]%7 ]>M:5%% !1110 4444 %
M%%% !1110!2GT?2[K48-1N--LYKZ 8AN9(%:2,<_=8C(ZGIZU7_X1G0!;W5N
M-#TWR;MP]S']DCVS,#D%QC#'/.36K10!YWIWPTN+&ZTB8WNAEM-N_M"S1:*4
MF926W1A_/(5<.0 %PN%P/E%=?_PC.@"WNK<:'IODW;A[F/[)'MF8'(+C&&.>
M<FM6B@"I;Z7I]I)');6-K#)% +>-HX54I$#D("!PH/;I7EWB?X2:CKFGZZ]O
M>6D&IW6J275I(7<*8)$1'CD^7C.W/ /*CU./7** /.M4^'5_K^I>(+O4=7:W
M2]M$L+6&U$;CR%7.)#)&2,R$M\A'USC$/BCP/KOBGPY8:=J5IH%W<Q60C-V\
MLT4MM<X ,L;A3O0XR4(7D#)/;TNB@#@4\->*-*U[5[[3&TV]^WV%M:K/>W<D
M<B/$C*9&58F#9+9QN'3KS5>W^&EVE]I4+ZS)#IFDZ5]AMFMTC:621^)G998W
M50P &!D^_KZ-10!YYI_@K7=,TOP[)%<V,^J: 9K> 22,L=Q:O\H5F"$HX4)R
M%897'0U;\$Z#XCL-=UO4?%#VUQ>7L-M&DUJV8BD8=<$$*=_.YOE"_,-N.0.X
MHH XSP]H?B7PU86>@63:5)I5K*0E[/)(9S 26V&$*%WC.W=YF,#.WM5!O NJ
MFZDT_P ^S_L:37O[:-QYC_:/O>88MFW;]_\ CW?=_ASS7H5% 'F6B?#K5]-L
M?#T$US8LVFZ7>V<Q1W(9YB"I7*\@=\X^AK-MO"WB?2]=L=/L;6TFDA\(C3I;
MF=I4MO,\PCB0(<D<':0"1Z=:]?HH \M'PRU:RTC4M"L+RSET_5K2TM[FYN&=
M98#"BQN40 A]RJ" 67:3W%7M:\!ZG=>-(M:TJ2TL) ]N&U""ZFCN&A3&^&6+
M#1S*VU<'*= #D#GT2B@#S73O &LZ=I7A*+S;&6?1KR[EN%\YT5XYS)]QMA.X
M!QP0 2#SWJQX)\ 7GAN^LVO?LLR:=!+;VUR+VYEDD5FX(B<^7"-H&54-D]",
M<^A44 %%%% !1110 4444 %%%% !5#4]#TC6EC75=+LK\1$F,75NDNS/7&X'
M&<#\JOT4 8]EX2\-Z;=QW=CX>TFUN8\[)H+*-'7(P<,!D<$BL3Q#X&75==FU
M6&VT2XDN(%AD75=/6Y\LKG:Z'((X."O0X'3G/9T4 87AKPAHWA:RABT^PM([
ME81%+=I;I'+-W)8J!U/..E66\,Z"^J?VF^B::VH!Q)]K-I&9=PZ-OQG/OFM2
MB@#S[Q3\/+CQ)KNK7YN(8?.L($L906\R"ZB=G5^F /F X.<$\54TOX=:TG_"
M,P7NK1VMOH>GO$C6.UW:X<X8XEB*[-G )&<D]._IE% 'G,/@?5H/!,'ABYMM
M%UBPM[J55AOI)$9[8EC$1*B?NY5S@X4C'0BH=(\#>(O#Q\+36LMAJ$ND6=S;
MS)=7<D0_>L&5481.2J ;1D#@#@=!Z910!YL_P]UBZ73XKC4X;='U>;6M1>UY
M83D?NDB#H595.,EQSM!QGI(GP]U2+3=5L(]3ADVZM%K&DW%PH++."'<2HBHH
M4N#]SLQ..,5Z+10!P6FZ)XLF^(D&M>(!8M86]M<1V:6<YD: R%#B0LB;AA2
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MH-% 'F5U\.=5U753J=]<6<,UWJ+W-W#!*[+%%]F,"K&Q4%FP022%'/MS8L/
M^KM'I\6KRV@@TC1Y=+M?L,C-)<AU5-[!PH0[47Y<L,D_, *]%HH \/T#3-2U
M41IKFD7EMI]CX4;29-MC<&1F+(JX5HP6?"DD1APN =QSQW_PSTC4-+\'0S:P
MK+JVH2&[NPXPRLP 52.Q"*@QV(-=C10 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ&_LC*UM,NZ-I87B+#UVN <'L<<CD<4S3M8LM67?9/)+&5+"0PNJ'#,A 8@
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8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>pacb-20211231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 22.1.0.2 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/28/2022 12:55:15 PM-->
<!--Modified on: 2/28/2022 12:55:15 PM-->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" targetNamespace="http://www.pacificbiosciences.com/20211231" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:pacb="http://www.pacificbiosciences.com/20211231" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <annotation>
    <appinfo><link:roleType roleURI="http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets"><link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"><link:definition>00200 - Statement - Consolidated Statements of Operations and Comprehensive (Loss) Income</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows"><link:definition>00500 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"><link:definition>40502 - Disclosure - Financial Instruments (Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails" id="DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"><link:definition>40504 - Disclosure - Financial Instruments (Summary of Cash, Cash Equivalents and Investments) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails" id="DisclosureFinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails"><link:definition>40505 - Disclosure - Financial Instruments (Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfInventoryDetails" id="DisclosureBalanceSheetComponentsComponentsOfInventoryDetails"><link:definition>40602 - Disclosure - Balance Sheet Components (Components of Inventory) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails" id="DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails"><link:definition>40603 - Disclosure - Balance Sheet Components (Components of Property and Equipment, Net) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" id="DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"><link:definition>40605 - Disclosure - Balance Sheet Components (Definite-lived Intangible Assets from Business Acquisitions) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails" id="DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails"><link:definition>40606 - Disclosure - Balance Sheet Components (Estimated Future Amortization Expense Of Acquisition-Related Intangible Assets With Definite Lives) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails" id="DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails"><link:definition>40607 - Disclosure - Balance Sheet Components (Schedule of Accrued Expenses) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails" id="DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails"><link:definition>40608 - Disclosure - Balance Sheet Components (Furture Principal Payments) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfOtherLiabilitiesCurrentDetails" id="DisclosureBalanceSheetComponentsScheduleOfOtherLiabilitiesCurrentDetails"><link:definition>40611 - Disclosure - Balance Sheet Components (Schedule of Other Liabilities, Current) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfNetCarryingAmountDetails" id="DisclosureConvertibleSeniorNotesScheduleOfNetCarryingAmountDetails"><link:definition>40702 - Disclosure - Convertible Senior Notes (Schedule of Net Carrying Amount) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfInterestExpenseDetails" id="DisclosureConvertibleSeniorNotesScheduleOfInterestExpenseDetails"><link:definition>40703 - Disclosure - Convertible Senior Notes (Schedule of Interest Expense) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails"><link:definition>40802 - Disclosure - Commitments and Contingencies (Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetailsAltCalc" id="DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetailsAltCalc"><link:definition>40802 - Disclosure - Commitments and Contingencies (Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases) (Details) (Alt Calc)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails" id="DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails"><link:definition>40902 - Disclosure - Income Taxes (Reconciliation of Federal Income Tax Rate) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"><link:definition>40903 - Disclosure - Income Taxes (Reconciliation of Deferred Tax Assets and Liabilities) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails"><link:definition>41101 - Disclosure - Net (Loss) Income Per Share (Computation Of Basic And Diluted Net Loss Per Share) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation"><link:definition>00090 - Document - Document And Entity Information</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical"><link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity"><link:definition>00400 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies"><link:definition>10102 - Disclosure - Summary of Significant Accounting Policies</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangement" id="DisclosureInvitaeCollaborationArrangement"><link:definition>10301 - Disclosure - Invitae Collaboration Arrangement</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIllumina" id="DisclosureTerminationOfMergerWithIllumina"><link:definition>10401 - Disclosure - Termination of Merger with Illumina</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstruments" id="DisclosureFinancialInstruments"><link:definition>10501 - Disclosure - Financial Instruments</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponents" id="DisclosureBalanceSheetComponents"><link:definition>10601 - Disclosure - Balance Sheet Components</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotes" id="DisclosureConvertibleSeniorNotes"><link:definition>10701 - Disclosure - Convertible Senior Notes</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies"><link:definition>10801 - Disclosure - Commitments and Contingencies</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes"><link:definition>10901 - Disclosure - Income Taxes</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity"><link:definition>11002 - Disclosure - Stockholders&apos; Equity</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShare" id="DisclosureNetLossIncomePerShare"><link:definition>11101 - Disclosure - Net (Loss) Income Per Share</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformation" id="DisclosureSegmentAndGeographicInformation"><link:definition>11201 - Disclosure - Segment And Geographic Information</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicy"><link:definition>20402 - Disclosure - Summary of Significant Accounting Policies (Policy)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables" id="DisclosureBusinessAcquisitionTables"><link:definition>30203 - Disclosure - Business Acquisition (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsTables" id="DisclosureFinancialInstrumentsTables"><link:definition>30503 - Disclosure - Financial Instruments (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables"><link:definition>30603 - Disclosure - Balance Sheet Components (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesTables" id="DisclosureConvertibleSeniorNotesTables"><link:definition>30703 - Disclosure - Convertible Senior Notes (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables"><link:definition>30803 - Disclosure - Commitments and Contingencies (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables"><link:definition>30903 - Disclosure - Income Taxes (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables"><link:definition>31003 - Disclosure - Stockholders&apos; Equity (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureNetIncomeLossPerShareTables" id="DisclosureNetIncomeLossPerShareTables"><link:definition>31103 - Disclosure - Net Income (Loss) Per Share (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationTables" id="DisclosureSegmentAndGeographicInformationTables"><link:definition>31203 - Disclosure - Segment And Geographic Information (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"><link:definition>40101 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails" id="DisclosureBusinessAcquisitionsNarrativeDetails"><link:definition>40201 - Disclosure - Business Acquisitions (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails" id="DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"><link:definition>40202 - Disclosure - Business Acquisitions (Schedule by Acquisitions) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangementNarrativeDetails" id="DisclosureInvitaeCollaborationArrangementNarrativeDetails"><link:definition>40301 - Disclosure - Invitae Collaboration Arrangement (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails" id="DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"><link:definition>40401 - Disclosure - Termination of Merger with Illumina (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails" id="DisclosureFinancialInstrumentsNarrativeDetails"><link:definition>40501 - Disclosure - Financial Instruments (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails" id="DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails"><link:definition>40503 - Disclosure - Financial Instruments (Changes in estimated fair value of contingent consideration) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails" id="DisclosureBalanceSheetComponentsNarrativeDetails"><link:definition>40601 - Disclosure - Balance Sheet Components (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails" id="DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails"><link:definition>40604 - Disclosure - Balance Sheet Components (Changes in carrying amount of goodwill) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails" id="DisclosureConvertibleSeniorNotesNarrativeDetails"><link:definition>40701 - Disclosure - Convertible Senior Notes (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" id="DisclosureCommitmentsAndContingenciesNarrativeDetails"><link:definition>40801 - Disclosure - Commitments and Contingencies (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails"><link:definition>40901 - Disclosure - Income Taxes (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitAccountsDetails" id="DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitAccountsDetails"><link:definition>40904 - Disclosure - Income Taxes (Reconciliation of Unrecognized Tax Benefit Accounts) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails" id="DisclosureStockholdersEquityNarrativeDetails"><link:definition>41001 - Disclosure - Stockholders&apos; Equity (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" id="DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"><link:definition>41002 - Disclosure - Stockholders&apos; Equity (Summary of Stock Option Activity) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails" id="DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails"><link:definition>41003 - Disclosure - Stockholders&apos; Equity (Reconciliation of Outstanding and Exercisable Stock Options) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails" id="DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails"><link:definition>41004 - Disclosure - Stockholders&apos; Equity (Summary of Time-Based RSUs Activity) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails" id="DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails"><link:definition>41005 - Disclosure - Stockholders&apos; Equity (Summary of Performance-Based RSUs Activity) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails" id="DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails"><link:definition>41006 - Disclosure - Stockholders&apos; Equity (Schedule of Stock-Based Compensation Expense) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails" id="DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails"><link:definition>41007 - Disclosure - Stockholders&apos; Equity (Schedule of Fair Value of Employee Stock Options) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails" id="DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails"><link:definition>41008 - Disclosure - Stockholders&apos; Equity (Schedule of Fair Value of Employee Stock Purchase Plan) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" id="DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"><link:definition>41102 - Disclosure - Net (Loss) Income Per Share (Antidilutive Shares Excluded From Computation Of Diluted Net Loss Per Share) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationNarrativeDetails" id="DisclosureSegmentAndGeographicInformationNarrativeDetails"><link:definition>41201 - Disclosure - Segment And Geographic Information (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails" id="DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails"><link:definition>41202 - Disclosure - Segment And Geographic Information (Schedule of Revenue by Geographic Location) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails" id="DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails"><link:definition>41203 - Disclosure - Segment And Geographic Information (Summary of Revenue by Category) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitions" id="DisclosureBusinessAcquisitions"><link:definition>10201 - Disclosure - Business Acquisitions</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables"><link:definition>30103 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutiveNetIncomeLossPerShareDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutiveNetIncomeLossPerShareDetails"><link:definition>40105 - Disclosure - Summary of Significant Accounting Policies (Calculation of Basic and Dilutive Net Income (Loss) per Share) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="pacb-20211231_cal.xml" xlink:title="Calculation Links, all"></link:linkbaseRef><link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="pacb-20211231_def.xml" xlink:title="Definition Links, all"></link:linkbaseRef><link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="pacb-20211231_lab.xml" xlink:title="Label Links, all"></link:linkbaseRef><link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="pacb-20211231_pre.xml" xlink:title="Presentation Links, all"></link:linkbaseRef></appinfo></annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"></import>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"></import>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"></import>
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"></import>
  <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"></import>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"></import>
  <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"></import>
  <import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"></import>
  <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"></import>
  <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"></import>
  <import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"></import>
  <element id="pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments" name="AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"></element>
  <element id="pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" name="AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"></element>
  <element name="CashAndMoneyMarketFundsMember" id="pacb_CashAndMoneyMarketFundsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"></element>
  <element name="NumberOfPurchasePeriods" id="pacb_NumberOfPurchasePeriods" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"></element>
  <element id="pacb_OfferingShareAmountMaximum" name="OfferingShareAmountMaximum" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant"></element>
  <element name="PercentageOfFairMarketValueAtWhichStockCanBePurchased" id="pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"></element>
  <element id="pacb_PurchasePeriodOfEmployeeStockPurchasePlan" name="PurchasePeriodOfEmployeeStockPurchasePlan" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_InventoryTransferredToFromPropertyAndEquipment" name="InventoryTransferredToFromPropertyAndEquipment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"></element>
  <element id="pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" name="PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" nillable="true" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" nillable="true" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ExercisePriceRangeOneMember" name="ExercisePriceRangeOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_ExercisePriceRangeTwoMember" name="ExercisePriceRangeTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_ExercisePriceRangeThreeMember" name="ExercisePriceRangeThreeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_ExercisePriceRangeFourMember" name="ExercisePriceRangeFourMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_ExercisePriceRangeFiveMember" name="ExercisePriceRangeFiveMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_ExercisePriceRangeSixMember" name="ExercisePriceRangeSixMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_ExercisePriceRangeSevenMember" name="ExercisePriceRangeSevenMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_ExercisePriceRangeEightMember" name="ExercisePriceRangeEightMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_TwoThousandTenEquityIncentivePlanMember" name="TwoThousandTenEquityIncentivePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" name="ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"></element>
  <element id="pacb_ExercisePriceRangeNineMember" name="ExercisePriceRangeNineMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ExercisePriceRangeTenMember" name="ExercisePriceRangeTenMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" name="CommonStockVotingRightsNumberOfVotesPerShareOwned" nillable="true" type="xbrli:positiveIntegerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_StockholdersEquityTable" name="StockholdersEquityTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_StockholdersEquityLineItems" name="StockholdersEquityLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_ExercisePriceRangeElevenMember" name="ExercisePriceRangeElevenMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ExercisePriceRangeThirteenMember" name="ExercisePriceRangeThirteenMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ExercisePriceRangeFourteenMember" name="ExercisePriceRangeFourteenMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ExercisePriceRangeFifteenMember" name="ExercisePriceRangeFifteenMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_LaboratoryEquipmentAndMachineryMember" name="LaboratoryEquipmentAndMachineryMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_DomesticCustomersMember" name="DomesticCustomersMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_CustomerBMember" name="CustomerBMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_CustomerDMember" name="CustomerDMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_IncomeTaxesTable" name="IncomeTaxesTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_IncomeTaxesLineItems" name="IncomeTaxesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_ObrienLeaseAgreementMember" name="ObrienLeaseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" name="SupplementalBalanceSheetComponentsDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_ScheduleOfBalanceSheetComponentsTable" name="ScheduleOfBalanceSheetComponentsTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_BalanceSheetComponentsLineItems" name="BalanceSheetComponentsLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_LongTermRestrictedCashFairValueDisclosure" name="LongTermRestrictedCashFairValueDisclosure" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"></element>
  <element id="pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" name="AdditionalLiabilityAssociatedWithIndemnificationObligations" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"></element>
  <element id="pacb_UnderwrittenPublicEquityOfferingMember" name="UnderwrittenPublicEquityOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_PublicOfferingShares" name="PublicOfferingShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" name="PublicOfferingOptionToPurchaseAdditionalSharesPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" name="PublicOfferingOptionToPurchaseAdditionalSharesShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_UnderwritingAgreementMember" name="UnderwritingAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_TimeBasedRestrictedStockUnitsRsusMember" name="TimeBasedRestrictedStockUnitsRsusMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_PerformanceBasedRestrictedStockUnitsRsusMember" name="PerformanceBasedRestrictedStockUnitsRsusMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember" name="ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ServiceAndOtherMember" name="ServiceAndOtherMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_IlluminaFcOpsCorpMember" name="IlluminaFcOpsCorpMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" name="UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_LongTermRestrictedCashMember" name="LongTermRestrictedCashMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_CashCashEquivalentsAndInvestmentsMember" name="CashCashEquivalentsAndInvestmentsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_NumberOfOfferings" name="NumberOfOfferings" nillable="true" type="xbrli:positiveIntegerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_AccruedTenantImprovementsCurrent" name="AccruedTenantImprovementsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"></element>
  <element id="pacb_AccruedProductDevelopmentCostsCurrent" name="AccruedProductDevelopmentCostsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"></element>
  <element id="pacb_LesseeOperatingLeaseDescriptionTableTextBlock" name="LesseeOperatingLeaseDescriptionTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_BalanceSheetClassificationAbstract" name="BalanceSheetClassificationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_InstrumentMember" name="InstrumentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ConsumableMember" name="ConsumableMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" name="ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ShareInstrumentNumberOfSharesConversionRatio" name="ShareInstrumentNumberOfSharesConversionRatio" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_InventoryTransferredFromPropertyAndEquipment" name="InventoryTransferredFromPropertyAndEquipment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"></element>
  <element id="pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction" name="MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"></element>
  <element id="pacb_MergerTerminationAbstract" name="MergerTerminationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_MergerTermination" name="MergerTermination" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ProceedsFromContractTermination" name="ProceedsFromContractTermination" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"></element>
  <element id="pacb_MergerTerminationTable" name="MergerTerminationTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_MergerTerminationLineItems" name="MergerTerminationLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"></element>
  <element id="pacb_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"></element>
  <element id="pacb_PaymentsForAdvisorFees" name="PaymentsForAdvisorFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"></element>
  <element id="pacb_EquityIncentivePlan2020Member" name="EquityIncentivePlan2020Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" name="AccruedEmployeeStockPurchasePlanLiabilityCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"></element>
  <element id="pacb_GainLossOnReverseTerminationFee" name="GainLossOnReverseTerminationFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"></element>
  <element id="pacb_FinancialInstrumentsTable" name="FinancialInstrumentsTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_FinancialInstrumentsLineItems" name="FinancialInstrumentsLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_ShortTermRestrictedCashFairValueDisclosure" name="ShortTermRestrictedCashFairValueDisclosure" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"></element>
  <element id="pacb_ShortTermRestrictedCashMember" name="ShortTermRestrictedCashMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_InducementEquityIncentivePlan2020Member" name="InducementEquityIncentivePlan2020Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ScheduleOfEarningsPerShareTable" name="ScheduleOfEarningsPerShareTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_ScheduleOfEarningsPerShareLineItems" name="ScheduleOfEarningsPerShareLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace" name="ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"></element>
  <element id="pacb_ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock" name="ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock" name="LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_WithExpirationMember" name="WithExpirationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount" name="DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_DebtInstrumentStatedPrincipalAmountForConversionRate" name="DebtInstrumentStatedPrincipalAmountForConversionRate" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"></element>
  <element id="pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" name="EffectiveIncomeTaxRateReconciliationTaxCredit" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_CustomerDepositMember" name="CustomerDepositMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_SecurityDepositMember" name="SecurityDepositMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_InvitaeCorporationMember" name="InvitaeCorporationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ConvertibleSeniorNotesMember" name="ConvertibleSeniorNotesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_DebtInstrumentAdditionalInterestInEventOfDefault" name="DebtInstrumentAdditionalInterestInEventOfDefault" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_EachDayDuringFirst180DaysMember" name="EachDayDuringFirst180DaysMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_OneHundredAndEightyFirstDayTo360thDayMember" name="OneHundredAndEightyFirstDayTo360thDayMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ScheduleOfInterestExpenseTableTextBlock" name="ScheduleOfInterestExpenseTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ContractualInterestExpense" name="ContractualInterestExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"></element>
  <element id="pacb_DevelopmentAndCommercializationAgreementAbstract" name="DevelopmentAndCommercializationAgreementAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_DevelopmentAndCommercializationAgreementDisclosureTextBlock" name="DevelopmentAndCommercializationAgreementDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable" name="ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems" name="DevelopmentAndCommercializationAgreementTransactionsLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="pacb_ProceedsFromRepaymentsOfContractTermination" name="ProceedsFromRepaymentsOfContractTermination" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"></element>
  <element id="pacb_RepaymentsOfContractTermination" name="RepaymentsOfContractTermination" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"></element>
  <element id="pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" name="DebtInstrumentRedemptionPricePercentageOfConversionPrice" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_DebtInstrumentRedemptionPriceTradingDays" name="DebtInstrumentRedemptionPriceTradingDays" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" name="DebtInstrumentRedemptionPriceConsecutiveTradingDays" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_AnnualDecreaseInLongTermRestrictedCash" name="AnnualDecreaseInLongTermRestrictedCash" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"></element>
  <element id="pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" name="StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"></element>
  <element id="pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares" name="IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_OmniomeIncMember" name="OmniomeIncMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_CirculomicsIncMember" name="CirculomicsIncMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" name="StockBasedCompensationExpenseExcludedFromConsiderationTransferred" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"></element>
  <element id="pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet" name="BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"></element>
  <element id="pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" name="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" nillable="true" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_AchievementOfMilestoneMember" name="AchievementOfMilestoneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_OmniomeStockAwardsRelatedToAcquisitionMember" name="OmniomeStockAwardsRelatedToAcquisitionMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance" name="IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"></element>
  <element id="pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts" name="ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"></element>
  <element id="pacb_OmniomePlanMember" name="OmniomePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ExchangeRatio" name="ExchangeRatio" nillable="true" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ExercisePriceRangeAcqusitionMember" name="ExercisePriceRangeAcqusitionMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ExercisePriceRangeAcqusitionTwoMember" name="ExercisePriceRangeAcqusitionTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_MergerRelatedExpensesStockSettledMember" name="MergerRelatedExpensesStockSettledMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_MergerRelatedExpensesMilestoneMember" name="MergerRelatedExpensesMilestoneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_StockBasedCompensationMember" name="StockBasedCompensationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_MergerRelatedExpensesCashSettledMember" name="MergerRelatedExpensesCashSettledMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_PercentageOfFeeToPrepayDebt" name="PercentageOfFeeToPrepayDebt" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" name="AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"></element>
  <element id="pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock" name="ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_TimeBasedStockOptionsMember" name="TimeBasedStockOptionsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ContingentConsiderationMember" name="ContingentConsiderationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ContingentConsiderationIncurredDuringPeriod" name="ContingentConsiderationIncurredDuringPeriod" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock" name="ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" name="InProcessResearchAndDevelopmentIndefiniteLivedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_ServiceContractMember" name="ServiceContractMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_TimeBasedStockOptionMember" name="TimeBasedStockOptionMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock" name="EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_TenPercentOrGreaterBalanceAccountsReceivableMember" name="TenPercentOrGreaterBalanceAccountsReceivableMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_AnnualReductionInNonCurrentRestrictedCash" name="AnnualReductionInNonCurrentRestrictedCash" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"></element>
  <element id="pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember" name="SharesIssuableUponConversionOfConvertibleSeniorNotesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_PrivatePlacementOfCommonStockMember" name="PrivatePlacementOfCommonStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="pacb_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element></schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>pacb-20211231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 22.1.0.2 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/28/2022 12:55:15 PM-->
<!--Modified on: 2/28/2022 12:55:15 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" roleURI="http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureFinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsComponentsOfInventoryDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfInventoryDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsScheduleOfOtherLiabilitiesCurrentDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfOtherLiabilitiesCurrentDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureConvertibleSeniorNotesScheduleOfNetCarryingAmountDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfNetCarryingAmountDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureConvertibleSeniorNotesScheduleOfInterestExpenseDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfInterestExpenseDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetailsAltCalc" roleURI="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetailsAltCalc"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails"></roleRef>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637816497119505033" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637816497119505033" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637816497119505033" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637816497119505033" xlink:to="us-gaap_ShortTermInvestments_637816497119505033" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637816497119505033" xlink:to="us-gaap_AccountsReceivableNetCurrent_637816497119505033" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637816497119505033" xlink:to="us-gaap_InventoryNet_637816497119505033" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637816497119505033" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637816497119505033" order="5" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637816497119505033" xlink:to="us-gaap_RestrictedCashCurrent_637816497119505033" order="6" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637816497119505033" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637816497119505033" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_637816497119505033" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_637816497119505033" order="5" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_637816497119505033" order="6" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill_637816497119505033" order="7" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637816497119505033" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637816497119505033" xlink:to="us-gaap_LiabilitiesCurrent_637816497119505033" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637816497119505033" xlink:to="us-gaap_AccountsPayableCurrent_637816497119505033" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637816497119505033" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637816497119505033" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637816497119505033" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637816497119505033" order="3" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637816497119505033" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637816497119505033" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637816497119505033" xlink:to="us-gaap_OtherLiabilitiesCurrent_637816497119505033" order="5" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637816497119505033" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637816497119505033" order="2" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637816497119505033" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637816497119505033" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637816497119505033" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_637816497119505033" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637816497119505033" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637816497119505033" order="5" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637816497119505033" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_637816497119505033" order="6" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637816497119505033"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637816497119505033" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637816497119505033" xlink:to="us-gaap_PreferredStockValue_637816497119515005" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637816497119505033" xlink:to="us-gaap_CommonStockValue_637816497119515005" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637816497119505033" xlink:to="us-gaap_AdditionalPaidInCapital_637816497119515005" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637816497119505033" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637816497119515005" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637816497119505033" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637816497119515005" order="5" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_637816497119515005" order="3" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations and Comprehensive (Loss) Income">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_637816497119515005" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637816497119515005" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637816497119515005" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_GainLossOnReverseTerminationFee" xlink:label="pacb_GainLossOnReverseTerminationFee_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637816497119515005" xlink:to="pacb_GainLossOnReverseTerminationFee_637816497119515005" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637816497119515005" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637816497119515005" order="2" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637816497119515005" xlink:to="us-gaap_InterestExpense_637816497119515005" order="3" use="optional" weight="-1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637816497119515005" xlink:to="us-gaap_GainLossOnContractTermination_637816497119515005" order="4" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637816497119515005" xlink:to="us-gaap_OperatingIncomeLoss_637816497119515005" order="5" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637816497119515005" xlink:to="us-gaap_GrossProfit_637816497119515005" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_637816497119515005" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637816497119515005" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_637816497119515005" xlink:to="us-gaap_CostOfRevenue_637816497119515005" order="2" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostOfRevenue_637816497119515005" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_637816497119515005" order="1" use="optional" weight="1" priority="4"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostOfRevenue_637816497119515005" xlink:to="us-gaap_CostOfGoodsAndServicesSold_637816497119515005" order="2" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637816497119515005" xlink:to="us-gaap_OperatingExpenses_637816497119515005" order="2" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637816497119515005" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637816497119515005" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637816497119515005" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637816497119515005" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637816497119515005" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_637816497119515005" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637816497119515005" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637816497119515005" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637816497119515005"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637816497119515005" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637816497119515005" order="2" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_637816497119524972" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Condensed Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" xlink:label="pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense_637816497119524972" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_NetIncomeLoss_637816497119524972" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_GainLossOnContractTermination_637816497119524972" order="3" use="optional" weight="-1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_Depreciation_637816497119524972" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637816497119524972" order="5" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637816497119524972" order="6" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_637816497119524972" order="7" use="optional" weight="-1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637816497119524972" order="8" use="optional" weight="-1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_ShareBasedCompensation_637816497119524972" order="9" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_637816497119524972" order="10" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637816497119524972" order="11" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_IncreaseDecreaseInInventories_637816497119524972" order="12" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637816497119524972" order="13" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637816497119524972" order="14" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637816497119524972" order="15" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_637816497119524972" order="16" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_637816497119524972" order="17" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_OperatingLeasePayments_637816497119524972" order="18" use="optional" weight="-1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_637816497119524972" order="19" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637816497119524972"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497119524972" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637816497119524972" order="20" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637816497119534953"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637816497119534953" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637816497119534953"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637816497119534953" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637816497119534953" order="1" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments_637816497119534953"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637816497119534953" xlink:to="us-gaap_PaymentsToAcquireInvestments_637816497119534953" order="2" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_637816497119534953"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637816497119534953" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_637816497119534953" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_637816497119534953"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637816497119534953" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_637816497119534953" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_637816497119534953"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637816497119534953" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_637816497119534953" order="5" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637816497119534953"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637816497119534953" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ProceedsFromRepaymentsOfContractTermination" xlink:label="pacb_ProceedsFromRepaymentsOfContractTermination_637816497119534953"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637816497119534953" xlink:to="pacb_ProceedsFromRepaymentsOfContractTermination_637816497119534953" order="1" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637816497119534953"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637816497119534953" xlink:to="us-gaap_RepaymentsOfNotesPayable_637816497119534953" order="2" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_637816497119534953"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637816497119534953" xlink:to="us-gaap_ProceedsFromConvertibleDebt_637816497119534953" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637816497119534953"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637816497119534953" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637816497119534953" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_637816497119534953"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637816497119534953" xlink:to="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_637816497119534953" order="5" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637816497119534953"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637816497119534953" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637816497119534953" order="6" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_637816497119534953"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637816497119534953" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_637816497119534953" order="7" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Financial Instruments (Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637816497119544919" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_637816497119544919" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_LongTermRestrictedCashFairValueDisclosure" xlink:label="pacb_LongTermRestrictedCashFairValueDisclosure_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="pacb_LongTermRestrictedCashFairValueDisclosure_637816497119544919" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:label="pacb_ShortTermRestrictedCashFairValueDisclosure_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="pacb_ShortTermRestrictedCashFairValueDisclosure_637816497119544919" order="4" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Financial Instruments (Summary of Cash, Cash Equivalents and Investments) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"></loc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments" xlink:label="pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments_637816497119544919" order="1" use="optional" weight="-1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:label="pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments_637816497119544919" order="2" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637816497119544919" order="3" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails" xlink:type="extended" xlink:title="40505 - Disclosure - Financial Instruments (Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637480469614159593"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637480469614159593" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_637816497119544919" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637480469614159593" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_637816497119544919" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfInventoryDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Balance Sheet Components (Components of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_635888865099742422"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_635888865099742422" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637816497119544919" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_635888865099742422" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637816497119544919" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_635888865099742422" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637816497119544919" order="3" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Balance Sheet Components (Components of Property and Equipment, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637816497119544919" order="1" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637816497119544919" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="extended" xlink:title="40605 - Disclosure - Balance Sheet Components (Definite-lived Intangible Assets from Business Acquisitions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_637816497119544919" order="1" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_637816497119544919" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails" xlink:type="extended" xlink:title="40606 - Disclosure - Balance Sheet Components (Estimated Future Amortization Expense Of Acquisition-Related Intangible Assets With Definite Lives) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_637816497119544919" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_637816497119544919"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_637816497119544919" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_637816497119554890" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_637816497119554890" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_637816497119554890" order="5" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:type="extended" xlink:title="40607 - Disclosure - Balance Sheet Components (Schedule of Accrued Expenses) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637816497119554890" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AccruedProductDevelopmentCostsCurrent" xlink:label="pacb_AccruedProductDevelopmentCostsCurrent_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pacb_AccruedProductDevelopmentCostsCurrent_637816497119554890" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637816497119554890" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AccruedTenantImprovementsCurrent" xlink:label="pacb_AccruedTenantImprovementsCurrent_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pacb_AccruedTenantImprovementsCurrent_637816497119554890" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637816497119554890" order="5" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductLiabilityContingencyAccrualPresentValue" xlink:label="us-gaap_ProductLiabilityContingencyAccrualPresentValue_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_ProductLiabilityContingencyAccrualPresentValue_637816497119554890" order="6" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails" xlink:type="extended" xlink:title="40608 - Disclosure - Balance Sheet Components (Furture Principal Payments) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637816497119554890" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637816497119554890" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637816497119554890" order="3" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfOtherLiabilitiesCurrentDetails" xlink:type="extended" xlink:title="40611 - Disclosure - Balance Sheet Components (Schedule of Other Liabilities, Current) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"></loc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" xlink:label="pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_637816497119554890" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent_637816497119554890" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfNetCarryingAmountDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Convertible Senior Notes (Schedule of Net Carrying Amount) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_637816497119554890" order="1" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637816497119554890" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfInterestExpenseDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Convertible Senior Notes (Schedule of Interest Expense) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_AmortizationOfFinancingCosts_637816497119554890" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContractualInterestExpense" xlink:label="pacb_ContractualInterestExpense_637816497119554890"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="pacb_ContractualInterestExpense_637816497119554890" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Commitments and Contingencies (Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637816497119564869" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637816497119564869" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637816497119564869" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637816497119564869" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637816497119564869" order="5" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637816497119564869" order="6" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetailsAltCalc" xlink:type="extended" xlink:title="40802 - Disclosure - Commitments and Contingencies (Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases) (Details) (Alt Calc)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637816497119564869" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_637816497119564869" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_637816497119564869" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637816497119564869" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_637816497119564869" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637816497119564869" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Income Taxes (Reconciliation of Federal Income Tax Rate) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637816497119564869" order="1" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637816497119564869" order="2" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637816497119564869" order="3" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" xlink:label="pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_637816497119564869" order="4" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637816497119564869" order="5" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637816497119564869" order="6" use="optional" weight="1" priority="1"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Income Taxes (Reconciliation of Deferred Tax Assets and Liabilities) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_637816497119564869" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637816497119564869" xlink:to="us-gaap_DeferredTaxAssetsGross_637816497119564869" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637816497119564869" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637816497119564869" order="1" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637816497119564869" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637816497119564869" order="2" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_637816497119564869"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637816497119564869" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense_637816497119564869" order="3" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637816497119724435"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637816497119564869" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637816497119724435" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="pacb_DeferredTaxAssetsOperatingLeaseLiabilities_637816497119724435"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637816497119564869" xlink:to="pacb_DeferredTaxAssetsOperatingLeaseLiabilities_637816497119724435" order="5" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637816497119724435"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637816497119564869" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637816497119724435" order="2" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637816497119724435"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637816497119724435" order="2" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="pacb_DeferredTaxLiabilitiesRightOfUseAssets_637816497119724435"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637816497119724435" xlink:to="pacb_DeferredTaxLiabilitiesRightOfUseAssets_637816497119724435" order="1" use="optional" weight="1" priority="1"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Net (Loss) Income Per Share (Computation Of Basic And Diluted Net Loss Per Share) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_637816497119724435"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_637816497119724435" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637816497119724435"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637816497119724435" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>pacb-20211231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 22.1.0.2 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/28/2022 12:55:15 PM-->
<!--Modified on: 2/28/2022 12:55:15 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#defaults" roleURI="http://xbrl.sec.gov/dei/role/document/Defaults"></roleRef>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dep-dei" roleURI="http://xbrl.sec.gov/dei/role/deprecated/dei"></roleRef>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country" roleURI="http://xbrl.sec.gov/country/role/document/Country"></roleRef>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency" roleURI="http://xbrl.sec.gov/role/document/Currency"></roleRef>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#dep-currency" roleURI="http://xbrl.sec.gov/currency/role/deprecated/currency"></roleRef>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#dep-exch" roleURI="http://xbrl.sec.gov/exch/role/deprecated/exch"></roleRef>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch" roleURI="http://xbrl.sec.gov/exch/role/document/Exchange"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBusinessAcquisitions" roleURI="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitions"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutiveNetIncomeLossPerShareDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutiveNetIncomeLossPerShareDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" roleURI="http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBusinessAcquisitionTables" roleURI="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBusinessAcquisitionsNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureInvitaeCollaborationArrangementNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangementNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureTerminationOfMergerWithIlluminaNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureFinancialInstrumentsNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureConvertibleSeniorNotesNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails"></roleRef>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"></arcroleRef>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"></arcroleRef>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"></arcroleRef>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"></arcroleRef>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"></arcroleRef>
  <definitionLink xlink:role="http://xbrl.sec.gov/dei/role/document/Defaults" xlink:type="extended" xlink:title="995411 - Document - Document and Entity Information, Defaults"></definitionLink>
  <definitionLink xlink:role="http://xbrl.sec.gov/dei/role/deprecated/dei" xlink:type="extended" xlink:title="999100 - Document - Deprecated Document Entity Concepts"></definitionLink>
  <definitionLink xlink:role="http://xbrl.sec.gov/country/role/document/Country" xlink:type="extended" xlink:title="995410 - Document - Country Code"></definitionLink>
  <definitionLink xlink:role="http://xbrl.sec.gov/role/document/Currency" xlink:type="extended" xlink:title="995430 - Document - Currency"></definitionLink>
  <definitionLink xlink:role="http://xbrl.sec.gov/currency/role/deprecated/currency" xlink:type="extended" xlink:title="999030 - Document - Deprecated Currency Concepts"></definitionLink>
  <definitionLink xlink:role="http://xbrl.sec.gov/exch/role/deprecated/exch" xlink:type="extended" xlink:title="999020 - Document - Deprecated Exchange Concepts"></definitionLink>
  <definitionLink xlink:role="http://xbrl.sec.gov/exch/role/document/Exchange" xlink:type="extended" xlink:title="995440 - Document - Exchange"></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitions" xlink:type="extended" xlink:title="10201 - Disclosure - Business Acquisitions"></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutiveNetIncomeLossPerShareDetails" xlink:type="extended" xlink:title="40105 - Disclosure - Summary of Significant Accounting Policies (Calculation of Basic and Dilutive Net Income (Loss) per Share) (Details)"></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations and Comprehensive (Loss) Income">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637816497119724435"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_637816497119724435" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ServiceAndOtherMember" xlink:label="pacb_ServiceAndOtherMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="pacb_ServiceAndOtherMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenueAbstract" xlink:label="us-gaap_CostOfRevenueAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenueAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_GainLossOnReverseTerminationFee" xlink:label="pacb_GainLossOnReverseTerminationFee"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="pacb_GainLossOnReverseTerminationFee" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnContractTermination" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Stockholders&#8217; Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637816497119754359"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637816497119754359" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_637816497119754359"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_637816497119754359" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637816497119754359"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_637816497119754359" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201904Member" xlink:label="us-gaap_AccountingStandardsUpdate201904Member"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201904Member" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" xlink:label="pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares" xlink:label="pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Condensed Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637816497119764333"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637816497119764333" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CirculomicsIncMember" xlink:label="pacb_CirculomicsIncMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pacb_CirculomicsIncMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pacb_OmniomeIncMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnContractTermination" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" xlink:label="pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="us-gaap_GainLossOnSaleOfDerivatives"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfDerivatives" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ProceedsFromRepaymentsOfContractTermination" xlink:label="pacb_ProceedsFromRepaymentsOfContractTermination"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pacb_ProceedsFromRepaymentsOfContractTermination" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InventoryTransferredToFromPropertyAndEquipment" xlink:label="pacb_InventoryTransferredToFromPropertyAndEquipment"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pacb_InventoryTransferredToFromPropertyAndEquipment" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InventoryTransferredFromPropertyAndEquipment" xlink:label="pacb_InventoryTransferredFromPropertyAndEquipment"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pacb_InventoryTransferredFromPropertyAndEquipment" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables" xlink:type="extended" xlink:title="30203 - Disclosure - Business Acquisition (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pacb_OmniomeIncMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CirculomicsIncMember" xlink:label="pacb_CirculomicsIncMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pacb_CirculomicsIncMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock" xlink:label="pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="31003 - Disclosure - Stockholders&apos; Equity (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497119824174"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497119824174" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TimeBasedStockOptionsMember" xlink:label="pacb_TimeBasedStockOptionsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pacb_TimeBasedStockOptionsMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:label="pacb_SummaryOfSignificantAccountingPoliciesTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637816497119834145"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637816497119834145" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SecurityDepositMember" xlink:label="pacb_SecurityDepositMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="pacb_SecurityDepositMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_637816497119834145"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_637816497119834145" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_637816497119834145"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_637816497119834145" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_637816497119834145"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_637816497119834145" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TenPercentOrGreaterBalanceAccountsReceivableMember" xlink:label="pacb_TenPercentOrGreaterBalanceAccountsReceivableMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="pacb_TenPercentOrGreaterBalanceAccountsReceivableMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CustomerBMember" xlink:label="pacb_CustomerBMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="pacb_CustomerBMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DomesticCustomersMember" xlink:label="pacb_DomesticCustomersMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="pacb_DomesticCustomersMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CustomerDMember" xlink:label="pacb_CustomerDMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="pacb_CustomerDMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637816497119844119"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637816497119844119" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637816497119844119"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_637816497119844119" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ConvertibleSeniorNotesMember" xlink:label="pacb_ConvertibleSeniorNotesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pacb_ConvertibleSeniorNotesMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_637816497119854092"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_637816497119854092" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637816497119864067"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637816497119864067" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="9" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637816497119874041"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_637816497119874041" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="10" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637816497119874041"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637816497119874041" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ObrienLeaseAgreementMember" xlink:label="pacb_ObrienLeaseAgreementMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pacb_ObrienLeaseAgreementMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="11" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pacb_OmniomeIncMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pacb_SummaryOfSignificantAccountingPoliciesLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pacb_SummaryOfSignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashEquivalentsCurrent" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AnnualReductionInNonCurrentRestrictedCash" xlink:label="pacb_AnnualReductionInNonCurrentRestrictedCash"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pacb_AnnualReductionInNonCurrentRestrictedCash" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndNotesReceivableNet" xlink:label="us-gaap_AccountsAndNotesReceivableNet"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountsAndNotesReceivableNet" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Business Acquisitions (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637816497119903959"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637816497119903959" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_637816497119903959"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_637816497119903959" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AchievementOfMilestoneMember" xlink:label="pacb_AchievementOfMilestoneMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="pacb_AchievementOfMilestoneMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CirculomicsIncMember" xlink:label="pacb_CirculomicsIncMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pacb_CirculomicsIncMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pacb_OmniomeIncMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeStockAwardsRelatedToAcquisitionMember" xlink:label="pacb_OmniomeStockAwardsRelatedToAcquisitionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pacb_OmniomeStockAwardsRelatedToAcquisitionMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RestatementAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContingentConsiderationIncurredDuringPeriod" xlink:label="pacb_ContingentConsiderationIncurredDuringPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="pacb_ContingentConsiderationIncurredDuringPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares" xlink:label="pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" xlink:label="pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance" xlink:label="pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts" xlink:label="pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Business Acquisitions (Schedule by Acquisitions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CirculomicsIncMember" xlink:label="pacb_CirculomicsIncMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pacb_CirculomicsIncMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pacb_OmniomeIncMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContingentConsiderationIncurredDuringPeriod" xlink:label="pacb_ContingentConsiderationIncurredDuringPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="pacb_ContingentConsiderationIncurredDuringPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" xlink:label="pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet" xlink:label="pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_Goodwill" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:to="pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangementNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Invitae Collaboration Arrangement (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable" xlink:label="pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable" xlink:to="srt_MajorCustomersAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InvitaeCorporationMember" xlink:label="pacb_InvitaeCorporationMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="pacb_InvitaeCorporationMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems" xlink:label="pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems" xlink:to="pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Termination of Merger with Illumina (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerTerminationTable" xlink:label="pacb_MergerTerminationTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="pacb_MergerTerminationTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ConvertibleSeniorNotesMember" xlink:label="pacb_ConvertibleSeniorNotesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pacb_ConvertibleSeniorNotesMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="pacb_MergerTerminationTable" xlink:to="dei_LegalEntityAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637816497119943858"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_637816497119943858" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_IlluminaFcOpsCorpMember" xlink:label="pacb_IlluminaFcOpsCorpMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="pacb_IlluminaFcOpsCorpMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerTerminationLineItems" xlink:label="pacb_MergerTerminationLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="pacb_MergerTerminationLineItems" xlink:to="pacb_MergerTerminationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ProceedsFromContractTermination" xlink:label="pacb_ProceedsFromContractTermination"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pacb_MergerTerminationLineItems" xlink:to="pacb_ProceedsFromContractTermination" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pacb_MergerTerminationLineItems" xlink:to="us-gaap_GainLossOnContractTermination" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace" xlink:label="pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="pacb_MergerTerminationLineItems" xlink:to="pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction" xlink:label="pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="pacb_MergerTerminationLineItems" xlink:to="pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="pacb_MergerTerminationLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="pacb_MergerTerminationLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="pacb_MergerTerminationLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_RepaymentsOfContractTermination" xlink:label="pacb_RepaymentsOfContractTermination"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="pacb_MergerTerminationLineItems" xlink:to="pacb_RepaymentsOfContractTermination" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="us-gaap_ProceedsFromFeesReceived"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="pacb_MergerTerminationLineItems" xlink:to="us-gaap_ProceedsFromFeesReceived" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PaymentsForAdvisorFees" xlink:label="pacb_PaymentsForAdvisorFees"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="pacb_MergerTerminationLineItems" xlink:to="pacb_PaymentsForAdvisorFees" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="pacb_MergerTerminationLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Financial Instruments (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_FinancialInstrumentsTable" xlink:label="pacb_FinancialInstrumentsTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="pacb_FinancialInstrumentsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="pacb_FinancialInstrumentsTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ConvertibleSeniorNotesMember" xlink:label="pacb_ConvertibleSeniorNotesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pacb_ConvertibleSeniorNotesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="pacb_FinancialInstrumentsTable" xlink:to="srt_RangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="pacb_FinancialInstrumentsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637816497119963800"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637816497119963800" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_FinancialInstrumentsLineItems" xlink:label="pacb_FinancialInstrumentsLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="pacb_FinancialInstrumentsLineItems" xlink:to="pacb_FinancialInstrumentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pacb_FinancialInstrumentsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pacb_FinancialInstrumentsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="pacb_FinancialInstrumentsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_RepaymentsOfContractTermination" xlink:label="pacb_RepaymentsOfContractTermination"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="pacb_FinancialInstrumentsLineItems" xlink:to="pacb_RepaymentsOfContractTermination" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="pacb_FinancialInstrumentsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Financial Instruments (Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637816497119973775"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637816497119973775" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CashAndMoneyMarketFundsMember" xlink:label="pacb_CashAndMoneyMarketFundsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="pacb_CashAndMoneyMarketFundsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsMember" xlink:label="us-gaap_InvestmentsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_InvestmentsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InvestmentsMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:label="pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InvestmentsMember" xlink:to="pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_637816497119973775"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_637816497119973775" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContingentConsiderationMember" xlink:label="pacb_ContingentConsiderationMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="pacb_ContingentConsiderationMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:label="pacb_ShortTermRestrictedCashFairValueDisclosure"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="pacb_ShortTermRestrictedCashFairValueDisclosure" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_LongTermRestrictedCashFairValueDisclosure" xlink:label="pacb_LongTermRestrictedCashFairValueDisclosure"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="pacb_LongTermRestrictedCashFairValueDisclosure" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Financial Instruments (Changes in estimated fair value of contingent consideration) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContingentConsiderationIncurredDuringPeriod" xlink:label="pacb_ContingentConsiderationIncurredDuringPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="pacb_ContingentConsiderationIncurredDuringPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Financial Instruments (Summary of Cash, Cash Equivalents and Investments) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637816497119993720"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637816497119993720" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CashCashEquivalentsAndInvestmentsMember" xlink:label="pacb_CashCashEquivalentsAndInvestmentsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="pacb_CashCashEquivalentsAndInvestmentsMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pacb_CashCashEquivalentsAndInvestmentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CashAndMoneyMarketFundsMember" xlink:label="pacb_CashAndMoneyMarketFundsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="pacb_CashAndMoneyMarketFundsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsMember" xlink:label="us-gaap_InvestmentsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pacb_CashCashEquivalentsAndInvestmentsMember" xlink:to="us-gaap_InvestmentsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InvestmentsMember" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InvestmentsMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:label="pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_InvestmentsMember" xlink:to="pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ShortTermRestrictedCashMember" xlink:label="pacb_ShortTermRestrictedCashMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="pacb_ShortTermRestrictedCashMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_LongTermRestrictedCashMember" xlink:label="pacb_LongTermRestrictedCashMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="pacb_LongTermRestrictedCashMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments" xlink:label="pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:label="pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Balance Sheet Components (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfBalanceSheetComponentsTable" xlink:label="pacb_ScheduleOfBalanceSheetComponentsTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable" xlink:to="srt_MajorCustomersAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InvitaeCorporationMember" xlink:label="pacb_InvitaeCorporationMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="pacb_InvitaeCorporationMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CustomerDepositMember" xlink:label="pacb_CustomerDepositMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="pacb_CustomerDepositMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SecurityDepositMember" xlink:label="pacb_SecurityDepositMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="pacb_SecurityDepositMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637816497120013666"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637816497120013666" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ServiceContractMember" xlink:label="pacb_ServiceContractMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pacb_ServiceContractMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable" xlink:to="srt_CounterpartyNameAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ObrienLeaseAgreementMember" xlink:label="pacb_ObrienLeaseAgreementMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pacb_ObrienLeaseAgreementMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable" xlink:to="srt_ProductOrServiceAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable" xlink:to="srt_RangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pacb_OmniomeIncMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="9" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_637816497120033616"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_637816497120033616" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:label="pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_BalanceSheetComponentsLineItems" xlink:label="pacb_BalanceSheetComponentsLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="pacb_ScheduleOfBalanceSheetComponentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PercentageOfFeeToPrepayDebt" xlink:label="pacb_PercentageOfFeeToPrepayDebt"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="pacb_PercentageOfFeeToPrepayDebt" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_RestrictedCashCurrent" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_Depreciation" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AnnualDecreaseInLongTermRestrictedCash" xlink:label="pacb_AnnualDecreaseInLongTermRestrictedCash"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="pacb_AnnualDecreaseInLongTermRestrictedCash" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:label="pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_NotesPayable" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_NotesPayableCurrent" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_LongTermNotesPayable" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_InterestExpenseBorrowings" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Balance Sheet Components (Components of Property and Equipment, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_LaboratoryEquipmentAndMachineryMember" xlink:label="pacb_LaboratoryEquipmentAndMachineryMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pacb_LaboratoryEquipmentAndMachineryMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails" xlink:type="extended" xlink:title="40604 - Disclosure - Balance Sheet Components (Changes in carrying amount of goodwill) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pacb_OmniomeIncMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CirculomicsIncMember" xlink:label="pacb_CirculomicsIncMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pacb_CirculomicsIncMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_ScheduleOfGoodwillTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_Goodwill" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="extended" xlink:title="40605 - Disclosure - Balance Sheet Components (Definite-lived Intangible Assets from Business Acquisitions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pacb_OmniomeIncMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="us-gaap_CustomerRelationshipsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_CustomerRelationshipsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails" xlink:type="extended" xlink:title="40608 - Disclosure - Balance Sheet Components (Furture Principal Payments) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pacb_OmniomeIncMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_LongTermDebtByMaturityAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Convertible Senior Notes (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ConvertibleSeniorNotesMember" xlink:label="pacb_ConvertibleSeniorNotesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pacb_ConvertibleSeniorNotesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637816497120083482"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_637816497120083482" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EachDayDuringFirst180DaysMember" xlink:label="pacb_EachDayDuringFirst180DaysMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="pacb_EachDayDuringFirst180DaysMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OneHundredAndEightyFirstDayTo360thDayMember" xlink:label="pacb_OneHundredAndEightyFirstDayTo360thDayMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="pacb_OneHundredAndEightyFirstDayTo360thDayMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="us-gaap_DebtInstrumentIssuanceDate1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuanceDate1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount" xlink:label="pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentStatedPrincipalAmountForConversionRate" xlink:label="pacb_DebtInstrumentStatedPrincipalAmountForConversionRate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pacb_DebtInstrumentStatedPrincipalAmountForConversionRate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:label="pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:label="pacb_DebtInstrumentRedemptionPriceTradingDays"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pacb_DebtInstrumentRedemptionPriceTradingDays" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:label="pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:label="pacb_DebtInstrumentAdditionalInterestInEventOfDefault"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pacb_DebtInstrumentAdditionalInterestInEventOfDefault" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Commitments and Contingencies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CommitmentsAndContingenciesTable" xlink:label="pacb_CommitmentsAndContingenciesTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="pacb_CommitmentsAndContingenciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pacb_OmniomeIncMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CommitmentsAndContingenciesLineItems" xlink:label="pacb_CommitmentsAndContingenciesLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="pacb_CommitmentsAndContingenciesLineItems" xlink:to="pacb_CommitmentsAndContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pacb_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pacb_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="pacb_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="pacb_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_PaymentsForRent" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="pacb_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:label="pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="pacb_CommitmentsAndContingenciesLineItems" xlink:to="pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="pacb_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="pacb_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Income Taxes (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_IncomeTaxesTable" xlink:label="pacb_IncomeTaxesTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="pacb_IncomeTaxesTable" xlink:to="srt_RangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="pacb_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637816497120103425"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637816497120103425" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="pacb_IncomeTaxesTable" xlink:to="srt_StatementScenarioAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_WithExpirationMember" xlink:label="pacb_WithExpirationMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="pacb_WithExpirationMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_IncomeTaxesLineItems" xlink:label="pacb_IncomeTaxesLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="pacb_IncomeTaxesLineItems" xlink:to="pacb_IncomeTaxesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pacb_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pacb_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="pacb_IncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="pacb_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="pacb_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="pacb_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OperatingLossCarryforwardsExpirationYear" xlink:label="pacb_OperatingLossCarryforwardsExpirationYear"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="pacb_IncomeTaxesLineItems" xlink:to="pacb_OperatingLossCarryforwardsExpirationYear" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="pacb_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TaxCreditCarryforwardExpirationYear" xlink:label="pacb_TaxCreditCarryforwardExpirationYear"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="pacb_IncomeTaxesLineItems" xlink:to="pacb_TaxCreditCarryforwardExpirationYear" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="pacb_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="pacb_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Stockholders&apos; Equity (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_StockholdersEquityTable" xlink:label="pacb_StockholdersEquityTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="pacb_StockholdersEquityTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_UnderwrittenPublicEquityOfferingMember" xlink:label="pacb_UnderwrittenPublicEquityOfferingMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="pacb_UnderwrittenPublicEquityOfferingMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_UnderwritingAgreementMember" xlink:label="pacb_UnderwritingAgreementMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="pacb_UnderwritingAgreementMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="pacb_StockholdersEquityTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120123369"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120123369" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomePlanMember" xlink:label="pacb_OmniomePlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="pacb_OmniomePlanMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TwoThousandTenEquityIncentivePlanMember" xlink:label="pacb_TwoThousandTenEquityIncentivePlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="pacb_TwoThousandTenEquityIncentivePlanMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EmployeeStockPurchasePlanMember" xlink:label="pacb_EmployeeStockPurchasePlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="pacb_EmployeeStockPurchasePlanMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EquityIncentivePlan2020Member" xlink:label="pacb_EquityIncentivePlan2020Member"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="pacb_EquityIncentivePlan2020Member" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InducementEquityIncentivePlan2020Member" xlink:label="pacb_InducementEquityIncentivePlan2020Member"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="pacb_InducementEquityIncentivePlan2020Member" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="pacb_StockholdersEquityTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OptionsToPurchaseCommonStockMember" xlink:label="pacb_OptionsToPurchaseCommonStockMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pacb_OptionsToPurchaseCommonStockMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:label="pacb_TimeBasedRestrictedStockUnitsRsusMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pacb_TimeBasedRestrictedStockUnitsRsusMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="pacb_StockholdersEquityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PrivatePlacementOfCommonStockMember" xlink:label="pacb_PrivatePlacementOfCommonStockMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pacb_PrivatePlacementOfCommonStockMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="pacb_StockholdersEquityTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120143321"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120143321" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeOneMember" xlink:label="pacb_ExercisePriceRangeOneMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pacb_ExercisePriceRangeOneMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="pacb_StockholdersEquityTable" xlink:to="us-gaap_VestingAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637816497120143321"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_637816497120143321" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember" xlink:label="pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_StockholdersEquityLineItems" xlink:label="pacb_StockholdersEquityLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="pacb_StockholdersEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExchangeRatio" xlink:label="pacb_ExchangeRatio"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="pacb_ExchangeRatio" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" xlink:label="pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PublicOfferingShares" xlink:label="pacb_PublicOfferingShares"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="pacb_PublicOfferingShares" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OfferingShareAmountMaximum" xlink:label="pacb_OfferingShareAmountMaximum"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="pacb_OfferingShareAmountMaximum" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:label="pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:label="pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:label="pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_NumberOfOfferings" xlink:label="pacb_NumberOfOfferings"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="pacb_NumberOfOfferings" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_NumberOfPurchasePeriods" xlink:label="pacb_NumberOfPurchasePeriods"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="pacb_NumberOfPurchasePeriods" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PurchasePeriodOfEmployeeStockPurchasePlan" xlink:label="pacb_PurchasePeriodOfEmployeeStockPurchasePlan"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="pacb_PurchasePeriodOfEmployeeStockPurchasePlan" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" xlink:label="pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ShareInstrumentNumberOfSharesConversionRatio" xlink:label="pacb_ShareInstrumentNumberOfSharesConversionRatio"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="pacb_ShareInstrumentNumberOfSharesConversionRatio" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="39" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="40" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="41" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="42" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="43" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="44" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Stockholders&apos; Equity (Summary of Stock Option Activity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeOneMember" xlink:label="pacb_ExercisePriceRangeOneMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pacb_ExercisePriceRangeOneMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeTwoMember" xlink:label="pacb_ExercisePriceRangeTwoMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pacb_ExercisePriceRangeTwoMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeAcqusitionMember" xlink:label="pacb_ExercisePriceRangeAcqusitionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pacb_ExercisePriceRangeAcqusitionMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeAcqusitionTwoMember" xlink:label="pacb_ExercisePriceRangeAcqusitionTwoMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pacb_ExercisePriceRangeAcqusitionTwoMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeThreeMember" xlink:label="pacb_ExercisePriceRangeThreeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pacb_ExercisePriceRangeThreeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeFourMember" xlink:label="pacb_ExercisePriceRangeFourMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pacb_ExercisePriceRangeFourMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeFiveMember" xlink:label="pacb_ExercisePriceRangeFiveMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pacb_ExercisePriceRangeFiveMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TimeBasedStockOptionMember" xlink:label="pacb_TimeBasedStockOptionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pacb_TimeBasedStockOptionMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OptionsToPurchaseCommonStockMember" xlink:label="pacb_OptionsToPurchaseCommonStockMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pacb_OptionsToPurchaseCommonStockMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomePlanMember" xlink:label="pacb_OmniomePlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="pacb_OmniomePlanMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Stockholders&apos; Equity (Reconciliation of Outstanding and Exercisable Stock Options) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OptionsToPurchaseCommonStockMember" xlink:label="pacb_OptionsToPurchaseCommonStockMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pacb_OptionsToPurchaseCommonStockMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeSixMember" xlink:label="pacb_ExercisePriceRangeSixMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pacb_ExercisePriceRangeSixMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeSevenMember" xlink:label="pacb_ExercisePriceRangeSevenMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pacb_ExercisePriceRangeSevenMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeEightMember" xlink:label="pacb_ExercisePriceRangeEightMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pacb_ExercisePriceRangeEightMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeNineMember" xlink:label="pacb_ExercisePriceRangeNineMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pacb_ExercisePriceRangeNineMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeTenMember" xlink:label="pacb_ExercisePriceRangeTenMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pacb_ExercisePriceRangeTenMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeElevenMember" xlink:label="pacb_ExercisePriceRangeElevenMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pacb_ExercisePriceRangeElevenMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeThirteenMember" xlink:label="pacb_ExercisePriceRangeThirteenMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pacb_ExercisePriceRangeThirteenMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeFourteenMember" xlink:label="pacb_ExercisePriceRangeFourteenMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pacb_ExercisePriceRangeFourteenMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeFifteenMember" xlink:label="pacb_ExercisePriceRangeFifteenMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pacb_ExercisePriceRangeFifteenMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Stockholders&apos; Equity (Summary of Time-Based RSUs Activity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:label="pacb_TimeBasedRestrictedStockUnitsRsusMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pacb_TimeBasedRestrictedStockUnitsRsusMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Stockholders&apos; Equity (Summary of Performance-Based RSUs Activity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PerformanceBasedRestrictedStockUnitsRsusMember" xlink:label="pacb_PerformanceBasedRestrictedStockUnitsRsusMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pacb_PerformanceBasedRestrictedStockUnitsRsusMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41006 - Disclosure - Stockholders&apos; Equity (Schedule of Stock-Based Compensation Expense) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637816497120263001"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637816497120263001" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerRelatedExpensesStockSettledMember" xlink:label="pacb_MergerRelatedExpensesStockSettledMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pacb_MergerRelatedExpensesStockSettledMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerRelatedExpensesMilestoneMember" xlink:label="pacb_MergerRelatedExpensesMilestoneMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pacb_MergerRelatedExpensesMilestoneMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_StockBasedCompensationMember" xlink:label="pacb_StockBasedCompensationMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pacb_StockBasedCompensationMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerRelatedExpensesCashSettledMember" xlink:label="pacb_MergerRelatedExpensesCashSettledMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pacb_MergerRelatedExpensesCashSettledMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails" xlink:type="extended" xlink:title="41007 - Disclosure - Stockholders&apos; Equity (Schedule of Fair Value of Employee Stock Options) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OptionsToPurchaseCommonStockMember" xlink:label="pacb_OptionsToPurchaseCommonStockMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pacb_OptionsToPurchaseCommonStockMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails" xlink:type="extended" xlink:title="41008 - Disclosure - Stockholders&apos; Equity (Schedule of Fair Value of Employee Stock Purchase Plan) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EmployeeStockPurchasePlanMember" xlink:label="pacb_EmployeeStockPurchasePlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="pacb_EmployeeStockPurchasePlanMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Net (Loss) Income Per Share (Computation Of Basic And Diluted Net Loss Per Share) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfEarningsPerShareTable" xlink:label="pacb_ScheduleOfEarningsPerShareTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="pacb_ScheduleOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OptionsToPurchaseCommonStockMember" xlink:label="pacb_OptionsToPurchaseCommonStockMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pacb_OptionsToPurchaseCommonStockMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="pacb_ScheduleOfEarningsPerShareTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EmployeeStockPurchasePlanMember" xlink:label="pacb_EmployeeStockPurchasePlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="pacb_EmployeeStockPurchasePlanMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfEarningsPerShareLineItems" xlink:label="pacb_ScheduleOfEarningsPerShareLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="pacb_ScheduleOfEarningsPerShareLineItems" xlink:to="pacb_ScheduleOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pacb_ScheduleOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Net (Loss) Income Per Share (Antidilutive Shares Excluded From Computation Of Diluted Net Loss Per Share) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637816497120372710"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637816497120372710" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember" xlink:label="pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OptionsToPurchaseCommonStockMember" xlink:label="pacb_OptionsToPurchaseCommonStockMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pacb_OptionsToPurchaseCommonStockMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:label="pacb_TimeBasedRestrictedStockUnitsRsusMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pacb_TimeBasedRestrictedStockUnitsRsusMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PerformanceBasedRestrictedStockUnitsRsusMember" xlink:label="pacb_PerformanceBasedRestrictedStockUnitsRsusMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pacb_PerformanceBasedRestrictedStockUnitsRsusMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EmployeeStockPurchasePlanMember" xlink:label="pacb_EmployeeStockPurchasePlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="pacb_EmployeeStockPurchasePlanMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Segment And Geographic Information (Schedule of Revenue by Geographic Location) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_StatementGeographicalAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637816497120382686"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_637816497120382686" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_NorthAmericaMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AsiaPacificMember" xlink:label="srt_AsiaPacificMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_AsiaPacificMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Segment And Geographic Information (Summary of Revenue by Category) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_ProductOrServiceAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InstrumentMember" xlink:label="pacb_InstrumentMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProductMember" xlink:to="pacb_InstrumentMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ConsumableMember" xlink:label="pacb_ConsumableMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ProductMember" xlink:to="pacb_ConsumableMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ServiceAndOtherMember" xlink:label="pacb_ServiceAndOtherMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="pacb_ServiceAndOtherMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional"></definitionArc></definitionLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>pacb-20211231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 22.1.0.2 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/28/2022 12:55:15 PM-->
<!--Modified on: 2/28/2022 12:55:15 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"></roleRef>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"></roleRef>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm Id</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Condensed Consolidated Balance Sheets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable Net Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense And Other Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Short-term restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US">Long-term restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other Assets Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other long-term assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Deferred revenue, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other liabilities, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other liabilities, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Deferred revenue, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xml:lang="en-US">Contingent consideration liability, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible Notes Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible senior notes, net, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other liabilities, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&apos; equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value: Authorized 50,000 shares; No shares issued or outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value Authorized 1,000,000 shares; issued and outstanding 220,978 and 192,294 shares at December 31, 2021 and December 31, 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income Loss Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive (loss) income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&apos; equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&apos; equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Products And Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ServiceAndOtherMember" xlink:label="pacb_ServiceAndOtherMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ServiceAndOtherMember" xlink:to="pacb_ServiceAndOtherMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ServiceAndOtherMember_lbl" xml:lang="en-US">Service and Other [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ServiceAndOtherMember_lbl" xml:lang="en-US">Service And Other [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ServiceAndOtherMember_lbl" xml:lang="en-US">Service and Other [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenue:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Total revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenueAbstract" xlink:label="us-gaap_CostOfRevenueAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_CostOfRevenueAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenueAbstract_lbl" xml:lang="en-US">Cost Of Revenue [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenueAbstract_lbl" xml:lang="en-US">Cost of revenue:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of Goods and Services Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of product revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl" xml:lang="en-US">Cost Of Goods And Services Sold Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl" xml:lang="en-US">Amortization of Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Total cost of revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expense:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Sales, general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US">Merger-related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US">Acquisition-related costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US">Change in fair value of contingent consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US">Change in the estimated fair value of contingent consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US">Change in estimated fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_GainLossOnReverseTerminationFee" xlink:label="pacb_GainLossOnReverseTerminationFee"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_GainLossOnReverseTerminationFee" xlink:to="pacb_GainLossOnReverseTerminationFee_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_GainLossOnReverseTerminationFee_lbl" xml:lang="en-US">Gain (Loss) On Reverse Termination Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_GainLossOnReverseTerminationFee_lbl" xml:lang="en-US">Gain (Loss) On Reverse Termination Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_GainLossOnReverseTerminationFee_lbl" xml:lang="en-US">Gain from Reverse Termination Fee from Illumina</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnContractTermination" xlink:to="us-gaap_GainLossOnContractTermination_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnContractTermination_lbl" xml:lang="en-US">Gain (Loss) on Contract Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnContractTermination_lbl" xml:lang="en-US">Loss (gain) from Continuation Advances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnContractTermination_lbl" xml:lang="en-US">(Loss)/Gain from Continuation Advances from Illumina</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before benefit from income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Benefit from income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (loss) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Unrealized (loss) gain on investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Other comprehensive income loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Income Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Earnings Per Share Basic And Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net income (loss) per share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net loss per share:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net income (loss) per share, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net (loss) income per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net (loss) income per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Weighted average shares outstanding used in computing net income (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares used in computing basic net income (loss) per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares used in computing net income (loss) per share, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares used in computing diluted net income (loss) per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statement of Stockholders&apos; Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US">Restatement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US">Revision of Prior Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xml:lang="en-US">Revision Of Prior Period Accounting Standards Update Adjustment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xml:lang="en-US">Revision of Prior Period, Accounting Standards Update, Adjustment [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Issuance of common stock in conjunction with equity plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Issuance of common stock in conjunction with equity plans, shares</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" xlink:label="pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" xlink:to="pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts_lbl" xml:lang="en-US">Value of stock issued in private placement net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of common stock in Private Placement, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares" xlink:label="pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares" xlink:to="pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares_lbl" xml:lang="en-US">Issuance of common stock in Private Placement, net of issuance costs, number of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares_lbl" xml:lang="en-US">Issuance of common stock in Private Placement, net of issuance costs shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Issuance of common stock in acquisition of Omniome</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Issuance of common stock in acquisition of Omniome, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock from underwritten public equity offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock from underwritten public equity offering, net of issuance costs, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" xlink:label="pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" xlink:to="pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense_lbl" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) and research development expense in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense_lbl" xml:lang="en-US">Amortization of intangible assets and research development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense_lbl" xml:lang="en-US">Amortization of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization Of Financing Costs And Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt discount and financing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="us-gaap_GainLossOnSaleOfDerivatives"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDerivatives" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_lbl" xml:lang="en-US">Gain (Loss) on Sale of Derivatives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_lbl" xml:lang="en-US">Loss from derivative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xml:lang="en-US">Amortization (accretion) from investment premium (discount)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposition of equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase Decrease In Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase Decrease In Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase Decrease In Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Service Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl" xml:lang="en-US">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Increase Decrease In Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments To Acquire Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Cash paid for purchase of business acquisition, net of cash acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Cash paid for purchase of business acquisition, net of cash acquired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Payments To Acquire Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Purchase of investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Proceeds From Sale Of Available For Sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Sales of investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Maturities of investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ProceedsFromRepaymentsOfContractTermination" xlink:label="pacb_ProceedsFromRepaymentsOfContractTermination"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ProceedsFromRepaymentsOfContractTermination" xlink:to="pacb_ProceedsFromRepaymentsOfContractTermination_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ProceedsFromRepaymentsOfContractTermination_lbl" xml:lang="en-US">Proceeds from (Repayments of) Contract Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ProceedsFromRepaymentsOfContractTermination_lbl" xml:lang="en-US">Proceeds from (Repayments of) Contract Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ProceedsFromRepaymentsOfContractTermination_lbl" xml:lang="en-US">Continuation Advances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Notes payable principal payoff</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of Convertible Senior Notes, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:to="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock, Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from issuance of common stock from underwritten public equity offerings, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Estimated issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Proceeds from issuance of common stock under equity offerings, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock from equity plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash and cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents and restricted cash at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents and restricted cash at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted cash at end of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InventoryTransferredToFromPropertyAndEquipment" xlink:label="pacb_InventoryTransferredToFromPropertyAndEquipment"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_InventoryTransferredToFromPropertyAndEquipment" xlink:to="pacb_InventoryTransferredToFromPropertyAndEquipment_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_InventoryTransferredToFromPropertyAndEquipment_lbl" xml:lang="en-US">Value of inventory transferred (from) to the entity&apos;s property and equipment in noncash transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_InventoryTransferredToFromPropertyAndEquipment_lbl" xml:lang="en-US">Inventory Transferred To (From) Property And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_InventoryTransferredToFromPropertyAndEquipment_lbl" xml:lang="en-US">Inventory transferred to property and equipment</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InventoryTransferredFromPropertyAndEquipment" xlink:label="pacb_InventoryTransferredFromPropertyAndEquipment"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_InventoryTransferredFromPropertyAndEquipment" xlink:to="pacb_InventoryTransferredFromPropertyAndEquipment_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_InventoryTransferredFromPropertyAndEquipment_lbl" xml:lang="en-US">Inventory Transferred From Property And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_InventoryTransferredFromPropertyAndEquipment_lbl" xml:lang="en-US">Inventory Transferred From Property And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pacb_InventoryTransferredFromPropertyAndEquipment_lbl" xml:lang="en-US">Property and equipment transferred to inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use asset and liability additions and modifications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US">Business acquisitions [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">Business acquisitions</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DevelopmentAndCommercializationAgreementAbstract" xlink:label="pacb_DevelopmentAndCommercializationAgreementAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_DevelopmentAndCommercializationAgreementAbstract" xlink:to="pacb_DevelopmentAndCommercializationAgreementAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_DevelopmentAndCommercializationAgreementAbstract_lbl" xml:lang="en-US">Development and Commercialization Agreement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_DevelopmentAndCommercializationAgreementAbstract_lbl" xml:lang="en-US">Invitae Collaboration [Abstract]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DevelopmentAndCommercializationAgreementDisclosureTextBlock" xlink:label="pacb_DevelopmentAndCommercializationAgreementDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_DevelopmentAndCommercializationAgreementDisclosureTextBlock" xlink:to="pacb_DevelopmentAndCommercializationAgreementDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_DevelopmentAndCommercializationAgreementDisclosureTextBlock_lbl" xml:lang="en-US">Development and Commercialization Agreement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_DevelopmentAndCommercializationAgreementDisclosureTextBlock_lbl" xml:lang="en-US">Development and Commercialization Agreement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_DevelopmentAndCommercializationAgreementDisclosureTextBlock_lbl" xml:lang="en-US">Invitae Collaboration</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerTerminationAbstract" xlink:label="pacb_MergerTerminationAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_MergerTerminationAbstract" xlink:to="pacb_MergerTerminationAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_MergerTerminationAbstract_lbl" xml:lang="en-US">Merger Termination [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_MergerTerminationAbstract_lbl" xml:lang="en-US">Termination of Merger with Illumina [Abstract]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerTermination" xlink:label="pacb_MergerTermination"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_MergerTermination" xlink:to="pacb_MergerTermination_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_MergerTermination_lbl" xml:lang="en-US">Merger Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_MergerTermination_lbl" xml:lang="en-US">Merger Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_MergerTermination_lbl" xml:lang="en-US">Termination of Merger with Illumina</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US">Financial Instruments [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US">Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:label="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_lbl" xml:lang="en-US">Supplemental Balance Sheet Components Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_lbl" xml:lang="en-US">Balance Sheet Components [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">Balance Sheet Components</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Convertible Senior Notes [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Senior Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDisclosures" xlink:to="us-gaap_LossContingencyDisclosures_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDisclosures_lbl" xml:lang="en-US">Loss Contingency Disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyDisclosures_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&apos; Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net (Loss) Income Per Share [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Income (Loss) Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment And Geographic Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment And Geographic Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">Basis Of Accounting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">Basis of Presentation and Consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use Of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional Currency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash, Cash Equivalents and Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration and Credit Risks</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Tangible Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lease, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Operating Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill and Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock" xlink:label="pacb_ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock" xlink:to="pacb_ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Short-Term Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Short-Term Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Short-term Restriced Cash</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock" xlink:label="pacb_LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock" xlink:to="pacb_LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Long-Term Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Long-Term Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Long-term Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Sales, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_lbl" xml:lang="en-US">Credit Loss, Financial Instrument [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_lbl" xml:lang="en-US">Credit Losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Other Comprehensive Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xml:lang="en-US">Shipping and Handling Cost, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xml:lang="en-US">Shipping and Handling</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock" xlink:label="pacb_EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock" xlink:to="pacb_EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock_lbl" xml:lang="en-US">Estimated useful lives of the major classes of property and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock_lbl" xml:lang="en-US">Estimated useful lives of major classes of property and equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock_lbl" xml:lang="en-US">Estimated useful lives of the major classes of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Acquisition [Line Items]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock" xlink:label="pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock" xlink:to="pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of a material business combination completed during the period, details of total considerations transferred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock_lbl" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition Consideration Tranferred [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock_lbl" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition Consideration Tranferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US">Schedule of Unaudited Pro Forma Financial Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock" xlink:label="pacb_ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock" xlink:to="pacb_ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Changes in the estimated fair value of contingent consideration liabilities table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Changes in the estimated fair value of contingent consideration liabilities [Table Text Block]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US">Schedule Of Cash Cash Equivalents And Short Term Investments Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US">Summary of Cash, Cash Equivalents and Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Marketable Securities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule Of Inventory Current Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Components of Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Components of Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of the components of accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule Of Accrued Expenses And Other Current Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Other Current Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Liabilities, Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US">Changes to Goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of definite-lived intangible assets from business acquisitions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Estimated Future Amortization Expense Of Acquisition-Related Intangible Assets With Definite Lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US">Future Principal Payments , Fiscal Year Maturity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of Net Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:label="pacb_ScheduleOfInterestExpenseTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:to="pacb_ScheduleOfInterestExpenseTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ScheduleOfInterestExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Interest Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ScheduleOfInterestExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Interest Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ScheduleOfInterestExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Interest Expense</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:label="pacb_LesseeOperatingLeaseDescriptionTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:to="pacb_LesseeOperatingLeaseDescriptionTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_LesseeOperatingLeaseDescriptionTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Description [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_LesseeOperatingLeaseDescriptionTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Description [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_LesseeOperatingLeaseDescriptionTableTextBlock_lbl" xml:lang="en-US">Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Reconciliation of Federal Income Tax Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Reconciliation of Deferred Tax Assets and Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefit Accounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Reconciliation of Outstanding and Exercisable Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Time-Based RSUs Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation, Performance Shares Award Nonvested Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Performance-Based RSUs Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Employee Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Computation of Basic and Diluted Net Income (Loss) per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Antidilutive Shares Excluded from Computation of Diluted Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of Revenue by Geographic Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US">Summary of Revenue by Category</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:label="pacb_SummaryOfSignificantAccountingPoliciesTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="pacb_SummaryOfSignificantAccountingPoliciesTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ConvertibleSeniorNotesMember" xlink:label="pacb_ConvertibleSeniorNotesMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ConvertibleSeniorNotesMember" xlink:to="pacb_ConvertibleSeniorNotesMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ConvertibleSeniorNotesMember_lbl" xml:lang="en-US">Convertible Senior Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ConvertibleSeniorNotesMember_lbl" xml:lang="en-US">Convertible Senior Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ConvertibleSeniorNotesMember_lbl" xml:lang="en-US">Convertible Senior Notes [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SecurityDepositMember" xlink:label="pacb_SecurityDepositMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_SecurityDepositMember" xlink:to="pacb_SecurityDepositMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_SecurityDepositMember_lbl" xml:lang="en-US">Security Deposit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_SecurityDepositMember_lbl" xml:lang="en-US">Security Deposit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_SecurityDepositMember_lbl" xml:lang="en-US">Security Deposit [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Lab Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Computer Software Intangible Asset [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Computer software [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture And Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Sales Revenue Net [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Sales Revenue, Net [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Name Of Major Customer [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TenPercentOrGreaterBalanceAccountsReceivableMember" xlink:label="pacb_TenPercentOrGreaterBalanceAccountsReceivableMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_TenPercentOrGreaterBalanceAccountsReceivableMember" xlink:to="pacb_TenPercentOrGreaterBalanceAccountsReceivableMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_TenPercentOrGreaterBalanceAccountsReceivableMember_lbl" xml:lang="en-US">Ten percent or greater balance accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_TenPercentOrGreaterBalanceAccountsReceivableMember_lbl" xml:lang="en-US">Ten Percent Or Greater Balance Accounts Receivable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_TenPercentOrGreaterBalanceAccountsReceivableMember_lbl" xml:lang="en-US">Customers with 10% or greater accounts receivable [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CustomerBMember" xlink:label="pacb_CustomerBMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_CustomerBMember" xlink:to="pacb_CustomerBMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_CustomerBMember_lbl" xml:lang="en-US">Customer B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_CustomerBMember_lbl" xml:lang="en-US">Customer B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_CustomerBMember_lbl" xml:lang="en-US">Gene Company Limited [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DomesticCustomersMember" xlink:label="pacb_DomesticCustomersMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_DomesticCustomersMember" xlink:to="pacb_DomesticCustomersMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_DomesticCustomersMember_lbl" xml:lang="en-US">Domestic Customers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_DomesticCustomersMember_lbl" xml:lang="en-US">Domestic Customers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_DomesticCustomersMember_lbl" xml:lang="en-US">Domestic Customers [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CustomerDMember" xlink:label="pacb_CustomerDMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_CustomerDMember" xlink:to="pacb_CustomerDMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_CustomerDMember_lbl" xml:lang="en-US">Customer D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_CustomerDMember_lbl" xml:lang="en-US">Customer D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_CustomerDMember_lbl" xml:lang="en-US">Berry Genomics Co., Ltd [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US">Credit Facility [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US">Credit Facility [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LetterOfCreditMember_lbl" xml:lang="en-US">Letter Of Credit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LetterOfCreditMember_lbl" xml:lang="en-US">Letter of Credit [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US">Measurement Input Discount Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US">Measurement Input, Discount Rate [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pacb_SummaryOfSignificantAccountingPoliciesLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pacb_SummaryOfSignificantAccountingPoliciesLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property and equipment estimated useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashEquivalentsCurrent" xlink:to="us-gaap_RestrictedCashEquivalentsCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent_lbl" xml:lang="en-US">Restricted Cash Equivalents, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent_lbl" xml:lang="en-US">Short-term restriced cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent_lbl" xml:lang="en-US">Restricted Cash Equivalents, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent_lbl" xml:lang="en-US">Long-term restricted cash</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AnnualReductionInNonCurrentRestrictedCash" xlink:label="pacb_AnnualReductionInNonCurrentRestrictedCash"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_AnnualReductionInNonCurrentRestrictedCash" xlink:to="pacb_AnnualReductionInNonCurrentRestrictedCash_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_AnnualReductionInNonCurrentRestrictedCash_lbl" xml:lang="en-US">Annual reduction in non-current restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_AnnualReductionInNonCurrentRestrictedCash_lbl" xml:lang="en-US">Annual reduction in non-current restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndNotesReceivableNet" xlink:label="us-gaap_AccountsAndNotesReceivableNet"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndNotesReceivableNet" xlink:to="us-gaap_AccountsAndNotesReceivableNet_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndNotesReceivableNet_lbl" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Fair value of contingent consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Contingent repayment liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount of notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument Interest Rate Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt instrument, stated interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration Risk, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk, percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xml:lang="en-US">Diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Total cash paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xml:lang="en-US">Fair value of share consideration</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContingentConsiderationIncurredDuringPeriod" xlink:label="pacb_ContingentConsiderationIncurredDuringPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ContingentConsiderationIncurredDuringPeriod" xlink:to="pacb_ContingentConsiderationIncurredDuringPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ContingentConsiderationIncurredDuringPeriod_lbl" xml:lang="en-US">Contingent Consideration Incurred during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ContingentConsiderationIncurredDuringPeriod_lbl" xml:lang="en-US">Contingent Consideration Incurred during period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ContingentConsiderationIncurredDuringPeriod_lbl" xml:lang="en-US">Acquisition of Omniome</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pacb_ContingentConsiderationIncurredDuringPeriod_lbl" xml:lang="en-US">Fair value of contingent consideration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Business Combination, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Total consideration transferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock options issued by PacBio in replacement of Omniome&#8217;s unvested options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Price Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance" xlink:label="pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance" xlink:to="pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Income tax benefit from reduction in deferred tax assets valuation allowance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Income tax benefit from reduction in deferred tax assets valuation allowance</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts" xlink:label="pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts" xlink:to="pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts_lbl" xml:lang="en-US">Pro forma adjustment to reflect acquiree&apos;s acquisition-related costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts_lbl" xml:lang="en-US">Pro forma adjustment related to acquiree&apos;s acquisition-related costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_lbl" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_lbl" xml:lang="en-US">Since the date of acquisition, revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_lbl" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_lbl" xml:lang="en-US">Since the date of acquisition, net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense_lbl" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl" xml:lang="en-US">Business Combination, Consideration Transferred [Abstract]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" xlink:label="pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" xlink:to="pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_lbl" xml:lang="en-US">Stock-based compensation expense excluded from consideration transferred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_lbl" xml:lang="en-US">Stock-based compensation expense excluded from consideration transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_lbl" xml:lang="en-US">Less: Stock-based compensation expense excluded from consideration transferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_lbl" xml:lang="en-US">Major classes of assets and liabilities allocated to total fair value of consideration transferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet" xlink:label="pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet" xlink:to="pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet_lbl" xml:lang="en-US">The amount of property, operating lease right of use assets net recognized as of the acquisition date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Operating lease right-of-use assets, net Acquired and Liabilities Assumed Operating Lease Right of use assets Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet_lbl" xml:lang="en-US">Operating lease right-of-use assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xml:lang="en-US">Allocation of purchase price to intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xml:lang="en-US">Intangible assets, finite lived</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl" xml:lang="en-US">In-process research and development (&quot;IPR&amp;D&quot;)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xml:lang="en-US">Deferred income tax liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US">Liabilities assumed</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Total consideration transferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationAbstract_lbl" xml:lang="en-US">Business Acquisition, Pro Forma Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US">Pro forma total revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US">Pro Forma Net Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:to="pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Pro forma net (loss) income per share - basic and diluted</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable" xlink:label="pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable" xlink:to="pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_lbl" xml:lang="en-US">Schedule of Development and Commercialization Agreement Transactions [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_lbl" xml:lang="en-US">Schedule of Development and Commercialization Agreement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems" xlink:label="pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems" xlink:to="pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_lbl" xml:lang="en-US">Development and Commercialization Agreement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_lbl" xml:lang="en-US">Development and Commercialization Agreement Transactions [Line Items]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerTerminationTable" xlink:label="pacb_MergerTerminationTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_MergerTerminationTable" xlink:to="pacb_MergerTerminationTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_MergerTerminationTable_lbl" xml:lang="en-US">Merger Termination [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_MergerTerminationTable_lbl" xml:lang="en-US">Merger Termination [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_IlluminaFcOpsCorpMember" xlink:label="pacb_IlluminaFcOpsCorpMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_IlluminaFcOpsCorpMember" xlink:to="pacb_IlluminaFcOpsCorpMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_IlluminaFcOpsCorpMember_lbl" xml:lang="en-US">Illumina, FC Ops Corp [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_IlluminaFcOpsCorpMember_lbl" xml:lang="en-US">Illumina Fc Ops Corp [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_IlluminaFcOpsCorpMember_lbl" xml:lang="en-US">Illumina, FC Ops Corp [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerTerminationLineItems" xlink:label="pacb_MergerTerminationLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_MergerTerminationLineItems" xlink:to="pacb_MergerTerminationLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_MergerTerminationLineItems_lbl" xml:lang="en-US">Merger Termination [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_MergerTerminationLineItems_lbl" xml:lang="en-US">Merger Termination [Line Items]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ProceedsFromContractTermination" xlink:label="pacb_ProceedsFromContractTermination"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ProceedsFromContractTermination" xlink:to="pacb_ProceedsFromContractTermination_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ProceedsFromContractTermination_lbl" xml:lang="en-US">Proceeds from Contract Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ProceedsFromContractTermination_lbl" xml:lang="en-US">Proceeds from Contract Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ProceedsFromContractTermination_lbl" xml:lang="en-US">Continuation Advances</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace" xlink:label="pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace" xlink:to="pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace_lbl" xml:lang="en-US">Continuation Advances Payable Per Agreement To Repay Advance If Change In Control Transaction Or Single Equity Or Debt Financing Takes Place</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace_lbl" xml:lang="en-US">Continuation Advances Payable Per Agreement To Repay Advance If Change In Control Transaction Or Single Equity Or Debt Financing Takes Place</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace_lbl" xml:lang="en-US">Possible Continuation Advances payable</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction" xlink:label="pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction" xlink:to="pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction_lbl" xml:lang="en-US">Merger Agreement, Continuation Advances Repayable, Minimum Company must Raise in Equity or Debt Financing in a Single Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction_lbl" xml:lang="en-US">Merger Agreement, Continuation Advances Repayable, Minimum Company must Raise in Equity or Debt Financing in a Single Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction_lbl" xml:lang="en-US">Equity or debt financing that must be raised in a single transaction</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_RepaymentsOfContractTermination" xlink:label="pacb_RepaymentsOfContractTermination"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_RepaymentsOfContractTermination" xlink:to="pacb_RepaymentsOfContractTermination_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_RepaymentsOfContractTermination_lbl" xml:lang="en-US">Repayments of Contract Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_RepaymentsOfContractTermination_lbl" xml:lang="en-US">Repayments of) Contract Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_RepaymentsOfContractTermination_lbl" xml:lang="en-US">Continuation Advances paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="us-gaap_ProceedsFromFeesReceived"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl" xml:lang="en-US">Proceeds from Fees Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl" xml:lang="en-US">Termination fee received</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PaymentsForAdvisorFees" xlink:label="pacb_PaymentsForAdvisorFees"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_PaymentsForAdvisorFees" xlink:to="pacb_PaymentsForAdvisorFees_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_PaymentsForAdvisorFees_lbl" xml:lang="en-US">Payments for Advisor Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_PaymentsForAdvisorFees_lbl" xml:lang="en-US">Payments for Advisor Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_PaymentsForAdvisorFees_lbl" xml:lang="en-US">Advisor fees paid</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_FinancialInstrumentsTable" xlink:label="pacb_FinancialInstrumentsTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_FinancialInstrumentsTable" xlink:to="pacb_FinancialInstrumentsTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_FinancialInstrumentsTable_lbl" xml:lang="en-US">Financial Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_FinancialInstrumentsTable_lbl" xml:lang="en-US">Financial Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_FinancialInstrumentsLineItems" xlink:label="pacb_FinancialInstrumentsLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_FinancialInstrumentsLineItems" xlink:to="pacb_FinancialInstrumentsLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_FinancialInstrumentsLineItems_lbl" xml:lang="en-US">Financial Instruments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_FinancialInstrumentsLineItems_lbl" xml:lang="en-US">Financial Instruments [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Estimated fair value of the liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Fair Value By Asset Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash And Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and cash equivalents [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CashAndMoneyMarketFundsMember" xlink:label="pacb_CashAndMoneyMarketFundsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_CashAndMoneyMarketFundsMember" xlink:to="pacb_CashAndMoneyMarketFundsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_CashAndMoneyMarketFundsMember_lbl" xml:lang="en-US">Cash and money market funds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_CashAndMoneyMarketFundsMember_lbl" xml:lang="en-US">Cash And Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_CashAndMoneyMarketFundsMember_lbl" xml:lang="en-US">Cash and money market funds [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US">Commercial Paper [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US">Commercial paper [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xml:lang="en-US">U S Government Corporations And Agencies Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xml:lang="en-US">U.S. government and agency securities [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US">U S Treasury Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US">U.S. Treasury security [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsMember" xlink:label="us-gaap_InvestmentsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsMember" xlink:to="us-gaap_InvestmentsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsMember_lbl" xml:lang="en-US">Investments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsMember_lbl" xml:lang="en-US">Investments [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US">Corporate Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US">Corporate debt securities [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:label="pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:to="pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_lbl" xml:lang="en-US">US Government Corporations and Agencies Securities, , Not Included with Cash and Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Us Government Corporations And Agencies Securities Not Included With Cash And Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_lbl" xml:lang="en-US">U.S. government &amp; agency securities, not included with cash and cash equivalents [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US">Liability Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContingentConsiderationMember" xlink:label="pacb_ContingentConsiderationMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ContingentConsiderationMember" xlink:to="pacb_ContingentConsiderationMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ContingentConsiderationMember_lbl" xml:lang="en-US">Contingent consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ContingentConsiderationMember_lbl" xml:lang="en-US">Contingent Consideration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ContingentConsiderationMember_lbl" xml:lang="en-US">Contingent consideration [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">Cash And Cash Equivalents Fair Value Disclosure</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US">Investments Fair Value Disclosure</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:label="pacb_ShortTermRestrictedCashFairValueDisclosure"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:to="pacb_ShortTermRestrictedCashFairValueDisclosure_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ShortTermRestrictedCashFairValueDisclosure_lbl" xml:lang="en-US">Short-Term Restricted Cash Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ShortTermRestrictedCashFairValueDisclosure_lbl" xml:lang="en-US">Short-Term Restricted Cash Fair Value Disclosure</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_LongTermRestrictedCashFairValueDisclosure" xlink:label="pacb_LongTermRestrictedCashFairValueDisclosure"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_LongTermRestrictedCashFairValueDisclosure" xlink:to="pacb_LongTermRestrictedCashFairValueDisclosure_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_LongTermRestrictedCashFairValueDisclosure_lbl" xml:lang="en-US">Long-Term Restricted Cash Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_LongTermRestrictedCashFairValueDisclosure_lbl" xml:lang="en-US">Long Term Restricted Cash Fair Value Disclosure</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Assets Fair Value Disclosure</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Liabilities Fair Value Disclosure</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US">Schedule Of Available For Sale Securities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Fair Value, Option, Eligible Item or Group [Domain]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CashCashEquivalentsAndInvestmentsMember" xlink:label="pacb_CashCashEquivalentsAndInvestmentsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_CashCashEquivalentsAndInvestmentsMember" xlink:to="pacb_CashCashEquivalentsAndInvestmentsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_CashCashEquivalentsAndInvestmentsMember_lbl" xml:lang="en-US">Cash, Cash Equivalents and Investments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_CashCashEquivalentsAndInvestmentsMember_lbl" xml:lang="en-US">Cash Cash Equivalents And Investments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_CashCashEquivalentsAndInvestmentsMember_lbl" xml:lang="en-US">Cash, cash equivalents and investments [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Commercial Paper Not Included With Cash And Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Commercial paper, not included with cash and cash equivalents [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ShortTermRestrictedCashMember" xlink:label="pacb_ShortTermRestrictedCashMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ShortTermRestrictedCashMember" xlink:to="pacb_ShortTermRestrictedCashMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ShortTermRestrictedCashMember_lbl" xml:lang="en-US">Short-Term Restricted Cash [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ShortTermRestrictedCashMember_lbl" xml:lang="en-US">Short Term Restricted Cash [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ShortTermRestrictedCashMember_lbl" xml:lang="en-US">Short-Term Restricted Cash [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_LongTermRestrictedCashMember" xlink:label="pacb_LongTermRestrictedCashMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_LongTermRestrictedCashMember" xlink:to="pacb_LongTermRestrictedCashMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_LongTermRestrictedCashMember_lbl" xml:lang="en-US">Long-Term Restricted Cash [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_LongTermRestrictedCashMember_lbl" xml:lang="en-US">Long Term Restricted Cash [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_LongTermRestrictedCashMember_lbl" xml:lang="en-US">Long-term restricted cash [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US">Schedule Of Available For Sale Securities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Available For Sale Securities Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Amortized cost</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments" xlink:label="pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments" xlink:to="pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments_lbl" xml:lang="en-US">Amount of accumulated pre-tax unrealized gain before deducting pre-tax unrealized losses on investments in available-for-sale securities impacting investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments_lbl" xml:lang="en-US">Available For Sale Securities Gross Unrealized Gain Accumulated In Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments_lbl" xml:lang="en-US">Gross unrealized gains</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:label="pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:to="pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments_lbl" xml:lang="en-US">Amount of accumulated pre-tax unrealized loss before deducting pre-tax unrealized gain on investments in available-for-sale securities impacting investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments_lbl" xml:lang="en-US">Available For Sale Securities Gross Unrealized Loss Accumulated In Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments_lbl" xml:lang="en-US">Gross unrealized losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Available For Sale Securities Debt Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Total investments in debt securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Total investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US">Available-for-sale Securities, Debt Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US">Due in one year or less</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xml:lang="en-US">Available-for-sale Securities, Debt Securities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xml:lang="en-US">Due after one year through 5 years</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfBalanceSheetComponentsTable" xlink:label="pacb_ScheduleOfBalanceSheetComponentsTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable" xlink:to="pacb_ScheduleOfBalanceSheetComponentsTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ScheduleOfBalanceSheetComponentsTable_lbl" xml:lang="en-US">Schedule of Balance Sheet Components [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ScheduleOfBalanceSheetComponentsTable_lbl" xml:lang="en-US">Schedule of Balance Sheet Components [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ServiceContractMember" xlink:label="pacb_ServiceContractMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ServiceContractMember" xlink:to="pacb_ServiceContractMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ServiceContractMember_lbl" xml:lang="en-US">Service contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ServiceContractMember_lbl" xml:lang="en-US">Service Contract [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ServiceContractMember_lbl" xml:lang="en-US">Service contract [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ServiceMember_lbl" xml:lang="en-US">Service [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ServiceMember_lbl" xml:lang="en-US">Service [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ObrienLeaseAgreementMember" xlink:label="pacb_ObrienLeaseAgreementMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ObrienLeaseAgreementMember" xlink:to="pacb_ObrienLeaseAgreementMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ObrienLeaseAgreementMember_lbl" xml:lang="en-US">O&#8217;Brien Lease Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ObrienLeaseAgreementMember_lbl" xml:lang="en-US">Obrien Lease Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ObrienLeaseAgreementMember_lbl" xml:lang="en-US">O&#8217;Brien Lease Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_BalanceSheetComponentsLineItems" xlink:label="pacb_BalanceSheetComponentsLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_BalanceSheetComponentsLineItems" xlink:to="pacb_BalanceSheetComponentsLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_BalanceSheetComponentsLineItems_lbl" xml:lang="en-US">Balance Sheet Components [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_BalanceSheetComponentsLineItems_lbl" xml:lang="en-US">Balance Sheet Components [Line Items]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PercentageOfFeeToPrepayDebt" xlink:label="pacb_PercentageOfFeeToPrepayDebt"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_PercentageOfFeeToPrepayDebt" xlink:to="pacb_PercentageOfFeeToPrepayDebt_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_PercentageOfFeeToPrepayDebt_lbl" xml:lang="en-US">Percentage of fee of the outstanding debt to prepay the debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_PercentageOfFeeToPrepayDebt_lbl" xml:lang="en-US">Percentage of fee to prepay debt</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AnnualDecreaseInLongTermRestrictedCash" xlink:label="pacb_AnnualDecreaseInLongTermRestrictedCash"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_AnnualDecreaseInLongTermRestrictedCash" xlink:to="pacb_AnnualDecreaseInLongTermRestrictedCash_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_AnnualDecreaseInLongTermRestrictedCash_lbl" xml:lang="en-US">Annual Decrease in Long-Term Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_AnnualDecreaseInLongTermRestrictedCash_lbl" xml:lang="en-US">Annual Decrease in Long-Term Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_AnnualDecreaseInLongTermRestrictedCash_lbl" xml:lang="en-US">May 1 annual decrease to long-term restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Revenue recognized</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:label="pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:to="pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_lbl" xml:lang="en-US">Contract with Customer, Liability, Noncurrent, Recognition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_lbl" xml:lang="en-US">Contract with Customer, Liability, Noncurrent, Recognition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_lbl" xml:lang="en-US">Deferred service revenue, noncurrent, recognition period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Long Term Notes Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseBorrowings" xlink:to="us-gaap_InterestExpenseBorrowings_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xml:lang="en-US">Interest Expense, Borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xml:lang="en-US">Interest Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl" xml:lang="en-US">Short term debt acquired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_lbl" xml:lang="en-US">Long-term debt acquired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt Instrument, Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory Raw Materials Net Of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Purchased materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory Work In Process Net Of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory Finished Goods Net Of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_LaboratoryEquipmentAndMachineryMember" xlink:label="pacb_LaboratoryEquipmentAndMachineryMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_LaboratoryEquipmentAndMachineryMember" xlink:to="pacb_LaboratoryEquipmentAndMachineryMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_LaboratoryEquipmentAndMachineryMember_lbl" xml:lang="en-US">Laboratory Equipment And Machinery [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_LaboratoryEquipmentAndMachineryMember_lbl" xml:lang="en-US">Laboratory Equipment And Machinery [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_LaboratoryEquipmentAndMachineryMember_lbl" xml:lang="en-US">Laboratory Equipment And Machinery [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction In Progress [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in Progress [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_ScheduleOfGoodwillTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTable_lbl" xml:lang="en-US">Schedule of Goodwill [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillLineItems_lbl" xml:lang="en-US">Goodwill [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod_lbl" xml:lang="en-US">Goodwill, Acquired During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod_lbl" xml:lang="en-US">Acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Net Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Estimated Useful Life (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">2027 and thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Employee Benefits, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Salaries and benefits</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AccruedProductDevelopmentCostsCurrent" xlink:label="pacb_AccruedProductDevelopmentCostsCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_AccruedProductDevelopmentCostsCurrent" xlink:to="pacb_AccruedProductDevelopmentCostsCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_AccruedProductDevelopmentCostsCurrent_lbl" xml:lang="en-US">Accrued Product Development Costs, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_AccruedProductDevelopmentCostsCurrent_lbl" xml:lang="en-US">Accrued Product Development Costs, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_AccruedProductDevelopmentCostsCurrent_lbl" xml:lang="en-US">Accrued product development costs</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AccruedTenantImprovementsCurrent" xlink:label="pacb_AccruedTenantImprovementsCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_AccruedTenantImprovementsCurrent" xlink:to="pacb_AccruedTenantImprovementsCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_AccruedTenantImprovementsCurrent_lbl" xml:lang="en-US">Accrued Tenant Improvements, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_AccruedTenantImprovementsCurrent_lbl" xml:lang="en-US">Accrued Tenant Improvements, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_AccruedTenantImprovementsCurrent_lbl" xml:lang="en-US">Accrued interest payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductLiabilityContingencyAccrualPresentValue" xlink:label="us-gaap_ProductLiabilityContingencyAccrualPresentValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyAccrualPresentValue" xlink:to="us-gaap_ProductLiabilityContingencyAccrualPresentValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyAccrualPresentValue_lbl" xml:lang="en-US">Product Liability Contingency, Accrual, Present Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductLiabilityContingencyAccrualPresentValue_lbl" xml:lang="en-US">Inventory accrual</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="us-gaap_ProductWarrantyAccrualClassifiedCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent_lbl" xml:lang="en-US">Warranty</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional services and legal fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Net carrying amount</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" xlink:label="pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" xlink:to="pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_lbl" xml:lang="en-US">Accrued Employee Stock Purchase Plan Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_lbl" xml:lang="en-US">Accrued Employee Stock Purchase Plan Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_lbl" xml:lang="en-US">Accrued ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent_lbl" xml:lang="en-US">Other Sundry Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EachDayDuringFirst180DaysMember" xlink:label="pacb_EachDayDuringFirst180DaysMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_EachDayDuringFirst180DaysMember" xlink:to="pacb_EachDayDuringFirst180DaysMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_EachDayDuringFirst180DaysMember_lbl" xml:lang="en-US">Each Day During the First 180 Days [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_EachDayDuringFirst180DaysMember_lbl" xml:lang="en-US">Each Day During First180 Days [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_EachDayDuringFirst180DaysMember_lbl" xml:lang="en-US">Each Day During the First 180 Days [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OneHundredAndEightyFirstDayTo360thDayMember" xlink:label="pacb_OneHundredAndEightyFirstDayTo360thDayMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_OneHundredAndEightyFirstDayTo360thDayMember" xlink:to="pacb_OneHundredAndEightyFirstDayTo360thDayMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_OneHundredAndEightyFirstDayTo360thDayMember_lbl" xml:lang="en-US">One Hundred and Eighty-First Day to 360th Day [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_OneHundredAndEightyFirstDayTo360thDayMember_lbl" xml:lang="en-US">One Hundred And Eighty First Day To360th Day [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_OneHundredAndEightyFirstDayTo360thDayMember_lbl" xml:lang="en-US">181st Day to 360th Day [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="us-gaap_DebtInstrumentIssuanceDate1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuanceDate1" xlink:to="us-gaap_DebtInstrumentIssuanceDate1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuanceDate1_lbl" xml:lang="en-US">Debt Instrument, Issuance Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIssuanceDate1_lbl" xml:lang="en-US">Issuance date</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount" xlink:label="pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount" xlink:to="pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount_lbl" xml:lang="en-US">Debt Instrument, Conversion Rate, Shares Issued Per Stated Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount_lbl" xml:lang="en-US">Debt Instrument, Conversion Rate, Shares Issued Per Stated Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount_lbl" xml:lang="en-US">Shares issued conversion rate per $1,000 principal amount</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentStatedPrincipalAmountForConversionRate" xlink:label="pacb_DebtInstrumentStatedPrincipalAmountForConversionRate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_DebtInstrumentStatedPrincipalAmountForConversionRate" xlink:to="pacb_DebtInstrumentStatedPrincipalAmountForConversionRate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_DebtInstrumentStatedPrincipalAmountForConversionRate_lbl" xml:lang="en-US">Debt Instrument, Stated Principal Amount for Conversion Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_DebtInstrumentStatedPrincipalAmountForConversionRate_lbl" xml:lang="en-US">Debt Instrument, Stated Principal Amount for Conversion Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_DebtInstrumentStatedPrincipalAmountForConversionRate_lbl" xml:lang="en-US">Principal amount for conversion rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price per share</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:label="pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:to="pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_lbl" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_lbl" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_lbl" xml:lang="en-US">Debt redemption, percentage of conversion price</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:label="pacb_DebtInstrumentRedemptionPriceTradingDays"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:to="pacb_DebtInstrumentRedemptionPriceTradingDays_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_DebtInstrumentRedemptionPriceTradingDays_lbl" xml:lang="en-US">Debt Instrument, Redemption Price, Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_DebtInstrumentRedemptionPriceTradingDays_lbl" xml:lang="en-US">Debt Instrument, Redemption Price, Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_DebtInstrumentRedemptionPriceTradingDays_lbl" xml:lang="en-US">Debt redemption, trading days</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:label="pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:to="pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_lbl" xml:lang="en-US">Debt Instrument, Redemption Price, Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_lbl" xml:lang="en-US">Debt Instrument, Redemption Price, Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_lbl" xml:lang="en-US">Debt redemption, consecutive trading days</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xml:lang="en-US">Redemption price, percentage</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:label="pacb_DebtInstrumentAdditionalInterestInEventOfDefault"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:to="pacb_DebtInstrumentAdditionalInterestInEventOfDefault_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_DebtInstrumentAdditionalInterestInEventOfDefault_lbl" xml:lang="en-US">Debt Instrument, Additional Interest in the Event of Default</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_DebtInstrumentAdditionalInterestInEventOfDefault_lbl" xml:lang="en-US">Debt Instrument, Additional Interest in the Event of Default</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_DebtInstrumentAdditionalInterestInEventOfDefault_lbl" xml:lang="en-US">Additional interest in the event of default</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US">Debt Issuance Costs, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US">Debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt instrument, effective interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Fair value of convertible debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Principal amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Unamortized debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContractualInterestExpense" xlink:label="pacb_ContractualInterestExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ContractualInterestExpense" xlink:to="pacb_ContractualInterestExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ContractualInterestExpense_lbl" xml:lang="en-US">Contractual Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ContractualInterestExpense_lbl" xml:lang="en-US">Contractual Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ContractualInterestExpense_lbl" xml:lang="en-US">Contractual interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Total interest expense</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CommitmentsAndContingenciesTable" xlink:label="pacb_CommitmentsAndContingenciesTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_CommitmentsAndContingenciesTable" xlink:to="pacb_CommitmentsAndContingenciesTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US">Commitments and Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US">Commitments and Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CommitmentsAndContingenciesLineItems" xlink:label="pacb_CommitmentsAndContingenciesLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_CommitmentsAndContingenciesLineItems" xlink:to="pacb_CommitmentsAndContingenciesLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Renewal term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Payments for Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:label="pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:to="pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_lbl" xml:lang="en-US">Additional Liability Associated With Indemnification Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_lbl" xml:lang="en-US">Additional Liability Associated With Indemnification Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_lbl" xml:lang="en-US">Additional liability associated with indemnification obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Maturity of Lease Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted operating lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_BalanceSheetClassificationAbstract" xlink:label="pacb_BalanceSheetClassificationAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_BalanceSheetClassificationAbstract" xlink:to="pacb_BalanceSheetClassificationAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_BalanceSheetClassificationAbstract_lbl" xml:lang="en-US">Balance Sheet Classification [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_BalanceSheetClassificationAbstract_lbl" xml:lang="en-US">Balance Sheet Classification [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_BalanceSheetClassificationAbstract_lbl" xml:lang="en-US">Balance Sheet Classification</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_IncomeTaxesTable" xlink:label="pacb_IncomeTaxesTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_IncomeTaxesTable" xlink:to="pacb_IncomeTaxesTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_IncomeTaxesTable_lbl" xml:lang="en-US">Income Taxes [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_IncomeTaxesTable_lbl" xml:lang="en-US">Income Taxes [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Country [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Federal [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State And Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_WithExpirationMember" xlink:label="pacb_WithExpirationMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_WithExpirationMember" xlink:to="pacb_WithExpirationMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_WithExpirationMember_lbl" xml:lang="en-US">With Expiration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_WithExpirationMember_lbl" xml:lang="en-US">With Expiration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_WithExpirationMember_lbl" xml:lang="en-US">With Expiration [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_IncomeTaxesLineItems" xlink:label="pacb_IncomeTaxesLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_IncomeTaxesLineItems" xlink:to="pacb_IncomeTaxesLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_IncomeTaxesLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_IncomeTaxesLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Income (loss) before taxes from U.S. operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Income before taxes from foreign operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OperatingLossCarryforwardsExpirationYear" xlink:label="pacb_OperatingLossCarryforwardsExpirationYear"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_OperatingLossCarryforwardsExpirationYear" xlink:to="pacb_OperatingLossCarryforwardsExpirationYear_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US">Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYYformat.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US">Operating Loss Carryforwards, Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US">Net operating loss carryforward, expiration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Research and development credit carryforward</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TaxCreditCarryforwardExpirationYear" xlink:label="pacb_TaxCreditCarryforwardExpirationYear"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_TaxCreditCarryforwardExpirationYear" xlink:to="pacb_TaxCreditCarryforwardExpirationYear_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_TaxCreditCarryforwardExpirationYear_lbl" xml:lang="en-US">Expiration date of the tax credit carryforward, in CCYY format.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_TaxCreditCarryforwardExpirationYear_lbl" xml:lang="en-US">Tax Credit Carryforward, Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_TaxCreditCarryforwardExpirationYear_lbl" xml:lang="en-US">Research and development tax credit carryforward, expiration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefit, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefit, Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Total unrecognized tax benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US">Accrued interest or penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" xlink:label="pacb_EffectiveIncomeTaxRateReconciliationTaxCredit"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" xlink:to="pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit,</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_lbl" xml:lang="en-US">Tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" xlink:label="pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" xlink:to="pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Merger Expense, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Merger Expense, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_lbl" xml:lang="en-US">Merger Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xml:lang="en-US">Accruals and reserves</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="pacb_DeferredTaxAssetsOperatingLeaseLiabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="pacb_DeferredTaxAssetsOperatingLeaseLiabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US">ASC842 Operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Intangibles</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed assets</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="pacb_DeferredTaxLiabilitiesRightOfUseAssets"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="pacb_DeferredTaxLiabilitiesRightOfUseAssets_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US">Deferred Tax Liabilities, Right-of-use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US">Deferred Tax Liabilities, Right-of-use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pacb_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US">ASC842 Operating Lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Net deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">Increase in balance related to tax positions taken in prior year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">Decrease in balance related to tax positions taken in prior year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Increase in balance related to tax positions taken during current year</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_StockholdersEquityTable" xlink:label="pacb_StockholdersEquityTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_StockholdersEquityTable" xlink:to="pacb_StockholdersEquityTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_StockholdersEquityTable_lbl" xml:lang="en-US">Stockholders&apos; Equity [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_StockholdersEquityTable_lbl" xml:lang="en-US">Stockholders&apos; Equity [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember" xlink:label="pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember" xlink:to="pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember_lbl" xml:lang="en-US">Share-based Compensation Award, Tranche One, Two, Three and Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember_lbl" xml:lang="en-US">Share Based Compensation Award Tranche One Two Three And Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember_lbl" xml:lang="en-US">Share-based Compensation Award, Tranche One, Two, Three and Four [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OptionsToPurchaseCommonStockMember" xlink:label="pacb_OptionsToPurchaseCommonStockMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_OptionsToPurchaseCommonStockMember" xlink:to="pacb_OptionsToPurchaseCommonStockMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_OptionsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Options to purchase common stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_OptionsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Options To Purchase Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_OptionsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Options to purchase common stock [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:label="pacb_TimeBasedRestrictedStockUnitsRsusMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:to="pacb_TimeBasedRestrictedStockUnitsRsusMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_TimeBasedRestrictedStockUnitsRsusMember_lbl" xml:lang="en-US">Time-Based Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_TimeBasedRestrictedStockUnitsRsusMember_lbl" xml:lang="en-US">Time Based Restricted Stock Units Rsus [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_TimeBasedRestrictedStockUnitsRsusMember_lbl" xml:lang="en-US">RSUs with time-based vesting [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_UnderwrittenPublicEquityOfferingMember" xlink:label="pacb_UnderwrittenPublicEquityOfferingMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_UnderwrittenPublicEquityOfferingMember" xlink:to="pacb_UnderwrittenPublicEquityOfferingMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_UnderwrittenPublicEquityOfferingMember_lbl" xml:lang="en-US">Underwritten Public Equity Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_UnderwrittenPublicEquityOfferingMember_lbl" xml:lang="en-US">Underwritten Public Equity Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_UnderwrittenPublicEquityOfferingMember_lbl" xml:lang="en-US">Underwritten Public Equity Offering [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_UnderwritingAgreementMember" xlink:label="pacb_UnderwritingAgreementMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_UnderwritingAgreementMember" xlink:to="pacb_UnderwritingAgreementMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_UnderwritingAgreementMember_lbl" xml:lang="en-US">Underwriting Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_UnderwritingAgreementMember_lbl" xml:lang="en-US">Underwriting Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_UnderwritingAgreementMember_lbl" xml:lang="en-US">Underwriting Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl" xml:lang="en-US">Equity Based Arrangements Individual Contracts Type Of Deferred Compensation [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomePlanMember" xlink:label="pacb_OmniomePlanMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_OmniomePlanMember" xlink:to="pacb_OmniomePlanMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_OmniomePlanMember_lbl" xml:lang="en-US">Omniome Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_OmniomePlanMember_lbl" xml:lang="en-US">Omniome Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_OmniomePlanMember_lbl" xml:lang="en-US">Omniome Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TwoThousandTenEquityIncentivePlanMember" xlink:label="pacb_TwoThousandTenEquityIncentivePlanMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_TwoThousandTenEquityIncentivePlanMember" xlink:to="pacb_TwoThousandTenEquityIncentivePlanMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_TwoThousandTenEquityIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand Ten Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_TwoThousandTenEquityIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand Ten Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_TwoThousandTenEquityIncentivePlanMember_lbl" xml:lang="en-US">2010 Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EmployeeStockPurchasePlanMember" xlink:label="pacb_EmployeeStockPurchasePlanMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_EmployeeStockPurchasePlanMember" xlink:to="pacb_EmployeeStockPurchasePlanMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">ESPP [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EquityIncentivePlan2020Member" xlink:label="pacb_EquityIncentivePlan2020Member"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_EquityIncentivePlan2020Member" xlink:to="pacb_EquityIncentivePlan2020Member_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_EquityIncentivePlan2020Member_lbl" xml:lang="en-US">2020 Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_EquityIncentivePlan2020Member_lbl" xml:lang="en-US">Equity Incentive Plan2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_EquityIncentivePlan2020Member_lbl" xml:lang="en-US">2020 Equity Incentive Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InducementEquityIncentivePlan2020Member" xlink:label="pacb_InducementEquityIncentivePlan2020Member"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_InducementEquityIncentivePlan2020Member" xlink:to="pacb_InducementEquityIncentivePlan2020Member_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_InducementEquityIncentivePlan2020Member_lbl" xml:lang="en-US">2020 Inducement Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_InducementEquityIncentivePlan2020Member_lbl" xml:lang="en-US">Inducement Equity Incentive Plan2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_InducementEquityIncentivePlan2020Member_lbl" xml:lang="en-US">2020 Inducement Equity Incentive Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PrivatePlacementOfCommonStockMember" xlink:label="pacb_PrivatePlacementOfCommonStockMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_PrivatePlacementOfCommonStockMember" xlink:to="pacb_PrivatePlacementOfCommonStockMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_PrivatePlacementOfCommonStockMember_lbl" xml:lang="en-US">Private Placement of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_PrivatePlacementOfCommonStockMember_lbl" xml:lang="en-US">Private Placement Of Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_PrivatePlacementOfCommonStockMember_lbl" xml:lang="en-US">Private Placement of Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_StockholdersEquityLineItems" xlink:label="pacb_StockholdersEquityLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_StockholdersEquityLineItems" xlink:to="pacb_StockholdersEquityLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_StockholdersEquityLineItems_lbl" xml:lang="en-US">Stockholders&apos; Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_StockholdersEquityLineItems_lbl" xml:lang="en-US">Stockholders&apos; Equity [Line Items]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExchangeRatio" xlink:label="pacb_ExchangeRatio"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ExchangeRatio" xlink:to="pacb_ExchangeRatio_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ExchangeRatio_lbl" xml:lang="en-US">The relative number of new shares that will be given to existing shareholders of a company that has been acquired or that has merged with another.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ExchangeRatio_lbl" xml:lang="en-US">Exchange ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xml:lang="en-US">Common stock, dividends declared</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Common Stock, Voting Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Voting right of common stock share holders</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" xlink:label="pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" xlink:to="pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_lbl" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes Per Share Owned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_lbl" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes Per Share Owned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_lbl" xml:lang="en-US">Voting right of common stock share holders, number of votes</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PublicOfferingShares" xlink:label="pacb_PublicOfferingShares"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_PublicOfferingShares" xlink:to="pacb_PublicOfferingShares_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_PublicOfferingShares_lbl" xml:lang="en-US">Public Offering, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_PublicOfferingShares_lbl" xml:lang="en-US">Public Offering, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_PublicOfferingShares_lbl" xml:lang="en-US">Public offering</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OfferingShareAmountMaximum" xlink:label="pacb_OfferingShareAmountMaximum"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_OfferingShareAmountMaximum" xlink:to="pacb_OfferingShareAmountMaximum_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_OfferingShareAmountMaximum_lbl" xml:lang="en-US">Offering Share Amount Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_OfferingShareAmountMaximum_lbl" xml:lang="en-US">Offering Share Amount Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_OfferingShareAmountMaximum_lbl" xml:lang="en-US">Common stock offering price per share</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:label="pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:to="pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_lbl" xml:lang="en-US">Public Offering, Option to Purchase Additional Shares, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_lbl" xml:lang="en-US">Public Offering, Option to Purchase Additional Shares, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_lbl" xml:lang="en-US">Public offering, option to purchase additional shares, period</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:label="pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:to="pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_lbl" xml:lang="en-US">Public Offering, Option to Purchase Additional Shares, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_lbl" xml:lang="en-US">Public Offering, Option to Purchase Additional Shares, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_lbl" xml:lang="en-US">Public offering, option to purchase additional shares, shares</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:label="pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:to="pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_lbl" xml:lang="en-US">Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_lbl" xml:lang="en-US">Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_lbl" xml:lang="en-US">Commissions, percentage of gross proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Offering costs</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_NumberOfOfferings" xlink:label="pacb_NumberOfOfferings"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_NumberOfOfferings" xlink:to="pacb_NumberOfOfferings_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_NumberOfOfferings_lbl" xml:lang="en-US">Number of Offerings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_NumberOfOfferings_lbl" xml:lang="en-US">Number of Offerings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_NumberOfOfferings_lbl" xml:lang="en-US">Number of offerings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional common stock reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Common stock remain available for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US">Percentage of outstanding common stock used to determine annual plan increase</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_NumberOfPurchasePeriods" xlink:label="pacb_NumberOfPurchasePeriods"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_NumberOfPurchasePeriods" xlink:to="pacb_NumberOfPurchasePeriods_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_NumberOfPurchasePeriods_lbl" xml:lang="en-US">Number of purchase periods.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_NumberOfPurchasePeriods_lbl" xml:lang="en-US">Number Of Purchase Periods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_NumberOfPurchasePeriods_lbl" xml:lang="en-US">Number of purchase periods</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PurchasePeriodOfEmployeeStockPurchasePlan" xlink:label="pacb_PurchasePeriodOfEmployeeStockPurchasePlan"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_PurchasePeriodOfEmployeeStockPurchasePlan" xlink:to="pacb_PurchasePeriodOfEmployeeStockPurchasePlan_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_PurchasePeriodOfEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Purchase period of employee stock purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_PurchasePeriodOfEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Purchase Period Of Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_PurchasePeriodOfEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Purchase period of ESPP</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" xlink:label="pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" xlink:to="pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_lbl" xml:lang="en-US">Percentage of fair market value at which stock can be purchased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_lbl" xml:lang="en-US">Percentage Of Fair Market Value At Which Stock Can Be Purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_lbl" xml:lang="en-US">Percentage of fair market value at which stock can be purchased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Options expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options expired, weighted average exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value exercisable options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average remaining contractual life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested and expected to vest, outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Vested and expected to vest, aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested and expected to vest, weighted average exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Vested and expected to vest, weighted average remaining contractual life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Total intrinsic value of options exercised</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ShareInstrumentNumberOfSharesConversionRatio" xlink:label="pacb_ShareInstrumentNumberOfSharesConversionRatio"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ShareInstrumentNumberOfSharesConversionRatio" xlink:to="pacb_ShareInstrumentNumberOfSharesConversionRatio_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ShareInstrumentNumberOfSharesConversionRatio_lbl" xml:lang="en-US">Number of shares into which the share instrument may be converted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ShareInstrumentNumberOfSharesConversionRatio_lbl" xml:lang="en-US">Share Instrument, Number of Shares, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ShareInstrumentNumberOfSharesConversionRatio_lbl" xml:lang="en-US">Ratio of number of shares into which the share instrument may be converted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vesting percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xml:lang="en-US">Stock-based compensation cost capitalized in inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Ownership Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Common stock purchased under plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Cash received from option exercises</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeOneMember" xlink:label="pacb_ExercisePriceRangeOneMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ExercisePriceRangeOneMember" xlink:to="pacb_ExercisePriceRangeOneMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ExercisePriceRangeOneMember_lbl" xml:lang="en-US">Exercise price range one member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ExercisePriceRangeOneMember_lbl" xml:lang="en-US">Exercise Price Range One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ExercisePriceRangeOneMember_lbl" xml:lang="en-US">$1.16 &#8211; 20.90 [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeTwoMember" xlink:label="pacb_ExercisePriceRangeTwoMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ExercisePriceRangeTwoMember" xlink:to="pacb_ExercisePriceRangeTwoMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US">Exercise price range two member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US">Exercise Price Range Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US">$23.06 &#8211; 46.37 [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeAcqusitionMember" xlink:label="pacb_ExercisePriceRangeAcqusitionMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ExercisePriceRangeAcqusitionMember" xlink:to="pacb_ExercisePriceRangeAcqusitionMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ExercisePriceRangeAcqusitionMember_lbl" xml:lang="en-US">Exercise Price Range related to Omniome acqusition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ExercisePriceRangeAcqusitionMember_lbl" xml:lang="en-US">Exercise Price Range Acqusition [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ExercisePriceRangeAcqusitionMember_lbl" xml:lang="en-US">$2.05 &#8211; $4.90 [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeAcqusitionTwoMember" xlink:label="pacb_ExercisePriceRangeAcqusitionTwoMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ExercisePriceRangeAcqusitionTwoMember" xlink:to="pacb_ExercisePriceRangeAcqusitionTwoMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ExercisePriceRangeAcqusitionTwoMember_lbl" xml:lang="en-US">Exercise Price Range Acqusition two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ExercisePriceRangeAcqusitionTwoMember_lbl" xml:lang="en-US">Exercise Price Range Acqusition Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ExercisePriceRangeAcqusitionTwoMember_lbl" xml:lang="en-US">$4.71 - $4.90 [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeThreeMember" xlink:label="pacb_ExercisePriceRangeThreeMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ExercisePriceRangeThreeMember" xlink:to="pacb_ExercisePriceRangeThreeMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ExercisePriceRangeThreeMember_lbl" xml:lang="en-US">Exercise price range three member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ExercisePriceRangeThreeMember_lbl" xml:lang="en-US">Exercise Price Range Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ExercisePriceRangeThreeMember_lbl" xml:lang="en-US">$1.16 &#8211; 15.98 [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeFourMember" xlink:label="pacb_ExercisePriceRangeFourMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ExercisePriceRangeFourMember" xlink:to="pacb_ExercisePriceRangeFourMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ExercisePriceRangeFourMember_lbl" xml:lang="en-US">Exercise price range four member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ExercisePriceRangeFourMember_lbl" xml:lang="en-US">Exercise Price Range Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ExercisePriceRangeFourMember_lbl" xml:lang="en-US">$2.54 &#8211; 46.37 [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeFiveMember" xlink:label="pacb_ExercisePriceRangeFiveMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ExercisePriceRangeFiveMember" xlink:to="pacb_ExercisePriceRangeFiveMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ExercisePriceRangeFiveMember_lbl" xml:lang="en-US">Exercise price range five member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ExercisePriceRangeFiveMember_lbl" xml:lang="en-US">Exercise Price Range Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ExercisePriceRangeFiveMember_lbl" xml:lang="en-US">$1.16 &#8211; 46.37 [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TimeBasedStockOptionMember" xlink:label="pacb_TimeBasedStockOptionMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_TimeBasedStockOptionMember" xlink:to="pacb_TimeBasedStockOptionMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_TimeBasedStockOptionMember_lbl" xml:lang="en-US">Time-based stock option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_TimeBasedStockOptionMember_lbl" xml:lang="en-US">Time Based Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_TimeBasedStockOptionMember_lbl" xml:lang="en-US">Time-based stock option [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, Outstanding at December 31, 2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, Outstanding at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period Shares Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of shares, Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of shares, Canceled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Exercise price, lower range</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Exercise price, upper range</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding at December 31, 2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Canceled</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeSixMember" xlink:label="pacb_ExercisePriceRangeSixMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ExercisePriceRangeSixMember" xlink:to="pacb_ExercisePriceRangeSixMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ExercisePriceRangeSixMember_lbl" xml:lang="en-US">Exercise price range six member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ExercisePriceRangeSixMember_lbl" xml:lang="en-US">Exercise Price Range Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ExercisePriceRangeSixMember_lbl" xml:lang="en-US">$0.00 &#8211; 4.64 [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeSevenMember" xlink:label="pacb_ExercisePriceRangeSevenMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ExercisePriceRangeSevenMember" xlink:to="pacb_ExercisePriceRangeSevenMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ExercisePriceRangeSevenMember_lbl" xml:lang="en-US">Exercise price range seven member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ExercisePriceRangeSevenMember_lbl" xml:lang="en-US">Exercise Price Range Seven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ExercisePriceRangeSevenMember_lbl" xml:lang="en-US">$4.64 - 9.27 [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeEightMember" xlink:label="pacb_ExercisePriceRangeEightMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ExercisePriceRangeEightMember" xlink:to="pacb_ExercisePriceRangeEightMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ExercisePriceRangeEightMember_lbl" xml:lang="en-US">Exercise price range eight member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ExercisePriceRangeEightMember_lbl" xml:lang="en-US">Exercise Price Range Eight [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ExercisePriceRangeEightMember_lbl" xml:lang="en-US">$9.27 - 13.91 [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeNineMember" xlink:label="pacb_ExercisePriceRangeNineMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ExercisePriceRangeNineMember" xlink:to="pacb_ExercisePriceRangeNineMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ExercisePriceRangeNineMember_lbl" xml:lang="en-US">Exercise Price Range Nine [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ExercisePriceRangeNineMember_lbl" xml:lang="en-US">Exercise Price Range Nine [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ExercisePriceRangeNineMember_lbl" xml:lang="en-US">$13.91 - 18.55 [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeTenMember" xlink:label="pacb_ExercisePriceRangeTenMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ExercisePriceRangeTenMember" xlink:to="pacb_ExercisePriceRangeTenMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ExercisePriceRangeTenMember_lbl" xml:lang="en-US">Exercise Price Range Ten [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ExercisePriceRangeTenMember_lbl" xml:lang="en-US">Exercise Price Range Ten [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ExercisePriceRangeTenMember_lbl" xml:lang="en-US">$18.55 - 23.19 [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeElevenMember" xlink:label="pacb_ExercisePriceRangeElevenMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ExercisePriceRangeElevenMember" xlink:to="pacb_ExercisePriceRangeElevenMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ExercisePriceRangeElevenMember_lbl" xml:lang="en-US">Exercise Price Range Eleven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ExercisePriceRangeElevenMember_lbl" xml:lang="en-US">Exercise Price Range Eleven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ExercisePriceRangeElevenMember_lbl" xml:lang="en-US">$23.19 - 27.82[Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeThirteenMember" xlink:label="pacb_ExercisePriceRangeThirteenMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ExercisePriceRangeThirteenMember" xlink:to="pacb_ExercisePriceRangeThirteenMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ExercisePriceRangeThirteenMember_lbl" xml:lang="en-US">Exercise Price Range Thirteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ExercisePriceRangeThirteenMember_lbl" xml:lang="en-US">Exercise Price Range Thirteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ExercisePriceRangeThirteenMember_lbl" xml:lang="en-US">$27.82 - 32.46 [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeFourteenMember" xlink:label="pacb_ExercisePriceRangeFourteenMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ExercisePriceRangeFourteenMember" xlink:to="pacb_ExercisePriceRangeFourteenMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ExercisePriceRangeFourteenMember_lbl" xml:lang="en-US">Exercise Price Range Fourteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ExercisePriceRangeFourteenMember_lbl" xml:lang="en-US">Exercise Price Range Fourteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ExercisePriceRangeFourteenMember_lbl" xml:lang="en-US">$32.46 - 37.10 [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeFifteenMember" xlink:label="pacb_ExercisePriceRangeFifteenMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ExercisePriceRangeFifteenMember" xlink:to="pacb_ExercisePriceRangeFifteenMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ExercisePriceRangeFifteenMember_lbl" xml:lang="en-US">Exercise Price Range Fifteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ExercisePriceRangeFifteenMember_lbl" xml:lang="en-US">Exercise Price Range Fifteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ExercisePriceRangeFifteenMember_lbl" xml:lang="en-US">$41.73 - 46.37 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (Years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted average exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted average exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares, Outstanding at December 31, 2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares, Outstanding at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of shares, Released</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of shares, Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Outstanding at December 31, 2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Outstanding at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Released</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Forfeited</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PerformanceBasedRestrictedStockUnitsRsusMember" xlink:label="pacb_PerformanceBasedRestrictedStockUnitsRsusMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_PerformanceBasedRestrictedStockUnitsRsusMember" xlink:to="pacb_PerformanceBasedRestrictedStockUnitsRsusMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_PerformanceBasedRestrictedStockUnitsRsusMember_lbl" xml:lang="en-US">Performance-Based Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_PerformanceBasedRestrictedStockUnitsRsusMember_lbl" xml:lang="en-US">Performance Based Restricted Stock Units Rsus [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_PerformanceBasedRestrictedStockUnitsRsusMember_lbl" xml:lang="en-US">RSUs with performance-based vesting [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost Of Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of revenue [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling General And Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Sales, general and administrative [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term in years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, maximum</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfEarningsPerShareTable" xlink:label="pacb_ScheduleOfEarningsPerShareTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ScheduleOfEarningsPerShareTable" xlink:to="pacb_ScheduleOfEarningsPerShareTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ScheduleOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ScheduleOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfEarningsPerShareLineItems" xlink:label="pacb_ScheduleOfEarningsPerShareLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ScheduleOfEarningsPerShareLineItems" xlink:to="pacb_ScheduleOfEarningsPerShareLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ScheduleOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ScheduleOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US">Weighted Average Number Of Shares Outstanding Diluted Disclosure Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US">Computation of basic and diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net Income Loss [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Numerator</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Add: weighted average</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember" xlink:label="pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember" xlink:to="pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember_lbl" xml:lang="en-US">Shares issuable upon conversion of convertible senior notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember_lbl" xml:lang="en-US">Shares Issuable Upon Conversion Of Convertible Senior Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember_lbl" xml:lang="en-US">Shares issuable upon conversion of convertible senior notes [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from the computation of earnings per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Segment, Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NorthAmericaMember" xlink:to="srt_NorthAmericaMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NorthAmericaMember_lbl" xml:lang="en-US">North America [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_NorthAmericaMember_lbl" xml:lang="en-US">North America [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US">Europe [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US">Europe (including the Middle East and Africa) [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AsiaPacificMember" xlink:label="srt_AsiaPacificMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaPacificMember" xlink:to="srt_AsiaPacificMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AsiaPacificMember_lbl" xml:lang="en-US">Asia Pacific [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_AsiaPacificMember_lbl" xml:lang="en-US">Asia Pacific [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InstrumentMember" xlink:label="pacb_InstrumentMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_InstrumentMember" xlink:to="pacb_InstrumentMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_InstrumentMember_lbl" xml:lang="en-US">Instrument [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_InstrumentMember_lbl" xml:lang="en-US">Instrument [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_InstrumentMember_lbl" xml:lang="en-US">Instrument [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ConsumableMember" xlink:label="pacb_ConsumableMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_ConsumableMember" xlink:to="pacb_ConsumableMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_ConsumableMember_lbl" xml:lang="en-US">Consumable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_ConsumableMember_lbl" xml:lang="en-US">Consumable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_ConsumableMember_lbl" xml:lang="en-US">Consumable [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US">Type Of Adoption [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US">Type of Adoption [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201904Member" xlink:label="us-gaap_AccountingStandardsUpdate201904Member"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201904Member" xlink:to="us-gaap_AccountingStandardsUpdate201904Member_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201904Member_lbl" xml:lang="en-US">Accounting Standards Update201904 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate201904Member_lbl" xml:lang="en-US">Accounting Standards Update, Topic 326 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CirculomicsIncMember" xlink:label="pacb_CirculomicsIncMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_CirculomicsIncMember" xlink:to="pacb_CirculomicsIncMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_CirculomicsIncMember_lbl" xml:lang="en-US">Circulomics Inc. (&#8220;Circulomics&#8221;), a Maryland-based biotechnology company focused on delivering highly differentiated sample preparation products that enable genomic workflows.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_CirculomicsIncMember_lbl" xml:lang="en-US">Circulomics Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_CirculomicsIncMember_lbl" xml:lang="en-US">Circulomics, Inc [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_OmniomeIncMember" xlink:to="pacb_OmniomeIncMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_OmniomeIncMember_lbl" xml:lang="en-US">Omniome, Inc. (&#8220;Omniome&#8221;), a San Diego-based company developing a highly differentiated, proprietary short-read DNA sequencing platform capable of delivering high accuracy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_OmniomeIncMember_lbl" xml:lang="en-US">Omniome Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_OmniomeIncMember_lbl" xml:lang="en-US">Omniome, Inc [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TimeBasedStockOptionsMember" xlink:label="pacb_TimeBasedStockOptionsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_TimeBasedStockOptionsMember" xlink:to="pacb_TimeBasedStockOptionsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_TimeBasedStockOptionsMember_lbl" xml:lang="en-US">Time-based stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_TimeBasedStockOptionsMember_lbl" xml:lang="en-US">Time Based Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_TimeBasedStockOptionsMember_lbl" xml:lang="en-US">Time-based stock options [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance-based stock options [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite Lived Intangible Assets Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xml:lang="en-US">In Process Research And Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xml:lang="en-US">In Process Research and Development [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xml:lang="en-US">Developed Technology Rights [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xml:lang="en-US">Developed Technology [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xml:lang="en-US">Contingent Consideration by Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xml:lang="en-US">Contingent Consideration Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xml:lang="en-US">Contingent Consideration Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AchievementOfMilestoneMember" xlink:label="pacb_AchievementOfMilestoneMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_AchievementOfMilestoneMember" xlink:to="pacb_AchievementOfMilestoneMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_AchievementOfMilestoneMember_lbl" xml:lang="en-US">Upon achievement of a milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_AchievementOfMilestoneMember_lbl" xml:lang="en-US">Achievement Of Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_AchievementOfMilestoneMember_lbl" xml:lang="en-US">Achievement of milestone [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeStockAwardsRelatedToAcquisitionMember" xlink:label="pacb_OmniomeStockAwardsRelatedToAcquisitionMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_OmniomeStockAwardsRelatedToAcquisitionMember" xlink:to="pacb_OmniomeStockAwardsRelatedToAcquisitionMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_OmniomeStockAwardsRelatedToAcquisitionMember_lbl" xml:lang="en-US">Omniome stock awards in connection with the acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_OmniomeStockAwardsRelatedToAcquisitionMember_lbl" xml:lang="en-US">Omniome Stock Awards Related To Acquisition [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_OmniomeStockAwardsRelatedToAcquisitionMember_lbl" xml:lang="en-US">Omniome stock awards related to acquisition [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US">Restatement Adjustment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US">Effect of Change Higher/(Lower) [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InvitaeCorporationMember" xlink:label="pacb_InvitaeCorporationMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_InvitaeCorporationMember" xlink:to="pacb_InvitaeCorporationMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_InvitaeCorporationMember_lbl" xml:lang="en-US">Invitae Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_InvitaeCorporationMember_lbl" xml:lang="en-US">Invitae Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_InvitaeCorporationMember_lbl" xml:lang="en-US">Invitae Corporation [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value Inputs Level1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value Inputs Level2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CustomerDepositMember" xlink:label="pacb_CustomerDepositMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_CustomerDepositMember" xlink:to="pacb_CustomerDepositMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_CustomerDepositMember_lbl" xml:lang="en-US">Customer Deposit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_CustomerDepositMember_lbl" xml:lang="en-US">Customer Deposit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_CustomerDepositMember_lbl" xml:lang="en-US">Customer Deposit [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Indefinite Lived Intangible Assets Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:label="pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:to="pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_lbl" xml:lang="en-US">In-process research and development indefinite lived</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_lbl" xml:lang="en-US">In Process Research And Development Indefinite Lived [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_lbl" xml:lang="en-US">In-process research and development indefinite lived [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="us-gaap_CustomerRelationshipsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US">Customer Relationships [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US">Customer Relationships [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerRelatedExpensesStockSettledMember" xlink:label="pacb_MergerRelatedExpensesStockSettledMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_MergerRelatedExpensesStockSettledMember" xlink:to="pacb_MergerRelatedExpensesStockSettledMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_MergerRelatedExpensesStockSettledMember_lbl" xml:lang="en-US">Merger-related expenses - stock-settled.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_MergerRelatedExpensesStockSettledMember_lbl" xml:lang="en-US">Merger Related Expenses Stock Settled [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_MergerRelatedExpensesStockSettledMember_lbl" xml:lang="en-US">Merger-related expenses - stock-settled [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerRelatedExpensesMilestoneMember" xlink:label="pacb_MergerRelatedExpensesMilestoneMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_MergerRelatedExpensesMilestoneMember" xlink:to="pacb_MergerRelatedExpensesMilestoneMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_MergerRelatedExpensesMilestoneMember_lbl" xml:lang="en-US">Merger-related expenses - milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_MergerRelatedExpensesMilestoneMember_lbl" xml:lang="en-US">Merger Related Expenses Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_MergerRelatedExpensesMilestoneMember_lbl" xml:lang="en-US">Merger-related expenses - milestone [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_StockBasedCompensationMember" xlink:label="pacb_StockBasedCompensationMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_StockBasedCompensationMember" xlink:to="pacb_StockBasedCompensationMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_StockBasedCompensationMember_lbl" xml:lang="en-US">Stock-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_StockBasedCompensationMember_lbl" xml:lang="en-US">Stock Based Compensation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_StockBasedCompensationMember_lbl" xml:lang="en-US">Stock-based compensation [Member]</label>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerRelatedExpensesCashSettledMember" xlink:label="pacb_MergerRelatedExpensesCashSettledMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pacb_MergerRelatedExpensesCashSettledMember" xlink:to="pacb_MergerRelatedExpensesCashSettledMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pacb_MergerRelatedExpensesCashSettledMember_lbl" xml:lang="en-US">Merger-related expenses - cash-settled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pacb_MergerRelatedExpensesCashSettledMember_lbl" xml:lang="en-US">Merger Related Expenses Cash Settled [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pacb_MergerRelatedExpensesCashSettledMember_lbl" xml:lang="en-US">Merger-related expenses - cash-settled [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units R S U [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label></labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>pacb-20211231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 22.1.0.2 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/28/2022 12:55:15 PM-->
<!--Modified on: 2/28/2022 12:55:15 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" roleURI="http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBusinessAcquisitions" roleURI="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitions"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureInvitaeCollaborationArrangement" roleURI="http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangement"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureTerminationOfMergerWithIllumina" roleURI="http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIllumina"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureFinancialInstruments" roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstruments"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponents" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponents"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureConvertibleSeniorNotes" roleURI="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotes"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingencies"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureIncomeTaxes" roleURI="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxes"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquity" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquity"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureNetLossIncomePerShare" roleURI="http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShare"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureSegmentAndGeographicInformation" roleURI="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformation"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicy" roleURI="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBusinessAcquisitionTables" roleURI="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureFinancialInstrumentsTables" roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsTables" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureConvertibleSeniorNotesTables" roleURI="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureNetIncomeLossPerShareTables" roleURI="http://www.pacificbiosciences.com/role/DisclosureNetIncomeLossPerShareTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureSegmentAndGeographicInformationTables" roleURI="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutiveNetIncomeLossPerShareDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutiveNetIncomeLossPerShareDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBusinessAcquisitionsNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureInvitaeCollaborationArrangementNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangementNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureTerminationOfMergerWithIlluminaNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureFinancialInstrumentsNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureFinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsComponentsOfInventoryDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfInventoryDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureBalanceSheetComponentsScheduleOfOtherLiabilitiesCurrentDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfOtherLiabilitiesCurrentDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureConvertibleSeniorNotesNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureConvertibleSeniorNotesScheduleOfNetCarryingAmountDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfNetCarryingAmountDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureConvertibleSeniorNotesScheduleOfInterestExpenseDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfInterestExpenseDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitAccountsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitAccountsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureSegmentAndGeographicInformationNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="pacb-20211231.xsd#DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails" roleURI="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails"></roleRef>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document And Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract_637123381217134254"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637816497120412604"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_DocumentType_637816497120412604" order="1" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637816497120412604"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_DocumentAnnualReport_637816497120412604" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637816497120412604"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_CurrentFiscalYearEndDate_637816497120412604" order="3" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637816497120412604"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_DocumentPeriodEndDate_637816497120412604" order="4" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637816497120412604"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_DocumentFiscalYearFocus_637816497120412604" order="5" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637816497120412604"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_DocumentTransitionReport_637816497120412604" order="6" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637816497120412604"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityFileNumber_637816497120412604" order="7" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637816497120412604"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityRegistrantName_637816497120412604" order="8" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637816497120412604"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityIncorporationStateCountryCode_637816497120412604" order="9" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637816497120412604"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityTaxIdentificationNumber_637816497120412604" order="10" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637816497120412604"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityAddressAddressLine1_637816497120412604" order="11" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637816497120412604"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityAddressCityOrTown_637816497120412604" order="12" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637816497120412604"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityAddressStateOrProvince_637816497120412604" order="13" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637816497120412604"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityAddressPostalZipCode_637816497120412604" order="14" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637816497120412604"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_CityAreaCode_637816497120412604" order="15" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637816497120412604"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_LocalPhoneNumber_637816497120412604" order="16" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_Security12bTitle_637816497120422575" order="17" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_TradingSymbol_637816497120422575" order="18" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_SecurityExchangeName_637816497120422575" order="19" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityWellKnownSeasonedIssuer_637816497120422575" order="20" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityVoluntaryFilers_637816497120422575" order="21" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityCurrentReportingStatus_637816497120422575" order="22" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityInteractiveDataCurrent_637816497120422575" order="23" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityFilerCategory_637816497120422575" order="24" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntitySmallBusiness_637816497120422575" order="25" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityEmergingGrowthCompany_637816497120422575" order="26" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_IcfrAuditorAttestationFlag_637816497120422575" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityShellCompany_637816497120422575" order="28" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityPublicFloat_637816497120422575" order="29" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityCommonStockSharesOutstanding_637816497120422575" order="30" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_AmendmentFlag_637816497120422575" order="31" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_EntityCentralIndexKey_637816497120422575" order="32" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_DocumentFiscalPeriodFocus_637816497120422575" order="33" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_637816497120422575" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_AuditorName_637816497120422575" order="35" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_637816497120422575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_AuditorLocation_637816497120422575" order="36" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637123381217134254" xlink:to="dei_AuditorFirmId_637816497120432546" order="37" use="optional"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_637816497120432546" order="1" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637816497120432546" xlink:to="us-gaap_AssetsCurrentAbstract_637816497120432546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637816497120432546" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637816497120432546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637816497120432546" xlink:to="us-gaap_ShortTermInvestments_637816497120432546" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637816497120432546" xlink:to="us-gaap_AccountsReceivableNetCurrent_637816497120432546" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637816497120432546" xlink:to="us-gaap_InventoryNet_637816497120432546" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637816497120432546" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637816497120432546" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637816497120432546" xlink:to="us-gaap_RestrictedCashCurrent_637816497120432546" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637816497120432546" xlink:to="us-gaap_AssetsCurrent_637816497120432546" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637816497120432546" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637816497120432546" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637816497120432546" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637816497120432546" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637816497120432546" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_637816497120432546" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637816497120432546" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_637816497120432546" order="5" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637816497120432546" xlink:to="us-gaap_Goodwill_637816497120432546" order="6" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637816497120432546" xlink:to="us-gaap_OtherAssetsNoncurrent_637816497120432546" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637816497120432546" xlink:to="us-gaap_Assets_637816497120432546" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637816497120432546" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637816497120432546" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637816497120432546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637816497120432546" xlink:to="us-gaap_AccountsPayableCurrent_637816497120432546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637816497120432546" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637816497120432546" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637816497120432546" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637816497120432546" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637816497120432546" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637816497120432546" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637816497120432546" xlink:to="us-gaap_OtherLiabilitiesCurrent_637816497120432546" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637816497120432546" xlink:to="us-gaap_LiabilitiesCurrent_637816497120432546" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637816497120432546" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637816497120432546" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637816497120432546" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_637816497120432546" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637816497120432546"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637816497120432546" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637816497120432546" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637816497120432546" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_637816497120442522" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637816497120432546" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637816497120442522" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637816497120432546" xlink:to="us-gaap_Liabilities_637816497120442522" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637816497120432546" xlink:to="us-gaap_CommitmentsAndContingencies_637816497120442522" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637816497120432546" xlink:to="us-gaap_StockholdersEquityAbstract_637816497120442522" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637816497120442522" xlink:to="us-gaap_PreferredStockValue_637816497120442522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637816497120442522" xlink:to="us-gaap_CommonStockValue_637816497120442522" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637816497120442522" xlink:to="us-gaap_AdditionalPaidInCapital_637816497120442522" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637816497120442522" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637816497120442522" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637816497120442522" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637816497120442522" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637816497120442522" xlink:to="us-gaap_StockholdersEquity_637816497120442522" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637816497120432546" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637816497120442522" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637816497120442522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_637816497120442522" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_637816497120442522" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_637816497120442522" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637816497120442522" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_637816497120442522" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_637816497120442522" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_637816497120442522" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations and Comprehensive (Loss) Income">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable_637816497120442522" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637816497120442522"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637816497120442522" xlink:to="srt_ProductOrServiceAxis_637816497120442522" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637816497120442522" xlink:to="srt_ProductsAndServicesDomain_637816497120452493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637816497120452493" xlink:to="us-gaap_ProductMember_637816497120452493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ServiceAndOtherMember" xlink:label="pacb_ServiceAndOtherMember_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637816497120452493" xlink:to="pacb_ServiceAndOtherMember_637816497120452493" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637816497120442522" xlink:to="us-gaap_StatementLineItems_637816497120452493" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120452493" xlink:to="us-gaap_RevenuesAbstract_637816497120452493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_637816497120452493" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637816497120452493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenueAbstract" xlink:label="us-gaap_CostOfRevenueAbstract_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120452493" xlink:to="us-gaap_CostOfRevenueAbstract_637816497120452493" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfRevenueAbstract_637816497120452493" xlink:to="us-gaap_CostOfGoodsAndServicesSold_637816497120452493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfRevenueAbstract_637816497120452493" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_637816497120452493" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfRevenueAbstract_637816497120452493" xlink:to="us-gaap_CostOfRevenue_637816497120452493" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120452493" xlink:to="us-gaap_GrossProfit_637816497120452493" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120452493" xlink:to="us-gaap_OperatingExpensesAbstract_637816497120452493" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637816497120452493" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637816497120452493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637816497120452493" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637816497120452493" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637816497120452493" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_637816497120452493" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637816497120452493" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637816497120452493" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637816497120452493" xlink:to="us-gaap_OperatingExpenses_637816497120452493" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120452493" xlink:to="us-gaap_OperatingIncomeLoss_637816497120452493" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_GainLossOnReverseTerminationFee" xlink:label="pacb_GainLossOnReverseTerminationFee_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120452493" xlink:to="pacb_GainLossOnReverseTerminationFee_637816497120452493" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120452493" xlink:to="us-gaap_GainLossOnContractTermination_637816497120452493" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120452493" xlink:to="us-gaap_InterestExpense_637816497120452493" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120452493" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637816497120452493" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_637816497120452493" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637816497120452493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_637816497120452493" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637816497120452493" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120452493" xlink:to="us-gaap_NetIncomeLoss_637816497120452493" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120452493" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637816497120452493" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637816497120452493" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_637816497120452493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120452493" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637816497120452493" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637816497120452493"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120452493" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637816497120452493" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637816497120452493" xlink:to="us-gaap_EarningsPerShareBasic_637816497120462467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637816497120452493" xlink:to="us-gaap_EarningsPerShareDiluted_637816497120462467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120452493" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637816497120462467" order="14" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637816497120462467" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637816497120462467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637816497120462467" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637816497120462467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Stockholders&#8217; Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_635296296869836615"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_635296296869836615" xlink:to="us-gaap_StatementTable_637816497120462467" order="1" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637816497120462467" xlink:to="us-gaap_StatementEquityComponentsAxis_637816497120462467" order="1" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637816497120462467" xlink:to="us-gaap_CommonStockMember_637816497120462467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637816497120462467" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637816497120462467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637816497120462467" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637816497120462467" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637816497120462467" xlink:to="us-gaap_RetainedEarningsMember_637816497120462467" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637816497120462467" xlink:to="us-gaap_EquityComponentDomain_637816497120462467" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637816497120462467" xlink:to="srt_RestatementAxis_637816497120462467" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_637816497120462467" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_637816497120462467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_637816497120462467" xlink:to="srt_RestatementDomain_637816497120462467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637816497120462467" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637816497120462467" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201904Member" xlink:label="us-gaap_AccountingStandardsUpdate201904Member_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637816497120462467" xlink:to="us-gaap_AccountingStandardsUpdate201904Member_637816497120462467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637816497120462467" xlink:to="us-gaap_TypeOfAdoptionMember_637816497120462467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637816497120462467" xlink:to="us-gaap_StatementLineItems_637816497120462467" order="4" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120462467" xlink:to="us-gaap_StockholdersEquity_637816497120462467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120462467" xlink:to="us-gaap_CommonStockSharesOutstanding_637816497120462467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120462467" xlink:to="us-gaap_NetIncomeLoss_637816497120462467" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120462467" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_637816497120462467" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120462467" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637816497120462467" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120462467" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_637816497120462467" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" xlink:label="pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120462467" xlink:to="pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts_637816497120462467" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares" xlink:label="pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares_637816497120462467"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120462467" xlink:to="pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares_637816497120462467" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120462467" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_637816497120472440" order="9" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120462467" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_637816497120472440" order="10" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120462467" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637816497120472440" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120462467" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637816497120472440" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120462467" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637816497120472440" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120462467" xlink:to="us-gaap_StockholdersEquity_637816497120472440" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120462467" xlink:to="us-gaap_CommonStockSharesOutstanding_637816497120472440" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Condensed Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable_637816497120472440" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637816497120472440" xlink:to="us-gaap_BusinessAcquisitionAxis_637816497120472440" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637816497120472440" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120472440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CirculomicsIncMember" xlink:label="pacb_CirculomicsIncMember_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120472440" xlink:to="pacb_CirculomicsIncMember_637816497120472440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120472440" xlink:to="pacb_OmniomeIncMember_637816497120472440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637816497120472440" xlink:to="us-gaap_StatementLineItems_637816497120472440" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120472440" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440" xlink:to="us-gaap_NetIncomeLoss_637816497120472440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440" xlink:to="us-gaap_GainLossOnContractTermination_637816497120472440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440" xlink:to="us-gaap_Depreciation_637816497120472440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" xlink:label="pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440" xlink:to="pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense_637816497120472440" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637816497120472440" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637816497120472440" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440" xlink:to="us-gaap_ShareBasedCompensation_637816497120472440" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_637816497120472440" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_637816497120472440" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637816497120472440" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637816497120472440" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_637816497120472440"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_637816497120472440" order="11" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637816497120482413" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637816497120482413" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637816497120482413" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637816497120482413" xlink:to="us-gaap_IncreaseDecreaseInInventories_637816497120482413" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637816497120482413" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637816497120482413" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637816497120482413" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637816497120482413" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637816497120482413" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637816497120482413" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637816497120482413" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_637816497120482413" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637816497120482413" xlink:to="us-gaap_OperatingLeasePayments_637816497120482413" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637816497120482413" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_637816497120482413" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637816497120472440" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637816497120482413" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120472440" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637816497120482413" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637816497120482413" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637816497120482413" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637816497120482413" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_637816497120482413" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637816497120482413" xlink:to="us-gaap_PaymentsToAcquireInvestments_637816497120482413" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637816497120482413" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_637816497120482413" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637816497120482413" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_637816497120482413" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637816497120482413" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637816497120482413" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120472440" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637816497120482413" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ProceedsFromRepaymentsOfContractTermination" xlink:label="pacb_ProceedsFromRepaymentsOfContractTermination_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637816497120482413" xlink:to="pacb_ProceedsFromRepaymentsOfContractTermination_637816497120482413" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637816497120482413"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637816497120482413" xlink:to="us-gaap_RepaymentsOfNotesPayable_637816497120482413" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_637816497120492388"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637816497120482413" xlink:to="us-gaap_ProceedsFromConvertibleDebt_637816497120492388" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_637816497120492388"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637816497120482413" xlink:to="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_637816497120492388" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637816497120492388"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637816497120482413" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637816497120492388" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637816497120492388"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637816497120482413" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637816497120492388" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_637816497120492388"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637816497120482413" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_637816497120492388" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637816497120492388"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637816497120482413" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637816497120492388" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637816497120502367"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120472440" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637816497120502367" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637816497120502367"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120472440" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637816497120502367" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378164971205023671"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120472440" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378164971205023671" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637816497120502367"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120472440" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637816497120502367" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_637816497120502367"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120472440" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_637816497120502367" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637816497120502367"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120472440" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637816497120502367" order="9" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_637816497120502367"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637816497120502367" xlink:to="us-gaap_InterestPaidNet_637816497120502367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637816497120512335"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120472440" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637816497120512335" order="10" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InventoryTransferredToFromPropertyAndEquipment" xlink:label="pacb_InventoryTransferredToFromPropertyAndEquipment_637816497120512335"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637816497120512335" xlink:to="pacb_InventoryTransferredToFromPropertyAndEquipment_637816497120512335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InventoryTransferredFromPropertyAndEquipment" xlink:label="pacb_InventoryTransferredFromPropertyAndEquipment_637816497120512335"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637816497120512335" xlink:to="pacb_InventoryTransferredFromPropertyAndEquipment_637816497120512335" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637816497120512335"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637816497120512335" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637816497120512335" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_637816497120512335"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637816497120512335" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_637816497120512335" order="4" use="optional" priority="2"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10102 - Disclosure - Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637816497120512335"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637816497120512335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitions" xlink:type="extended" xlink:title="10201 - Disclosure - Business Acquisitions">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_637816497120512335"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_637816497120512335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangement" xlink:type="extended" xlink:title="10301 - Disclosure - Invitae Collaboration Arrangement">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DevelopmentAndCommercializationAgreementAbstract" xlink:label="pacb_DevelopmentAndCommercializationAgreementAbstract"></loc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DevelopmentAndCommercializationAgreementDisclosureTextBlock" xlink:label="pacb_DevelopmentAndCommercializationAgreementDisclosureTextBlock_637816497120512335"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_DevelopmentAndCommercializationAgreementAbstract" xlink:to="pacb_DevelopmentAndCommercializationAgreementDisclosureTextBlock_637816497120512335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIllumina" xlink:type="extended" xlink:title="10401 - Disclosure - Termination of Merger with Illumina">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerTerminationAbstract" xlink:label="pacb_MergerTerminationAbstract"></loc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerTermination" xlink:label="pacb_MergerTermination_637816497120512335"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_MergerTerminationAbstract" xlink:to="pacb_MergerTermination_637816497120512335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureFinancialInstruments" xlink:type="extended" xlink:title="10501 - Disclosure - Financial Instruments">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_637816497120522303" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponents" xlink:type="extended" xlink:title="10601 - Disclosure - Balance Sheet Components">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:label="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_637816497120522303" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotes" xlink:type="extended" xlink:title="10701 - Disclosure - Convertible Senior Notes">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_637816497120522303" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10801 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingencyDisclosures_637816497120522303" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10901 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_635230509056717959"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509056717959" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637816497120522303" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="11002 - Disclosure - Stockholders&apos; Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637816497120522303" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShare" xlink:type="extended" xlink:title="11101 - Disclosure - Net (Loss) Income Per Share">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_635230437916807959"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_635230437916807959" xlink:to="us-gaap_EarningsPerShareTextBlock_637816497120522303" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformation" xlink:type="extended" xlink:title="11201 - Disclosure - Segment And Geographic Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_635230399192459815"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_635230399192459815" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_637816497120522303" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy" xlink:type="extended" xlink:title="20402 - Disclosure - Summary of Significant Accounting Policies (Policy)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccounting_637816497120522303" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637816497120522303" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_637816497120522303" order="3" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637816497120522303" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637816497120522303" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_637816497120522303" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637816497120522303" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637816497120522303" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_637816497120522303" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_637816497120522303" order="10" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock" xlink:label="pacb_ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pacb_ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock_637816497120522303" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock" xlink:label="pacb_LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pacb_LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock_637816497120522303" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_637816497120522303" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_637816497120522303"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_637816497120522303" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637816497120532275" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_637816497120532275" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637816497120532275" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637816497120532275" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637816497120532275" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock_637816497120532275" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30103 - Disclosure - Summary of Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"></loc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock" xlink:label="pacb_EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pacb_EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock_637816497120532275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables" xlink:type="extended" xlink:title="30203 - Disclosure - Business Acquisition (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120532275" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120532275" xlink:to="us-gaap_BusinessAcquisitionAxis_637816497120532275" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637816497120532275" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120532275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120532275" xlink:to="pacb_OmniomeIncMember_637816497120532275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CirculomicsIncMember" xlink:label="pacb_CirculomicsIncMember_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120532275" xlink:to="pacb_CirculomicsIncMember_637816497120532275" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120532275" xlink:to="us-gaap_BusinessAcquisitionLineItems_637816497120532275" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock" xlink:label="pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120532275" xlink:to="pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock_637816497120532275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120532275" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_637816497120532275" order="2" use="optional" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120532275" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_637816497120532275" order="3" use="optional" priority="3"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Financial Instruments (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_637480465251622749"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract_637480465251622749" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_637816497120532275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock" xlink:label="pacb_ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_637816497120532275" xlink:to="pacb_ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock_637816497120532275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract_637480465251622749" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_637816497120532275" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract_637480465251622749" xlink:to="us-gaap_MarketableSecuritiesTextBlock_637816497120532275" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Balance Sheet Components (Tables)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:label="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637816497120532275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637816497120532275" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_637816497120532275" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_637816497120532275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_637816497120532275" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_637816497120542257" order="5" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_637816497120542257" order="6" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_637816497120542257" order="7" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_637816497120542257" order="8" use="optional"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Convertible Senior Notes (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_637816497120542257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:label="pacb_ScheduleOfInterestExpenseTableTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="pacb_ScheduleOfInterestExpenseTableTextBlock_637816497120542257" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Commitments and Contingencies (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_635231235438895884"></loc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:label="pacb_LesseeOperatingLeaseDescriptionTableTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_635231235438895884" xlink:to="pacb_LesseeOperatingLeaseDescriptionTableTextBlock_637816497120542257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30903 - Disclosure - Income Taxes (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_635230509057087959"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057087959" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637816497120542257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057087959" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637816497120542257" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057087959" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_637816497120542257" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="31003 - Disclosure - Stockholders&apos; Equity (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_637816497120542257" order="1" use="optional" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637816497120542257" xlink:to="us-gaap_AwardTypeAxis_637816497120542257" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637816497120542257" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120542257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TimeBasedStockOptionsMember" xlink:label="pacb_TimeBasedStockOptionsMember_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120542257" xlink:to="pacb_TimeBasedStockOptionsMember_637816497120542257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120542257" xlink:to="us-gaap_PerformanceSharesMember_637816497120542257" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637816497120542257" xlink:to="us-gaap_StatementLineItems_637816497120542257" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120542257" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637816497120542257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120542257" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_637816497120542257" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120542257" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_637816497120542257" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120542257" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_637816497120542257" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120542257" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637816497120542257" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120542257" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637816497120542257" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637816497120542257" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_637816497120542257" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureNetIncomeLossPerShareTables" xlink:type="extended" xlink:title="31103 - Disclosure - Net Income (Loss) Per Share (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637816497120542257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637816497120542257"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637816497120542257" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationTables" xlink:type="extended" xlink:title="31203 - Disclosure - Segment And Geographic Information (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_637816497120552228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_637816497120552228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_635229547625694461"></loc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:label="pacb_SummaryOfSignificantAccountingPoliciesTable_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635229547625694461" xlink:to="pacb_SummaryOfSignificantAccountingPoliciesTable_637816497120552228" order="1" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable_637816497120552228" xlink:to="us-gaap_DebtInstrumentAxis_637816497120552228" order="1" use="optional" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637816497120552228" xlink:to="us-gaap_DebtInstrumentNameDomain_637816497120552228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ConvertibleSeniorNotesMember" xlink:label="pacb_ConvertibleSeniorNotesMember_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637816497120552228" xlink:to="pacb_ConvertibleSeniorNotesMember_637816497120552228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable_637816497120552228" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_637816497120552228" order="2" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_637816497120552228" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637816497120552228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SecurityDepositMember" xlink:label="pacb_SecurityDepositMember_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637816497120552228" xlink:to="pacb_SecurityDepositMember_637816497120552228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable_637816497120552228" xlink:to="srt_RangeAxis_637816497120552228" order="3" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637816497120552228" xlink:to="srt_RangeMember_637816497120552228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637816497120552228" xlink:to="srt_MinimumMember_637816497120552228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637816497120552228" xlink:to="srt_MaximumMember_637816497120552228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable_637816497120552228" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637816497120552228" order="4" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637816497120552228" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637816497120552228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637816497120552228" xlink:to="us-gaap_LeaseholdImprovementsMember_637816497120552228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637816497120552228" xlink:to="us-gaap_EquipmentMember_637816497120552228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637816497120552228" xlink:to="us-gaap_ComputerEquipmentMember_637816497120552228" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637816497120552228" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_637816497120552228" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637816497120552228" xlink:to="us-gaap_FurnitureAndFixturesMember_637816497120552228" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable_637816497120552228" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_637816497120552228" order="5" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_637816497120552228" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_637816497120552228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_637816497120552228" xlink:to="us-gaap_SalesRevenueNetMember_637816497120552228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_637816497120552228" xlink:to="us-gaap_AccountsReceivableMember_637816497120552228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable_637816497120552228" xlink:to="srt_MajorCustomersAxis_637816497120552228" order="6" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_637816497120552228" xlink:to="srt_NameOfMajorCustomerDomain_637816497120552228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TenPercentOrGreaterBalanceAccountsReceivableMember" xlink:label="pacb_TenPercentOrGreaterBalanceAccountsReceivableMember_637816497120552228"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637816497120552228" xlink:to="pacb_TenPercentOrGreaterBalanceAccountsReceivableMember_637816497120552228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CustomerBMember" xlink:label="pacb_CustomerBMember_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637816497120552228" xlink:to="pacb_CustomerBMember_637816497120562204" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DomesticCustomersMember" xlink:label="pacb_DomesticCustomersMember_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637816497120552228" xlink:to="pacb_DomesticCustomersMember_637816497120562204" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CustomerDMember" xlink:label="pacb_CustomerDMember_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637816497120552228" xlink:to="pacb_CustomerDMember_637816497120562204" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable_637816497120552228" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_637816497120562204" order="7" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_637816497120562204" xlink:to="us-gaap_ConcentrationRiskTypeDomain_637816497120562204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_637816497120562204" xlink:to="us-gaap_CustomerConcentrationRiskMember_637816497120562204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable_637816497120552228" xlink:to="us-gaap_CreditFacilityAxis_637816497120562204" order="8" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_637816497120562204" xlink:to="us-gaap_CreditFacilityDomain_637816497120562204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_637816497120562204" xlink:to="us-gaap_LetterOfCreditMember_637816497120562204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable_637816497120552228" xlink:to="us-gaap_MeasurementInputTypeAxis_637816497120562204" order="9" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637816497120562204" xlink:to="us-gaap_MeasurementInputTypeDomain_637816497120562204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637816497120562204" xlink:to="us-gaap_MeasurementInputDiscountRateMember_637816497120562204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable_637816497120552228" xlink:to="srt_CounterpartyNameAxis_637816497120562204" order="10" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637816497120562204" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637816497120562204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ObrienLeaseAgreementMember" xlink:label="pacb_ObrienLeaseAgreementMember_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637816497120562204" xlink:to="pacb_ObrienLeaseAgreementMember_637816497120562204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable_637816497120552228" xlink:to="us-gaap_BusinessAcquisitionAxis_637816497120562204" order="11" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637816497120562204" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120562204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember_637816497120562204"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120562204" xlink:to="pacb_OmniomeIncMember_637816497120562204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pacb_SummaryOfSignificantAccountingPoliciesLineItems_637816497120572175"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesTable_637816497120552228" xlink:to="pacb_SummaryOfSignificantAccountingPoliciesLineItems_637816497120572175" order="12" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637816497120572175"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems_637816497120572175" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637816497120572175" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent_637816497120572175"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems_637816497120572175" xlink:to="us-gaap_RestrictedCashEquivalentsCurrent_637816497120572175" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent_637816497120572175"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems_637816497120572175" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent_637816497120572175" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AnnualReductionInNonCurrentRestrictedCash" xlink:label="pacb_AnnualReductionInNonCurrentRestrictedCash_637816497120572175"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems_637816497120572175" xlink:to="pacb_AnnualReductionInNonCurrentRestrictedCash_637816497120572175" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndNotesReceivableNet" xlink:label="us-gaap_AccountsAndNotesReceivableNet_637816497120572175"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems_637816497120572175" xlink:to="us-gaap_AccountsAndNotesReceivableNet_637816497120572175" order="5" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_637816497120572175"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems_637816497120572175" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_637816497120572175" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637816497120572175"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems_637816497120572175" xlink:to="us-gaap_DebtInstrumentFaceAmount_637816497120572175" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637816497120572175"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems_637816497120572175" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637816497120572175" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_637816497120572175"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems_637816497120572175" xlink:to="us-gaap_DebtInstrumentMaturityDate_637816497120572175" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_637816497120572175"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SummaryOfSignificantAccountingPoliciesLineItems_637816497120572175" xlink:to="us-gaap_ConcentrationRiskPercentage1_637816497120572175" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutiveNetIncomeLossPerShareDetails" xlink:type="extended" xlink:title="40105 - Disclosure - Summary of Significant Accounting Policies (Calculation of Basic and Dilutive Net Income (Loss) per Share) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_637816497120582147" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_637816497120582147" xlink:to="us-gaap_EarningsPerShareBasic_637816497120582147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_637816497120582147" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_637816497120582147" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637816497120582147" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_637816497120582147" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637816497120582147" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_637816497120582147" xlink:to="us-gaap_EarningsPerShareDiluted_637816497120582147" order="3" use="optional" priority="2"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Business Acquisitions (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120582147" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120582147" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637816497120582147" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637816497120582147" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637816497120582147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637816497120582147" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_637816497120582147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637816497120582147" xlink:to="us-gaap_DevelopedTechnologyRightsMember_637816497120582147" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120582147" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_637816497120582147" order="2" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis_637816497120582147" xlink:to="us-gaap_ContingentConsiderationTypeDomain_637816497120582147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AchievementOfMilestoneMember" xlink:label="pacb_AchievementOfMilestoneMember_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_637816497120582147" xlink:to="pacb_AchievementOfMilestoneMember_637816497120582147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120582147" xlink:to="us-gaap_BusinessAcquisitionAxis_637816497120582147" order="3" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637816497120582147" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120582147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CirculomicsIncMember" xlink:label="pacb_CirculomicsIncMember_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120582147" xlink:to="pacb_CirculomicsIncMember_637816497120582147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120582147" xlink:to="pacb_OmniomeIncMember_637816497120582147" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120582147" xlink:to="us-gaap_AwardTypeAxis_637816497120582147" order="4" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637816497120582147" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120582147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeStockAwardsRelatedToAcquisitionMember" xlink:label="pacb_OmniomeStockAwardsRelatedToAcquisitionMember_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120582147" xlink:to="pacb_OmniomeStockAwardsRelatedToAcquisitionMember_637816497120582147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120582147" xlink:to="srt_RestatementAxis_637816497120582147" order="5" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_637816497120582147" xlink:to="srt_RestatementDomain_637816497120582147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_637816497120582147" xlink:to="srt_RestatementAdjustmentMember_637816497120582147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120582147" xlink:to="us-gaap_BusinessAcquisitionLineItems_637816497120582147" order="6" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_637816497120582147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_637816497120582147" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_637816497120582147" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContingentConsiderationIncurredDuringPeriod" xlink:label="pacb_ContingentConsiderationIncurredDuringPeriod_637816497120582147"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="pacb_ContingentConsiderationIncurredDuringPeriod_637816497120582147" order="4" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_637816497120592121" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_637816497120592121" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637816497120592121" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="us-gaap_SaleOfStockPricePerShare_637816497120592121" order="8" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares" xlink:label="pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares_637816497120592121" order="9" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637816497120592121" order="10" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" xlink:label="pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts_637816497120592121" order="11" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637816497120592121" order="12" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_637816497120592121" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637816497120592121" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance" xlink:label="pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance_637816497120592121" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts" xlink:label="pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts_637816497120592121" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_637816497120592121" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_637816497120592121" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="us-gaap_Goodwill_637816497120592121" order="19" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_637816497120592121" order="20" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense_637816497120592121" order="21" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637816497120592121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120582147" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637816497120592121" order="22" use="optional" priority="2"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Business Acquisitions (Schedule by Acquisitions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120602093" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120602093" xlink:to="us-gaap_BusinessAcquisitionAxis_637816497120602093" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637816497120602093" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120602093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CirculomicsIncMember" xlink:label="pacb_CirculomicsIncMember_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120602093" xlink:to="pacb_CirculomicsIncMember_637816497120602093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120602093" xlink:to="pacb_OmniomeIncMember_637816497120602093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120602093" xlink:to="us-gaap_BusinessAcquisitionLineItems_637816497120602093" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120602093" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract_637816497120602093" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract_637816497120602093" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_637816497120602093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract_637816497120602093" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_637816497120602093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract_637816497120602093" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_637816497120602093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContingentConsiderationIncurredDuringPeriod" xlink:label="pacb_ContingentConsiderationIncurredDuringPeriod_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract_637816497120602093" xlink:to="pacb_ContingentConsiderationIncurredDuringPeriod_637816497120602093" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" xlink:label="pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract_637816497120602093" xlink:to="pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_637816497120602093" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract_637816497120602093" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_637816497120602093" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120602093" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637816497120602093" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637816497120602093" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_637816497120602093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637816497120602093" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_637816497120602093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet" xlink:label="pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637816497120602093" xlink:to="pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet_637816497120602093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637816497120602093" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_637816497120602093" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637816497120602093" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_637816497120602093" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637816497120602093" xlink:to="us-gaap_Goodwill_637816497120602093" order="6" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637816497120602093" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_637816497120602093" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637816497120602093" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_637816497120602093" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637816497120602093" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_637816497120602093" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637816497120602093" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_637816497120602093" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationAbstract_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120602093" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationAbstract_637816497120602093" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_637816497120602093"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationAbstract_637816497120602093" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_637816497120602093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationAbstract_637816497120602093" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_637816497120612069" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationAbstract_637816497120602093" xlink:to="pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_637816497120612069" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangementNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Invitae Collaboration Arrangement (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DevelopmentAndCommercializationAgreementAbstract" xlink:label="pacb_DevelopmentAndCommercializationAgreementAbstract"></loc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable" xlink:label="pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_DevelopmentAndCommercializationAgreementAbstract" xlink:to="pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_637816497120612069" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_637816497120612069" xlink:to="srt_MajorCustomersAxis_637816497120612069" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_637816497120612069" xlink:to="srt_NameOfMajorCustomerDomain_637816497120612069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InvitaeCorporationMember" xlink:label="pacb_InvitaeCorporationMember_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637816497120612069" xlink:to="pacb_InvitaeCorporationMember_637816497120612069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems" xlink:label="pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_637816497120612069" xlink:to="pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_637816497120612069" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_637816497120612069" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637816497120612069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Termination of Merger with Illumina (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerTerminationAbstract" xlink:label="pacb_MergerTerminationAbstract_637178742692975608"></loc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerTerminationTable" xlink:label="pacb_MergerTerminationTable_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_MergerTerminationAbstract_637178742692975608" xlink:to="pacb_MergerTerminationTable_637816497120612069" order="1" use="optional" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_MergerTerminationTable_637816497120612069" xlink:to="us-gaap_DebtInstrumentAxis_637816497120612069" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637816497120612069" xlink:to="us-gaap_DebtInstrumentNameDomain_637816497120612069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ConvertibleSeniorNotesMember" xlink:label="pacb_ConvertibleSeniorNotesMember_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637816497120612069" xlink:to="pacb_ConvertibleSeniorNotesMember_637816497120612069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_MergerTerminationTable_637816497120612069" xlink:to="dei_LegalEntityAxis_637816497120612069" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637816497120612069" xlink:to="dei_EntityDomain_637816497120612069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_IlluminaFcOpsCorpMember" xlink:label="pacb_IlluminaFcOpsCorpMember_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637816497120612069" xlink:to="pacb_IlluminaFcOpsCorpMember_637816497120612069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerTerminationLineItems" xlink:label="pacb_MergerTerminationLineItems_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_MergerTerminationTable_637816497120612069" xlink:to="pacb_MergerTerminationLineItems_637816497120612069" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ProceedsFromContractTermination" xlink:label="pacb_ProceedsFromContractTermination_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_MergerTerminationLineItems_637816497120612069" xlink:to="pacb_ProceedsFromContractTermination_637816497120612069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_MergerTerminationLineItems_637816497120612069" xlink:to="us-gaap_GainLossOnContractTermination_637816497120612069" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace" xlink:label="pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_MergerTerminationLineItems_637816497120612069" xlink:to="pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace_637816497120612069" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction" xlink:label="pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_MergerTerminationLineItems_637816497120612069" xlink:to="pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction_637816497120612069" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_MergerTerminationLineItems_637816497120612069" xlink:to="us-gaap_DebtInstrumentFaceAmount_637816497120612069" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_MergerTerminationLineItems_637816497120612069" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637816497120612069" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_MergerTerminationLineItems_637816497120612069" xlink:to="us-gaap_DebtInstrumentMaturityDate_637816497120612069" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_RepaymentsOfContractTermination" xlink:label="pacb_RepaymentsOfContractTermination_637816497120612069"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_MergerTerminationLineItems_637816497120612069" xlink:to="pacb_RepaymentsOfContractTermination_637816497120612069" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="us-gaap_ProceedsFromFeesReceived_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_MergerTerminationLineItems_637816497120612069" xlink:to="us-gaap_ProceedsFromFeesReceived_637816497120622041" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PaymentsForAdvisorFees" xlink:label="pacb_PaymentsForAdvisorFees_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_MergerTerminationLineItems_637816497120612069" xlink:to="pacb_PaymentsForAdvisorFees_637816497120622041" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_MergerTerminationLineItems_637816497120612069" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637816497120622041" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Financial Instruments (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_FinancialInstrumentsTable" xlink:label="pacb_FinancialInstrumentsTable_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="pacb_FinancialInstrumentsTable_637816497120622041" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_FinancialInstrumentsTable_637816497120622041" xlink:to="us-gaap_MeasurementInputTypeAxis_637816497120622041" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637816497120622041" xlink:to="us-gaap_MeasurementInputTypeDomain_637816497120622041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637816497120622041" xlink:to="us-gaap_MeasurementInputDiscountRateMember_637816497120622041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_FinancialInstrumentsTable_637816497120622041" xlink:to="us-gaap_DebtInstrumentAxis_637816497120622041" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637816497120622041" xlink:to="us-gaap_DebtInstrumentNameDomain_637816497120622041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ConvertibleSeniorNotesMember" xlink:label="pacb_ConvertibleSeniorNotesMember_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637816497120622041" xlink:to="pacb_ConvertibleSeniorNotesMember_637816497120622041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_FinancialInstrumentsTable_637816497120622041" xlink:to="srt_RangeAxis_637816497120622041" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637816497120622041" xlink:to="srt_RangeMember_637816497120622041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637816497120622041" xlink:to="srt_MaximumMember_637816497120622041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637816497120622041" xlink:to="srt_MinimumMember_637816497120622041" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_FinancialInstrumentsTable_637816497120622041" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637816497120622041" order="4" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637816497120622041" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637816497120622041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637816497120622041" xlink:to="us-gaap_FairValueInputsLevel3Member_637816497120622041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_FinancialInstrumentsLineItems" xlink:label="pacb_FinancialInstrumentsLineItems_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_FinancialInstrumentsTable_637816497120622041" xlink:to="pacb_FinancialInstrumentsLineItems_637816497120622041" order="5" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_FinancialInstrumentsLineItems_637816497120622041" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637816497120622041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_FinancialInstrumentsLineItems_637816497120622041" xlink:to="us-gaap_DebtInstrumentFaceAmount_637816497120622041" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_FinancialInstrumentsLineItems_637816497120622041" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637816497120622041" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_RepaymentsOfContractTermination" xlink:label="pacb_RepaymentsOfContractTermination_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_FinancialInstrumentsLineItems_637816497120622041" xlink:to="pacb_RepaymentsOfContractTermination_637816497120622041" order="4" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_637816497120622041"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_FinancialInstrumentsLineItems_637816497120622041" xlink:to="us-gaap_DebtInstrumentMaturityDate_637816497120622041" order="5" use="optional" priority="2"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Financial Instruments (Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_637484658069422180"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637816497120632014"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract_637484658069422180" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637816497120632014" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_637816497120632014"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637816497120632014" xlink:to="us-gaap_FairValueByAssetClassAxis_637816497120632014" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637816497120632014"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis_637816497120632014" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637816497120632014" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember_637816497120632014"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637816497120632014" xlink:to="us-gaap_CashAndCashEquivalentsMember_637816497120632014" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CashAndMoneyMarketFundsMember" xlink:label="pacb_CashAndMoneyMarketFundsMember_637816497120632014"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsMember_637816497120632014" xlink:to="pacb_CashAndMoneyMarketFundsMember_637816497120632014" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_637816497120632014"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsMember_637816497120632014" xlink:to="us-gaap_CommercialPaperMember_637816497120632014" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsMember_637816497120632014" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_637816497120681885" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsMember_637816497120632014" xlink:to="us-gaap_USTreasurySecuritiesMember_637816497120681885" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsMember" xlink:label="us-gaap_InvestmentsMember_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637816497120632014" xlink:to="us-gaap_InvestmentsMember_637816497120681885" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsMember_637816497120681885" xlink:to="us-gaap_CorporateDebtSecuritiesMember_637816497120681885" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:label="pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsMember_637816497120681885" xlink:to="pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_637816497120681885" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637816497120632014" xlink:to="us-gaap_FairValueByLiabilityClassAxis_637816497120681885" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_637816497120681885" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_637816497120681885" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContingentConsiderationMember" xlink:label="pacb_ContingentConsiderationMember_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_637816497120681885" xlink:to="pacb_ContingentConsiderationMember_637816497120681885" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637816497120632014" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637816497120681885" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637816497120681885" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637816497120681885" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637816497120681885" xlink:to="us-gaap_FairValueInputsLevel1Member_637816497120681885" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637816497120681885" xlink:to="us-gaap_FairValueInputsLevel2Member_637816497120681885" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637816497120681885" xlink:to="us-gaap_FairValueInputsLevel3Member_637816497120681885" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637816497120632014" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637816497120681885" order="4" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637816497120681885" xlink:to="us-gaap_AssetsAbstract_637816497120681885" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637816497120681885" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637816497120681885" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637816497120681885" xlink:to="us-gaap_InvestmentsFairValueDisclosure_637816497120681885" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:label="pacb_ShortTermRestrictedCashFairValueDisclosure_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637816497120681885" xlink:to="pacb_ShortTermRestrictedCashFairValueDisclosure_637816497120681885" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_LongTermRestrictedCashFairValueDisclosure" xlink:label="pacb_LongTermRestrictedCashFairValueDisclosure_637816497120681885"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637816497120681885" xlink:to="pacb_LongTermRestrictedCashFairValueDisclosure_637816497120681885" order="4" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637816497120681885" xlink:to="us-gaap_AssetsFairValueDisclosure_637816497120691857" order="5" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637816497120681885" xlink:to="us-gaap_LiabilitiesAbstract_637816497120691857" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_637816497120691857" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_637816497120691857" order="1" use="optional" priority="2"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Financial Instruments (Changes in estimated fair value of contingent consideration) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637816497120691857" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637816497120691857" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637816497120691857" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637816497120691857" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637816497120691857" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637816497120691857" xlink:to="us-gaap_FairValueInputsLevel3Member_637816497120691857" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637816497120691857" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637816497120691857" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637816497120691857" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_637816497120691857" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContingentConsiderationIncurredDuringPeriod" xlink:label="pacb_ContingentConsiderationIncurredDuringPeriod_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637816497120691857" xlink:to="pacb_ContingentConsiderationIncurredDuringPeriod_637816497120691857" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637816497120691857" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637816497120691857" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_6378164971206918571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637816497120691857" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_6378164971206918571" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Financial Instruments (Summary of Cash, Cash Equivalents and Investments) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_637816497120691857" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_637816497120691857" xlink:to="us-gaap_FinancialInstrumentAxis_637816497120691857" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637816497120691857" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637816497120691857" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CashCashEquivalentsAndInvestmentsMember" xlink:label="pacb_CashCashEquivalentsAndInvestmentsMember_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637816497120691857" xlink:to="pacb_CashCashEquivalentsAndInvestmentsMember_637816497120691857" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_CashCashEquivalentsAndInvestmentsMember_637816497120691857" xlink:to="us-gaap_CashAndCashEquivalentsMember_637816497120691857" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CashAndMoneyMarketFundsMember" xlink:label="pacb_CashAndMoneyMarketFundsMember_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsMember_637816497120691857" xlink:to="pacb_CashAndMoneyMarketFundsMember_637816497120691857" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsMember_637816497120691857" xlink:to="us-gaap_CommercialPaperMember_637816497120691857" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_637816497120691857"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsMember_637816497120691857" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_637816497120691857" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_637816497120701852"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsMember_637816497120691857" xlink:to="us-gaap_USTreasurySecuritiesMember_637816497120701852" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsMember" xlink:label="us-gaap_InvestmentsMember_637816497120701852"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_CashCashEquivalentsAndInvestmentsMember_637816497120691857" xlink:to="us-gaap_InvestmentsMember_637816497120701852" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_637816497120701852"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsMember_637816497120701852" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_637816497120701852" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_637816497120701852"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsMember_637816497120701852" xlink:to="us-gaap_CorporateDebtSecuritiesMember_637816497120701852" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:label="pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_637816497120701852"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsMember_637816497120701852" xlink:to="pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_637816497120701852" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ShortTermRestrictedCashMember" xlink:label="pacb_ShortTermRestrictedCashMember_637816497120701852"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637816497120691857" xlink:to="pacb_ShortTermRestrictedCashMember_637816497120701852" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_LongTermRestrictedCashMember" xlink:label="pacb_LongTermRestrictedCashMember_637816497120701852"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637816497120691857" xlink:to="pacb_LongTermRestrictedCashMember_637816497120701852" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637816497120701852"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_637816497120691857" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637816497120701852" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_637816497120701852"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637816497120701852" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_637816497120701852" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments" xlink:label="pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments_637816497120701852"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637816497120701852" xlink:to="pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments_637816497120701852" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:label="pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments_637816497120701852"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637816497120701852" xlink:to="pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments_637816497120701852" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637816497120701852"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637816497120701852" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637816497120701852" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails" xlink:type="extended" xlink:title="40505 - Disclosure - Financial Instruments (Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_637816497120701852"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_637816497120701852" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_637816497120701852"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_637816497120701852" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637816497120701852"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637816497120701852" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Balance Sheet Components (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:label="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfBalanceSheetComponentsTable" xlink:label="pacb_ScheduleOfBalanceSheetComponentsTable_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="pacb_ScheduleOfBalanceSheetComponentsTable_637816497120711862" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable_637816497120711862" xlink:to="srt_MajorCustomersAxis_637816497120711862" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_637816497120711862" xlink:to="srt_NameOfMajorCustomerDomain_637816497120711862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InvitaeCorporationMember" xlink:label="pacb_InvitaeCorporationMember_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637816497120711862" xlink:to="pacb_InvitaeCorporationMember_637816497120711862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable_637816497120711862" xlink:to="us-gaap_TypeOfArrangementAxis_637816497120711862" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637816497120711862" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637816497120711862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ServiceContractMember" xlink:label="pacb_ServiceContractMember_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637816497120711862" xlink:to="pacb_ServiceContractMember_637816497120711862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable_637816497120711862" xlink:to="us-gaap_MeasurementInputTypeAxis_637816497120711862" order="3" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637816497120711862" xlink:to="us-gaap_MeasurementInputTypeDomain_637816497120711862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637816497120711862" xlink:to="us-gaap_MeasurementInputDiscountRateMember_637816497120711862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable_637816497120711862" xlink:to="srt_ProductOrServiceAxis_637816497120711862" order="4" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637816497120711862" xlink:to="srt_ProductsAndServicesDomain_637816497120711862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637816497120711862" xlink:to="us-gaap_ServiceMember_637816497120711862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable_637816497120711862" xlink:to="srt_CounterpartyNameAxis_637816497120711862" order="5" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637816497120711862" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637816497120711862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ObrienLeaseAgreementMember" xlink:label="pacb_ObrienLeaseAgreementMember_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637816497120711862" xlink:to="pacb_ObrienLeaseAgreementMember_637816497120711862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable_637816497120711862" xlink:to="srt_RangeAxis_637816497120711862" order="6" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637816497120711862" xlink:to="srt_RangeMember_637816497120711862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637816497120711862" xlink:to="srt_MinimumMember_637816497120711862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637816497120711862" xlink:to="srt_MaximumMember_637816497120711862" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable_637816497120711862" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_637816497120711862" order="7" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637816497120711862"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_637816497120711862" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637816497120711862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CustomerDepositMember" xlink:label="pacb_CustomerDepositMember_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637816497120711862" xlink:to="pacb_CustomerDepositMember_637816497120721776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SecurityDepositMember" xlink:label="pacb_SecurityDepositMember_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637816497120711862" xlink:to="pacb_SecurityDepositMember_637816497120721776" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable_637816497120711862" xlink:to="us-gaap_BusinessAcquisitionAxis_637816497120721776" order="8" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637816497120721776" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120721776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120721776" xlink:to="pacb_OmniomeIncMember_637816497120721776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable_637816497120711862" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_637816497120721776" order="9" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_637816497120721776" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_637816497120721776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:label="pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_637816497120721776" xlink:to="pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_637816497120721776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_BalanceSheetComponentsLineItems" xlink:label="pacb_BalanceSheetComponentsLineItems_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_ScheduleOfBalanceSheetComponentsTable_637816497120711862" xlink:to="pacb_BalanceSheetComponentsLineItems_637816497120721776" order="10" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PercentageOfFeeToPrepayDebt" xlink:label="pacb_PercentageOfFeeToPrepayDebt_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="pacb_PercentageOfFeeToPrepayDebt_637816497120721776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_RestrictedCashCurrent_637816497120721776" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashCurrent_637816497120721776" xlink:to="us-gaap_Depreciation_637816497120721776" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_637816497120721776" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AnnualDecreaseInLongTermRestrictedCash" xlink:label="pacb_AnnualDecreaseInLongTermRestrictedCash_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="pacb_AnnualDecreaseInLongTermRestrictedCash_637816497120721776" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_637816497120721776" order="5" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_AmortizationOfIntangibleAssets_637816497120721776" order="6" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_ContractWithCustomerLiability_637816497120721776" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637816497120721776"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637816497120721776" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637816497120731750"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637816497120731750" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_637816497120731750"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_637816497120731750" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:label="pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_637816497120731750"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_637816497120731750" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637816497120731750"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637816497120731750" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable_637816497120731750"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_NotesPayable_637816497120731750" order="13" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637816497120731750"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_NotesPayableCurrent_637816497120731750" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_637816497120731750"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_LongTermNotesPayable_637816497120731750" order="15" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings_637816497120731750"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_InterestExpenseBorrowings_637816497120731750" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637816497120731750"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637816497120731750" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_637816497120731750"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_637816497120731750" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_637816497120731750"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_637816497120731750" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_637816497120731750"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_637816497120731750" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_637816497120731750"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_DebtInstrumentTerm_637816497120731750" order="21" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetComponentsLineItems_637816497120721776" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637816497120741725" order="22" use="optional" priority="2"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfInventoryDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Balance Sheet Components (Components of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:label="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637816497120741725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637816497120741725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637816497120741725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_InventoryNet_637816497120741725" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Balance Sheet Components (Components of Property and Equipment, Net) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:label="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637816497120741725" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637816497120741725" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637816497120741725" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637816497120741725" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637816497120741725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_LaboratoryEquipmentAndMachineryMember" xlink:label="pacb_LaboratoryEquipmentAndMachineryMember_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637816497120741725" xlink:to="pacb_LaboratoryEquipmentAndMachineryMember_637816497120741725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637816497120741725" xlink:to="us-gaap_LeaseholdImprovementsMember_637816497120741725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637816497120741725" xlink:to="us-gaap_ComputerEquipmentMember_637816497120741725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637816497120741725" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_637816497120741725" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637816497120741725" xlink:to="us-gaap_FurnitureAndFixturesMember_637816497120741725" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637816497120741725" xlink:to="us-gaap_ConstructionInProgressMember_637816497120741725" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637816497120741725" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637816497120741725" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637816497120741725" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637816497120741725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637816497120741725" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637816497120741725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637816497120741725" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637816497120741725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails" xlink:type="extended" xlink:title="40604 - Disclosure - Balance Sheet Components (Changes in carrying amount of goodwill) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:label="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTable_637816497120741725" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable_637816497120741725" xlink:to="us-gaap_BusinessAcquisitionAxis_637816497120741725" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637816497120741725" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120741725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120741725" xlink:to="pacb_OmniomeIncMember_637816497120741725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CirculomicsIncMember" xlink:label="pacb_CirculomicsIncMember_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120741725" xlink:to="pacb_CirculomicsIncMember_637816497120741725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable_637816497120741725" xlink:to="us-gaap_GoodwillLineItems_637816497120741725" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems_637816497120741725" xlink:to="us-gaap_Goodwill_637816497120741725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod_637816497120741725"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems_637816497120741725" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod_637816497120741725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_6378164971207417251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems_637816497120741725" xlink:to="us-gaap_Goodwill_6378164971207417251" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="extended" xlink:title="40605 - Disclosure - Balance Sheet Components (Definite-lived Intangible Assets from Business Acquisitions) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:label="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120751694" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120751694" xlink:to="us-gaap_BusinessAcquisitionAxis_637816497120751694" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637816497120751694" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120751694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120751694" xlink:to="pacb_OmniomeIncMember_637816497120751694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120751694" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637816497120751694" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637816497120751694" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637816497120751694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637816497120751694" xlink:to="us-gaap_DevelopedTechnologyRightsMember_637816497120751694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="us-gaap_CustomerRelationshipsMember_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637816497120751694" xlink:to="us-gaap_CustomerRelationshipsMember_637816497120751694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120751694" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_637816497120751694" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637816497120751694" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_637816497120751694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637816497120751694" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_637816497120751694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637816497120751694" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_637816497120751694" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637816497120751694" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_637816497120751694" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails" xlink:type="extended" xlink:title="40606 - Disclosure - Balance Sheet Components (Estimated Future Amortization Expense Of Acquisition-Related Intangible Assets With Definite Lives) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:label="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_637816497120751694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_637816497120751694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_637816497120751694" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_637816497120751694" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_637816497120751694" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_637816497120751694" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_637816497120751694" order="7" use="optional"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:type="extended" xlink:title="40607 - Disclosure - Balance Sheet Components (Schedule of Accrued Expenses) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:label="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637816497120751694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AccruedProductDevelopmentCostsCurrent" xlink:label="pacb_AccruedProductDevelopmentCostsCurrent_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="pacb_AccruedProductDevelopmentCostsCurrent_637816497120751694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AccruedTenantImprovementsCurrent" xlink:label="pacb_AccruedTenantImprovementsCurrent_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="pacb_AccruedTenantImprovementsCurrent_637816497120751694" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductLiabilityContingencyAccrualPresentValue" xlink:label="us-gaap_ProductLiabilityContingencyAccrualPresentValue_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_ProductLiabilityContingencyAccrualPresentValue_637816497120751694" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_ProductWarrantyAccrualClassifiedCurrent_637816497120751694" order="5" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637816497120751694" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637816497120751694" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637816497120751694"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637816497120751694" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails" xlink:type="extended" xlink:title="40608 - Disclosure - Balance Sheet Components (Furture Principal Payments) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:label="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120761668" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120761668" xlink:to="us-gaap_BusinessAcquisitionAxis_637816497120761668" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637816497120761668" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120761668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120761668" xlink:to="pacb_OmniomeIncMember_637816497120761668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637816497120761668" xlink:to="us-gaap_BusinessAcquisitionLineItems_637816497120761668" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637816497120761668" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_637816497120761668" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_637816497120761668" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637816497120761668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_637816497120761668" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637816497120761668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_637816497120761668" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637816497120761668" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_637816497120761668" xlink:to="us-gaap_LongTermDebt_637816497120761668" order="4" use="optional" priority="2"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfOtherLiabilitiesCurrentDetails" xlink:type="extended" xlink:title="40611 - Disclosure - Balance Sheet Components (Schedule of Other Liabilities, Current) (Details)">
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:label="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_637491496906015321"></loc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" xlink:label="pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_637491496906015321" xlink:to="pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_637816497120761668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_637491496906015321" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent_637816497120761668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_637491496906015321" xlink:to="us-gaap_OtherLiabilitiesCurrent_637816497120761668" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Convertible Senior Notes (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_637816497120761668" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637816497120761668" xlink:to="srt_StatementScenarioAxis_637816497120761668" order="1" use="optional" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637816497120761668" xlink:to="srt_ScenarioUnspecifiedDomain_637816497120761668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EachDayDuringFirst180DaysMember" xlink:label="pacb_EachDayDuringFirst180DaysMember_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637816497120761668" xlink:to="pacb_EachDayDuringFirst180DaysMember_637816497120761668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OneHundredAndEightyFirstDayTo360thDayMember" xlink:label="pacb_OneHundredAndEightyFirstDayTo360thDayMember_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637816497120761668" xlink:to="pacb_OneHundredAndEightyFirstDayTo360thDayMember_637816497120761668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637816497120761668" xlink:to="us-gaap_DebtInstrumentAxis_637816497120761668" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637816497120761668" xlink:to="us-gaap_DebtInstrumentNameDomain_637816497120761668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ConvertibleSeniorNotesMember" xlink:label="pacb_ConvertibleSeniorNotesMember_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637816497120761668" xlink:to="pacb_ConvertibleSeniorNotesMember_637816497120761668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637816497120761668" xlink:to="us-gaap_DebtInstrumentLineItems_637816497120761668" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637816497120761668" xlink:to="us-gaap_DebtInstrumentFaceAmount_637816497120761668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637816497120761668" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637816497120761668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637816497120761668" xlink:to="us-gaap_DebtInstrumentMaturityDate_637816497120761668" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="us-gaap_DebtInstrumentIssuanceDate1_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637816497120761668" xlink:to="us-gaap_DebtInstrumentIssuanceDate1_637816497120761668" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount" xlink:label="pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637816497120761668" xlink:to="pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount_637816497120761668" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentStatedPrincipalAmountForConversionRate" xlink:label="pacb_DebtInstrumentStatedPrincipalAmountForConversionRate_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637816497120761668" xlink:to="pacb_DebtInstrumentStatedPrincipalAmountForConversionRate_637816497120761668" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637816497120761668" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_637816497120761668" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:label="pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_637816497120761668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637816497120761668" xlink:to="pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_637816497120761668" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:label="pacb_DebtInstrumentRedemptionPriceTradingDays_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637816497120761668" xlink:to="pacb_DebtInstrumentRedemptionPriceTradingDays_637816497120771641" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:label="pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637816497120761668" xlink:to="pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_637816497120771641" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637816497120761668" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_637816497120771641" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:label="pacb_DebtInstrumentAdditionalInterestInEventOfDefault_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637816497120761668" xlink:to="pacb_DebtInstrumentAdditionalInterestInEventOfDefault_637816497120771641" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637816497120761668" xlink:to="us-gaap_DeferredFinanceCostsGross_637816497120771641" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637816497120761668" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_637816497120771641" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637816497120761668" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_637816497120771641" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfNetCarryingAmountDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Convertible Senior Notes (Schedule of Net Carrying Amount) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637553021126764918"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637553021126764918" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637816497120771641" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637553021126764918" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_637816497120771641" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637553021126764918" xlink:to="us-gaap_LongTermDebt_637816497120771641" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfInterestExpenseDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Convertible Senior Notes (Schedule of Interest Expense) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637553013407566168"></loc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ContractualInterestExpense" xlink:label="pacb_ContractualInterestExpense_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637553013407566168" xlink:to="pacb_ContractualInterestExpense_637816497120771641" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637553013407566168" xlink:to="us-gaap_AmortizationOfFinancingCosts_637816497120771641" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637553013407566168" xlink:to="us-gaap_InterestExpenseDebt_637816497120771641" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Commitments and Contingencies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CommitmentsAndContingenciesTable" xlink:label="pacb_CommitmentsAndContingenciesTable_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pacb_CommitmentsAndContingenciesTable_637816497120771641" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_CommitmentsAndContingenciesTable_637816497120771641" xlink:to="us-gaap_BusinessAcquisitionAxis_637816497120771641" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637816497120771641" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120771641" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomeIncMember" xlink:label="pacb_OmniomeIncMember_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637816497120771641" xlink:to="pacb_OmniomeIncMember_637816497120771641" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CommitmentsAndContingenciesLineItems" xlink:label="pacb_CommitmentsAndContingenciesLineItems_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_CommitmentsAndContingenciesTable_637816497120771641" xlink:to="pacb_CommitmentsAndContingenciesLineItems_637816497120771641" order="2" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_CommitmentsAndContingenciesLineItems_637816497120771641" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_637816497120771641" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_CommitmentsAndContingenciesLineItems_637816497120771641" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637816497120771641" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_CommitmentsAndContingenciesLineItems_637816497120771641" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637816497120771641" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_CommitmentsAndContingenciesLineItems_637816497120771641" xlink:to="us-gaap_PaymentsForRent_637816497120771641" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_CommitmentsAndContingenciesLineItems_637816497120771641" xlink:to="us-gaap_OperatingLeaseCost_637816497120771641" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:label="pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_CommitmentsAndContingenciesLineItems_637816497120771641" xlink:to="pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_637816497120771641" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_CommitmentsAndContingenciesLineItems_637816497120771641" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637816497120771641" order="7" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637816497120771641"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_CommitmentsAndContingenciesLineItems_637816497120771641" xlink:to="us-gaap_OperatingLeaseLiability_637816497120771641" order="8" use="optional" priority="2"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Commitments and Contingencies (Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_636918727687937499"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_636918727687937499" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637816497120781614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637816497120781614" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637816497120781614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637816497120781614" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637816497120781614" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637816497120781614" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637816497120781614" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637816497120781614" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637816497120781614" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637816497120781614" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637816497120781614" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637816497120781614" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637816497120781614" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637816497120781614" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637816497120781614" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637816497120781614" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637816497120781614" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637816497120781614" xlink:to="us-gaap_OperatingLeaseLiability_637816497120781614" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_BalanceSheetClassificationAbstract" xlink:label="pacb_BalanceSheetClassificationAbstract_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_636918727687937499" xlink:to="pacb_BalanceSheetClassificationAbstract_637816497120781614" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetClassificationAbstract_637816497120781614" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637816497120781614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetClassificationAbstract_637816497120781614" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637816497120781614" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_6378164971207816141"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_BalanceSheetClassificationAbstract_637816497120781614" xlink:to="us-gaap_OperatingLeaseLiability_6378164971207816141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Income Taxes (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_635230509057197959"></loc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_IncomeTaxesTable" xlink:label="pacb_IncomeTaxesTable_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057197959" xlink:to="pacb_IncomeTaxesTable_637816497120781614" order="1" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_IncomeTaxesTable_637816497120781614" xlink:to="srt_RangeAxis_637816497120781614" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637816497120781614" xlink:to="srt_RangeMember_637816497120781614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637816497120781614" xlink:to="srt_MinimumMember_637816497120781614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_IncomeTaxesTable_637816497120781614" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637816497120781614" order="2" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637816497120781614" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637816497120781614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637816497120781614" xlink:to="us-gaap_DomesticCountryMember_637816497120781614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637816497120781614" xlink:to="us-gaap_StateAndLocalJurisdictionMember_637816497120781614" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_IncomeTaxesTable_637816497120781614" xlink:to="srt_StatementScenarioAxis_637816497120781614" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637816497120781614" xlink:to="srt_ScenarioUnspecifiedDomain_637816497120781614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_WithExpirationMember" xlink:label="pacb_WithExpirationMember_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637816497120781614" xlink:to="pacb_WithExpirationMember_637816497120781614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_IncomeTaxesLineItems" xlink:label="pacb_IncomeTaxesLineItems_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_IncomeTaxesTable_637816497120781614" xlink:to="pacb_IncomeTaxesLineItems_637816497120781614" order="4" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_IncomeTaxesLineItems_637816497120781614" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_637816497120781614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_IncomeTaxesLineItems_637816497120781614" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_637816497120781614" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_IncomeTaxesLineItems_637816497120781614" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637816497120781614" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_637816497120781614"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_IncomeTaxesLineItems_637816497120781614" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_637816497120781614" order="4" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_IncomeTaxesLineItems_637816497120781614" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637816497120791586" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_IncomeTaxesLineItems_637816497120781614" xlink:to="us-gaap_OperatingLossCarryforwards_637816497120791586" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OperatingLossCarryforwardsExpirationYear" xlink:label="pacb_OperatingLossCarryforwardsExpirationYear_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_IncomeTaxesLineItems_637816497120781614" xlink:to="pacb_OperatingLossCarryforwardsExpirationYear_637816497120791586" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_IncomeTaxesLineItems_637816497120781614" xlink:to="us-gaap_TaxCreditCarryforwardAmount_637816497120791586" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TaxCreditCarryforwardExpirationYear" xlink:label="pacb_TaxCreditCarryforwardExpirationYear_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_IncomeTaxesLineItems_637816497120781614" xlink:to="pacb_TaxCreditCarryforwardExpirationYear_637816497120791586" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_IncomeTaxesLineItems_637816497120781614" xlink:to="us-gaap_UnrecognizedTaxBenefits_637816497120791586" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_IncomeTaxesLineItems_637816497120781614" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637816497120791586" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Income Taxes (Reconciliation of Federal Income Tax Rate) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_635230509057097959"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057097959" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637816497120791586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057097959" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637816497120791586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057097959" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637816497120791586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" xlink:label="pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057097959" xlink:to="pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_637816497120791586" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057097959" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637816497120791586" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" xlink:label="pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057097959" xlink:to="pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_637816497120791586" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057097959" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637816497120791586" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057097959" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637816497120791586" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Income Taxes (Reconciliation of Deferred Tax Assets and Liabilities) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_635230509057157959"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057157959" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_637816497120791586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637816497120791586" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637816497120791586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637816497120791586" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637816497120791586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637816497120791586" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense_637816497120791586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637816497120791586" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637816497120791586" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="pacb_DeferredTaxAssetsOperatingLeaseLiabilities_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637816497120791586" xlink:to="pacb_DeferredTaxAssetsOperatingLeaseLiabilities_637816497120791586" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637816497120791586" xlink:to="us-gaap_DeferredTaxAssetsGross_637816497120791586" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637816497120791586" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637816497120791586" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637816497120791586" xlink:to="us-gaap_DeferredTaxAssetsNet_637816497120791586" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057157959" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_637816497120791586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057157959" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637816497120791586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="pacb_DeferredTaxLiabilitiesRightOfUseAssets_637816497120791586"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057157959" xlink:to="pacb_DeferredTaxLiabilitiesRightOfUseAssets_637816497120791586" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057157959" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637816497120801560" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057157959" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_637816497120801560" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057157959" xlink:to="us-gaap_DeferredTaxLiabilities_637816497120801560" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitAccountsDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Income Taxes (Reconciliation of Unrecognized Tax Benefit Accounts) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_635230509057187959"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057187959" xlink:to="us-gaap_UnrecognizedTaxBenefits_637816497120801560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057187959" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_637816497120801560" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057187959" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_637816497120801560" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057187959" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_637816497120801560" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_6378164971208015601"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635230509057187959" xlink:to="us-gaap_UnrecognizedTaxBenefits_6378164971208015601" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Stockholders&apos; Equity (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637237514642063163"></loc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_StockholdersEquityTable" xlink:label="pacb_StockholdersEquityTable_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637237514642063163" xlink:to="pacb_StockholdersEquityTable_637816497120801560" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityTable_637816497120801560" xlink:to="us-gaap_VestingAxis_637816497120801560" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637816497120801560" xlink:to="us-gaap_VestingDomain_637816497120801560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember" xlink:label="pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637816497120801560" xlink:to="pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember_637816497120801560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityTable_637816497120801560" xlink:to="us-gaap_AwardTypeAxis_637816497120801560" order="2" use="optional" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637816497120801560" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120801560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OptionsToPurchaseCommonStockMember" xlink:label="pacb_OptionsToPurchaseCommonStockMember_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120801560" xlink:to="pacb_OptionsToPurchaseCommonStockMember_637816497120801560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:label="pacb_TimeBasedRestrictedStockUnitsRsusMember_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120801560" xlink:to="pacb_TimeBasedRestrictedStockUnitsRsusMember_637816497120801560" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityTable_637816497120801560" xlink:to="srt_StatementScenarioAxis_637816497120801560" order="3" use="optional" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637816497120801560" xlink:to="srt_ScenarioUnspecifiedDomain_637816497120801560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_UnderwrittenPublicEquityOfferingMember" xlink:label="pacb_UnderwrittenPublicEquityOfferingMember_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637816497120801560" xlink:to="pacb_UnderwrittenPublicEquityOfferingMember_637816497120801560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_UnderwritingAgreementMember" xlink:label="pacb_UnderwritingAgreementMember_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637816497120801560" xlink:to="pacb_UnderwritingAgreementMember_637816497120801560" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityTable_637816497120801560" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_637816497120801560" order="4" use="optional" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120801560"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_637816497120801560" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120801560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomePlanMember" xlink:label="pacb_OmniomePlanMember_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120801560" xlink:to="pacb_OmniomePlanMember_637816497120841457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TwoThousandTenEquityIncentivePlanMember" xlink:label="pacb_TwoThousandTenEquityIncentivePlanMember_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120801560" xlink:to="pacb_TwoThousandTenEquityIncentivePlanMember_637816497120841457" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EmployeeStockPurchasePlanMember" xlink:label="pacb_EmployeeStockPurchasePlanMember_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120801560" xlink:to="pacb_EmployeeStockPurchasePlanMember_637816497120841457" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EquityIncentivePlan2020Member" xlink:label="pacb_EquityIncentivePlan2020Member_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120801560" xlink:to="pacb_EquityIncentivePlan2020Member_637816497120841457" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InducementEquityIncentivePlan2020Member" xlink:label="pacb_InducementEquityIncentivePlan2020Member_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120801560" xlink:to="pacb_InducementEquityIncentivePlan2020Member_637816497120841457" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityTable_637816497120801560" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637816497120841457" order="5" use="optional" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637816497120841457" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120841457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeOneMember" xlink:label="pacb_ExercisePriceRangeOneMember_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120841457" xlink:to="pacb_ExercisePriceRangeOneMember_637816497120841457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityTable_637816497120801560" xlink:to="us-gaap_StatementEquityComponentsAxis_637816497120841457" order="6" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637816497120841457" xlink:to="us-gaap_EquityComponentDomain_637816497120841457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PrivatePlacementOfCommonStockMember" xlink:label="pacb_PrivatePlacementOfCommonStockMember_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637816497120841457" xlink:to="pacb_PrivatePlacementOfCommonStockMember_637816497120841457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637816497120841457" xlink:to="us-gaap_CommonStockMember_637816497120841457" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_StockholdersEquityLineItems" xlink:label="pacb_StockholdersEquityLineItems_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityTable_637816497120801560" xlink:to="pacb_StockholdersEquityLineItems_637816497120841457" order="7" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExchangeRatio" xlink:label="pacb_ExchangeRatio_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="pacb_ExchangeRatio_637816497120841457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_637816497120841457" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_CommonStockVotingRights_637816497120841457" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" xlink:label="pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_637816497120841457" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PublicOfferingShares" xlink:label="pacb_PublicOfferingShares_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="pacb_PublicOfferingShares_637816497120841457" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OfferingShareAmountMaximum" xlink:label="pacb_OfferingShareAmountMaximum_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="pacb_OfferingShareAmountMaximum_637816497120841457" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:label="pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_637816497120841457"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_637816497120841457" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:label="pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_637816497120851427"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_637816497120851427" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637816497120851427"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637816497120851427" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:label="pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_637816497120851427"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_637816497120851427" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_637816497120851427"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_637816497120851427" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_637816497120851427"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_DeferredOfferingCosts_637816497120851427" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_NumberOfOfferings" xlink:label="pacb_NumberOfOfferings_637816497120851427"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="pacb_NumberOfOfferings_637816497120851427" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637816497120851427"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_SharesIssuedPricePerShare_637816497120851427" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637816497120851427"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637816497120851427" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_637816497120851427"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_637816497120851427" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637816497120851427"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637816497120851427" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_637816497120851427"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_637816497120851427" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_NumberOfPurchasePeriods" xlink:label="pacb_NumberOfPurchasePeriods_637816497120851427"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="pacb_NumberOfPurchasePeriods_637816497120851427" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PurchasePeriodOfEmployeeStockPurchasePlan" xlink:label="pacb_PurchasePeriodOfEmployeeStockPurchasePlan_637816497120851427"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="pacb_PurchasePeriodOfEmployeeStockPurchasePlan_637816497120851427" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" xlink:label="pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_637816497120851427"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_637816497120851427" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_637816497120861401"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_637816497120861401" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_637816497120861401"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_637816497120861401" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637816497120861401"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637816497120861401" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637816497120861401"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637816497120861401" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637816497120861401"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_SharePrice_637816497120861401" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637816497120861401"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637816497120861401" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637816497120861401"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637816497120861401" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637816497120861401"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637816497120861401" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637816497120861401"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637816497120861401" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637816497120871372"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637816497120871372" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637816497120871372"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637816497120871372" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ShareInstrumentNumberOfSharesConversionRatio" xlink:label="pacb_ShareInstrumentNumberOfSharesConversionRatio_637816497120871372"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="pacb_ShareInstrumentNumberOfSharesConversionRatio_637816497120871372" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637816497120871372"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637816497120871372" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637816497120871372"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637816497120871372" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_637816497120871372"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_637816497120871372" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637816497120871372"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637816497120871372" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_637816497120871372"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_637816497120871372" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637816497120871372"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637816497120871372" order="39" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637816497120871372"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_CommonStockSharesIssued_637816497120871372" order="40" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637816497120881357"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637816497120881357" order="41" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637816497120881357"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637816497120881357" order="42" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637816497120881357"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_StockholdersEquityLineItems_637816497120841457" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637816497120881357" order="43" use="optional" priority="2"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Stockholders&apos; Equity (Summary of Stock Option Activity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637816497120881357"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637816497120881357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637816497120881357"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637816497120881357" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637816497120881357" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120881357"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637816497120881357" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120881357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeOneMember" xlink:label="pacb_ExercisePriceRangeOneMember_637816497120881357"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120881357" xlink:to="pacb_ExercisePriceRangeOneMember_637816497120881357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeTwoMember" xlink:label="pacb_ExercisePriceRangeTwoMember_637816497120881357"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120881357" xlink:to="pacb_ExercisePriceRangeTwoMember_637816497120881357" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeAcqusitionMember" xlink:label="pacb_ExercisePriceRangeAcqusitionMember_637816497120881357"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120881357" xlink:to="pacb_ExercisePriceRangeAcqusitionMember_637816497120881357" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeAcqusitionTwoMember" xlink:label="pacb_ExercisePriceRangeAcqusitionTwoMember_637816497120881357"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120881357" xlink:to="pacb_ExercisePriceRangeAcqusitionTwoMember_637816497120881357" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeThreeMember" xlink:label="pacb_ExercisePriceRangeThreeMember_637816497120881357"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120881357" xlink:to="pacb_ExercisePriceRangeThreeMember_637816497120881357" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeFourMember" xlink:label="pacb_ExercisePriceRangeFourMember_637816497120881357"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120881357" xlink:to="pacb_ExercisePriceRangeFourMember_637816497120881357" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeFiveMember" xlink:label="pacb_ExercisePriceRangeFiveMember_637816497120881357"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120881357" xlink:to="pacb_ExercisePriceRangeFiveMember_637816497120881357" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637816497120881357"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637816497120881357" xlink:to="us-gaap_AwardTypeAxis_637816497120881357" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120881357"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637816497120881357" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120881357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TimeBasedStockOptionMember" xlink:label="pacb_TimeBasedStockOptionMember_637816497120881357"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120881357" xlink:to="pacb_TimeBasedStockOptionMember_637816497120881357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OptionsToPurchaseCommonStockMember" xlink:label="pacb_OptionsToPurchaseCommonStockMember_637816497120891323"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120881357" xlink:to="pacb_OptionsToPurchaseCommonStockMember_637816497120891323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_637816497120891323"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120881357" xlink:to="us-gaap_PerformanceSharesMember_637816497120891323" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_637816497120891323"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637816497120881357" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_637816497120891323" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120891323"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_637816497120891323" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120891323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OmniomePlanMember" xlink:label="pacb_OmniomePlanMember_637816497120891323"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120891323" xlink:to="pacb_OmniomePlanMember_637816497120891323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120891323"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637816497120881357" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120891323" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637816497120891323"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120891323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637816497120891323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_637816497120891323"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120891323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_637816497120891323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637816497120891323"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120891323" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637816497120891323" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637816497120891323"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120891323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637816497120891323" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378164971208913231"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120891323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378164971208913231" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_637816497120891323"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120891323" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_637816497120891323" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_637816497120891323"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120891323" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_637816497120891323" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637816497120891323"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120891323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637816497120891323" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637816497120891323"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120891323" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637816497120891323" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637816497120891323"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120891323" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637816497120891323" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637816497120891323"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120891323" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637816497120891323" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378164971208913231"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120891323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378164971208913231" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Stockholders&apos; Equity (Reconciliation of Outstanding and Exercisable Stock Options) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637816497120891323"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637816497120891323" order="1" use="optional" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637816497120891323" xlink:to="us-gaap_AwardTypeAxis_637816497120901294" order="1" use="optional" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120901294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OptionsToPurchaseCommonStockMember" xlink:label="pacb_OptionsToPurchaseCommonStockMember_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120901294" xlink:to="pacb_OptionsToPurchaseCommonStockMember_637816497120901294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637816497120891323" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637816497120901294" order="2" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120901294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeSixMember" xlink:label="pacb_ExercisePriceRangeSixMember_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120901294" xlink:to="pacb_ExercisePriceRangeSixMember_637816497120901294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeSevenMember" xlink:label="pacb_ExercisePriceRangeSevenMember_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120901294" xlink:to="pacb_ExercisePriceRangeSevenMember_637816497120901294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeEightMember" xlink:label="pacb_ExercisePriceRangeEightMember_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120901294" xlink:to="pacb_ExercisePriceRangeEightMember_637816497120901294" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeNineMember" xlink:label="pacb_ExercisePriceRangeNineMember_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120901294" xlink:to="pacb_ExercisePriceRangeNineMember_637816497120901294" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeTenMember" xlink:label="pacb_ExercisePriceRangeTenMember_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120901294" xlink:to="pacb_ExercisePriceRangeTenMember_637816497120901294" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeElevenMember" xlink:label="pacb_ExercisePriceRangeElevenMember_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120901294" xlink:to="pacb_ExercisePriceRangeElevenMember_637816497120901294" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeThirteenMember" xlink:label="pacb_ExercisePriceRangeThirteenMember_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120901294" xlink:to="pacb_ExercisePriceRangeThirteenMember_637816497120901294" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeFourteenMember" xlink:label="pacb_ExercisePriceRangeFourteenMember_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120901294" xlink:to="pacb_ExercisePriceRangeFourteenMember_637816497120901294" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ExercisePriceRangeFifteenMember" xlink:label="pacb_ExercisePriceRangeFifteenMember_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637816497120901294" xlink:to="pacb_ExercisePriceRangeFifteenMember_637816497120901294" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637816497120891323" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120901294" order="3" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_637816497120901294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_637816497120901294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_637816497120901294" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120901294" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_637816497120901294" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120901294" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_637816497120901294" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_637816497120901294" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637816497120901294" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_637816497120901294" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Stockholders&apos; Equity (Summary of Time-Based RSUs Activity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120901294" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120901294" xlink:to="us-gaap_AwardTypeAxis_637816497120901294" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120901294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:label="pacb_TimeBasedRestrictedStockUnitsRsusMember_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120901294" xlink:to="pacb_TimeBasedRestrictedStockUnitsRsusMember_637816497120901294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120901294" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637816497120901294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637816497120901294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637816497120901294"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637816497120901294" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637816497120911269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637816497120911269" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637816497120911269" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637816497120911269" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637816497120911269" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637816497120911269" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6378164971209112691"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120901294" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6378164971209112691" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Stockholders&apos; Equity (Summary of Performance-Based RSUs Activity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636681277739601561"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636681277739601561" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120911269" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120911269" xlink:to="us-gaap_AwardTypeAxis_637816497120911269" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637816497120911269" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120911269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PerformanceBasedRestrictedStockUnitsRsusMember" xlink:label="pacb_PerformanceBasedRestrictedStockUnitsRsusMember_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120911269" xlink:to="pacb_PerformanceBasedRestrictedStockUnitsRsusMember_637816497120911269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120911269" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120911269" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120911269" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637816497120911269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120911269" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637816497120911269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120911269" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637816497120911269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120911269" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637816497120911269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6378164971209112691"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120911269" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6378164971209112691" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120911269" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637816497120911269" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120911269" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637816497120911269" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120911269" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637816497120911269" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120911269" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637816497120911269" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6378164971209112691"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120911269" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6378164971209112691" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41006 - Disclosure - Stockholders&apos; Equity (Schedule of Stock-Based Compensation Expense) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637816497120911269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637816497120911269" xlink:to="us-gaap_IncomeStatementLocationAxis_637816497120911269" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637816497120911269" xlink:to="us-gaap_IncomeStatementLocationDomain_637816497120911269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637816497120911269" xlink:to="us-gaap_CostOfSalesMember_637816497120911269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637816497120911269" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637816497120911269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637816497120911269" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637816497120911269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerRelatedExpensesStockSettledMember" xlink:label="pacb_MergerRelatedExpensesStockSettledMember_637816497120911269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637816497120911269" xlink:to="pacb_MergerRelatedExpensesStockSettledMember_637816497120911269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerRelatedExpensesMilestoneMember" xlink:label="pacb_MergerRelatedExpensesMilestoneMember_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637816497120911269" xlink:to="pacb_MergerRelatedExpensesMilestoneMember_637816497120921241" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_StockBasedCompensationMember" xlink:label="pacb_StockBasedCompensationMember_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637816497120911269" xlink:to="pacb_StockBasedCompensationMember_637816497120921241" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_MergerRelatedExpensesCashSettledMember" xlink:label="pacb_MergerRelatedExpensesCashSettledMember_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637816497120911269" xlink:to="pacb_MergerRelatedExpensesCashSettledMember_637816497120921241" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637816497120911269" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637816497120921241" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637816497120921241" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637816497120921241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails" xlink:type="extended" xlink:title="41007 - Disclosure - Stockholders&apos; Equity (Schedule of Fair Value of Employee Stock Options) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120921241" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120921241" xlink:to="us-gaap_AwardTypeAxis_637816497120921241" order="1" use="optional" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637816497120921241" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120921241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OptionsToPurchaseCommonStockMember" xlink:label="pacb_OptionsToPurchaseCommonStockMember_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120921241" xlink:to="pacb_OptionsToPurchaseCommonStockMember_637816497120921241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120921241" xlink:to="srt_RangeAxis_637816497120921241" order="2" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637816497120921241" xlink:to="srt_RangeMember_637816497120921241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637816497120921241" xlink:to="srt_MinimumMember_637816497120921241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637816497120921241" xlink:to="srt_MaximumMember_637816497120921241" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120921241" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120921241" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120921241" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637816497120921241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120921241" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_637816497120921241" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120921241" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637816497120921241" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120921241" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637816497120921241" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120921241" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637816497120921241" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120921241" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637816497120921241" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails" xlink:type="extended" xlink:title="41008 - Disclosure - Stockholders&apos; Equity (Schedule of Fair Value of Employee Stock Purchase Plan) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636368481121359562"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636368481121359562" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120921241" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120921241" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_637816497120921241" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_637816497120921241" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120921241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EmployeeStockPurchasePlanMember" xlink:label="pacb_EmployeeStockPurchasePlanMember_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120921241" xlink:to="pacb_EmployeeStockPurchasePlanMember_637816497120921241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120921241" xlink:to="srt_RangeAxis_637816497120921241" order="2" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637816497120921241" xlink:to="srt_RangeMember_637816497120921241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637816497120921241" xlink:to="srt_MinimumMember_637816497120921241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637816497120921241" xlink:to="srt_MaximumMember_637816497120921241" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120921241"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637816497120921241" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120921241" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120921241" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637816497120931219" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120921241" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_637816497120931219" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120921241" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637816497120931219" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120921241" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637816497120931219" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120921241" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637816497120931219" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637816497120921241" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637816497120931219" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Net (Loss) Income Per Share (Computation Of Basic And Diluted Net Loss Per Share) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_637480582002511880"></loc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfEarningsPerShareTable" xlink:label="pacb_ScheduleOfEarningsPerShareTable_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637480582002511880" xlink:to="pacb_ScheduleOfEarningsPerShareTable_637816497120931219" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_ScheduleOfEarningsPerShareTable_637816497120931219" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_637816497120931219" order="1" use="optional" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_637816497120931219" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120931219" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EmployeeStockPurchasePlanMember" xlink:label="pacb_EmployeeStockPurchasePlanMember_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120931219" xlink:to="pacb_EmployeeStockPurchasePlanMember_637816497120931219" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_ScheduleOfEarningsPerShareTable_637816497120931219" xlink:to="us-gaap_AwardTypeAxis_637816497120931219" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637816497120931219" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120931219" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OptionsToPurchaseCommonStockMember" xlink:label="pacb_OptionsToPurchaseCommonStockMember_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120931219" xlink:to="pacb_OptionsToPurchaseCommonStockMember_637816497120931219" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637816497120931219" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637816497120931219" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ScheduleOfEarningsPerShareLineItems" xlink:label="pacb_ScheduleOfEarningsPerShareLineItems_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_ScheduleOfEarningsPerShareTable_637816497120931219" xlink:to="pacb_ScheduleOfEarningsPerShareLineItems_637816497120931219" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pacb_ScheduleOfEarningsPerShareLineItems_637816497120931219" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_637816497120931219" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_637816497120931219" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637816497120931219" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637816497120931219" xlink:to="us-gaap_NetIncomeLossAbstract_637816497120931219" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_637816497120931219" xlink:to="us-gaap_NetIncomeLoss_637816497120931219" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637816497120931219" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637816497120931219" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637816497120931219" xlink:to="us-gaap_EarningsPerShareBasicAbstract_637816497120931219" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_637816497120931219" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637816497120931219" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_637816497120931219" xlink:to="us-gaap_EarningsPerShareBasic_637816497120931219" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637816497120931219" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_637816497120931219" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6378164971209312191"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_637816497120931219" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6378164971209312191" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_637816497120931219" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_637816497120931219" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_637816497120931219" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637816497120931219" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637816497120931219"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637816497120931219" xlink:to="us-gaap_EarningsPerShareDiluted_637816497120931219" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Net (Loss) Income Per Share (Antidilutive Shares Excluded From Computation Of Diluted Net Loss Per Share) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_635230437916857959"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_635230437916857959" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637816497120941189" order="1" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637816497120941189" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_637816497120941189" order="1" use="optional" priority="7"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_637816497120941189" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120941189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_EmployeeStockPurchasePlanMember" xlink:label="pacb_EmployeeStockPurchasePlanMember_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_637816497120941189" xlink:to="pacb_EmployeeStockPurchasePlanMember_637816497120941189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637816497120941189" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637816497120941189" order="2" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637816497120941189" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637816497120941189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember" xlink:label="pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637816497120941189" xlink:to="pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember_637816497120941189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_OptionsToPurchaseCommonStockMember" xlink:label="pacb_OptionsToPurchaseCommonStockMember_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637816497120941189" xlink:to="pacb_OptionsToPurchaseCommonStockMember_637816497120941189" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:label="pacb_TimeBasedRestrictedStockUnitsRsusMember_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637816497120941189" xlink:to="pacb_TimeBasedRestrictedStockUnitsRsusMember_637816497120941189" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_PerformanceBasedRestrictedStockUnitsRsusMember" xlink:label="pacb_PerformanceBasedRestrictedStockUnitsRsusMember_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637816497120941189" xlink:to="pacb_PerformanceBasedRestrictedStockUnitsRsusMember_637816497120941189" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637816497120941189" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637816497120941189" order="3" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637816497120941189" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637816497120941189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationNarrativeDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Segment And Geographic Information (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_637179142023113443"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_637179142023113443" xlink:to="us-gaap_NumberOfReportableSegments_637816497120941189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Segment And Geographic Information (Schedule of Revenue by Geographic Location) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_635230399192809850"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_635230399192809850" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_637816497120941189" order="1" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_637816497120941189" xlink:to="srt_StatementGeographicalAxis_637816497120941189" order="1" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637816497120941189" xlink:to="srt_SegmentGeographicalDomain_637816497120941189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637816497120941189" xlink:to="srt_NorthAmericaMember_637816497120941189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637816497120941189" xlink:to="srt_EuropeMember_637816497120941189" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AsiaPacificMember" xlink:label="srt_AsiaPacificMember_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637816497120941189" xlink:to="srt_AsiaPacificMember_637816497120941189" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_637816497120941189" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_637816497120941189" order="2" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_637816497120941189" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637816497120941189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Segment And Geographic Information (Summary of Revenue by Category) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_637179139371944750"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_637179139371944750" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_637816497120941189" order="1" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637816497120941189"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_637816497120941189" xlink:to="srt_ProductOrServiceAxis_637816497120941189" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637816497120951163"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637816497120941189" xlink:to="srt_ProductsAndServicesDomain_637816497120951163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637816497120951163"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637816497120951163" xlink:to="us-gaap_ProductMember_637816497120951163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_InstrumentMember" xlink:label="pacb_InstrumentMember_637816497120951163"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_637816497120951163" xlink:to="pacb_InstrumentMember_637816497120951163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ConsumableMember" xlink:label="pacb_ConsumableMember_637816497120951163"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_637816497120951163" xlink:to="pacb_ConsumableMember_637816497120951163" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="pacb-20211231.xsd#pacb_ServiceAndOtherMember" xlink:label="pacb_ServiceAndOtherMember_637816497120951163"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637816497120951163" xlink:to="pacb_ServiceAndOtherMember_637816497120951163" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_637816497120951163"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_637816497120941189" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_637816497120951163" order="2" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637816497120951163"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_637816497120951163" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637816497120951163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc></presentationLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284762844792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Pacific Biosciences of California, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">16-1590339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1305 O&#8217;Brien Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Menlo Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">521-8000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PACB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,791,088,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,182,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001299130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive Proxy Statement relating to its 2022 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K where indicated. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Redwood City, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm Id</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284761292984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 460,725,000<span></span>
</td>
<td class="nump">$ 81,611,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="nump">583,675,000<span></span>
</td>
<td class="nump">237,203,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">24,241,000<span></span>
</td>
<td class="nump">16,837,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">24,599,000<span></span>
</td>
<td class="nump">14,230,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,394,000<span></span>
</td>
<td class="nump">4,870,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">836,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,101,134,000<span></span>
</td>
<td class="nump">355,587,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">32,504,000<span></span>
</td>
<td class="nump">24,899,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">46,617,000<span></span>
</td>
<td class="nump">29,951,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">4,592,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">410,979,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">409,974,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">1,170,000<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,006,970,000<span></span>
</td>
<td class="nump">413,980,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,002,000<span></span>
</td>
<td class="nump">3,579,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">36,261,000<span></span>
</td>
<td class="nump">17,350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">10,977,000<span></span>
</td>
<td class="nump">8,722,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">7,710,000<span></span>
</td>
<td class="nump">4,332,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities, current</a></td>
<td class="nump">5,759,000<span></span>
</td>
<td class="nump">4,519,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">71,709,000<span></span>
</td>
<td class="nump">38,502,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">25,049,000<span></span>
</td>
<td class="nump">1,568,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration liability, non-current</a></td>
<td class="nump">169,717,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">49,970,000<span></span>
</td>
<td class="nump">37,667,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible senior notes, net, non-current</a></td>
<td class="nump">896,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities, non-current</a></td>
<td class="nump">3,471,000<span></span>
</td>
<td class="nump">752,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,215,983,000<span></span>
</td>
<td class="nump">78,489,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value: Authorized 50,000 shares; No shares issued or outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value Authorized 1,000,000 shares; issued and outstanding 220,978 and 192,294 shares at December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">221,000<span></span>
</td>
<td class="nump">192,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,009,945,000<span></span>
</td>
<td class="nump">1,372,083,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(1,087,000)<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,218,092,000)<span></span>
</td>
<td class="num">(1,036,869,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">790,987,000<span></span>
</td>
<td class="nump">335,491,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 2,006,970,000<span></span>
</td>
<td class="nump">$ 413,980,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284762826152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
<td class="nump">220,978,000<span></span>
</td>
<td class="nump">192,294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
<td class="nump">220,978,000<span></span>
</td>
<td class="nump">192,294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284758791144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 130,513,000<span></span>
</td>
<td class="nump">$ 78,893,000<span></span>
</td>
<td class="nump">$ 90,891,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of Intangible Assets</a></td>
<td class="nump">306,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenue</a></td>
<td class="nump">71,653,000<span></span>
</td>
<td class="nump">46,327,000<span></span>
</td>
<td class="nump">56,315,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">58,860,000<span></span>
</td>
<td class="nump">32,566,000<span></span>
</td>
<td class="nump">34,576,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">112,899,000<span></span>
</td>
<td class="nump">64,152,000<span></span>
</td>
<td class="nump">59,630,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general and administrative</a></td>
<td class="nump">124,124,000<span></span>
</td>
<td class="nump">72,799,000<span></span>
</td>
<td class="nump">75,491,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Merger-related expenses</a></td>
<td class="nump">31,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">1,143,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">269,295,000<span></span>
</td>
<td class="nump">136,951,000<span></span>
</td>
<td class="nump">135,121,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(210,435,000)<span></span>
</td>
<td class="num">(104,385,000)<span></span>
</td>
<td class="num">(100,545,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_GainLossOnReverseTerminationFee', window );">Gain from Reverse Termination Fee from Illumina</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">(Loss)/Gain from Continuation Advances from Illumina</a></td>
<td class="num">(52,000,000)<span></span>
</td>
<td class="nump">34,000,000<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(12,530,000)<span></span>
</td>
<td class="num">(267,000)<span></span>
</td>
<td class="num">(2,611,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">93,000<span></span>
</td>
<td class="nump">2,055,000<span></span>
</td>
<td class="nump">1,022,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before benefit from income taxes</a></td>
<td class="num">(274,872,000)<span></span>
</td>
<td class="nump">29,403,000<span></span>
</td>
<td class="num">(84,134,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="num">(93,649,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(181,223,000)<span></span>
</td>
<td class="nump">29,403,000<span></span>
</td>
<td class="num">(84,134,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized (loss) gain on investments</a></td>
<td class="num">(1,172,000)<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (182,395,000)<span></span>
</td>
<td class="nump">$ 29,483,000<span></span>
</td>
<td class="num">$ (84,093,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average shares outstanding used in computing net income (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">204,136<span></span>
</td>
<td class="nump">165,187<span></span>
</td>
<td class="nump">152,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">204,136<span></span>
</td>
<td class="nump">174,970<span></span>
</td>
<td class="nump">152,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 113,505,000<span></span>
</td>
<td class="nump">$ 65,424,000<span></span>
</td>
<td class="nump">$ 77,742,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product revenue</a></td>
<td class="nump">56,358,000<span></span>
</td>
<td class="nump">35,424,000<span></span>
</td>
<td class="nump">44,771,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember', window );">Service and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">17,008,000<span></span>
</td>
<td class="nump">13,469,000<span></span>
</td>
<td class="nump">13,149,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product revenue</a></td>
<td class="nump">$ 14,989,000<span></span>
</td>
<td class="nump">$ 10,903,000<span></span>
</td>
<td class="nump">$ 11,544,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_GainLossOnReverseTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Reverse Termination Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_GainLossOnReverseTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284755779592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th">
<div>Accumulated Deficit [Member] </div>
<div>Revision of Prior Period, Accounting Standards Update, Adjustment [Member]</div>
</th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Revision of Prior Period, Accounting Standards Update, Adjustment [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 1,096,053<span></span>
</td>
<td class="num">$ (36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (982,106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,061<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="nump">150,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">8,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans, shares</a></td>
<td class="nump">2,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,401<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 153<span></span>
</td>
<td class="nump">1,120,999<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,066,240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,917<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="nump">153,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">46,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans, shares</a></td>
<td class="nump">9,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from underwritten public equity offering, net of issuance costs</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">187,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from underwritten public equity offering, net of issuance costs, shares</a></td>
<td class="nump">29,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,533<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance (Accounting Standards Update, Topic 326 [Member]) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">1,372,083<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,036,869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335,491<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">192,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(181,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (181,223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">31,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans, shares</a></td>
<td class="nump">8,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts', window );">Issuance of common stock in Private Placement, net of issuance costs</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">294,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares', window );">Issuance of common stock in Private Placement, net of issuance costs shares</a></td>
<td class="nump">11,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in acquisition of Omniome</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">237,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in acquisition of Omniome, shares</a></td>
<td class="nump">8,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,355<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">$ 2,009,945<span></span>
</td>
<td class="num">$ (1,087)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,218,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 790,987<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">220,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,978<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in Private Placement, net of issuance costs, number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in private placement net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201904Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201904Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284755887304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (181,223)<span></span>
</td>
<td class="nump">$ 29,403<span></span>
</td>
<td class="num">$ (84,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Loss (gain) from Continuation Advances</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="num">(34,000)<span></span>
</td>
<td class="num">(18,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">7,199<span></span>
</td>
<td class="nump">6,428<span></span>
</td>
<td class="nump">7,265<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense', window );">Amortization of intangible assets</a></td>
<td class="nump">381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">4,005<span></span>
</td>
<td class="nump">2,876<span></span>
</td>
<td class="nump">2,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and financing costs</a></td>
<td class="nump">539<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">1,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">73,355<span></span>
</td>
<td class="nump">17,533<span></span>
</td>
<td class="nump">16,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfDerivatives', window );">Loss from derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization (accretion) from investment premium (discount)</a></td>
<td class="nump">4,011<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="num">(913)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in the estimated fair value of contingent consideration</a></td>
<td class="nump">1,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposition of equipment</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(93,649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(7,166)<span></span>
</td>
<td class="num">(1,603)<span></span>
</td>
<td class="num">(6,671)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(12,431)<span></span>
</td>
<td class="num">(1,096)<span></span>
</td>
<td class="nump">3,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(1,024)<span></span>
</td>
<td class="num">(1,063)<span></span>
</td>
<td class="num">(523)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">6,363<span></span>
</td>
<td class="num">(5,072)<span></span>
</td>
<td class="nump">1,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">15,320<span></span>
</td>
<td class="nump">4,102<span></span>
</td>
<td class="nump">2,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Deferred revenue</a></td>
<td class="nump">25,736<span></span>
</td>
<td class="nump">729<span></span>
</td>
<td class="nump">2,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease liabilities</a></td>
<td class="num">(4,990)<span></span>
</td>
<td class="num">(3,802)<span></span>
</td>
<td class="num">(3,428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="num">(803)<span></span>
</td>
<td class="nump">5,046<span></span>
</td>
<td class="num">(2,477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(111,180)<span></span>
</td>
<td class="nump">19,503<span></span>
</td>
<td class="num">(78,312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(5,931)<span></span>
</td>
<td class="num">(1,039)<span></span>
</td>
<td class="num">(2,836)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="num">(988,046)<span></span>
</td>
<td class="num">(373,283)<span></span>
</td>
<td class="num">(57,727)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="nump">212,734<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">422,505<span></span>
</td>
<td class="nump">153,600<span></span>
</td>
<td class="nump">121,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by in investing activities</a></td>
<td class="num">(678,531)<span></span>
</td>
<td class="num">(219,322)<span></span>
</td>
<td class="nump">62,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ProceedsFromRepaymentsOfContractTermination', window );">Continuation Advances</a></td>
<td class="num">(52,000)<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Notes payable principal payoff</a></td>
<td class="num">(361)<span></span>
</td>
<td class="num">(16,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of Convertible Senior Notes, net of issuance costs</a></td>
<td class="nump">895,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Proceeds from issuance of common stock from underwritten public equity offerings, net of issuance costs</a></td>
<td class="nump">294,845<span></span>
</td>
<td class="nump">187,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock from equity plans</a></td>
<td class="nump">31,806<span></span>
</td>
<td class="nump">46,360<span></span>
</td>
<td class="nump">8,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,169,581<span></span>
</td>
<td class="nump">251,839<span></span>
</td>
<td class="nump">26,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents and restricted cash</a></td>
<td class="nump">379,870<span></span>
</td>
<td class="nump">52,020<span></span>
</td>
<td class="nump">10,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">85,947<span></span>
</td>
<td class="nump">33,927<span></span>
</td>
<td class="nump">33,927<span></span>
</td>
<td class="nump">23,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at end of period</a></td>
<td class="nump">465,817<span></span>
</td>
<td class="nump">85,947<span></span>
</td>
<td class="nump">33,927<span></span>
</td>
<td class="nump">$ 33,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">460,725<span></span>
</td>
<td class="nump">81,611<span></span>
</td>
<td class="nump">29,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash at end of period</a></td>
<td class="nump">5,092<span></span>
</td>
<td class="nump">4,336<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">6,928<span></span>
</td>
<td class="nump">491<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_InventoryTransferredToFromPropertyAndEquipment', window );">Inventory transferred to property and equipment</a></td>
<td class="nump">2,586<span></span>
</td>
<td class="nump">1,097<span></span>
</td>
<td class="nump">2,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_InventoryTransferredFromPropertyAndEquipment', window );">Property and equipment transferred to inventory</a></td>
<td class="num">(383)<span></span>
</td>
<td class="num">$ (919)<span></span>
</td>
<td class="num">$ (1,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset and liability additions and modifications</a></td>
<td class="nump">2,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in acquisition of Omniome</a></td>
<td class="nump">237,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember', window );">Circulomics, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for purchase of business acquisition, net of cash acquired</a></td>
<td class="num">(28,560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for purchase of business acquisition, net of cash acquired</a></td>
<td class="num">$ (291,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) and research development expense in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_InventoryTransferredFromPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory Transferred From Property And Equipment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_InventoryTransferredFromPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_InventoryTransferredToFromPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of inventory transferred (from) to the entity's property and equipment in noncash transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_InventoryTransferredToFromPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ProceedsFromRepaymentsOfContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from (Repayments of) Contract Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ProceedsFromRepaymentsOfContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284759961896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIESBusiness OverviewWe are a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems.  Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing technology and our emerging short read Sequencing by Binding (SBB&#174;) technology. Our products address solutions across a broad set of applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Our focus is on providing our customers with advanced sequencing technologies with higher throughput and improved workflows that we believe will enable dramatic advancements in routine healthcare.  Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies and agricultural companies.References in this report to &#8220;PacBio,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; and &#8220;our&#8221; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.Basis of Presentation Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. Use of Estimates The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates including, but not limited to, the valuation of inventory, the determination of stand-alone selling prices for revenue recognition, the fair value of contingent consideration, the valuation of acquired intangible assets, the fair value of certain equity awards, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, the borrowing rate used in calculating the operating lease right-of-use assets and operating lease liabilities, the probability associated with variable payments under partnership development agreements, and the valuations related to our convertible senior notes. While the extent of the impact of the COVID-19 pandemic on our business is highly uncertain, we considered the impact on our assumptions and estimates used to determine the results reported and asset valuations as of December 31, 2021. Actual results could differ materially from these estimates. Functional CurrencyThe U.S. dollar is the functional currency of our international operations.  We remeasure foreign subsidiaries monetary assets and liabilities to the U.S. dollar and record net gains or losses from remeasurement in other income, net, in the consolidated statement of operations and comprehensive (loss) income.Cash, Cash Equivalents, and Investments We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. We classify our investments in debt securities as available-for sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related.  Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive (loss) income in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net.  Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and US government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.Concentration and Credit Risks Financial instruments that potentially subject us to credit risk consist principally of interest-bearing investments and trade receivables. We maintain cash, cash equivalents and investments with various major financial institutions. The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities and government agencies of high credit standing. At December 31, 2021, most of our cash was deposited with U.S. financial institutions.  Our investment policy generally restricts the amount of credit exposure to any one issuer. There is no limit to the percentage of the portfolio that may be maintained in securities issued by the U.S. Treasury and U.S. Government Agencies, or other securities fully backed by US Treasury or Government agencies. We have not experienced significant credit losses from financial institutions.Our trade receivables are derived from net revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers&#8217; financial condition and, generally, require no collateral from our customers. The allowance for doubtful accounts is based on our assessment of the collectability of customer accounts. We regularly review our trade receivable including consideration of factors such as historical experience, the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. We have not experienced any significant credit losses to date. Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. For the years ended December 31, 2021, 2020 and 2019, one customer, Gene Company Limited, accounted for approximately 13%, 14% and 17% our total revenue, respectively. As of December 31, 2021 and 2020, 53% and 43% of our accounts receivable were from domestic customers, respectively. As of December 31, 2021, no customer represented 10% of greater of our net accounts receivable. As of December 31, 2020, two customers, Berry Genomics Co., Ltd and Gene Company Limited, represented approximately 15% and 12% of our net accounts receivable, respectively. We currently purchase several key parts and components used in the manufacture of our products from a limited number of suppliers. Generally, we have been able to obtain an adequate supply of such parts and components but in certain instances have incurred additional costs to secure supply constrained materials. An extended interruption in the supply of parts and components currently obtained from our suppliers could adversely affect our business and consolidated financial statements. Inventory Inventories are stated at the lower of average cost or net realizable value. Cost is determined using the first-in, first-out (&#8220;FIFO&#8221;) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs while determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories. &#160;  We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.Property and Equipment, Net Property and equipment are stated at cost, reviewed regularly for impairment charges, and depreciated over the estimated useful lives of the assets, using the straight-line method.  Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred. Estimated useful lives of the major classes of property and equipment are as follows:         Estimated Useful LivesLeasehold improvements 3 to 10 yearsLab equipment 3 to 5 yearsComputer equipment 3 to 5 yearsComputer software 3 yearsFurniture and fixtures 3 to 5 yearsImpairment of Tangible Long-Lived Assets We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset is impaired or the estimated useful lives are no longer appropriate. Fair value is estimated based on discounted future cash flows. If indicators of impairment exist and the undiscounted projected cash flows associated with such assets are less than the carrying amount of the asset, an impairment loss is recorded to write the asset down to its estimated fair value. To date, we have not recorded any impairment charges.Operating Leases We record operating lease right-of-use assets and liabilities on our Consolidated Balance Sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. Operating lease expense is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period incurred. Goodwill and Intangible AssetsWe perform annual impairment testing of goodwill and in-process research and development project (&#8220;IPR&D&#8221;) in the second quarter of each year, or more frequently if indicators of potential impairment exist.We capitalize IPR&D assets and will begin to amortize the asset over the life of the product upon commercialization or record an impairment charge if the project is abandoned. We also capitalize finite-lived intangibles assets and amortize them on a straight-line basis over the estimated useful lives.Finite-lived intangibles assets include our acquired developed technology and customer relationships. We regularly review the carrying amount and useful lives of our finite-lived assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives.&#160;Short-term Restricted Cash At December 31, 2021, the short-term restricted cash balance of $0.5 million consisted of security deposits for employee credit cards.Long-term Restricted Cash Under the lease agreement for our corporate offices, we were required to establish a letter of credit for the benefits of the landlord and to submit $4.5 million as a deposit for the letter of credit in October 2015. Subsequently pursuant to the terms of the O&#8217;Brien Lease, beginning on May 1, 2019, the amount of the letter of credit was reduced by $0.5 million each year thereafter on May 1. As such, $3.0 million and $3.5 million was recorded in long-term restricted cash related to the O&#8217;Brien Lease in the Consolidated Balance Sheets as of December 31, 2021 and December 31, 2020, respectively.In connection with the acquisition of Omniome in September 2021, we acquired $1.6 million of long-term restricted cash related to a letter of credit established for a facility lease.Revenue Recognition Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables. Service and other revenue consists primarily of revenue earned from product maintenance agreements. We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods or services is transferred to our customers or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our instrument sales are generally sold in a bundled arrangement and commonly include the instrument, instrument accessories, installation, training, and consumables. Additionally, our instrument sale arrangements generally include a&#160;one-year period of service. For such bundled arrangements, we account for individual products and services separately if they are distinct, that is, if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. Our customers cannot benefit from our instrument systems without installation, and installation can only be performed by us or qualified distributors. As a result, the system and installation are considered to be a single performance obligation recognized after installation is completed except for sales to qualified distributors, in which case the system is distinct and recognized when control has transferred to the distributor which typically occurs upon shipment.  The consideration for bundled arrangements is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using average selling prices over a 12-month period combined with an assessment of current market conditions. If the standalone selling price is not directly observable, then we will estimate the SSP by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices and other observable inputs. We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts, distributor commissions, and sales taxes collected on behalf of governmental authorities.  We record deferred revenues when cash payments are received or due in advance of our performance. Deferred revenue for instrument service contracts is recognized over the related performance period, generally one year to five years, on a straight-line basis as we are standing ready to provide services and a time-based measure of progress best reflects the satisfaction of the performance obligation. Cost of RevenueCost of revenue reflects the direct cost of product components, third-party manufacturing services and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain and support our instruments, consumables, and services. There are no incremental costs associated with our contractual revenue; all product development costs are reflected in research and development expense.Manufacturing overhead is predominantly comprised of labor and facility costs. We determine and capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs.  Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support our installed customer base. Research and Development Research and development expense consists primarily of expenses for personnel engaged in the development of our core technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, partner development costs, facilities costs and other related overhead. We expense research and development costs during the period in which the costs are incurred. However, we defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered. Credit LossesWe adopted Topic 326 on January 1, 2020. The adoption of Topic 326 did not have a material impact on our financial statements and our bad debt expense was immaterial as of the years ended December 31, 2020 and 2021. Trade accounts receivable - The allowance for doubtful accounts is based on our assessment of the collectability of customer accounts. We regularly review the allowance by considering factors such as the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. Available-for-sale debt securities - Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and US government and agency securities. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as significance of loss, historical experience, market data, issuer-specific factors, and current economic conditions and concluded that an allowance for credit losses was immaterial as of December 31, 2021. The unrealized losses on our investments are mainly attributable to government securities, including U.S. government and U.S. agency bond securities, impacted by movements in market rates and not due to issuer credit ratings. We have the ability to hold and do not intend to sell the investments in unrealized loss positions before the recovery of their amortized cost bases.Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruptions associated with the evolution of the COVID-19 pandemic, or other customer-specific factors. Income Taxes We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. The effect of a change in tax rates on the deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized. We regularly review our positions taken relative to income taxes. To the extent our tax positions are more likely than not going to result in additional taxes, we accrue the estimated amount of tax related to such uncertain positions. Stock-based Compensation We account for share-based payments using a fair-value based method for costs related to all share-based payments, including stock options, restricted stock units, and stock issued under our employee stock purchase plan (&#8220;ESPP&#8221;). We estimate the fair value of share-based payment awards that are stock options and issued under our ESPP on the date of grant using an option-pricing model. See Note 10. Stockholders&#8217; Equity for further information regarding stock-based compensation.Other Comprehensive (Loss) IncomeOther comprehensive (loss) income is comprised of unrealized gains (losses) on our investment securities. Shipping and HandlingCosts related to shipping and handling are included in cost of revenues for all periods presented.Recent Accounting Pronouncements Recently Adopted Accounting StandardsIn August 2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2020-06,&#160;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity. This guidance simplifies the accounting for convertible instruments primarily by eliminating the existing cash conversion and beneficial conversion models within Subtopic 470-20, which will result in fewer embedded conversion options being accounted for separately from the debt host. The guidance also amends and simplifies the calculation of earnings per share relating to convertible instruments. This guidance is effective for annual periods beginning after December 15, 2021, including interim periods within that reporting period, excluding smaller reporting companies. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within that reporting period, using either a full or modified retrospective approach. We adopted ASU 2020-06 on January 1, 2021. Because we had no convertible instruments within the scope of ASU 2020-06 at the time of adoption, there was no impact of adoption on our consolidated financial statements. In February 2021, we issued $900 million of 1.50% Convertible Senior Notes due February 15, 2028, as described in Note 7. Convertible Senior Notes, which are accounted for under ASU 2020-06.In&#160;December 2019,&#160;the FASB issued ASU&#160;No.&#160;2019-12,&#160;Income Taxes (Topic&#160;740): Simplifying the Accounting for Income Taxes. This ASU simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step up in the tax basis of goodwill, and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. The standard is effective for our annual reporting periods beginning after December 15, 2020, including interim reporting periods within those fiscal years. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not&#160;have a material impact on our consolidated financial statements. Accounting Pronouncements Pending AdoptionIn October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU provides specific guidance on how to recognize contract assets and contract liabilities related to revenue contracts with customers acquired in a business combination. This amendment improves comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. This authoritative guidance will be effective for us in the first quarter of 2023, with early adoption permitted. We are currently evaluating the effect of this new guidance on our consolidated financial statements.&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284759737768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business acquisitions</a></td>
<td class="text">NOTE 2. BUSINESS ACQUISITIONSOmniome, Inc.On September 20, 2021, we completed our acquisition of Omniome, Inc. (&#8220;Omniome&#8221;), a San Diego-based company developing a highly differentiated, proprietary short-read DNA sequencing platform capable of delivering high accuracy. In connection with the acquisition, all outstanding equity securities of Omniome were cancelled in exchange for approximately $315.7 million in cash, 8,911,580 shares of our common stock with a fair value of $249.4 million and contingent consideration with a fair value of $168.6 million. The fair value of the 8,911,580 common shares issued was determined based on the closing market price of PacBio&#8217;s common shares on the acquisition date.In addition, approximately $18.9 million, comprised of $7.4 million of cash, 226,811 shares of our common stock with a fair value of $6.3 million, and $5.2 million related to contingent consideration, was accounted for as a one-time post acquisition stock-based compensation expense. This stock-based compensation expense was due to accelerated vesting of Omniome stock awards in connection with the acquisition.Total consideration transferred for the acquisition is as follows (in thousands):     Total cash paid$ 315,703Fair value of share consideration  249,435Fair value of contingent consideration  168,574Less: Stock-based compensation expense excluded from consideration transferred  (18,923)Total consideration transferred$ 714,789   The contingent consideration of $200 million (composed of $100 million in cash and $100 million in shares of our common stock) is due upon the achievement of a milestone, defined as the first commercial shipment to a customer of a nucleotide sequencing platform, comprising both an instrument and related consumables, that utilizes SBB technology. The number of shares of stock to be issued will be determined using the volume-weighted average of the trading prices of our common stock for the twenty trading days ending with and including the trading day that is two days immediately prior to the achievement of the milestone. Of the $100 million in shares of our common stock to be issued as part of the milestone, $4.1 million is attributable to stock options issued by PacBio in replacement of Omniome&#8217;s unvested options as part of the transaction.The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized in our Consolidated Statements of Operations and Comprehensive (Loss) Income. The fair value of the contingent consideration liability, with the assistance from a third-party valuation firm, is based on a scenario-based method which considers a range of possible outcomes and their assigned probabilities of occurrence. The potential outcomes are discounted to present value at a discount rate equal to the sum of the term-matched risk-free-interest rate plus PacBio&#8217;s credit spread.  The acquisition was accounted for as a business combination and, accordingly, the total fair value of the consideration transferred was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values on the acquisition date. The major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):    Cash and cash equivalents$ 15,338Property and equipment, net   6,123Operating lease right-of-use assets, net   18,095In-process research and development ("IPR&D")  400,000Goodwill  390,665Other assets  3,203Deferred income tax liability  (91,814)Liabilities assumed  (26,821)Total consideration transferred$ 714,789   The purchase price allocation is preliminary. We continue to collect information regarding certain estimates and assumptions, including potential liabilities and contingencies. We will recognize adjustments to the preliminary amounts with a corresponding adjustment to goodwill in the reporting period in which the adjustments to the preliminary amounts are determined over a period not to exceed twelve months.During the year ended December 31, 2021, we recorded a measurement period adjustment of $1.6 million to decrease goodwill and a corresponding $0.4 million to decrease the deferred tax liability on the Consolidated Balance Sheet, and a $1.2 million decrease to our benefit from income taxes on the Consolidated Statements of Operations and Comprehensive (Loss) Income. The measurement period adjustment was due to new information that became available to us upon the completion of the IRC Section 382 Tax Study, where we identified additional net operating losses that are available to us from acquired assets. Refer to Note 9. Income Taxes for more information.The goodwill recognized was primarily attributable to the assembled workforce and synergies that are expected to occur from the integration of Omniome and is not deductible for income tax purposes. We allocated $400 million of the purchase price to acquired in-process research and development.  The fair value of the IPR&D was determined, with the assistance of a third-party valuation firm, using an income approach based on a forecast of expected future cash flows. Expected future cash flows utilize significant assumptions such as assumed revenue growth, discount rate and obsolescence factors. The IPR&D will remain on our consolidated balance sheet as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development activities. During the development period following the acquisition, IPR&D will not be amortized, but instead will be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.We incurred costs related to the Omniome acquisition of approximately $12.0 million during the twelve months ended December 31, 2021, which are included in merger-related costs on the Consolidated Statement of Operations and Comprehensive (Loss) Income.Separately, in connection with the Omniome acquisition, on September 20, 2021, we issued and sold 11,214,953 shares of common stock in a private placement transaction at a price of $26.75 per share, for aggregate proceeds of approximately $294.8 million, net of issuance costs of approximately $5.2 million.  We were also required to register the private placement shares for resale following the closing of the merger. The following unaudited pro forma financial information presents combined results of operations for each of the periods presented as if Omniome had been acquired as of the beginning of the comparable fiscal year prior to the year of acquisition, giving effect on a pro forma basis to the purchase accounting adjustments such as $12.0 million of PacBio acquisition-related costs, $18.9 million of stock-based compensation expense related to acceleration of certain Omniome stock options not attributable to pre-combination service, and a $91.0 million one-time income tax benefit from the reduction of our deferred tax asset valuation allowance resulting from the Omniome acquisition, as well as a pro forma adjustment to reflect $16.7 million of Omniome&#8217;s acquisition-related costs. The unaudited pro forma information presented below is for informational purposes only and is not necessarily indicative of the consolidated results of the combined business had the acquisition actually occurred at the beginning of the fiscal year 2020 or the results of future operations of the combined business.The following table summarizes the unaudited pro forma financial information:         Years Ended December 31,(in thousands, except per share amounts)2021 2020      Pro forma total revenue$ 130,513 $ 78,893Pro forma net (loss) income$ (278,451) $ 17,510Pro forma net (loss) income per share - basic and diluted$ (1.27) $ 0.09Our consolidated financial statements include the results of operations for Omniome beginning September 20, 2021. Since the date of acquisition, revenues of $0 and a net loss of $15.6 million from the acquired Omniome business have been included in our Consolidated Statement of Operations and Comprehensive (Loss) Income for the twelve months ended December 31, 2021.Circulomics, Inc.On July 20, 2021, we acquired Circulomics Inc. (&#8220;Circulomics&#8221;), a Maryland-based biotechnology company focused on delivering highly differentiated sample preparation products that enable genomic workflows.  We paid $29.5 million in cash in exchange for all outstanding shares of common stock of Circulomics. We allocated the consideration transferred to the identifiable assets acquired and liabilities assumed based on their respective fair values at the date of the completion of the acquisition. The major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):    Cash and cash equivalents$ 987Property and equipment, net   214Intangible assets  11,360Goodwill  19,309Other assets  467Deferred income tax liability  (2,672)Liabilities assumed  (118)Total consideration transferred$ 29,547The excess of the value of consideration paid over the aggregate fair value of those net assets has been recorded as goodwill. We recognized goodwill of $19.3 million, which is primarily attributable to the synergies expected from capabilities in extraction and sample preparation and is not deductible for income tax purposes.  We recorded $11.4 million for the fair value of acquired intangible assets, of which $11.0 million consists of developed technology. The fair value of the developed technology was determined, with the assistance from a third-party valuation firm, using an income approach based on a forecast of expected future cash flows. The purchase price allocation is preliminary as we continue to collect information with regard to certain estimates and assumptions. We will record adjustments to the fair value of the assets acquired, liabilities assumed and goodwill within the twelve-month measurement period, if necessary.&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284759732536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Invitae Collaboration Arrangement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_DevelopmentAndCommercializationAgreementAbstract', window );"><strong>Invitae Collaboration [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_DevelopmentAndCommercializationAgreementDisclosureTextBlock', window );">Invitae Collaboration</a></td>
<td class="text">NOTE 3. INVITAE COLLABORATION ARRANGEMENTOn January 12, 2021 we entered into a multi-year Development and Commercialization Agreement (the &#8220;Development Agreement&#8221;) with Invitae Corporation (&#8220;Invitae&#8221;). Pursuant to the Development Agreement, Invitae is providing certain funding to us to develop products relating to production-scale high-throughput sequencing (&#8220;Program Products&#8221;). If Program Products become commercially available, Invitae may purchase the Program Products. In addition to selling the Program Products to Invitae, we will have the right to broadly commercialize Program Products for sale to other customers. Under the Development Agreement, Invitae is funding certain development costs we incur in connection with the Program Products (&#8220;Program Development Costs&#8221;). Under the Development Agreement, we will be responsible for conducting a program to develop Program Products, and subsequently for manufacturing the Program Product. We jointly make general decisions regarding the development program with Invitae but we are responsible for research and development activities. The development program is expected to last approximately sixty months but may be shorter or longer.  The primary benefit of the arrangement to Invitae is preferred pricing on the Program Products. Each Program Product will have a preferential pricing period, which will not exceed four years from the date of the first delivery of that Program Product (&#8220;Preferential Pricing Period&#8221;). During the Preferential Pricing Period for each Program Product, we are obligated to sell the Program Product at a substantial discount to Invitae until a multiple of the contribution received from Invitae is repaid. For a specified period after the end of the Preferential Pricing Period, we have arranged to sell the Program Product to Invitae at a higher price, as determined by a formula, than the price during the Preferential Pricing Period (&#8220;Extended Pricing Period&#8221;).  The Extended Pricing Periods will terminate early if Invitae does not meet certain volume minimums.We and Invitae may terminate the Development Agreement if the other party remains in material breach of the Development Agreement following a cure period to remedy the material breach and certain other circumstances by each party, including circumstances where Invitae may terminate for delays, intellectual property concerns, our change in control, or without cause. In certain termination circumstances, (i) we will be obligated to refund all or a portion of the development costs advanced by Invitae and/or (ii) we will owe Invitae a share of the revenue that may be generated from the sale of the Program Products to third parties if and when they are commercialized, until such time as Invitae has recouped the amounts paid to us, and in certain circumstances, a mutually agreed return.  We have incurred and expect to incur significant development costs over the duration of the Development Agreement. There can be no assurances that the development program will be successful or that the Program Products will become ready for commercial sale.The contract is accounted for in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers as the primary benefit from the arrangement to Invitae is the ability to procure the Program Products during the Preferential Pricing Period at substantial discounts. Invitae is not expected to substantially benefit from the intellectual property developed under the arrangement, or benefit from other goods or services during the development period. We will recognize proportionate amounts of the material right in revenue as the performance obligations are satisfied, which is when Invitae places purchase orders for Program Products and the associated goods or services are delivered. Discounts that are not expected to be used will be recognized consistent with the guidance in Topic 606 relating to breakage, in proportion to the expected purchases by Invitae. Any remaining unused discounts will be recognized when they expire. All amounts received from Invitae are initially deferred and accumulated in deferred revenue, non-current. As of December 31, 2021, we have recognized payments received from Invitae of $23.5 million in deferred revenue, non-current, on the Consolidated Balance Sheet. Costs incurred to develop the Program Products are research and development costs and are expensed as incurred. There were no capitalized origination or fulfilment costs related to the arrangement with Invitae that are eligible to be capitalized. <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DevelopmentAndCommercializationAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development and Commercialization Agreement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DevelopmentAndCommercializationAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DevelopmentAndCommercializationAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development and Commercialization Agreement Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DevelopmentAndCommercializationAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284759939960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Termination of Merger with Illumina<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_MergerTerminationAbstract', window );"><strong>Termination of Merger with Illumina [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_MergerTermination', window );">Termination of Merger with Illumina</a></td>
<td class="text">NOTE 4. TERMINATION OF MERGER WITH ILLUMINAOn November 1, 2018, we entered into an Agreement and Plan of Merger (as amended, the &#8220;Illumina Merger Agreement&#8221;) with Illumina, Inc. (&#8220;Illumina&#8221;) and FC Ops Corp., a wholly owned subsidiary of Illumina (&#8220;Illumina Merger Sub&#8221;). On January 2, 2020, we, Illumina and Illumina Merger Sub, entered into an agreement to terminate the Merger Agreement (the &#8220;Termination Agreement&#8221;).  Continuation Advances from IlluminaAs part of the Termination Agreement, Illumina paid us cash payments (&#8220;Continuation Advances&#8221;) of $18.0 million during the fourth quarter of 2019 and $34.0 million during the first quarter of 2020. We recorded the $34.0 million and $18.0 million as non-operating income in the Consolidated Statements of Operations and Comprehensive (Loss) Income for the years ended December 31, 2020 and 2019, respectively. Up to the full $52.0 million of Continuation Advances paid to us were repayable without interest to Illumina if, within two years of March 31, 2020, we entered into, or consummated a Change of Control Transaction or raised at least $100 million in a single equity or debt financing (that may have multiple closings), with the amount repayable dependent on the amount raised by us. Resulting from the issuance and sale of $900 million of 1.50% Convertible Senior Notes due February 15, 2028, $52.0 million of Continuation Advances were paid without interest to Illumina in February 2021 and recorded a non-operating expense in the Consolidated Statements of Operations and Comprehensive (Loss) Income for the year ended December 31, 2021. Please refer to Note 1. Organization and Significant Accounting Policies for the accounting treatment of the Continuation Advances.Reverse Termination Fee from IlluminaAs part of the Termination Agreement, Illumina paid us a $98.0 million termination fee (the &#8220;Reverse Termination Fee&#8221;), from which we paid our financial advisor associated fees of $6.0 million in April 2020. Pursuant to the Termination Agreement, in the event that, on or prior to September 30, 2020, we entered into a definitive agreement providing for, or consummated, a Change of Control Transaction, then we may have been required to repay the Reverse Termination Fee (without interest) to Illumina in connection with the consummation of such Change of Control Transaction. As indicated in ASC 450, Contingencies, a gain contingency usually is not recognized in the financial statements until the period in which all contingencies are resolved and the gain is realizable. As such, we deferred the gain from the Reverse Termination Fee from Illumina until the date when the associated contingency lapsed. On October 1, 2020, the contingency clauses lapsed and we recorded the $98.0 million as a part of non-operating income in the fourth quarter of 2020.&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_MergerTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_MergerTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_MergerTerminationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger Termination [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_MergerTerminationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284846178808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">NOTE 5. FINANCIAL INSTRUMENTS Fair Value of Financial InstrumentsFair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy established under GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: &#61623;Level&#160;1: quoted prices in active markets for identical assets or liabilities;&#61623;Level&#160;2: inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and&#61623;Level&#160;3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers.&#160;Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities. Assets and Liabilities Measured at Fair Value on a Recurring BasisThe following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of&#160;December 31, 2021 and December 31, 2020 respectively:                                                   December 31, 2021 December 31, 2020 (in thousands)Level 1 Level&#160;2 Level 3 Total Level 1 Level&#160;2 Level 3 Total Assets                        Cash and cash equivalents:                        Cash and money market funds $ 327,315&#160; $ &#8212; $ &#8212; $ 327,315&#160; $ 43,040&#160; $ &#8212; $ &#8212; $ 43,040&#160; Commercial paper   &#8212;   133,185&#160;   &#8212;   133,185&#160;   &#8212;   32,537&#160;   &#8212;   32,537&#160; U.S. government & agency securities  &#8212;   225&#160;   &#8212;   225&#160;   &#8212;   170&#160;   &#8212;   170&#160; U.S. Treasury security  &#8212;   &#8212;   &#8212;   &#8212;   &#8212;   5,864&#160;   &#8212;   5,864&#160; Total cash and cash equivalents   327,315&#160;   133,410&#160;   &#8212;   460,725&#160;   43,040&#160;   38,571&#160;   &#8212;   81,611&#160; Investments:                        Commercial paper   &#8212;   187,632&#160;   &#8212;   187,632&#160;   &#8212;   112,644&#160;   &#8212;   112,644&#160; Corporate debt securities   &#8212;   8,968&#160;   &#8212;   8,968&#160;   &#8212;   17,456&#160;   &#8212;   17,456&#160; U.S. government & agency securities  &#8212;   387,075&#160;   &#8212;   387,075&#160;   &#8212;   107,103&#160;   &#8212;   107,103&#160; Total investments   &#8212;   583,675&#160;   &#8212;   583,675&#160;   &#8212;   237,203&#160;   &#8212;   237,203&#160; Short-term restricted cash:                        Cash   500&#160;   &#8212;   &#8212;   500&#160;   836&#160;   &#8212;   &#8212;   836&#160; Long-term restricted cash:                        Cash   4,592&#160;   &#8212;   &#8212;   4,592&#160;   3,500&#160;   &#8212;   &#8212;   3,500&#160; Total assets measured at fair value $ 332,407&#160; $ 717,085&#160; $ &#8212; $ 1,049,492&#160; $ 47,376&#160; $ 275,774&#160; $ &#8212; $ 323,150&#160;                          Liabilities                        Continuation advances $ &#8212; $ &#8212; $ &#8212; $ &#8212; $ &#8212; $ &#8212; $ &#8212; $ &#8212; Contingent consideration  &#8212;   &#8212;   169,717&#160;   169,717&#160;   &#8212;   &#8212;   &#8212;   &#8212; Total liabilities measured at fair value $ &#8212; $ &#8212; $ 169,717&#160; $ 169,717&#160; $ &#8212; $ &#8212; $ &#8212; $ &#8212; We classify contingent consideration, which was incurred in connection with the acquisition of Omniome, within Level 3 as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value.  On a quarterly basis, we estimate the fair value of the contingent consideration liability by discounting the probability-weighted outcomes to present value using an estimate of our borrowing rate and the risk-free rate. The potential outcomes of milestone achievement dates are within the period from December 31, 2022 to June 30, 2025. A decrease in the probability of an earlier scenario within this range would result in a decrease in the fair value of the liability.  The discount rates used are the sum of the U.S. risk-free rate and the estimated subordinated credit spread for B- and B credit rating, which ranges from 4.8% to 5.5%. Changes in our estimated subordinated credit spread can result in changes in the fair value of the contingent consideration liability, where a lower credit spread may result in an increased liability valuation.Changes in the estimated fair value of the contingent consideration liability for the year ended December 31, 2021 were as follows:    (in thousands)Level 3Beginning balance as of January 1, 2021 -Acquisition of Omniome 168,574Change in estimated fair value 1,143Ending balance as of December 31, 2021 169,717 Changes to the fair value are recorded as the Change in fair value of contingent consideration in the Consolidated Statement of Operations and Comprehensive (Loss) Income.As of December 31, 2020, we classified the Continuation Advances, which were incurred in connection with the Illumina Merger Agreement and were subject to repayment under certain circumstances, as a financial liability and were reported at fair value. The estimated fair value of the liability related to the Continuation Advances was determined using Level 3 inputs, or significant unobservable inputs. Management assessed the fair value of this financial instrument to be zero at December 31, 2020.We were first approached by SB Northstar LP during the quarter ended March 31, 2021 regarding a potential convertible debt transaction.  As discussed further below in Note 7. Convertible Senior Notes, in February 2021, we entered into an investment agreement with SB Northstar LP for the issuance and sale of $900 million of 1.50% Convertible Senior Notes due February 15, 2028. As a result, $52.0 million of Continuation Advances were repaid without interest to Illumina in February 2021 and recorded as a non-operating expense in the Consolidated Statements of Operations and Comprehensive (Loss) Income for the year ended December 31, 2021. There was no further liability exposure for Continuation Advances as of December 31, 2021.  For the year ended December 31, 2021, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and our valuation techniques did not change compared to the prior year. As discussed above, we recorded a contingent consideration liability in connection with our acquisition of Omniome during the year ended December 31, 2021.  Cash, Cash Equivalents and InvestmentsThe following table summarizes our cash, cash equivalents and investments as of December&#160;31, 2021 and 2020:                         As of December 31, 2021    Gross Gross   Amortized unrealized unrealized Fair(in thousands) Cost  gains  losses  Value Cash and cash equivalents:           Cash and money market funds$ 327,316 $ &#8212; $ &#8212; $ 327,316Commercial paper   133,190   &#8212;   (5)   133,185U.S. government & agency securities  225   &#8212;   &#8212;   224Total cash and cash equivalents   460,731   &#8212;   (5)   460,725Investments:           Commercial paper   187,705   &#8212;   (73)   187,632Corporate debt securities   8,964   9   (5)   8,968U.S. government & agency securities  388,088   1   (1,014)   387,075Total investments   584,757   10   (1,092)   583,675Total cash, cash equivalents and investments $ 1,045,488 $ 10 $ (1,097) $ 1,044,400Short-term restricted cash:           Cash $ 500 $ &#8212; $ &#8212; $ 500Long-term restricted cash:           Cash $ 4,592 $ &#8212; $ &#8212; $ 4,592             As of December 31, 2020    Gross Gross   Amortized unrealized unrealized Fair(in thousands) Cost  gains  losses  Value Cash and cash equivalents:           Cash and money market funds$ 43,040 $ &#8212; $ &#8212; $ 43,040Commercial paper  32,538   &#8212;   (1)   32,537U.S. government & agency securities  170   &#8212;   &#8212;   170U.S. Treasury security  5,864   &#8212;   &#8212;   5,864Total cash and cash equivalents   81,612   &#8212;   (1)   81,611Investments:           Commercial paper   112,648   4   (8)   112,644Corporate debt securities   17,360   96   &#8212;   17,456U.S. government & agency securities  107,109   6   (12)   107,103Total investments   237,117   106   (20)   237,203Total cash, cash equivalents and investments $ 318,729 $ 106 $ (21) $ 318,814Short-term restricted cash:           Cash $ 836 $ &#8212; $ &#8212; $ 836Long-term restricted cash:           Cash $ 3,500 $ &#8212; $ &#8212; $ 3,500 The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of December 31, 2021:   (in thousands)Fair ValueDue in one year or less $ 595,063Due after one year through 5 years   122,022Total investments $ 717,085    Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284755573976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">NOTE 6. BALANCE SHEET COMPONENTS Short-term restricted cash As of December 31, 2021, the short-term restricted cash balance of $0.5 million was comprised of security deposits for the credit cards of employees. As of December 31, 2020, the short-term restricted cash balance of $0.8 million was comprised of $0.5 million for a customer deposit and $0.3 million for a security deposit for the credit cards of employees. In connection with the acquisition of Omniome in September 2021, we acquired $0.2 million of short-term restricted cash consisting of a security deposit for credit cards of Omniome employees.InventoryAs of December 31, 2021 and 2020, our inventory consisted of the following components:              December 31, (in thousands)2021 2020Purchased materials$ 7,993 $ 3,531Work in process  8,611   6,651Finished goods  7,995   4,048Inventory$ 24,599 $ 14,230Property and Equipment, NetAs of December&#160;31, 2021 and 2020, our property and equipment, net, consisted of the following components:              December 31,(in thousands)2021 2020Laboratory equipment and machinery $ 31,534 $ 24,948Leasehold improvements  31,114   29,931Computer equipment  15,059   12,400Software  5,578   4,940Furniture and fixtures  3,202   2,434Construction in progress  2,303   137   88,790   74,790Less: Accumulated depreciation   (56,286)   (49,891)Property and equipment, net $ 32,504 $ 24,899Depreciation expense during the years ended December 31, 2021, 2020 and 2019 was $7.2 million, $6.4 million and $7.3 million, respectively. Long-term restricted cash For our facility located at 1305 O&#8217;Brien Drive, Menlo Park, California (the &#8220;O&#8217;Brien Lease&#8221;), we were required to establish a letter of credit for the benefit of the landlord and to submit $4.5 million as a deposit for the letter of credit in October 2015. Subsequently, pursuant to the terms of the O&#8217;Brien Lease, beginning on May 1, 2019, the amount of the letter of credit was reduced by $0.5 million each year thereafter on May 1. As such, $3.0 million and $3.5 million was recorded in long-term restricted cash related to the O&#8217;Brien Lease in the Consolidated Balance Sheets as of December 31, 2021 and December 31, 2020, respectively.  In connection with the acquisition of Omniome in September 2021, we acquired $1.6 million of long-term restricted cash related to a letter of credit established for a facility lease.Goodwill and intangible assetsGoodwillGoodwill arises from business combinations and represents the excess of the purchase price over the fair value of the net assets and other identifiable intangible assets acquired. The fair values of net tangible assets and intangible assets acquired are based upon preliminary valuations and our estimates and assumptions are subject to change within the measurement period (potentially up to one year from the acquisition date).The following table presents the changes in the carrying amount of goodwill for the periods indicated (in thousands):Wa   Balance as of December 31, 2020$ -Acquisition of Omniome  390,665Acquisition of Circulomics  19,309Balance as of December 31, 2021$ 409,974Acquired Intangible AssetsIntangible assets include acquired in-process research and development (IPR&D) of $400 million as a result of the Omniome acquisition in September 2021. In addition to IPR&D, we had the following acquired definite-lived intangible assets as of December 31, 2021 (in thousands, except years):             Estimated  Gross    Net Useful Life Carrying Accumulated Carrying (in years) Amount Amortization AmountDeveloped technology15 $ 11,000 $ (306) $ 10,694Customer relationships2   360   (75)   285Total  $ 11,360 $ (381) $ 10,979           Amortization expense of intangibles was $0.4 million for the year ended December 31, 2021. We had no amortization expense of intangibles for the years ended December 31, 2020 and 2019.The estimated future amortization expense of acquisition-related intangible assets with definite lives is estimated as follows (in thousands):       2022$ 9132023  8382024  7332025  7332026  7332027 and thereafter  7,029Total$ 10,979    Accrued ExpensesAs of December&#160;31, 2021 and 2020, our accrued expenses consisted of the following components:              December 31,(in thousands)2021 2020Salaries and benefits$ 25,282 $ 15,261Accrued product development costs  1,936   415Accrued interest payable  5,100   &#8212;Inventory accrual  108   218Warranty  594   161Accrued professional services and legal fees  1,640   726Other   1,601   569Accrued expenses $ 36,261 $ 17,350Deferred RevenueAs of December 31, 2021, we had a total of $ 36.0 million of deferred revenue, $11.0 million of which was recorded as deferred revenue, current and primarily relates to deferred service contract revenues to be recognized over the next year and the remaining $25.0 million was recorded as deferred revenue, non-current. Of the deferred revenue, non-current balance, $23.5 million relates to payments received under the Invitae collaboration and $1.5 million primarily relates to deferred service contract revenues and is scheduled to be recognized in the next 5 years. Revenue recorded in the year ended&#160;December 31, 2021 includes&#160;$8.6 million of previously deferred revenue that was included in &#8220;Deferred revenue, current&#8221; as of&#160;December&#160;31, 2020. Contract assets as of&#160;December 31, 2021 and December 31, 2020 were not material.As of December 31, 2021, we had a total of $0.7 million of deferred commissions included in &#8220;Prepaid expenses and other current assets&#8221; which is recognized as the related revenue is recognized. Additionally, as a practical expedient, we expense costs to obtain a contract as incurred if the amortization period would have been a year or less.Term LoansIn connection with the acquisition of Omniome, we acquired $1.3 million in short-term debt and $3.0 million in long-term debt relating to a term loan facility that Omniome obtained in April 2020. Borrowings on the term loan facility were used to fund Omniome&#8217;s purchases of equipment, which serves as collateral. Each term loan has a term of 43 months and bears a fixed interest rate of approximately 17% annually. The fee for the elective option to prepay all, but not less than all, of the borrowed amounts at any time after the 24th month and before the 43rd month after the commencement date, is 4% of the outstanding loan balance. Payments are made in equal monthly installments including principal and interest. As of December 31, 2021, the carrying value of term loans outstanding was $3.9 million. The related long-term portion of $2.3 million was recorded as part of &#8220;Other liabilities, non-current&#8221; and the short-term portion of $1.6 million was recorded as part of &#8220;Other liabilities, current&#8221; on the Consolidated Balance Sheet. The interest expense was $0.2 million for the year ended December 31, 2021, which was included as part of interest expense in the Consolidated Statement of Operations and Comprehensive (Loss) Income.As of December 31, 2021, the future principal payments remaining on term loans was the following:    (in thousands)  2022$ 1,6082023  1,8422024  490Total$ 3,940 Other liabilities, currentAs of December&#160;31, 2021 and 2020, our Other liabilities, current consisted of the following components:         December 31,(in thousands)2021 2020Accrued ESPP$ 3,598 $ 2,037Other   2,161   2,482Other liabilities, current$ 5,759 $ 4,519&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284763674696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Convertible Senior Notes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Senior Notes</a></td>
<td class="text">NOTE 7. CONVERTIBLE SENIOR NOTESOn February&#160;9, 2021, we entered into an investment agreement (the &#8220;Investment Agreement&#8221;) with SB Northstar LP (the &#8220;Purchaser&#8221;), a subsidiary of SoftBank Group Corp., relating to the issuance and sale to the Purchaser of $900 million in aggregate principal amount of our 1.50% Convertible Senior Notes (the &#8220;Notes&#8221;). The Notes were issued on February 16, 2021.The Notes are governed by an indenture (the &#8220;Indenture&#8221;) between the Company and U.S. Bank National Association, as trustee. The Notes bear interest at a rate of 1.50% per annum. Interest on the Notes is payable semi-annually in arrears on February&#160;15 and August&#160;15 and commenced on August&#160;15, 2021. The Notes will mature on February&#160;15, 2028, subject to earlier conversion, redemption or repurchase.The Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The Notes are convertible into shares of our common stock based on an initial conversion rate of 22.9885 shares of common stock per $1,000 principal amount of the Notes (which is equal to an initial conversion price of $43.50 per share), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the Notes, we may elect to settle such conversion obligation in shares, cash or a combination of shares and cash.On or after February&#160;20, 2026, the Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.With certain exceptions, upon a change of control of the Company or the failure of our common stock to be listed on certain stock exchanges (a &#8220;Fundamental Change&#8221;), the holders of the Notes may require that we repurchase all or part of the principal amount of the Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.The Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the Notes under the Indenture. The Indenture also includes customary covenants for convertible notes of this type.To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the Notes at a rate equal to (i)&#160;0.25% per annum of the principal amount of the Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the Notes outstanding for each day from, and including, the 181st calendar day to, and including, the 360th calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the Indenture). On the 361st day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361st day), the Notes shall be subject to acceleration as provided for in the Indenture. The notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the Notes were not issued at a premium; therefore, the Notes are accounted for in their entirety as a liability.  Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current. The requirement to repurchase the Notes including unpaid interest to the maturity date in the event of a Fundamental Change is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; Derivatives and Hedging. However, given the low probability of a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.We incurred issuance costs related to the Notes of approximately $4.5 million, which were recorded as debt issuance cost and are presented as a reduction to the Notes on our Consolidated Balance Sheets and are amortized to interest expense using the effective interest method over the term of the Notes, resulting in an effective interest rate of 1.6%. As of December 31, 2021, the net carrying amount of the liability for the Notes is recorded as convertible senior notes, net in the Consolidated Balance Sheets as follows (in thousands):    Principal amount$ 900,000Unamortized debt issuance costs  (3,933)Net carrying amount$ 896,067For the year ended December 31, 2021, interest expense for the Notes was as follows (in thousands):    Contractual interest expense$ 11,812Amortization of debt issuance costs  532Total interest expense$ 12,344 As of December 31, 2021, the estimated fair value (Level 2) of the Notes was $787.5 million. The fair value of the Notes is estimated using a pricing model that is primarily affected by the trading price of our common stock and market interest rates.&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284759914776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">Commitments and Contingencies</a></td>
<td class="text">NOTE 8. COMMITMENTS AND CONTINGENCIES LeasesWe record operating lease right-of-use assets and liabilities on our Consolidated Balance Sheets for all leases with a term of more than 12 months. In connection with the acquisition of Omniome, we acquired $18.1 million in right-of-use assets and liabilities on our Consolidated Balance Sheets. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. All of our leases are operating leases. Lease payments comprise the base rent per the term of the Lease. Lease expense for these leases is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period those payments are incurred. We often have options to renew lease terms for buildings. For the O&#8217;Brien Lease, the renewal option is 5 years and the rent will be based on fair market value at the time of renewal and was not included in the lease term. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors. The following table presents information as to the amount and timing of cash flows arising from our operating leases as of December 31, 2021:          Maturity of Lease LiabilitiesAmount Years ending December 31,(in thousands)2022$ 11,3262023  11,8512024  12,0402025  12,3282026  12,437Thereafter  9,930Total undiscounted operating lease payments  69,912Less: imputed interest  (12,232)Present value of operating lease liabilities   57,680   Balance Sheet Classification  Operating lease liabilities, current  7,710Operating lease liabilities, non-current  49,970Total operating lease liabilities  57,680We use our incremental borrowing rate to determine the present value of lease payments, as the implicit rates in our leases are not readily determinable. The weighted average discount rate used to measure our operating lease liabilities was 6.7%. The weighted average remaining lease term for our operating leases as of December 31, 2021 was 5.7 years.Cash FlowsCash paid for amounts included in the present value of operating lease liabilities was $8.2 million and $7.2 million for the years ended December 31, 2021 and 2020, respectively and were included in operating cash flow. Operating Lease CostsOperating lease costs were $7.2 million and $6.2 million for the years ended December 31, 2021 and 2020, respectively. For both 2021 and 2020 the total lease costs primarily related to our operating leases, but also included immaterial amounts for variable leases.Contingencies We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.Legal ProceedingsU.S. District Court Proceedings On September 26, 2019, Personal Genomics of Taiwan, Inc. (&#8220;PGI&#8221;) filed a complaint in the U.S. District Court for the District of Delaware against us for patent infringement (C.A. No. 19-cv-1810) (the &#8220;PGI District Court matter&#8221;). The matter from this complaint is based on PGI&#8217;s U.S. Patent No. 7,767,441 (the &#8220;&#8216;441 Patent&#8221;). We plan to vigorously defend in this matter. On November 20, 2019, we filed our answer to the complaint, denying infringement and seeking a declaratory judgement of invalidity of the &#8216;441 Patent. On June 22, 2020, we filed a petition requesting institution of an inter-partes review (IPR) to the Patent Trial and Appeals Board (the &#8220;Board&#8221;) at the United States Patent Office requesting the Board to find a set of claims in the &#8216;441 Patent invalid. On June 27, 2020, we filed a second petition requesting institution of an IPR requesting the Board to find another set of claims in the &#8216;441 Patent invalid. The two petitions (the &#8220;PacBio IPR Petitions&#8221;) requesting IPRs assert that all of the claims relevant to the PGI complaint are invalid. On January 19, 2021, the Board ordered that both PacBio IPR Petitions are instituted on all grounds presented. On January 18, 2022, the Board issued decisions on the two IPRs.  In one IPR, all challenged claims were found unpatentable including PGI&#8217;s core device claims. In the second IPR, the board did not find the disputed claims unpatentable. We are appealing the decision in the second IPR to the U.S. Court of Appeals for the Federal Circuit.On August 19, 2020, the court ordered a stay of the PGI District Court matter based on a joint stipulation by the parties pending a final written decision on the IPRs. Following the final decision on the IPRs described above, on February 2, 2022, the judge ordered that the PGI District Court matter be reopened. We plan to vigorously defend against the remaining claims.Proceedings in ChinaOn May 12, 2020, PGI filed a complaint in the Wuhan Intermediate People&#8217;s Court in China alleging infringement of one or more claims of China patent No. CN101743321B (the &#8220;CN321 Patent&#8221;), which is related to the &#8216;441 Patent.  We were served on January 20, 2021 and plan to vigorously defend in this matter.  On November 23, 2020 we filed an Invalidation Petition at the China National Intellectual Property Administration (CNIPA) demonstrating the invalidity of the claims in the CN321 Patent on grounds of insufficient disclosure, and the lack of support, essential technical features, clarity, novelty, and inventiveness. A hearing in the invalidation proceeding at the CNIPA was held on April 29, 2021. On September 2, 2021, the CNIPA issued its decision on the Invalidation Petition and determined that all claims (1-61) of the CN321 patent were invalid.  We have filed a petition with the Wuhan Intermediate People&#8217;s court requesting dismissal of the infringement action. On December 1, 2021, PGI filed an appeal with the Beijing IP Court, contesting the CNIPA decision.  Other ProceedingsFrom time to time, we may also be involved in a variety of other claims, lawsuits, investigations and proceedings relating to securities laws, product liability, patent infringement, contract disputes, employment and other matters that arise in the normal course of our business. In addition, third parties may, from time to time, assert claims against us in the form of letters and other communications. We record a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We currently do not believe that the ultimate outcome of any of the matters described above is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources and other factors.IndemnificationPursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification obligations has been recorded as of December 31, 2021.&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=2127197<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2127163<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284759928728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">NOTE 9. INCOME TAXESWe are subject to income taxes in the United States and certain states in which we operate, and we use estimates in determining our provisions for income taxes. Significant management judgement is required in determining our provision for income taxes, deferred tax assets and liabilities and valuation allowances recorded against net deferred tax assets in accordance with U.S. GAAP. These estimates and judgements occur in the calculation of tax credits, benefits, and deductions, and in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes, as well as the interest and penalties related to uncertain tax positions. Significant changes to these estimates may result in an increase or decrease to our tax provision in the current or subsequent period.We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether the factors underlying the sustainability assertion have changed and the amount of the recognized tax benefit is still appropriate.We account for Global Intangible Low-taxed Income as a period cost.During the years ended December 31, 2021, 2020 and 2019 income (loss) before taxes from U.S. operations were ($275.4) million, $28.9 million and ($84.8) million, respectively, and income before taxes from foreign operations was $0.8 million, $0.6 million and $0.9 million, respectively. Income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of 21% to pretax income or loss as follows:                    Years ended December 31, 2021  2020  2019 Statutory tax rate  21.0%  21.0%  21.0%State tax rate, net of federal benefit 5.5   (8.3)   4.9 Change in valuation allowance  (4.9)   6.3   (27.5) Tax credits 2.5   (3.6)   2.2 Stock-based compensation 10.9   (15.2)   (0.8) Merger Expenses (0.9)   -   - Other (0.1)   (0.2)   0.2 Total 34.0%  0.0%  (0.0)%  Deferred income taxes reflect the net tax effects of loss and credit carry forwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):              December 31,Deferred tax assets:2021 2020Net operating loss carryforwards$ 378,035 $ 233,225Research and development credits   60,672   49,179Accruals and reserves  10,822   6,337Stock-based compensation  12,838   9,717ASC 842 Operating lease liability  13,105   9,870Total deferred tax assets   475,472   308,328Less: Valuation allowance  (366,940)   (300,505)Total deferred tax assets:  108,532   7,823Intangibles  (97,345)   &#8212;Fixed assets  (1,523)   (786)ASC 842 Operating lease right-of-use assets  (10,502)   (7,037)Total deferred tax liabilities  (109,370)   (7,823)Net deferred tax assets $ (838) $ &#8212;At December&#160;31, 2021, we maintained a full valuation allowance against all of our deferred tax assets which totaled $366.9 million, including net operating loss carryforwards and research and development credits of $378.0 million and $60.7 million, respectively.A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. We regularly assess the need for a valuation allowance against our deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that our deferred income tax assets will be realized. In evaluating our ability to recover our deferred income tax assets within the jurisdiction from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. A deferred income tax benefit of $93.6 million for the year ended December 31, 2021, is related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Omniome and Circulomics acquisitions. We maintain a valuation allowance on the net deferred tax assets of our U.S. entities as we have concluded that it is more likely than not that we will not realize our deferred tax assets. Accordingly, this benefit from income taxes is reflected on our Consolidated Statements of Operations and Comprehensive (Loss) Income for the year ended December 31, 2021. For the year ended December 31, 2021, our valuation allowance increased to $366.9 million, primarily because of an increase in our net operating losses, credits and acquisition of deferred tax assets that were fully offset by a valuation allowance. For the year ended December 31, 2020, our valuation allowance increased to $300.5 million, primarily because of an increase in our net operating losses and tax credits offset by a decrease to our stock-based compensation deferred tax asset. As of December&#160;31, 2021, we had a net operating loss carryforward for federal income tax purposes of approximately $1,491.3 million, of which $774.9 million will begin to expire in 2024 if not utilized. We had a total state net operating loss carryforward of approximately $997.4 million, which are subject to annual expirations. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the &#8220;change of ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization. We have federal credits of approximately $39.1 million, which will begin to expire in 2024 if not utilized and state research credits of approximately $36.9 million which have no expiration date. These tax credits are subject to the same limitations discussed above.  As of December&#160;31, 2021, our total unrecognized tax benefit was $8.3 million.  A reconciliation of the beginning and ending unrecognized tax benefit balance is as follows (in thousands):       Balance as of December 31, 2018$ 20,447Decrease in balance related to tax positions taken in prior year   &#8212;Increase in balance related to tax positions taken during current year   1,532Balance as of December 31, 2019$ 21,979Decrease in balance related to tax positions taken in prior year   (17,255)Increase in balance related to tax positions taken during current year   1,230Balance as of December 31, 2020$ 5,954Increase in balance related to tax positions taken in prior year   189Increase in balance related to tax positions taken during current year   2,192Balance as of December 31, 2021$ 8,335Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of both December&#160;31, 2021 and 2020, we had no accrued interest or penalties due to our net operating losses available to offset any tax adjustment. If total unrecognized tax benefits were realized in the future, it would not result in any tax benefit as we currently have a full valuation allowance. We file U.S. federal and various state income tax returns. For U.S. federal and state income tax purposes, the statute of limitations currently remains open for the years ending December&#160;31, 2018 to present and December&#160;31, 2017 to present, respectively. In addition, all of the net operating losses and research and development credit carryforwards that may be utilized in future years may be subject to examination. We are not currently under examination by income tax authorities in any jurisdiction.On December 27, 2020, the U.S. government enacted the Consolidated Appropriations Act, 2021, which enhances and expands certain provisions of the CARES Act. This legislative act did not have a material impact on the Company&#8217;s consolidated financial results.On March 11, 2021, the American Rescue Plan Act of 2021 (&#8220;American Rescue Plan&#8221;) was signed into law to provide additional relief in connection with the ongoing COVID-19 pandemic. The American Rescue Plan includes, among other things, provisions relating to PPP loan expansion, defined pension contributions, excessive employee remuneration, and the repeal of the election to allocate interest expense on a worldwide basis. Under ASC 740, the effects of new legislation are recognized upon enactment. Accordingly, the American Rescue Plan is effective beginning in the quarter that includes March 11, 2021. These provisions did not have a material impact on the Company&#8217;s Consolidated Financial Statements.&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284759783416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">NOTE 10. STOCKHOLDERS&#8217; EQUITYPreferred Stock Our Certificate of Incorporation, as amended and restated in October 2010 in connection with the closing of our initial public offering, authorizes us to issue 1,000,000,000 shares of $0.001 par value common stock and 50,000,000 shares of $0.001 par value preferred stock. As of December&#160;31, 2021 and 2020, there were no shares of preferred stock issued or outstanding. Common Stock Common stockholders are entitled to dividends when and if declared by our board of directors. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote. Underwritten Public Equity OfferingsIn August 2020, we entered into an underwriting agreement, relating to the public offering of 19,430,000 shares of our common stock, $0.001 par value per share, at a price to the public of $4.47 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 2,914,500 shares of our common stock, which was subsequently exercised in full, and the offering including the sale of shares of common stock subject to the underwriters&#8217; option, closed in August 2020.&#160;In total, we sold 22.3 million shares of our common stock. We paid a commission equal to 6% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $93.9 million, excluding approximately $0.3 million of offering expenses. In November 2020, we entered into an underwriting agreement, relating to the public offering of 6,096,112 shares of our common stock, $0.001 par value per share, at a price to the public of $14.25 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 914,416 shares of our common stock, which was subsequently exercised in full, and the offering including the sale of shares of common stock subject to the underwriters&#8217; option, closed in November 2020.&#160;In total, we sold 7.0 million shares of our common stock. We paid a commission equal to 6% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $93.9 million, excluding approximately $0.3 million of offering expenses.  In total, for the year ended December 31, 2020, we issued 29.4 million shares of our common stock through our two underwritten public offerings with an average offering price of $6.40. The total net proceeds to us from the two offerings, after deducting the underwriting commission and offering expenses, were approximately $187.2 million. Private Placement of Common StockOn July&#160;19, 2021, in connection with the Omniome acquisition, we entered into a purchase agreement with certain qualified institutional buyers and institutional accredited investors, pursuant to which we agreed to sell an aggregate of 11,214,953 shares of common stock, at a price of $26.75 per share, for aggregate gross proceeds of approximately $300&#160;million. The transaction closed on September 20, 2021. We registered the private placement shares for resale following the closing of the merger.Equity Plans The 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), the 2020 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;) and the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#8220;Omniome Plan&#8221;) allow for the issuance of stock options, restricted units and awards and performance-based awards.On August 4, 2020, stockholders approved the 2020 Plan and reserved 11,000,000 shares of our common stock for issuance pursuant to equity awards granted under the 2020 Plan.On December 2, 2020, the Board of Directors (the &#8220;Board&#8221;) adopted the Inducement Plan and reserved&#160;2,500,000 shares of our common stock for issuance pursuant to equity awards granted under the Inducement Plan. On April 18, 2021 and November 22, 2021, the Board amended the Inducement Plan to reserve an additional 750,000 and 360,000 shares, respectively. On September 20, 2021, in connection with the acquisition of Omniome, we adopted the Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#8220;Omniome Plan&#8221;). Under the Omniome Merger Agreement, each unvested option to purchase Omniome common stock, granted under the Omniome Plan held by employees continuing with us, were assumed by PacBio and converted into an option to purchase shares of our common stock. The terms and conditions of the converted options are substantially the same (including vesting and exercisability), except that (A) the assumed options cover shares of PacBio&#8217;s common stock; (B) the number of shares of our common stock subject to the assumed option is equal to the product of (i) the number of shares of Omniome common stock subject to the corresponding unvested option, multiplied by (ii) the exchange ratio (as defined below), with any resulting fractional share rounded down to the nearest whole share; and (C) the exercise price per share of the assumed options is equal to the quotient of (i) the exercise price per share of the corresponding unvested option to purchase shares of Omniome common stock, divided by (ii) the exchange ratio (as defined below), with any resulting fractional cent rounded up to the nearest whole cent. The exchange ratio was equal to 0.259204639. We reserved 2,494,128 shares of our common stock for issuance pursuant to equity awards under the Omniome Plan.  2020 Equity Incentive Plan Under the 2020 Plan, with the approval of the Board of Directors or the Compensation Committee of the Board of Directors, we may grant equity-based awards, including non-statutory stock options, restricted stock units (&#8220;RSUs&#8221;), restricted stock, stock appreciation rights, performance shares and performance units. Stock options granted under the 2020 Plan may be either incentive stock options (&#8220;ISOs&#8221;) within the meaning of Internal Revenue code Section 422 or non-qualified stock options (&#8220;NSOs&#8221;). Stock options under the 2020 Plan may be granted with a term of up to ten years and at prices no less than the fair market value of our common stock on the date of grant. To date, stock options granted to existing employees generally vest over four years on a monthly basis and stock options granted to new employees vest at a rate of 25% upon the first anniversary of the vesting commencement date and 1/48th&#160;per month thereafter, in each case, subject to continued service with us through the applicable vesting dates.2020 Inducement Equity Incentive PlanUnder the Inducement Plan, with the approval of the Board of Directors or the Compensation Committee of the Board of Directors, we may grant equity-based awards, including non-statutory stock options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance units. The terms of the Inducement Plan are substantially similar to the 2020&#160;Plan, including with respect to treatment of equity awards in the event of a &#8220;merger&#8221; or &#8220;change in control&#8221; as defined under the Inducement Plan, but with such other terms and conditions intended to comply with the NASDAQ Inducement Award exception. In accordance with Rule 5635(c)(4) of the NASDAQ Listing Rules, awards under the Inducement Plan may only be made to individuals not previously employees or non-employee directors of the Company (or following such individuals&#8217; bona fide period of non-employment with the Company), as an inducement material to the individuals&#8217; entry into employment with the Company or in connection with a merger or acquisition, to the extent permitted by Rule 5635(c)(3) of the NASDAQ Listing Rules.As of December&#160;31, 2021, we had 8.1 million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan. Stock OptionsTime-based stock optionsThe following table summarizes time-based stock option activity for all of our equity compensation plans for the year ended December 31, 2021 (in thousands, except per share amounts):                       Stock Options Outstanding       Weighted  Number    average  of shares Exercise price exercise priceOutstanding at December 31, 2020  14,638 $ 1.16 &#8211; 20.90 $ 5.53Granted   2,489  23.06 &#8211; 46.37   33.78Assumed Omniome options  339  2.05 &#8211; 4.90   4.43Exercised   (4,766)  1.16 &#8211; 15.98   5.31Canceled   (541)  2.54 &#8211; 46.37   5.25Outstanding at December 31, 2021  12,159 $1.16 &#8211; 46.37 $ 11.38The expired options during the year ended December 31, 2021 totaled 0.02 million with exercise prices ranging from $2.54 to $46.37 per share and a weighted average exercise price per share of $9.80. Performance-based stock optionsThe following table summarizes performance-based stock option activity for all of our equity compensation plans for the year ended December 31, 2021 (in thousands, except per share amounts):                     Stock Options Outstanding       Weighted  Number    average  of shares Exercise price exercise priceOutstanding at December 31, 2020  &#8212; $ &#8212; $ &#8212;Granted   &#8212;   &#8212;   &#8212;Assumed Omniome options  304  4.71 - 4.90   4.71Exercised   &#8212;   &#8212;   &#8212;Canceled   &#8212;   &#8212;   &#8212;Outstanding at December 31, 2021  304 $4.71 - 4.90 $ 4.71 The following table summarizes information with respect to stock options outstanding and exercisable under our equity compensation plans at December&#160;31, 2021:                                Options Outstanding Options Exercisable   Number Weighted average    Number      outstanding remaining contractual Weighted average  vested Weighted average  Exercise price(in 000s) life (Years) exercise price (in 000s) exercise price $0.00 - 4.64 3,676  5.37 $ 2.91  3,508 $ 2.91 $4.64 - 9.27 5,480  5.88 $ 6.64  4,010 $ 6.68 $9.27 - 13.91 702  6.69 $ 9.81  427 $ 9.94 $13.91 - 18.55 35  8.79 $ 14.34  14 $ 14.34 $ 18.55 - 23.19 180  9.38 $ 21.86  25 $ 20.90 $23.19 - 27.82 320  9.50 $ 24.22  &#8212; $ &#8212; $27.82 - 32.46 472  9.43 $ 28.77  52 $ 27.90 $ 32.46 - 37.10 1,380  9.00 $ 36.18  &#8212; $ &#8212; $41.73 - 46.37 218  9.13 $ 46.37  45 $ 46.37    12,463  6.47 $ 11.22  8,081 $ 5.63The aggregate intrinsic value of the outstanding and exercisable options presented in the table above totaled $147.9 million and $121.4 million, respectively. The aggregate intrinsic value represents the total pretax intrinsic value (i.e., the difference between $20.46, our closing stock price on the last trading day of our fourth quarter of 2021 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2021. The aggregate intrinsic value changes at each reporting date based on the fair market value of our common stock. The weighted average remaining contractual life for exercisable options is 5.12 years.The vested and expected to vest options as of December 31, 2021 totaled 11,535,217, with aggregate intrinsic value of $141.9 million, weighted average exercise price per share of $10.46 and weighted average remaining contractual life of 6.28 years. The total intrinsic value of stock options exercised during the years ended December&#160;31, 2021, 2020 and 2019 was $146.1 million, $63.1 million and $2.6 million, respectively. The weighted-average grant-date fair value of all options granted with exercise prices equal to fair market value was $18.36 in 2021 and $4.14 in 2020 determined by the Black-Scholes option valuation method. No stock options were granted in 2019. Time-based RSUs&#160;Each RSU represents one equivalent share of our common stock to be issued after satisfying the applicable continued service-based vesting criteria over a specified period. These RSUs vest over four years at a rate of 25% annually. The fair value for these RSUs is based on the closing price of our common stock on the date of grant. We measure compensation expense for these RSUs at fair value on the date of grant and recognize the expense over the expected vesting period on a straight-line basis. The RSUs do not entitle participants to the rights of holders of common stock, such as voting rights, until the shares are issued. RSUs that are expected to vest are net of estimated future forfeitures. The following table summarizes the time-based RSUs activity for the year ended December 31, 2021 (in thousands, except per share amounts):          Weighted average Number grant date of shares fair valueRSUs outstanding at December 31, 2020 5,919 $ 5.25RSUs granted 3,744   35.33RSUs released (1,798)   5.13RSUs forfeited (473)   16.68Unvested RSUs outstanding at December 31, 2021 7,392 $ 19.78Performance-based RSUs&#160;The Compensation Committee of the Board of Directors approved awards of RSUs with performance-based vesting under the 2010 Plan to certain employees which expired on July 29, 2020. Performance-based RSUs are governed under the 2020 Plan.The following table summarizes the performance-based RSUs activity for the year ended December 31, 2021 (in thousands, except per share amounts):          Weighted average Number grant date of shares fair valuePSUs outstanding at December 31, 2020 94 $$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2.63PSUs granted &#8212;   &#8212;PSUs released &#8212;   &#8212;PSUs forfeited (94)   2.63Unvested PSUs outstanding at December 31, 2021 &#8212; $ &#8212;2010 Employee Stock Purchase Plan As of December 31, 2021, a total of 21.5 million shares of our common stock have been reserved for issuance under our 2010 Employee Stock Purchase Plan (ESPP).  The ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Each offering period will generally consist of four purchase periods, each purchase period being approximately six months. The price at which the stock is purchased is equal to the lower of 85% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period. Each offering period will generally end and the shares will be purchased twice yearly on March 1 and September 1. If the stock price at the end of the purchase period is lower than the stock price at the beginning of the offering period, that offering period will then be terminated and new offering period comes to place. The ESPP provides for an annual increase to the shares available for issuance at the beginning of each fiscal year equal to the lessor of 2% of the common shares then outstanding, 4,000,000 shares, or an amount determined by the ESPP&#8217;s administrator. Pursuant to the terms of the then-in-process Merger Agreement with Illumina, offerings under our 2010 ESPP were suspended after the completion of the purchase period ended March 1, 2019. After the merger with Illumina was terminated in January 2020, we began offerings under the ESPP again starting with the offering period beginning March 1, 2020.  For the years ended December&#160;31, 2021, 2020 and 2019, 1,913,968 shares, 834,677 shares and 1,306,329 shares of common stock were purchased under the ESPP, respectively. As of December 31, 2021, 7,810,673 shares of our common stock remain available for issuance under our ESPP. Stock-based Compensation Total stock-based compensation expense consists of the following (in thousands):                    Years Ended December 31,  2021 2020 2019Cost of revenue$ 6,126 $ 2,236 $ 1,857Research and development  20,275   7,061   7,699Sales, general and administrative  35,403   8,236   6,845Merger-related expenses - stock-settled  6,349   &#8212;   &#8212;Merger-related expenses - milestone  5,202   &#8212;   &#8212;Stock-based compensation  73,355   17,533   16,401Merger-related expenses - cash-settled  7,373   &#8212;   &#8212;Total stock-based compensation expense$ 80,728 $ 17,533 $ 16,401As of December 31, 2021 and 2020, $0.9 million and $0.3 million of stock-based compensation cost was capitalized in inventory on our consolidated balance sheets, respectively. The tax benefit of stock-based compensation expense was immaterial for the years ended December 31, 2021, 2020 and 2019. Determining Fair ValueWe estimate the fair value of share options granted using the Black-Scholes valuation method and a single option award approach. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSU awards granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting period. For shares purchased under our Employee Stock Purchase Plan, or ESPP, we estimate the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model.Expected Term - The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock options and vesting schedules.Expected Volatility - The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.Expected Dividend - We have never paid dividends on our shares and, accordingly, the dividend yield percentage is zero for all periods.Risk-Free Interest Rate - The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.Stock OptionsWe estimated the fair value of employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. For the year ended December 31, 2019, we did not grant any stock options. When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference observable market prices of similar or identical instruments in active markets.  For the years ended December 31, 2021, 2020 and 2019, the fair value of employee stock options was estimated using the following weighted average assumptions:                      Years Ended December 31,   2021 2020 2019Expected term in years  2.1 - 4.6  5.0 years   &#8212;&#160;&#160;Expected volatility   67% - 80%  70.7%  &#8212;&#160;&#160;Risk-free interest rate   0.05% &#8211; 1.10%  0.3%  &#8212;&#160;&#160;Dividend yield   &#8212;&#160;&#160;  &#8212;&#160;&#160;  &#8212;&#160;&#160;Weighted average grant date fair value per share  $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;15.53  $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7.20  &#8212;&#160;&#160;          Cash received from option exercises for the years ended December&#160;31, 2021, 2020 and 2019 was $25.4 million, $43.9 million and $5.9 million, respectively.  ESPP We estimate the fair value of shares to be issued under the ESPP using the Black-Scholes option pricing model. For the years ended December 31, 2021, 2020 and 2019, the fair value of shares to be issued under the ESPP was estimated using the following assumptions:                      Years Ended December 31,   2021 2020 2019Expected term in years  0.5 - 2.0  0.5 - 2.0  &#8212;&#160;&#160;Expected volatility   67% - 68%  57% - 71%  &#8212;&#160;&#160;Risk-free interest rate   0.1% - 0.2%  0.1%-1.0%  &#8212;&#160;&#160;Dividend yield    &#8212;  &#8212;&#160;&#160;  &#8212;&#160;&#160;Weighted average grant date fair value per share  $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25.07  $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1.87  &#8212;&#160;&#160; Cash received through the ESPP for the years ended December 31, 2021, 2020 and 2019 was $6.4 million, $2.4 million and $2.7 million, respectively. As of December&#160;31, 2021, $122.9 million of total unrecognized compensation expense related to stock options, restricted stock and ESPP shares was expected to be recognized over a weighted-average period of 2.9 years.&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284759897240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net (Loss) Income Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text">NOTE 11. NET (LOSS) INCOME PER SHAREBasic net (loss) income per share and diluted net (loss) income per share are presented for the three years presented. Basic net (loss) income per share is computed by dividing net (loss) income by the weighted average number of shares of common stock outstanding during the period. Diluted net (loss) income per share is computed using the weighted average number of shares of common stock outstanding and potential shares assuming the dilutive effect of outstanding stock options, restricted stock units and common stock issuable pursuant to our ESPP, using the treasury stock method.  The following table presents the calculation of weighted average shares of common stock used in the computations of basic and diluted net (loss) income per share amounts presented in the accompanying consolidated statements of operations and comprehensive (loss) income (in thousands, except per share amounts):           Years Ended December 31, 2021 2020 2019Numerator:    Net (loss) income$ (181,223) $ 29,403 $ (84,134)         Denominator:        Basic        Weighted average shares used in computing basic net income (loss) per share  204,136   165,187   152,527Basic net (loss) income per share$ (0.89) $ 0.18 $ (0.55)Diluted        Weighted average shares used in computing basic net (loss) income per share  204,136   165,187   152,527Add: weighted average stock options  &#8212;   6,092   &#8212;Add: weighted average restricted stock units  &#8212;   2,324   &#8212;Add: weighted average common stock issuable pursuant to our ESPP  &#8212;   1,367   &#8212;Weighted average shares used in computing diluted net (loss) income per share  204,136   174,970   152,527Diluted net (loss) income per share$ (0.89) $ 0.17 $ (0.55)The following shares issuable upon conversion of convertible senior notes, options outstanding, time-based RSUs, performance-based RSUs and ESPP shares to purchase common stock were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:            Years Ended December 31,(in thousands)2021 2020 2019Shares issuable upon conversion of convertible senior notes 18,026  &#8212;  &#8212;Options to purchase common stock  12,463  4,908  22,697RSUs with time-based vesting  7,392  100  1,086RSUs with performance-based vesting  &#8212;  94  138ESPP shares 1,564  2,890  &#8212; &#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284763687416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment And Geographic Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment And Geographic Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment And Geographic Information</a></td>
<td class="text">NOTE 12. SEGMENT AND GEOGRAPHIC INFORMATIONWe are organized as, and operate in, one reportable segment: the development, manufacturing and marketing of an integrated platform for genetic analysis. Our chief operating decision-maker is our Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis for purposes of evaluating financial performance and allocating resources, accompanied by information about revenue by geographic regions. Our assets are primarily located in the United States of America and not allocated to any specific region and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue. Revenue by geographic region is based on the ship to address on the customer order.A summary of our revenue by geographic location for the years ended December 31, 2021, 2020 and 2019 is as follows:                   Years Ended December 31,(in thousands)2021 2020 2019North America$ 64,521 $ 37,277 $ 44,681Europe (including the Middle East and Africa)  30,271&#160;&#160;  19,065&#160;&#160;  19,600Asia Pacific  35,721   22,551   26,610Total $ 130,513 $ 78,893 $ 90,891 A summary of our revenue by category for the years ended December 31, 2021, 2020 and 2019 is as follows:                    Years Ended December 31,(in thousands)2021 2020 2019Instrument revenue$ 61,324 $ 34,282 $ 45,126Consumable revenue  52,181&#160;&#160;  31,142    32,616Product revenue  113,505   65,424   77,742Service and other revenue  17,008   13,469   13,149Total revenue$ 130,513 $ 78,893 $ 90,891         &#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284760171768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policy)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation and Consolidation</a></td>
<td class="text">Basis of Presentation Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of Estimates The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates including, but not limited to, the valuation of inventory, the determination of stand-alone selling prices for revenue recognition, the fair value of contingent consideration, the valuation of acquired intangible assets, the fair value of certain equity awards, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, the borrowing rate used in calculating the operating lease right-of-use assets and operating lease liabilities, the probability associated with variable payments under partnership development agreements, and the valuations related to our convertible senior notes. While the extent of the impact of the COVID-19 pandemic on our business is highly uncertain, we considered the impact on our assumptions and estimates used to determine the results reported and asset valuations as of December 31, 2021. Actual results could differ materially from these estimates. <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional Currency</a></td>
<td class="text">Functional CurrencyThe U.S. dollar is the functional currency of our international operations.  We remeasure foreign subsidiaries monetary assets and liabilities to the U.S. dollar and record net gains or losses from remeasurement in other income, net, in the consolidated statement of operations and comprehensive (loss) income.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Investments</a></td>
<td class="text">Cash, Cash Equivalents, and Investments We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. We classify our investments in debt securities as available-for sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related.  Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive (loss) income in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net.  Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and US government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration and Credit Risks</a></td>
<td class="text">Concentration and Credit Risks Financial instruments that potentially subject us to credit risk consist principally of interest-bearing investments and trade receivables. We maintain cash, cash equivalents and investments with various major financial institutions. The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities and government agencies of high credit standing. At December 31, 2021, most of our cash was deposited with U.S. financial institutions.  Our investment policy generally restricts the amount of credit exposure to any one issuer. There is no limit to the percentage of the portfolio that may be maintained in securities issued by the U.S. Treasury and U.S. Government Agencies, or other securities fully backed by US Treasury or Government agencies. We have not experienced significant credit losses from financial institutions.Our trade receivables are derived from net revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers&#8217; financial condition and, generally, require no collateral from our customers. The allowance for doubtful accounts is based on our assessment of the collectability of customer accounts. We regularly review our trade receivable including consideration of factors such as historical experience, the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. We have not experienced any significant credit losses to date. Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. For the years ended December 31, 2021, 2020 and 2019, one customer, Gene Company Limited, accounted for approximately 13%, 14% and 17% our total revenue, respectively. As of December 31, 2021 and 2020, 53% and 43% of our accounts receivable were from domestic customers, respectively. As of December 31, 2021, no customer represented 10% of greater of our net accounts receivable. As of December 31, 2020, two customers, Berry Genomics Co., Ltd and Gene Company Limited, represented approximately 15% and 12% of our net accounts receivable, respectively. We currently purchase several key parts and components used in the manufacture of our products from a limited number of suppliers. Generally, we have been able to obtain an adequate supply of such parts and components but in certain instances have incurred additional costs to secure supply constrained materials. An extended interruption in the supply of parts and components currently obtained from our suppliers could adversely affect our business and consolidated financial statements. <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">Inventory Inventories are stated at the lower of average cost or net realizable value. Cost is determined using the first-in, first-out (&#8220;FIFO&#8221;) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs while determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories. &#160;  We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net Property and equipment are stated at cost, reviewed regularly for impairment charges, and depreciated over the estimated useful lives of the assets, using the straight-line method.  Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred. Estimated useful lives of the major classes of property and equipment are as follows:         Estimated Useful LivesLeasehold improvements 3 to 10 yearsLab equipment 3 to 5 yearsComputer equipment 3 to 5 yearsComputer software 3 yearsFurniture and fixtures 3 to 5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Tangible Long-Lived Assets</a></td>
<td class="text">Impairment of Tangible Long-Lived Assets We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset is impaired or the estimated useful lives are no longer appropriate. Fair value is estimated based on discounted future cash flows. If indicators of impairment exist and the undiscounted projected cash flows associated with such assets are less than the carrying amount of the asset, an impairment loss is recorded to write the asset down to its estimated fair value. To date, we have not recorded any impairment charges.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating Leases</a></td>
<td class="text">Operating Leases We record operating lease right-of-use assets and liabilities on our Consolidated Balance Sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. Operating lease expense is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period incurred. <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible AssetsWe perform annual impairment testing of goodwill and in-process research and development project (&#8220;IPR&D&#8221;) in the second quarter of each year, or more frequently if indicators of potential impairment exist.We capitalize IPR&D assets and will begin to amortize the asset over the life of the product upon commercialization or record an impairment charge if the project is abandoned. We also capitalize finite-lived intangibles assets and amortize them on a straight-line basis over the estimated useful lives.Finite-lived intangibles assets include our acquired developed technology and customer relationships. We regularly review the carrying amount and useful lives of our finite-lived assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives.&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock', window );">Short-term Restriced Cash</a></td>
<td class="text">Short-term Restricted Cash At December 31, 2021, the short-term restricted cash balance of $0.5 million consisted of security deposits for employee credit cards.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock', window );">Long-term Restricted Cash</a></td>
<td class="text">Long-term Restricted Cash Under the lease agreement for our corporate offices, we were required to establish a letter of credit for the benefits of the landlord and to submit $4.5 million as a deposit for the letter of credit in October 2015. Subsequently pursuant to the terms of the O&#8217;Brien Lease, beginning on May 1, 2019, the amount of the letter of credit was reduced by $0.5 million each year thereafter on May 1. As such, $3.0 million and $3.5 million was recorded in long-term restricted cash related to the O&#8217;Brien Lease in the Consolidated Balance Sheets as of December 31, 2021 and December 31, 2020, respectively.In connection with the acquisition of Omniome in September 2021, we acquired $1.6 million of long-term restricted cash related to a letter of credit established for a facility lease.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables. Service and other revenue consists primarily of revenue earned from product maintenance agreements. We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods or services is transferred to our customers or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our instrument sales are generally sold in a bundled arrangement and commonly include the instrument, instrument accessories, installation, training, and consumables. Additionally, our instrument sale arrangements generally include a&#160;one-year period of service. For such bundled arrangements, we account for individual products and services separately if they are distinct, that is, if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. Our customers cannot benefit from our instrument systems without installation, and installation can only be performed by us or qualified distributors. As a result, the system and installation are considered to be a single performance obligation recognized after installation is completed except for sales to qualified distributors, in which case the system is distinct and recognized when control has transferred to the distributor which typically occurs upon shipment.  The consideration for bundled arrangements is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using average selling prices over a 12-month period combined with an assessment of current market conditions. If the standalone selling price is not directly observable, then we will estimate the SSP by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices and other observable inputs. We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts, distributor commissions, and sales taxes collected on behalf of governmental authorities.  We record deferred revenues when cash payments are received or due in advance of our performance. Deferred revenue for instrument service contracts is recognized over the related performance period, generally one year to five years, on a straight-line basis as we are standing ready to provide services and a time-based measure of progress best reflects the satisfaction of the performance obligation. <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenue</a></td>
<td class="text">Cost of RevenueCost of revenue reflects the direct cost of product components, third-party manufacturing services and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain and support our instruments, consumables, and services. There are no incremental costs associated with our contractual revenue; all product development costs are reflected in research and development expense.Manufacturing overhead is predominantly comprised of labor and facility costs. We determine and capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs.  Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support our installed customer base. <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">Research and Development Research and development expense consists primarily of expenses for personnel engaged in the development of our core technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, partner development costs, facilities costs and other related overhead. We expense research and development costs during the period in which the costs are incurred. However, we defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered. <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Credit Losses</a></td>
<td class="text">Credit LossesWe adopted Topic 326 on January 1, 2020. The adoption of Topic 326 did not have a material impact on our financial statements and our bad debt expense was immaterial as of the years ended December 31, 2020 and 2021. Trade accounts receivable - The allowance for doubtful accounts is based on our assessment of the collectability of customer accounts. We regularly review the allowance by considering factors such as the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. Available-for-sale debt securities - Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and US government and agency securities. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as significance of loss, historical experience, market data, issuer-specific factors, and current economic conditions and concluded that an allowance for credit losses was immaterial as of December 31, 2021. The unrealized losses on our investments are mainly attributable to government securities, including U.S. government and U.S. agency bond securities, impacted by movements in market rates and not due to issuer credit ratings. We have the ability to hold and do not intend to sell the investments in unrealized loss positions before the recovery of their amortized cost bases.Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruptions associated with the evolution of the COVID-19 pandemic, or other customer-specific factors. <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. The effect of a change in tax rates on the deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized. We regularly review our positions taken relative to income taxes. To the extent our tax positions are more likely than not going to result in additional taxes, we accrue the estimated amount of tax related to such uncertain positions. <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-based Compensation We account for share-based payments using a fair-value based method for costs related to all share-based payments, including stock options, restricted stock units, and stock issued under our employee stock purchase plan (&#8220;ESPP&#8221;). We estimate the fair value of share-based payment awards that are stock options and issued under our ESPP on the date of grant using an option-pricing model. See Note 10. Stockholders&#8217; Equity for further information regarding stock-based compensation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text">Other Comprehensive (Loss) IncomeOther comprehensive (loss) income is comprised of unrealized gains (losses) on our investment securities. <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and Handling</a></td>
<td class="text">Shipping and HandlingCosts related to shipping and handling are included in cost of revenues for all periods presented.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-Term Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 35<br> -Paragraph 7A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515542&amp;loc=SL120269220-210453<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3D<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267969-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922895-210455<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 35<br> -Paragraph 13A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515542&amp;loc=SL120267917-210453<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 35<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124266218&amp;loc=SL120267834-210445<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 30<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=124256539&amp;loc=SL120269210-210444<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919260-210447<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL120267845-210446<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 30<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=124256539&amp;loc=SL120254536-210444<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3C<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267966-210447<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 30<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=124268681&amp;loc=SL120267897-210452<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3D<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267862-210455<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.Q4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122651532&amp;loc=SL122037091-237805<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3C<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267859-210455<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284759771992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock', window );">Estimated useful lives of the major classes of property and equipment</a></td>
<td class="text">        Estimated Useful LivesLeasehold improvements 3 to 10 yearsLab equipment 3 to 5 yearsComputer equipment 3 to 5 yearsComputer software 3 yearsFurniture and fixtures 3 to 5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated useful lives of the major classes of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284760028376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock', window );">Schedule of Business Acquisitions, by Acquisition Consideration Tranferred</a></td>
<td class="text">   Total cash paid$ 315,703Fair value of share consideration  249,435Fair value of contingent consideration  168,574Less: Stock-based compensation expense excluded from consideration transferred  (18,923)Total consideration transferred$ 714,789   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text">   Cash and cash equivalents$ 15,338Property and equipment, net   6,123Operating lease right-of-use assets, net   18,095In-process research and development ("IPR&D")  400,000Goodwill  390,665Other assets  3,203Deferred income tax liability  (91,814)Liabilities assumed  (26,821)Total consideration transferred$ 714,789   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Unaudited Pro Forma Financial Information</a></td>
<td class="text">       Years Ended December 31,(in thousands, except per share amounts)2021 2020      Pro forma total revenue$ 130,513 $ 78,893Pro forma net (loss) income$ (278,451) $ 17,510Pro forma net (loss) income per share - basic and diluted$ (1.27) $ 0.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember', window );">Circulomics, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock', window );">Schedule of Business Acquisitions, by Acquisition Consideration Tranferred</a></td>
<td class="text">   Cash and cash equivalents$ 987Property and equipment, net   214Intangible assets  11,360Goodwill  19,309Other assets  467Deferred income tax liability  (2,672)Liabilities assumed  (118)Total consideration transferred$ 29,547<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, details of total considerations transferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284764304104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text">                                                   December 31, 2021 December 31, 2020 (in thousands)Level 1 Level&#160;2 Level 3 Total Level 1 Level&#160;2 Level 3 Total Assets                        Cash and cash equivalents:                        Cash and money market funds $ 327,315&#160; $ &#8212; $ &#8212; $ 327,315&#160; $ 43,040&#160; $ &#8212; $ &#8212; $ 43,040&#160; Commercial paper   &#8212;   133,185&#160;   &#8212;   133,185&#160;   &#8212;   32,537&#160;   &#8212;   32,537&#160; U.S. government & agency securities  &#8212;   225&#160;   &#8212;   225&#160;   &#8212;   170&#160;   &#8212;   170&#160; U.S. Treasury security  &#8212;   &#8212;   &#8212;   &#8212;   &#8212;   5,864&#160;   &#8212;   5,864&#160; Total cash and cash equivalents   327,315&#160;   133,410&#160;   &#8212;   460,725&#160;   43,040&#160;   38,571&#160;   &#8212;   81,611&#160; Investments:                        Commercial paper   &#8212;   187,632&#160;   &#8212;   187,632&#160;   &#8212;   112,644&#160;   &#8212;   112,644&#160; Corporate debt securities   &#8212;   8,968&#160;   &#8212;   8,968&#160;   &#8212;   17,456&#160;   &#8212;   17,456&#160; U.S. government & agency securities  &#8212;   387,075&#160;   &#8212;   387,075&#160;   &#8212;   107,103&#160;   &#8212;   107,103&#160; Total investments   &#8212;   583,675&#160;   &#8212;   583,675&#160;   &#8212;   237,203&#160;   &#8212;   237,203&#160; Short-term restricted cash:                        Cash   500&#160;   &#8212;   &#8212;   500&#160;   836&#160;   &#8212;   &#8212;   836&#160; Long-term restricted cash:                        Cash   4,592&#160;   &#8212;   &#8212;   4,592&#160;   3,500&#160;   &#8212;   &#8212;   3,500&#160; Total assets measured at fair value $ 332,407&#160; $ 717,085&#160; $ &#8212; $ 1,049,492&#160; $ 47,376&#160; $ 275,774&#160; $ &#8212; $ 323,150&#160;                          Liabilities                        Continuation advances $ &#8212; $ &#8212; $ &#8212; $ &#8212; $ &#8212; $ &#8212; $ &#8212; $ &#8212; Contingent consideration  &#8212;   &#8212;   169,717&#160;   169,717&#160;   &#8212;   &#8212;   &#8212;   &#8212; Total liabilities measured at fair value $ &#8212; $ &#8212; $ 169,717&#160; $ 169,717&#160; $ &#8212; $ &#8212; $ &#8212; $ &#8212; <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock', window );">Changes in the estimated fair value of contingent consideration liabilities [Table Text Block]</a></td>
<td class="text">  (in thousands)Level 3Beginning balance as of January 1, 2021 -Acquisition of Omniome 168,574Change in estimated fair value 1,143Ending balance as of December 31, 2021 169,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of Cash, Cash Equivalents and Investments</a></td>
<td class="text">                         As of December 31, 2021    Gross Gross   Amortized unrealized unrealized Fair(in thousands) Cost  gains  losses  Value Cash and cash equivalents:           Cash and money market funds$ 327,316 $ &#8212; $ &#8212; $ 327,316Commercial paper   133,190   &#8212;   (5)   133,185U.S. government & agency securities  225   &#8212;   &#8212;   224Total cash and cash equivalents   460,731   &#8212;   (5)   460,725Investments:           Commercial paper   187,705   &#8212;   (73)   187,632Corporate debt securities   8,964   9   (5)   8,968U.S. government & agency securities  388,088   1   (1,014)   387,075Total investments   584,757   10   (1,092)   583,675Total cash, cash equivalents and investments $ 1,045,488 $ 10 $ (1,097) $ 1,044,400Short-term restricted cash:           Cash $ 500 $ &#8212; $ &#8212; $ 500Long-term restricted cash:           Cash $ 4,592 $ &#8212; $ &#8212; $ 4,592             As of December 31, 2020    Gross Gross   Amortized unrealized unrealized Fair(in thousands) Cost  gains  losses  Value Cash and cash equivalents:           Cash and money market funds$ 43,040 $ &#8212; $ &#8212; $ 43,040Commercial paper  32,538   &#8212;   (1)   32,537U.S. government & agency securities  170   &#8212;   &#8212;   170U.S. Treasury security  5,864   &#8212;   &#8212;   5,864Total cash and cash equivalents   81,612   &#8212;   (1)   81,611Investments:           Commercial paper   112,648   4   (8)   112,644Corporate debt securities   17,360   96   &#8212;   17,456U.S. government & agency securities  107,109   6   (12)   107,103Total investments   237,117   106   (20)   237,203Total cash, cash equivalents and investments $ 318,729 $ 106 $ (21) $ 318,814Short-term restricted cash:           Cash $ 836 $ &#8212; $ &#8212; $ 836Long-term restricted cash:           Cash $ 3,500 $ &#8212; $ &#8212; $ 3,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments</a></td>
<td class="text">   (in thousands)Fair ValueDue in one year or less $ 595,063Due after one year through 5 years   122,022Total investments $ 717,085    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in the estimated fair value of contingent consideration liabilities table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284763055096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of Inventory</a></td>
<td class="text">             December 31, (in thousands)2021 2020Purchased materials$ 7,993 $ 3,531Work in process  8,611   6,651Finished goods  7,995   4,048Inventory$ 24,599 $ 14,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Components of Property and Equipment, Net</a></td>
<td class="text">             December 31,(in thousands)2021 2020Laboratory equipment and machinery $ 31,534 $ 24,948Leasehold improvements  31,114   29,931Computer equipment  15,059   12,400Software  5,578   4,940Furniture and fixtures  3,202   2,434Construction in progress  2,303   137   88,790   74,790Less: Accumulated depreciation   (56,286)   (49,891)Property and equipment, net $ 32,504 $ 24,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text">             December 31,(in thousands)2021 2020Salaries and benefits$ 25,282 $ 15,261Accrued product development costs  1,936   415Accrued interest payable  5,100   &#8212;Inventory accrual  108   218Warranty  594   161Accrued professional services and legal fees  1,640   726Other   1,601   569Accrued expenses $ 36,261 $ 17,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Liabilities, Current</a></td>
<td class="text">       December 31,(in thousands)2021 2020Accrued ESPP$ 3,598 $ 2,037Other   2,161   2,482Other liabilities, current$ 5,759 $ 4,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Changes to Goodwill</a></td>
<td class="text">   Balance as of December 31, 2020$ -Acquisition of Omniome  390,665Acquisition of Circulomics  19,309Balance as of December 31, 2021$ 409,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of definite-lived intangible assets from business acquisitions</a></td>
<td class="text">            Estimated  Gross    Net Useful Life Carrying Accumulated Carrying (in years) Amount Amortization AmountDeveloped technology15 $ 11,000 $ (306) $ 10,694Customer relationships2   360   (75)   285Total  $ 11,360 $ (381) $ 10,979           <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated Future Amortization Expense Of Acquisition-Related Intangible Assets With Definite Lives</a></td>
<td class="text">      2022$ 9132023  8382024  7332025  7332026  7332027 and thereafter  7,029Total$ 10,979    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Future Principal Payments , Fiscal Year Maturity</a></td>
<td class="text">   (in thousands)  2022$ 1,6082023  1,8422024  490Total$ 3,940 <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284763930040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Convertible Senior Notes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Net Carrying Amount</a></td>
<td class="text">   Principal amount$ 900,000Unamortized debt issuance costs  (3,933)Net carrying amount$ 896,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ScheduleOfInterestExpenseTableTextBlock', window );">Schedule of Interest Expense</a></td>
<td class="text">   Contractual interest expense$ 11,812Amortization of debt issuance costs  532Total interest expense$ 12,344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ScheduleOfInterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Interest Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ScheduleOfInterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284759799576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_LesseeOperatingLeaseDescriptionTableTextBlock', window );">Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases</a></td>
<td class="text">      Maturity of Lease LiabilitiesAmount Years ending December 31,(in thousands)2022$ 11,3262023  11,8512024  12,0402025  12,3282026  12,437Thereafter  9,930Total undiscounted operating lease payments  69,912Less: imputed interest  (12,232)Present value of operating lease liabilities   57,680   Balance Sheet Classification  Operating lease liabilities, current  7,710Operating lease liabilities, non-current  49,970Total operating lease liabilities  57,680<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_LesseeOperatingLeaseDescriptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Description [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_LesseeOperatingLeaseDescriptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284759985064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Income Tax Rate</a></td>
<td class="text">                   Years ended December 31, 2021  2020  2019 Statutory tax rate  21.0%  21.0%  21.0%State tax rate, net of federal benefit 5.5   (8.3)   4.9 Change in valuation allowance  (4.9)   6.3   (27.5) Tax credits 2.5   (3.6)   2.2 Stock-based compensation 10.9   (15.2)   (0.8) Merger Expenses (0.9)   -   - Other (0.1)   (0.2)   0.2 Total 34.0%  0.0%  (0.0)%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Reconciliation of Deferred Tax Assets and Liabilities</a></td>
<td class="text">             December 31,Deferred tax assets:2021 2020Net operating loss carryforwards$ 378,035 $ 233,225Research and development credits   60,672   49,179Accruals and reserves  10,822   6,337Stock-based compensation  12,838   9,717ASC 842 Operating lease liability  13,105   9,870Total deferred tax assets   475,472   308,328Less: Valuation allowance  (366,940)   (300,505)Total deferred tax assets:  108,532   7,823Intangibles  (97,345)   &#8212;Fixed assets  (1,523)   (786)ASC 842 Operating lease right-of-use assets  (10,502)   (7,037)Total deferred tax liabilities  (109,370)   (7,823)Net deferred tax assets $ (838) $ &#8212;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of Unrecognized Tax Benefit Accounts</a></td>
<td class="text">      Balance as of December 31, 2018$ 20,447Decrease in balance related to tax positions taken in prior year   &#8212;Increase in balance related to tax positions taken during current year   1,532Balance as of December 31, 2019$ 21,979Decrease in balance related to tax positions taken in prior year   (17,255)Increase in balance related to tax positions taken during current year   1,230Balance as of December 31, 2020$ 5,954Increase in balance related to tax positions taken in prior year   189Increase in balance related to tax positions taken during current year   2,192Balance as of December 31, 2021$ 8,335<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284755759496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Reconciliation of Outstanding and Exercisable Stock Options</a></td>
<td class="text">                               Options Outstanding Options Exercisable   Number Weighted average    Number      outstanding remaining contractual Weighted average  vested Weighted average  Exercise price(in 000s) life (Years) exercise price (in 000s) exercise price $0.00 - 4.64 3,676  5.37 $ 2.91  3,508 $ 2.91 $4.64 - 9.27 5,480  5.88 $ 6.64  4,010 $ 6.68 $9.27 - 13.91 702  6.69 $ 9.81  427 $ 9.94 $13.91 - 18.55 35  8.79 $ 14.34  14 $ 14.34 $ 18.55 - 23.19 180  9.38 $ 21.86  25 $ 20.90 $23.19 - 27.82 320  9.50 $ 24.22  &#8212; $ &#8212; $27.82 - 32.46 472  9.43 $ 28.77  52 $ 27.90 $ 32.46 - 37.10 1,380  9.00 $ 36.18  &#8212; $ &#8212; $41.73 - 46.37 218  9.13 $ 46.37  45 $ 46.37    12,463  6.47 $ 11.22  8,081 $ 5.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Time-Based RSUs Activity</a></td>
<td class="text">        Weighted average Number grant date of shares fair valueRSUs outstanding at December 31, 2020 5,919 $ 5.25RSUs granted 3,744   35.33RSUs released (1,798)   5.13RSUs forfeited (473)   16.68Unvested RSUs outstanding at December 31, 2021 7,392 $ 19.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Summary of Performance-Based RSUs Activity</a></td>
<td class="text">        Weighted average Number grant date of shares fair valuePSUs outstanding at December 31, 2020 94 $$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2.63PSUs granted &#8212;   &#8212;PSUs released &#8212;   &#8212;PSUs forfeited (94)   2.63Unvested PSUs outstanding at December 31, 2021 &#8212; $ &#8212;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text">                   Years Ended December 31,  2021 2020 2019Cost of revenue$ 6,126 $ 2,236 $ 1,857Research and development  20,275   7,061   7,699Sales, general and administrative  35,403   8,236   6,845Merger-related expenses - stock-settled  6,349   &#8212;   &#8212;Merger-related expenses - milestone  5,202   &#8212;   &#8212;Stock-based compensation  73,355   17,533   16,401Merger-related expenses - cash-settled  7,373   &#8212;   &#8212;Total stock-based compensation expense$ 80,728 $ 17,533 $ 16,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Stock Options</a></td>
<td class="text">                      Years Ended December 31,   2021 2020 2019Expected term in years  2.1 - 4.6  5.0 years   &#8212;&#160;&#160;Expected volatility   67% - 80%  70.7%  &#8212;&#160;&#160;Risk-free interest rate   0.05% &#8211; 1.10%  0.3%  &#8212;&#160;&#160;Dividend yield   &#8212;&#160;&#160;  &#8212;&#160;&#160;  &#8212;&#160;&#160;Weighted average grant date fair value per share  $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;15.53  $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7.20  &#8212;&#160;&#160;          <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Stock Purchase Plan</a></td>
<td class="text">                      Years Ended December 31,   2021 2020 2019Expected term in years  0.5 - 2.0  0.5 - 2.0  &#8212;&#160;&#160;Expected volatility   67% - 68%  57% - 71%  &#8212;&#160;&#160;Risk-free interest rate   0.1% - 0.2%  0.1%-1.0%  &#8212;&#160;&#160;Dividend yield    &#8212;  &#8212;&#160;&#160;  &#8212;&#160;&#160;Weighted average grant date fair value per share  $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25.07  $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1.87  &#8212;&#160;&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedStockOptionsMember', window );">Time-based stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">                    Stock Options Outstanding       Weighted  Number    average  of shares Exercise price exercise priceOutstanding at December 31, 2020  14,638 $ 1.16 &#8211; 20.90 $ 5.53Granted   2,489  23.06 &#8211; 46.37   33.78Assumed Omniome options  339  2.05 &#8211; 4.90   4.43Exercised   (4,766)  1.16 &#8211; 15.98   5.31Canceled   (541)  2.54 &#8211; 46.37   5.25Outstanding at December 31, 2021  12,159 $1.16 &#8211; 46.37 $ 11.38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">                    Stock Options Outstanding       Weighted  Number    average  of shares Exercise price exercise priceOutstanding at December 31, 2020  &#8212; $ &#8212; $ &#8212;Granted   &#8212;   &#8212;   &#8212;Assumed Omniome options  304  4.71 - 4.90   4.71Exercised   &#8212;   &#8212;   &#8212;Canceled   &#8212;   &#8212;   &#8212;Outstanding at December 31, 2021  304 $4.71 - 4.90 $ 4.71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284759854472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net (Loss) Income Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Income (Loss) per Share</a></td>
<td class="text">          Years Ended December 31, 2021 2020 2019Numerator:    Net (loss) income$ (181,223) $ 29,403 $ (84,134)         Denominator:        Basic        Weighted average shares used in computing basic net income (loss) per share  204,136   165,187   152,527Basic net (loss) income per share$ (0.89) $ 0.18 $ (0.55)Diluted        Weighted average shares used in computing basic net (loss) income per share  204,136   165,187   152,527Add: weighted average stock options  &#8212;   6,092   &#8212;Add: weighted average restricted stock units  &#8212;   2,324   &#8212;Add: weighted average common stock issuable pursuant to our ESPP  &#8212;   1,367   &#8212;Weighted average shares used in computing diluted net (loss) income per share  204,136   174,970   152,527Diluted net (loss) income per share$ (0.89) $ 0.17 $ (0.55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Shares Excluded from Computation of Diluted Net Loss per Share</a></td>
<td class="text">       Years Ended December 31,(in thousands)2021 2020 2019Shares issuable upon conversion of convertible senior notes 18,026  &#8212;  &#8212;Options to purchase common stock  12,463  4,908  22,697RSUs with time-based vesting  7,392  100  1,086RSUs with performance-based vesting  &#8212;  94  138ESPP shares 1,564  2,890  &#8212;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284759854472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment And Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment And Geographic Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue by Geographic Location</a></td>
<td class="text">                   Years Ended December 31,(in thousands)2021 2020 2019North America$ 64,521 $ 37,277 $ 44,681Europe (including the Middle East and Africa)  30,271&#160;&#160;  19,065&#160;&#160;  19,600Asia Pacific  35,721   22,551   26,610Total $ 130,513 $ 78,893 $ 90,891 <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of Revenue by Category</a></td>
<td class="text">                   Years Ended December 31,(in thousands)2021 2020 2019Instrument revenue$ 61,324 $ 34,282 $ 45,126Consumable revenue  52,181&#160;&#160;  31,142    32,616Product revenue  113,505   65,424   77,742Service and other revenue  17,008   13,469   13,149Total revenue$ 130,513 $ 78,893 $ 90,891         <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284753567576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 09, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pacb_ObrienLeaseAgreementMember', window );">O&#8217;Brien Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit [Member] | Omniome, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit [Member] | O&#8217;Brien Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AnnualReductionInNonCurrentRestrictedCash', window );">Annual reduction in non-current restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=pacb_TenPercentOrGreaterBalanceAccountsReceivableMember', window );">Customers with 10% or greater accounts receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndNotesReceivableNet', window );">Accounts and Financing Receivable, after Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net [Member] | Gene Company Limited [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Gene Company Limited [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Domestic Customers [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Berry Genomics Co., Ltd [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=pacb_SecurityDepositMember', window );">Security Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Short-term restriced cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of notes</a></td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Feb. 15,  2028<span></span>
</td>
<td class="text">Feb. 15,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AnnualReductionInNonCurrentRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual reduction in non-current restricted cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AnnualReductionInNonCurrentRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndNotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndNotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pacb_ObrienLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pacb_ObrienLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pacb_TenPercentOrGreaterBalanceAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pacb_TenPercentOrGreaterBalanceAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pacb_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pacb_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pacb_DomesticCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pacb_DomesticCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pacb_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pacb_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=pacb_SecurityDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=pacb_SecurityDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284761320792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Calculation of Basic and Dilutive Net Income (Loss) per Share) (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings Per Share, Basic [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic</a></td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings Per Share, Diluted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number of Shares Outstanding, Basic</a></td>
<td class="nump">204,136<span></span>
</td>
<td class="nump">165,187<span></span>
</td>
<td class="nump">152,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in computing net income (loss) per share, diluted</a></td>
<td class="nump">204,136<span></span>
</td>
<td class="nump">174,970<span></span>
</td>
<td class="nump">152,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284754762440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisitions (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 20, 2021</div></th>
<th class="th"><div>Jul. 20, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares', window );">Issuance of common stock in Private Placement, net of issuance costs shares</a></td>
<td class="nump">11,214,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds From Issuance Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,806,000<span></span>
</td>
<td class="nump">$ 46,360,000<span></span>
</td>
<td class="nump">$ 8,548,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts', window );">Issuance of common stock in Private Placement, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,728,000<span></span>
</td>
<td class="nump">$ 17,533,000<span></span>
</td>
<td class="nump">$ 16,401,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409,974,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400,000<span></span>
</td>
<td class="nump">11,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,649,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember', window );">Circulomics, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,309,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid</a></td>
<td class="nump">$ 315,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of share consideration</a></td>
<td class="nump">249,435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ContingentConsiderationIncurredDuringPeriod', window );">Contingent Consideration Incurred during period</a></td>
<td class="nump">$ 168,574,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock</a></td>
<td class="nump">8,911,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration</a></td>
<td class="nump">$ 714,789,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price Per Share</a></td>
<td class="nump">$ 26.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds From Issuance Of Common Stock</a></td>
<td class="nump">$ 294,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Estimated issuance costs</a></td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related costs</a></td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">18,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance', window );">Income tax benefit from reduction in deferred tax assets valuation allowance</a></td>
<td class="nump">91,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts', window );">Pro forma adjustment related to acquiree's acquisition-related costs</a></td>
<td class="nump">16,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Since the date of acquisition, revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Since the date of acquisition, net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">390,665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc [Member] | Effect of Change Higher/(Lower) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpense', window );">Deferred Tax Liabilities, Deferred Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc [Member] | Omniome stock awards related to acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid</a></td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of share consideration</a></td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ContingentConsiderationIncurredDuringPeriod', window );">Contingent Consideration Incurred during period</a></td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock</a></td>
<td class="nump">226,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration</a></td>
<td class="nump">$ 18,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=pacb_AchievementOfMilestoneMember', window );">Achievement of milestone [Member] | Omniome, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of share consideration</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options issued by PacBio in replacement of Omniome&#8217;s unvested options</a></td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Omniome, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ContingentConsiderationIncurredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Incurred during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ContingentConsiderationIncurredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax benefit from reduction in deferred tax assets valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in Private Placement, net of issuance costs, number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pro forma adjustment to reflect acquiree's acquisition-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in private placement net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_OmniomeStockAwardsRelatedToAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_OmniomeStockAwardsRelatedToAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=pacb_AchievementOfMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=pacb_AchievementOfMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284758410504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisitions (Schedule by Acquisitions) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 20, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 20, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Major classes of assets and liabilities allocated to total fair value of consideration transferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 409,974,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember', window );">Circulomics, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Business Combination, Consideration Transferred [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Major classes of assets and liabilities allocated to total fair value of consideration transferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">987,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets, finite lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,309,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,672,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,547,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Business Combination, Consideration Transferred [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid</a></td>
<td class="nump">$ 315,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of share consideration</a></td>
<td class="nump">249,435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ContingentConsiderationIncurredDuringPeriod', window );">Fair value of contingent consideration</a></td>
<td class="nump">168,574,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred', window );">Less: Stock-based compensation expense excluded from consideration transferred</a></td>
<td class="num">(18,923,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration transferred</a></td>
<td class="nump">714,789,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Major classes of assets and liabilities allocated to total fair value of consideration transferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">15,338,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">6,123,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">18,095,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development ("IPR&amp;D")</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">390,665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">3,203,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liability</a></td>
<td class="num">(91,814,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities assumed</a></td>
<td class="num">(26,821,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration transferred</a></td>
<td class="nump">$ 714,789,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract', window );"><strong>Business Acquisition, Pro Forma Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Pro forma total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,513,000<span></span>
</td>
<td class="nump">$ 78,893,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Pro Forma Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (278,451,000)<span></span>
</td>
<td class="nump">$ 17,510,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted', window );">Pro forma net (loss) income per share - basic and diluted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.27)<span></span>
</td>
<td class="nump">0.09<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, operating lease right of use assets net recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ContingentConsiderationIncurredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Incurred during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ContingentConsiderationIncurredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense excluded from consideration transferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284763039816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Invitae Collaboration Arrangement (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems', window );"><strong>Development and Commercialization Agreement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">$ 25,049<span></span>
</td>
<td class="nump">$ 1,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=pacb_InvitaeCorporationMember', window );">Invitae Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems', window );"><strong>Development and Commercialization Agreement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">$ 23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development and Commercialization Agreement Transactions [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pacb_InvitaeCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pacb_InvitaeCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284758857848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Termination of Merger with Illumina (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 09, 2021</div></th>
<th class="th"><div>Apr. 20, 2020</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_MergerTerminationLineItems', window );"><strong>Merger Termination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">(Loss)/Gain from Continuation Advances from Illumina</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (52,000)<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace', window );">Possible Continuation Advances payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction', window );">Equity or debt financing that must be raised in a single transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Termination fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_PaymentsForAdvisorFees', window );">Advisor fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">2,055<span></span>
</td>
<td class="nump">1,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pacb_IlluminaFcOpsCorpMember', window );">Illumina, FC Ops Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_MergerTerminationLineItems', window );"><strong>Merger Termination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ProceedsFromContractTermination', window );">Continuation Advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_MergerTerminationLineItems', window );"><strong>Merger Termination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of notes</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Feb. 15,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 15,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_RepaymentsOfContractTermination', window );">Continuation Advances paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Continuation Advances Payable Per Agreement To Repay Advance If Change In Control Transaction Or Single Equity Or Debt Financing Takes Place</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger Agreement, Continuation Advances Repayable, Minimum Company must Raise in Equity or Debt Financing in a Single Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_MergerTerminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger Termination [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_MergerTerminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PaymentsForAdvisorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Advisor Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PaymentsForAdvisorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ProceedsFromContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Contract Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ProceedsFromContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RepaymentsOfContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments of Contract Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RepaymentsOfContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for fees during the current period. This element excludes cash proceeds from license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pacb_IlluminaFcOpsCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pacb_IlluminaFcOpsCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284754735688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 09, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value of the liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument Face Amount</a></td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument Interest Rate Stated Percentage</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_RepaymentsOfContractTermination', window );">Repayments of) Contract Termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Feb. 15,  2028<span></span>
</td>
<td class="text">Feb. 15,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate [Member] | Convertible Senior Notes [Member] | Maximum [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument Interest Rate Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate [Member] | Convertible Senior Notes [Member] | Minimum [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument Interest Rate Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_FinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_FinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RepaymentsOfContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments of Contract Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RepaymentsOfContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284755514712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash And Cash Equivalents Fair Value Disclosure</a></td>
<td class="nump">$ 460,725,000<span></span>
</td>
<td class="nump">$ 81,611,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments Fair Value Disclosure</a></td>
<td class="nump">583,675,000<span></span>
</td>
<td class="nump">237,203,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-Term Restricted Cash Fair Value Disclosure</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">836,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long Term Restricted Cash Fair Value Disclosure</a></td>
<td class="nump">4,592,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets Fair Value Disclosure</a></td>
<td class="nump">1,049,492,000<span></span>
</td>
<td class="nump">323,150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities Fair Value Disclosure</a></td>
<td class="nump">169,717,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash And Cash Equivalents Fair Value Disclosure</a></td>
<td class="nump">327,315,000<span></span>
</td>
<td class="nump">43,040,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-Term Restricted Cash Fair Value Disclosure</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">836,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long Term Restricted Cash Fair Value Disclosure</a></td>
<td class="nump">4,592,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets Fair Value Disclosure</a></td>
<td class="nump">332,407,000<span></span>
</td>
<td class="nump">47,376,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash And Cash Equivalents Fair Value Disclosure</a></td>
<td class="nump">133,410,000<span></span>
</td>
<td class="nump">38,571,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments Fair Value Disclosure</a></td>
<td class="nump">583,675,000<span></span>
</td>
<td class="nump">237,203,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets Fair Value Disclosure</a></td>
<td class="nump">717,085,000<span></span>
</td>
<td class="nump">275,774,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities Fair Value Disclosure</a></td>
<td class="nump">169,717,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=pacb_ContingentConsiderationMember', window );">Contingent consideration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities Fair Value Disclosure</a></td>
<td class="nump">169,717,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=pacb_ContingentConsiderationMember', window );">Contingent consideration [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities Fair Value Disclosure</a></td>
<td class="nump">169,717,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=pacb_CashAndMoneyMarketFundsMember', window );">Cash and money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash And Cash Equivalents Fair Value Disclosure</a></td>
<td class="nump">327,315,000<span></span>
</td>
<td class="nump">43,040,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=pacb_CashAndMoneyMarketFundsMember', window );">Cash and money market funds [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash And Cash Equivalents Fair Value Disclosure</a></td>
<td class="nump">327,315,000<span></span>
</td>
<td class="nump">43,040,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash And Cash Equivalents Fair Value Disclosure</a></td>
<td class="nump">133,185,000<span></span>
</td>
<td class="nump">32,537,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments Fair Value Disclosure</a></td>
<td class="nump">187,632,000<span></span>
</td>
<td class="nump">112,644,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial paper [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash And Cash Equivalents Fair Value Disclosure</a></td>
<td class="nump">133,185,000<span></span>
</td>
<td class="nump">32,537,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments Fair Value Disclosure</a></td>
<td class="nump">187,632,000<span></span>
</td>
<td class="nump">112,644,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government and agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash And Cash Equivalents Fair Value Disclosure</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government and agency securities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash And Cash Equivalents Fair Value Disclosure</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury security [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash And Cash Equivalents Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,864,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury security [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash And Cash Equivalents Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,864,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments Fair Value Disclosure</a></td>
<td class="nump">8,968,000<span></span>
</td>
<td class="nump">17,456,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments Fair Value Disclosure</a></td>
<td class="nump">8,968,000<span></span>
</td>
<td class="nump">17,456,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember', window );">U.S. government &amp; agency securities, not included with cash and cash equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments Fair Value Disclosure</a></td>
<td class="nump">387,075,000<span></span>
</td>
<td class="nump">107,103,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember', window );">U.S. government &amp; agency securities, not included with cash and cash equivalents [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments Fair Value Disclosure</a></td>
<td class="nump">$ 387,075,000<span></span>
</td>
<td class="nump">$ 107,103,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_LongTermRestrictedCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Restricted Cash Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_LongTermRestrictedCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ShortTermRestrictedCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-Term Restricted Cash Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ShortTermRestrictedCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=pacb_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=pacb_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=pacb_CashAndMoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=pacb_CashAndMoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284764170712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Changes in estimated fair value of contingent consideration) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in estimated fair value</a></td>
<td class="nump">$ 1,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ContingentConsiderationIncurredDuringPeriod', window );">Acquisition of Omniome</a></td>
<td class="nump">168,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in estimated fair value</a></td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 169,717<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ContingentConsiderationIncurredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Incurred during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ContingentConsiderationIncurredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284755392392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Summary of Cash, Cash Equivalents and Investments) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments in debt securities</a></td>
<td class="nump">$ 717,085,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pacb_CashCashEquivalentsAndInvestmentsMember', window );">Cash, cash equivalents and investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">1,045,488,000<span></span>
</td>
<td class="nump">$ 318,729,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments', window );">Gross unrealized gains</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross unrealized losses</a></td>
<td class="num">(1,097,000)<span></span>
</td>
<td class="num">(21,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments in debt securities</a></td>
<td class="nump">1,044,400,000<span></span>
</td>
<td class="nump">318,814,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">460,731,000<span></span>
</td>
<td class="nump">81,612,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross unrealized losses</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments in debt securities</a></td>
<td class="nump">460,725,000<span></span>
</td>
<td class="nump">81,611,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pacb_CashAndMoneyMarketFundsMember', window );">Cash and money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">327,316,000<span></span>
</td>
<td class="nump">43,040,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments in debt securities</a></td>
<td class="nump">327,316,000<span></span>
</td>
<td class="nump">43,040,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">133,190,000<span></span>
</td>
<td class="nump">32,538,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross unrealized losses</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments in debt securities</a></td>
<td class="nump">133,185,000<span></span>
</td>
<td class="nump">32,537,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government and agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments in debt securities</a></td>
<td class="nump">224,000<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury security [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,864,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments in debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,864,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember', window );">Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">584,757,000<span></span>
</td>
<td class="nump">237,117,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments', window );">Gross unrealized gains</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross unrealized losses</a></td>
<td class="num">(1,092,000)<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments in debt securities</a></td>
<td class="nump">583,675,000<span></span>
</td>
<td class="nump">237,203,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper, not included with cash and cash equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">187,705,000<span></span>
</td>
<td class="nump">112,648,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross unrealized losses</a></td>
<td class="num">(73,000)<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments in debt securities</a></td>
<td class="nump">187,632,000<span></span>
</td>
<td class="nump">112,644,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">8,964,000<span></span>
</td>
<td class="nump">17,360,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments', window );">Gross unrealized gains</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">96,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross unrealized losses</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments in debt securities</a></td>
<td class="nump">8,968,000<span></span>
</td>
<td class="nump">17,456,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember', window );">U.S. government &amp; agency securities, not included with cash and cash equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">388,088,000<span></span>
</td>
<td class="nump">107,109,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments', window );">Gross unrealized gains</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross unrealized losses</a></td>
<td class="num">(1,014,000)<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments in debt securities</a></td>
<td class="nump">387,075,000<span></span>
</td>
<td class="nump">107,103,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pacb_ShortTermRestrictedCashMember', window );">Short-Term Restricted Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">836,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments in debt securities</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">836,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pacb_LongTermRestrictedCashMember', window );">Long-term restricted cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">4,592,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments in debt securities</a></td>
<td class="nump">$ 4,592,000<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated pre-tax unrealized gain before deducting pre-tax unrealized losses on investments in available-for-sale securities impacting investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated pre-tax unrealized loss before deducting pre-tax unrealized gain on investments in available-for-sale securities impacting investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pacb_CashCashEquivalentsAndInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pacb_CashCashEquivalentsAndInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pacb_CashAndMoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pacb_CashAndMoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pacb_ShortTermRestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pacb_ShortTermRestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pacb_LongTermRestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pacb_LongTermRestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284846409480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Due in one year or less</a></td>
<td class="nump">$ 595,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Due after one year through 5 years</a></td>
<td class="nump">122,022<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments</a></td>
<td class="nump">$ 717,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284754346488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_PercentageOfFeeToPrepayDebt', window );">Percentage of fee to prepay debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 836,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,199,000<span></span>
</td>
<td class="nump">6,428,000<span></span>
</td>
<td class="nump">$ 7,265,000<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,592,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AnnualDecreaseInLongTermRestrictedCash', window );">May 1 annual decrease to long-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,977,000<span></span>
</td>
<td class="nump">8,722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,049,000<span></span>
</td>
<td class="nump">1,568,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod', window );">Deferred service revenue, noncurrent, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,394,000<span></span>
</td>
<td class="nump">4,870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Long Term Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value of the liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Short term debt acquired</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt', window );">Long-term debt acquired</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term</a></td>
<td class="text">43 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument Interest Rate Stated Percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc [Member] | In-process research and development indefinite lived [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=pacb_CustomerDepositMember', window );">Customer Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=pacb_SecurityDepositMember', window );">Security Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=pacb_SecurityDepositMember', window );">Security Deposit [Member] | Omniome, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pacb_ObrienLeaseAgreementMember', window );">O&#8217;Brien Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pacb_ServiceContractMember', window );">Service contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=pacb_InvitaeCorporationMember', window );">Invitae Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AnnualDecreaseInLongTermRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Decrease in Long-Term Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AnnualDecreaseInLongTermRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BalanceSheetComponentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance Sheet Components [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BalanceSheetComponentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Noncurrent, Recognition Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PercentageOfFeeToPrepayDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fee of the outstanding debt to prepay the debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PercentageOfFeeToPrepayDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest expense on all borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7,8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=pacb_CustomerDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=pacb_CustomerDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=pacb_SecurityDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=pacb_SecurityDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pacb_ObrienLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pacb_ObrienLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pacb_ServiceContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pacb_ServiceContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pacb_InvitaeCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pacb_InvitaeCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284764128088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components (Components of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Purchased materials</a></td>
<td class="nump">$ 7,993<span></span>
</td>
<td class="nump">$ 3,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">8,611<span></span>
</td>
<td class="nump">6,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">7,995<span></span>
</td>
<td class="nump">4,048<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 24,599<span></span>
</td>
<td class="nump">$ 14,230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284754750648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components (Components of Property and Equipment, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 88,790<span></span>
</td>
<td class="nump">$ 74,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(56,286)<span></span>
</td>
<td class="num">(49,891)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">32,504<span></span>
</td>
<td class="nump">24,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pacb_LaboratoryEquipmentAndMachineryMember', window );">Laboratory Equipment And Machinery [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">31,534<span></span>
</td>
<td class="nump">24,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">31,114<span></span>
</td>
<td class="nump">29,931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">15,059<span></span>
</td>
<td class="nump">12,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">5,578<span></span>
</td>
<td class="nump">4,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">3,202<span></span>
</td>
<td class="nump">2,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 2,303<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pacb_LaboratoryEquipmentAndMachineryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pacb_LaboratoryEquipmentAndMachineryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284764265096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Changes in carrying amount of goodwill) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance</a></td>
<td class="nump">$ 409,974,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisition</a></td>
<td class="nump">390,665,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember', window );">Circulomics, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisition</a></td>
<td class="nump">$ 19,309,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284755896568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Definite-lived Intangible Assets from Business Acquisitions) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 20, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 11,360,000<span></span>
</td>
<td class="nump">$ 11,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(381,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">10,979,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">11,000,000<span></span>
</td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(306,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 10,694,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(75,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284758845416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components (Estimated Future Amortization Expense Of Acquisition-Related Intangible Assets With Definite Lives) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 913,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">838,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">733,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">733,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">733,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">2027 and thereafter</a></td>
<td class="nump">7,029,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 10,979,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284755322872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components (Schedule of Accrued Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Salaries and benefits</a></td>
<td class="nump">$ 25,282<span></span>
</td>
<td class="nump">$ 15,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AccruedProductDevelopmentCostsCurrent', window );">Accrued product development costs</a></td>
<td class="nump">1,936<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AccruedTenantImprovementsCurrent', window );">Accrued interest payable</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyAccrualPresentValue', window );">Inventory accrual</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Warranty</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services and legal fees</a></td>
<td class="nump">1,640<span></span>
</td>
<td class="nump">726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,601<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 36,261<span></span>
</td>
<td class="nump">$ 17,350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AccruedProductDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Product Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AccruedProductDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AccruedTenantImprovementsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Tenant Improvements, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AccruedTenantImprovementsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyAccrualPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of the accrual for product liability loss contingencies as of the balance sheet date (if the accrual qualifies for discounting).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyAccrualPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123377177&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284760014856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components (Furture Principal Payments) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 896,067,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,608,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">1,842,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">490,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 3,940,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284754749896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components (Schedule of Other Liabilities, Current) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent', window );">Accrued ESPP</a></td>
<td class="nump">$ 3,598<span></span>
</td>
<td class="nump">$ 2,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">2,161<span></span>
</td>
<td class="nump">2,482<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities, current</a></td>
<td class="nump">$ 5,759<span></span>
</td>
<td class="nump">$ 4,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Employee Stock Purchase Plan Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284758674696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes (Narrative) (Details) - Convertible Senior Notes [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2021</div></th>
<th class="th"><div>Feb. 09, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 15,  2028<span></span>
</td>
<td class="text">Feb. 15,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance date</a></td>
<td class="text">Feb. 16,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount', window );">Shares issued conversion rate per $1,000 principal amount</a></td>
<td class="nump">22.9885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_DebtInstrumentStatedPrincipalAmountForConversionRate', window );">Principal amount for conversion rate</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
<td class="nump">$ 43.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice', window );">Debt redemption, percentage of conversion price</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPriceTradingDays', window );">Debt redemption, trading days</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays', window );">Debt redemption, consecutive trading days</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 787,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=pacb_EachDayDuringFirst180DaysMember', window );">Each Day During the First 180 Days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_DebtInstrumentAdditionalInterestInEventOfDefault', window );">Additional interest in the event of default</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=pacb_OneHundredAndEightyFirstDayTo360thDayMember', window );">181st Day to 360th Day [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_DebtInstrumentAdditionalInterestInEventOfDefault', window );">Additional interest in the event of default</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentAdditionalInterestInEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Interest in the Event of Default</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentAdditionalInterestInEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Conversion Rate, Shares Issued Per Stated Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPriceTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPriceTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentStatedPrincipalAmountForConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Stated Principal Amount for Conversion Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentStatedPrincipalAmountForConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuanceDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the debt instrument was issued, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuanceDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=pacb_EachDayDuringFirst180DaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=pacb_EachDayDuringFirst180DaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=pacb_OneHundredAndEightyFirstDayTo360thDayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=pacb_OneHundredAndEightyFirstDayTo360thDayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284916704216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Senior Notes (Schedule of Net Carrying Amount) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Convertible Senior Notes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 900,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(3,933,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 896,067,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284916704216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes (Schedule of Interest Expense) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Convertible Senior Notes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ContractualInterestExpense', window );">Contractual interest expense</a></td>
<td class="nump">$ 11,812,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">532,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 12,344,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ContractualInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ContractualInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284755898840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 20, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent payments</a></td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">7,200,000<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations', window );">Additional liability associated with indemnification obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">46,617,000<span></span>
</td>
<td class="nump">$ 29,951,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 57,680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Liability Associated With Indemnification Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284755491576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 11,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">11,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">12,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">12,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">12,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">9,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">69,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(12,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">57,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_BalanceSheetClassificationAbstract', window );"><strong>Balance Sheet Classification</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">7,710<span></span>
</td>
<td class="nump">$ 4,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">49,970<span></span>
</td>
<td class="nump">$ 37,667<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 57,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BalanceSheetClassificationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance Sheet Classification [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BalanceSheetClassificationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284758854552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Income (loss) before taxes from U.S. operations</a></td>
<td class="num">$ (275,400)<span></span>
</td>
<td class="nump">$ 28,900<span></span>
</td>
<td class="num">$ (84,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Income before taxes from foreign operations</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">$ (93,649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">366,940<span></span>
</td>
<td class="nump">$ 300,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development credit carryforward</a></td>
<td class="nump">60,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Total unrecognized tax benefit</a></td>
<td class="nump">8,335<span></span>
</td>
<td class="nump">5,954<span></span>
</td>
<td class="nump">$ 21,979<span></span>
</td>
<td class="nump">$ 20,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">1,491,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development credit carryforward</a></td>
<td class="nump">$ 39,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_TaxCreditCarryforwardExpirationYear', window );">Research and development tax credit carryforward, expiration</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | With Expiration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 774,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">997,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development credit carryforward</a></td>
<td class="nump">$ 36,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforward, expiration</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYYformat.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=pacb_WithExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=pacb_WithExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284755845064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Reconciliation of Federal Income Tax Rate) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal benefit</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="num">(8.30%)<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="num">(6.30%)<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit', window );">Tax credits</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="num">(3.60%)<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">10.90%<span></span>
</td>
<td class="num">(15.20%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent', window );">Merger Expenses</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Merger Expense, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Credit,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_EffectiveIncomeTaxRateReconciliationTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284755968840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Reconciliation of Deferred Tax Assets and Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 378,035<span></span>
</td>
<td class="nump">$ 233,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">60,672<span></span>
</td>
<td class="nump">49,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">Accruals and reserves</a></td>
<td class="nump">10,822<span></span>
</td>
<td class="nump">6,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">12,838<span></span>
</td>
<td class="nump">9,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_DeferredTaxAssetsOperatingLeaseLiabilities', window );">ASC842 Operating lease liability</a></td>
<td class="num">(13,105)<span></span>
</td>
<td class="num">(9,870)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">475,472<span></span>
</td>
<td class="nump">308,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(366,940)<span></span>
</td>
<td class="num">(300,505)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets:</a></td>
<td class="nump">108,532<span></span>
</td>
<td class="nump">7,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangibles</a></td>
<td class="num">(97,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(1,523)<span></span>
</td>
<td class="num">(786)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_DeferredTaxLiabilitiesRightOfUseAssets', window );">ASC842 Operating Lease right-of-use assets</a></td>
<td class="num">(10,502)<span></span>
</td>
<td class="num">(7,037)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(109,370)<span></span>
</td>
<td class="num">(7,823)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (838)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right-of-use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284764164088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Reconciliation of Unrecognized Tax Benefit Accounts) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefit, Beginning balance</a></td>
<td class="nump">$ 5,954<span></span>
</td>
<td class="nump">$ 21,979<span></span>
</td>
<td class="nump">$ 20,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase in balance related to tax positions taken in prior year</a></td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decrease in balance related to tax positions taken in prior year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,255)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase in balance related to tax positions taken during current year</a></td>
<td class="nump">2,192<span></span>
</td>
<td class="nump">1,230<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefit, Ending balance</a></td>
<td class="nump">$ 8,335<span></span>
</td>
<td class="nump">$ 5,954<span></span>
</td>
<td class="nump">$ 21,979<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284750355000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Narrative) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 22, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 20, 2021 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 21, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 02, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 04, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2010 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Voting right of common stock share holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned', window );">Voting right of common stock share holders, number of votes | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Proceeds from issuance of common stock from underwritten public equity offerings, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294,845<span></span>
</td>
<td class="nump">$ 187,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation cost capitalized in inventory | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,978,000<span></span>
</td>
<td class="nump">192,294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds From Issuance Of Common Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,806<span></span>
</td>
<td class="nump">$ 46,360<span></span>
</td>
<td class="nump">$ 8,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.36<span></span>
</td>
<td class="nump">$ 4.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock Par Or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=pacb_PrivatePlacementOfCommonStockMember', window );">Private Placement of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,214,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds From Issuance Of Common Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,356,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_OmniomePlanMember', window );">Omniome Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ExchangeRatio', window );">Exchange ratio | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.259204639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,494,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_TwoThousandTenEquityIncentivePlanMember', window );">2010 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remain available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remain available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,810,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding common stock used to determine annual plan increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_NumberOfPurchasePeriods', window );">Number of purchase periods | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_PurchasePeriodOfEmployeeStockPurchasePlan', window );">Purchase period of ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased', window );">Percentage of fair market value at which stock can be purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Common stock purchased under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,913,968<span></span>
</td>
<td class="nump">834,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,306,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from option exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_InducementEquityIncentivePlan2020Member', window );">2020 Inducement Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional common stock reserved for issuance</a></td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remain available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=pacb_UnderwrittenPublicEquityOfferingMember', window );">Underwritten Public Equity Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Proceeds from issuance of common stock from underwritten public equity offerings, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_NumberOfOfferings', window );">Number of offerings | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=pacb_UnderwritingAgreementMember', window );">Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_PublicOfferingShares', window );">Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,096,112<span></span>
</td>
<td class="nump">19,430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_OfferingShareAmountMaximum', window );">Common stock offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.25<span></span>
</td>
<td class="nump">$ 4.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod', window );">Public offering, option to purchase additional shares, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares', window );">Public offering, option to purchase additional shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">914,416<span></span>
</td>
<td class="nump">2,914,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="nump">22,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering', window );">Commissions, percentage of gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Proceeds from issuance of common stock from underwritten public equity offerings, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,900<span></span>
</td>
<td class="nump">$ 93,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock Par Or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value exercisable options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,535,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, aggregate intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, weighted average exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,100<span></span>
</td>
<td class="nump">$ 63,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from option exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,400<span></span>
</td>
<td class="nump">$ 43,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.53<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock [Member] | $1.16 &#8211; 20.90 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options expired, weighted average exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember', window );">RSUs with time-based vesting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_ShareInstrumentNumberOfSharesConversionRatio', window );">Ratio of number of shares into which the share instrument may be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember', window );">Share-based Compensation Award, Tranche One, Two, Three and Four [Member] | RSUs with time-based vesting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Voting Rights, Number Of Votes Per Share Owned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:positiveIntegerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The relative number of new shares that will be given to existing shareholders of a company that has been acquired or that has merged with another.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_NumberOfOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Offerings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_NumberOfOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:positiveIntegerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_NumberOfPurchasePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of purchase periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_NumberOfPurchasePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_OfferingShareAmountMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Share Amount Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_OfferingShareAmountMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair market value at which stock can be purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Public Offering, Option to Purchase Additional Shares, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Public Offering, Option to Purchase Additional Shares, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PublicOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Public Offering, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PublicOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PurchasePeriodOfEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase period of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PurchasePeriodOfEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ShareInstrumentNumberOfSharesConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares into which the share instrument may be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ShareInstrumentNumberOfSharesConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pacb_PrivatePlacementOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pacb_PrivatePlacementOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_OmniomePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_OmniomePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_TwoThousandTenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_TwoThousandTenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_InducementEquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_InducementEquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=pacb_UnderwrittenPublicEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=pacb_UnderwrittenPublicEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=pacb_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=pacb_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284754258392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Summary of Stock Option Activity) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeOneMember', window );">$1.16 &#8211; 20.90 [Member] | Time-based stock option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at December 31, 2020</a></td>
<td class="nump">14,638,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,638,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at December 31, 2020</a></td>
<td class="nump">$ 5.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeOneMember', window );">$1.16 &#8211; 20.90 [Member] | Options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="nump">2.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="nump">$ 46.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeTwoMember', window );">$23.06 &#8211; 46.37 [Member] | Time-based stock option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of shares, Granted</a></td>
<td class="nump">2,489,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="nump">$ 23.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="nump">46.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">$ 33.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeAcqusitionMember', window );">$2.05 &#8211; $4.90 [Member] | Time-based stock option [Member] | Omniome Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of shares, Granted</a></td>
<td class="nump">339,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="nump">$ 2.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="nump">4.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">4.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeAcqusitionTwoMember', window );">$4.71 - $4.90 [Member] | Performance-based stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="nump">4.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="nump">$ 4.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeAcqusitionTwoMember', window );">$4.71 - $4.90 [Member] | Performance-based stock options [Member] | Omniome Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of shares, Granted</a></td>
<td class="nump">304,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at December 31, 2021</a></td>
<td class="nump">304,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="nump">4.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">4.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at December 31, 2021</a></td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeThreeMember', window );">$1.16 &#8211; 15.98 [Member] | Time-based stock option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="num">(4,766,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="nump">15.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">$ 5.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeFourMember', window );">$2.54 &#8211; 46.37 [Member] | Time-based stock option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Canceled</a></td>
<td class="num">(541,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="nump">46.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Canceled</a></td>
<td class="nump">5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeFiveMember', window );">$1.16 &#8211; 46.37 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="nump">1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="nump">$ 46.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeFiveMember', window );">$1.16 &#8211; 46.37 [Member] | Time-based stock option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at December 31, 2021</a></td>
<td class="nump">12,159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at December 31, 2021</a></td>
<td class="nump">$ 11.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeAcqusitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeAcqusitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_OmniomePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_OmniomePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeAcqusitionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeAcqusitionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284755245768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Reconciliation of Outstanding and Exercisable Stock Options) (Details) - Options to purchase common stock [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding | shares</a></td>
<td class="nump">12,463,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">6 years 5 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 11.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number vested | shares</a></td>
<td class="nump">8,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 5.63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">$0.00 &#8211; 4.64 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="nump">$ 4.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding | shares</a></td>
<td class="nump">3,676,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">5 years 4 months 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number vested | shares</a></td>
<td class="nump">3,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">$4.64 - 9.27 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="nump">4.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="nump">$ 9.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding | shares</a></td>
<td class="nump">5,480,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number vested | shares</a></td>
<td class="nump">4,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">$9.27 - 13.91 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="nump">9.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="nump">$ 13.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding | shares</a></td>
<td class="nump">702,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">6 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 9.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number vested | shares</a></td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 9.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">$13.91 - 18.55 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="nump">13.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="nump">$ 18.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding | shares</a></td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">8 years 9 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 14.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number vested | shares</a></td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 14.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">$18.55 - 23.19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="nump">18.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="nump">$ 23.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding | shares</a></td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">9 years 4 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 21.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number vested | shares</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 20.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">$23.19 - 27.82[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="nump">23.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="nump">$ 27.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding | shares</a></td>
<td class="nump">320,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">9 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 24.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">$27.82 - 32.46 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="nump">27.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="nump">$ 32.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding | shares</a></td>
<td class="nump">472,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">9 years 5 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 28.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number vested | shares</a></td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 27.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">$32.46 - 37.10 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="nump">32.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="nump">$ 37.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding | shares</a></td>
<td class="nump">1,380,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 36.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">$41.73 - 46.37 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range</a></td>
<td class="nump">41.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range</a></td>
<td class="nump">$ 46.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding | shares</a></td>
<td class="nump">218,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">9 years 1 month 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 46.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number vested | shares</a></td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 46.37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pacb_ExercisePriceRangeFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284764232632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Summary of Time-Based RSUs Activity) (Details) - RSUs with time-based vesting [Member]<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Outstanding at December 31, 2020 | shares</a></td>
<td class="nump">5,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Granted | shares</a></td>
<td class="nump">3,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, Released | shares</a></td>
<td class="num">(1,798)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, Forfeited | shares</a></td>
<td class="num">(473)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Outstanding at December 31, 2021 | shares</a></td>
<td class="nump">7,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Outstanding at December 31, 2020 | $ / shares</a></td>
<td class="nump">$ 5.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, per share | $ / shares</a></td>
<td class="nump">5.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Released | $ / shares</a></td>
<td class="nump">16.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Forfeited | $ / shares</a></td>
<td class="nump">19.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Outstanding at December 31, 2021 | $ / shares</a></td>
<td class="nump">$ 35.33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284764234712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Summary of Performance-Based RSUs Activity) (Details) - RSUs with performance-based vesting [Member]<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Outstanding at December 31, 2020 | shares</a></td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, Released | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, Forfeited | shares</a></td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Outstanding at December 31, 2021 | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Outstanding at December 31, 2020 | $ / shares</a></td>
<td class="nump">$ 2.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, per share | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Released | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Forfeited | $ / shares</a></td>
<td class="nump">2.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Outstanding at December 31, 2021 | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_PerformanceBasedRestrictedStockUnitsRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_PerformanceBasedRestrictedStockUnitsRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284755084696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Schedule of Stock-Based Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 80,728<span></span>
</td>
<td class="nump">$ 17,533<span></span>
</td>
<td class="nump">$ 16,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">6,126<span></span>
</td>
<td class="nump">2,236<span></span>
</td>
<td class="nump">1,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">20,275<span></span>
</td>
<td class="nump">7,061<span></span>
</td>
<td class="nump">7,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Sales, general and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">35,403<span></span>
</td>
<td class="nump">8,236<span></span>
</td>
<td class="nump">6,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesStockSettledMember', window );">Merger-related expenses - stock-settled [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">6,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesMilestoneMember', window );">Merger-related expenses - milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">5,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pacb_StockBasedCompensationMember', window );">Stock-based compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">73,355<span></span>
</td>
<td class="nump">$ 17,533<span></span>
</td>
<td class="nump">$ 16,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesCashSettledMember', window );">Merger-related expenses - cash-settled [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 7,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesStockSettledMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesStockSettledMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pacb_StockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pacb_StockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesCashSettledMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesCashSettledMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284754326184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Schedule of Fair Value of Employee Stock Options) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share</a></td>
<td class="nump">$ 18.36<span></span>
</td>
<td class="nump">$ 4.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share</a></td>
<td class="nump">$ 15.53<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284755916232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Schedule of Fair Value of Employee Stock Purchase Plan) (Details) - ESPP [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, per share</a></td>
<td class="nump">$ 25.07<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284758364184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share (Computation Of Basic And Diluted Net Loss Per Share) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (181,223)<span></span>
</td>
<td class="nump">$ 29,403<span></span>
</td>
<td class="num">$ (84,134)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in computing basic net income (loss) per share</a></td>
<td class="nump">204,136<span></span>
</td>
<td class="nump">165,187<span></span>
</td>
<td class="nump">152,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share</a></td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in computing basic net income (loss) per share</a></td>
<td class="nump">204,136<span></span>
</td>
<td class="nump">165,187<span></span>
</td>
<td class="nump">152,527<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in computing diluted net income (loss) per share</a></td>
<td class="nump">204,136<span></span>
</td>
<td class="nump">174,970<span></span>
</td>
<td class="nump">152,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share</a></td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Add: weighted average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Add: weighted average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Add: weighted average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284755968248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share (Antidilutive Shares Excluded From Computation Of Diluted Net Loss Per Share) (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember', window );">Shares issuable upon conversion of convertible senior notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="nump">18,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="nump">12,463<span></span>
</td>
<td class="nump">4,908<span></span>
</td>
<td class="nump">22,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember', window );">RSUs with time-based vesting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="nump">7,392<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pacb_PerformanceBasedRestrictedStockUnitsRsusMember', window );">RSUs with performance-based vesting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="nump">1,564<span></span>
</td>
<td class="nump">2,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pacb_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pacb_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pacb_PerformanceBasedRestrictedStockUnitsRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pacb_PerformanceBasedRestrictedStockUnitsRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284759893048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment And Geographic Information (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment And Geographic Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284758734552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment And Geographic Information (Schedule of Revenue by Geographic Location) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 130,513,000<span></span>
</td>
<td class="nump">$ 78,893,000<span></span>
</td>
<td class="nump">$ 90,891,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">64,521,000<span></span>
</td>
<td class="nump">37,277,000<span></span>
</td>
<td class="nump">44,681,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe (including the Middle East and Africa) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">30,271,000<span></span>
</td>
<td class="nump">19,065,000<span></span>
</td>
<td class="nump">19,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 35,721,000<span></span>
</td>
<td class="nump">$ 22,551,000<span></span>
</td>
<td class="nump">$ 26,610,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140284753471464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment And Geographic Information (Summary of Revenue by Category) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 130,513,000<span></span>
</td>
<td class="nump">$ 78,893,000<span></span>
</td>
<td class="nump">$ 90,891,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">113,505,000<span></span>
</td>
<td class="nump">65,424,000<span></span>
</td>
<td class="nump">77,742,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_InstrumentMember', window );">Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">61,324,000<span></span>
</td>
<td class="nump">34,282,000<span></span>
</td>
<td class="nump">45,126,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ConsumableMember', window );">Consumable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">52,181,000<span></span>
</td>
<td class="nump">31,142,000<span></span>
</td>
<td class="nump">32,616,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember', window );">Service and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 17,008,000<span></span>
</td>
<td class="nump">$ 13,469,000<span></span>
</td>
<td class="nump">$ 13,149,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_InstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_InstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ConsumableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ConsumableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>pacb-20211231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pacb="http://www.pacificbiosciences.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pacb-20211231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_RestatementAxis_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201904Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201904Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_RestatementAxis_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201904Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201904Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementScenarioAxis_pacb_UnderwrittenPublicEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:UnderwrittenPublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeAcqusitionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeAcqusitionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeAcqusitionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeAcqusitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pacb:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_TwoThousandTenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:TwoThousandTenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_InducementEquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:InducementEquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_20_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-20</instant>
        </period>
    </context>
    <context id="As_Of_12_2_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_InducementEquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:InducementEquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-02</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-04</instant>
        </period>
    </context>
    <context id="Duration_11_22_2021_To_11_22_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_InducementEquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:InducementEquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-22</startDate>
            <endDate>2021-11-22</endDate>
        </period>
    </context>
    <context id="Duration_4_21_2021_To_4_21_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_InducementEquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:InducementEquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-21</startDate>
            <endDate>2021-04-21</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:PerformanceBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:PerformanceBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:PerformanceBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_VestingAxis_pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">pacb:ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_NorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_AsiaPacificMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_pacb_InstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_pacb_ConsumableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_srt_NorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_srt_AsiaPacificMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_pacb_InstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_pacb_ConsumableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_StatementGeographicalAxis_srt_NorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_StatementGeographicalAxis_srt_AsiaPacificMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_pacb_InstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_pacb_ConsumableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2015_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_SecurityDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">pacb:SecurityDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_SecurityDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">pacb:SecurityDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_SecurityDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">pacb:SecurityDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_CustomerDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">pacb:CustomerDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pacb:ObrienLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pacb:ObrienLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2015_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pacb:ObrienLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pacb_LaboratoryEquipmentAndMachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pacb:LaboratoryEquipmentAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pacb_LaboratoryEquipmentAndMachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pacb:LaboratoryEquipmentAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_20_2021_To_9_20_2021_us-gaap_StatementEquityComponentsAxis_pacb_PrivatePlacementOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pacb:PrivatePlacementOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-20</startDate>
            <endDate>2021-09-20</endDate>
        </period>
    </context>
    <context id="Duration_7_20_2021_To_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:CirculomicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-20</startDate>
            <endDate>2021-07-20</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_pacb_IlluminaFcOpsCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pacb:IlluminaFcOpsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_dei_LegalEntityAxis_pacb_IlluminaFcOpsCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pacb:IlluminaFcOpsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementScenarioAxis_pacb_WithExpirationMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:WithExpirationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_pacb_ContingentConsiderationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pacb:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_pacb_ContingentConsiderationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pacb:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pacb:InProcessResearchAndDevelopmentIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-20</instant>
        </period>
    </context>
    <context id="As_Of_7_20_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-20</instant>
        </period>
    </context>
    <context id="As_Of_7_20_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2021-07-20</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_9_1_2021_To_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_2_9_2021_To_2_9_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-09</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="As_Of_2_9_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-09</instant>
        </period>
    </context>
    <context id="As_Of_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_pacb_ServiceContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pacb:ServiceContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_MajorCustomersAxis_pacb_InvitaeCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:InvitaeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_pacb_DomesticCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_pacb_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_pacb_DomesticCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_pacb_CustomerDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_pacb_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_MajorCustomersAxis_pacb_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_MajorCustomersAxis_pacb_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_20_2021_us-gaap_StatementEquityComponentsAxis_pacb_PrivatePlacementOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pacb:PrivatePlacementOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-20</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2010-10-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_pacb_CashAndMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_pacb_CashAndMoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_pacb_CashAndMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_pacb_CashAndMoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-20</instant>
        </period>
    </context>
    <context id="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:CirculomicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-20</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_ContingentConsiderationByTypeAxis_pacb_AchievementOfMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">pacb:AchievementOfMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-20</instant>
        </period>
    </context>
    <context id="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_ContingentConsiderationByTypeAxis_pacb_AchievementOfMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">pacb:AchievementOfMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-20</startDate>
            <endDate>2021-09-20</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_ShortTermRestrictedCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:ShortTermRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_LongTermRestrictedCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:LongTermRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_CashAndMoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_ShortTermRestrictedCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:ShortTermRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_LongTermRestrictedCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:LongTermRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_CashAndMoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:SharesIssuableUponConversionOfConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:PerformanceBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:PerformanceBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_pacb_StockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_pacb_MergerRelatedExpensesStockSettledMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesStockSettledMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_pacb_MergerRelatedExpensesMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_pacb_MergerRelatedExpensesCashSettledMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesCashSettledMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_pacb_StockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_pacb_StockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_MajorCustomersAxis_pacb_TenPercentOrGreaterBalanceAccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:TenPercentOrGreaterBalanceAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:CirculomicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_dei_LegalEntityAxis_pacb_IlluminaFcOpsCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pacb:IlluminaFcOpsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_12_31_2019_dei_LegalEntityAxis_pacb_IlluminaFcOpsCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pacb:IlluminaFcOpsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2020_To_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="Duration_4_20_2020_To_4_20_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2020-04-20</startDate>
            <endDate>2020-04-20</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_pacb_UnderwrittenPublicEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:UnderwrittenPublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_9_20_2021_To_9_20_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2021-09-20</startDate>
            <endDate>2021-09-20</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_20_2021_To_9_20_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-20</startDate>
            <endDate>2021-09-20</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_16_2021_To_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="Duration_2_16_2021_To_2_16_2021_srt_StatementScenarioAxis_pacb_OneHundredAndEightyFirstDayTo360thDayMember_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:OneHundredAndEightyFirstDayTo360thDayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="Duration_2_16_2021_To_2_16_2021_srt_StatementScenarioAxis_pacb_EachDayDuringFirst180DaysMember_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pacb:EachDayDuringFirst180DaysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="Duration_9_20_2021_To_9_20_2021_us-gaap_AwardTypeAxis_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OmniomeStockAwardsRelatedToAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-20</startDate>
            <endDate>2021-09-20</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-20</startDate>
            <endDate>2021-09-20</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashCashEquivalentsAndInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashCashEquivalentsAndInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pacb:ObrienLeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="Unit16">
        <measure>pacb:segment</measure>
    </unit>
    <unit id="Unit15">
        <measure>pure</measure>
    </unit>
    <unit id="Unit14">
        <measure>pacb:item</measure>
    </unit>
    <unit id="Unit13">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit12">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit1">
        <measure>shares</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-eca2eb9e-c1c6-4865-9be8-5ac88411ec9d">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-5e1d2db1-c833-458d-8dc8-1749fb810bc9">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-41696a35-e0f7-4da9-9d8d-f13c283818b7">0001299130</dei:EntityCentralIndexKey>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-79396175-d825-42a4-aae0-e7ec43a3819e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-68c96891-44c6-44c0-87ea-784654e81cf5">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-840695b2-f4d5-4538-8f01-50526802d26c">No</dei:EntityVoluntaryFilers>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-3538407f-725e-45e3-b430-f7eb8eb2549c">Yes</dei:EntityWellKnownSeasonedIssuer>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020"
      id="ct-nonFraction-91c7be65-3a9c-4f3f-baf5-bb6c340382ae"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021"
      id="ct-nonFraction-272c0ad2-cbce-4b43-8c6a-5f3a931cfd02"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2020"
      id="ct-nonFraction-f6bf32a1-eba1-44b5-9c64-71c3bce57c57"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2019_To_12_31_2019"
      id="ct-nonFraction-369660c8-8827-4509-8766-859d252aae68"
      unitRef="Unit15"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020"
      id="ct-nonFraction-0217e24c-f3e2-41a5-a3e4-da83db5c7554"
      unitRef="Unit15"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2020"
      id="ct-nonFraction-32b2087d-0dc9-4882-923e-433e378fe9f9"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021"
      id="ct-nonFraction-d2485028-363e-4392-a795-dcac64f2aaa6"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember"
      id="ct-nonFraction-157432ee-ccb2-4053-b0e5-c7935377bc43"
      unitRef="Unit1"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember"
      id="ct-nonFraction-ea27d075-ab14-46bd-a50a-ca1f6250a2fa"
      unitRef="Unit13"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember"
      id="ct-nonFraction-e9acf03d-13df-451d-9874-2f208766a4f5"
      unitRef="Unit1"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember"
      id="ct-nonFraction-1d49af19-806d-4049-a513-6d773e6a0680"
      unitRef="Unit13"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember"
      id="ct-nonFraction-30bbf7d7-4b14-4f75-9fd7-3cbfdadeb778"
      unitRef="Unit1"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember"
      id="ct-nonFraction-1ab6d777-8192-4d46-8320-5a5063ac3e21"
      unitRef="Unit13"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      id="ct-nonNumeric-8beefc21-f615-4705-ab86-3b5ae2a9a9cc">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      id="ct-nonNumeric-6736a5db-23ed-4317-8508-2a31e2442346">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      id="ct-nonFraction-a1755a45-08c0-4740-a627-f6abb27a4908"
      unitRef="Unit13"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2019_To_12_31_2019"
      id="ct-nonFraction-01e6ae09-6c26-4e08-8828-7a21518d3f2e"
      unitRef="Unit12"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-f78b3ec5-f592-4d1c-9fa1-d2a3948e7de4">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-5cf6a085-c25b-490a-97d8-4962159b6465">true</dei:DocumentAnnualReport>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-00eeec03-31d3-4a13-a0c0-5838d70fb068">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-ad907059-4858-4959-8047-e22cea9a6165">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-c657aa9d-aa9b-466e-8aed-dbc0250c2601">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-3f7a22f4-43e1-4084-996e-e740839708e7">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-7e41b509-9c45-4fb2-990b-a07bb9de80e9">001-34899</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-8849fb0d-1b5e-4e57-bff6-e1054007812b">Pacific Biosciences of California, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-8f893a01-ccf6-4177-9e92-0f5d5bfa3940">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-ef8f88c1-a62e-4dc1-ae48-e70f9dc6c0f5">16-1590339</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-3037c611-eeb9-4033-85b1-070d52bf6516">1305 O&#x2019;Brien Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-832f8ecb-450f-4c06-bf18-615cd6cbea1f">Menlo Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-9fcd8178-c13a-4dc6-8a85-82b82ec53134">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-ba192e1b-35ef-473f-a153-ea3cb2f422e6">94025</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-904c5db5-486b-469e-be55-8a31fdd81fd4">94025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-2afa2f03-946d-428b-85e2-88688d046950">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-84fde0d5-e188-4bf4-9002-42094e91897e">521-8000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-fce5e74f-4b3e-45c5-9339-31c8e22f9d48">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-85ec7f48-9766-4e13-874f-9900d3e4e936">PACB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-b72087f6-16a0-4e6f-bc4b-c9bacb05d62e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-e9f341c3-a130-47e1-b331-03eebb6c5a1f">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-d0f8c658-7b70-4a9e-b6c6-25da9ea2f02c">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-fb902d1e-0309-4fa7-b943-8385356ab2d8">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-06271725-bd27-4606-ab11-64a66d5345df">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-d751ce2d-a144-432d-86c5-396c2addfbbb">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2021"
      decimals="0"
      id="ct-nonFraction-9b0beadb-c1c4-410a-b698-0eab20b8189c"
      unitRef="Unit12">6791088144</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_1_31_2022"
      decimals="INF"
      id="ct-nonFraction-3c1bdb9b-2255-4985-9017-4ed427d0d595"
      unitRef="Unit1">221182457</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-9399595d-34a1-42d5-9ac9-bb85b3fc2d00">Portions of the registrant&#x2019;s definitive Proxy Statement relating to its 2022 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K where indicated. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-31de3ef3-92ae-4fa9-a379-d1e96bd177dd">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-f72f7870-5e2a-4f8e-9821-ce9940605ba4">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-94636b27-6333-4811-b529-c191adebe36c">Redwood City, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-d5c2e910-3685-4f73-9136-07df07162169"
      unitRef="Unit12">460725000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-aa283256-2652-4460-ae81-c43e9840e966"
      unitRef="Unit12">81611000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-9b9963e7-99b4-416b-85bd-e6a967548973"
      unitRef="Unit12">583675000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-cd98a3ed-ae6d-4a6b-8d51-7a2286988855"
      unitRef="Unit12">237203000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-163cc2ae-7709-4daf-af26-20c5773c8d43"
      unitRef="Unit12">24241000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-bb008d58-4453-487a-8fc3-eec1f4d9eb88"
      unitRef="Unit12">16837000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-54eb918b-e15c-4841-8543-8fc6c7ef93e2"
      unitRef="Unit12">24599000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-c9c2054f-be7e-4d9d-9f27-676a4942a9e3"
      unitRef="Unit12">14230000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-4787d6b2-3ae8-435c-b2cf-a3e1135a091a"
      unitRef="Unit12">7394000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-dfd2f86a-4cf6-458f-b4d5-5874985a0a10"
      unitRef="Unit12">4870000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-fcf0c16f-5d40-428f-81ba-dafaf867a4fa"
      unitRef="Unit12">500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-06f465d7-e5a7-4f9f-841a-278c71651a7d"
      unitRef="Unit12">836000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-6adaf220-2866-4b91-ae74-e3bbb2e53a05"
      unitRef="Unit12">1101134000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-a0a02f68-ba27-4bd3-9dd9-e35dedccdc53"
      unitRef="Unit12">355587000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-bc414ce4-5681-435b-940c-90f3bc746058"
      unitRef="Unit12">32504000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-b330fa70-21da-461f-ac1f-568703e5feb7"
      unitRef="Unit12">24899000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-6d378aa8-5ff9-4859-8f3e-daef16828beb"
      unitRef="Unit12">46617000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-4a476362-86dd-4e24-929d-79a63122fa30"
      unitRef="Unit12">29951000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-02679caa-f657-495b-8b9a-95d14bf1f561"
      unitRef="Unit12">4592000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-c21c788b-6620-4be1-a124-8001f2ab260e"
      unitRef="Unit12">3500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c3df477e-aa74-4410-b3b7-b01c63b4d1a5"
      unitRef="Unit12">410979000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-bd8e0b25-8e98-42ee-a345-4cf6902bdae0"
      unitRef="Unit12">409974000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-47ebf613-9cbd-4389-b081-9f79db477757"
      unitRef="Unit12">1170000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-c69aa942-eef6-4214-9bcf-9985c0e1a1e9"
      unitRef="Unit12">43000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-da51de65-352c-475a-9f7f-b4662d01492a"
      unitRef="Unit12">2006970000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-f791b945-4245-412c-ad48-a83fdb8c1211"
      unitRef="Unit12">413980000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-2355c66b-d54a-4805-ad3c-2c789ddab419"
      unitRef="Unit12">11002000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-14afaa21-e678-4f51-a0e0-9de966a241d6"
      unitRef="Unit12">3579000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-090d5190-6d91-4b50-a96f-46d70c2fe830"
      unitRef="Unit12">36261000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-83d5bbc0-e855-479d-9056-00a76f296034"
      unitRef="Unit12">17350000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-80c285f7-bfca-440c-ba93-41f9f26c2101"
      unitRef="Unit12">10977000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-fe1e1929-eb69-45e2-b519-2d5312523aea"
      unitRef="Unit12">8722000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-cc03452f-de2e-4638-b948-02e6abb3c2ad"
      unitRef="Unit12">7710000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-ada47c97-117a-4b53-a56b-cba95504f5af"
      unitRef="Unit12">4332000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-647d3423-c39a-447a-9dcc-89c6158f5b59"
      unitRef="Unit12">5759000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-aaa5e04b-428b-4c3c-8034-9b135ceee99d"
      unitRef="Unit12">4519000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-1f5bf8f7-6842-498a-bc56-8daaf1df4674"
      unitRef="Unit12">71709000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-90491f07-8bbc-42c4-aa5f-783bd8077bda"
      unitRef="Unit12">38502000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-b6d12111-e024-491d-a49d-e010c57d0297"
      unitRef="Unit12">25049000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-33e4d20e-b3d5-4824-8511-a2cec55d09bc"
      unitRef="Unit12">1568000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-56cbb077-cb54-4c01-aa82-695d6dcef92f"
      unitRef="Unit12">169717000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-cd4cd0a4-db3c-4a83-8987-fbe06b3c70e2"
      unitRef="Unit12">49970000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-a6cf280c-7534-415b-99b6-ba435e084063"
      unitRef="Unit12">37667000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-7aa35061-0bf1-4b0d-8568-77117cfce1a5"
      unitRef="Unit12">896067000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-1a10d532-e0d8-49b4-8684-b1210d9b98b8"
      unitRef="Unit12">3471000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-7548881a-fa72-44d6-8408-6b0cd149205d"
      unitRef="Unit12">752000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-20a8acb8-ce5d-40ea-b78a-df983de746c8"
      unitRef="Unit12">1215983000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-56ab023e-1ec8-4a6d-9538-9f12ac3b7b7f"
      unitRef="Unit12">78489000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020"
      decimals="INF"
      id="ct-nonFraction-0e8d609c-dbfa-4ba5-9465-c6372418a8e4"
      unitRef="Unit13">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-6e70a175-b3c8-4f8f-8ab0-603e71b87c37"
      unitRef="Unit13">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-839205ba-e092-40b7-9c2b-79aec13846b1"
      unitRef="Unit1">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-ebc2c3c9-85d3-415c-b880-4358e64ba44a"
      unitRef="Unit1">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020"
      decimals="INF"
      id="ct-nonFraction-567af0dd-6806-4538-a7db-624c8d6d2e31"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-ad00071b-6c8e-4013-83dc-8018fa965501"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020"
      decimals="INF"
      id="ct-nonFraction-7414eb41-c3f6-465b-bd03-771b139ec0ee"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-db062ac3-daf7-4255-a69d-559438e3e7f3"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020"
      decimals="INF"
      id="ct-nonFraction-e7db06b8-57ea-4e14-878c-a42cbbbefe69"
      unitRef="Unit13">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-2433308d-b8a7-46fe-a605-d84abd7f8e47"
      unitRef="Unit13">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-2ceccb10-affc-42eb-a900-8b72a900867b"
      unitRef="Unit1">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-d311accb-9075-453a-a03c-f0bf54b3de58"
      unitRef="Unit1">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-daf434d1-2218-43a4-9f15-d69d1f0c4609"
      unitRef="Unit1">220978000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-95cc0506-dbbf-4a67-b29d-960b5ad232a7"
      unitRef="Unit1">220978000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-24e15aa4-6497-4c82-9a2d-117bd9fec7f3"
      unitRef="Unit1">192294000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-d290c820-bf64-49e4-bdeb-f3530f50619d"
      unitRef="Unit1">192294000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-74f0dde5-8886-4d07-9a33-90bc224b18ca"
      unitRef="Unit12">221000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-ccf72dd3-e3bf-4919-a82f-333cb0c2bc30"
      unitRef="Unit12">192000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-0a4517c7-b633-4852-bdc1-e2a42ecb840d"
      unitRef="Unit12">2009945000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-a4218f14-fa19-4f34-999b-1738637079a5"
      unitRef="Unit12">1372083000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-e74690b9-303d-4928-959f-4afea9a4c5fd"
      unitRef="Unit12">-1087000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-e8879b85-3eb6-462c-b004-236b14639553"
      unitRef="Unit12">85000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-3eec3ea6-940d-4fab-8b91-c61f5d2c21e1"
      unitRef="Unit12">-1218092000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-d334d431-0822-4bdd-9b0f-4d00fc014989"
      unitRef="Unit12">-1036869000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-650c4763-49a9-4393-9d98-876c20ba459f"
      unitRef="Unit12">790987000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-39360d4e-229f-4ad0-9a9b-a5050c18f07a"
      unitRef="Unit12">335491000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-093bc273-decf-4a6f-8d4f-f67c84a8b4b8"
      unitRef="Unit12">2006970000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-d0ed45e4-5a16-4e06-a8ca-4619518c9414"
      unitRef="Unit12">413980000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="ct-nonFraction-2e94d8f3-c5b3-4520-b8b7-7a49360a94b0"
      unitRef="Unit12">113505000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="ct-nonFraction-e75e3d75-448b-4780-b236-58c96caec32f"
      unitRef="Unit12">65424000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="ct-nonFraction-bf4a035c-cb15-4422-8e3c-ca4d9c0a49ee"
      unitRef="Unit12">77742000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember"
      decimals="-3"
      id="ct-nonFraction-32131022-14b0-41d6-bb17-fe678a2b3f77"
      unitRef="Unit12">17008000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember"
      decimals="-3"
      id="ct-nonFraction-c276da63-fe5b-4dd5-a876-d5a81c571cb8"
      unitRef="Unit12">13469000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember"
      decimals="-3"
      id="ct-nonFraction-5fd5cd2b-f05e-407d-953d-eb0a9c1fd4c2"
      unitRef="Unit12">13149000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-234521a3-ef62-4613-bf2d-d963edc970a4"
      unitRef="Unit12">130513000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-eabc7729-9651-48d0-b805-c0c20234e3d1"
      unitRef="Unit12">78893000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-3381eb9a-bfaa-4ce1-8928-d693eb71a207"
      unitRef="Unit12">90891000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="ct-nonFraction-77063e35-fb51-4c42-b8c1-d946f500350b"
      unitRef="Unit12">56358000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="ct-nonFraction-d5cd058a-e9d6-46f8-be07-e84347e5183d"
      unitRef="Unit12">35424000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="ct-nonFraction-12706945-c6d1-4b30-a8ef-254515643fd1"
      unitRef="Unit12">44771000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember"
      decimals="-3"
      id="ct-nonFraction-81fb636a-02e9-4f59-8f22-0d32dd0e24c7"
      unitRef="Unit12">14989000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember"
      decimals="-3"
      id="ct-nonFraction-59143282-90be-450e-9b8c-a02a455451b7"
      unitRef="Unit12">10903000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember"
      decimals="-3"
      id="ct-nonFraction-98a51f76-a7a0-44a2-b218-fe508c26d95d"
      unitRef="Unit12">11544000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-ff8f8dcd-5384-40ac-a4b1-99ddfd1a076c"
      unitRef="Unit12">306000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-a18b513a-3f9e-4f2b-bbea-98d20793665a"
      unitRef="Unit12">71653000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-4af6f348-5b1c-4cb8-8fd2-26d1dcc858c0"
      unitRef="Unit12">46327000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-288f20b3-1860-4eb9-b938-f3745316ee71"
      unitRef="Unit12">56315000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-620ee34d-5920-4bb0-ac28-c532eb8c9780"
      unitRef="Unit12">58860000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-574e33e6-6bab-40b6-89b9-73890d906913"
      unitRef="Unit12">32566000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-3851b177-0cf6-4aaf-a6d4-bd09dff401bc"
      unitRef="Unit12">34576000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c1b3f7af-81eb-46ed-9934-66b0b3001c72"
      unitRef="Unit12">112899000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-db6a6d4c-7a4f-4569-8c7b-97d8133b5e0f"
      unitRef="Unit12">64152000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-f64ad57f-2c41-49fc-a56d-dab5142a0641"
      unitRef="Unit12">59630000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-341edae7-d737-4e89-818e-fd22f2bc2eb2"
      unitRef="Unit12">124124000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-a294ed95-b752-43be-81db-c7601e501d70"
      unitRef="Unit12">72799000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-3eb2e8c8-31a3-44a6-b96f-6541db593f13"
      unitRef="Unit12">75491000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-060c7ac2-12d1-41b1-a851-a42cc757ac01"
      unitRef="Unit12">31129000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-8bc19d83-993b-4e38-935d-4483a232d4b3"
      unitRef="Unit12">1143000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-3cd449d9-83ad-4e5d-a91c-4c3fb493b431"
      unitRef="Unit12">269295000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-c6139f6e-1d5b-4237-857c-742160179eb7"
      unitRef="Unit12">136951000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-f94a5264-6c38-4d26-8941-4768f717345d"
      unitRef="Unit12">135121000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-e181c5f0-ff1e-4d4e-b28f-cb6294701d58"
      unitRef="Unit12">-210435000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-b0bec31b-1cea-4fe6-9e00-c9070d45caec"
      unitRef="Unit12">-104385000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-38df6862-2fbd-44d2-9c57-0c33106d7cd1"
      unitRef="Unit12">-100545000</us-gaap:OperatingIncomeLoss>
    <pacb:GainLossOnReverseTerminationFee
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-234f126b-19f3-4354-be80-3295d577c947"
      unitRef="Unit12">98000000</pacb:GainLossOnReverseTerminationFee>
    <us-gaap:GainLossOnContractTermination
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-0568c9e9-6717-4f8f-8ec6-8b8d2bf2276d"
      unitRef="Unit12">-52000000</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-f68074f0-8209-49ce-a5fa-96d1b37b27ed"
      unitRef="Unit12">34000000</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-8e8fdc76-776d-4d7a-b5c0-7002aff91457"
      unitRef="Unit12">18000000</us-gaap:GainLossOnContractTermination>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-995f4e52-84d0-4afc-a92f-a3e350a27d26"
      unitRef="Unit12">12530000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-c42af5fb-54ef-4155-9a98-a383d372622f"
      unitRef="Unit12">267000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-0a93b37f-1d54-4eaa-8e17-9b0bc549b2ad"
      unitRef="Unit12">2611000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-5c8202e0-f6cb-4b31-9ad7-815b322c0d71"
      unitRef="Unit12">93000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-6ca132de-1444-4553-ad8c-920ac5bb5645"
      unitRef="Unit12">2055000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-bcfbb0e8-14b2-49cd-9173-9307c943eaf5"
      unitRef="Unit12">1022000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-88d8ef40-df4a-4aa7-8d1b-16635df61371"
      unitRef="Unit12">-274872000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-c231b71a-b996-4238-b794-f24de08591e6"
      unitRef="Unit12">29403000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-ea7b3384-b650-4885-b598-dbb320deb7c8"
      unitRef="Unit12">-84134000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-126312a8-959d-4e91-9c2b-c7332949b140"
      unitRef="Unit12">-93649000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-a41c134a-fd79-4d79-ac0f-690c26e8f49b"
      unitRef="Unit12">-181223000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-5a769d77-28dc-4f60-af4a-6f60a4d99d73"
      unitRef="Unit12">29403000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-3ebea204-9ff6-46e2-b351-10d6a141a80c"
      unitRef="Unit12">-84134000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-002a13ff-34d1-41ad-9040-1333c88cc5b2"
      unitRef="Unit12">-1172000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-a11ad2b2-2a3b-4ae2-89a7-99ffd1bed5d3"
      unitRef="Unit12">80000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-8c4d614e-3795-447e-b446-dcd133f6252e"
      unitRef="Unit12">41000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-fb3c14e2-a6f4-40c8-b640-5f4502d68d15"
      unitRef="Unit12">-182395000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-bb37ceee-be98-481c-b5bb-cb66cc5e1c2e"
      unitRef="Unit12">29483000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-93959884-dc7a-470f-a785-bf6e243e5e90"
      unitRef="Unit12">-84093000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-814c604d-7f90-457c-bc99-040abfb7c166"
      unitRef="Unit13">-0.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="2"
      id="ct-nonFraction-8db2e302-114b-4160-9674-1867750d3a46"
      unitRef="Unit13">0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="2"
      id="ct-nonFraction-03ab7caa-b795-46f7-89b8-c01302c01bc3"
      unitRef="Unit13">-0.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-f4ddecfa-2086-4e89-b006-ece379b6487c"
      unitRef="Unit13">-0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="2"
      id="ct-nonFraction-74d37f14-8353-4d34-8f85-a0cddc785511"
      unitRef="Unit13">0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="2"
      id="ct-nonFraction-36e217e6-1807-4f53-b388-36ca3d2215a7"
      unitRef="Unit13">-0.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-2fe115e8-aea4-49f2-89c7-8bc4cbec4710"
      unitRef="Unit1">204136000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-3216134b-9673-4e5d-8941-83ab4ab20a33"
      unitRef="Unit1">165187000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-5a7cdc85-4e56-48a9-8079-01a43616f07d"
      unitRef="Unit1">152527000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-148905bf-920b-4664-8c2c-01d277f13b2f"
      unitRef="Unit1">204136000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-1dca59b4-5904-4145-b0a1-b99baf3062a6"
      unitRef="Unit1">174970000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-4920865d-f196-4679-81ab-e2ead3eb329b"
      unitRef="Unit1">152527000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-c06ebfc1-0dc7-41a2-96f5-1803c4737d76"
      unitRef="Unit1">150244000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-a40aeaf2-5e76-433a-8ea1-6688c805c8d5"
      unitRef="Unit12">150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-f0e93292-4de8-45f0-a4f7-99c3503960c7"
      unitRef="Unit12">1096053000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="ct-nonFraction-2bbdd5ed-ef32-4c27-b30b-d460d8603107"
      unitRef="Unit12">-36000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-19891ae8-f854-41fa-b1c3-ba925927f386"
      unitRef="Unit12">-982106000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018"
      decimals="-3"
      id="ct-nonFraction-0efce515-7a2d-4fe9-a694-87904866f98b"
      unitRef="Unit12">114061000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-848bded8-01c4-465d-ad35-bf185334a5d8"
      unitRef="Unit12">-84134000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-8d6f46d5-827b-4e5d-9199-984f52dd87f4"
      unitRef="Unit12">-84134000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="ct-nonFraction-7c30e17f-b872-496b-ad73-30cc4a4a358f"
      unitRef="Unit12">41000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-be363dbe-59e0-4448-b486-252820123fc5"
      unitRef="Unit12">41000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-84a7e3ca-f8dd-4181-9487-ba1a262a2a3a"
      unitRef="Unit1">2875000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-f39749b2-f555-43b4-b37d-68cc659eb5e4"
      unitRef="Unit12">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-5cf95d35-e805-4fb8-9704-f3837260e9d5"
      unitRef="Unit12">8545000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-e349c695-3e22-4377-a3c3-30609e9d1cb5"
      unitRef="Unit12">8548000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-6e5aa3f0-41b9-4885-83fb-f1fb5fe22661"
      unitRef="Unit12">16401000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-8612c3cc-997f-48de-ad0c-5a636e4284e6"
      unitRef="Unit12">16401000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-4abfcf62-ed90-4f7d-bd48-17b9b72401d9"
      unitRef="Unit1">153119000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-5879f360-83fc-40f9-859b-057084f30844"
      unitRef="Unit12">153000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-42f85971-354b-4c26-abcc-9dbaac46d39c"
      unitRef="Unit12">1120999000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="ct-nonFraction-520a68fd-5837-43e1-b670-f7123cd89f80"
      unitRef="Unit12">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-f51b1af7-5ae7-41f8-8b2f-6331b9e3f3b4"
      unitRef="Unit12">-1066240000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-d1b6c9ee-8e3d-4796-ab6c-9f64d46214cd"
      unitRef="Unit12">54917000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-4857c16e-4c44-4629-90eb-75cf542d69a6"
      unitRef="Unit12">29403000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-b5775874-ae34-48a1-af64-ace025d37282"
      unitRef="Unit12">29403000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="ct-nonFraction-98d0708b-ed82-4bee-b964-638f721e1308"
      unitRef="Unit12">80000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-9f46e95b-5247-44dd-b15e-d8277a785284"
      unitRef="Unit12">80000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_srt_RestatementAxis_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201904Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-1bc08bba-6140-4f7e-8064-60802fdd3864"
      unitRef="Unit12">-32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_srt_RestatementAxis_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201904Member"
      decimals="-3"
      id="ct-nonFraction-774fbd7c-3b77-4ef6-b686-efc9fcc88f0f"
      unitRef="Unit12">-32000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-97577e23-3273-4e74-afca-2f66314b0604"
      unitRef="Unit1">9819000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-bd580523-d45b-4e07-aa81-1095df41ccae"
      unitRef="Unit12">10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-7871755e-7616-4ebb-bb97-01f7e46a5579"
      unitRef="Unit12">46350000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-48d8d27b-0bbe-44b7-9343-ef48ee017ae4"
      unitRef="Unit12">46360000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-ab291aa9-49c7-41a7-9a6a-fbf0924f968d"
      unitRef="Unit1">29356000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-66b16c27-f890-4fb3-b242-1ffc3eda1cc0"
      unitRef="Unit12">29000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-99d3dc88-d949-4141-ac88-9230d01c9606"
      unitRef="Unit12">187201000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-ee004ff2-167e-4f2e-97a5-f0d2b17f5ca2"
      unitRef="Unit12">187230000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-dfde40a8-fc4f-415f-9c5b-9d8b036c8b7a"
      unitRef="Unit12">17533000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-c4fcf05e-d8c0-424e-9a08-9e1f634eafa7"
      unitRef="Unit12">17533000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-7f275066-212f-4ec3-a6bc-ab425fc3ee13"
      unitRef="Unit1">192294000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-4f4ef83c-2fe6-4b9b-a988-7ca74e390680"
      unitRef="Unit12">192000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-36c4e9ed-5286-4bb1-8558-a8284e034d84"
      unitRef="Unit12">1372083000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="ct-nonFraction-4b84a06a-0f63-4736-8bf9-16289b8b83be"
      unitRef="Unit12">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-739680a8-d6bb-47ad-a17c-2616ac85a87a"
      unitRef="Unit12">-1036869000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-949eb8e1-4636-4053-b5f5-2ed183f53d5d"
      unitRef="Unit12">335491000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-ab6b6cdd-2441-4290-9849-e7039bf911e8"
      unitRef="Unit12">-181223000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-44d33126-a098-481b-821e-4a86cc87013b"
      unitRef="Unit12">-181223000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="ct-nonFraction-8dd80f50-34a2-4fbd-9c16-b5a168f88a3a"
      unitRef="Unit12">-1172000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c703cd7c-05af-4236-924f-538bafc9eaf7"
      unitRef="Unit12">-1172000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-5a53ccea-0309-4116-aad3-9cc40e422e66"
      unitRef="Unit1">8557000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-01d2f7f4-f2b5-4e46-9c16-96c7ec87a667"
      unitRef="Unit12">9000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-169b2c7f-3c84-4bfe-8512-99296c9be24a"
      unitRef="Unit12">31797000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-a89c6b01-e640-416a-a2c9-cddaa4b0391c"
      unitRef="Unit12">31806000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <pacb:IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-d8ebc3ce-94b7-457d-bfef-2d6936e5aebd"
      unitRef="Unit1">11215000</pacb:IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares>
    <pacb:StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-20478285-4a26-4215-b84f-0111d6d6017d"
      unitRef="Unit12">11000</pacb:StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts>
    <pacb:StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-04079d83-417e-4d9f-9f2a-19002a37fb73"
      unitRef="Unit12">294834000</pacb:StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts>
    <pacb:StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-08a1d3d6-fd86-4b44-8335-383e1fb6dc07"
      unitRef="Unit12">294845000</pacb:StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-487574a3-3726-48cf-8b67-ca8c38fdd0a7"
      unitRef="Unit1">8912000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-fe92d27d-5f75-4421-a8da-e7cc4c401031"
      unitRef="Unit12">9000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-a6e0ccd7-a3ef-49c3-8c6f-6c10e4426ff6"
      unitRef="Unit12">237876000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-bbcb4411-9c3a-4df8-a1f9-f93e8afd464d"
      unitRef="Unit12">237885000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-4cbfccdd-604c-4837-aa25-f25d40b29fc1"
      unitRef="Unit12">73355000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-f4cfc0cd-d528-4dbc-ad96-aea22f056b01"
      unitRef="Unit12">73355000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-37a3d983-6780-4d97-91e2-d5274956e4b2"
      unitRef="Unit1">220978000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-fc28d275-a551-4280-8c33-80f19db1a7e2"
      unitRef="Unit12">221000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-7b23897c-77f4-4fdb-92bd-a3f08430876a"
      unitRef="Unit12">2009945000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="ct-nonFraction-b10b2e16-102e-489c-8c0f-7042f929c7e1"
      unitRef="Unit12">-1087000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-526657c1-3b35-475b-a2f9-607d04565bdc"
      unitRef="Unit12">-1218092000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-0702cbb2-83cc-44be-a688-f83ad778cb0e"
      unitRef="Unit12">790987000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-36ca32c5-0728-4bb5-b7cc-b5b4981ca170"
      unitRef="Unit12">-181223000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-7744681c-e5ba-4730-ab81-fc174716872c"
      unitRef="Unit12">29403000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-7d091be2-d905-4b95-901f-df8467a79887"
      unitRef="Unit12">-84134000</us-gaap:NetIncomeLoss>
    <us-gaap:GainLossOnContractTermination
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-1894aa79-143c-40bb-837e-e14dfd85cf26"
      unitRef="Unit12">-52000000</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-a584a6bd-9f8b-45fb-abc4-1ca21b7ea2e8"
      unitRef="Unit12">34000000</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-64ef155f-54ad-4133-8e6b-1bf73ccc8a8d"
      unitRef="Unit12">18000000</us-gaap:GainLossOnContractTermination>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-1f89ee5d-45b5-4fed-9405-9eefab78c04d"
      unitRef="Unit12">7199000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-cf3cb136-f46e-4200-9c57-9817ceb48324"
      unitRef="Unit12">6428000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-12953702-3709-4d18-87f9-722470ad5197"
      unitRef="Unit12">7265000</us-gaap:Depreciation>
    <pacb:AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-1ebb746b-c5ad-44a2-845d-e66eae7b94a3"
      unitRef="Unit12">381000</pacb:AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-620b764c-5301-41e0-8559-3097e12044a7"
      unitRef="Unit12">4005000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-dcd658d2-50f3-4501-8743-7b5abc7ccd15"
      unitRef="Unit12">2876000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-0d081f88-7f3c-4a6a-8838-564a07b3a0ca"
      unitRef="Unit12">2683000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-39697cd8-30e7-46c2-a2be-fc34b88d47c7"
      unitRef="Unit12">539000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-3e7064ff-4bfa-4736-8a1c-dea29a2751b8"
      unitRef="Unit12">129000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-abc91cdc-c9e9-4bf4-9571-b9f256ef3f86"
      unitRef="Unit12">1212000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-d07f19f4-ce64-4462-886e-50e0ec818be3"
      unitRef="Unit12">73355000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-177095d3-3ae7-43d8-bf58-dcfaed662e96"
      unitRef="Unit12">17533000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-f936cca9-32fc-4edc-a6d7-689e67d2b724"
      unitRef="Unit12">16401000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-35376783-df52-4a37-bbf4-ba3294073a75"
      unitRef="Unit12">16000</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-cdbdd1e4-3074-439c-8e19-20eaeade34b6"
      unitRef="Unit12">-4011000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-794e4f02-8a71-4bce-889b-d541c590588c"
      unitRef="Unit12">107000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-af9b7f96-7adf-4b45-ad58-ab415aee937c"
      unitRef="Unit12">913000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-221e47fa-0767-4e9a-9001-51ca10cd148c"
      unitRef="Unit12">1143000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-342dd1b8-6d7a-4002-be69-3a3cb5ffe86a"
      unitRef="Unit12">-54000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-a57022b6-b4fb-4917-a4f6-27673f46b975"
      unitRef="Unit12">-194000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-1cf085a5-9335-48af-806c-db4c267eaa88"
      unitRef="Unit12">-93649000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c2e6dd2d-64ab-4d6a-9f38-51a172ee048d"
      unitRef="Unit12">7166000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-4696d09c-7b8c-4d61-b9c7-d5035afcd00f"
      unitRef="Unit12">1603000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-d2d89753-1a00-440d-b4f8-baa4807ed38e"
      unitRef="Unit12">6671000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-45608407-3331-4f40-b612-27e9d7ce538b"
      unitRef="Unit12">12431000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-0fe76a92-a8b4-446a-9101-a79195db3651"
      unitRef="Unit12">1096000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-60f702fa-ee4d-48f2-85f7-489390ccb62b"
      unitRef="Unit12">-3915000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-98ff2d4a-054b-42fd-a076-ac535b776bdd"
      unitRef="Unit12">1024000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-1663d0f3-8985-476c-92d5-f740611a71f5"
      unitRef="Unit12">1063000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-3229ada8-43ca-4028-89d2-4f06bec82929"
      unitRef="Unit12">523000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-940311e6-dcef-4b32-8bc1-e01757ec5fc2"
      unitRef="Unit12">6363000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-1cc0773e-ff4b-4309-bf51-68b070edb851"
      unitRef="Unit12">-5072000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-5e7d0548-47c8-421b-8c30-e1674e40e5a7"
      unitRef="Unit12">1713000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-936fbccb-39dd-4488-8f2b-0eadada45ca9"
      unitRef="Unit12">15320000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-0edacfa7-306c-437e-b9ff-fb5145fdc7ec"
      unitRef="Unit12">4102000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-b9a632de-3d38-42af-93c2-08fbbb96a6b2"
      unitRef="Unit12">2333000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-21b86b7e-7694-4ff6-85b2-64890aa9e998"
      unitRef="Unit12">-25736000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-fd61088e-8c38-4ecd-91da-c03c4442da51"
      unitRef="Unit12">-729000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-53167d06-6cb9-4369-ab2d-1b93776bfab3"
      unitRef="Unit12">-2134000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-12fbac7b-0a7a-4d3b-8921-d02cb661dc58"
      unitRef="Unit12">4990000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-ca3770c4-75bf-4cde-88c1-6794fabeb76f"
      unitRef="Unit12">3802000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-e7f1d412-0787-4c59-a2ef-52bd64762221"
      unitRef="Unit12">3428000</us-gaap:OperatingLeasePayments>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-cae0163e-2c1e-4c4b-a110-2a318d01891f"
      unitRef="Unit12">-803000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-4cd3679c-3092-4a65-b6f9-400544e853b1"
      unitRef="Unit12">5046000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-3f62bf7e-7d86-413f-a2d8-f4f2660364df"
      unitRef="Unit12">-2477000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-a0ed39e9-a452-44b5-9cc9-d894da4aeae5"
      unitRef="Unit12">-111180000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-57a0fa91-fe68-4e47-811b-2b3fbf8644a8"
      unitRef="Unit12">19503000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-25a1787c-7519-4187-b43f-055af4c9dc94"
      unitRef="Unit12">-78312000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-12ef068b-8b0e-47a7-99b9-ec44d8c855bd"
      unitRef="Unit12">5931000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-3d18cf89-f602-43eb-92bf-94f41a28dd6e"
      unitRef="Unit12">1039000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-4ad246d3-84a6-498f-94f9-a05fbe4a5425"
      unitRef="Unit12">2836000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember"
      decimals="-3"
      id="ct-nonFraction-aeaa15fc-9af5-4b04-952b-96bebabb786e"
      unitRef="Unit12">28560000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-3c31b26d-2c4e-4331-994a-b423babc9cce"
      unitRef="Unit12">291233000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-cf027acb-29cf-490a-90b7-59b76e414567"
      unitRef="Unit12">988046000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-3fe7a01d-c77b-44d0-ab93-405417036120"
      unitRef="Unit12">373283000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-e9d6c88a-3646-4b3e-ae22-263cc7baf266"
      unitRef="Unit12">57727000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-9f15382d-a2ad-4f71-b0fe-b6acb4914389"
      unitRef="Unit12">212734000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-62db91e6-af6a-4117-a6e4-647f485c7a39"
      unitRef="Unit12">1400000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-398f97ff-0bed-4fdd-b691-ad976124b73b"
      unitRef="Unit12">1500000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-b640867d-5b20-45a6-9662-3f92d9b7d945"
      unitRef="Unit12">422505000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-09c5a1ed-fb9b-4ac4-a235-6a80b033bf61"
      unitRef="Unit12">153600000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-8ce243c9-f48a-496c-9c8f-ff4fd1bcae80"
      unitRef="Unit12">121110000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-76952398-447c-45a9-9a2f-155d30da87f8"
      unitRef="Unit12">-678531000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-9c0e1d6b-040d-481d-bfe8-ff1eb7038b95"
      unitRef="Unit12">-219322000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-0d39c0e9-06fd-46b1-91ab-816e54498810"
      unitRef="Unit12">62047000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <pacb:ProceedsFromRepaymentsOfContractTermination
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-97b7ca78-01e0-4e99-b25c-a4aa904d59e4"
      unitRef="Unit12">-52000000</pacb:ProceedsFromRepaymentsOfContractTermination>
    <pacb:ProceedsFromRepaymentsOfContractTermination
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-ccf287aa-b25e-40e8-a68e-e162f36eb149"
      unitRef="Unit12">34000000</pacb:ProceedsFromRepaymentsOfContractTermination>
    <pacb:ProceedsFromRepaymentsOfContractTermination
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-f6f453c5-286f-48cd-8112-e9328379347c"
      unitRef="Unit12">18000000</pacb:ProceedsFromRepaymentsOfContractTermination>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-007c342c-86bb-4364-812f-14aafdf12299"
      unitRef="Unit12">895536000</us-gaap:ProceedsFromConvertibleDebt>
    <pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-d74b4a5e-29ab-4a77-8337-30cc5f024ef5"
      unitRef="Unit12">294845000</pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-4ff4237c-add1-4932-a2ee-158250882646"
      unitRef="Unit12">187479000</pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-dc9f16af-6f32-468a-8922-bce6e1098931"
      unitRef="Unit12">31806000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-8845eeb5-1c16-4a54-b117-744c519ffdec"
      unitRef="Unit12">46360000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-495e3c55-f855-4d37-b360-3808f0119583"
      unitRef="Unit12">8548000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-ff0a80e2-d4cd-4f52-907b-53715d7a01e9"
      unitRef="Unit12">361000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-53b9f35c-5e79-4830-969d-0f6e3092966c"
      unitRef="Unit12">16000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-a2b0b68a-071d-4b8f-a158-9b02d95efb07"
      unitRef="Unit12">-245000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-0a130728-3d70-4bb8-bd5f-f4833c7def87"
      unitRef="Unit12">1169581000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-0bd14ef3-c908-4bed-8fb3-fb27f3a297b8"
      unitRef="Unit12">251839000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-0b5ff76f-986c-43f2-aa5d-ad52f0378b5b"
      unitRef="Unit12">26548000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-67fd90b9-b502-4eda-af32-6edac5e13e3f"
      unitRef="Unit12">379870000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-2137f2c6-85c0-484e-a09e-8247119ddac2"
      unitRef="Unit12">52020000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-01bfd42e-ef67-4950-bf0c-f9c948906279"
      unitRef="Unit12">10283000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-2a501384-b962-4e01-b9bd-decda3e12271"
      unitRef="Unit12">85947000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2018"
      decimals="-3"
      id="ct-nonFraction-28974f1d-bd96-4598-ab55-e7d2d09f4457"
      unitRef="Unit12">33927000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2017"
      decimals="-3"
      id="ct-nonFraction-69a6a5e8-6e4b-410f-b975-7a2e6fa65e98"
      unitRef="Unit12">23644000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-89b88439-3acc-4781-a8b3-f9f4ffbb2c8e"
      unitRef="Unit12">465817000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-8e0ab16b-d178-407e-b80d-c22c2c8cd803"
      unitRef="Unit12">85947000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-1ec234b3-17bf-4fa3-922b-eb0a904c662f"
      unitRef="Unit12">33927000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-7d7a2bfa-057c-43d8-a082-8e118cfe8e30"
      unitRef="Unit12">460725000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-06cb146c-2857-4396-9e42-d4cf4e2ad33d"
      unitRef="Unit12">81611000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-bd2d7b83-e4a7-4b82-bc2a-53a74a0dde7a"
      unitRef="Unit12">29627000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c8a49315-4532-47ba-a8a5-eb63122af2ba"
      unitRef="Unit12">5092000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-3d5279bc-9caa-4bc2-ba47-340e6322bd4c"
      unitRef="Unit12">4336000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="As_Of_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-2617fd80-e69d-4212-b400-10dfe45d7989"
      unitRef="Unit12">4300000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-7666d46f-1fb3-42bf-8a8b-e1526cc00af8"
      unitRef="Unit12">465817000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-79bf65fb-b63e-4866-a8ad-1ca0316f2778"
      unitRef="Unit12">85947000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-409134e3-e172-4bbf-8ed8-57656c583cb0"
      unitRef="Unit12">33927000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-7877ac50-827c-420f-945d-632e4d2dfc49"
      unitRef="Unit12">6928000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-3c5d0d92-16a3-4222-a04b-ab1090d66727"
      unitRef="Unit12">491000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-d8f1c225-aaff-4b34-a3b1-c69710857ca2"
      unitRef="Unit12">1400000</us-gaap:InterestPaidNet>
    <pacb:InventoryTransferredToFromPropertyAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-6e7745ed-e7aa-4b7e-a060-b065b6c54ffd"
      unitRef="Unit12">2586000</pacb:InventoryTransferredToFromPropertyAndEquipment>
    <pacb:InventoryTransferredToFromPropertyAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-9bd77e73-4650-4a48-8d33-6a3365d3bd17"
      unitRef="Unit12">1097000</pacb:InventoryTransferredToFromPropertyAndEquipment>
    <pacb:InventoryTransferredToFromPropertyAndEquipment
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-58f81175-d831-486d-b25b-970bcede660b"
      unitRef="Unit12">2062000</pacb:InventoryTransferredToFromPropertyAndEquipment>
    <pacb:InventoryTransferredFromPropertyAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-abab3cae-e78c-41f4-9daa-6cbb2efd6c5e"
      unitRef="Unit12">383000</pacb:InventoryTransferredFromPropertyAndEquipment>
    <pacb:InventoryTransferredFromPropertyAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-0f7aa8af-81af-4916-9150-b60c7d11506e"
      unitRef="Unit12">919000</pacb:InventoryTransferredFromPropertyAndEquipment>
    <pacb:InventoryTransferredFromPropertyAndEquipment
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-8f7aac32-9a1d-476a-93b7-e68e8b553923"
      unitRef="Unit12">1536000</pacb:InventoryTransferredFromPropertyAndEquipment>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c1ade6e5-b63d-407a-a5ad-4ef6f2943be6"
      unitRef="Unit12">2576000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-f48d25e7-9e58-4712-bed0-a84d1d06894f"
      unitRef="Unit12">237885000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-4c0dec01-8acb-4609-8ccf-f27526c956bb">NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIESBusiness OverviewWe are a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems.  Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing technology and our emerging short read Sequencing by Binding (SBB&#xae;) technology. Our products address solutions across a broad set of applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Our focus is on providing our customers with advanced sequencing technologies with higher throughput and improved workflows that we believe will enable dramatic advancements in routine healthcare.  Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies and agricultural companies.References in this report to &#x201c;PacBio,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; the &#x201c;Company,&#x201d; and &#x201c;our&#x201d; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.Basis of Presentation Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. Use of Estimates The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates including, but not limited to, the valuation of inventory, the determination of stand-alone selling prices for revenue recognition, the fair value of contingent consideration, the valuation of acquired intangible assets, the fair value of certain equity awards, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, the borrowing rate used in calculating the operating lease right-of-use assets and operating lease liabilities, the probability associated with variable payments under partnership development agreements, and the valuations related to our convertible senior notes. While the extent of the impact of the COVID-19 pandemic on our business is highly uncertain, we considered the impact on our assumptions and estimates used to determine the results reported and asset valuations as of December 31, 2021. Actual results could differ materially from these estimates. Functional CurrencyThe U.S. dollar is the functional currency of our international operations.  We remeasure foreign subsidiaries monetary assets and liabilities to the U.S. dollar and record net gains or losses from remeasurement in other income, net, in the consolidated statement of operations and comprehensive (loss) income.Cash, Cash Equivalents, and Investments We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. We classify our investments in debt securities as available-for sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related.  Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive (loss) income in stockholders&#x2019; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net.  Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and US government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.Concentration and Credit Risks Financial instruments that potentially subject us to credit risk consist principally of interest-bearing investments and trade receivables. We maintain cash, cash equivalents and investments with various major financial institutions. The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities and government agencies of high credit standing. At December 31, 2021, most of our cash was deposited with U.S. financial institutions.  Our investment policy generally restricts the amount of credit exposure to any one issuer. There is no limit to the percentage of the portfolio that may be maintained in securities issued by the U.S. Treasury and U.S. Government Agencies, or other securities fully backed by US Treasury or Government agencies. We have not experienced significant credit losses from financial institutions.Our trade receivables are derived from net revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers&#x2019; financial condition and, generally, require no collateral from our customers. The allowance for doubtful accounts is based on our assessment of the collectability of customer accounts. We regularly review our trade receivable including consideration of factors such as historical experience, the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#x2019;s ability to pay. We have not experienced any significant credit losses to date. Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. For the years ended December 31, 2021, 2020 and 2019, one customer, Gene Company Limited, accounted for approximately 13%, 14% and 17% our total revenue, respectively. As of December 31, 2021 and 2020, 53% and 43% of our accounts receivable were from domestic customers, respectively. As of December 31, 2021, no customer represented 10% of greater of our net accounts receivable. As of December 31, 2020, two customers, Berry Genomics Co., Ltd and Gene Company Limited, represented approximately 15% and 12% of our net accounts receivable, respectively. We currently purchase several key parts and components used in the manufacture of our products from a limited number of suppliers. Generally, we have been able to obtain an adequate supply of such parts and components but in certain instances have incurred additional costs to secure supply constrained materials. An extended interruption in the supply of parts and components currently obtained from our suppliers could adversely affect our business and consolidated financial statements. Inventory Inventories are stated at the lower of average cost or net realizable value. Cost is determined using the first-in, first-out (&#x201c;FIFO&#x201d;) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs while determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories. &#160;  We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.Property and Equipment, Net Property and equipment are stated at cost, reviewed regularly for impairment charges, and depreciated over the estimated useful lives of the assets, using the straight-line method.  Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred. Estimated useful lives of the major classes of property and equipment are as follows:         Estimated Useful LivesLeasehold improvements 3 to 10 yearsLab equipment 3 to 5 yearsComputer equipment 3 to 5 yearsComputer software 3 yearsFurniture and fixtures 3 to 5 yearsImpairment of Tangible Long-Lived Assets We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset is impaired or the estimated useful lives are no longer appropriate. Fair value is estimated based on discounted future cash flows. If indicators of impairment exist and the undiscounted projected cash flows associated with such assets are less than the carrying amount of the asset, an impairment loss is recorded to write the asset down to its estimated fair value. To date, we have not recorded any impairment charges.Operating Leases We record operating lease right-of-use assets and liabilities on our Consolidated Balance Sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. Operating lease expense is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period incurred. Goodwill and Intangible AssetsWe perform annual impairment testing of goodwill and in-process research and development project (&#x201c;IPR&amp;D&#x201d;) in the second quarter of each year, or more frequently if indicators of potential impairment exist.We capitalize IPR&amp;D assets and will begin to amortize the asset over the life of the product upon commercialization or record an impairment charge if the project is abandoned. We also capitalize finite-lived intangibles assets and amortize them on a straight-line basis over the estimated useful lives.Finite-lived intangibles assets include our acquired developed technology and customer relationships. We regularly review the carrying amount and useful lives of our finite-lived assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives.&#160;Short-term Restricted Cash At December 31, 2021, the short-term restricted cash balance of $0.5 million consisted of security deposits for employee credit cards.Long-term Restricted Cash Under the lease agreement for our corporate offices, we were required to establish a letter of credit for the benefits of the landlord and to submit $4.5 million as a deposit for the letter of credit in October 2015. Subsequently pursuant to the terms of the O&#x2019;Brien Lease, beginning on May 1, 2019, the amount of the letter of credit was reduced by $0.5 million each year thereafter on May 1. As such, $3.0 million and $3.5 million was recorded in long-term restricted cash related to the O&#x2019;Brien Lease in the Consolidated Balance Sheets as of December 31, 2021 and December 31, 2020, respectively.In connection with the acquisition of Omniome in September 2021, we acquired $1.6 million of long-term restricted cash related to a letter of credit established for a facility lease.Revenue Recognition Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables. Service and other revenue consists primarily of revenue earned from product maintenance agreements. We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods or services is transferred to our customers or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our instrument sales are generally sold in a bundled arrangement and commonly include the instrument, instrument accessories, installation, training, and consumables. Additionally, our instrument sale arrangements generally include a&#160;one-year period of service. For such bundled arrangements, we account for individual products and services separately if they are distinct, that is, if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. Our customers cannot benefit from our instrument systems without installation, and installation can only be performed by us or qualified distributors. As a result, the system and installation are considered to be a single performance obligation recognized after installation is completed except for sales to qualified distributors, in which case the system is distinct and recognized when control has transferred to the distributor which typically occurs upon shipment.  The consideration for bundled arrangements is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using average selling prices over a 12-month period combined with an assessment of current market conditions. If the standalone selling price is not directly observable, then we will estimate the SSP by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices and other observable inputs. We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts, distributor commissions, and sales taxes collected on behalf of governmental authorities.  We record deferred revenues when cash payments are received or due in advance of our performance. Deferred revenue for instrument service contracts is recognized over the related performance period, generally one year to five years, on a straight-line basis as we are standing ready to provide services and a time-based measure of progress best reflects the satisfaction of the performance obligation. Cost of RevenueCost of revenue reflects the direct cost of product components, third-party manufacturing services and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain and support our instruments, consumables, and services. There are no incremental costs associated with our contractual revenue; all product development costs are reflected in research and development expense.Manufacturing overhead is predominantly comprised of labor and facility costs. We determine and capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs.  Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support our installed customer base. Research and Development Research and development expense consists primarily of expenses for personnel engaged in the development of our core technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, partner development costs, facilities costs and other related overhead. We expense research and development costs during the period in which the costs are incurred. However, we defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered. Credit LossesWe adopted Topic 326 on January 1, 2020. The adoption of Topic 326 did not have a material impact on our financial statements and our bad debt expense was immaterial as of the years ended December 31, 2020 and 2021. Trade accounts receivable - The allowance for doubtful accounts is based on our assessment of the collectability of customer accounts. We regularly review the allowance by considering factors such as the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#x2019;s ability to pay. Available-for-sale debt securities - Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and US government and agency securities. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as significance of loss, historical experience, market data, issuer-specific factors, and current economic conditions and concluded that an allowance for credit losses was immaterial as of December 31, 2021. The unrealized losses on our investments are mainly attributable to government securities, including U.S. government and U.S. agency bond securities, impacted by movements in market rates and not due to issuer credit ratings. We have the ability to hold and do not intend to sell the investments in unrealized loss positions before the recovery of their amortized cost bases.Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruptions associated with the evolution of the COVID-19 pandemic, or other customer-specific factors. Income Taxes We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. The effect of a change in tax rates on the deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized. We regularly review our positions taken relative to income taxes. To the extent our tax positions are more likely than not going to result in additional taxes, we accrue the estimated amount of tax related to such uncertain positions. Stock-based Compensation We account for share-based payments using a fair-value based method for costs related to all share-based payments, including stock options, restricted stock units, and stock issued under our employee stock purchase plan (&#x201c;ESPP&#x201d;). We estimate the fair value of share-based payment awards that are stock options and issued under our ESPP on the date of grant using an option-pricing model. See Note 10. Stockholders&#x2019; Equity for further information regarding stock-based compensation.Other Comprehensive (Loss) IncomeOther comprehensive (loss) income is comprised of unrealized gains (losses) on our investment securities. Shipping and HandlingCosts related to shipping and handling are included in cost of revenues for all periods presented.Recent Accounting Pronouncements Recently Adopted Accounting StandardsIn August 2020, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2020-06,&#160;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity. This guidance simplifies the accounting for convertible instruments primarily by eliminating the existing cash conversion and beneficial conversion models within Subtopic 470-20, which will result in fewer embedded conversion options being accounted for separately from the debt host. The guidance also amends and simplifies the calculation of earnings per share relating to convertible instruments. This guidance is effective for annual periods beginning after December 15, 2021, including interim periods within that reporting period, excluding smaller reporting companies. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within that reporting period, using either a full or modified retrospective approach. We adopted ASU 2020-06 on January 1, 2021. Because we had no convertible instruments within the scope of ASU 2020-06 at the time of adoption, there was no impact of adoption on our consolidated financial statements. In February 2021, we issued $900 million of 1.50% Convertible Senior Notes due February 15, 2028, as described in Note 7. Convertible Senior Notes, which are accounted for under ASU 2020-06.In&#160;December 2019,&#160;the FASB issued ASU&#160;No.&#160;2019-12,&#160;Income Taxes (Topic&#160;740): Simplifying the Accounting for Income Taxes. This ASU simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step up in the tax basis of goodwill, and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. The standard is effective for our annual reporting periods beginning after December 15, 2020, including interim reporting periods within those fiscal years. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not&#160;have a material impact on our consolidated financial statements. Accounting Pronouncements Pending AdoptionIn October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU provides specific guidance on how to recognize contract assets and contract liabilities related to revenue contracts with customers acquired in a business combination. This amendment improves comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. This authoritative guidance will be effective for us in the first quarter of 2023, with early adoption permitted. We are currently evaluating the effect of this new guidance on our consolidated financial statements.&#160;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccounting
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-25e7d500-8739-4bae-ac1f-efdd4738640d">Basis of Presentation Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. </us-gaap:BasisOfAccounting>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-e873fc7d-431a-408d-a44a-ebc8d8e08efb">Use of Estimates The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates including, but not limited to, the valuation of inventory, the determination of stand-alone selling prices for revenue recognition, the fair value of contingent consideration, the valuation of acquired intangible assets, the fair value of certain equity awards, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, the borrowing rate used in calculating the operating lease right-of-use assets and operating lease liabilities, the probability associated with variable payments under partnership development agreements, and the valuations related to our convertible senior notes. While the extent of the impact of the COVID-19 pandemic on our business is highly uncertain, we considered the impact on our assumptions and estimates used to determine the results reported and asset valuations as of December 31, 2021. Actual results could differ materially from these estimates. </us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-ccd307b7-89a3-48c8-98e6-1fddef07aedf">Functional CurrencyThe U.S. dollar is the functional currency of our international operations.  We remeasure foreign subsidiaries monetary assets and liabilities to the U.S. dollar and record net gains or losses from remeasurement in other income, net, in the consolidated statement of operations and comprehensive (loss) income.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-9d749fcc-f437-4dc2-a33a-9465d0eb811b">Cash, Cash Equivalents, and Investments We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. We classify our investments in debt securities as available-for sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related.  Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive (loss) income in stockholders&#x2019; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net.  Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and US government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-280d9f4f-b16b-48b0-9741-f1041184212f">Concentration and Credit Risks Financial instruments that potentially subject us to credit risk consist principally of interest-bearing investments and trade receivables. We maintain cash, cash equivalents and investments with various major financial institutions. The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities and government agencies of high credit standing. At December 31, 2021, most of our cash was deposited with U.S. financial institutions.  Our investment policy generally restricts the amount of credit exposure to any one issuer. There is no limit to the percentage of the portfolio that may be maintained in securities issued by the U.S. Treasury and U.S. Government Agencies, or other securities fully backed by US Treasury or Government agencies. We have not experienced significant credit losses from financial institutions.Our trade receivables are derived from net revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers&#x2019; financial condition and, generally, require no collateral from our customers. The allowance for doubtful accounts is based on our assessment of the collectability of customer accounts. We regularly review our trade receivable including consideration of factors such as historical experience, the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#x2019;s ability to pay. We have not experienced any significant credit losses to date. Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. For the years ended December 31, 2021, 2020 and 2019, one customer, Gene Company Limited, accounted for approximately 13%, 14% and 17% our total revenue, respectively. As of December 31, 2021 and 2020, 53% and 43% of our accounts receivable were from domestic customers, respectively. As of December 31, 2021, no customer represented 10% of greater of our net accounts receivable. As of December 31, 2020, two customers, Berry Genomics Co., Ltd and Gene Company Limited, represented approximately 15% and 12% of our net accounts receivable, respectively. We currently purchase several key parts and components used in the manufacture of our products from a limited number of suppliers. Generally, we have been able to obtain an adequate supply of such parts and components but in certain instances have incurred additional costs to secure supply constrained materials. An extended interruption in the supply of parts and components currently obtained from our suppliers could adversely affect our business and consolidated financial statements. </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_pacb_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="ct-nonFraction-dfafaf69-b089-4857-ad1a-29e143e13415"
      unitRef="Unit15">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_pacb_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="ct-nonFraction-cd5b7ce0-7913-4dc6-92b6-206de2980504"
      unitRef="Unit15">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_MajorCustomersAxis_pacb_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="ct-nonFraction-68a53b09-5d3f-405e-b932-8beaf3d2eba2"
      unitRef="Unit15">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_pacb_DomesticCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="ct-nonFraction-3d28c7a1-5b95-4941-86bb-33a3cecb9ff0"
      unitRef="Unit15">0.53</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_pacb_DomesticCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="ct-nonFraction-41e7eb0c-9e5c-44eb-9870-c70c18b972a3"
      unitRef="Unit15">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsAndNotesReceivableNet
      contextRef="As_Of_12_31_2021_srt_MajorCustomersAxis_pacb_TenPercentOrGreaterBalanceAccountsReceivableMember"
      decimals="INF"
      id="ct-nonFraction-7eb8b5fe-8ed1-4006-8c11-e39f58b066e8"
      unitRef="Unit12">0</us-gaap:AccountsAndNotesReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_pacb_CustomerDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="ct-nonFraction-a75dabd6-a5b2-412d-bc0c-0e295b6916be"
      unitRef="Unit15">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_MajorCustomersAxis_pacb_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="ct-nonFraction-498deb68-a347-4101-9abd-fd2a5220c5e3"
      unitRef="Unit15">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-04672a80-35cc-4e24-a1a5-34a1b947e90f">Inventory Inventories are stated at the lower of average cost or net realizable value. Cost is determined using the first-in, first-out (&#x201c;FIFO&#x201d;) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs while determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories. &#160;  We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-9be23bb0-ca4d-42f7-8933-6981e59d4908">Property and Equipment, Net Property and equipment are stated at cost, reviewed regularly for impairment charges, and depreciated over the estimated useful lives of the assets, using the straight-line method.  Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred. Estimated useful lives of the major classes of property and equipment are as follows:         Estimated Useful LivesLeasehold improvements 3 to 10 yearsLab equipment 3 to 5 yearsComputer equipment 3 to 5 yearsComputer software 3 yearsFurniture and fixtures 3 to 5 years</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <pacb:EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-849d340d-e5b7-4613-bc43-d8803c48ff56">        Estimated Useful LivesLeasehold improvements 3 to 10 yearsLab equipment 3 to 5 yearsComputer equipment 3 to 5 yearsComputer software 3 yearsFurniture and fixtures 3 to 5 years</pacb:EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      id="ct-nonNumeric-ec0412c0-ac62-41c0-adfd-01be459fe548">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      id="ct-nonNumeric-d98c87c4-9364-4112-80b0-194237897ea4">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"
      id="ct-nonNumeric-89a56f48-3918-4a7b-b791-899751316220">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"
      id="ct-nonNumeric-afdfb85f-9357-4edb-a69b-9d207e1c81cd">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"
      id="ct-nonNumeric-ef2fe2e1-aca3-4720-8c63-732fe4f22d53">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"
      id="ct-nonNumeric-a9fe764e-dce4-4f3b-98fb-851c9f2e4ddd">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember"
      id="ct-nonNumeric-e4a8504c-fe26-4aa5-9d8f-8a9219d8584e">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      id="ct-nonNumeric-b10e388b-b221-4b1c-b2a1-1765bdac5b1b">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      id="ct-nonNumeric-a813a487-0d17-4b1d-bb6d-d40badf08956">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-ae87abb3-eb14-4da4-b151-b1a33ed0c2e5">Impairment of Tangible Long-Lived Assets We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset is impaired or the estimated useful lives are no longer appropriate. Fair value is estimated based on discounted future cash flows. If indicators of impairment exist and the undiscounted projected cash flows associated with such assets are less than the carrying amount of the asset, an impairment loss is recorded to write the asset down to its estimated fair value. To date, we have not recorded any impairment charges.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-2353071e-1770-4bf1-8193-d23f4953e552">Operating Leases We record operating lease right-of-use assets and liabilities on our Consolidated Balance Sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. Operating lease expense is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period incurred. </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-7bd3870f-1ae1-43a9-8ddd-72f5b37c245a">Goodwill and Intangible AssetsWe perform annual impairment testing of goodwill and in-process research and development project (&#x201c;IPR&amp;D&#x201d;) in the second quarter of each year, or more frequently if indicators of potential impairment exist.We capitalize IPR&amp;D assets and will begin to amortize the asset over the life of the product upon commercialization or record an impairment charge if the project is abandoned. We also capitalize finite-lived intangibles assets and amortize them on a straight-line basis over the estimated useful lives.Finite-lived intangibles assets include our acquired developed technology and customer relationships. We regularly review the carrying amount and useful lives of our finite-lived assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives.&#160;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <pacb:ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-543e4754-2f48-417a-89a9-64fba227d727">Short-term Restricted Cash At December 31, 2021, the short-term restricted cash balance of $0.5 million consisted of security deposits for employee credit cards.</pacb:ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="As_Of_12_31_2021_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_SecurityDepositMember"
      decimals="-5"
      id="ct-nonFraction-554dafcd-195c-4d38-af45-e2d185f01204"
      unitRef="Unit12">500000</us-gaap:RestrictedCashEquivalentsCurrent>
    <pacb:LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-3e261846-f4ab-4d7f-ac30-fd8a0edfb973">Long-term Restricted Cash Under the lease agreement for our corporate offices, we were required to establish a letter of credit for the benefits of the landlord and to submit $4.5 million as a deposit for the letter of credit in October 2015. Subsequently pursuant to the terms of the O&#x2019;Brien Lease, beginning on May 1, 2019, the amount of the letter of credit was reduced by $0.5 million each year thereafter on May 1. As such, $3.0 million and $3.5 million was recorded in long-term restricted cash related to the O&#x2019;Brien Lease in the Consolidated Balance Sheets as of December 31, 2021 and December 31, 2020, respectively.In connection with the acquisition of Omniome in September 2021, we acquired $1.6 million of long-term restricted cash related to a letter of credit established for a facility lease.</pacb:LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="As_Of_10_31_2015_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember"
      decimals="-5"
      id="ct-nonFraction-55fcc704-2473-4971-b5d2-aba85e9fffc5"
      unitRef="Unit12">4500000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <pacb:AnnualReductionInNonCurrentRestrictedCash
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember"
      decimals="-5"
      id="ct-nonFraction-56dd3074-0643-4a00-b288-1e662c6b8cd6"
      unitRef="Unit12">500000</pacb:AnnualReductionInNonCurrentRestrictedCash>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember"
      decimals="-5"
      id="ct-nonFraction-807629d9-497f-4773-bbe0-dcbde140a9ea"
      unitRef="Unit12">3000000.0</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember"
      decimals="-5"
      id="ct-nonFraction-b82ab556-fc16-4be8-94aa-680674d34639"
      unitRef="Unit12">3500000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember"
      decimals="-5"
      id="ct-nonFraction-8737e76c-d88d-4de5-9fa8-92dca60ffbc2"
      unitRef="Unit12">1600000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-94e8be2a-b97a-4223-9696-ca9973e637db">Revenue Recognition Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables. Service and other revenue consists primarily of revenue earned from product maintenance agreements. We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods or services is transferred to our customers or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our instrument sales are generally sold in a bundled arrangement and commonly include the instrument, instrument accessories, installation, training, and consumables. Additionally, our instrument sale arrangements generally include a&#160;one-year period of service. For such bundled arrangements, we account for individual products and services separately if they are distinct, that is, if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. Our customers cannot benefit from our instrument systems without installation, and installation can only be performed by us or qualified distributors. As a result, the system and installation are considered to be a single performance obligation recognized after installation is completed except for sales to qualified distributors, in which case the system is distinct and recognized when control has transferred to the distributor which typically occurs upon shipment.  The consideration for bundled arrangements is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using average selling prices over a 12-month period combined with an assessment of current market conditions. If the standalone selling price is not directly observable, then we will estimate the SSP by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices and other observable inputs. We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts, distributor commissions, and sales taxes collected on behalf of governmental authorities.  We record deferred revenues when cash payments are received or due in advance of our performance. Deferred revenue for instrument service contracts is recognized over the related performance period, generally one year to five years, on a straight-line basis as we are standing ready to provide services and a time-based measure of progress best reflects the satisfaction of the performance obligation. </us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-82bfa7a2-e864-4795-8e9a-0f9241f55214">Cost of RevenueCost of revenue reflects the direct cost of product components, third-party manufacturing services and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain and support our instruments, consumables, and services. There are no incremental costs associated with our contractual revenue; all product development costs are reflected in research and development expense.Manufacturing overhead is predominantly comprised of labor and facility costs. We determine and capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs.  Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support our installed customer base. </us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-36111a4c-dda1-4067-9aac-42015eb7961d">Research and Development Research and development expense consists primarily of expenses for personnel engaged in the development of our core technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, partner development costs, facilities costs and other related overhead. We expense research and development costs during the period in which the costs are incurred. However, we defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered. </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-85301920-8f02-40c8-82d3-7a73a45acdc1">Credit LossesWe adopted Topic 326 on January 1, 2020. The adoption of Topic 326 did not have a material impact on our financial statements and our bad debt expense was immaterial as of the years ended December 31, 2020 and 2021. Trade accounts receivable - The allowance for doubtful accounts is based on our assessment of the collectability of customer accounts. We regularly review the allowance by considering factors such as the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#x2019;s ability to pay. Available-for-sale debt securities - Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and US government and agency securities. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as significance of loss, historical experience, market data, issuer-specific factors, and current economic conditions and concluded that an allowance for credit losses was immaterial as of December 31, 2021. The unrealized losses on our investments are mainly attributable to government securities, including U.S. government and U.S. agency bond securities, impacted by movements in market rates and not due to issuer credit ratings. We have the ability to hold and do not intend to sell the investments in unrealized loss positions before the recovery of their amortized cost bases.Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruptions associated with the evolution of the COVID-19 pandemic, or other customer-specific factors. </us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-c700afa5-bce9-4340-8c94-4312405ff2ff">Income Taxes We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. The effect of a change in tax rates on the deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized. We regularly review our positions taken relative to income taxes. To the extent our tax positions are more likely than not going to result in additional taxes, we accrue the estimated amount of tax related to such uncertain positions. </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-1b801c94-a29e-4e84-bd0a-56a776358240">Stock-based Compensation We account for share-based payments using a fair-value based method for costs related to all share-based payments, including stock options, restricted stock units, and stock issued under our employee stock purchase plan (&#x201c;ESPP&#x201d;). We estimate the fair value of share-based payment awards that are stock options and issued under our ESPP on the date of grant using an option-pricing model. See Note 10. Stockholders&#x2019; Equity for further information regarding stock-based compensation.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-64ac521c-6b02-47ea-be05-fbe99dee97e7">Other Comprehensive (Loss) IncomeOther comprehensive (loss) income is comprised of unrealized gains (losses) on our investment securities. </us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ShippingAndHandlingCostPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-09580229-680f-4d90-b5be-88fad2acd497">Shipping and HandlingCosts related to shipping and handling are included in cost of revenues for all periods presented.</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-ccd3e286-0983-49a8-8f67-f3f85b7168bf">NOTE 2. BUSINESS ACQUISITIONSOmniome, Inc.On September 20, 2021, we completed our acquisition of Omniome, Inc. (&#x201c;Omniome&#x201d;), a San Diego-based company developing a highly differentiated, proprietary short-read DNA sequencing platform capable of delivering high accuracy. In connection with the acquisition, all outstanding equity securities of Omniome were cancelled in exchange for approximately $315.7 million in cash, 8,911,580 shares of our common stock with a fair value of $249.4 million and contingent consideration with a fair value of $168.6 million. The fair value of the 8,911,580 common shares issued was determined based on the closing market price of PacBio&#x2019;s common shares on the acquisition date.In addition, approximately $18.9 million, comprised of $7.4 million of cash, 226,811 shares of our common stock with a fair value of $6.3 million, and $5.2 million related to contingent consideration, was accounted for as a one-time post acquisition stock-based compensation expense. This stock-based compensation expense was due to accelerated vesting of Omniome stock awards in connection with the acquisition.Total consideration transferred for the acquisition is as follows (in thousands):     Total cash paid$ 315,703Fair value of share consideration  249,435Fair value of contingent consideration  168,574Less: Stock-based compensation expense excluded from consideration transferred  (18,923)Total consideration transferred$ 714,789   The contingent consideration of $200 million (composed of $100 million in cash and $100 million in shares of our common stock) is due upon the achievement of a milestone, defined as the first commercial shipment to a customer of a nucleotide sequencing platform, comprising both an instrument and related consumables, that utilizes SBB technology. The number of shares of stock to be issued will be determined using the volume-weighted average of the trading prices of our common stock for the twenty trading days ending with and including the trading day that is two days immediately prior to the achievement of the milestone. Of the $100 million in shares of our common stock to be issued as part of the milestone, $4.1 million is attributable to stock options issued by PacBio in replacement of Omniome&#x2019;s unvested options as part of the transaction.The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized in our Consolidated Statements of Operations and Comprehensive (Loss) Income. The fair value of the contingent consideration liability, with the assistance from a third-party valuation firm, is based on a scenario-based method which considers a range of possible outcomes and their assigned probabilities of occurrence. The potential outcomes are discounted to present value at a discount rate equal to the sum of the term-matched risk-free-interest rate plus PacBio&#x2019;s credit spread.  The acquisition was accounted for as a business combination and, accordingly, the total fair value of the consideration transferred was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values on the acquisition date. The major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):    Cash and cash equivalents$ 15,338Property and equipment, net   6,123Operating lease right-of-use assets, net   18,095In-process research and development ("IPR&amp;D")  400,000Goodwill  390,665Other assets  3,203Deferred income tax liability  (91,814)Liabilities assumed  (26,821)Total consideration transferred$ 714,789   The purchase price allocation is preliminary. We continue to collect information regarding certain estimates and assumptions, including potential liabilities and contingencies. We will recognize adjustments to the preliminary amounts with a corresponding adjustment to goodwill in the reporting period in which the adjustments to the preliminary amounts are determined over a period not to exceed twelve months.During the year ended December 31, 2021, we recorded a measurement period adjustment of $1.6 million to decrease goodwill and a corresponding $0.4 million to decrease the deferred tax liability on the Consolidated Balance Sheet, and a $1.2 million decrease to our benefit from income taxes on the Consolidated Statements of Operations and Comprehensive (Loss) Income. The measurement period adjustment was due to new information that became available to us upon the completion of the IRC Section 382 Tax Study, where we identified additional net operating losses that are available to us from acquired assets. Refer to Note 9. Income Taxes for more information.The goodwill recognized was primarily attributable to the assembled workforce and synergies that are expected to occur from the integration of Omniome and is not deductible for income tax purposes. We allocated $400 million of the purchase price to acquired in-process research and development.  The fair value of the IPR&amp;D was determined, with the assistance of a third-party valuation firm, using an income approach based on a forecast of expected future cash flows. Expected future cash flows utilize significant assumptions such as assumed revenue growth, discount rate and obsolescence factors. The IPR&amp;D will remain on our consolidated balance sheet as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development activities. During the development period following the acquisition, IPR&amp;D will not be amortized, but instead will be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.We incurred costs related to the Omniome acquisition of approximately $12.0 million during the twelve months ended December 31, 2021, which are included in merger-related costs on the Consolidated Statement of Operations and Comprehensive (Loss) Income.Separately, in connection with the Omniome acquisition, on September 20, 2021, we issued and sold 11,214,953 shares of common stock in a private placement transaction at a price of $26.75 per share, for aggregate proceeds of approximately $294.8 million, net of issuance costs of approximately $5.2 million.  We were also required to register the private placement shares for resale following the closing of the merger. The following unaudited pro forma financial information presents combined results of operations for each of the periods presented as if Omniome had been acquired as of the beginning of the comparable fiscal year prior to the year of acquisition, giving effect on a pro forma basis to the purchase accounting adjustments such as $12.0 million of PacBio acquisition-related costs, $18.9 million of stock-based compensation expense related to acceleration of certain Omniome stock options not attributable to pre-combination service, and a $91.0 million one-time income tax benefit from the reduction of our deferred tax asset valuation allowance resulting from the Omniome acquisition, as well as a pro forma adjustment to reflect $16.7 million of Omniome&#x2019;s acquisition-related costs. The unaudited pro forma information presented below is for informational purposes only and is not necessarily indicative of the consolidated results of the combined business had the acquisition actually occurred at the beginning of the fiscal year 2020 or the results of future operations of the combined business.The following table summarizes the unaudited pro forma financial information:         Years Ended December 31,(in thousands, except per share amounts)2021 2020      Pro forma total revenue$ 130,513 $ 78,893Pro forma net (loss) income$ (278,451) $ 17,510Pro forma net (loss) income per share - basic and diluted$ (1.27) $ 0.09Our consolidated financial statements include the results of operations for Omniome beginning September 20, 2021. Since the date of acquisition, revenues of $0 and a net loss of $15.6 million from the acquired Omniome business have been included in our Consolidated Statement of Operations and Comprehensive (Loss) Income for the twelve months ended December 31, 2021.Circulomics, Inc.On July 20, 2021, we acquired Circulomics Inc. (&#x201c;Circulomics&#x201d;), a Maryland-based biotechnology company focused on delivering highly differentiated sample preparation products that enable genomic workflows.  We paid $29.5 million in cash in exchange for all outstanding shares of common stock of Circulomics. We allocated the consideration transferred to the identifiable assets acquired and liabilities assumed based on their respective fair values at the date of the completion of the acquisition. The major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):    Cash and cash equivalents$ 987Property and equipment, net   214Intangible assets  11,360Goodwill  19,309Other assets  467Deferred income tax liability  (2,672)Liabilities assumed  (118)Total consideration transferred$ 29,547The excess of the value of consideration paid over the aggregate fair value of those net assets has been recorded as goodwill. We recognized goodwill of $19.3 million, which is primarily attributable to the synergies expected from capabilities in extraction and sample preparation and is not deductible for income tax purposes.  We recorded $11.4 million for the fair value of acquired intangible assets, of which $11.0 million consists of developed technology. The fair value of the developed technology was determined, with the assistance from a third-party valuation firm, using an income approach based on a forecast of expected future cash flows. The purchase price allocation is preliminary as we continue to collect information with regard to certain estimates and assumptions. We will record adjustments to the fair value of the assets acquired, liabilities assumed and goodwill within the twelve-month measurement period, if necessary.&#160;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-cffb3bc3-9440-4551-8da2-af67e0590627"
      unitRef="Unit12">315700000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="INF"
      id="ct-nonFraction-0f42e2c2-7280-4867-bb78-679df44bf032"
      unitRef="Unit1">8911580</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-e91a9e64-6737-4e2f-ba1e-d170a8d2a756"
      unitRef="Unit12">249400000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <pacb:ContingentConsiderationIncurredDuringPeriod
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-0d0e760e-1aba-44aa-b4e2-892caca7d946"
      unitRef="Unit12">168600000</pacb:ContingentConsiderationIncurredDuringPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="INF"
      id="ct-nonFraction-5023feb1-c92d-42e3-850e-2654c3fa4c91"
      unitRef="Unit1">8911580</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_AwardTypeAxis_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-9f7d0397-039b-42df-925d-0679006f55ae"
      unitRef="Unit12">18900000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_AwardTypeAxis_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-c8ca8ea2-0317-4e89-8727-76ffef2607ad"
      unitRef="Unit12">7400000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_AwardTypeAxis_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="INF"
      id="ct-nonFraction-db84688c-df4f-49f0-bedd-e952763e2a89"
      unitRef="Unit1">226811</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_AwardTypeAxis_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-bb171b94-0fd7-4e08-ad38-92e865ff7743"
      unitRef="Unit12">6300000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <pacb:ContingentConsiderationIncurredDuringPeriod
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_AwardTypeAxis_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-3d065c8f-fadc-41ce-90bc-65c37bd123f6"
      unitRef="Unit12">5200000</pacb:ContingentConsiderationIncurredDuringPeriod>
    <pacb:ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      id="ct-nonNumeric-d42b6fbf-ef03-414a-9dd9-ea0821842b13">   Total cash paid$ 315,703Fair value of share consideration  249,435Fair value of contingent consideration  168,574Less: Stock-based compensation expense excluded from consideration transferred  (18,923)Total consideration transferred$ 714,789   </pacb:ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-b29ee0ae-098d-4951-b427-aa8a88e6ed92"
      unitRef="Unit12">315703000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-e884bcb5-b7b0-49ea-b195-69cf7d3def8d"
      unitRef="Unit12">249435000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <pacb:ContingentConsiderationIncurredDuringPeriod
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-4cf05aa0-f4cf-4655-8d92-c7828164ea98"
      unitRef="Unit12">168574000</pacb:ContingentConsiderationIncurredDuringPeriod>
    <pacb:StockBasedCompensationExpenseExcludedFromConsiderationTransferred
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-a335bb5e-728a-46af-9730-d097f1fadf39"
      unitRef="Unit12">18923000</pacb:StockBasedCompensationExpenseExcludedFromConsiderationTransferred>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-1997c203-a5e5-4edd-81e2-f9a814961130"
      unitRef="Unit12">714789000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_ContingentConsiderationByTypeAxis_pacb_AchievementOfMilestoneMember"
      decimals="-6"
      id="ct-nonFraction-9d182fea-8ec1-49aa-a836-d36e03d19695"
      unitRef="Unit12">200000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_ContingentConsiderationByTypeAxis_pacb_AchievementOfMilestoneMember"
      decimals="-6"
      id="ct-nonFraction-fcf61d6c-96cb-4357-b4aa-ab1752ea1f2f"
      unitRef="Unit12">100000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_ContingentConsiderationByTypeAxis_pacb_AchievementOfMilestoneMember"
      decimals="-6"
      id="ct-nonFraction-5d049a13-b97a-46b5-a3bf-338e5cda47f5"
      unitRef="Unit12">100000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_ContingentConsiderationByTypeAxis_pacb_AchievementOfMilestoneMember"
      decimals="-5"
      id="ct-nonFraction-8f7aa6d5-0f0e-4f8e-9039-d2721666c1c7"
      unitRef="Unit12">100000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_ContingentConsiderationByTypeAxis_pacb_AchievementOfMilestoneMember"
      decimals="-5"
      id="ct-nonFraction-0da89a07-b183-4e82-aa06-8ff6c20ddd8c"
      unitRef="Unit12">4100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      id="ct-nonNumeric-316cbe3a-fbcc-46fd-bb8a-9a8cd0c9ed9c">   Cash and cash equivalents$ 15,338Property and equipment, net   6,123Operating lease right-of-use assets, net   18,095In-process research and development ("IPR&amp;D")  400,000Goodwill  390,665Other assets  3,203Deferred income tax liability  (91,814)Liabilities assumed  (26,821)Total consideration transferred$ 714,789   </us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-31891769-df44-49cf-9af5-ae1a34019d89"
      unitRef="Unit12">15338000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-703a9b89-008c-4cf0-8b4f-afd42512460e"
      unitRef="Unit12">6123000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <pacb:BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-20d2affb-0076-4db5-87b3-b2f50c23304c"
      unitRef="Unit12">18095000</pacb:BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-53b52366-70e1-4fff-97f9-38140a92f370"
      unitRef="Unit12">400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:Goodwill
      contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-001ac643-cf4a-4aa8-9d8a-b960653c581c"
      unitRef="Unit12">390665000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-d068b696-1ac7-405b-b07c-6bc903464cfd"
      unitRef="Unit12">3203000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-39e44d25-3a7e-4ff7-ab9b-2944fda73e2e"
      unitRef="Unit12">91814000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-dfd3eeab-e777-4c9f-951c-67129ccd391f"
      unitRef="Unit12">26821000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-7ef0eafb-5611-4c1b-9ab7-719e7de3f737"
      unitRef="Unit12">714789000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-7136bf13-27d1-47b3-b1bc-367adb5b62d2"
      unitRef="Unit12">-1600000</us-gaap:Goodwill>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpense
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-758b9ba1-d0e5-49f4-a52d-3c344ff0b457"
      unitRef="Unit12">-400000</us-gaap:DeferredTaxLiabilitiesDeferredExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-a1dfdfea-73dd-49a7-ae0f-781700e0f312"
      unitRef="Unit12">-1200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="ct-nonFraction-88e20336-be6e-4dad-8347-e24441081ae1"
      unitRef="Unit12">400000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-6"
      id="ct-nonFraction-49966522-88d1-4a7d-aeff-7b0ae834c7a0"
      unitRef="Unit12">12000000.0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <pacb:IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares
      contextRef="Duration_9_20_2021_To_9_20_2021"
      decimals="INF"
      id="ct-nonFraction-5a4474a3-bbf5-4aea-8d7c-5dab44cc0cd7"
      unitRef="Unit1">11214953</pacb:IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="2"
      id="ct-nonFraction-d828971a-3110-4c82-8481-293e7732f79b"
      unitRef="Unit13">26.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-6712a9a6-7bff-4614-a010-3de224e9b7c1"
      unitRef="Unit12">294800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-1eb38d0d-4361-4879-b0d2-cbe19519f963"
      unitRef="Unit12">5200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-b123d31b-2da1-42f3-9f85-837b5a8041d9"
      unitRef="Unit12">12000000.0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-82a7b72d-0add-4c8f-835d-fb5fea1dbb2c"
      unitRef="Unit12">18900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <pacb:IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-6"
      id="ct-nonFraction-1afdf8aa-3c7c-4241-a444-06630a6bacd5"
      unitRef="Unit12">91000000.0</pacb:IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance>
    <pacb:ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-3abcae01-5ee9-4e94-9d6d-862d78e8d59e"
      unitRef="Unit12">16700000</pacb:ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      id="ct-nonNumeric-88e6b057-e395-4442-8471-6d6b9e055b33">       Years Ended December 31,(in thousands, except per share amounts)2021 2020      Pro forma total revenue$ 130,513 $ 78,893Pro forma net (loss) income$ (278,451) $ 17,510Pro forma net (loss) income per share - basic and diluted$ (1.27) $ 0.09</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-34b50231-a774-4967-9c62-40d1733f76a6"
      unitRef="Unit12">130513000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-7ee23b2f-03a6-4b6a-bb00-1352c6e4df56"
      unitRef="Unit12">78893000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-eabfd9f5-7023-4f5b-a108-ba7a4b4c7c97"
      unitRef="Unit12">-278451000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-3"
      id="ct-nonFraction-730f93c1-2c06-4ad5-85be-5027a3e72f74"
      unitRef="Unit12">17510000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <pacb:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="2"
      id="ct-nonFraction-b241fdd6-f692-47d6-9565-986181b79508"
      unitRef="Unit13">-1.27</pacb:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted>
    <pacb:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="2"
      id="ct-nonFraction-711f5a92-2346-4d78-ab0a-b9679135af6b"
      unitRef="Unit13">0.09</pacb:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-19882983-1f15-4316-b810-1eae1210038d"
      unitRef="Unit12">0</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-5dcf0d2e-4cbd-4ea2-a1d7-760c517dca8c"
      unitRef="Unit12">15600000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="Duration_7_20_2021_To_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember"
      decimals="-5"
      id="ct-nonFraction-265d895c-d67a-4adb-a1e2-f96775e07fa4"
      unitRef="Unit12">29500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <pacb:ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember"
      id="ct-nonNumeric-bc7d2377-69a8-463d-9695-db3a74d09fd0">   Cash and cash equivalents$ 987Property and equipment, net   214Intangible assets  11,360Goodwill  19,309Other assets  467Deferred income tax liability  (2,672)Liabilities assumed  (118)Total consideration transferred$ 29,547</pacb:ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember"
      decimals="-3"
      id="ct-nonFraction-8a74f0e9-1552-458e-a294-8688ec4a299d"
      unitRef="Unit12">987000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember"
      decimals="-3"
      id="ct-nonFraction-fdf7c051-4a1b-4cb4-a5e9-ef73d83f9df1"
      unitRef="Unit12">214000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember"
      decimals="-3"
      id="ct-nonFraction-67530150-4f02-4acc-ad69-71de9a4065c3"
      unitRef="Unit12">11360000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember"
      decimals="-3"
      id="ct-nonFraction-6c3f664e-f6a3-4179-8290-010c7b5d6316"
      unitRef="Unit12">19309000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember"
      decimals="-3"
      id="ct-nonFraction-5e9e59cc-e9bd-4fa8-ad2f-3940e5f1389c"
      unitRef="Unit12">467000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember"
      decimals="-3"
      id="ct-nonFraction-50c8daec-27f3-4a05-aaf0-50efe75642c8"
      unitRef="Unit12">2672000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember"
      decimals="-3"
      id="ct-nonFraction-8049f47c-08e8-424c-9507-4c9cadc92ff3"
      unitRef="Unit12">118000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember"
      decimals="-3"
      id="ct-nonFraction-8e4f5e39-a96b-4f25-ad76-c1b74a0c2bfb"
      unitRef="Unit12">29547000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember"
      decimals="-5"
      id="ct-nonFraction-cd4c5b1d-1431-420a-88b6-369c5d757961"
      unitRef="Unit12">19300000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_7_20_2021"
      decimals="-5"
      id="ct-nonFraction-12c33e59-4edf-4e3b-88ca-5f5bbea5b712"
      unitRef="Unit12">11400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_7_20_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-5"
      id="ct-nonFraction-8751b82c-2d58-433b-ae15-e1ef91f15f73"
      unitRef="Unit12">11000000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <pacb:DevelopmentAndCommercializationAgreementDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-180acdbf-64b6-4ac1-a426-4a257e8fba71">NOTE 3. INVITAE COLLABORATION ARRANGEMENTOn January 12, 2021 we entered into a multi-year Development and Commercialization Agreement (the &#x201c;Development Agreement&#x201d;) with Invitae Corporation (&#x201c;Invitae&#x201d;). Pursuant to the Development Agreement, Invitae is providing certain funding to us to develop products relating to production-scale high-throughput sequencing (&#x201c;Program Products&#x201d;). If Program Products become commercially available, Invitae may purchase the Program Products. In addition to selling the Program Products to Invitae, we will have the right to broadly commercialize Program Products for sale to other customers. Under the Development Agreement, Invitae is funding certain development costs we incur in connection with the Program Products (&#x201c;Program Development Costs&#x201d;). Under the Development Agreement, we will be responsible for conducting a program to develop Program Products, and subsequently for manufacturing the Program Product. We jointly make general decisions regarding the development program with Invitae but we are responsible for research and development activities. The development program is expected to last approximately sixty months but may be shorter or longer.  The primary benefit of the arrangement to Invitae is preferred pricing on the Program Products. Each Program Product will have a preferential pricing period, which will not exceed four years from the date of the first delivery of that Program Product (&#x201c;Preferential Pricing Period&#x201d;). During the Preferential Pricing Period for each Program Product, we are obligated to sell the Program Product at a substantial discount to Invitae until a multiple of the contribution received from Invitae is repaid. For a specified period after the end of the Preferential Pricing Period, we have arranged to sell the Program Product to Invitae at a higher price, as determined by a formula, than the price during the Preferential Pricing Period (&#x201c;Extended Pricing Period&#x201d;).  The Extended Pricing Periods will terminate early if Invitae does not meet certain volume minimums.We and Invitae may terminate the Development Agreement if the other party remains in material breach of the Development Agreement following a cure period to remedy the material breach and certain other circumstances by each party, including circumstances where Invitae may terminate for delays, intellectual property concerns, our change in control, or without cause. In certain termination circumstances, (i) we will be obligated to refund all or a portion of the development costs advanced by Invitae and/or (ii) we will owe Invitae a share of the revenue that may be generated from the sale of the Program Products to third parties if and when they are commercialized, until such time as Invitae has recouped the amounts paid to us, and in certain circumstances, a mutually agreed return.  We have incurred and expect to incur significant development costs over the duration of the Development Agreement. There can be no assurances that the development program will be successful or that the Program Products will become ready for commercial sale.The contract is accounted for in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers as the primary benefit from the arrangement to Invitae is the ability to procure the Program Products during the Preferential Pricing Period at substantial discounts. Invitae is not expected to substantially benefit from the intellectual property developed under the arrangement, or benefit from other goods or services during the development period. We will recognize proportionate amounts of the material right in revenue as the performance obligations are satisfied, which is when Invitae places purchase orders for Program Products and the associated goods or services are delivered. Discounts that are not expected to be used will be recognized consistent with the guidance in Topic 606 relating to breakage, in proportion to the expected purchases by Invitae. Any remaining unused discounts will be recognized when they expire. All amounts received from Invitae are initially deferred and accumulated in deferred revenue, non-current. As of December 31, 2021, we have recognized payments received from Invitae of $23.5 million in deferred revenue, non-current, on the Consolidated Balance Sheet. Costs incurred to develop the Program Products are research and development costs and are expensed as incurred. There were no capitalized origination or fulfilment costs related to the arrangement with Invitae that are eligible to be capitalized. </pacb:DevelopmentAndCommercializationAgreementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_srt_MajorCustomersAxis_pacb_InvitaeCorporationMember"
      decimals="-5"
      id="ct-nonFraction-d9adb758-5dda-418e-b015-702270e5fb73"
      unitRef="Unit12">23500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <pacb:MergerTermination
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-af7590ab-fb86-4d4f-b6c7-8b3eb47d7790">NOTE 4. TERMINATION OF MERGER WITH ILLUMINAOn November 1, 2018, we entered into an Agreement and Plan of Merger (as amended, the &#x201c;Illumina Merger Agreement&#x201d;) with Illumina, Inc. (&#x201c;Illumina&#x201d;) and FC Ops Corp., a wholly owned subsidiary of Illumina (&#x201c;Illumina Merger Sub&#x201d;). On January 2, 2020, we, Illumina and Illumina Merger Sub, entered into an agreement to terminate the Merger Agreement (the &#x201c;Termination Agreement&#x201d;).  Continuation Advances from IlluminaAs part of the Termination Agreement, Illumina paid us cash payments (&#x201c;Continuation Advances&#x201d;) of $18.0 million during the fourth quarter of 2019 and $34.0 million during the first quarter of 2020. We recorded the $34.0 million and $18.0 million as non-operating income in the Consolidated Statements of Operations and Comprehensive (Loss) Income for the years ended December 31, 2020 and 2019, respectively. Up to the full $52.0 million of Continuation Advances paid to us were repayable without interest to Illumina if, within two years of March 31, 2020, we entered into, or consummated a Change of Control Transaction or raised at least $100 million in a single equity or debt financing (that may have multiple closings), with the amount repayable dependent on the amount raised by us. Resulting from the issuance and sale of $900 million of 1.50% Convertible Senior Notes due February 15, 2028, $52.0 million of Continuation Advances were paid without interest to Illumina in February 2021 and recorded a non-operating expense in the Consolidated Statements of Operations and Comprehensive (Loss) Income for the year ended December 31, 2021. Please refer to Note 1. Organization and Significant Accounting Policies for the accounting treatment of the Continuation Advances.Reverse Termination Fee from IlluminaAs part of the Termination Agreement, Illumina paid us a $98.0 million termination fee (the &#x201c;Reverse Termination Fee&#x201d;), from which we paid our financial advisor associated fees of $6.0 million in April 2020. Pursuant to the Termination Agreement, in the event that, on or prior to September 30, 2020, we entered into a definitive agreement providing for, or consummated, a Change of Control Transaction, then we may have been required to repay the Reverse Termination Fee (without interest) to Illumina in connection with the consummation of such Change of Control Transaction. As indicated in ASC 450, Contingencies, a gain contingency usually is not recognized in the financial statements until the period in which all contingencies are resolved and the gain is realizable. As such, we deferred the gain from the Reverse Termination Fee from Illumina until the date when the associated contingency lapsed. On October 1, 2020, the contingency clauses lapsed and we recorded the $98.0 million as a part of non-operating income in the fourth quarter of 2020.&#160;</pacb:MergerTermination>
    <pacb:ProceedsFromContractTermination
      contextRef="Duration_10_1_2019_To_12_31_2019_dei_LegalEntityAxis_pacb_IlluminaFcOpsCorpMember"
      decimals="-6"
      id="ct-nonFraction-2a3c34f4-0cec-4d35-8f7c-142c60356485"
      unitRef="Unit12">18000000.0</pacb:ProceedsFromContractTermination>
    <pacb:ProceedsFromContractTermination
      contextRef="Duration_1_1_2020_To_3_31_2020_dei_LegalEntityAxis_pacb_IlluminaFcOpsCorpMember"
      decimals="-6"
      id="ct-nonFraction-e83c2576-1f90-4330-b624-9ad35c72c1fd"
      unitRef="Unit12">34000000.0</pacb:ProceedsFromContractTermination>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_pacb_IlluminaFcOpsCorpMember"
      decimals="-5"
      id="ct-nonFraction-075847f3-35bf-45f8-b7c1-190d2d0bab19"
      unitRef="Unit12">34000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_dei_LegalEntityAxis_pacb_IlluminaFcOpsCorpMember"
      decimals="-5"
      id="ct-nonFraction-99210e34-7166-431f-b961-53a61d00b868"
      unitRef="Unit12">18000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <pacb:ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace
      contextRef="As_Of_3_31_2020"
      decimals="-6"
      id="ct-nonFraction-c0fbb82d-8546-45bd-8506-e967ebf00f88"
      unitRef="Unit12">52000000.0</pacb:ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace>
    <pacb:MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-6"
      id="ct-nonFraction-8fdea957-1aea-41fb-af95-9704275c59ea"
      unitRef="Unit12">100000000</pacb:MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="-6"
      id="ct-nonFraction-9199911e-08ec-45d3-b0d0-1d716fbd8e41"
      unitRef="Unit12">900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="INF"
      id="ct-nonFraction-78cbe027-ca29-4d52-b969-2f1ca7b03ae3"
      unitRef="Unit15">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      id="ct-nonNumeric-b5002bc6-986f-4d3f-b768-d6ecdf7594f6">2028-02-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:GainLossOnContractTermination
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-6"
      id="ct-nonFraction-702d1b36-baf9-419c-b7e9-a4a8ba833ed7"
      unitRef="Unit12">-52000000.0</us-gaap:GainLossOnContractTermination>
    <us-gaap:ProceedsFromFeesReceived
      contextRef="Duration_4_20_2020_To_4_20_2020"
      decimals="-5"
      id="ct-nonFraction-86dd5204-25b2-498a-b59d-6295ad270faa"
      unitRef="Unit12">98000000.0</us-gaap:ProceedsFromFeesReceived>
    <pacb:PaymentsForAdvisorFees
      contextRef="Duration_4_20_2020_To_4_20_2020"
      decimals="-5"
      id="ct-nonFraction-8628e126-3117-46c6-8c82-7b1d78b189f0"
      unitRef="Unit12">6000000.0</pacb:PaymentsForAdvisorFees>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_10_1_2020_To_12_31_2020"
      decimals="-6"
      id="ct-nonFraction-cec500bb-e33c-4b07-ba7d-56fc8df1b3b1"
      unitRef="Unit12">98000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-8d344414-e3d7-43e3-9ad1-cadaaf8b8321">NOTE 5. FINANCIAL INSTRUMENTS Fair Value of Financial InstrumentsFair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy established under GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: &#xf0b7;Level&#160;1: quoted prices in active markets for identical assets or liabilities;&#xf0b7;Level&#160;2: inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and&#xf0b7;Level&#160;3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers.&#160;Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities. Assets and Liabilities Measured at Fair Value on a Recurring BasisThe following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of&#160;December 31, 2021 and December 31, 2020 respectively:                                                   December 31, 2021 December 31, 2020 (in thousands)Level 1 Level&#160;2 Level 3 Total Level 1 Level&#160;2 Level 3 Total Assets                        Cash and cash equivalents:                        Cash and money market funds $ 327,315&#160; $ &#x2014; $ &#x2014; $ 327,315&#160; $ 43,040&#160; $ &#x2014; $ &#x2014; $ 43,040&#160; Commercial paper   &#x2014;   133,185&#160;   &#x2014;   133,185&#160;   &#x2014;   32,537&#160;   &#x2014;   32,537&#160; U.S. government &amp; agency securities  &#x2014;   225&#160;   &#x2014;   225&#160;   &#x2014;   170&#160;   &#x2014;   170&#160; U.S. Treasury security  &#x2014;   &#x2014;   &#x2014;   &#x2014;   &#x2014;   5,864&#160;   &#x2014;   5,864&#160; Total cash and cash equivalents   327,315&#160;   133,410&#160;   &#x2014;   460,725&#160;   43,040&#160;   38,571&#160;   &#x2014;   81,611&#160; Investments:                        Commercial paper   &#x2014;   187,632&#160;   &#x2014;   187,632&#160;   &#x2014;   112,644&#160;   &#x2014;   112,644&#160; Corporate debt securities   &#x2014;   8,968&#160;   &#x2014;   8,968&#160;   &#x2014;   17,456&#160;   &#x2014;   17,456&#160; U.S. government &amp; agency securities  &#x2014;   387,075&#160;   &#x2014;   387,075&#160;   &#x2014;   107,103&#160;   &#x2014;   107,103&#160; Total investments   &#x2014;   583,675&#160;   &#x2014;   583,675&#160;   &#x2014;   237,203&#160;   &#x2014;   237,203&#160; Short-term restricted cash:                        Cash   500&#160;   &#x2014;   &#x2014;   500&#160;   836&#160;   &#x2014;   &#x2014;   836&#160; Long-term restricted cash:                        Cash   4,592&#160;   &#x2014;   &#x2014;   4,592&#160;   3,500&#160;   &#x2014;   &#x2014;   3,500&#160; Total assets measured at fair value $ 332,407&#160; $ 717,085&#160; $ &#x2014; $ 1,049,492&#160; $ 47,376&#160; $ 275,774&#160; $ &#x2014; $ 323,150&#160;                          Liabilities                        Continuation advances $ &#x2014; $ &#x2014; $ &#x2014; $ &#x2014; $ &#x2014; $ &#x2014; $ &#x2014; $ &#x2014; Contingent consideration  &#x2014;   &#x2014;   169,717&#160;   169,717&#160;   &#x2014;   &#x2014;   &#x2014;   &#x2014; Total liabilities measured at fair value $ &#x2014; $ &#x2014; $ 169,717&#160; $ 169,717&#160; $ &#x2014; $ &#x2014; $ &#x2014; $ &#x2014; We classify contingent consideration, which was incurred in connection with the acquisition of Omniome, within Level 3 as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value.  On a quarterly basis, we estimate the fair value of the contingent consideration liability by discounting the probability-weighted outcomes to present value using an estimate of our borrowing rate and the risk-free rate. The potential outcomes of milestone achievement dates are within the period from December 31, 2022 to June 30, 2025. A decrease in the probability of an earlier scenario within this range would result in a decrease in the fair value of the liability.  The discount rates used are the sum of the U.S. risk-free rate and the estimated subordinated credit spread for B- and B credit rating, which ranges from 4.8% to 5.5%. Changes in our estimated subordinated credit spread can result in changes in the fair value of the contingent consideration liability, where a lower credit spread may result in an increased liability valuation.Changes in the estimated fair value of the contingent consideration liability for the year ended December 31, 2021 were as follows:    (in thousands)Level 3Beginning balance as of January 1, 2021 -Acquisition of Omniome 168,574Change in estimated fair value 1,143Ending balance as of December 31, 2021 169,717 Changes to the fair value are recorded as the Change in fair value of contingent consideration in the Consolidated Statement of Operations and Comprehensive (Loss) Income.As of December 31, 2020, we classified the Continuation Advances, which were incurred in connection with the Illumina Merger Agreement and were subject to repayment under certain circumstances, as a financial liability and were reported at fair value. The estimated fair value of the liability related to the Continuation Advances was determined using Level 3 inputs, or significant unobservable inputs. Management assessed the fair value of this financial instrument to be zero at December 31, 2020.We were first approached by SB Northstar LP during the quarter ended March 31, 2021 regarding a potential convertible debt transaction.  As discussed further below in Note 7. Convertible Senior Notes, in February 2021, we entered into an investment agreement with SB Northstar LP for the issuance and sale of $900 million of 1.50% Convertible Senior Notes due February 15, 2028. As a result, $52.0 million of Continuation Advances were repaid without interest to Illumina in February 2021 and recorded as a non-operating expense in the Consolidated Statements of Operations and Comprehensive (Loss) Income for the year ended December 31, 2021. There was no further liability exposure for Continuation Advances as of December 31, 2021.  For the year ended December 31, 2021, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and our valuation techniques did not change compared to the prior year. As discussed above, we recorded a contingent consideration liability in connection with our acquisition of Omniome during the year ended December 31, 2021.  Cash, Cash Equivalents and InvestmentsThe following table summarizes our cash, cash equivalents and investments as of December&#160;31, 2021 and 2020:                         As of December 31, 2021    Gross Gross   Amortized unrealized unrealized Fair(in thousands) Cost  gains  losses  Value Cash and cash equivalents:           Cash and money market funds$ 327,316 $ &#x2014; $ &#x2014; $ 327,316Commercial paper   133,190   &#x2014;   (5)   133,185U.S. government &amp; agency securities  225   &#x2014;   &#x2014;   224Total cash and cash equivalents   460,731   &#x2014;   (5)   460,725Investments:           Commercial paper   187,705   &#x2014;   (73)   187,632Corporate debt securities   8,964   9   (5)   8,968U.S. government &amp; agency securities  388,088   1   (1,014)   387,075Total investments   584,757   10   (1,092)   583,675Total cash, cash equivalents and investments $ 1,045,488 $ 10 $ (1,097) $ 1,044,400Short-term restricted cash:           Cash $ 500 $ &#x2014; $ &#x2014; $ 500Long-term restricted cash:           Cash $ 4,592 $ &#x2014; $ &#x2014; $ 4,592             As of December 31, 2020    Gross Gross   Amortized unrealized unrealized Fair(in thousands) Cost  gains  losses  Value Cash and cash equivalents:           Cash and money market funds$ 43,040 $ &#x2014; $ &#x2014; $ 43,040Commercial paper  32,538   &#x2014;   (1)   32,537U.S. government &amp; agency securities  170   &#x2014;   &#x2014;   170U.S. Treasury security  5,864   &#x2014;   &#x2014;   5,864Total cash and cash equivalents   81,612   &#x2014;   (1)   81,611Investments:           Commercial paper   112,648   4   (8)   112,644Corporate debt securities   17,360   96   &#x2014;   17,456U.S. government &amp; agency securities  107,109   6   (12)   107,103Total investments   237,117   106   (20)   237,203Total cash, cash equivalents and investments $ 318,729 $ 106 $ (21) $ 318,814Short-term restricted cash:           Cash $ 836 $ &#x2014; $ &#x2014; $ 836Long-term restricted cash:           Cash $ 3,500 $ &#x2014; $ &#x2014; $ 3,500 The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of December 31, 2021:   (in thousands)Fair ValueDue in one year or less $ 595,063Due after one year through 5 years   122,022Total investments $ 717,085    Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.&#160;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-26b872e4-38c5-49b2-a318-00eef67f5d56">                                                   December 31, 2021 December 31, 2020 (in thousands)Level 1 Level&#160;2 Level 3 Total Level 1 Level&#160;2 Level 3 Total Assets                        Cash and cash equivalents:                        Cash and money market funds $ 327,315&#160; $ &#x2014; $ &#x2014; $ 327,315&#160; $ 43,040&#160; $ &#x2014; $ &#x2014; $ 43,040&#160; Commercial paper   &#x2014;   133,185&#160;   &#x2014;   133,185&#160;   &#x2014;   32,537&#160;   &#x2014;   32,537&#160; U.S. government &amp; agency securities  &#x2014;   225&#160;   &#x2014;   225&#160;   &#x2014;   170&#160;   &#x2014;   170&#160; U.S. Treasury security  &#x2014;   &#x2014;   &#x2014;   &#x2014;   &#x2014;   5,864&#160;   &#x2014;   5,864&#160; Total cash and cash equivalents   327,315&#160;   133,410&#160;   &#x2014;   460,725&#160;   43,040&#160;   38,571&#160;   &#x2014;   81,611&#160; Investments:                        Commercial paper   &#x2014;   187,632&#160;   &#x2014;   187,632&#160;   &#x2014;   112,644&#160;   &#x2014;   112,644&#160; Corporate debt securities   &#x2014;   8,968&#160;   &#x2014;   8,968&#160;   &#x2014;   17,456&#160;   &#x2014;   17,456&#160; U.S. government &amp; agency securities  &#x2014;   387,075&#160;   &#x2014;   387,075&#160;   &#x2014;   107,103&#160;   &#x2014;   107,103&#160; Total investments   &#x2014;   583,675&#160;   &#x2014;   583,675&#160;   &#x2014;   237,203&#160;   &#x2014;   237,203&#160; Short-term restricted cash:                        Cash   500&#160;   &#x2014;   &#x2014;   500&#160;   836&#160;   &#x2014;   &#x2014;   836&#160; Long-term restricted cash:                        Cash   4,592&#160;   &#x2014;   &#x2014;   4,592&#160;   3,500&#160;   &#x2014;   &#x2014;   3,500&#160; Total assets measured at fair value $ 332,407&#160; $ 717,085&#160; $ &#x2014; $ 1,049,492&#160; $ 47,376&#160; $ 275,774&#160; $ &#x2014; $ 323,150&#160;                          Liabilities                        Continuation advances $ &#x2014; $ &#x2014; $ &#x2014; $ &#x2014; $ &#x2014; $ &#x2014; $ &#x2014; $ &#x2014; Contingent consideration  &#x2014;   &#x2014;   169,717&#160;   169,717&#160;   &#x2014;   &#x2014;   &#x2014;   &#x2014; Total liabilities measured at fair value $ &#x2014; $ &#x2014; $ 169,717&#160; $ 169,717&#160; $ &#x2014; $ &#x2014; $ &#x2014; $ &#x2014; </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_pacb_CashAndMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="ct-nonFraction-13555178-5c54-4cad-8234-5beed65e16a0"
      unitRef="Unit12">327315000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_pacb_CashAndMoneyMarketFundsMember"
      decimals="0"
      id="ct-nonFraction-0d98a7c4-29c1-49d4-a923-590f3ee249fe"
      unitRef="Unit12">327315000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_pacb_CashAndMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="ct-nonFraction-de52e5a4-42a5-4a44-b5a2-fd312e7448d9"
      unitRef="Unit12">43040000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_pacb_CashAndMoneyMarketFundsMember"
      decimals="0"
      id="ct-nonFraction-b9388566-8f77-40e7-a0c6-7ea5ac3280f4"
      unitRef="Unit12">43040000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="ct-nonFraction-fd84f0d7-4737-4e8a-bea6-fa03c322a110"
      unitRef="Unit12">133185000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember"
      decimals="0"
      id="ct-nonFraction-5be579d8-93ad-404a-8a48-a3083443c013"
      unitRef="Unit12">133185000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="ct-nonFraction-d8829c55-d74c-4209-aa3d-f4b392a1a265"
      unitRef="Unit12">32537000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember"
      decimals="0"
      id="ct-nonFraction-8b58e6b5-cc3c-4db0-a03b-dbdbe0a89658"
      unitRef="Unit12">32537000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="ct-nonFraction-98f750be-17bb-49af-a644-748d54025c3f"
      unitRef="Unit12">225000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="0"
      id="ct-nonFraction-af096940-2a4a-41cb-9117-59b36c2b5cc2"
      unitRef="Unit12">225000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="ct-nonFraction-df9f7ddb-7562-400e-a166-f3b45b540f76"
      unitRef="Unit12">170000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="0"
      id="ct-nonFraction-c5391703-1076-4ce0-a4a4-b10eb63da9af"
      unitRef="Unit12">170000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="ct-nonFraction-2a20278e-8f47-41ba-a760-1b0ce33a1e1c"
      unitRef="Unit12">5864000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="0"
      id="ct-nonFraction-603f4183-c2be-4b81-93c2-0e22ee175832"
      unitRef="Unit12">5864000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="ct-nonFraction-38a1a0ed-0d8e-4ea6-8e0f-7e309f528dd4"
      unitRef="Unit12">327315000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="ct-nonFraction-6b6d03da-d1db-4b7f-b31d-6797275ffa59"
      unitRef="Unit12">133410000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-d358b00f-ac16-4173-8228-1b9ab092f8f9"
      unitRef="Unit12">460725000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="ct-nonFraction-62361fd4-591a-4fd5-89ff-d2d54c7987b2"
      unitRef="Unit12">43040000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="ct-nonFraction-75867037-8337-491c-9f91-d1700d2157eb"
      unitRef="Unit12">38571000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020"
      decimals="0"
      id="ct-nonFraction-afd070c5-6a66-4d79-80aa-320b381400b6"
      unitRef="Unit12">81611000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="ct-nonFraction-5475ca3a-0672-42f5-a772-eca472cbb794"
      unitRef="Unit12">187632000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember"
      decimals="0"
      id="ct-nonFraction-7920cd52-645a-4e49-b594-2ffd8b664597"
      unitRef="Unit12">187632000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="ct-nonFraction-a6689625-7d44-4fbb-baa6-3764aa19d668"
      unitRef="Unit12">112644000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember"
      decimals="0"
      id="ct-nonFraction-c4ca05a9-d9ee-4942-a373-0da46c1a7d02"
      unitRef="Unit12">112644000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="ct-nonFraction-e11fc3a0-5467-496f-9494-dccdaecffc2a"
      unitRef="Unit12">8968000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="0"
      id="ct-nonFraction-1bfaf7c2-7b50-471c-addf-da37375db928"
      unitRef="Unit12">8968000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="ct-nonFraction-7bfd2fb5-0acf-4cdd-90ba-7472843552e0"
      unitRef="Unit12">17456000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="0"
      id="ct-nonFraction-17ee24c8-41d3-4866-9260-337154f83d67"
      unitRef="Unit12">17456000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="ct-nonFraction-1241f6bf-605f-4810-9bfe-995b6e3e1596"
      unitRef="Unit12">387075000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="ct-nonFraction-c70d47d8-2388-4057-b56d-f0177bd8e04b"
      unitRef="Unit12">387075000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="ct-nonFraction-fb374935-c44e-49b0-8e88-a47c6e10e384"
      unitRef="Unit12">107103000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="ct-nonFraction-769c2a65-6f8e-452e-9ce7-f6034ec8d61f"
      unitRef="Unit12">107103000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="ct-nonFraction-2c4bcd16-76a9-4e98-9b1a-9bb6bc886dc6"
      unitRef="Unit12">583675000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-84b6dbec-06af-47c8-ae52-350e47a82037"
      unitRef="Unit12">583675000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="ct-nonFraction-c328bea8-3619-46fc-ad51-20c04ea7c933"
      unitRef="Unit12">237203000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2020"
      decimals="0"
      id="ct-nonFraction-93c91dd0-6d7f-4e69-8206-dc00aba842f6"
      unitRef="Unit12">237203000</us-gaap:InvestmentsFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="ct-nonFraction-aedfe7c9-fa7b-446c-a688-9527396ebd20"
      unitRef="Unit12">500000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-c397831a-f1ed-4f58-9744-e2071201eb04"
      unitRef="Unit12">500000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="ct-nonFraction-cb202487-05f5-4035-96ed-c2b193a9058e"
      unitRef="Unit12">836000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure
      contextRef="As_Of_12_31_2020"
      decimals="0"
      id="ct-nonFraction-7adce2eb-edbd-492f-ba88-91089ef397fb"
      unitRef="Unit12">836000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="ct-nonFraction-c4f9471f-e882-463a-984f-0b0b911b9e50"
      unitRef="Unit12">4592000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-65cd1cdd-f842-4820-92dc-e66d43caedc6"
      unitRef="Unit12">4592000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="ct-nonFraction-e7873aca-9779-42b5-b07e-ecd5eb7d002e"
      unitRef="Unit12">3500000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure
      contextRef="As_Of_12_31_2020"
      decimals="0"
      id="ct-nonFraction-a0309296-bfff-40c2-a226-d513c44f7708"
      unitRef="Unit12">3500000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="ct-nonFraction-65b114ac-3ffa-4c6a-8e4a-046e64a84795"
      unitRef="Unit12">332407000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="ct-nonFraction-c8d3bd24-b83f-4f44-bc39-60e66644f6e8"
      unitRef="Unit12">717085000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-205673a8-b457-433c-803d-3e4b840b890c"
      unitRef="Unit12">1049492000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="ct-nonFraction-81b5143d-216b-42c5-aa73-b794632501a8"
      unitRef="Unit12">47376000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="ct-nonFraction-95494094-9d99-43f4-ada8-c4f62918d642"
      unitRef="Unit12">275774000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020"
      decimals="0"
      id="ct-nonFraction-04064e33-d41a-40bb-93d6-40d6dc8eeae2"
      unitRef="Unit12">323150000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_pacb_ContingentConsiderationMember"
      decimals="0"
      id="ct-nonFraction-49b303b9-28df-4662-8515-e76684ea13a5"
      unitRef="Unit12">169717000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_pacb_ContingentConsiderationMember"
      decimals="0"
      id="ct-nonFraction-db8d1800-dec6-4c54-8262-68fe02b81f01"
      unitRef="Unit12">169717000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="ct-nonFraction-6da24c07-9492-4b1a-9f29-f9f0c1397a91"
      unitRef="Unit12">169717000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-11cdd45e-09aa-4710-be48-622e761210f5"
      unitRef="Unit12">169717000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"
      decimals="INF"
      id="ct-nonFraction-1526ffeb-e8a5-4d87-a5a3-fbca973dd5a5"
      unitRef="Unit15">0.048</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"
      decimals="INF"
      id="ct-nonFraction-7fb0c10d-01b4-47b4-b7d9-ced8bd482710"
      unitRef="Unit15">0.055</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <pacb:ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-85b67614-a8e7-48a7-a70d-797798a73608">  (in thousands)Level 3Beginning balance as of January 1, 2021 -Acquisition of Omniome 168,574Change in estimated fair value 1,143Ending balance as of December 31, 2021 169,717</pacb:ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock>
    <pacb:ContingentConsiderationIncurredDuringPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="ct-nonFraction-e10eff03-4817-4d56-962c-cf6f48b28e57"
      unitRef="Unit12">168574000</pacb:ContingentConsiderationIncurredDuringPeriod>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="ct-nonFraction-fcb34a18-2197-4d0d-92e3-f07b36d3c5dd"
      unitRef="Unit12">1143000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="ct-nonFraction-bfdb8209-7c54-4227-9637-9ac4405e0bb1"
      unitRef="Unit12">169717000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2020"
      decimals="INF"
      id="ct-nonFraction-462006af-548a-4d3c-895a-46cb6728f374"
      unitRef="Unit12">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="-6"
      id="ct-nonFraction-d5c7d230-5648-4894-b61a-5c44e628ea16"
      unitRef="Unit12">900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="INF"
      id="ct-nonFraction-1f78a9c3-17b0-4093-8108-0f75fa505229"
      unitRef="Unit15">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      id="ct-nonNumeric-5a1d3761-ee1e-4042-af45-a657a7030db6">2028-02-15</us-gaap:DebtInstrumentMaturityDate>
    <pacb:RepaymentsOfContractTermination
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="-6"
      id="ct-nonFraction-2004abc7-b0cf-4d2b-ac32-d258da17e4f4"
      unitRef="Unit12">52000000.0</pacb:RepaymentsOfContractTermination>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2021"
      decimals="-6"
      id="ct-nonFraction-ae420a81-f0f8-4c42-95fd-40fed86b2fe2"
      unitRef="Unit12">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-708f53be-f812-412d-b986-90e83692d0d6">                         As of December 31, 2021    Gross Gross   Amortized unrealized unrealized Fair(in thousands) Cost  gains  losses  Value Cash and cash equivalents:           Cash and money market funds$ 327,316 $ &#x2014; $ &#x2014; $ 327,316Commercial paper   133,190   &#x2014;   (5)   133,185U.S. government &amp; agency securities  225   &#x2014;   &#x2014;   224Total cash and cash equivalents   460,731   &#x2014;   (5)   460,725Investments:           Commercial paper   187,705   &#x2014;   (73)   187,632Corporate debt securities   8,964   9   (5)   8,968U.S. government &amp; agency securities  388,088   1   (1,014)   387,075Total investments   584,757   10   (1,092)   583,675Total cash, cash equivalents and investments $ 1,045,488 $ 10 $ (1,097) $ 1,044,400Short-term restricted cash:           Cash $ 500 $ &#x2014; $ &#x2014; $ 500Long-term restricted cash:           Cash $ 4,592 $ &#x2014; $ &#x2014; $ 4,592             As of December 31, 2020    Gross Gross   Amortized unrealized unrealized Fair(in thousands) Cost  gains  losses  Value Cash and cash equivalents:           Cash and money market funds$ 43,040 $ &#x2014; $ &#x2014; $ 43,040Commercial paper  32,538   &#x2014;   (1)   32,537U.S. government &amp; agency securities  170   &#x2014;   &#x2014;   170U.S. Treasury security  5,864   &#x2014;   &#x2014;   5,864Total cash and cash equivalents   81,612   &#x2014;   (1)   81,611Investments:           Commercial paper   112,648   4   (8)   112,644Corporate debt securities   17,360   96   &#x2014;   17,456U.S. government &amp; agency securities  107,109   6   (12)   107,103Total investments   237,117   106   (20)   237,203Total cash, cash equivalents and investments $ 318,729 $ 106 $ (21) $ 318,814Short-term restricted cash:           Cash $ 836 $ &#x2014; $ &#x2014; $ 836Long-term restricted cash:           Cash $ 3,500 $ &#x2014; $ &#x2014; $ 3,500</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_CashAndMoneyMarketFundsMember"
      decimals="-3"
      id="ct-nonFraction-ffcfc8f5-9bb1-4007-a2b9-08f6497d7bf9"
      unitRef="Unit12">327316000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_CashAndMoneyMarketFundsMember"
      decimals="-3"
      id="ct-nonFraction-d134e253-6ecd-40c5-a6c9-ef88e9944f9a"
      unitRef="Unit12">327316000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="ct-nonFraction-472f2b82-e22f-439f-882e-fe3c9006d526"
      unitRef="Unit12">133190000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="ct-nonFraction-04a29bfe-85a8-42d7-8c5c-59a5dc00c582"
      unitRef="Unit12">5000</pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="ct-nonFraction-3579f72f-4d6d-49b5-b27e-d6478a56d37f"
      unitRef="Unit12">133185000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-984bb4ba-f804-43ad-93e6-b4ee2df7a3c4"
      unitRef="Unit12">225000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-666c6d6e-927f-44d8-bf66-67534bba1f31"
      unitRef="Unit12">224000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-a84708ed-411d-4d22-ad20-3b616f09c1fb"
      unitRef="Unit12">460731000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-363e9bbe-edcb-4526-a0a3-33127395b39b"
      unitRef="Unit12">5000</pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-ad90aaf3-b639-4103-b69b-ebb2172ab5f5"
      unitRef="Unit12">460725000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="ct-nonFraction-556cea28-88d9-4e83-8e1b-f4526737245d"
      unitRef="Unit12">187705000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="ct-nonFraction-8da127f4-9fa2-4490-9aed-63045a6b0b39"
      unitRef="Unit12">73000</pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="ct-nonFraction-a1e6198c-3817-424a-9eb3-a7490c98f2cf"
      unitRef="Unit12">187632000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-31cafb06-ef3b-42cc-a6df-c9be78cd211d"
      unitRef="Unit12">8964000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-7e5d7a56-7693-47a8-8e44-387c725c067b"
      unitRef="Unit12">9000</pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-a0604df3-22eb-4718-88a0-ffa0931f9104"
      unitRef="Unit12">5000</pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-bec372df-c76a-4b10-9c50-98c678c25fc7"
      unitRef="Unit12">8968000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-905a888e-aace-4753-a41f-ddf96d44cd78"
      unitRef="Unit12">388088000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-3e4e8c47-9455-4af3-8483-3b7745116f4d"
      unitRef="Unit12">1000</pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-940dcd40-409b-4da2-ba36-558f3f86a0d0"
      unitRef="Unit12">1014000</pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-04af086a-5b0b-4c55-b977-75c3675fe6e3"
      unitRef="Unit12">387075000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember"
      decimals="-3"
      id="ct-nonFraction-778a2ffd-18ad-4c92-a8cf-3bcf4b2485a3"
      unitRef="Unit12">584757000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember"
      decimals="-3"
      id="ct-nonFraction-02159222-34e9-458b-ac18-81e06724d806"
      unitRef="Unit12">10000</pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember"
      decimals="-3"
      id="ct-nonFraction-51d58577-b82e-4dfd-ba10-26f577cd31de"
      unitRef="Unit12">1092000</pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember"
      decimals="-3"
      id="ct-nonFraction-158ab14d-dded-48da-8763-e2548fcf7273"
      unitRef="Unit12">583675000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember"
      decimals="-3"
      id="ct-nonFraction-61a68c74-142b-4c7d-9593-df949fb5f5d1"
      unitRef="Unit12">1045488000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember"
      decimals="-3"
      id="ct-nonFraction-ed9c51a3-cbfa-4ad4-b415-da654348de73"
      unitRef="Unit12">10000</pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember"
      decimals="-3"
      id="ct-nonFraction-9be1953b-d09f-4289-8621-4639635f81ba"
      unitRef="Unit12">1097000</pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember"
      decimals="-3"
      id="ct-nonFraction-2ff8ce93-685d-44f8-8981-0294ee499058"
      unitRef="Unit12">1044400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_ShortTermRestrictedCashMember"
      decimals="-3"
      id="ct-nonFraction-70c2252d-dfb3-47b1-8d3c-d823661d7512"
      unitRef="Unit12">500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_ShortTermRestrictedCashMember"
      decimals="-3"
      id="ct-nonFraction-d6c0bc55-f675-46e6-ae34-e740fc9a1c48"
      unitRef="Unit12">500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_LongTermRestrictedCashMember"
      decimals="-3"
      id="ct-nonFraction-0b7bf337-febc-4e6e-9a18-94c6417aed38"
      unitRef="Unit12">4592000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_LongTermRestrictedCashMember"
      decimals="-3"
      id="ct-nonFraction-c898c1b9-dad2-4a0d-967b-b152898d46bf"
      unitRef="Unit12">4592000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_CashAndMoneyMarketFundsMember"
      decimals="0"
      id="ct-nonFraction-1ad8ba1b-588b-44df-91fb-b6b279b67d01"
      unitRef="Unit12">43040000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_CashAndMoneyMarketFundsMember"
      decimals="0"
      id="ct-nonFraction-569db562-90c3-484b-aed6-2d104c2853f8"
      unitRef="Unit12">43040000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="0"
      id="ct-nonFraction-a7aee793-0374-4ecf-83df-f6b6f81a1731"
      unitRef="Unit12">32538000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="0"
      id="ct-nonFraction-375d05d8-4ba8-45c4-bcc1-54f7015ae98e"
      unitRef="Unit12">1000</pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="0"
      id="ct-nonFraction-80781391-3ac4-4bf0-9cd9-862c5e618823"
      unitRef="Unit12">32537000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-5820220f-5bc8-4011-aade-be550bb5a2f7"
      unitRef="Unit12">170000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-ad1b4c71-8fc1-4b74-8985-bf56b7dc779d"
      unitRef="Unit12">170000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-95e37052-9668-4fe1-a6c0-f8deb5d008e8"
      unitRef="Unit12">5864000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-da196f34-aa43-44bf-a729-68122dc44e33"
      unitRef="Unit12">5864000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-67708776-01ef-436e-bd68-74d4da98b353"
      unitRef="Unit12">81612000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-131cfc73-fe85-4747-bca2-410ef84ca0b6"
      unitRef="Unit12">1000</pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-edbc89ea-9697-41df-b73a-65292e072a76"
      unitRef="Unit12">81611000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-401f9ca8-e7e9-452f-9d48-245838789d6a"
      unitRef="Unit12">112648000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-8c949558-746a-4492-94f7-8723a4036480"
      unitRef="Unit12">4000</pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-654083b5-8d03-4727-a99d-49b6dbca8df3"
      unitRef="Unit12">8000</pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-8d1642e1-9967-4f8b-8739-521f199dec52"
      unitRef="Unit12">112644000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-c3ae5997-20f5-4cc0-ab75-ce8a8edabafa"
      unitRef="Unit12">17360000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-189b50a9-ba67-48c8-accb-7f89ab8e55f6"
      unitRef="Unit12">96000</pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-97f9d490-4ca7-464e-8555-c3e9622f1eae"
      unitRef="Unit12">17456000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-b23ae31a-9c6a-4ecb-81dc-b02505ca78ac"
      unitRef="Unit12">107109000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-29c715eb-6a73-4564-891f-819d2457e680"
      unitRef="Unit12">6000</pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-b0c04e18-2920-4a16-9bc5-8eb45b93f1f1"
      unitRef="Unit12">12000</pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-e0eb57a3-f5d1-4101-9e0c-7de38b7e581e"
      unitRef="Unit12">107103000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember"
      decimals="-3"
      id="ct-nonFraction-42a4ca02-2f9a-48c1-88ae-f05a24065f0e"
      unitRef="Unit12">237117000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember"
      decimals="-3"
      id="ct-nonFraction-ba7d92c0-60c2-44c2-ac9f-5ed435b9158b"
      unitRef="Unit12">106000</pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember"
      decimals="-3"
      id="ct-nonFraction-53c38b5a-ac7d-4066-813e-74a873265914"
      unitRef="Unit12">20000</pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_InvestmentsMember"
      decimals="-3"
      id="ct-nonFraction-ff6e24c9-4304-4d0c-b276-d099c108bee4"
      unitRef="Unit12">237203000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember"
      decimals="-3"
      id="ct-nonFraction-d0329ac1-27ad-4ef4-823a-e30454c2e1ac"
      unitRef="Unit12">318729000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember"
      decimals="-3"
      id="ct-nonFraction-a7c0ae25-26ea-4aca-b00c-78fe0f788402"
      unitRef="Unit12">106000</pacb:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments>
    <pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember"
      decimals="-3"
      id="ct-nonFraction-798f2330-a2b8-42d8-80a6-1822d9c78022"
      unitRef="Unit12">21000</pacb:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember"
      decimals="-3"
      id="ct-nonFraction-9fb3a5ae-ce7e-4ab1-a85e-e9b62935bb68"
      unitRef="Unit12">318814000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_ShortTermRestrictedCashMember"
      decimals="-3"
      id="ct-nonFraction-967d9af1-e263-4fd9-b1ed-f74b7f6332b6"
      unitRef="Unit12">836000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_ShortTermRestrictedCashMember"
      decimals="-3"
      id="ct-nonFraction-d0dba90b-93d8-4e7c-a4bd-5df0b316fa9e"
      unitRef="Unit12">836000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_LongTermRestrictedCashMember"
      decimals="-3"
      id="ct-nonFraction-5d9f3ee5-9f4c-4307-b49e-d6f048d5d168"
      unitRef="Unit12">3500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_pacb_LongTermRestrictedCashMember"
      decimals="-3"
      id="ct-nonFraction-aa84dea2-72e0-4450-8daa-00bb5193f8b7"
      unitRef="Unit12">3500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-d7dd34d4-dde5-49e4-8b1c-76bd20917ac3">   (in thousands)Fair ValueDue in one year or less $ 595,063Due after one year through 5 years   122,022Total investments $ 717,085    </us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-8b534ce6-5580-4038-b44a-7ea92e59fce3"
      unitRef="Unit12">595063000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-0d8b7eea-6cf0-45d7-92e0-fb05c587210c"
      unitRef="Unit12">122022000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-186d140c-8bb0-4266-9284-245378ffe806"
      unitRef="Unit12">717085000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-38b9391e-3aa5-46bd-a952-e7f7dac1fa47">NOTE 6. BALANCE SHEET COMPONENTS Short-term restricted cash As of December 31, 2021, the short-term restricted cash balance of $0.5 million was comprised of security deposits for the credit cards of employees. As of December 31, 2020, the short-term restricted cash balance of $0.8 million was comprised of $0.5 million for a customer deposit and $0.3 million for a security deposit for the credit cards of employees. In connection with the acquisition of Omniome in September 2021, we acquired $0.2 million of short-term restricted cash consisting of a security deposit for credit cards of Omniome employees.InventoryAs of December 31, 2021 and 2020, our inventory consisted of the following components:              December 31, (in thousands)2021 2020Purchased materials$ 7,993 $ 3,531Work in process  8,611   6,651Finished goods  7,995   4,048Inventory$ 24,599 $ 14,230Property and Equipment, NetAs of December&#160;31, 2021 and 2020, our property and equipment, net, consisted of the following components:              December 31,(in thousands)2021 2020Laboratory equipment and machinery $ 31,534 $ 24,948Leasehold improvements  31,114   29,931Computer equipment  15,059   12,400Software  5,578   4,940Furniture and fixtures  3,202   2,434Construction in progress  2,303   137   88,790   74,790Less: Accumulated depreciation   (56,286)   (49,891)Property and equipment, net $ 32,504 $ 24,899Depreciation expense during the years ended December 31, 2021, 2020 and 2019 was $7.2 million, $6.4 million and $7.3 million, respectively. Long-term restricted cash For our facility located at 1305 O&#x2019;Brien Drive, Menlo Park, California (the &#x201c;O&#x2019;Brien Lease&#x201d;), we were required to establish a letter of credit for the benefit of the landlord and to submit $4.5 million as a deposit for the letter of credit in October 2015. Subsequently, pursuant to the terms of the O&#x2019;Brien Lease, beginning on May 1, 2019, the amount of the letter of credit was reduced by $0.5 million each year thereafter on May 1. As such, $3.0 million and $3.5 million was recorded in long-term restricted cash related to the O&#x2019;Brien Lease in the Consolidated Balance Sheets as of December 31, 2021 and December 31, 2020, respectively.  In connection with the acquisition of Omniome in September 2021, we acquired $1.6 million of long-term restricted cash related to a letter of credit established for a facility lease.Goodwill and intangible assetsGoodwillGoodwill arises from business combinations and represents the excess of the purchase price over the fair value of the net assets and other identifiable intangible assets acquired. The fair values of net tangible assets and intangible assets acquired are based upon preliminary valuations and our estimates and assumptions are subject to change within the measurement period (potentially up to one year from the acquisition date).The following table presents the changes in the carrying amount of goodwill for the periods indicated (in thousands):Wa   Balance as of December 31, 2020$ -Acquisition of Omniome  390,665Acquisition of Circulomics  19,309Balance as of December 31, 2021$ 409,974Acquired Intangible AssetsIntangible assets include acquired in-process research and development (IPR&amp;D) of $400 million as a result of the Omniome acquisition in September 2021. In addition to IPR&amp;D, we had the following acquired definite-lived intangible assets as of December 31, 2021 (in thousands, except years):             Estimated  Gross    Net Useful Life Carrying Accumulated Carrying (in years) Amount Amortization AmountDeveloped technology15 $ 11,000 $ (306) $ 10,694Customer relationships2   360   (75)   285Total  $ 11,360 $ (381) $ 10,979           Amortization expense of intangibles was $0.4 million for the year ended December 31, 2021. We had no amortization expense of intangibles for the years ended December 31, 2020 and 2019.The estimated future amortization expense of acquisition-related intangible assets with definite lives is estimated as follows (in thousands):       2022$ 9132023  8382024  7332025  7332026  7332027 and thereafter  7,029Total$ 10,979    Accrued ExpensesAs of December&#160;31, 2021 and 2020, our accrued expenses consisted of the following components:              December 31,(in thousands)2021 2020Salaries and benefits$ 25,282 $ 15,261Accrued product development costs  1,936   415Accrued interest payable  5,100   &#x2014;Inventory accrual  108   218Warranty  594   161Accrued professional services and legal fees  1,640   726Other   1,601   569Accrued expenses $ 36,261 $ 17,350Deferred RevenueAs of December 31, 2021, we had a total of $ 36.0 million of deferred revenue, $11.0 million of which was recorded as deferred revenue, current and primarily relates to deferred service contract revenues to be recognized over the next year and the remaining $25.0 million was recorded as deferred revenue, non-current. Of the deferred revenue, non-current balance, $23.5 million relates to payments received under the Invitae collaboration and $1.5 million primarily relates to deferred service contract revenues and is scheduled to be recognized in the next 5 years. Revenue recorded in the year ended&#160;December 31, 2021 includes&#160;$8.6 million of previously deferred revenue that was included in &#x201c;Deferred revenue, current&#x201d; as of&#160;December&#160;31, 2020. Contract assets as of&#160;December 31, 2021 and December 31, 2020 were not material.As of December 31, 2021, we had a total of $0.7 million of deferred commissions included in &#x201c;Prepaid expenses and other current assets&#x201d; which is recognized as the related revenue is recognized. Additionally, as a practical expedient, we expense costs to obtain a contract as incurred if the amortization period would have been a year or less.Term LoansIn connection with the acquisition of Omniome, we acquired $1.3 million in short-term debt and $3.0 million in long-term debt relating to a term loan facility that Omniome obtained in April 2020. Borrowings on the term loan facility were used to fund Omniome&#x2019;s purchases of equipment, which serves as collateral. Each term loan has a term of 43 months and bears a fixed interest rate of approximately 17% annually. The fee for the elective option to prepay all, but not less than all, of the borrowed amounts at any time after the 24th month and before the 43rd month after the commencement date, is 4% of the outstanding loan balance. Payments are made in equal monthly installments including principal and interest. As of December 31, 2021, the carrying value of term loans outstanding was $3.9 million. The related long-term portion of $2.3 million was recorded as part of &#x201c;Other liabilities, non-current&#x201d; and the short-term portion of $1.6 million was recorded as part of &#x201c;Other liabilities, current&#x201d; on the Consolidated Balance Sheet. The interest expense was $0.2 million for the year ended December 31, 2021, which was included as part of interest expense in the Consolidated Statement of Operations and Comprehensive (Loss) Income.As of December 31, 2021, the future principal payments remaining on term loans was the following:    (in thousands)  2022$ 1,6082023  1,8422024  490Total$ 3,940 Other liabilities, currentAs of December&#160;31, 2021 and 2020, our Other liabilities, current consisted of the following components:         December 31,(in thousands)2021 2020Accrued ESPP$ 3,598 $ 2,037Other   2,161   2,482Other liabilities, current$ 5,759 $ 4,519&#160;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2021_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_SecurityDepositMember"
      decimals="-5"
      id="ct-nonFraction-34a4d4bb-c252-4452-be75-c0b122fd834a"
      unitRef="Unit12">500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-5"
      id="ct-nonFraction-22363acd-b9ec-4b58-ad95-a4c4e9fb3d25"
      unitRef="Unit12">800000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_CustomerDepositMember"
      decimals="-5"
      id="ct-nonFraction-0f93f500-99cb-4971-abcf-136d733a5b90"
      unitRef="Unit12">500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_SecurityDepositMember"
      decimals="-5"
      id="ct-nonFraction-cead3ba3-eacf-4070-b69e-b2f4c23bc71e"
      unitRef="Unit12">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_pacb_SecurityDepositMember"
      decimals="-5"
      id="ct-nonFraction-f3798d15-507f-4528-9430-264a1ea27c3b"
      unitRef="Unit12">200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-a71f30fd-fae9-4c9e-bfca-7a41fe427119">             December 31, (in thousands)2021 2020Purchased materials$ 7,993 $ 3,531Work in process  8,611   6,651Finished goods  7,995   4,048Inventory$ 24,599 $ 14,230</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-b73b23eb-ddd4-48df-8030-f71d78f72838"
      unitRef="Unit12">7993000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-7e5a93dc-c584-4ba6-8167-11ec7ddf93e0"
      unitRef="Unit12">3531000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-0a73602c-14c5-4461-8899-fea8e906f2e9"
      unitRef="Unit12">8611000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-a52b39e2-e8cc-4cdd-b934-e408ff908930"
      unitRef="Unit12">6651000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-417bfc01-eeef-4853-ac89-8eb2181c8afc"
      unitRef="Unit12">7995000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-e7cba006-2581-4636-aeae-fde894cd476c"
      unitRef="Unit12">4048000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-ac5867b5-b578-4a67-8c20-e4597a8d0c51"
      unitRef="Unit12">24599000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-dd061eb2-b98d-41d0-a3c3-0d76495bcd69"
      unitRef="Unit12">14230000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-9894f5a7-fb5d-40ca-84b1-1ba1ec68c9fb">             December 31,(in thousands)2021 2020Laboratory equipment and machinery $ 31,534 $ 24,948Leasehold improvements  31,114   29,931Computer equipment  15,059   12,400Software  5,578   4,940Furniture and fixtures  3,202   2,434Construction in progress  2,303   137   88,790   74,790Less: Accumulated depreciation   (56,286)   (49,891)Property and equipment, net $ 32,504 $ 24,899</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pacb_LaboratoryEquipmentAndMachineryMember"
      decimals="-3"
      id="ct-nonFraction-448e3467-8f6f-40c9-b22b-68f205667538"
      unitRef="Unit12">31534000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pacb_LaboratoryEquipmentAndMachineryMember"
      decimals="-3"
      id="ct-nonFraction-edb71b5f-3f72-4b75-acf4-4c72eb27989b"
      unitRef="Unit12">24948000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="ct-nonFraction-60f657e6-fbf4-41be-8213-d896d69495a3"
      unitRef="Unit12">31114000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="ct-nonFraction-1a502da3-65ce-4e34-9339-3899f163559e"
      unitRef="Unit12">29931000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="ct-nonFraction-57e411f4-9f10-4049-b886-0849485f2f26"
      unitRef="Unit12">15059000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="ct-nonFraction-887fa72a-8844-42de-8a63-fe563bf4d837"
      unitRef="Unit12">12400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember"
      decimals="-3"
      id="ct-nonFraction-a9738a66-d6fd-4462-a53e-c753eb4070af"
      unitRef="Unit12">5578000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember"
      decimals="-3"
      id="ct-nonFraction-85532f47-4b4b-4982-873b-e238b4ab989c"
      unitRef="Unit12">4940000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="ct-nonFraction-eee6488e-5434-4dc1-a1ae-a4b8f9767dc2"
      unitRef="Unit12">3202000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="ct-nonFraction-253aa0dc-fbaf-40ba-9e6b-379ad3296bae"
      unitRef="Unit12">2434000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="ct-nonFraction-2361ce3d-deea-459f-8719-1a8b748bae55"
      unitRef="Unit12">2303000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="ct-nonFraction-f65ad122-eeca-4fc4-a285-227927d2297e"
      unitRef="Unit12">137000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-a321fff7-ade0-456f-aeec-ac95fd90be35"
      unitRef="Unit12">88790000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-ebda8369-6359-4480-b2f9-93420adfbb53"
      unitRef="Unit12">74790000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-da9be31b-e529-47f9-8b06-d2ce57e611e3"
      unitRef="Unit12">56286000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-d887749c-5c96-4e64-a5bd-0959a4de8c5e"
      unitRef="Unit12">49891000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-5b925ec8-2e9c-499e-8a71-4224b193f9a7"
      unitRef="Unit12">32504000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-8fe56ac3-983f-49fb-8476-ea9b2774b7b6"
      unitRef="Unit12">24899000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-b8c4fd5c-010c-4e36-9e94-f4722fbb934b"
      unitRef="Unit12">7200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-5"
      id="ct-nonFraction-0cf38f41-3fc3-456e-9254-1c77c6852cff"
      unitRef="Unit12">6400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2018_To_12_31_2018"
      decimals="-5"
      id="ct-nonFraction-d2a78bca-b2f6-47f7-b5e2-cd504cf3a2fe"
      unitRef="Unit12">7300000</us-gaap:Depreciation>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="As_Of_10_31_2015_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember"
      decimals="-5"
      id="ct-nonFraction-cfac663f-1fd8-4749-9011-0b6e1ee56a27"
      unitRef="Unit12">4500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <pacb:AnnualDecreaseInLongTermRestrictedCash
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-5dfadd5d-29c5-452b-b800-bc844df722d6"
      unitRef="Unit12">500000</pacb:AnnualDecreaseInLongTermRestrictedCash>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember"
      decimals="-6"
      id="ct-nonFraction-f0e2cc29-09ee-4729-a355-4c7666cc54ff"
      unitRef="Unit12">3000000.0</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember"
      decimals="-5"
      id="ct-nonFraction-e3925746-e02c-4d5f-9dc7-4bf77e3c02c1"
      unitRef="Unit12">3500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-a6824c35-3f5d-4e04-87ad-bdfb3b2d712d"
      unitRef="Unit12">1600000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-04efb01a-12b6-4812-901a-3392cade9bb1">   Balance as of December 31, 2020$ -Acquisition of Omniome  390,665Acquisition of Circulomics  19,309Balance as of December 31, 2021$ 409,974</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="0"
      id="ct-nonFraction-c2f7b681-d4be-4aa7-914d-a25897851a39"
      unitRef="Unit12">390665000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember"
      decimals="0"
      id="ct-nonFraction-f7faf70b-20f0-4fea-a738-53128bf234e5"
      unitRef="Unit12">19309000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-5602d843-089f-4939-8274-79f0121fb201"
      unitRef="Unit12">409974000</us-gaap:Goodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember"
      decimals="-6"
      id="ct-nonFraction-22ef98ec-62bd-4ef4-827a-2a92573741af"
      unitRef="Unit12">400000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-0a550bff-2f87-4033-8095-1e1e29bb098d">            Estimated  Gross    Net Useful Life Carrying Accumulated Carrying (in years) Amount Amortization AmountDeveloped technology15 $ 11,000 $ (306) $ 10,694Customer relationships2   360   (75)   285Total  $ 11,360 $ (381) $ 10,979           </us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="ct-nonNumeric-83993b2e-6414-4e78-b8f6-aa1695ca7973">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="0"
      id="ct-nonFraction-c3f519e8-c92e-4632-bc4b-3f04337799f0"
      unitRef="Unit12">11000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="0"
      id="ct-nonFraction-057ba42e-a4a9-4d70-946b-1b8390eb4346"
      unitRef="Unit12">306000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="0"
      id="ct-nonFraction-ca2bdbf0-c01d-440e-87e7-746b60e7ed0e"
      unitRef="Unit12">10694000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      id="ct-nonNumeric-aeeedadc-04f3-48cb-bf62-06e91ed59942">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      decimals="0"
      id="ct-nonFraction-b355d29f-2049-4e75-9dda-35a111c18847"
      unitRef="Unit12">360000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      decimals="0"
      id="ct-nonFraction-af927be1-dd12-4c62-8fbc-2b23bed9f64e"
      unitRef="Unit12">75000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      decimals="0"
      id="ct-nonFraction-63ddbb0d-2d4e-4d8f-a35c-7e781d9fb077"
      unitRef="Unit12">285000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-f70f8200-09cd-43fd-a473-1a27dfbe2dc6"
      unitRef="Unit12">11360000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-1f8af2f9-9718-4310-89a6-b2fd4e6f5be0"
      unitRef="Unit12">381000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-a1f8b0a4-5b61-4408-a22b-e4cf5ed89f1d"
      unitRef="Unit12">10979000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-b72ad955-a509-4538-9f1e-5b8d5a75dfe1"
      unitRef="Unit12">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="INF"
      id="ct-nonFraction-792894a6-179e-4229-8f27-e2d2bc7765d3"
      unitRef="Unit12">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="INF"
      id="ct-nonFraction-74c5a63d-034d-4f0d-8455-144b8e5b0d96"
      unitRef="Unit12">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-21e700d8-47c3-4ad5-8d82-a40927adc47e">      2022$ 9132023  8382024  7332025  7332026  7332027 and thereafter  7,029Total$ 10,979    </us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-ad42d1b1-7bed-495a-b8a6-d89989ef8300"
      unitRef="Unit12">913000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-114d44d9-6b1f-402b-9c73-9bb4d4e2899a"
      unitRef="Unit12">838000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-8eeefe31-2129-4860-8b01-420d7385875c"
      unitRef="Unit12">733000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-25997480-411c-4145-9796-f87a8b20d1f6"
      unitRef="Unit12">733000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-5c4097d2-67d0-495e-9b75-04af1741276d"
      unitRef="Unit12">733000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-ed7361cc-2f93-4ff2-b2d1-cc951570867c"
      unitRef="Unit12">7029000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-d78d9e5f-78d0-400d-bff5-e733548bf3a1"
      unitRef="Unit12">10979000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <pacb:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-3827c5cb-fa17-4ea3-9904-99424ccdfbf4">             December 31,(in thousands)2021 2020Salaries and benefits$ 25,282 $ 15,261Accrued product development costs  1,936   415Accrued interest payable  5,100   &#x2014;Inventory accrual  108   218Warranty  594   161Accrued professional services and legal fees  1,640   726Other   1,601   569Accrued expenses $ 36,261 $ 17,350</pacb:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-8dcbbba7-23f7-4684-8e64-18bf536e096a"
      unitRef="Unit12">25282000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-219a4684-88e9-454a-a3e4-31796741ec88"
      unitRef="Unit12">15261000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <pacb:AccruedProductDevelopmentCostsCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-37223fb2-e047-4e50-bc2e-e4bab88b5a27"
      unitRef="Unit12">1936000</pacb:AccruedProductDevelopmentCostsCurrent>
    <pacb:AccruedProductDevelopmentCostsCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-96523f6d-af90-4d6c-8b8f-5e1ac5871a7f"
      unitRef="Unit12">415000</pacb:AccruedProductDevelopmentCostsCurrent>
    <pacb:AccruedTenantImprovementsCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-2d6f3963-c79f-4be0-a59c-ff783d5477ea"
      unitRef="Unit12">5100000</pacb:AccruedTenantImprovementsCurrent>
    <us-gaap:ProductLiabilityContingencyAccrualPresentValue
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-89cffa0f-a431-47bd-9bfa-13caf89042f1"
      unitRef="Unit12">108000</us-gaap:ProductLiabilityContingencyAccrualPresentValue>
    <us-gaap:ProductLiabilityContingencyAccrualPresentValue
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-56c61898-0594-45de-b80f-7b70be47a7f1"
      unitRef="Unit12">218000</us-gaap:ProductLiabilityContingencyAccrualPresentValue>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-6834fb00-7e1c-4962-a8b5-660f10a58eeb"
      unitRef="Unit12">594000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-65a9a010-ddae-43c9-a509-8938f5130b98"
      unitRef="Unit12">161000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-4175eef9-257f-41f1-931b-c9a8652bc1bb"
      unitRef="Unit12">1640000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-dcc44095-8f09-4461-8ae2-9a5d41b6fd6c"
      unitRef="Unit12">726000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-f7783830-9707-485a-a5f7-630cde685c85"
      unitRef="Unit12">1601000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-24339c11-12de-4527-8755-106ac2e7b3ab"
      unitRef="Unit12">569000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-463ed506-49a6-4610-8f73-d19eb95cd5a8"
      unitRef="Unit12">36261000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-9d21ca3d-129d-45e3-be91-784329c04232"
      unitRef="Unit12">17350000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ServiceMember"
      decimals="-5"
      id="ct-nonFraction-ad793e25-5209-4dcc-a905-1003a3393c9e"
      unitRef="Unit12">36000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ServiceMember"
      decimals="-5"
      id="ct-nonFraction-2e0c1d5e-9755-4119-b206-f71c61377eb6"
      unitRef="Unit12">11000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ServiceMember"
      decimals="-5"
      id="ct-nonFraction-af1da831-6bc4-4da0-a725-b4abea11f3de"
      unitRef="Unit12">25000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_srt_MajorCustomersAxis_pacb_InvitaeCorporationMember"
      decimals="-5"
      id="ct-nonFraction-aa47eb0a-05eb-4b3f-b913-634564173fb7"
      unitRef="Unit12">23500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_pacb_ServiceContractMember"
      decimals="-5"
      id="ct-nonFraction-d6691c45-9e4a-48b0-be8e-5b56dcec3e38"
      unitRef="Unit12">1500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <pacb:ContractWithCustomerLiabilityNoncurrentRecognitionPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-6cb64c39-71e9-47b4-a62e-fa9f9d19c076">P5Y</pacb:ContractWithCustomerLiabilityNoncurrentRecognitionPeriod>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-5"
      id="ct-nonFraction-359d7975-2c51-4634-925f-9cfdf4af889e"
      unitRef="Unit12">8600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ServiceMember"
      decimals="-5"
      id="ct-nonFraction-905a8087-e6b9-4b8a-87ca-6e8749610266"
      unitRef="Unit12">700000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-d17b9c0d-1d9a-4eec-b936-d4161735be4a"
      unitRef="Unit12">1300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
      contextRef="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-6"
      id="ct-nonFraction-5dd642fb-c99c-4909-8b8e-d6ee82f1b047"
      unitRef="Unit12">3000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_9_1_2021_To_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      id="ct-nonNumeric-8e604603-edff-44f7-93a9-d823cefe9f79">P43M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="INF"
      id="ct-nonFraction-5897ac90-db1f-4138-b38f-61598d9a7ccb"
      unitRef="Unit15">0.17</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <pacb:PercentageOfFeeToPrepayDebt
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="0"
      id="ct-nonFraction-eb53f2ef-a92c-4dc0-80f2-33a3fd0d77ea"
      unitRef="Unit15">4</pacb:PercentageOfFeeToPrepayDebt>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-c96915c0-edda-4497-9217-52b6b167459a"
      unitRef="Unit12">3900000</us-gaap:NotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-b4848321-e12b-44da-a0d4-66fdf39f90fd"
      unitRef="Unit12">2300000</us-gaap:LongTermNotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-c1beffca-42dd-40ce-bb20-10c1e07c70d2"
      unitRef="Unit12">1600000</us-gaap:NotesPayableCurrent>
    <us-gaap:InterestExpenseBorrowings
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-6bbf7e21-8bac-4723-94da-20a00a46100a"
      unitRef="Unit12">200000</us-gaap:InterestExpenseBorrowings>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-479350d6-eec8-4d68-8d07-3fec328ba8a7">   (in thousands)  2022$ 1,6082023  1,8422024  490Total$ 3,940 </srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="0"
      id="ct-nonFraction-909f9653-a65d-4aeb-a55f-1d9265f24a8d"
      unitRef="Unit12">1608000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="0"
      id="ct-nonFraction-db7edeea-32fa-4f9d-aa38-3871e65b2211"
      unitRef="Unit12">1842000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="0"
      id="ct-nonFraction-9729f52e-1fd0-4c3a-8459-e7066cce43db"
      unitRef="Unit12">490000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="0"
      id="ct-nonFraction-1ddaca2e-01ba-4ab0-81fe-370a56804b05"
      unitRef="Unit12">3940000</us-gaap:LongTermDebt>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-50f2f3af-cad4-4cd4-b98c-786e6bf4878e">       December 31,(in thousands)2021 2020Accrued ESPP$ 3,598 $ 2,037Other   2,161   2,482Other liabilities, current$ 5,759 $ 4,519</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-0c000925-50f4-4611-8590-8bc456a703fa"
      unitRef="Unit12">3598000</pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent>
    <pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-4725200e-e587-4f71-8e9c-5bcc9bd29d28"
      unitRef="Unit12">2037000</pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-ea8dd885-237d-4758-8f5f-e4b4f381cec0"
      unitRef="Unit12">2161000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-cfe91bcb-f4d0-4159-8856-0ec195e468b0"
      unitRef="Unit12">2482000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-5836b02a-410d-47fd-9e8f-37d54ff9af1d"
      unitRef="Unit12">5759000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-6b80ba23-d73f-4023-8721-d76d8fb0b6f1"
      unitRef="Unit12">4519000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-3bc7bf1e-1a97-4d36-b215-e75968b89835">NOTE 7. CONVERTIBLE SENIOR NOTESOn February&#160;9, 2021, we entered into an investment agreement (the &#x201c;Investment Agreement&#x201d;) with SB Northstar LP (the &#x201c;Purchaser&#x201d;), a subsidiary of SoftBank Group Corp., relating to the issuance and sale to the Purchaser of $900 million in aggregate principal amount of our 1.50% Convertible Senior Notes (the &#x201c;Notes&#x201d;). The Notes were issued on February 16, 2021.The Notes are governed by an indenture (the &#x201c;Indenture&#x201d;) between the Company and U.S. Bank National Association, as trustee. The Notes bear interest at a rate of 1.50% per annum. Interest on the Notes is payable semi-annually in arrears on February&#160;15 and August&#160;15 and commenced on August&#160;15, 2021. The Notes will mature on February&#160;15, 2028, subject to earlier conversion, redemption or repurchase.The Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The Notes are convertible into shares of our common stock based on an initial conversion rate of 22.9885 shares of common stock per $1,000 principal amount of the Notes (which is equal to an initial conversion price of $43.50 per share), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the Notes, we may elect to settle such conversion obligation in shares, cash or a combination of shares and cash.On or after February&#160;20, 2026, the Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.With certain exceptions, upon a change of control of the Company or the failure of our common stock to be listed on certain stock exchanges (a &#x201c;Fundamental Change&#x201d;), the holders of the Notes may require that we repurchase all or part of the principal amount of the Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.The Indenture includes customary &#x201c;events of default,&#x201d; which may result in the acceleration of the maturity of the Notes under the Indenture. The Indenture also includes customary covenants for convertible notes of this type.To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the Notes at a rate equal to (i)&#160;0.25% per annum of the principal amount of the Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the Notes outstanding for each day from, and including, the 181st calendar day to, and including, the 360th calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the Indenture). On the 361st day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361st day), the Notes shall be subject to acceleration as provided for in the Indenture. The notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the Notes were not issued at a premium; therefore, the Notes are accounted for in their entirety as a liability.  Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current. The requirement to repurchase the Notes including unpaid interest to the maturity date in the event of a Fundamental Change is considered a put option for certain periods requiring bifurcation under ASC 815 &#x2013; Derivatives and Hedging. However, given the low probability of a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.We incurred issuance costs related to the Notes of approximately $4.5 million, which were recorded as debt issuance cost and are presented as a reduction to the Notes on our Consolidated Balance Sheets and are amortized to interest expense using the effective interest method over the term of the Notes, resulting in an effective interest rate of 1.6%. As of December 31, 2021, the net carrying amount of the liability for the Notes is recorded as convertible senior notes, net in the Consolidated Balance Sheets as follows (in thousands):    Principal amount$ 900,000Unamortized debt issuance costs  (3,933)Net carrying amount$ 896,067For the year ended December 31, 2021, interest expense for the Notes was as follows (in thousands):    Contractual interest expense$ 11,812Amortization of debt issuance costs  532Total interest expense$ 12,344 As of December 31, 2021, the estimated fair value (Level 2) of the Notes was $787.5 million. The fair value of the Notes is estimated using a pricing model that is primarily affected by the trading price of our common stock and market interest rates.&#160;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_2_9_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="-6"
      id="ct-nonFraction-8a365df5-8d69-4bb8-9a49-88aa727ae358"
      unitRef="Unit12">900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_2_9_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="INF"
      id="ct-nonFraction-4bb0888a-2851-48ed-9ce7-4337c19e071f"
      unitRef="Unit15">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentIssuanceDate1
      contextRef="Duration_2_16_2021_To_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      id="ct-nonNumeric-96148dcb-f7f0-4bb7-8053-ee12d769bfa4">2021-02-16</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_2_9_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="INF"
      id="ct-nonFraction-b1df45ce-ae2a-4e2b-a111-8e248643aaa5"
      unitRef="Unit15">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="Duration_2_9_2021_To_2_9_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      id="ct-nonNumeric-128e88e7-990c-4456-b630-c6bdb38d9ac9">2028-02-15</us-gaap:DebtInstrumentMaturityDate>
    <pacb:DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount
      contextRef="Duration_2_16_2021_To_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="INF"
      id="ct-nonFraction-ad5c32a5-3d27-493b-8696-b38a93f15f6f"
      unitRef="Unit1">22.9885</pacb:DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount>
    <pacb:DebtInstrumentStatedPrincipalAmountForConversionRate
      contextRef="Duration_2_16_2021_To_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="INF"
      id="ct-nonFraction-ae7fc92a-8555-4a2a-9845-e0334a346eaf"
      unitRef="Unit12">1000</pacb:DebtInstrumentStatedPrincipalAmountForConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="2"
      id="ct-nonFraction-360ebf4e-ede6-4cdf-b87b-e9975ee2409e"
      unitRef="Unit13">43.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice
      contextRef="Duration_2_16_2021_To_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="2"
      id="ct-nonFraction-8bd53313-825a-4429-b9e4-fd9b17c42ede"
      unitRef="Unit15">1.50</pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice>
    <pacb:DebtInstrumentRedemptionPriceTradingDays
      contextRef="Duration_2_16_2021_To_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      id="ct-nonNumeric-14d82926-b234-4432-a79d-6d06f21baf4a">P20D</pacb:DebtInstrumentRedemptionPriceTradingDays>
    <pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays
      contextRef="Duration_2_16_2021_To_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      id="ct-nonNumeric-57862226-41d8-417a-9cc6-e6978f3203c7">P30D</pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="Duration_2_16_2021_To_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="2"
      id="ct-nonFraction-613b9045-945f-4518-8050-0f8a36d83cfd"
      unitRef="Unit15">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <pacb:DebtInstrumentAdditionalInterestInEventOfDefault
      contextRef="Duration_2_16_2021_To_2_16_2021_srt_StatementScenarioAxis_pacb_EachDayDuringFirst180DaysMember_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="5"
      id="ct-nonFraction-aa985380-8659-4606-8337-12552f9118f2"
      unitRef="Unit15">0.0025</pacb:DebtInstrumentAdditionalInterestInEventOfDefault>
    <pacb:DebtInstrumentAdditionalInterestInEventOfDefault
      contextRef="Duration_2_16_2021_To_2_16_2021_srt_StatementScenarioAxis_pacb_OneHundredAndEightyFirstDayTo360thDayMember_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="4"
      id="ct-nonFraction-8f7636f3-bbc0-4d60-82a5-5a374db93d48"
      unitRef="Unit15">0.0050</pacb:DebtInstrumentAdditionalInterestInEventOfDefault>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="-5"
      id="ct-nonFraction-436d722f-853e-4204-9b2f-3fb256d64288"
      unitRef="Unit12">4500000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="INF"
      id="ct-nonFraction-8272a82b-c898-4515-813c-c69748805183"
      unitRef="Unit15">0.016</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-efe198bc-9069-4ece-b2e0-4068147d2d50">   Principal amount$ 900,000Unamortized debt issuance costs  (3,933)Net carrying amount$ 896,067</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-a499866a-5297-4fb4-8910-5e561d3b5258"
      unitRef="Unit12">900000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-cf991059-3052-4be1-901f-e42d166fa0a4"
      unitRef="Unit12">3933000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2021"
      decimals="0"
      id="ct-nonFraction-32d15380-4b09-4558-be66-85b8da97ff12"
      unitRef="Unit12">896067000</us-gaap:LongTermDebt>
    <pacb:ScheduleOfInterestExpenseTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-ecaa0a63-c2c7-4aba-9747-3c749fa398ee">   Contractual interest expense$ 11,812Amortization of debt issuance costs  532Total interest expense$ 12,344</pacb:ScheduleOfInterestExpenseTableTextBlock>
    <pacb:ContractualInterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="0"
      id="ct-nonFraction-caef0b14-176b-4e22-a068-ee0495517730"
      unitRef="Unit12">11812000</pacb:ContractualInterestExpense>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="0"
      id="ct-nonFraction-264f7e0e-f1f7-4483-bd1e-f908fa89cfc5"
      unitRef="Unit12">532000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="0"
      id="ct-nonFraction-b528f5ec-3bc7-4245-be9c-1ce9a3fce110"
      unitRef="Unit12">12344000</us-gaap:InterestExpenseDebt>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember"
      decimals="-5"
      id="ct-nonFraction-b9752710-42d5-4fcc-9039-07921afaca59"
      unitRef="Unit12">787500000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:LossContingencyDisclosures
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-b6d4a54a-c9cb-49ca-9916-feb50846770f">NOTE 8. COMMITMENTS AND CONTINGENCIES LeasesWe record operating lease right-of-use assets and liabilities on our Consolidated Balance Sheets for all leases with a term of more than 12 months. In connection with the acquisition of Omniome, we acquired $18.1 million in right-of-use assets and liabilities on our Consolidated Balance Sheets. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. All of our leases are operating leases. Lease payments comprise the base rent per the term of the Lease. Lease expense for these leases is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period those payments are incurred. We often have options to renew lease terms for buildings. For the O&#x2019;Brien Lease, the renewal option is 5 years and the rent will be based on fair market value at the time of renewal and was not included in the lease term. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors. The following table presents information as to the amount and timing of cash flows arising from our operating leases as of December 31, 2021:          Maturity of Lease LiabilitiesAmount Years ending December 31,(in thousands)2022$ 11,3262023  11,8512024  12,0402025  12,3282026  12,437Thereafter  9,930Total undiscounted operating lease payments  69,912Less: imputed interest  (12,232)Present value of operating lease liabilities   57,680   Balance Sheet Classification  Operating lease liabilities, current  7,710Operating lease liabilities, non-current  49,970Total operating lease liabilities  57,680We use our incremental borrowing rate to determine the present value of lease payments, as the implicit rates in our leases are not readily determinable. The weighted average discount rate used to measure our operating lease liabilities was 6.7%. The weighted average remaining lease term for our operating leases as of December 31, 2021 was 5.7 years.Cash FlowsCash paid for amounts included in the present value of operating lease liabilities was $8.2 million and $7.2 million for the years ended December 31, 2021 and 2020, respectively and were included in operating cash flow. Operating Lease CostsOperating lease costs were $7.2 million and $6.2 million for the years ended December 31, 2021 and 2020, respectively. For both 2021 and 2020 the total lease costs primarily related to our operating leases, but also included immaterial amounts for variable leases.Contingencies We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.Legal ProceedingsU.S. District Court Proceedings On September 26, 2019, Personal Genomics of Taiwan, Inc. (&#x201c;PGI&#x201d;) filed a complaint in the U.S. District Court for the District of Delaware against us for patent infringement (C.A. No. 19-cv-1810) (the &#x201c;PGI District Court matter&#x201d;). The matter from this complaint is based on PGI&#x2019;s U.S. Patent No. 7,767,441 (the &#x201c;&#x2018;441 Patent&#x201d;). We plan to vigorously defend in this matter. On November 20, 2019, we filed our answer to the complaint, denying infringement and seeking a declaratory judgement of invalidity of the &#x2018;441 Patent. On June 22, 2020, we filed a petition requesting institution of an inter-partes review (IPR) to the Patent Trial and Appeals Board (the &#x201c;Board&#x201d;) at the United States Patent Office requesting the Board to find a set of claims in the &#x2018;441 Patent invalid. On June 27, 2020, we filed a second petition requesting institution of an IPR requesting the Board to find another set of claims in the &#x2018;441 Patent invalid. The two petitions (the &#x201c;PacBio IPR Petitions&#x201d;) requesting IPRs assert that all of the claims relevant to the PGI complaint are invalid. On January 19, 2021, the Board ordered that both PacBio IPR Petitions are instituted on all grounds presented. On January 18, 2022, the Board issued decisions on the two IPRs.  In one IPR, all challenged claims were found unpatentable including PGI&#x2019;s core device claims. In the second IPR, the board did not find the disputed claims unpatentable. We are appealing the decision in the second IPR to the U.S. Court of Appeals for the Federal Circuit.On August 19, 2020, the court ordered a stay of the PGI District Court matter based on a joint stipulation by the parties pending a final written decision on the IPRs. Following the final decision on the IPRs described above, on February 2, 2022, the judge ordered that the PGI District Court matter be reopened. We plan to vigorously defend against the remaining claims.Proceedings in ChinaOn May 12, 2020, PGI filed a complaint in the Wuhan Intermediate People&#x2019;s Court in China alleging infringement of one or more claims of China patent No. CN101743321B (the &#x201c;CN321 Patent&#x201d;), which is related to the &#x2018;441 Patent.  We were served on January 20, 2021 and plan to vigorously defend in this matter.  On November 23, 2020 we filed an Invalidation Petition at the China National Intellectual Property Administration (CNIPA) demonstrating the invalidity of the claims in the CN321 Patent on grounds of insufficient disclosure, and the lack of support, essential technical features, clarity, novelty, and inventiveness. A hearing in the invalidation proceeding at the CNIPA was held on April 29, 2021. On September 2, 2021, the CNIPA issued its decision on the Invalidation Petition and determined that all claims (1-61) of the CN321 patent were invalid.  We have filed a petition with the Wuhan Intermediate People&#x2019;s court requesting dismissal of the infringement action. On December 1, 2021, PGI filed an appeal with the Beijing IP Court, contesting the CNIPA decision.  Other ProceedingsFrom time to time, we may also be involved in a variety of other claims, lawsuits, investigations and proceedings relating to securities laws, product liability, patent infringement, contract disputes, employment and other matters that arise in the normal course of our business. In addition, third parties may, from time to time, assert claims against us in the form of letters and other communications. We record a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We currently do not believe that the ultimate outcome of any of the matters described above is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources and other factors.IndemnificationPursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification obligations has been recorded as of December 31, 2021.&#160;</us-gaap:LossContingencyDisclosures>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-20dc595a-fa29-4928-a6eb-ef4c7f3691b4"
      unitRef="Unit12">18100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember"
      decimals="-5"
      id="ct-nonFraction-7257a4bd-e1d7-47f9-9bc0-e5620171d1e5"
      unitRef="Unit12">18100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2021"
      id="ct-nonNumeric-ec84200c-210e-412e-9f39-a9158d6ef137">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <pacb:LesseeOperatingLeaseDescriptionTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-93783207-5770-40a3-9025-12070a6bd490">      Maturity of Lease LiabilitiesAmount Years ending December 31,(in thousands)2022$ 11,3262023  11,8512024  12,0402025  12,3282026  12,437Thereafter  9,930Total undiscounted operating lease payments  69,912Less: imputed interest  (12,232)Present value of operating lease liabilities   57,680   Balance Sheet Classification  Operating lease liabilities, current  7,710Operating lease liabilities, non-current  49,970Total operating lease liabilities  57,680</pacb:LesseeOperatingLeaseDescriptionTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-a401c220-5c71-43ac-a63a-13c9098d9102"
      unitRef="Unit12">11326000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-353ef3d7-3130-4749-9384-d64f429bc91c"
      unitRef="Unit12">11851000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-fabf0c27-1613-4593-a41e-9df4a0c7cdfb"
      unitRef="Unit12">12040000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-109ce433-6a1b-48d0-900b-93e41ce929d3"
      unitRef="Unit12">12328000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-6f1318f6-92a0-45cd-8891-30942d9f5be7"
      unitRef="Unit12">12437000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-50a71054-3efc-4432-9276-351c57dd666a"
      unitRef="Unit12">9930000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-25abf7e3-6e7a-4a54-b734-7855c834ae33"
      unitRef="Unit12">69912000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-f7290562-ccf2-4de9-a9b0-85d6ddd54b3c"
      unitRef="Unit12">12232000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-401984d4-922f-4bc8-a160-739f5a0f7baf"
      unitRef="Unit12">57680000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-49afa191-1630-4a4d-a6d5-f4c4d86e5993"
      unitRef="Unit12">7710000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-d389f540-b0ba-489a-9ad6-a3879678f23d"
      unitRef="Unit12">49970000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-12878192-5353-41fb-83e8-3ef7a8e81658"
      unitRef="Unit12">57680000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2021"
      decimals="4"
      id="ct-nonFraction-bd41d851-0f7f-46ca-a958-88874a315d34"
      unitRef="Unit15">0.067</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2021"
      id="ct-nonNumeric-b9a00124-3e75-4aed-9cd8-a5c3f389bb29">P5Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:PaymentsForRent
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-e1ba8d8d-2a98-47ff-804b-44ffcc5cefac"
      unitRef="Unit12">8200000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-5"
      id="ct-nonFraction-9554f5ce-098c-49ce-9364-8e48561edd1c"
      unitRef="Unit12">7200000</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-af38aaef-1607-4136-a7a8-c0cc92c75af6"
      unitRef="Unit12">7200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-5"
      id="ct-nonFraction-ca8cac21-fb12-4f4f-880c-89a8ea9761ca"
      unitRef="Unit12">6200000</us-gaap:OperatingLeaseCost>
    <pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations
      contextRef="As_Of_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-564dd174-7f78-4668-9a46-232996964868"
      unitRef="Unit12">0</pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-ea595284-4e87-4429-b51f-8e1ed490bf2e">NOTE 9. INCOME TAXESWe are subject to income taxes in the United States and certain states in which we operate, and we use estimates in determining our provisions for income taxes. Significant management judgement is required in determining our provision for income taxes, deferred tax assets and liabilities and valuation allowances recorded against net deferred tax assets in accordance with U.S. GAAP. These estimates and judgements occur in the calculation of tax credits, benefits, and deductions, and in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes, as well as the interest and penalties related to uncertain tax positions. Significant changes to these estimates may result in an increase or decrease to our tax provision in the current or subsequent period.We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether the factors underlying the sustainability assertion have changed and the amount of the recognized tax benefit is still appropriate.We account for Global Intangible Low-taxed Income as a period cost.During the years ended December 31, 2021, 2020 and 2019 income (loss) before taxes from U.S. operations were ($275.4) million, $28.9 million and ($84.8) million, respectively, and income before taxes from foreign operations was $0.8 million, $0.6 million and $0.9 million, respectively. Income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of 21% to pretax income or loss as follows:                    Years ended December 31, 2021  2020  2019 Statutory tax rate  21.0%  21.0%  21.0%State tax rate, net of federal benefit 5.5   (8.3)   4.9 Change in valuation allowance  (4.9)   6.3   (27.5) Tax credits 2.5   (3.6)   2.2 Stock-based compensation 10.9   (15.2)   (0.8) Merger Expenses (0.9)   -   - Other (0.1)   (0.2)   0.2 Total 34.0%  0.0%  (0.0)%  Deferred income taxes reflect the net tax effects of loss and credit carry forwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):              December 31,Deferred tax assets:2021 2020Net operating loss carryforwards$ 378,035 $ 233,225Research and development credits   60,672   49,179Accruals and reserves  10,822   6,337Stock-based compensation  12,838   9,717ASC 842 Operating lease liability  13,105   9,870Total deferred tax assets   475,472   308,328Less: Valuation allowance  (366,940)   (300,505)Total deferred tax assets:  108,532   7,823Intangibles  (97,345)   &#x2014;Fixed assets  (1,523)   (786)ASC 842 Operating lease right-of-use assets  (10,502)   (7,037)Total deferred tax liabilities  (109,370)   (7,823)Net deferred tax assets $ (838) $ &#x2014;At December&#160;31, 2021, we maintained a full valuation allowance against all of our deferred tax assets which totaled $366.9 million, including net operating loss carryforwards and research and development credits of $378.0 million and $60.7 million, respectively.A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. We regularly assess the need for a valuation allowance against our deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that our deferred income tax assets will be realized. In evaluating our ability to recover our deferred income tax assets within the jurisdiction from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. A deferred income tax benefit of $93.6 million for the year ended December 31, 2021, is related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Omniome and Circulomics acquisitions. We maintain a valuation allowance on the net deferred tax assets of our U.S. entities as we have concluded that it is more likely than not that we will not realize our deferred tax assets. Accordingly, this benefit from income taxes is reflected on our Consolidated Statements of Operations and Comprehensive (Loss) Income for the year ended December 31, 2021. For the year ended December 31, 2021, our valuation allowance increased to $366.9 million, primarily because of an increase in our net operating losses, credits and acquisition of deferred tax assets that were fully offset by a valuation allowance. For the year ended December 31, 2020, our valuation allowance increased to $300.5 million, primarily because of an increase in our net operating losses and tax credits offset by a decrease to our stock-based compensation deferred tax asset. As of December&#160;31, 2021, we had a net operating loss carryforward for federal income tax purposes of approximately $1,491.3 million, of which $774.9 million will begin to expire in 2024 if not utilized. We had a total state net operating loss carryforward of approximately $997.4 million, which are subject to annual expirations. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the &#x201c;change of ownership&#x201d; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization. We have federal credits of approximately $39.1 million, which will begin to expire in 2024 if not utilized and state research credits of approximately $36.9 million which have no expiration date. These tax credits are subject to the same limitations discussed above.  As of December&#160;31, 2021, our total unrecognized tax benefit was $8.3 million.  A reconciliation of the beginning and ending unrecognized tax benefit balance is as follows (in thousands):       Balance as of December 31, 2018$ 20,447Decrease in balance related to tax positions taken in prior year   &#x2014;Increase in balance related to tax positions taken during current year   1,532Balance as of December 31, 2019$ 21,979Decrease in balance related to tax positions taken in prior year   (17,255)Increase in balance related to tax positions taken during current year   1,230Balance as of December 31, 2020$ 5,954Increase in balance related to tax positions taken in prior year   189Increase in balance related to tax positions taken during current year   2,192Balance as of December 31, 2021$ 8,335Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of both December&#160;31, 2021 and 2020, we had no accrued interest or penalties due to our net operating losses available to offset any tax adjustment. If total unrecognized tax benefits were realized in the future, it would not result in any tax benefit as we currently have a full valuation allowance. We file U.S. federal and various state income tax returns. For U.S. federal and state income tax purposes, the statute of limitations currently remains open for the years ending December&#160;31, 2018 to present and December&#160;31, 2017 to present, respectively. In addition, all of the net operating losses and research and development credit carryforwards that may be utilized in future years may be subject to examination. We are not currently under examination by income tax authorities in any jurisdiction.On December 27, 2020, the U.S. government enacted the Consolidated Appropriations Act, 2021, which enhances and expands certain provisions of the CARES Act. This legislative act did not have a material impact on the Company&#x2019;s consolidated financial results.On March 11, 2021, the American Rescue Plan Act of 2021 (&#x201c;American Rescue Plan&#x201d;) was signed into law to provide additional relief in connection with the ongoing COVID-19 pandemic. The American Rescue Plan includes, among other things, provisions relating to PPP loan expansion, defined pension contributions, excessive employee remuneration, and the repeal of the election to allocate interest expense on a worldwide basis. Under ASC 740, the effects of new legislation are recognized upon enactment. Accordingly, the American Rescue Plan is effective beginning in the quarter that includes March 11, 2021. These provisions did not have a material impact on the Company&#x2019;s Consolidated Financial Statements.&#160;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-bf150130-424b-4e05-b150-13bfeccf498a"
      unitRef="Unit12">-275400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-5"
      id="ct-nonFraction-48fb23ef-7ccd-4ee7-8919-ad2ebe46d822"
      unitRef="Unit12">28900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-5"
      id="ct-nonFraction-aac5f284-c275-496f-b7fe-350393a64703"
      unitRef="Unit12">-84800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-8cd35885-2767-4bdb-a8b5-a2b5c70b735c"
      unitRef="Unit12">800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-5"
      id="ct-nonFraction-6c701ddf-8d33-41e9-8e9b-46a9ce421f15"
      unitRef="Unit12">600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-5"
      id="ct-nonFraction-61daa1e5-ecb0-402d-aae1-bb733f031602"
      unitRef="Unit12">900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-a8a6151b-e06c-4232-81fa-ddd96f33ea8e"
      unitRef="Unit15">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-7651496e-7955-40e8-ac6f-4516c34562c9">                   Years ended December 31, 2021  2020  2019 Statutory tax rate  21.0%  21.0%  21.0%State tax rate, net of federal benefit 5.5   (8.3)   4.9 Change in valuation allowance  (4.9)   6.3   (27.5) Tax credits 2.5   (3.6)   2.2 Stock-based compensation 10.9   (15.2)   (0.8) Merger Expenses (0.9)   -   - Other (0.1)   (0.2)   0.2 Total 34.0%  0.0%  (0.0)%</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-b6feeb3e-19c2-4769-9acc-7e77b4aa0837"
      unitRef="Unit15">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="INF"
      id="ct-nonFraction-18b547e1-e13f-4faf-8013-95ad43a72c3a"
      unitRef="Unit15">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="INF"
      id="ct-nonFraction-df80a677-e9ff-4494-93aa-d360b0f943a9"
      unitRef="Unit15">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-608ecd15-ea85-4ddf-9cdb-67f5eed6f17d"
      unitRef="Unit15">0.055</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="INF"
      id="ct-nonFraction-a0d65d63-0f3a-4845-9b53-d0cb26d2855b"
      unitRef="Unit15">-0.083</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="INF"
      id="ct-nonFraction-240f4ed1-745c-4550-9944-ae4dd432099b"
      unitRef="Unit15">0.049</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-32a97d3b-892d-4cd0-9e5c-e956170b2dc0"
      unitRef="Unit15">0.049</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="INF"
      id="ct-nonFraction-743fded6-4dc1-41e5-be2e-3f3d3be46961"
      unitRef="Unit15">-0.063</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="INF"
      id="ct-nonFraction-f845801a-e82f-4f93-82f5-590de302d05b"
      unitRef="Unit15">0.275</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <pacb:EffectiveIncomeTaxRateReconciliationTaxCredit
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-35feec1f-357d-4a43-836d-3e3daf39cb80"
      unitRef="Unit15">0.025</pacb:EffectiveIncomeTaxRateReconciliationTaxCredit>
    <pacb:EffectiveIncomeTaxRateReconciliationTaxCredit
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="INF"
      id="ct-nonFraction-59f01227-ac5f-4917-b0cb-dd4ccfaf565d"
      unitRef="Unit15">-0.036</pacb:EffectiveIncomeTaxRateReconciliationTaxCredit>
    <pacb:EffectiveIncomeTaxRateReconciliationTaxCredit
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="INF"
      id="ct-nonFraction-2ad8d9cd-5f1f-4279-9ec9-d732df977551"
      unitRef="Unit15">0.022</pacb:EffectiveIncomeTaxRateReconciliationTaxCredit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-5a6f1fcb-adb9-4045-a946-d049f9ad4737"
      unitRef="Unit15">-0.109</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="INF"
      id="ct-nonFraction-e5fca548-0249-4916-b4fd-51d1ed03f968"
      unitRef="Unit15">0.152</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="INF"
      id="ct-nonFraction-f04876e7-0551-4bbc-9d7c-f9a3bfee87a7"
      unitRef="Unit15">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-fd7a0a0f-2793-485b-be23-bc33ce5c34f8"
      unitRef="Unit15">-0.9</pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-2e801f0c-5612-412d-b739-ed9281cf6143"
      unitRef="Unit15">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="INF"
      id="ct-nonFraction-f6434966-ee41-4445-b16c-00ff653b45e4"
      unitRef="Unit15">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="INF"
      id="ct-nonFraction-ea949e34-ab6c-4474-a5fc-3ed633799615"
      unitRef="Unit15">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-57ca3a3f-ce26-41a9-93d3-c0f582d4ec15"
      unitRef="Unit15">0.340</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-84ad5964-850f-4dd9-9c4d-e63db367528e">             December 31,Deferred tax assets:2021 2020Net operating loss carryforwards$ 378,035 $ 233,225Research and development credits   60,672   49,179Accruals and reserves  10,822   6,337Stock-based compensation  12,838   9,717ASC 842 Operating lease liability  13,105   9,870Total deferred tax assets   475,472   308,328Less: Valuation allowance  (366,940)   (300,505)Total deferred tax assets:  108,532   7,823Intangibles  (97,345)   &#x2014;Fixed assets  (1,523)   (786)ASC 842 Operating lease right-of-use assets  (10,502)   (7,037)Total deferred tax liabilities  (109,370)   (7,823)Net deferred tax assets $ (838) $ &#x2014;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-518f942b-0bb5-4e5b-b442-38bacefe414f"
      unitRef="Unit12">378035000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-9eaaa585-41af-4ad4-8320-3e63a87ee64a"
      unitRef="Unit12">233225000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-b17c34e7-e64d-4e98-9acb-ee2868605502"
      unitRef="Unit12">60672000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-466415fa-0054-4178-9f53-0785eb74a8ae"
      unitRef="Unit12">49179000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-71e6dc14-d8a1-4c55-b961-aaf86c99812c"
      unitRef="Unit12">10822000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-5d0dabc2-3bbd-42fd-a33c-fffe2a68d8f3"
      unitRef="Unit12">6337000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-26cde2c6-7a85-47bd-84ce-02a1f1b4bb07"
      unitRef="Unit12">12838000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-eb69071d-78df-4858-91cc-8c4ec7c88ac6"
      unitRef="Unit12">9717000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <pacb:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-f211d836-8a86-4333-af46-b6871ef18391"
      unitRef="Unit12">-13105000</pacb:DeferredTaxAssetsOperatingLeaseLiabilities>
    <pacb:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-b5c30ed1-b2d2-45dc-b03a-a94b583cdd78"
      unitRef="Unit12">-9870000</pacb:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-dda76bd0-d910-419a-a84c-8979e5865a34"
      unitRef="Unit12">475472000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-2ad8effd-192a-48e3-a732-122a372fe31c"
      unitRef="Unit12">308328000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-6f64f83c-d5b7-4bcf-8f24-e56f850f2495"
      unitRef="Unit12">366940000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-abe8fe9c-fba4-4345-9977-ac6fa476ab74"
      unitRef="Unit12">300505000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-639cce06-2eb8-4105-bf60-bc47437f9c39"
      unitRef="Unit12">108532000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-f69217f2-0b4a-4887-83ba-bbb3254cdc62"
      unitRef="Unit12">7823000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-a31a795a-c5ec-4544-86c7-42426534f89f"
      unitRef="Unit12">97345000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-b363ddb5-ddf9-4a46-9811-566f20ba5294"
      unitRef="Unit12">1523000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-69082b4c-80dc-4757-a3af-003b12e06827"
      unitRef="Unit12">786000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <pacb:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-00f44bfe-e45e-4658-baf2-471bfffdf6e1"
      unitRef="Unit12">10502000</pacb:DeferredTaxLiabilitiesRightOfUseAssets>
    <pacb:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-904ac10c-0097-49d9-9e7d-b207b400e723"
      unitRef="Unit12">7037000</pacb:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-33db6fef-4ff9-4837-a9ff-c3cf5d0e11f8"
      unitRef="Unit12">109370000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-3610b040-9393-4805-8981-3f36f801c95a"
      unitRef="Unit12">7823000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-b1531f69-8a62-4549-a7fc-90c7be3461c5"
      unitRef="Unit12">838000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-d65754c5-ad33-433e-b9b5-564b9135277d"
      unitRef="Unit12">366900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-bb8b076b-5cee-49e3-9d43-da52d7e49c15"
      unitRef="Unit12">378000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-bed229e7-42a5-420d-84f3-819ea47569f3"
      unitRef="Unit12">60700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-d2fec537-1c08-41eb-81f9-71b6682cc080"
      unitRef="Unit12">-93600000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-010b4b78-ca75-4f3e-81f2-3f0f3bc0d9a5"
      unitRef="Unit12">366900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020"
      decimals="-5"
      id="ct-nonFraction-37b4ef2c-0183-4834-9431-cab57e8ed902"
      unitRef="Unit12">300500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="ct-nonFraction-3bfb09f2-45bb-49d8-a1ac-232309ed42b4"
      unitRef="Unit12">1491300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_srt_StatementScenarioAxis_pacb_WithExpirationMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="ct-nonFraction-7a318f34-67f6-47df-8c64-f2cefcedd726"
      unitRef="Unit12">774900000</us-gaap:OperatingLossCarryforwards>
    <pacb:OperatingLossCarryforwardsExpirationYear
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      id="ct-nonNumeric-77d49eae-de67-4c2b-a7de-8df2931fd891">2024</pacb:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="ct-nonFraction-dc97985d-6595-4e44-82e4-da67fbfc9d45"
      unitRef="Unit12">997400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="ct-nonFraction-496ccb96-ecc4-483d-aa9e-f78fae0434c1"
      unitRef="Unit12">39100000</us-gaap:TaxCreditCarryforwardAmount>
    <pacb:TaxCreditCarryforwardExpirationYear
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      id="ct-nonNumeric-9a9f782e-c59c-4b72-a02f-8fe0cff46d57">2024</pacb:TaxCreditCarryforwardExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="ct-nonFraction-e6967d1a-0a15-42ad-9a4b-d1f57b2a8895"
      unitRef="Unit12">36900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-b389d2e2-9d0b-4051-a069-d1d3a08eb963"
      unitRef="Unit12">8300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-726edfef-3c8e-45fa-afb2-38cec193d854">      Balance as of December 31, 2018$ 20,447Decrease in balance related to tax positions taken in prior year   &#x2014;Increase in balance related to tax positions taken during current year   1,532Balance as of December 31, 2019$ 21,979Decrease in balance related to tax positions taken in prior year   (17,255)Increase in balance related to tax positions taken during current year   1,230Balance as of December 31, 2020$ 5,954Increase in balance related to tax positions taken in prior year   189Increase in balance related to tax positions taken during current year   2,192Balance as of December 31, 2021$ 8,335</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2018"
      decimals="-3"
      id="ct-nonFraction-296cf037-6e2f-49e3-bef4-31de181a7076"
      unitRef="Unit12">20447000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-bef74b6e-e786-475e-b3f5-3f2647ad75ae"
      unitRef="Unit12">1532000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-e51a8afc-5a4e-4443-9915-d5c9ffbeb995"
      unitRef="Unit12">21979000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-bf119f64-c9f9-4855-ae69-dab9ea440b76"
      unitRef="Unit12">17255000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-08c91b9f-70c9-47be-908b-629862d727f9"
      unitRef="Unit12">1230000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-612b9d41-9f30-482c-8489-b9fa081217da"
      unitRef="Unit12">5954000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-19505527-bf44-452b-b021-4c0eadd1c3e9"
      unitRef="Unit12">189000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-97db72ea-8036-4a8d-b451-69db936b30db"
      unitRef="Unit12">2192000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-686914ec-9e45-4c45-adcf-57465646b061"
      unitRef="Unit12">8335000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2020"
      decimals="-5"
      id="ct-nonFraction-a7510685-8ef9-456a-a6d9-92f3b9652fc7"
      unitRef="Unit12">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-0f6e3ada-d88d-4d40-ab76-cab717e103b4"
      unitRef="Unit12">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-2c07a262-b76b-47d3-a2aa-a26a19c689ae">NOTE 10. STOCKHOLDERS&#x2019; EQUITYPreferred Stock Our Certificate of Incorporation, as amended and restated in October 2010 in connection with the closing of our initial public offering, authorizes us to issue 1,000,000,000 shares of $0.001 par value common stock and 50,000,000 shares of $0.001 par value preferred stock. As of December&#160;31, 2021 and 2020, there were no shares of preferred stock issued or outstanding. Common Stock Common stockholders are entitled to dividends when and if declared by our board of directors. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote. Underwritten Public Equity OfferingsIn August 2020, we entered into an underwriting agreement, relating to the public offering of 19,430,000 shares of our common stock, $0.001 par value per share, at a price to the public of $4.47 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 2,914,500 shares of our common stock, which was subsequently exercised in full, and the offering including the sale of shares of common stock subject to the underwriters&#x2019; option, closed in August 2020.&#160;In total, we sold 22.3 million shares of our common stock. We paid a commission equal to 6% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $93.9 million, excluding approximately $0.3 million of offering expenses. In November 2020, we entered into an underwriting agreement, relating to the public offering of 6,096,112 shares of our common stock, $0.001 par value per share, at a price to the public of $14.25 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 914,416 shares of our common stock, which was subsequently exercised in full, and the offering including the sale of shares of common stock subject to the underwriters&#x2019; option, closed in November 2020.&#160;In total, we sold 7.0 million shares of our common stock. We paid a commission equal to 6% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $93.9 million, excluding approximately $0.3 million of offering expenses.  In total, for the year ended December 31, 2020, we issued 29.4 million shares of our common stock through our two underwritten public offerings with an average offering price of $6.40. The total net proceeds to us from the two offerings, after deducting the underwriting commission and offering expenses, were approximately $187.2 million. Private Placement of Common StockOn July&#160;19, 2021, in connection with the Omniome acquisition, we entered into a purchase agreement with certain qualified institutional buyers and institutional accredited investors, pursuant to which we agreed to sell an aggregate of 11,214,953 shares of common stock, at a price of $26.75 per share, for aggregate gross proceeds of approximately $300&#160;million. The transaction closed on September 20, 2021. We registered the private placement shares for resale following the closing of the merger.Equity Plans The 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;), the 2020 Inducement Equity Incentive Plan (the &#x201c;Inducement Plan&#x201d;) and the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#x201c;Omniome Plan&#x201d;) allow for the issuance of stock options, restricted units and awards and performance-based awards.On August 4, 2020, stockholders approved the 2020 Plan and reserved 11,000,000 shares of our common stock for issuance pursuant to equity awards granted under the 2020 Plan.On December 2, 2020, the Board of Directors (the &#x201c;Board&#x201d;) adopted the Inducement Plan and reserved&#160;2,500,000 shares of our common stock for issuance pursuant to equity awards granted under the Inducement Plan. On April 18, 2021 and November 22, 2021, the Board amended the Inducement Plan to reserve an additional 750,000 and 360,000 shares, respectively. On September 20, 2021, in connection with the acquisition of Omniome, we adopted the Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#x201c;Omniome Plan&#x201d;). Under the Omniome Merger Agreement, each unvested option to purchase Omniome common stock, granted under the Omniome Plan held by employees continuing with us, were assumed by PacBio and converted into an option to purchase shares of our common stock. The terms and conditions of the converted options are substantially the same (including vesting and exercisability), except that (A) the assumed options cover shares of PacBio&#x2019;s common stock; (B) the number of shares of our common stock subject to the assumed option is equal to the product of (i) the number of shares of Omniome common stock subject to the corresponding unvested option, multiplied by (ii) the exchange ratio (as defined below), with any resulting fractional share rounded down to the nearest whole share; and (C) the exercise price per share of the assumed options is equal to the quotient of (i) the exercise price per share of the corresponding unvested option to purchase shares of Omniome common stock, divided by (ii) the exchange ratio (as defined below), with any resulting fractional cent rounded up to the nearest whole cent. The exchange ratio was equal to 0.259204639. We reserved 2,494,128 shares of our common stock for issuance pursuant to equity awards under the Omniome Plan.  2020 Equity Incentive Plan Under the 2020 Plan, with the approval of the Board of Directors or the Compensation Committee of the Board of Directors, we may grant equity-based awards, including non-statutory stock options, restricted stock units (&#x201c;RSUs&#x201d;), restricted stock, stock appreciation rights, performance shares and performance units. Stock options granted under the 2020 Plan may be either incentive stock options (&#x201c;ISOs&#x201d;) within the meaning of Internal Revenue code Section 422 or non-qualified stock options (&#x201c;NSOs&#x201d;). Stock options under the 2020 Plan may be granted with a term of up to ten years and at prices no less than the fair market value of our common stock on the date of grant. To date, stock options granted to existing employees generally vest over four years on a monthly basis and stock options granted to new employees vest at a rate of 25% upon the first anniversary of the vesting commencement date and 1/48th&#160;per month thereafter, in each case, subject to continued service with us through the applicable vesting dates.2020 Inducement Equity Incentive PlanUnder the Inducement Plan, with the approval of the Board of Directors or the Compensation Committee of the Board of Directors, we may grant equity-based awards, including non-statutory stock options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance units. The terms of the Inducement Plan are substantially similar to the 2020&#160;Plan, including with respect to treatment of equity awards in the event of a &#x201c;merger&#x201d; or &#x201c;change in control&#x201d; as defined under the Inducement Plan, but with such other terms and conditions intended to comply with the NASDAQ Inducement Award exception. In accordance with Rule 5635(c)(4) of the NASDAQ Listing Rules, awards under the Inducement Plan may only be made to individuals not previously employees or non-employee directors of the Company (or following such individuals&#x2019; bona fide period of non-employment with the Company), as an inducement material to the individuals&#x2019; entry into employment with the Company or in connection with a merger or acquisition, to the extent permitted by Rule 5635(c)(3) of the NASDAQ Listing Rules.As of December&#160;31, 2021, we had 8.1 million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan. Stock OptionsTime-based stock optionsThe following table summarizes time-based stock option activity for all of our equity compensation plans for the year ended December 31, 2021 (in thousands, except per share amounts):                       Stock Options Outstanding       Weighted  Number    average  of shares Exercise price exercise priceOutstanding at December 31, 2020  14,638 $ 1.16 &#x2013; 20.90 $ 5.53Granted   2,489  23.06 &#x2013; 46.37   33.78Assumed Omniome options  339  2.05 &#x2013; 4.90   4.43Exercised   (4,766)  1.16 &#x2013; 15.98   5.31Canceled   (541)  2.54 &#x2013; 46.37   5.25Outstanding at December 31, 2021  12,159 $1.16 &#x2013; 46.37 $ 11.38The expired options during the year ended December 31, 2021 totaled 0.02 million with exercise prices ranging from $2.54 to $46.37 per share and a weighted average exercise price per share of $9.80. Performance-based stock optionsThe following table summarizes performance-based stock option activity for all of our equity compensation plans for the year ended December 31, 2021 (in thousands, except per share amounts):                     Stock Options Outstanding       Weighted  Number    average  of shares Exercise price exercise priceOutstanding at December 31, 2020  &#x2014; $ &#x2014; $ &#x2014;Granted   &#x2014;   &#x2014;   &#x2014;Assumed Omniome options  304  4.71 - 4.90   4.71Exercised   &#x2014;   &#x2014;   &#x2014;Canceled   &#x2014;   &#x2014;   &#x2014;Outstanding at December 31, 2021  304 $4.71 - 4.90 $ 4.71 The following table summarizes information with respect to stock options outstanding and exercisable under our equity compensation plans at December&#160;31, 2021:                                Options Outstanding Options Exercisable   Number Weighted average    Number      outstanding remaining contractual Weighted average  vested Weighted average  Exercise price(in 000s) life (Years) exercise price (in 000s) exercise price $0.00 - 4.64 3,676  5.37 $ 2.91  3,508 $ 2.91 $4.64 - 9.27 5,480  5.88 $ 6.64  4,010 $ 6.68 $9.27 - 13.91 702  6.69 $ 9.81  427 $ 9.94 $13.91 - 18.55 35  8.79 $ 14.34  14 $ 14.34 $ 18.55 - 23.19 180  9.38 $ 21.86  25 $ 20.90 $23.19 - 27.82 320  9.50 $ 24.22  &#x2014; $ &#x2014; $27.82 - 32.46 472  9.43 $ 28.77  52 $ 27.90 $ 32.46 - 37.10 1,380  9.00 $ 36.18  &#x2014; $ &#x2014; $41.73 - 46.37 218  9.13 $ 46.37  45 $ 46.37    12,463  6.47 $ 11.22  8,081 $ 5.63The aggregate intrinsic value of the outstanding and exercisable options presented in the table above totaled $147.9 million and $121.4 million, respectively. The aggregate intrinsic value represents the total pretax intrinsic value (i.e., the difference between $20.46, our closing stock price on the last trading day of our fourth quarter of 2021 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2021. The aggregate intrinsic value changes at each reporting date based on the fair market value of our common stock. The weighted average remaining contractual life for exercisable options is 5.12 years.The vested and expected to vest options as of December 31, 2021 totaled 11,535,217, with aggregate intrinsic value of $141.9 million, weighted average exercise price per share of $10.46 and weighted average remaining contractual life of 6.28 years. The total intrinsic value of stock options exercised during the years ended December&#160;31, 2021, 2020 and 2019 was $146.1 million, $63.1 million and $2.6 million, respectively. The weighted-average grant-date fair value of all options granted with exercise prices equal to fair market value was $18.36 in 2021 and $4.14 in 2020 determined by the Black-Scholes option valuation method. No stock options were granted in 2019. Time-based RSUs&#160;Each RSU represents one equivalent share of our common stock to be issued after satisfying the applicable continued service-based vesting criteria over a specified period. These RSUs vest over four years at a rate of 25% annually. The fair value for these RSUs is based on the closing price of our common stock on the date of grant. We measure compensation expense for these RSUs at fair value on the date of grant and recognize the expense over the expected vesting period on a straight-line basis. The RSUs do not entitle participants to the rights of holders of common stock, such as voting rights, until the shares are issued. RSUs that are expected to vest are net of estimated future forfeitures. The following table summarizes the time-based RSUs activity for the year ended December 31, 2021 (in thousands, except per share amounts):          Weighted average Number grant date of shares fair valueRSUs outstanding at December 31, 2020 5,919 $ 5.25RSUs granted 3,744   35.33RSUs released (1,798)   5.13RSUs forfeited (473)   16.68Unvested RSUs outstanding at December 31, 2021 7,392 $ 19.78Performance-based RSUs&#160;The Compensation Committee of the Board of Directors approved awards of RSUs with performance-based vesting under the 2010 Plan to certain employees which expired on July 29, 2020. Performance-based RSUs are governed under the 2020 Plan.The following table summarizes the performance-based RSUs activity for the year ended December 31, 2021 (in thousands, except per share amounts):          Weighted average Number grant date of shares fair valuePSUs outstanding at December 31, 2020 94 $$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2.63PSUs granted &#x2014;   &#x2014;PSUs released &#x2014;   &#x2014;PSUs forfeited (94)   2.63Unvested PSUs outstanding at December 31, 2021 &#x2014; $ &#x2014;2010 Employee Stock Purchase Plan As of December 31, 2021, a total of 21.5 million shares of our common stock have been reserved for issuance under our 2010 Employee Stock Purchase Plan (ESPP).  The ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Each offering period will generally consist of four purchase periods, each purchase period being approximately six months. The price at which the stock is purchased is equal to the lower of 85% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period. Each offering period will generally end and the shares will be purchased twice yearly on March 1 and September 1. If the stock price at the end of the purchase period is lower than the stock price at the beginning of the offering period, that offering period will then be terminated and new offering period comes to place. The ESPP provides for an annual increase to the shares available for issuance at the beginning of each fiscal year equal to the lessor of 2% of the common shares then outstanding, 4,000,000 shares, or an amount determined by the ESPP&#x2019;s administrator. Pursuant to the terms of the then-in-process Merger Agreement with Illumina, offerings under our 2010 ESPP were suspended after the completion of the purchase period ended March 1, 2019. After the merger with Illumina was terminated in January 2020, we began offerings under the ESPP again starting with the offering period beginning March 1, 2020.  For the years ended December&#160;31, 2021, 2020 and 2019, 1,913,968 shares, 834,677 shares and 1,306,329 shares of common stock were purchased under the ESPP, respectively. As of December 31, 2021, 7,810,673 shares of our common stock remain available for issuance under our ESPP. Stock-based Compensation Total stock-based compensation expense consists of the following (in thousands):                    Years Ended December 31,  2021 2020 2019Cost of revenue$ 6,126 $ 2,236 $ 1,857Research and development  20,275   7,061   7,699Sales, general and administrative  35,403   8,236   6,845Merger-related expenses - stock-settled  6,349   &#x2014;   &#x2014;Merger-related expenses - milestone  5,202   &#x2014;   &#x2014;Stock-based compensation  73,355   17,533   16,401Merger-related expenses - cash-settled  7,373   &#x2014;   &#x2014;Total stock-based compensation expense$ 80,728 $ 17,533 $ 16,401As of December 31, 2021 and 2020, $0.9 million and $0.3 million of stock-based compensation cost was capitalized in inventory on our consolidated balance sheets, respectively. The tax benefit of stock-based compensation expense was immaterial for the years ended December 31, 2021, 2020 and 2019. Determining Fair ValueWe estimate the fair value of share options granted using the Black-Scholes valuation method and a single option award approach. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSU awards granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting period. For shares purchased under our Employee Stock Purchase Plan, or ESPP, we estimate the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model.Expected Term - The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock options and vesting schedules.Expected Volatility - The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.Expected Dividend - We have never paid dividends on our shares and, accordingly, the dividend yield percentage is zero for all periods.Risk-Free Interest Rate - The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.Stock OptionsWe estimated the fair value of employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. For the year ended December 31, 2019, we did not grant any stock options. When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference observable market prices of similar or identical instruments in active markets.  For the years ended December 31, 2021, 2020 and 2019, the fair value of employee stock options was estimated using the following weighted average assumptions:                      Years Ended December 31,   2021 2020 2019Expected term in years  2.1 - 4.6  5.0 years   &#x2014;&#160;&#160;Expected volatility   67% - 80%  70.7%  &#x2014;&#160;&#160;Risk-free interest rate   0.05% &#x2013; 1.10%  0.3%  &#x2014;&#160;&#160;Dividend yield   &#x2014;&#160;&#160;  &#x2014;&#160;&#160;  &#x2014;&#160;&#160;Weighted average grant date fair value per share  $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;15.53  $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7.20  &#x2014;&#160;&#160;          Cash received from option exercises for the years ended December&#160;31, 2021, 2020 and 2019 was $25.4 million, $43.9 million and $5.9 million, respectively.  ESPP We estimate the fair value of shares to be issued under the ESPP using the Black-Scholes option pricing model. For the years ended December 31, 2021, 2020 and 2019, the fair value of shares to be issued under the ESPP was estimated using the following assumptions:                      Years Ended December 31,   2021 2020 2019Expected term in years  0.5 - 2.0  0.5 - 2.0  &#x2014;&#160;&#160;Expected volatility   67% - 68%  57% - 71%  &#x2014;&#160;&#160;Risk-free interest rate   0.1% - 0.2%  0.1%-1.0%  &#x2014;&#160;&#160;Dividend yield    &#x2014;  &#x2014;&#160;&#160;  &#x2014;&#160;&#160;Weighted average grant date fair value per share  $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25.07  $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1.87  &#x2014;&#160;&#160; Cash received through the ESPP for the years ended December 31, 2021, 2020 and 2019 was $6.4 million, $2.4 million and $2.7 million, respectively. As of December&#160;31, 2021, $122.9 million of total unrecognized compensation expense related to stock options, restricted stock and ESPP shares was expected to be recognized over a weighted-average period of 2.9 years.&#160;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_10_31_2010"
      decimals="INF"
      id="ct-nonFraction-96542b5e-e9b7-4b34-8f6e-58bf81424904"
      unitRef="Unit1">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_10_31_2010"
      decimals="3"
      id="ct-nonFraction-5e540e51-7e73-42ac-89d5-49bd4fb3dbea"
      unitRef="Unit13">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_10_31_2010"
      decimals="0"
      id="ct-nonFraction-56d22280-d2e7-43e5-bc0d-834a9ee72990"
      unitRef="Unit1">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_10_31_2010"
      decimals="3"
      id="ct-nonFraction-d063e17a-9c29-4447-aff5-2af6711b68a4"
      unitRef="Unit13">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020"
      decimals="INF"
      id="ct-nonFraction-3eefa605-2348-4e9e-bdd6-dbf57db69207"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-50ecd1f8-f0f2-4311-b41c-4b7c8a9b0fa1"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020"
      decimals="INF"
      id="ct-nonFraction-a36203d4-7efe-4588-94cd-3f05c60875bd"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-ae8b49ec-bbbc-4620-aced-de7e20ab0f33"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-bd97a32a-672c-4035-8b1c-c0f1c14cfc56"
      unitRef="Unit13">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockVotingRights
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-1356ebf1-f440-422f-bca9-5b5f795fd2e7">one</us-gaap:CommonStockVotingRights>
    <pacb:CommonStockVotingRightsNumberOfVotesPerShareOwned
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-66fa351e-8852-4381-a2bb-aa03816c9796"
      unitRef="Unit14">1</pacb:CommonStockVotingRightsNumberOfVotesPerShareOwned>
    <pacb:PublicOfferingShares
      contextRef="Duration_8_1_2020_To_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      decimals="INF"
      id="ct-nonFraction-5b1a3696-39ee-4e89-bf75-ee75ff7f06c3"
      unitRef="Unit1">19430000</pacb:PublicOfferingShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      decimals="3"
      id="ct-nonFraction-186b023a-4071-426a-aadf-f2c9c7d2fdcb"
      unitRef="Unit13">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <pacb:OfferingShareAmountMaximum
      contextRef="As_Of_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      decimals="INF"
      id="ct-nonFraction-f5a21929-aff9-407d-a1c3-dbb579e9b95d"
      unitRef="Unit13">4.47</pacb:OfferingShareAmountMaximum>
    <pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod
      contextRef="Duration_8_1_2020_To_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      id="ct-nonNumeric-92c6ce20-ff63-4eb2-bc7e-ef705461a5a6">P30D</pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod>
    <pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares
      contextRef="Duration_8_1_2020_To_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      decimals="INF"
      id="ct-nonFraction-5ec9797e-26d8-435d-b63f-f8afa6a301d4"
      unitRef="Unit1">2914500</pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_1_2020_To_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      decimals="-5"
      id="ct-nonFraction-5fc4bcb5-19c0-4629-a12c-2bafa9379898"
      unitRef="Unit1">22300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering
      contextRef="Duration_8_1_2020_To_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      decimals="INF"
      id="ct-nonFraction-d9d4cd71-db29-428e-af46-d4e0563a75e6"
      unitRef="Unit15">0.06</pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering>
    <pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="Duration_8_1_2020_To_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      decimals="-5"
      id="ct-nonFraction-0611f5a8-8d19-4f71-b264-1fe5472827bf"
      unitRef="Unit12">93900000</pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="As_Of_8_31_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      decimals="-5"
      id="ct-nonFraction-ff8dd3ab-1fe8-44e9-b2e6-28769fc2e5ef"
      unitRef="Unit12">300000</us-gaap:DeferredOfferingCosts>
    <pacb:PublicOfferingShares
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      decimals="INF"
      id="ct-nonFraction-fc7c0c6e-3e3c-40c3-83cc-f802309004ad"
      unitRef="Unit1">6096112</pacb:PublicOfferingShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      decimals="3"
      id="ct-nonFraction-2ae7e250-2709-4632-ba82-13fbab03981c"
      unitRef="Unit13">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <pacb:OfferingShareAmountMaximum
      contextRef="As_Of_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      decimals="INF"
      id="ct-nonFraction-a1bf90d2-3ba6-41a5-9686-efb7ad640959"
      unitRef="Unit13">14.25</pacb:OfferingShareAmountMaximum>
    <pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      id="ct-nonNumeric-7b664084-ab0e-47fa-9966-8b519194516e">P30D</pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod>
    <pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      decimals="INF"
      id="ct-nonFraction-e384a21c-060c-48ac-a778-ca9e6f51b5cb"
      unitRef="Unit1">914416</pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      decimals="-5"
      id="ct-nonFraction-fca2c2b6-b642-46a7-8e0e-5ae744ec18bc"
      unitRef="Unit1">7000000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      decimals="INF"
      id="ct-nonFraction-05ebe1e9-e8a3-461a-9693-7eb1a26d0cfe"
      unitRef="Unit15">0.06</pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering>
    <pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      decimals="-5"
      id="ct-nonFraction-7e32f61c-72da-414d-b15a-fc3a2a6f59e3"
      unitRef="Unit12">93900000</pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="As_Of_11_30_2020_srt_StatementScenarioAxis_pacb_UnderwritingAgreementMember"
      decimals="-5"
      id="ct-nonFraction-219e158b-2be0-4e74-a643-71395056c9f9"
      unitRef="Unit12">300000</us-gaap:DeferredOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_pacb_UnderwrittenPublicEquityOfferingMember"
      decimals="-5"
      id="ct-nonFraction-9d1140cb-12fb-4861-9f65-b77281c6a08f"
      unitRef="Unit1">29400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <pacb:NumberOfOfferings
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_pacb_UnderwrittenPublicEquityOfferingMember"
      decimals="INF"
      id="ct-nonFraction-1ae30328-cbc5-4a6e-8860-279408b4f9ba"
      unitRef="Unit14">2</pacb:NumberOfOfferings>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2021_srt_StatementScenarioAxis_pacb_UnderwrittenPublicEquityOfferingMember"
      decimals="2"
      id="ct-nonFraction-e55eb629-fcd1-4334-a992-a4ed631c99a4"
      unitRef="Unit13">6.40</us-gaap:SharesIssuedPricePerShare>
    <pacb:NumberOfOfferings
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_pacb_UnderwrittenPublicEquityOfferingMember"
      decimals="INF"
      id="ct-nonFraction-e264baee-2445-423a-819c-613ff840ffa4"
      unitRef="Unit14">2</pacb:NumberOfOfferings>
    <pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_pacb_UnderwrittenPublicEquityOfferingMember"
      decimals="-5"
      id="ct-nonFraction-924cae20-5cb7-49fd-9e3c-1e68d6731f9b"
      unitRef="Unit12">187200000</pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_20_2021_us-gaap_StatementEquityComponentsAxis_pacb_PrivatePlacementOfCommonStockMember"
      decimals="INF"
      id="ct-nonFraction-0ec15364-fa9c-4d9d-8c36-cbceaf18c41c"
      unitRef="Unit1">11214953</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_9_20_2021_us-gaap_StatementEquityComponentsAxis_pacb_PrivatePlacementOfCommonStockMember"
      decimals="2"
      id="ct-nonFraction-8c457f30-590f-411c-827b-d160402b1473"
      unitRef="Unit13">26.75</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_StatementEquityComponentsAxis_pacb_PrivatePlacementOfCommonStockMember"
      decimals="-6"
      id="ct-nonFraction-423f7a88-c441-47f4-9cbc-76536684b76a"
      unitRef="Unit12">300000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_8_4_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EquityIncentivePlan2020Member"
      decimals="0"
      id="ct-nonFraction-74d35d38-907c-4741-b244-829fe8c860ef"
      unitRef="Unit1">11000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_2_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_InducementEquityIncentivePlan2020Member"
      decimals="0"
      id="ct-nonFraction-502ba08d-5989-4746-a51f-fdf14d16f9e3"
      unitRef="Unit1">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_4_21_2021_To_4_21_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_InducementEquityIncentivePlan2020Member"
      decimals="0"
      id="ct-nonFraction-fbcc4a41-deba-46a8-a1f0-1c9b5d8e307b"
      unitRef="Unit1">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_11_22_2021_To_11_22_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_InducementEquityIncentivePlan2020Member"
      decimals="0"
      id="ct-nonFraction-c3adacbd-7c59-4e4f-b6ea-1ddcd71a0151"
      unitRef="Unit1">360000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <pacb:ExchangeRatio
      contextRef="Duration_9_20_2021_To_9_20_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember"
      decimals="INF"
      id="ct-nonFraction-320d54b5-c5b0-40c5-a305-36e383ebcd53"
      unitRef="Unit14">0.259204639</pacb:ExchangeRatio>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_9_20_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember"
      decimals="INF"
      id="ct-nonFraction-f7ca43fd-caf3-43da-ad34-dc2caf10adcf"
      unitRef="Unit1">2494128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_InducementEquityIncentivePlan2020Member"
      decimals="-5"
      id="ct-nonFraction-7abd6315-accf-429b-a040-dd29cd042b47"
      unitRef="Unit1">8100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionsMember"
      id="ct-nonNumeric-04441bd1-997f-4c72-a26b-5874a82d1f49">                    Stock Options Outstanding       Weighted  Number    average  of shares Exercise price exercise priceOutstanding at December 31, 2020  14,638 $ 1.16 &#x2013; 20.90 $ 5.53Granted   2,489  23.06 &#x2013; 46.37   33.78Assumed Omniome options  339  2.05 &#x2013; 4.90   4.43Exercised   (4,766)  1.16 &#x2013; 15.98   5.31Canceled   (541)  2.54 &#x2013; 46.37   5.25Outstanding at December 31, 2021  12,159 $1.16 &#x2013; 46.37 $ 11.38</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember"
      decimals="-3"
      id="ct-nonFraction-bd0a3235-9737-4452-8442-cb89fad1964e"
      unitRef="Unit1">14638000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember"
      decimals="INF"
      id="ct-nonFraction-009aa21b-f8f9-4cb6-9df7-ee02c76df623"
      unitRef="Unit13">1.16</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember"
      decimals="INF"
      id="ct-nonFraction-13d0ddba-68c7-4921-8f8b-dd70779a40b9"
      unitRef="Unit13">20.90</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember"
      decimals="INF"
      id="ct-nonFraction-820a24c3-e2e6-4ebe-b058-e00144055a36"
      unitRef="Unit13">5.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTwoMember"
      decimals="-3"
      id="ct-nonFraction-9d929e1b-b523-4d49-8a56-4ffbbc25fac9"
      unitRef="Unit1">2489000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTwoMember"
      decimals="INF"
      id="ct-nonFraction-92de6e4a-96ea-40a7-a8c3-450c6c86d4ce"
      unitRef="Unit13">23.06</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTwoMember"
      decimals="INF"
      id="ct-nonFraction-0dd53b58-0fa2-45af-aaac-aca5ec15b1ae"
      unitRef="Unit13">46.37</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTwoMember"
      decimals="INF"
      id="ct-nonFraction-2ee5e7b3-4f8b-4e4a-932a-35611645394a"
      unitRef="Unit13">33.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionMember"
      decimals="-3"
      id="ct-nonFraction-0a6e3b54-0e68-4c88-96ad-146f4342d868"
      unitRef="Unit1">339000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionMember"
      decimals="INF"
      id="ct-nonFraction-02bece14-5377-4333-b739-db7e1478d742"
      unitRef="Unit13">2.05</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionMember"
      decimals="INF"
      id="ct-nonFraction-2580acbc-afe6-4219-b1ea-f5c987ac80c3"
      unitRef="Unit13">4.90</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionMember"
      decimals="INF"
      id="ct-nonFraction-be3623d7-b282-48dd-bdb6-969c6a681e3d"
      unitRef="Unit13">4.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThreeMember"
      decimals="-3"
      id="ct-nonFraction-a625d643-a65d-4856-a7a5-09c8609e562f"
      unitRef="Unit1">4766000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThreeMember"
      decimals="INF"
      id="ct-nonFraction-17677cbc-96d8-45f9-9e6c-ff9a8030f65e"
      unitRef="Unit13">1.16</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThreeMember"
      decimals="INF"
      id="ct-nonFraction-42cfc3b6-8489-4e95-b661-d77b2284c6e6"
      unitRef="Unit13">15.98</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThreeMember"
      decimals="INF"
      id="ct-nonFraction-4888b02c-1490-48d3-bca8-a5e71257e688"
      unitRef="Unit13">5.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourMember"
      decimals="-3"
      id="ct-nonFraction-68a61345-0e42-44f9-bc48-6a9381b28307"
      unitRef="Unit1">541000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourMember"
      decimals="INF"
      id="ct-nonFraction-552ce895-5b1d-4ef0-9aac-7b7c0ecf6a85"
      unitRef="Unit13">2.54</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourMember"
      decimals="INF"
      id="ct-nonFraction-7ba04cb8-d3ca-4cfb-863c-0445287d5fa1"
      unitRef="Unit13">46.37</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourMember"
      decimals="INF"
      id="ct-nonFraction-16ea7c44-e69a-4102-9a4b-c92c06e36a41"
      unitRef="Unit13">5.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFiveMember"
      decimals="-3"
      id="ct-nonFraction-1ff0130c-b3f3-4747-9eff-be97a7c8d679"
      unitRef="Unit1">12159000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFiveMember"
      decimals="INF"
      id="ct-nonFraction-fcc9671b-de99-4bda-9d07-996b9c035c59"
      unitRef="Unit13">1.16</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFiveMember"
      decimals="INF"
      id="ct-nonFraction-a9c170a9-03b5-41ac-a268-784e042033a8"
      unitRef="Unit13">46.37</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFiveMember"
      decimals="INF"
      id="ct-nonFraction-35b06228-9146-461a-848d-976d91a574a4"
      unitRef="Unit13">11.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="-4"
      id="ct-nonFraction-e681d321-01cb-44d7-9853-29740a89eb16"
      unitRef="Unit1">20000.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember"
      decimals="2"
      id="ct-nonFraction-d6780d00-a2b6-40e3-a64b-20b2c9bf5a86"
      unitRef="Unit13">2.54</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember"
      decimals="2"
      id="ct-nonFraction-657be5b8-8643-4fb5-94de-69d6ddec0c9f"
      unitRef="Unit13">46.37</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeOneMember"
      decimals="2"
      id="ct-nonFraction-3ea1ee24-b394-4b15-ac80-18d91462f7ca"
      unitRef="Unit13">9.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      id="ct-nonNumeric-7786e635-76dc-4381-b12e-444e3d8a0b13">                    Stock Options Outstanding       Weighted  Number    average  of shares Exercise price exercise priceOutstanding at December 31, 2020  &#x2014; $ &#x2014; $ &#x2014;Granted   &#x2014;   &#x2014;   &#x2014;Assumed Omniome options  304  4.71 - 4.90   4.71Exercised   &#x2014;   &#x2014;   &#x2014;Canceled   &#x2014;   &#x2014;   &#x2014;Outstanding at December 31, 2021  304 $4.71 - 4.90 $ 4.71</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember"
      decimals="0"
      id="ct-nonFraction-207120a0-8164-4a92-9c22-3c0376e35f01"
      unitRef="Unit1">304000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember"
      decimals="2"
      id="ct-nonFraction-a3e5062c-d317-477b-a9cb-5762632873f3"
      unitRef="Unit13">4.71</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember"
      decimals="2"
      id="ct-nonFraction-04d2e1cd-8c18-4b34-b212-634dbb03d3f4"
      unitRef="Unit13">4.90</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember"
      decimals="2"
      id="ct-nonFraction-64f9d9c5-b182-4ca6-acaf-cd95c8994bb5"
      unitRef="Unit13">4.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember"
      decimals="0"
      id="ct-nonFraction-6f8f98cc-80d8-4bf8-8ab5-93465eb52896"
      unitRef="Unit1">304000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember"
      decimals="2"
      id="ct-nonFraction-952d3d55-9400-432c-bbb8-72a8cedac1a5"
      unitRef="Unit13">4.71</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember"
      decimals="2"
      id="ct-nonFraction-1945d1e9-554b-479d-a71e-3e0c51092812"
      unitRef="Unit13">4.90</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_OmniomePlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeAcqusitionTwoMember"
      decimals="2"
      id="ct-nonFraction-b7c89c33-7097-4b1c-9eee-0b527d1abe5d"
      unitRef="Unit13">4.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-7ec79656-3b74-4e55-9372-8a57324f60e5">                               Options Outstanding Options Exercisable   Number Weighted average    Number      outstanding remaining contractual Weighted average  vested Weighted average  Exercise price(in 000s) life (Years) exercise price (in 000s) exercise price $0.00 - 4.64 3,676  5.37 $ 2.91  3,508 $ 2.91 $4.64 - 9.27 5,480  5.88 $ 6.64  4,010 $ 6.68 $9.27 - 13.91 702  6.69 $ 9.81  427 $ 9.94 $13.91 - 18.55 35  8.79 $ 14.34  14 $ 14.34 $ 18.55 - 23.19 180  9.38 $ 21.86  25 $ 20.90 $23.19 - 27.82 320  9.50 $ 24.22  &#x2014; $ &#x2014; $27.82 - 32.46 472  9.43 $ 28.77  52 $ 27.90 $ 32.46 - 37.10 1,380  9.00 $ 36.18  &#x2014; $ &#x2014; $41.73 - 46.37 218  9.13 $ 46.37  45 $ 46.37    12,463  6.47 $ 11.22  8,081 $ 5.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember"
      decimals="INF"
      id="ct-nonFraction-6d3ccb66-6ea1-4996-a525-4a0314b48794"
      unitRef="Unit13">0.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember"
      decimals="INF"
      id="ct-nonFraction-a28b32b2-f5da-4845-8142-ceb05aafd4dc"
      unitRef="Unit13">4.64</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember"
      decimals="-3"
      id="ct-nonFraction-3b2a2cd6-1b3a-4222-9f22-4351aded3159"
      unitRef="Unit1">3676000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember"
      id="ct-nonNumeric-267c2923-40c7-4324-bb30-40bcedf63a7d">P5Y4M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember"
      decimals="2"
      id="ct-nonFraction-5d648b1f-06b4-47fe-9656-252b4460f6c0"
      unitRef="Unit13">2.91</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember"
      decimals="0"
      id="ct-nonFraction-0afae772-42bb-485b-852e-82a738bc579e"
      unitRef="Unit1">3508</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSixMember"
      decimals="2"
      id="ct-nonFraction-5dc52550-6e86-4d44-9149-c9ab9702ecba"
      unitRef="Unit13">2.91</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember"
      decimals="INF"
      id="ct-nonFraction-b6bc4a85-36e7-4c1f-a83f-9c60698d426f"
      unitRef="Unit13">4.64</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember"
      decimals="INF"
      id="ct-nonFraction-347854a2-0a05-436a-a79d-fcb347c3f935"
      unitRef="Unit13">9.27</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember"
      decimals="-3"
      id="ct-nonFraction-334e0171-ad51-4732-bba2-b8fce81e5953"
      unitRef="Unit1">5480000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember"
      id="ct-nonNumeric-7560aca1-8b18-492a-b10d-d2eafe956b40">P5Y10M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember"
      decimals="2"
      id="ct-nonFraction-57d2a885-4be7-4b3a-adf1-b9d76e7ccd18"
      unitRef="Unit13">6.64</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember"
      decimals="0"
      id="ct-nonFraction-abea4916-6d2b-4925-9ede-ae065c3e9e64"
      unitRef="Unit1">4010</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeSevenMember"
      decimals="2"
      id="ct-nonFraction-cccf8efa-c6bf-4b0c-a814-f3d1d6a65d30"
      unitRef="Unit13">6.68</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember"
      decimals="INF"
      id="ct-nonFraction-441a6f52-0b3b-4a7d-9fac-0db8eea6fc7f"
      unitRef="Unit13">9.27</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember"
      decimals="INF"
      id="ct-nonFraction-5e9acfc3-6d41-4b36-b4f3-9b901e811fae"
      unitRef="Unit13">13.91</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember"
      decimals="-3"
      id="ct-nonFraction-ec777f85-1d94-43d5-8b91-827bb69c12b9"
      unitRef="Unit1">702000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember"
      id="ct-nonNumeric-729e6ac6-8a3c-4b9b-a139-3d6f8cd71ba9">P6Y8M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember"
      decimals="2"
      id="ct-nonFraction-a6d92eab-e5cd-4e64-809d-905c475893ff"
      unitRef="Unit13">9.81</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember"
      decimals="0"
      id="ct-nonFraction-c5ca2927-3520-4070-bb0d-5421c3fea5b0"
      unitRef="Unit1">427</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeEightMember"
      decimals="2"
      id="ct-nonFraction-b151738a-d4a4-4a43-9fb5-e227c4eabf37"
      unitRef="Unit13">9.94</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember"
      decimals="INF"
      id="ct-nonFraction-0ffb110b-d0ae-45ee-a3ec-1e39d5758880"
      unitRef="Unit13">13.91</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember"
      decimals="INF"
      id="ct-nonFraction-ddc4698d-4805-4a43-9cb9-bc3366d4a0fe"
      unitRef="Unit13">18.55</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember"
      decimals="-3"
      id="ct-nonFraction-c1ffd3d8-ea87-4c22-b418-99d52a1cea60"
      unitRef="Unit1">35000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember"
      id="ct-nonNumeric-eb65caf3-7bf6-40b9-aaf8-f1b746cfb1bf">P8Y9M14D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember"
      decimals="2"
      id="ct-nonFraction-1c6e267d-e98b-4ea0-b2fc-ac7e04b19000"
      unitRef="Unit13">14.34</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember"
      decimals="0"
      id="ct-nonFraction-fd7922d4-ffe4-4ec7-a1c3-cd393f1b998a"
      unitRef="Unit1">14</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeNineMember"
      decimals="2"
      id="ct-nonFraction-7e07150b-f15b-46ac-9a31-59ffe8122569"
      unitRef="Unit13">14.34</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember"
      decimals="INF"
      id="ct-nonFraction-6209f12d-6bbb-47ff-9840-8df27210c2d4"
      unitRef="Unit13">18.55</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember"
      decimals="INF"
      id="ct-nonFraction-64278d91-1fa9-4144-8145-7b653ffaaaab"
      unitRef="Unit13">23.19</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember"
      decimals="-3"
      id="ct-nonFraction-cde44e46-4905-4ed8-9ddf-7fffcc65b529"
      unitRef="Unit1">180000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember"
      id="ct-nonNumeric-f754cd39-3b2c-4b66-960b-35f28021dc1d">P9Y4M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember"
      decimals="2"
      id="ct-nonFraction-c215b008-ece2-4247-9052-6a188cb76901"
      unitRef="Unit13">21.86</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember"
      decimals="0"
      id="ct-nonFraction-d01dab73-3d7c-41ad-9c9c-febf4ff45155"
      unitRef="Unit1">25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeTenMember"
      decimals="2"
      id="ct-nonFraction-f2513e93-dfc3-4d5b-ae54-2e690b72cf64"
      unitRef="Unit13">20.90</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeElevenMember"
      decimals="INF"
      id="ct-nonFraction-7bba64ec-96ae-4349-9710-6cf787b65c43"
      unitRef="Unit13">23.19</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeElevenMember"
      decimals="INF"
      id="ct-nonFraction-fe688ab0-0ccb-42b6-b355-5f08d2083880"
      unitRef="Unit13">27.82</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeElevenMember"
      decimals="-3"
      id="ct-nonFraction-a53a01bb-8e43-485c-98ab-ec620051ce6d"
      unitRef="Unit1">320000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeElevenMember"
      id="ct-nonNumeric-d0d47cff-5d41-4bec-9453-b983adfe023c">P9Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeElevenMember"
      decimals="2"
      id="ct-nonFraction-ed7623d5-d77f-4c33-bbf1-b18104d9095e"
      unitRef="Unit13">24.22</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember"
      decimals="2"
      id="ct-nonFraction-3054b960-1053-45a2-a9ba-bf19c3e2ee21"
      unitRef="Unit13">27.82</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember"
      decimals="2"
      id="ct-nonFraction-6cda0aca-39ac-4a1c-84e0-a2575444a000"
      unitRef="Unit13">32.46</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember"
      decimals="-3"
      id="ct-nonFraction-816775b6-158b-4937-9d1c-383427abeeec"
      unitRef="Unit1">472000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember"
      id="ct-nonNumeric-8838ab9e-c301-4817-b3e8-e0f67040428b">P9Y5M4D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember"
      decimals="2"
      id="ct-nonFraction-ef9c94cd-5992-4d70-b293-8f5f1414bf9a"
      unitRef="Unit13">28.77</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember"
      decimals="0"
      id="ct-nonFraction-20598e8d-bd90-4692-870a-3d96e944366b"
      unitRef="Unit1">52</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeThirteenMember"
      decimals="2"
      id="ct-nonFraction-e4f63b7b-9da6-4a74-ba11-a77a1d4078cb"
      unitRef="Unit13">27.90</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourteenMember"
      decimals="2"
      id="ct-nonFraction-518d84a4-ca8a-4ac7-9ea7-58b9308c80f1"
      unitRef="Unit13">32.46</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourteenMember"
      decimals="2"
      id="ct-nonFraction-aba41de2-c0f3-4305-9b74-0223a53a07ab"
      unitRef="Unit13">37.10</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourteenMember"
      decimals="-3"
      id="ct-nonFraction-6c8af849-2f5c-49d9-8faf-852cf01aea4c"
      unitRef="Unit1">1380000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourteenMember"
      id="ct-nonNumeric-84712b46-6ea4-4f6d-968e-75fd1a7d93b7">P9Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFourteenMember"
      decimals="2"
      id="ct-nonFraction-6743c6ce-0dec-4f17-a6bc-d6209bacdd42"
      unitRef="Unit13">36.18</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember"
      decimals="INF"
      id="ct-nonFraction-16686fd2-4344-4834-8314-d4eaaf0d1e92"
      unitRef="Unit13">41.73</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember"
      decimals="INF"
      id="ct-nonFraction-13ad147e-f247-4686-a792-1aa091376fd8"
      unitRef="Unit13">46.37</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember"
      decimals="-3"
      id="ct-nonFraction-e2b05ab9-b60e-40e2-9cb3-222e2178ded1"
      unitRef="Unit1">218000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember"
      id="ct-nonNumeric-40ed5421-bd81-403f-9c0f-3009f660b84b">P9Y1M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember"
      decimals="2"
      id="ct-nonFraction-f2bd0996-ca28-4514-b9cb-605b40f4ebbc"
      unitRef="Unit13">46.37</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember"
      decimals="0"
      id="ct-nonFraction-99f93bd1-ec0c-4740-b0ca-34dcb93d006b"
      unitRef="Unit1">45</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_pacb_ExercisePriceRangeFifteenMember"
      decimals="2"
      id="ct-nonFraction-063cfae5-2ba8-4e5c-b822-1effef3197bc"
      unitRef="Unit13">46.37</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="-3"
      id="ct-nonFraction-4885d3ad-0d31-4190-b4d3-9599c176f016"
      unitRef="Unit1">12463000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      id="ct-nonNumeric-fc2fe679-f37a-427b-9cd2-fde365f885ee">P6Y5M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="2"
      id="ct-nonFraction-72f98c10-eb75-479f-a35f-265b8d6aaa28"
      unitRef="Unit13">11.22</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="0"
      id="ct-nonFraction-b0c51488-cebf-4393-8e39-21cd6b52ebdb"
      unitRef="Unit1">8081</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="2"
      id="ct-nonFraction-7d0fd138-f84e-4d3d-9b89-c3f42fb60cfa"
      unitRef="Unit13">5.63</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="-5"
      id="ct-nonFraction-4b2f062d-df3e-4162-9aaa-01a032761234"
      unitRef="Unit12">147900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="-5"
      id="ct-nonFraction-6511611a-1a11-46fa-b65b-c3593abe92cd"
      unitRef="Unit12">121400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="2"
      id="ct-nonFraction-d870224b-a895-494b-ac8a-672bb69396a9"
      unitRef="Unit13">20.46</us-gaap:SharePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonNumeric-391ba3ba-6f74-4bd5-b81b-51e001b5484c">P5Y1M13D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="INF"
      id="ct-nonFraction-8bce952c-4a31-4c22-af61-5f657c6234e6"
      unitRef="Unit1">11535217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="-5"
      id="ct-nonFraction-05697323-8984-4a24-939e-1ec9a86a8fd7"
      unitRef="Unit12">141900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="2"
      id="ct-nonFraction-469f88cb-103e-4feb-aaa3-dc20a9b512cd"
      unitRef="Unit13">10.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      id="ct-nonNumeric-325ecf7e-3921-43d4-a9d1-082e08e3d6b4">P6Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="-5"
      id="ct-nonFraction-f8c8a2ac-0389-4916-bc4b-6dd9eb2d1d5f"
      unitRef="Unit12">146100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="-5"
      id="ct-nonFraction-257d6fc7-6c62-4a2f-b746-f57bde63f072"
      unitRef="Unit12">63100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="-5"
      id="ct-nonFraction-6e1190d0-2b79-4549-bb8a-d20bd387b94a"
      unitRef="Unit12">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-2860afa6-2160-4830-9482-41da78b95ea9"
      unitRef="Unit13">18.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="2"
      id="ct-nonFraction-9c2884dd-d6ec-4bbe-a7fe-4fa703855426"
      unitRef="Unit13">4.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <pacb:ShareInstrumentNumberOfSharesConversionRatio
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"
      decimals="INF"
      id="ct-nonFraction-00ca43e5-0815-46cf-a8ca-416088168b74"
      unitRef="Unit1">1</pacb:ShareInstrumentNumberOfSharesConversionRatio>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"
      id="ct-nonNumeric-e6b3aab0-7c22-4975-91bb-1cbef8f186bb">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_VestingAxis_pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember"
      decimals="INF"
      id="ct-nonFraction-694f8b3f-ae72-4776-b776-a0774e1860ab"
      unitRef="Unit15">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-ee83c78b-7d2e-4acf-a04a-92d90a0c8423">        Weighted average Number grant date of shares fair valueRSUs outstanding at December 31, 2020 5,919 $ 5.25RSUs granted 3,744   35.33RSUs released (1,798)   5.13RSUs forfeited (473)   16.68Unvested RSUs outstanding at December 31, 2021 7,392 $ 19.78</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"
      decimals="-3"
      id="ct-nonFraction-ef155ab0-5c83-47a1-a666-b583c25eafa9"
      unitRef="Unit1">5919000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"
      decimals="INF"
      id="ct-nonFraction-6fe753cf-7f14-4410-9e24-d9c3c938b3de"
      unitRef="Unit13">5.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"
      decimals="-3"
      id="ct-nonFraction-2517020a-31c2-4053-a8ae-1651d3c8dc02"
      unitRef="Unit1">3744000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"
      decimals="2"
      id="ct-nonFraction-baa6fdf5-78ea-4582-bae9-1ac6189d7e56"
      unitRef="Unit13">35.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"
      decimals="-3"
      id="ct-nonFraction-66653d9e-f780-4639-b6bc-79a63fdaf83b"
      unitRef="Unit1">1798000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"
      decimals="2"
      id="ct-nonFraction-7a1a00ec-9307-4051-b95b-6c8c4547e59a"
      unitRef="Unit13">5.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"
      decimals="-3"
      id="ct-nonFraction-3efdb89f-2685-4fe5-b24d-229fa33b2b4c"
      unitRef="Unit1">473000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"
      decimals="2"
      id="ct-nonFraction-95cd3856-5b5f-4218-bd4b-5d5b7f5ff898"
      unitRef="Unit13">16.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"
      decimals="-3"
      id="ct-nonFraction-d3923107-9cb2-4263-a705-58bf0d64b355"
      unitRef="Unit1">7392000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"
      decimals="2"
      id="ct-nonFraction-7735b3e3-79d9-4aca-a8ca-d9f7d8fd9ffc"
      unitRef="Unit13">19.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-dff1dc09-6e4d-4543-aa0e-b56a23e9acc9">        Weighted average Number grant date of shares fair valuePSUs outstanding at December 31, 2020 94 $$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2.63PSUs granted &#x2014;   &#x2014;PSUs released &#x2014;   &#x2014;PSUs forfeited (94)   2.63Unvested PSUs outstanding at December 31, 2021 &#x2014; $ &#x2014;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember"
      decimals="-3"
      id="ct-nonFraction-e4513b6b-f9da-445a-8bb7-40accb7b0897"
      unitRef="Unit1">94000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember"
      decimals="2"
      id="ct-nonFraction-071a014e-530e-481c-9591-43e6bb534ea0"
      unitRef="Unit13">2.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember"
      decimals="-3"
      id="ct-nonFraction-939c05c1-c68f-4924-a68b-2881ed015669"
      unitRef="Unit1">94000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember"
      decimals="2"
      id="ct-nonFraction-8717c31b-cedd-49bb-ad3b-df09f92ded0a"
      unitRef="Unit13">2.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_TwoThousandTenEquityIncentivePlanMember"
      decimals="-5"
      id="ct-nonFraction-7cd7c553-e0df-4c41-b0b9-077664fa950a"
      unitRef="Unit1">21500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pacb:NumberOfPurchasePeriods
      contextRef="As_Of_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="ct-nonFraction-4315f005-1573-48e5-b36c-f1cb8be4b32b"
      unitRef="Unit14">4</pacb:NumberOfPurchasePeriods>
    <pacb:PurchasePeriodOfEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      id="ct-nonNumeric-3a5c2e66-67f9-4720-a041-10b0671dc1b9">P6M</pacb:PurchasePeriodOfEmployeeStockPurchasePlan>
    <pacb:PercentageOfFairMarketValueAtWhichStockCanBePurchased
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="ct-nonFraction-548ca816-e2e3-41fd-9312-baf6f5cbe657"
      unitRef="Unit15">0.85</pacb:PercentageOfFairMarketValueAtWhichStockCanBePurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="2"
      id="ct-nonFraction-a9c507f6-11aa-486b-8ea2-a7dcf61d423d"
      unitRef="Unit15">0.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="0"
      id="ct-nonFraction-9bef6782-7f18-4776-bc34-64a4f77852e2"
      unitRef="Unit1">4000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="ct-nonFraction-9d90b554-10a0-4257-b766-74b8c13a889e"
      unitRef="Unit1">1913968</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="ct-nonFraction-786dfe2d-b6da-4262-b266-120055d29215"
      unitRef="Unit1">834677</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="ct-nonFraction-ff0cf5e9-610e-4f6f-bf3c-4f74d19261a5"
      unitRef="Unit1">1306329</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="ct-nonFraction-ea9d4ab2-d036-47aa-a33e-8f6569e9f349"
      unitRef="Unit1">7810673</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-ce062468-1e8c-4ab5-8e4b-2bd30d0fb6d4">                   Years Ended December 31,  2021 2020 2019Cost of revenue$ 6,126 $ 2,236 $ 1,857Research and development  20,275   7,061   7,699Sales, general and administrative  35,403   8,236   6,845Merger-related expenses - stock-settled  6,349   &#x2014;   &#x2014;Merger-related expenses - milestone  5,202   &#x2014;   &#x2014;Stock-based compensation  73,355   17,533   16,401Merger-related expenses - cash-settled  7,373   &#x2014;   &#x2014;Total stock-based compensation expense$ 80,728 $ 17,533 $ 16,401</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="ct-nonFraction-17e3be15-2033-42b8-8794-ab72903e91c9"
      unitRef="Unit12">6126000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="ct-nonFraction-ef52399c-3894-41c3-83ad-05e4c05966a0"
      unitRef="Unit12">2236000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="ct-nonFraction-eb4ab13b-fc9b-4377-a8e0-16eb644b2373"
      unitRef="Unit12">1857000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="ct-nonFraction-b93e7610-8a79-4ee5-81aa-f9f9a28360ab"
      unitRef="Unit12">20275000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="ct-nonFraction-110f1a26-d777-4624-961c-4ccce3c0db2f"
      unitRef="Unit12">7061000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="ct-nonFraction-6e4850fd-6ba0-4f93-aef4-02a48c2ab420"
      unitRef="Unit12">7699000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="ct-nonFraction-42cf26d8-17d0-44f8-b9b8-8989b05c82d9"
      unitRef="Unit12">35403000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="ct-nonFraction-56e40865-4347-443b-bc02-4b7e2e7abf0e"
      unitRef="Unit12">8236000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="ct-nonFraction-37bf6527-1140-42cc-818a-46406491b2aa"
      unitRef="Unit12">6845000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_pacb_MergerRelatedExpensesStockSettledMember"
      decimals="-3"
      id="ct-nonFraction-0f8fd475-6bfc-4da5-b298-d67bbac5bf3a"
      unitRef="Unit12">6349000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_pacb_MergerRelatedExpensesMilestoneMember"
      decimals="-3"
      id="ct-nonFraction-5abad583-a577-4ec1-a170-94e6d7461a17"
      unitRef="Unit12">5202000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_pacb_StockBasedCompensationMember"
      decimals="-3"
      id="ct-nonFraction-cd9fab44-fe41-4a48-b00e-2c37c5650aa6"
      unitRef="Unit12">73355000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_pacb_StockBasedCompensationMember"
      decimals="-3"
      id="ct-nonFraction-341d7418-7ea3-4da4-af31-c021145ed352"
      unitRef="Unit12">17533000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_pacb_StockBasedCompensationMember"
      decimals="-3"
      id="ct-nonFraction-10e9b3f5-15d2-4707-917b-4cbae82ee09d"
      unitRef="Unit12">16401000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_pacb_MergerRelatedExpensesCashSettledMember"
      decimals="-3"
      id="ct-nonFraction-ca68c3c9-dc2e-4618-bf9f-1e4985017b5d"
      unitRef="Unit12">7373000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-07751413-df9d-4fb7-bb31-2095bc196b61"
      unitRef="Unit12">80728000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-d424eed9-8e93-4c84-8685-c20de0a4d31b"
      unitRef="Unit12">17533000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-09053142-788c-4a9a-b8a8-bdf84bbc7047"
      unitRef="Unit12">16401000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-97ef6cfd-f35f-42d6-bffc-b0218373a481"
      unitRef="Unit12">900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-5"
      id="ct-nonFraction-3cf146db-133d-46d9-87c9-949c2cdf5364"
      unitRef="Unit12">300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="INF"
      id="ct-nonFraction-d99e41dd-4e8a-4d02-994f-ef7808d0f0c9"
      unitRef="Unit1">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-ec15ea9e-2851-4c49-8f8a-0e8ecc157477">                      Years Ended December 31,   2021 2020 2019Expected term in years  2.1 - 4.6  5.0 years   &#x2014;&#160;&#160;Expected volatility   67% - 80%  70.7%  &#x2014;&#160;&#160;Risk-free interest rate   0.05% &#x2013; 1.10%  0.3%  &#x2014;&#160;&#160;Dividend yield   &#x2014;&#160;&#160;  &#x2014;&#160;&#160;  &#x2014;&#160;&#160;Weighted average grant date fair value per share  $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;15.53  $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7.20  &#x2014;&#160;&#160;          </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      id="ct-nonNumeric-d544368e-c55e-4057-8c75-5bada83ea210">P2Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      id="ct-nonNumeric-c29241b4-9425-44f4-9022-dac127b57eca">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      id="ct-nonNumeric-a910f758-df3e-4397-946e-b04613e006b4">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="2"
      id="ct-nonFraction-78b1f4cd-028b-44f8-b286-1ba88f447e4c"
      unitRef="Unit15">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="2"
      id="ct-nonFraction-44b0249a-bb44-4a9b-be1c-58d93d8cbe9c"
      unitRef="Unit15">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="3"
      id="ct-nonFraction-8e7af148-fee7-4994-9efa-d96c0db0e57c"
      unitRef="Unit15">0.707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="4"
      id="ct-nonFraction-5afe349d-7b3a-481c-b1fe-7c67ee322127"
      unitRef="Unit15">0.0005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="4"
      id="ct-nonFraction-ff069c6e-2b44-43e4-86e6-3750d8c53dc4"
      unitRef="Unit15">0.0110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="3"
      id="ct-nonFraction-02f389c5-a8a5-42be-88ae-1064d04f48bf"
      unitRef="Unit15">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="2"
      id="ct-nonFraction-b3bcaf46-f52b-41fb-ae9a-cf6f6bcf884b"
      unitRef="Unit13">15.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="1"
      id="ct-nonFraction-f91faecf-5b21-455b-a652-ed2b8af55580"
      unitRef="Unit13">7.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="-5"
      id="ct-nonFraction-5a5b9e23-a755-41db-a862-87867ce30347"
      unitRef="Unit12">25400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="-5"
      id="ct-nonFraction-5b3d2655-ed97-4da4-80fd-59bedf99ec4d"
      unitRef="Unit12">43900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="-5"
      id="ct-nonFraction-4b79970b-8afe-4602-a063-99a9ed0550ab"
      unitRef="Unit12">5900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-38d5b823-97d9-43c4-b58b-d6c3c2fc791a">                      Years Ended December 31,   2021 2020 2019Expected term in years  0.5 - 2.0  0.5 - 2.0  &#x2014;&#160;&#160;Expected volatility   67% - 68%  57% - 71%  &#x2014;&#160;&#160;Risk-free interest rate   0.1% - 0.2%  0.1%-1.0%  &#x2014;&#160;&#160;Dividend yield    &#x2014;  &#x2014;&#160;&#160;  &#x2014;&#160;&#160;Weighted average grant date fair value per share  $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25.07  $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1.87  &#x2014;&#160;&#160;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      id="ct-nonNumeric-bd0370ae-f1d9-49fa-83d8-57147b5191f8">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      id="ct-nonNumeric-7734cc86-ae4e-4c2d-85b5-686e415128f4">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      id="ct-nonNumeric-a99c74fb-ffcc-4bbf-ac86-2c57dd87ee88">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      id="ct-nonNumeric-3eb193ef-be81-4ae6-a751-f83a66f60b68">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="2"
      id="ct-nonFraction-adeffcd8-da4a-409f-9a49-7ad171835900"
      unitRef="Unit15">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="2"
      id="ct-nonFraction-771e2a9e-9a20-4573-82f9-c03813b583e2"
      unitRef="Unit15">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="2"
      id="ct-nonFraction-4b4e3f7a-d950-4c85-bbb0-2cb0bbf5ef16"
      unitRef="Unit15">0.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="2"
      id="ct-nonFraction-61cfd96c-25e7-4e35-83b4-418d7690c416"
      unitRef="Unit15">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="ct-nonFraction-2064fcb9-4a42-4161-bbc2-22672131f36c"
      unitRef="Unit15">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="ct-nonFraction-e73cb34b-a24e-497e-bee3-8b934b58a8b8"
      unitRef="Unit15">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="ct-nonFraction-8e4b7f88-8ac1-4348-a7e6-3b3f7f52e685"
      unitRef="Unit15">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="2"
      id="ct-nonFraction-e19054c0-6531-4914-a390-c69893f35483"
      unitRef="Unit15">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="2"
      id="ct-nonFraction-5a905af3-d5b3-4575-b03c-6a7e81c99716"
      unitRef="Unit13">25.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="2"
      id="ct-nonFraction-1f1eae48-4eb4-4077-b996-ee2b3a6e3d66"
      unitRef="Unit13">1.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="ct-nonFraction-ceb8ec41-252f-4205-b2ae-0c9c8e7e00d3"
      unitRef="Unit12">6400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="ct-nonFraction-26c8aca1-2287-4b4f-8bae-793b78aea799"
      unitRef="Unit12">2400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="ct-nonFraction-ce811de1-8735-4999-8f53-5964ffd1f90d"
      unitRef="Unit12">2700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="-5"
      id="ct-nonFraction-9a9f4f7f-596c-4503-b3b8-fac5211d630e"
      unitRef="Unit12">122900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonNumeric-81ef5e87-f4d4-4dd7-b3f7-7a25bb2007dd">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-668332c7-8032-4850-9dc2-997722b0a9d2">NOTE 11. NET (LOSS) INCOME PER SHAREBasic net (loss) income per share and diluted net (loss) income per share are presented for the three years presented. Basic net (loss) income per share is computed by dividing net (loss) income by the weighted average number of shares of common stock outstanding during the period. Diluted net (loss) income per share is computed using the weighted average number of shares of common stock outstanding and potential shares assuming the dilutive effect of outstanding stock options, restricted stock units and common stock issuable pursuant to our ESPP, using the treasury stock method.  The following table presents the calculation of weighted average shares of common stock used in the computations of basic and diluted net (loss) income per share amounts presented in the accompanying consolidated statements of operations and comprehensive (loss) income (in thousands, except per share amounts):           Years Ended December 31, 2021 2020 2019Numerator:    Net (loss) income$ (181,223) $ 29,403 $ (84,134)         Denominator:        Basic        Weighted average shares used in computing basic net income (loss) per share  204,136   165,187   152,527Basic net (loss) income per share$ (0.89) $ 0.18 $ (0.55)Diluted        Weighted average shares used in computing basic net (loss) income per share  204,136   165,187   152,527Add: weighted average stock options  &#x2014;   6,092   &#x2014;Add: weighted average restricted stock units  &#x2014;   2,324   &#x2014;Add: weighted average common stock issuable pursuant to our ESPP  &#x2014;   1,367   &#x2014;Weighted average shares used in computing diluted net (loss) income per share  204,136   174,970   152,527Diluted net (loss) income per share$ (0.89) $ 0.17 $ (0.55)The following shares issuable upon conversion of convertible senior notes, options outstanding, time-based RSUs, performance-based RSUs and ESPP shares to purchase common stock were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:            Years Ended December 31,(in thousands)2021 2020 2019Shares issuable upon conversion of convertible senior notes 18,026  &#x2014;  &#x2014;Options to purchase common stock  12,463  4,908  22,697RSUs with time-based vesting  7,392  100  1,086RSUs with performance-based vesting  &#x2014;  94  138ESPP shares 1,564  2,890  &#x2014; &#160;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-e839daa0-bbab-49ad-a70f-af7cda91328c">          Years Ended December 31, 2021 2020 2019Numerator:    Net (loss) income$ (181,223) $ 29,403 $ (84,134)         Denominator:        Basic        Weighted average shares used in computing basic net income (loss) per share  204,136   165,187   152,527Basic net (loss) income per share$ (0.89) $ 0.18 $ (0.55)Diluted        Weighted average shares used in computing basic net (loss) income per share  204,136   165,187   152,527Add: weighted average stock options  &#x2014;   6,092   &#x2014;Add: weighted average restricted stock units  &#x2014;   2,324   &#x2014;Add: weighted average common stock issuable pursuant to our ESPP  &#x2014;   1,367   &#x2014;Weighted average shares used in computing diluted net (loss) income per share  204,136   174,970   152,527Diluted net (loss) income per share$ (0.89) $ 0.17 $ (0.55)</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-d9b0207d-9ca0-4d15-9adf-095cf4d59fb5"
      unitRef="Unit12">-181223000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-2c580219-ed63-4e10-a8c0-657877e20ea0"
      unitRef="Unit12">29403000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-cc9d1ef5-9d16-4c0a-8be4-bd050971c3cf"
      unitRef="Unit12">-84134000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-fce75830-07d7-47a9-8c02-800c696ee16a"
      unitRef="Unit1">204136000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-a48b74dc-e871-4c84-bcbd-09a166305e35"
      unitRef="Unit1">165187000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-2c7455c4-969d-4ef9-8cd6-83f99cefd957"
      unitRef="Unit1">152527000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-1402b19b-4dd2-494d-95e5-f9673dacab78"
      unitRef="Unit13">-0.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="INF"
      id="ct-nonFraction-139e0d38-e08c-4163-8ce7-ad377dd62a42"
      unitRef="Unit13">0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="INF"
      id="ct-nonFraction-bd49e345-6c30-4c23-ab4c-2ae276f2884d"
      unitRef="Unit13">-0.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-67f9dcd5-3a36-47b7-baeb-20658ce044d5"
      unitRef="Unit1">204136000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-04c93e10-6e70-4b5e-853e-32680c58f136"
      unitRef="Unit1">165187000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-d6846bc5-81e1-4164-ae8c-0ca95c63212c"
      unitRef="Unit1">152527000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="-3"
      id="ct-nonFraction-d406b1b1-f990-4582-a8bf-9f66c7e5826d"
      unitRef="Unit1">6092000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="ct-nonFraction-9e48ffe7-f38d-4cfc-87dc-978a33bf3181"
      unitRef="Unit1">2324000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="ct-nonFraction-6b79c4fc-81b5-488a-9d48-286e7fc48d7a"
      unitRef="Unit1">1367000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-3863f49c-5d22-424e-a36d-5cbb03d9b462"
      unitRef="Unit1">204136000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-97b93a56-0f56-4278-9ad3-4067a18f91ed"
      unitRef="Unit1">174970000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-211adb0c-b8b2-46c9-9950-66bc922df58c"
      unitRef="Unit1">152527000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-c7edd9f4-c9b1-403b-a427-38762a22de25"
      unitRef="Unit13">-0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="2"
      id="ct-nonFraction-bc22b6a0-c101-48d5-8328-062a0dc50626"
      unitRef="Unit13">0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="2"
      id="ct-nonFraction-50d9d73d-35ff-4483-aac8-f42948ba02f0"
      unitRef="Unit13">-0.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-0d232fd4-e3f5-4a66-b5a8-42c59b6b9fec">       Years Ended December 31,(in thousands)2021 2020 2019Shares issuable upon conversion of convertible senior notes 18,026  &#x2014;  &#x2014;Options to purchase common stock  12,463  4,908  22,697RSUs with time-based vesting  7,392  100  1,086RSUs with performance-based vesting  &#x2014;  94  138ESPP shares 1,564  2,890  &#x2014;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember"
      decimals="-3"
      id="ct-nonFraction-b52fdabb-fd78-413e-b635-d83a0537bdd9"
      unitRef="Unit1">18026000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="-3"
      id="ct-nonFraction-0f06716d-8669-467e-8cbf-f2c67cb9fda7"
      unitRef="Unit1">12463000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="-3"
      id="ct-nonFraction-4b7be88a-1b49-4077-a17e-edf232056d98"
      unitRef="Unit1">4908000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_OptionsToPurchaseCommonStockMember"
      decimals="-3"
      id="ct-nonFraction-257e81fc-4b2b-42c7-8bb3-f0b38cc28f3b"
      unitRef="Unit1">22697000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"
      decimals="-3"
      id="ct-nonFraction-fe6c0063-ccbc-4fa8-b396-8d0527bb568a"
      unitRef="Unit1">7392000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"
      decimals="-3"
      id="ct-nonFraction-304409d9-b9af-4d5f-ac64-46ed1e4f7afe"
      unitRef="Unit1">100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember"
      decimals="-3"
      id="ct-nonFraction-9027c6fe-282e-40be-96a9-db68c312323d"
      unitRef="Unit1">1086000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember"
      decimals="-3"
      id="ct-nonFraction-06c8af4b-190b-4102-966a-32cd32caf883"
      unitRef="Unit1">94000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember"
      decimals="-3"
      id="ct-nonFraction-50cf0d8f-8b3a-4114-90ad-a7feb59165c2"
      unitRef="Unit1">138000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="ct-nonFraction-07f482cf-a5a0-4e82-96b5-38ccf1ca3a45"
      unitRef="Unit1">1564000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="ct-nonFraction-c3389e97-0370-4cc5-ad81-260cbd6f4c74"
      unitRef="Unit1">2890000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-f5b2c1a1-bf86-4319-a602-2506161a7962">NOTE 12. SEGMENT AND GEOGRAPHIC INFORMATIONWe are organized as, and operate in, one reportable segment: the development, manufacturing and marketing of an integrated platform for genetic analysis. Our chief operating decision-maker is our Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis for purposes of evaluating financial performance and allocating resources, accompanied by information about revenue by geographic regions. Our assets are primarily located in the United States of America and not allocated to any specific region and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue. Revenue by geographic region is based on the ship to address on the customer order.A summary of our revenue by geographic location for the years ended December 31, 2021, 2020 and 2019 is as follows:                   Years Ended December 31,(in thousands)2021 2020 2019North America$ 64,521 $ 37,277 $ 44,681Europe (including the Middle East and Africa)  30,271&#160;&#160;  19,065&#160;&#160;  19,600Asia Pacific  35,721   22,551   26,610Total $ 130,513 $ 78,893 $ 90,891 A summary of our revenue by category for the years ended December 31, 2021, 2020 and 2019 is as follows:                    Years Ended December 31,(in thousands)2021 2020 2019Instrument revenue$ 61,324 $ 34,282 $ 45,126Consumable revenue  52,181&#160;&#160;  31,142    32,616Product revenue  113,505   65,424   77,742Service and other revenue  17,008   13,469   13,149Total revenue$ 130,513 $ 78,893 $ 90,891         &#160;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-b26d7e2b-7b4d-4c3d-8380-f88d8e9fe774"
      unitRef="Unit16">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-0f0ee084-c47d-441a-97c6-0ac26c2ebc97">                   Years Ended December 31,(in thousands)2021 2020 2019North America$ 64,521 $ 37,277 $ 44,681Europe (including the Middle East and Africa)  30,271&#160;&#160;  19,065&#160;&#160;  19,600Asia Pacific  35,721   22,551   26,610Total $ 130,513 $ 78,893 $ 90,891 </us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_NorthAmericaMember"
      decimals="-3"
      id="ct-nonFraction-3b90dc40-14cb-44a4-a7ad-6758e73a3b67"
      unitRef="Unit12">64521000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_srt_NorthAmericaMember"
      decimals="-3"
      id="ct-nonFraction-6bbd0015-c5da-4d06-bf90-9d2f8fa04ba1"
      unitRef="Unit12">37277000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_StatementGeographicalAxis_srt_NorthAmericaMember"
      decimals="-3"
      id="ct-nonFraction-51b3a71e-eb8c-4b93-b623-8a73683cf57c"
      unitRef="Unit12">44681000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="ct-nonFraction-1149e714-9afc-4ec8-8dd8-0b31d1723bfe"
      unitRef="Unit12">30271000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="ct-nonFraction-eac3cd5f-b0f9-46f0-937a-9c70463a18d9"
      unitRef="Unit12">19065000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="ct-nonFraction-0a57f599-1692-43e1-a36b-4ac1e3a0eebc"
      unitRef="Unit12">19600000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_AsiaPacificMember"
      decimals="-3"
      id="ct-nonFraction-d198dcda-e9ea-45a2-8e36-64282128920d"
      unitRef="Unit12">35721000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_srt_AsiaPacificMember"
      decimals="-3"
      id="ct-nonFraction-0f8fccc3-6ebf-48a8-b44e-e790d38039e0"
      unitRef="Unit12">22551000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_StatementGeographicalAxis_srt_AsiaPacificMember"
      decimals="-3"
      id="ct-nonFraction-c3c272cb-534c-4316-864e-d96e0c753bc2"
      unitRef="Unit12">26610000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-dbc86676-68ad-43ab-8032-560ee4d310de"
      unitRef="Unit12">130513000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-9858561c-4db1-4b47-82c2-378575fa32de"
      unitRef="Unit12">78893000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-38a4181c-3d45-4dbd-8677-eae50e21659d"
      unitRef="Unit12">90891000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-32bf20e5-fe9f-4119-83e3-74ed9ca6a2f2">                   Years Ended December 31,(in thousands)2021 2020 2019Instrument revenue$ 61,324 $ 34,282 $ 45,126Consumable revenue  52,181&#160;&#160;  31,142    32,616Product revenue  113,505   65,424   77,742Service and other revenue  17,008   13,469   13,149Total revenue$ 130,513 $ 78,893 $ 90,891         </us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_pacb_InstrumentMember"
      decimals="0"
      id="ct-nonFraction-e0b5651a-af35-4213-ab4d-dc5546c06a0c"
      unitRef="Unit12">61324000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_pacb_InstrumentMember"
      decimals="0"
      id="ct-nonFraction-a919ee37-117a-4f68-81f2-56cc34973dc2"
      unitRef="Unit12">34282000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_pacb_InstrumentMember"
      decimals="0"
      id="ct-nonFraction-fbbcc11d-9bba-415b-8569-70bea6dc398e"
      unitRef="Unit12">45126000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_pacb_ConsumableMember"
      decimals="0"
      id="ct-nonFraction-1126fae9-bee4-4d00-934c-ced21d0f4ffb"
      unitRef="Unit12">52181000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_pacb_ConsumableMember"
      decimals="0"
      id="ct-nonFraction-b5c43d49-d8e0-4d8b-9809-94f2a598be87"
      unitRef="Unit12">31142000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_pacb_ConsumableMember"
      decimals="0"
      id="ct-nonFraction-e32a6591-234e-43c3-971b-04fbf86e5afa"
      unitRef="Unit12">32616000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="0"
      id="ct-nonFraction-decabd30-8ba3-4ad4-8d82-3c1180fac294"
      unitRef="Unit12">113505000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="0"
      id="ct-nonFraction-c5bfa427-25ba-4b5a-9ca2-7ebd244e5186"
      unitRef="Unit12">65424000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="0"
      id="ct-nonFraction-75b1ec28-1bdf-48bd-b038-ef75d290e6f1"
      unitRef="Unit12">77742000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember"
      decimals="0"
      id="ct-nonFraction-eac48340-b972-49d0-935b-480c74441ef2"
      unitRef="Unit12">17008000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember"
      decimals="0"
      id="ct-nonFraction-b3166d07-eb85-49ea-8dce-d5fd007a581e"
      unitRef="Unit12">13469000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_pacb_ServiceAndOtherMember"
      decimals="0"
      id="ct-nonFraction-17cb6c67-b1dc-4f83-ac70-a6b8831191b6"
      unitRef="Unit12">13149000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="0"
      id="ct-nonFraction-084b6af6-bd21-405c-9296-8672e6ec9467"
      unitRef="Unit12">130513000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="0"
      id="ct-nonFraction-85134a94-ae0e-4a3e-99af-56ac11c8528c"
      unitRef="Unit12">78893000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019"
      decimals="0"
      id="ct-nonFraction-f6102fb3-01a2-48ac-8bb3-6d60adfdeb13"
      unitRef="Unit12">90891000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
MC8%<5"XW'+L*!P  01P  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6RE
M65USXC84?6Y_A89V.MN9$&P9$N@FF2$06MKL+@V[[6P[?1"VP)K8%I7DD/S[
M7LD&LZFY]K0O"?ZX1T=7TCFZ\M5.JD<=<V[(<YID^KH3&[/]H=?38<Q3IL_E
MEF?P9"U5R@Q<JDU/;Q5GD0M*DQ[UO(M>RD36N;ER]Q;JYDKF)A$97RBB\S1E
MZN66)W)WW?$[^QL/8A,;>Z-W<[5E&[[DYM-VH>"J=T")1,HS+61&%%]?=\;^
M#].^9P/<&[\)OM-'OXGMRDK*1WLQCZX[GF7$$QX:"\'@WQ.?\"2Q2,#C[Q*T
M<VC3!A[_WJ//7.>A,RNF^40FOXO(Q->=88=$?,WRQ#S(W4^\[-# XH4RT>XO
MV17O]OL=$N;:R+0,!@:IR(K_[+E,Q%' T#L10,L ^BK /]5"4 8$KP,&)P+Z
M94#?9:;HBLO#E!EV<Z7DCBC[-J#9'RZ9+AJZ+S([[DNCX*F .',SE6$.PVC(
M.(O(76:$>2'SK)A/=ERZY--R2MY\^_U5ST!S-J@7EM"W!30] >U3\DYF)M:
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M!C<:8]0J[_!QR7]-;2&U 9W^0VQ/KQ$<<=3WZ #C5GF'CPN^&\0QU">GJ>
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M8>1['N;[0Q,68BDKB3(1=PE["CD^C[#1!2H<\31/ VE^)'@>)O@=)>F3B6\
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M&("^O^%<'2;FV-"<*X-_4$L#!!0    ( (V!7%3T"<%#Z08  !L>   8
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&ULK5EM;]LV$/XKA+$/+5#'XHO>@B1
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M$=")0U8SABD;INKTG83U_>J[Z/D2/,YIPH;5CS@-)F$-_H/KY^>_L47X+>B
MK[YCG&%"@#P"L$/Q!:Q^([Y.U$EX$]BMC/F+7?D+FJ$6E#AU)F%U_M1(7E3E
M5].]=&;1RI954T?+9F=J37M< $;45]4QQF"^^L@,*)P C V7&.(DFH0E>CH<
M0I!7[&U?3:80"C4A -9D2@9E"F U8U$^W& 1)]8D"6:*MP"0:4JZDYI@CCB]
M)6&]O2I4.0=CU8W+#EE%)UE^'"8?%IW@[#A$H+$X'@B/4TT25LU966WU\2E3
M[W_V.O]]F/$_/?8?-#;HOY-($MY[?F[/-LWZ+$PG5I@^OS^#$UNMM-E6V>9S
MJ\Q]LVQMN=BV[6@SG!2A$RJG=#2L=(,Y00%UBDQ-3(Z""N!P$N/L.*P0+B8Q
M2>&X4B=@-"Q@@;R@OES!'(#M:LKR]'CU0[@0!Z=]-*Q]MU(LMG.-_K[A]0.7
M_X2F]N#T\8>/'ZG3%_J#!Y 4.($TV[,(*+< -(D9<#@P Y!IFK+A%H\Z.:$_
M[122NA).P_NM9Z.;?CY#\?+W57%"XPP(%W!0.1 N'\E8F@ZK+W7:0</:<<_E
MKISS]ORG:VE>DZNNN-/LAW/555H:WHQ\.U>!C8/9+T&Q!Y"4)<#I%(C$@<Z8
MN1K-HI^5JLR5318NF]^1JKVE%TN;Y1EP8@DAHQQJN2$DCAG0<4\.WIK5]IS.
MOGU41B*WC>[>+.VO[M]P7K;O]8ZN7^'36?>>TIGI7IO>%')5-@I5?&E,1B>I
M<4MV;R*['UILVG=S#T)K4;=?U[Q8<&D!YOY2"/W\PSY@_S[XXG]02P,$%
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M?3YP[PVW2KOT]J91ST&CT=";?NBMW[<&>Q6U=I2'KH%?"VC7W2Y5G<.RRSR
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MC8Q3OXP?<S,I.^X8B%@G<6PY^!(#LHC1V'(-!"BBB#JV C/*SOS*_I"6LKV
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MQV'WCWF^Q__CW6?_>3%WO24F^J^/K/LDK/N$UWWROX+UC\X-*?[!;8K2_/R
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M"8&CQNA!DKN@Y0.XFNMAK4N$1H2@2..;B0X5=9W:KTI#IDK2+=J?-VZV<#[
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M"9WY-R7VO&NK\5!6:Q)6KD,/%1%9T6G#D2H.YN5DEF#WZ.E1%NTH/-RBQ<9
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MD:( L[S*T70YF"EN/;D2FN/A-JM.\T^IS'*-='Q(*JSZ:?CZ45S$FH/Y_N/
M:C^(A.(!JWKT9B)N@XM9'DL>>G(PB+CEL9Z;,F.C'RR^R(M-;RKQZLA[@R$/
MP[>BMV8[HO/GR8)(U*&_@_$H^4LDN("?_]Z*DVNRY(^2A%\S_R==+N0OF<37
MY>_!_%[@_GZ7-69!0T]GWSY](.T]_@LYI?QW38C.1!_^B#*FL7B!GB\Z,G+Z
M!0N$/W3SRW\#4$L#!!0    ( (V!7%3 N@^4*P\  !8L   8    >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&ULU5IM<]NX$?XK&)_GQIZA:5&27Y2WF=C)M>[<
M)6F4:Z;3Z0>(A"1<*$)'D%9\O[[/+D 2U(N=M/>E^1!+%+C87>P^^^R2+S:F
M_&*72E7BZRHO[,NC956MGYV?VW2I5M+&9JT*_#(WY4I6^%HNSNVZ5#+CFU;Y
M^7 PN#Q?25T<O7K!USZ4KUZ8NLIUH3Z4PM:KE2P?;E1N-B^/DJ/FPD>]6%9T
MX?S5B[5<J*FJ?EU_*/'MO)62Z94JK#:%*-7\Y='KY-G-F-;S@G]HM;'!9T&6
MS(SY0E_NLI=' U)(Y2JM2(+$GWMUJ_*<!$&-W[W,HW9+NC'\W$C_B6V'+3-I
MU:W)/^NL6KX\NCX2F9K+.J\^FLU?E;?G@N2E)K?\O]BXM:/1D4AK6YF5OQD:
MK'3A_LJOW@_!#=># S<,_0U#UMMMQ%J^D95\]:(T&U'2:DBC#VPJWPWE=$&'
M,JU*_*IQ7_7JIK:X8JUXG?Y>:ZO)5?;%>071M. \]6)NG)CA 3')4/QBBFII
MQ=LB4UE?P#ET:A4;-HK=#!^5^$:EL1@ED1@.ALDC\D:MH2.6-WK*4!D8*O[U
M>F:K$J'Q[T>V&+=;C'F+\?=LL<^7CXJA-'QFUS)5+X^09U:5]^KHU;OWG]Z*
M82QN?IW>O7L[G8K7MW__]6YZ]^GN_;OI^U6AS4I%XJY(X_>%F*IUI58S5<)Y
MSH&1V"B1FM4Z5Y7*A*G+4$EAYJ(G0YS\^,/U<#AX[J_RM^3Y:22DF,I"O-%J
M8<XH&S*6*HL'I,(]4GRMBP46+9$,.:[I^5R5JJBTQ+:16)=F76I5(?V%79JR
M.B,@$6_>O196_5ZK(J7;U[FL"&Y$*M=REBM2+U,YLK>DGTDVM$]KG-M##'VA
M0E'X+-_H:BFJI0K-@]9Y#ILK6\DB(Q'82U=004$(EB@;> ">*N$K6:2 "MBG
M"Z&^IDM9+)2 5D*N8<57#4!0L/!XE%S$5\C,/*?ML3B5=AF)ZVB2)-'%]0!V
MRM)M0%Z'MU98A[Q.OSAEI9A+78I[F==LZ?%P/(G'K41H3/954!M^I(]69ZJ4
MG;4[ I++Z_BR$1"+3_!&?P7YIU.P4<GIJ:VM8?5&6OB\4B4P!U_=46,5W9KF
MQI(7@>)?4#9PHBF+_2#3&VTH5I*KYW9+KK\WC+H,+HQQ?#++FG/J^S:YCB>-
M'1$'6JE9#QAY%?@(WYW7A\/+Z#I)OM_GE_&HVXA<?GP1#UOYI<HI?D5E#AY%
MQ!Y#5)JZH*4<*;@ N]59A3(FUL96/?-9GR")4.G<J:JO]%G1R6G[Y#)W5+ #
MVF%_U+N2E;U7EC0-(]MY0&YDF5D.U<?S)OYD*IEOA1S0LK!(ZM(;N7VHT!CZ
MS$V.<F_%B:9C-[6%3^WI,T'_O%0<F%A+G1T#Y2^BJ\'HI]Z1\!%N[2V0&M%X
M=-%?>3 [!!(ANK@:_PQ,?B:F3_D169[7&9E5FM4C5HN3!,DS')T^X9YC<96,
MHZOK"=F\5(?UY*0?#-IP.R'U3!/H2?"+AQ<7H5L_'([Y4SH4BI!ZW6;A4@.N
M5Z0+;I D!^&"6(V(TG#*XQ1IZ5R7MF)QJDPU[+5+O>8;*=X\14&E83%%G>;*
M5#!M'YZW*4P79X;RD#1' :Y9(%G5I!IYJ%X1^ML(>LA*U)7.]1^P<'IS(RJ5
M+@N3F\6#P[>BYG+7Q V[P44[M)RI%M7@+OH:(%O-VI"E]R:''F<;)G+D -0;
M\-(&,'&R7#L8[O9C2Y,/U0;F/+1W9/+!"N4JCX.?@LH*15NS=[#468L3JS;&
MW:KA^TP[3,3NM(G9=XQTJ3W(6+QW5[X]3OJ^POFO9;DK.!+'XSCI)"+?JZK4
ML[KB6@T93IA9.XKEQ<T>?'T@'4J%F$A;Q0.6P96C+@B\*/Z]C"U=.,EDZC#J
ML<S2>R$YUW*&6,()P=%=(8C<X;A23PG#;$/!R:0OR J?/CB(H3!-S:) .#(_
M($?>8F.3ZXRC=UKA#UGGB,7:ZV/YY&\I"=22&IM[)4Y^-M:>$NN"!PX5ZX,&
MMJ9$ 8);JXGIH"@SDDE<U65V1AY\8+GN7F0V4A(N:HN[%#95A82%'B=7"N"-
MM%EJ.*'9F5Q8,AV"=L IJYFCU159X$R$&KID11:48RCJ,Z>GIUJ&V!MX8>HM
M7IN*26(>B 'Z9]HVAX>P8C(,#SC/X.ADNT!0R2-6!PD^-X >;;@@U\_ *=#0
MXN2T_7(V+Y4ZTQ ,D?[F=5[;'08#%->5<.UN[% \K'4'2OZLZ0-@R4P7SMMP
M2\2+2TKT_"%RJG$)V7O@!ZH/[XGBFC:,A,7@./@4'+)T7ZU5E>]'Z&;ZN0D9
M.@K\#LCKTSNHTNESF+>Q,U;R-QB=YK0/'VRSX=8^4-/%$+J0)7 UM."_\P)Q
M],=YQFU3*+EB$N.';$K)8P&^,1I=?T SHB@E:!']SF4M$@4XK1"743(<^<Q%
MWN<*+D+PH#2<F?E9;1OG-NO!"0:3B[OB#,&>TN%3M,HR=3KXYH@![^3H[L/'
M'^5J_?S-T:D0X\$@&@P&?S$FX_(D1I-!='EY\1X>*!N'BE$T'(S>*&^^9K3
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M[<'?FJY,$--#'*:2^K@.QD'#R 5='2KA":H0B])LJF6TQ>#(5V:&A%5$1(G
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MZW'$K[3-.27H*H0ARB)2P$7TS)RT,X:@D@.QN!:I]#@14CDF&S$F$:68MJ'
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M=;\6<.X,D3MKDGLPI;UK1J'\.@6>,?\4NE3HCC;GA);>%#[:I/X(CA6-=BM
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M[^5^AUQUJZQ>@BWB36YB ^Z%\>\<%W%V(H#UJ077UB_BH+G:'_\#4$L#!!0
M   ( (V!7%1XGN.7KPX  "DO   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;,U:67/;.!+^*RA/9BJNHF4>NNP<5;8GF<U4KHHS,P];^P"1D(0)22@
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MA"GX(I5@^@DKP>@T^^WFYB,P_K64H#9D J@@1\ I>(S,Y#^"-BD-J4DM4+=
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M_ZS)K.O]=NVYI_Z:>//IN&>O]GMK._&0=9!NVJ=HU3L.^F083WUOUI*Y<YA
M:.Y-9D'/NGG@38-JX$V3V(9-\ZAAS&?>- K[=#P\$H3>=-RGJ^[(G=(;JO*A
M+%D4'6-HR^-=3>=]<@Z\#V;>>#)];. 'S#("@?U9KR<,C@3^S O\Z-$1:SCM
M,J1C8O/(F_;2'QX)HYD7]N[<';G'+'5!#1/$Z@***2S3T'*/QS+8V^\SVQ9O
MK?%YU'<BK<.LQ]]"O?U#[(R]R56?-;8\JC,C\AX3H#W#'I#+GP,%'L1H"'UC
MOPI]3]@,;,Z?]\7U )SYRAO7_$"PAL PF]:/X6SBS6;CGJ51"!%YTK ^\->N
M,(8TIZ"\RTO;P_%D:XOU_ESRX[_L+BOTLJH,M#OV*CV87GF@MB9 [CV?%J[M
M<9U0E/>SWMWT\/DTP=O-33R@!,]UO0\<412J+ZDU@$FYP]BI0:<:.894 MT;
M==Q+]B'+I<J@>MWK6!#C<E5VA88E.*0VMJ0WA:U;@41+$;!Y6D)[?Q3YP/ZI
M@W[T 1Z/8ATCQCY@>?FUA*Z# $TJ+PDEJ+GKAT>&U-B"-8"K1!JJ\*O^&6KU
MA1N^>* K!:QPRR(&]1F+;0B#-.U>MH-%J+.E*BRD%PA,4>5-6<NB.[;%OU@B
M-*EK='4#W2[A"LT^0"23*=!$N(/'T$9N&TS6HA;N)(EGH:5*V%*K[*#D#9'G
MWTL@$_GT8@*]!1QRC'6.8!6%1FIJ\D >KE-H7IF)1<Z!?+,?%/>:8&N+58,Z
MRK0@(/& [.&AM%HVDKU2/ZG#&2%*1ZUG60-SE(*[NJM56FD^08A&Z00Z&,H#
MX!T23)"NR@@.NKV@-;?5$)I#OJJ\BF0R5HGCT?QGU-MD-/EYQ.[6=@B$PI,]
M:3^$)QO-Q V%'[559)- ).KV]=YVB&BW#@*1,WL22<O:<4>B.KKK\M-(]$->
M5$%M.[ 9)O#ZJ:<5HY:Q#:G#7U\S%MV*E<QSVT@2)&1;2?8[A^P#=7E%\.*F
M-\1!_,5J=VQ%1 E[I0N\8!R]RI/#?0Y9=Q&]MH-#' 4M%AI@O'-!B(V&&P:Z
M2AU4J#L,2(%&I3(ACN\+^*^"8SYLW%3;E4,M#H>_QOO9K6!/WRICSJ&(QP R
MNND5Q:>PV<*5W'Y-8K]QB;U.-7AJC^6:-VE:9N %[)W0*]CM9@4^2DPCFT0"
M/.5O6(:J0^!E1Z/VTB@6NN!(6>JXS!!BI?U!B[R%1C365M,$0C:W=+*T#:G'
M++HAI45*<]R!]FJ"LFT%LM:0994_;=+S[*U'D\9Z$N.(O6N +PNSN0/8YQ#B
M:R-W@V8BEPO!_A%:H<0'9XO /^EE*;4I+.H$F</FWOM;]AY1'U"O9F\_LL1>
MFN'V+K,ZQWV':&5C^EJLN"8GX:TT%1-:7TB4CMJQ%O(.<1V,#\-Z21(N2TW8
MV (_/T +>@]DV*R"_"V1>P&^JVD(E F37HN%)F]'+FRR1Q"<;!#T0 &NZG^@
M$ZOLC4QR7]8J/$EC2NOG8$&&IZ3N)U>^CZDV=5$D&$W\GP=Y(]"NYBV8D);F
M"-81 H;QUV-/)N&H0W/ KIP-(PJ)?$/N1^$$MC)XUK57[:N#^&]'&TX7"<I&
M!S@JATP>#RCF^R+*24&>? ]+$V J5_71-PX'G"E[U0K4^M4R$(3!K%Z?P('G
MKH1(N7ES06[JNV^'YWG5?0'Y;E,.]]U8]@>: =@3P>!2-[F6%2)>Y_(KWL?4
MUPHV-8!>-UPW\6>CT=!0O%'7A_A"X<WH0SO)G)*8>^*U!<1[$V<K)AP_9.JB
M/=M+OVHA5BA["T3JQ9_ITR/Y#Y:X[I[).X2^D-#>[4[+)MS%:QM+QO@WC!CW
M)\, AW[38./N7YB8P3D#<_@] U1/Z?Y/!-R[-0L8,7@K6T$" P*IPKC.'"9_
M$O![!.NM8-SI49!WV@/)$0Y[Y7>ZW:>3<U8CM"<C6F$X&>B>PW#\.())N&04
M]##B$,L!S+%/IOG,F_E=;I[.HG-6HXO'($($ ,?P_U7- $&")^LAFL\]?S['
MS9!"X/G!&*DX-*\/DIO,Q]YL,L,EOEMS%9ZS&H=KM'>"!U@0:.*-@8<G2/")
M)3@[=T-C;^S[I^%S9')/$'(;,"P8.0E9<X0(*ANZ5:"QQYW1__]W1HNI'[T]
M.31;NMZ8=XTV(,.A>X^3[2^8=;VY<WTQ=&]!MPT#RVCL<0>F"X*PAW][<_ =
M[DMH/FH".7HZ/Z_?C8_Y;0 A;HJB7TWWI$9\_G3U$8".SC\E"<@/':K>Y[L(
M>P>!]5U:$?KGK$;#O]-SHV .H>Z*_!9C^=,P.'>OY\'XNWQV'@TE QCY'I\E
MN'HHK]#8(]F[@@;PT\T2M-%<7=??K?1IAF^Y3)'6!52 %U2$MY3EX2>1:4G]
MQJ$+>D.U(<K7C03-S?BO!%?25T-4U&!I!ZT71KFKB>=/(YS E]@ U7.*M5;E
M:LTF]$AF&(:>'X:'IE+#]A3:#E2!L$PBE_B%)N%* QJK/H_!#@5K55RVYEOA
M$,/5FAJ"F*>I_3P).VBF%JE<N>*]ZA^Z4\@GH!7@*7U28.NFOL]L+UN?+V?8
MP^-'VL9^>62_9*[?UM^!W]C/GYOI]B-RZ!]7&'Y3L82E_F@V.;,25 ^%VM#'
MT M5%"JCGVO!H7C%"3"^5-!HN0?<H/XZ_N5_ 5!+ P04    " "-@5Q4&SK^
M)WD,  #=(0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6RU6MERXS86
M_164HZ3L*K;,30M[J_*6I*O<;5?<F7Z8F@>(A"1,*((!2*N5KY]S 9(B;:D3
MSV3\8%$D</?E7%!OMTK_9M9"5.SK)B_,NY-U596OS\]-NA8;;L:J% 6>+)7>
M\ I?]>K<E%KPS&[:Y.>A[T_/-UP6)^_?VGOW^OU;55>Y+,2]9J;>;+C>78I<
M;=^=!"?MC5_D:EW1C?/W;TN^$@^B^K6\U_AVWE')Y$841JJ":;%\=W(1O+Z,
M:;U=\ \IMJ9WS4B3A5*_T9</V;L3GP02N4@KHL#Q\2BN1)X3(8CQ>T/SI&-)
M&_O7+?4?K>[09<&-N%+Y%YE5ZW<G\Q.6B26O\^H7M?U9-/I,B%ZJ<F/_LZU;
M&TU/6%J;2FV:S9!@(POWR;\V=NAMF/M'-H3-AM#*[1A9*:]YQ=^_U6K+-*T&
M-;JPJMK=$$X6Y)2'2N.IQ+[J_27/>9$*]F CX$IM2E6(HC)OSRM0IS7G:4/I
MTE$*CU *0O91%=7:L)LB$]F0P#G$ZF0+6]DNPV]2O!;IF$6!QT(_#+Y!+^IT
MC2R]Z(6ZLG]>+$RE$2#_^@:7N.,26R[QWV#1;U*B?'QM2IZ*=R=(."/THSAY
M_^GN\PV;CMGEQ>W%IZL;]O#SS<UG=G7W\?[NT\VGSP_@JW3UJA)Z@Z2!6C*M
M1,92;M;LPC"U9#"KV"R$[DSKL6HMF#F^;]&HA,TC?SQ!'.8YI=26&Y9"02T-
MEN*I$6FM9;5#7I3*2)@69<-23[7(9 5R.K-"B$V9JYT09GQ$*O^%4LV/2S60
MF03B36:!6R,HXT5&ZZ(GZYXJ]%?T^5" ?5$T96<KJ[7=P=/?:PD2=!,;[C:%
MA 1,%NQ!E)73W7ECVRP&"Y(I[&0B"Q^W!Y@::2I9K&CA$=F?RMV*L9?_0_&(
M<%5Z=R1:K*F<@U2M(7^SO.7O;$X:+U6.FD_RI%T6O&:#OP'U4]BB6JO:@(,Y
ML[R(SWVMTS4G7Z(("RUY;D9LYB5)Q$8L\B91\ 6%GPQ9:I4*8QB;>],@ /FI
M-YT$/\I"HD!F;*44E+9;)W@8>WX\[[0=L3#V)DD"FD'LA9%_K]'Y-,Q'^M[
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MIFL(<.-4,B^87GBSM;&&^7]-+ ^H5L @KATTN!!#7C@!:@\I\' Q#5I%4',
MIZI!F4F5H7$EP) RI9$CF+2KX2I!8("5?&=K/.:2P*>0M^@G?-.-@$Y=BOW
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MLQQB0(K[+?.>4ZF7#?7M!A-*:IIB5:_CFU18ZA4TC#17);*X%N>S4VY-9^A
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M-@Q+F8\7)R>/.QL+.&ERHAN7$O7P%R1](>9'_?).5AT\/7_:YE:L+YV5^^U
M*S[&N.1[#/I5VEP5L<.CVWZ':4Y3]\*Q&[]@=&_!'KX:I!S#XJ\<6IUP]Y-X
M:AWZZG;<^:99*K?F+[<4N B%^'FS>=M\'+Z,WT3;Z?'+\J_2H?1X4:@5EDXG
M3T]'\=A=/P2[Y2^D2QN"+?GG1DF0'TW ^,H"K?1 &S2?S"_^#5!+ P04
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MW5]%17(1-3HT829@OZ7@*K1:4;D8WTA)@4B#6D%W;X X\K.U>0^;;L/X=A-
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M*Z5S]#[%#M\2$*^Q&$AJE,%S,0STZ5U]')W3;+3#(4WINX0^.+C7PF-"=16
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MZ;+&H#5[@@IKV9F$! 7B C-T':L29BP_0ZK*I:4I0RAX<*JS)EH:C(]+X,Z
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M&_IX*V-P8S@ [E\716V^X +MC\V^^%]02P,$%     @ C8%<5,ERE(8C!0
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M 9CNNM5MG&[\%6>F'36Q7R[IAHJ&!>C]7&NWW;"!W9UW_ ]02P,$%     @
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M"65;4YE&E^4)OYM#*^^V.Z/>5@7^NL,Z-E-UH]XN[A;JEYN;5YG25EG22[0
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M]O%$U&/,A7M]@I_A&4/484\WTPJY6IVB8_FF86=1)%G21!&]-PZ]G,\1M9I
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MZXC:!5A_J13M-@Y@?&^S%U!+ P04    " "-@5Q4IO1[VV0$   >#   &0
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M:]N8*L3"J]5V;_UJW_R>MBW?JWC;.5\1N69<825>H:IW9%I-V3:C[42+VC:
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MIWG5=WD.4%):E-1BT_D&, F3'7?)[[]9*4N=90D')#UGPDIL=3H.IPZX[:E
M/AL/*]?VN+*&"SK/K$WU7:'[XV&&]Z"XH$9Q02^*NUE1\)Q$!N$P!!F10A<
M5C1, (27=+FXZ8%O!E"C>_9+H>N,)S^^M\&Z7GVZ8%T; O.NV3(M"HTA9S33
MH07IHY7]BT+(P66\!70G5PE<D3(U"@/][[Q(><[ Z?J*\ZT+M =:K<<.]CW
M^?MR]J%C=8P]YQ+6YQ(.1=>Z_#BV"+UK7/7Z_F_<OFVN[A7Q0@1]U6$R/'\(
M+F7U%Q;F4._3?\&)90&P*'O^JCN!W>.$!)8*H25TU\ @ S:ZHMAF81 0[L&^
M6U@;]H+>L 6B&%PZ=7>R_S@8HQJQ#K[A 5AV5!-"_,.(SN T#[<H4B&X#@S6
M9A/@B,C=U>8X\L:H1EM]D$D#(A]^I[4"!B(-]H,7QW!9Q5J8Y@ W%/8UEPK=
MM$&4(/:=*(CT%K?:,R5C5..2)^\Y^Z[3_FRRLY=BX/B@PY%F>&091N.*Y,/=
MZ@[#*R;DCC0$Z0@LH Q"&A4C QVZNBQ#.YR,[O\_&6V/T=M-[H>M:??BW:#%
M)G!,'S@X_J!IZ\A#H'3U<:;[ZMAF:(<3V#1,I$5_VTF]('U-=Z,]H34ZCL?U
MG-^7MX 1O5";/@V?6:W[E>'N,PV%3O[06&#RL.HRVG)7MP$8V]PU.X@[1G5W
M\,+,]7 ,I6YJ\E;7\F."Q]5TC/T7Y2RT AT!")27Y*R![UWWBJ;UX("HQ@'1
M8!P &$Q_O"O!;[=4;<^E0@A[V.!J0]-, [*3!1<G=T Y!!=Z->F$"[OEX^D[
MW]O28"HH NB148&X0!F3^BR#:>"XH:<7T 7X^FF-6@E>+E<H,$,3NX0X+B'[
M\57W/OI VAP]:7POAD1:FJ_B$N!K62C[Z;B>K3^\7]GOS4_+[5?[6RJ6NAQF
M; %;W=,(,*RP7\+M0/&U^?H\XTKQW+RN& 60K!< ?<&YV@ZT@/K?$9?_ 5!+
M P04    " "-@5Q4X2/^!0@&  "P#P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R,RYX;6RM5VUOVS80_BN$9PP)H-:BWI4E!A(WZ0JDJU&W"X9A'VB)LHA*
MHDM2<;Q?OSO*5NS!T5)@^1!3?#G>/<_Q.?)R(]4W77)NR%-=-?IJ5!JSOIA,
M=%;RFNFW<LT;&"FDJIF!3[6:Z+7B++>+ZFKBN6XTJ9EH1M-+VS=7TTO9FDHT
M?*Z(;NN:J>T-K^3F:D1'^X[/8E4:[)A,+]=LQ1?<?%W/%7Q->BNYJ'FCA6R(
MXL75Z)I>W%"[P,[X7?"-/F@3#&4IY3?\^)!?C5STB%<\,VB"P<\CG_&J0DO@
MQ_>=T5&_)RX\;.^MW]G@(9@ETWPFJP>1F_)JE(Q(S@O65N:SW/S*=P&%:"^3
ME;;_R68WUQV1K-5&UKO%X$$MFNZ7/>V >,T";[? LWYW&UDOWS'#II=*;HC"
MV6 -&S94NQJ<$PVRLC *1@6L,],;5K$FXV1A4V FZ[5L>&,T.?O"EA77YY<3
M ]O@Y$FV,WG3F?1>,$D]\E$VIM3DMLEY?FQ@ O[U3GI[)V^\08OO>/:6^-0A
MGNO1 7M^'[1O[?D_&O2?UTMM%&3*7P.[!/TN@=TE>&&7 [NR(!^:1VA*M3T%
MZ* A/)@7>LTR?C6"DZ>Y>N2C*3G\ X!XO>3*@G0F&F)*V6K6Y/H<(4/<W'FK
MLA+R-X?T,5P)5NDQB9TT]<F8^$[HTP<X/P06KY7,N-:$)$Y$*9B/G"BD=Z(1
MD&<Y64F9PR N#6$P<-P@Z:,;$R]PPC0%FS1P/-\= #+L@0Q_ ,BY DE29DL@
M/'+[O15K$ GCD-^X.07MH.D?A/8%9._94BJ&T1.^]\=Z5[.LA VA?XS+0S\@
M%I\T2.XY4%'**B>B!KP?>6WCPVF4!K"OESJI3S'T%M@Z,$QHZ+AA"E.HYP2N
MNY"%V3#%"0F=,$XL(VG@WK6J$::%?O2D$$_8Q@T<<!GM.X$?S&0#^=YV MDQ
MOU*6>L_Q71_W\&/XGR1.G+K0B -LW,.4"W*=96W=5I!,.>@@P)<)9@T1<A9&
MCI=$Y]@,4B=)Z?D1;?R9M@9.(*#C.:&[0R=)TX&DB?JDB0:39@'U*V\KCBD#
MGJH6O+Q]@F*FN3Z5)X/6_I\\68#L* $D( 1+WO!"&#B#7@A8>7A@H!'1O;/
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M=C2O@EG3!P*-=Z#WE=;N:>$)^D_.XA=02P,$%     @ C8%<5!(3,/6U!
M- P  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULK5?_3^,V%/]7K*XW
MM5)('3MI$M96 N[0D(X= NZF:=H/;O+:1B1Q9[L4]M?OV0D!=FUU3""1Q/%[
MG_=Y7^-.ME+=Z16 (0]56>MI;V7,^G@TTMD**J%]N88:=Q925<+@4BU'>JU
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M\7"?T\I^BX[DXFB#BV==RZUIE1AS%^]B63X7H--(/1[35@7)#FUA[(I9'Z<
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M4Z9[7.&Q'I05P/V%E.9I80UT/Q1F_P)02P,$%     @ C8%<5'R5V(H\!P
MH1D  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULW1EI<]NX]:^\T<I;
M9X:B /!.;,_$CK?MAS0:.]F=3J<?:!*R..&A!2 [_O=]#Z0H*I89I;/'M/H@
MX7@7'MX)G3TVZK->26G@2U76^GRR,F;]>C[7V4I6J7:;M:QQ9]FH*C4X5?=S
MO58RS2U25<X%8^&\2HMZ<G%FUQ;JXJS9F+*HY4*!WE15JIXN9=D\GD_X9+MP
M4]RO#"W,+\[6Z;V\E>;3>J%P-N^IY$4E:UTT-2BY/)^\Y:\ON2 $"_%S(1_U
M8 QTE+NF^4R3O^?G$T82R5)FADBD^/,@KV19$B64X]>.Z*3G28C#\9;Z3_;P
M>)B[5,NKIORER,WJ?!)/()?+=%.:F^;Q;[([4$#TLJ;4]AL>6]B032#;:--4
M'3)*4!5U^YM^Z10Q0(A?0A =@E7$O&5DI7R7FO3B3#6/H @:J=' 'M5BHW!%
M3;=R:Q3N%HAG+FY-DWU>-64NE?X+7/^Z*<P3G'Y,[TJI7YW-#;(@P'G6D;ML
MR8D7R'$![YO:K#1<U[G,]PG,4;9>0+$5\%*,4GPG,Q<\[H!@@H_0\_H#>Y:>
M_P*]&YDU=5:416JMHEG"AXW1)JWSHKX'_('K+U)EA285@%4/?%@3K#ZDCE%F
MY%*O]3K-Y/D$?49+]2 G%S#^Z9CMB;5=&XH&\(]-=2<5_&(M3^:0/DB%G@2[
M+?MI!H24)$^E$6K!*/2)35H>H/ @-<V?;W022%BK(I.G10V,,?T*RF(IX?2?
M,E4XD7M L(/Z:F/*7,9@!KX;^N Y810"!*X7P12$FW# M8#%V]G4@LT@<44$
M@>/'C*!CV@]I!WR'<=;.<-&"S8![A!LQ ;2>X';BQDC:%Y$=)SY,6QB$C=T@
M "\ B-V(0+GO>DB8^_UXV@'-0'@N3W"&4B2N9Z7D;HPG$ &-F9N@+"T0 D=N
M+, 3%C@@(87O"I3IQQ]BP<4;7.A'+>P,H5T_!#\2A.-[A(-B17AH0>/(,NB@
M$#IR\?#<\5J!F-T+71X?Y.%S-_)(\R&I6Q!4XG+BT:Z '^S&J #A^*%'&O1)
M:YQ;V6.'H2:G> FA-^*9?N^9_JAGWK:)@5SR(P;^V24&VQQN;C]I>$NQ&R/3
M(0\<)3KN@<_,NW.;>Y76!O+42!)&KU+$A&5:*'A(RXVT(@V]*C6 84I:W"Y4
M,;30A"=6.R*P&)8J,O.<R$>C0CMS/<_N*$Q2]K"GW(F2^!608?-V#Q/O4A:$
M=^I''FUQLN]/=>>BQPB#]N]X"5D-3]PH'KFKH+^KX-B[6DAEBX,Z._K*1FG_
M+E>V..K**!9,?_R!A^S-'_\MT(L60SO9.FOOP(L]6SF\/3"7Q"=K(;*]L1RC
M!OX\7HP83-@;3#AN,%A.YIO2WHY-JIVM7#45%IBZ3<;77V@L#YG,*/6C\ZS-
M3VUILG_N]N#6" 3CR56C#4FJY(.L-Q)3BL-%2%'7$1[]<B<.HAODE*IL9:N&
M'$'+9HT%JR%JCH@PC:#?L9#;WS!);E,LJARXES6:;FFQTAQKND)C)J;BE&*"
MXS,,M!A;B1%&7"?V@_=2W4LUPZM/Z19EJR:-\5M;56II3(D;".WYR<XB=J.7
M*50%"F6:&ID'CJ T^1R[O; [>V'9\,(@\APOH(/RR D\ST8G/ %_F5^6ZM5.
M8(Q+D7>(Y<?&H(KT2XP[@E.(F1,)2KZ= --.@!&3C7J3C8XVV9\HDOQ,D81F
MU]6Z;)[D$>7A*(?O*0]?MMRO3)=\*".=&ZDJP,KKR6)B'.!MI46YA6U7M^H>
M!J*>PD.#MX>5,G8$:%K1">+'[ 0OC;DX.81Z4^C/LZ5"S108PO!(!A2%9 "L
M](*3%H6_ 8ZUR@DM>H?IO,/4D4OTCZ="EOEA,8]??)8S!LEBER)@C1JUB0/@
M3TL"X]\\< /O=Y4N<JE$/:C8[6?$L^+>L^+?QK,6&PROZ/VP*-/ZD'^-\OE#
M_8NYMBE UQH.O].]PAC](;##B'^_BW%"9*XX:2<S[K(C_6L7@/]/G$I@D(O^
M1$?&5C ZJ+<1]TEZ]TE&W<=V1VU2M D2FNYYX%_OK=W^>X0'9[N'(79LB3],
M<Z.%_3C)X_UQ+Z_NO81\U04,'CKZ)XI=_;__6/'5Z\.';W4#V/$[H6WL,5V%
M?>[J.GN@6/S7KE3'(.'X,59>V.^S'>BV?_8\[+K>:KVI$/9#51=-)?M+PUU"
MQ/RXPR,.V(-CU[\] O$X]9TH#+&HWY,'DT(2VX[1XU?4A94M<.#S5T0W\)_)
M0RWI-X[/;=// ^Q@][BU).P3@#?62/+! R0?M;-A__C?&K78,1._O5&/DOQ?
M,^H#CT';T<Z:GY7CN]'+9LSH"<Z-VC*S,^"(#PUXA.S <D>@OFVT),5T*,74
M2G'(>.:#5_.*^A7Z;T!CG[&I3?N WJ_V_S^\;5_==^#MGQ?O4W5?H!)*N414
M+(^#":CV_X!V8IJU?8._:XQI*CM<R327B@!P?]DT9CLA!OV_,A?_ 5!+ P04
M    " "-@5Q4(C6,,_ #  #S"0  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6RE5O]OHS84_U>>V&EJ)!; )(1T2:2FO6DG[6Y1N]MIFO:# TZP"C:S
M3=/]]WLVA"1KRYTT?@#;^'W>YWVU%P>I'G7!F('GJA1ZZ17&U-=!H+."552/
M9<T$_ME)55&#4[4/=*T8S9U0508D#).@HEQXJX5;VZC50C:FY()M%.BFJJCZ
M9\U*>5AZD7=<N.?[PMB%8+6HZ9X],/.YWBB<!3U*SBLF-)<"%-LMO9OH>CVU
M^]V&WSD[Z+,Q6$NV4C[:R8=\Z866$"M99BP"Q<\3NV5E:8&0QM\=IM>KM(+G
MXR/Z3\YVM&5+-;N5Y1>>FV+II1[D;$>;TMS+P\^LL\<1S&2IW1L.[=Y9XD'6
M:".K3A@95%RT7_K<^>%,( W?$""= '&\6T6.Y1TU=+50\@#*[D8T.W"F.FDD
MQX4-RH-1^)>CG%E]PKA_$)FL&%S](K4>P88I>"BHPH7?Z+9D>K0(#&JR^X.L
M0UVWJ.0-U(C 1RE,H>&]R%E^"1 @Q9XG.?)<DT'$.Y:-(8Y\("&)!O#BWN[8
MX<4#=G<&=^:?[/[S9JN-PGSY:T#1I%<T<8HF;RBZE57=&.I24.Y@337/@(H<
M[GC9&);#RPC41R:O.7Y0FRWA:UW3C"T]K%'-U!/S5M _?S"JNI@ >I156U1U
M]*I]A?B*YI^:BBEJI+JV0LY5I6/&'<]W<!6ED4](/()W0.;^)(QQ<)5._"B>
MC'IM=TQ(3-D>R#ZM_=WSQ=4,<J%/J&_/0%NK-30:U[B S/F.B[TM/!03R(1W
MKBI[5SDA0.)6?8*P43+UHW1F1U/B3\ELW4M?V'&21O+A.)U;<\)QE(*;3Z>C
M8XS^!]\W- [RO<GS:SB\4&9D]@BRMJFD ;[_+B41^1&E$C^<$^A77I=&GD;Q
MS"ZU0(W@Y@*&^#&9? T&K:@PDUL(KG5C6P34C<*1,& DR$;!^X?-YAPZ\N-D
M=H+^=C_F70"^U9.SB3^?A2=/WGU=_C+VLS[V [4_[6M_.EC[-\)P9P$>/&U%
M8_$]9V5CZV^G9 7_Z0[G/<'V@N%6,*A\L!6\U0>NT/FFD(W&!J5'ETVAX]_'
MO*FEC93 $.J.?CLSW/[63'"I0$B#0E'JAR0YRXAN\&N7S)@VF$)9@<?K989!
M1/Q)$@-@7,,40TW\9#Z[?_BL\9PT!1B\(/Q@3^4<GC#!;<K S(]M.41A:!,O
M3)/3=G2GN\>([(543VV.-1#%J4OA+B\C?YI,;(&D\[#?^5I^!&<',;;0O;MN
M:#2I$:8]D_O5_D9STQ[DI^WM=>@C57N.KBG9#D7#\0RCK=HK1CLQLG;'^E8:
MO"2X88&W,J;L!OR_D^CZ;F(5]/>\U;]02P,$%     @ C8%<5)'E<99# P
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M#;-L4VY3!AAG[^-,"#/0%N)4M!!5^''."ZN0T"V1H[Q )$+JJE$M ?1^!UP
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MPCXYCG]D;YS[?Y,!THV$O0$7<9 D?D@^)15HJMK)F%"40#@@PD&2^"/BO9D
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;+58P6[;.! ]=[^",+I
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MUY=2'(#,K?5L^4&1FV*TCB9*\S+>*ZF_C?0X=?TN2EFZC%@,[M),R9VND,K
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MWJWX"APBM0'+I^OHXH#7EG6?@AD4^GB\@AG2^6=X\.];'MB$@6>[[VTQA5X
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M%W+STM?F1(E%\][4C5!*%,WAG*=3+FL#_?],"/7KI'X5:_?JW?!_4$L#!!0
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MLJ*K#8Q+H/-2:WP-W+@-EV7^"U!+ P04    " "-@5Q4YH@9K-P&  "((0
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M=E !:[REZI'O?T!;3VSX<DZE_47[-M9S4+Z5BE<M6"NH"&N^^+7M0P_@1R<
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MHS@4AE_%0G/12IV"#02HDDAMNM56FJZBZ<[NQ6@O''(2T #.V*9IWWYM0H
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MJ72^.TKM.I)MBM/(@DEUMBF:D3I^ M<!ZOF*,;GOZ -.=:"=_@M02P,$%
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MN=GJ86$^/D!: _,\%T+O)_9Z:S]G)G\!4$L#!!0    ( (V!7%1[_67]: (
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MPY7]0H!V!^S^0BE\G[BNU7YSRC=02P,$%     @ C8%<5!8+[J=5 @  R04
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M>K%-0<$5-A2,AH,.;U"_;DO^X6Q7$$.ZL0-%WVJ(,.UQ>+&%*GHAL;75N+]
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MEBQ;R'*B1>&:JH70ID5SP[5INT':#>;[4@B]GU@#=2,__0U02P,$%     @
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M>WI+E4&>E!=GR[SX%SRIL<X(Q)N<9RLU66BP2M+R_^2;<D1M C)-0&H"VIF
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M5?RXH$3X0 X0?Y]E&=]^D%^;K+X8??I_4$L#!!0    ( (V!7%2QM.8G# 8
M - E   9    >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;,V:76_;-A2&_PKA
M!5L+)++X)=M=8B!VVZW N@;-MEX4NU!DQA8JB:Y$)^VP'S^24D0E$FFK=C'?
MQ-8'#U_RG/.0/N'Y/<\_%2O&!/B2)EEQ,5@)L7XQ'!;1BJ5AX?$UR^236YZG
MH9"7^7)8K',6+G2C-!DBWP^&:1AG@^FYOG>53\_Y1B1QQJYR4&S2-,R_SEC"
M[R\&</!PXWV\7 EU8S@]7X=+=LW$G^NK7%X-:RN+.&59$?,,Y.SV8G )7\P#
MW4"_\5?,[HO&=Z"&<L/Y)W7Q9G$Q\)4BEK!(*!.A_+AC<Y8DRI+4\;DR.JC[
M5 V;WQ^LO]:#EX.Y"0LVY\F'>"%6%X/Q "S8;;A)Q'M^_RNK!D25O8@GA?X+
M[JMW_0&(-H7@:=58*DCCK/P,OU03T6@  TL#5#5 3QL02P-<-<!ZH*4R/:R7
MH0BGYSF_![EZ6UI37_3<Z-9R-'&FW'@M<ODTENW$]%KPZ-.*)PN6%S^!5Y\W
ML?@*GEV73@7\%N@7P+NUGO1+->GRC>?@V4LFPC@IGH,S< *&H%B%.2O.AT)J
M4I:'4=7_K.P?6?J'"+SEF5@5X%6V8(O'!H9R,/6(T,.(9LAI\26+/(#A*4 ^
M@AV"YKLW]QUR<#W!6-LC%GOES!5 <+#>Y-%*AAR(>)K*V2STU'Y\R](;EO_M
MZ(O4?1'=%[8Y4SGA3$7U LQY*E.]"%7OIT _*<#E1JQX'O\CGV_D=.>/O7N5
MA%EQ"EY]87D42YE7>1PQ\#[,E@Q\_$WV!=X(EA8NI;162IVS\OM&C5G%5QDX
MI^"7/,S$TP H'5::"K0IA:6[J73,74?O0=U[X.S]!'HP #_^,$80_BP=[4W\
MV@W@7_"'Y%0UBZ6+>#D_.WAJ5"L8';FGQK72<4]/O=N(0H39(LZ6(!1 )HR>
M%DO2E"D[;KD0D@"/?=_BR4FM;G)8=9U$F/14!WU#5]^IK_;06GGH%,A54VK)
ME:.ZA%36QDTE,E0M*AJ,A[U4;-9KIXK2VJ2A0N6(104R*I!3Q0>]I,J #N]8
M+K<(@#V1]2V!5?79G#'J46S1:J -W=3>5VMGF%5][JC50!^2?6AVB 4(&JY#
M>N1@@V85@.YEH%]RSBIKC]+"H\3B/K,2P-$!DW-666L&$0D\/++(,)B';LZ?
M(.SY)HRTS0,MBM#0'$Z./'J003MRH[W/%F96V6HN,8B,)]85!AFVHWYLWQ+$
ME;5F^&C'6V08N",WW'M&<65MLEL4(\-MM">W73YJXQEC;S2V:#)\1EOXC#R?
MUHEU0GKN-A7"TRSF*=/QO4O"(8-K=.RX1@;7R(WK?@D7M!(.8T>^&5RC?KC>
MEF]M7*MPL*@PM$9N6O=-MW$[W6P;.F1HC=R;[[V2;=*AB%CV0MA &;NA++-K
M!%5)XFF67;%<U[RRJ"O9BEVR"ALF8WCD684-N'$_<&^)9]P!;CGE%K\UBB1N
M;O>,9]Q&M36>L0$UW@+J?8/G&U"-#:KQL:,:&U3C Z(:=Z#:)U948X-J[$;U
M08H#LZJ3G>49AN-^#-^6>>..F+=FGH$X=D.\;^9U<=N2><1@F[BQO<]*4IG>
MC4C$,)RX]]7?HP(P(^W=MT.K83AQ,_QQ!0!2;S(^T$\W8@A.\)'CB33*Y&[0
MM\'PT&]WA)$6 <[(* BL#" &ZL1=!^_)@,K:;O5!8G!-^A5"MC" M LA.N8L
M,@ROB9O76U/.[:7V3IMZV)9;AM)D6UW$H^2[E$6(830Y]K((-2BG?<LB<[5O
M2KJ=1MMUD3-*H#6SJ.$W/6A=A';41:S%/6K(3 ]:%J&]RB+4P)GN619Q^@BW
M1%$/67["4@-AVJ=L_3BQ7)'8^!?CL6^8J2$P/6@IFG80V+H.4 -@>M!2-.U5
MBJ8&N70+<AV1L1]RJ4$N/7;D!@:Y05_D?LO>-&BC&")([36SP+ X^!_VTD&;
MV!!Z^.DN9-@X&Y.R?*F/#!4@XIM,E(=*ZKOUL:1+?1CGR?T9?#$O#Q<9,^59
MI[=AOHRS B3L5IKTO9'D4EX>'RHO!%_K$S@W7 B>ZJ\K%LJ@42_(Y[><BX<+
MU4%]B&OZ'U!+ P04    " "-@5Q4UB/1 9@'  "X,0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6S-VUMOVS84 ."_0GC&U@*M+-ZE+@G0M!E68%V#
M%%TQ%'U0;"86*EFN)"?-L!\_ZF(=93(IJ1 *OR2^Z?#X4/Q,D_+)?9)^R=9*
MY>A;'&VRT]DZS[<O%HMLN59QD#G)5FWT,S=)&@>YOIO>+K)MJH)5>5 <+8CK
MBD4<A)O9V4GYV&5Z=I+L\BC<J,L49;LX#M*'<Q4E]Z<S/-L_<!7>KO/B@<79
MR3:X5>]5_F%[F>I[BR;**HS5)@N3#4K5S>GL)7YQ[O'B@/(5?X7J/FO=1L5;
MN4Z2+\6=-ZO3F5MDI"*US(L0@?YWIUZI*"HBZ3R^UD%G39O%@>W;^^B_E6]>
MOYGK(%.ODNACN,K7IS-OAE;J)MA%^55R_[NJWU"9X#*)LO(ONJ]?Z\[0<I?E
M25P?K#.(PTWU/_A6%Z)U #4=0.H#2)EWU5"9Y>L@#\Y.TN0>I<6K=;3B1OE6
MRZ-U<N&FZ)7W>:J?#?5Q^=G[/%E^62?12J79+^CBZR[,']"3*[5,-LLP"H.R
M=,D->K?+LSS8K,+-+=+_T,4WE2[#++B.%"ICH'?;XK794_3DM<J#,-*WGN\?
M1'F"MKMTN=;U0\LDCG70K#SJTUL57ZOT\\DBU^^FR&FQK#,_KS(GALPQ06^3
M3;[.T,5FI5:/ RQT&9I:D'TMSHDUXFNU=!#%SQ!Q"9ZC!<K60:JRZJ\E/FUJ
M3<OXU%3K(A ZUS58H5=)K =65M6W?")#+W?Y.DG#?_33'_1;2A\5%EU&@2YD
M77>%+M-PJ=!5L+E5Z-,?NB7T)E=Q]MF2)VOR9&6>S)#GG[NB2U#2ZO)_T:$J
M5$6M@HDR6(' G>X:)JCKNB>+NP-I\"8-;DWC8SFB=#&".Y5J(30"!3-%.OKL
MS%,]H'=!A*+P1J$G?ZL@S9X>2L_>B$ /Q9&(H[@ZF;"/5L&#K;M%D[\8E[_:
M]]VVZ+M#N58!O78IL4/(X3K*)@\YI#OO5%8D8^M)V>E)S_7PX=:]IG5OZBIX
MG2IP1]##:?A-&KXUC;GKN"[Z^2>/8/PK8HY@!GH>1<<N,.H>]=C&+?"QM1(7
MC^K_#.G/99U.6C1V$&'<.2D,XQH32(&,2F&WW5I3()T3HNA 0Q:@,:93,E='
M:Q>""BF,S&'@%MN]G0BZGE9X+1UKI*-]TF&@&H^TNG^4UQ';O4H<WZ -!G2Q
M7=WAVM6!'G4H=SU# J MMG/[/:608TH!\F([O?.2N>?(=X@<I!U@BOVCUHZ
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M)[NT.]GU'=] /P5YJ5W>>06=!L]S.!\"'@5+J3QJ\"C03.WSW)'@U='\@=2
MNW2<NWWB^5WQBEX\G 8#>)D=WK&K=^ZA;T$F\!C R^SP3@1>3RM>#9[?3/%8
MGW@,S&8CS>X?YZR[5(&90PT#G0&^;-!:Q0#R6'>9 IN:;RT(3S[99=W)KJT2
M@"^SXSNOJ'N."'6P/X0\!IPR<=3D,<"9V2>Z(\FKH_D#K0%YV3AY>\ACW97=
MLA<-:8"\S"[O6/+\[A"Q?*_E0"^WTSO5CH6]%;^SD-?[M98#VWPDV_TCG7=7
M*PAV/&&H)O#+!RU7##"/=U<JB.'<YD NGWR^R[OS7>(ZAM.;@[[<KN^\HDZ3
M)QV/#!"/M[;8^%&+Q\%F;I_JCA2OCN8/HX8#O'P<O#WB\0,KNT4G&M( >+D=
MWI'BU=$>3?*(13R0E]OEG4H\>RM[\40MGFUS%K 6([$>L#W;7:0@S+@_*P!=
M84=W7IX3>H!3XC Q9$XC0%%!CGJ$"P!7V,$=.<+K:/ZPH25 6V'7=N0(%]UY
M;MF+AC1 9C%H57?H"!<'EG:E>>%*M"YB&+FX^WTCO*<5__^78?1^C1- MIA\
M0TX<8-MSI&'E2 #;8A#; Z8THBLV-YW:H+48J?6 2G17*?0H,WR,2L!7VO&=
M5])I\:2#W2'B2=!4XJ,63X+-<MQU$#WBU='\8=1(@%>.@[='/-F=Y1:]:,@"
MW)637G4F#UQV1BW?XB3(*W_(=6<]K=3BV<XC,%I.O@$GNQMP5#C8L ,G6]>:
M]>S ,>Q(J@<V$PX==-6!!#WE<6_!28!63KH%)[M;<&49#5?>@;+>I'MP7G=Z
M6_:B(0T V9MT#\[K[L&1<GW&D =PZ_V0/;B>5O93&5Q-90:LSG@@M3?YFH37
MU=K6J<"U-]4FG'=@$\ZP.N,!TM[D>W!>=P_N4"46K8OI8Y7>EC\9R/09LMOD
MU77US:/-SQ)>5A?CP\NKWS2\#=+;4*,3J1M]J.L4'PEI]3.!ZDZ>;,M+\Z^3
M/$_B\N9:!9JNX@7Z^9LDR?=WB@::'VN<_0=02P,$%     @ C8%<5"#XL6E9
M P  S@H  !D   !X;"]W;W)K<VAE971S+W-H965T-C(N>&ULO99M;]HP$(#_
MRBF:M%5J29P @0F0H.VV2NM6E;U\F/;!D(-836)J.U"D_?C93@C9>%NE:E^2
MV+X[/_=BYWHK+AYDC*C@*4TRV7=BI19O75=.8TRI;/ %9GIEQD5*E1Z*N2L7
M FEDE=+$]3VO[::49<Z@9^?NQ*#'<Y6P#.\$R#Q-J5B/,.&KOD.<S<0]F\?*
M3+B#WH+.<8SJZ^).Z)%;68E8BIED/ .!L[XS)&]')# *5N(;PY6L?8-Q9<+Y
M@QG<1'W',T28X%09$U2_EGB)26(L:8['TJA3[6D4Z]\;Z^^L\]J9"95XR9/O
M+%)QW^DX$.&,YHFZYZL/6#K4,O:F/)'V":M2UG-@FDO%TU)9$Z0L*][TJ0Q$
M32$XI."7"K[E+C:RE%=4T4%/\!4((ZVMF0_KJM76<"PS61DKH5>9UE.#L>+3
MAY@G$0KY&JX?<Z;6\&9<Y CX#+[H'%R,M-\1W(^_2AB:,&JA,WASA8JR1)[!
M1;&T8BH&9>0G5GZ)4K%L#C]N,9V@^ DRI@(EL R^Q#R7-(MDSU7:"\/B3DOB
M44'L'R F/MSR3,42KK,(HS\-N-K]*@;^)@8C_ZC%*YPV("#GX'L^>05NR5D\
MC]@/JA@'UGYP*,;&$!0QO.2I/E"2VI(<"D&S.>HB5S!:0UWNCJ[M]'!%100_
M/FJ3<*,PE3^/ #4KH*8%:AX ^I2;?)CL%CZ>P^=<2:7S8=)%%>B(V)1MHN+!
M+]@7CB*ZQ69MNYFY!9:#5I=T>^YR#V*K0FP]$_&]CI72D3E&TMHA"<)F<S])
MNR)I/Y/D7M\I-DG'4-H[*!<D[';VLX052_A,%GTUS9"=BDNX"],,@_TLG8JE
M\[)%1(XB=G80PZ#K[T?L5HC=HXC?[9VL8T.7*/0_!N:FAB"B"F%&F8 E37+\
MI^K?7@O[X N,3OT$-/S6?GCB;:]F[T7P%QK5LIWD+#?L_@%*#A0"J?U#R(N
MU@[."4ZRPTG:C?:!TT/\+:C_(J#U4W6"U-\E[3;"0Z3;7P8)_D?IDM,.!#NU
M&[0:P=\UX=9:C!3%W#92$J8\SU31;52S5;,V+%J4K7C1Z=U2,6>9A 1G6M5K
MA/K6%D7S5 P47]B&9<*5;G_L9ZP;3A1&0*_/.%>;@=F@:F$'OP%02P,$%
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M9M4])O0!@LHNH/=K*<WSP&Y0?M*,_P502P,$%     @ C8%<5"Q&'J3Y P
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MI@SD^QVEXCA0"[27V>6_4$L#!!0    ( (V!7%21ADR?H ,  %,.   9
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M>!!(;JN*BN<;*/E^ZF#G9>.QR')E-MS99$,S6(+ZOGD0>N6V+&E1 9,%9TC
M>NI<XT\+'!F C?BO@+T\.D9&RHKSWV9QFTX=SV0$)23*4%#]LX,YE*5ATGG\
MWY Z[34-\/CXA?V+%:_%K*B$.2]_%*G*IT[LH!36=%NJ1[[_!HV@T/ EO)3V
M&^V;6,]!R58J7C5@G4%5L/J7/C6%. )HH?T T@#(WX#@!,!O /ZY@* !!+8R
MM11;AP55=#81?(^$B=9LYL 6TZ*U_((9WY=*Z+.%QJG9$C+MHD+7+$5?@6>"
M;O(B0;>LOJ6,-1?+^IY ?(T>80=L"VCUC.940<;%\R6Z6("B12DOT4?T?;E
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M!1 F0)]?<ZY>%N8"[:O'[ ]02P,$%     @ C8%<5-]<,.\Y P  X!,   T
M  !X;"]S='EL97,N>&ULW5A=:]LP%/TK1AVC@U$[\>K&:Q+8 H7!-@KMP]Z*
M$LN.0)8\6>F2_OKI6H[S4=W2]6%SY]!8NL?WG"/INE([KLU&L)LE8R98ET+6
M$[(TIOH8AO5BR4I:GZF*28OD2I?4V*XNPKK2C&8U))4B'$91$I:42S(=RU5Y
M59HZ6*B5-!.2=*' W;YD$S)(/I# T<U4QB;D[O3MSY4REV\"=S]Y?W(2W;V[
M/(Z?-L [$GI)SY]!>A9%.#& &'GR//*GN#'JBT/JS@J0[8RAZ2-O^EXNEIAB
MNM%C\:AS$+8K/!WG2NX6.B8N8)5HR8)[*B9D1@6?:PY9.2VYV+CP$ (+)90.
MC*TP*SV 2/W@X('K0?&U/"672C?:3L%]S]O'CX!M#PQR(3J#0^("TW%%C6%:
M7ME.\W 3? 0%;?MV4UF'A::;P?"<[!*:FQ69*YTQW<D,R#8T'0N6@QW-BR7<
MC:I" (U1I6UDG!9*TL;#-J-M6-H%$^(&WLP?^0'W.M];PPA64'9-:ZAM.AK7
M ?Y]-L>]3QN_B#>H^+TRGU=V.++I0[6S:\UROF[ZZ[PS@+$/<'9:56+S2?!"
MELP-_MF"TS'=Y@5+I?F#58-26=@ TR2X9]KPQ7[DEZ;5+5N;;3FM<]SS\!5Z
M_KOS7##)-!7[IFWM]WF67^RXW<K^A>?FU\JQ8Z_)^*+_'MOMN^\FD_Z;C-/^
M>VP//7TW.7H-)ONYW&%[R-@[R1R<8[IH .?%"?D.)U&Q$PWF*RX,EVUOR;.,
MR4?'&4MOZ-S^^7+ ;Y_/6$Y7PMQVX(3LVM]8QE=EVCUU#1/1/K5K?X7A#9+N
ML&JUN,S8FF6SMJN+>=,,;,.JMA<D'"-7S>5'L!R'^1' ,!W, 9;CLC"=_VD\
M(W0\#L.\C;S(",T9H3DNRX?,F@^FX\])[>4?:9K&<9)@,SJ;>1W,L'E+$OCQ
MLV'>( /3 :4_FVM\M?$*>;H.L#5]JD*PD>*5B(T4GVM _/,&&6GJ7VU,!S*P
M5<!J!_3].E!3_IPXAE7%O&%O,(ZD*89 +?IK-$F0V4G@XU\?["V)XS3U(X#Y
M'<0QAL#;B".8 _" (7'<[(-'^U&XW:?"W?_TIK\!4$L#!!0    ( (V!7%27
MBKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E
M\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!
M2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/
M06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3
MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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MD65351?^VC?U1?-RMWM\M_/][#]02P,$%     @ C8%<5+ % +TV @  '"H
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M%(':6$PN=AN'K$5AO6^;RJ:\SA[[^E/*]#6AS"?'/7'=^'B4-Q3LRX1AY?N
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M4$L! A0#%     @ C8%<5%O%6D_. @  8PH  !@              ("!+A8
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( (V!7%3T"<%#
MZ08  !L>   8              " @3(9  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " "-@5Q40*LK6U\&  !G'@  &
M@(%1(   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ C8%<
M5,=X'J(3"@  ZBT  !@              ("!YB8  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( (V!7%279$0E?2(  /1F   8
M      " @2\Q  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" "-@5Q4P+H/E"L/   6+   &               @('B4P  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ C8%<5);H4]BF"   M18  !@
M             ("!0V,  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( (V!7%1D7:]C0 8  .8/   9              " @1]L  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ C8%<5'B>XY>O#@
M*2\  !D              ("!EG(  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " "-@5Q4&SK^)WD,  #=(0  &0              @(%\
M@0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( (V!7%0"
MQS+?-PL  #X?   9              " @2R.  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ C8%<5$X")93W#@  UR<  !D
M     ("!FID  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M" "-@5Q4XML?K4L.  "/*   &0              @('(J   >&PO=V]R:W-H
M965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( (V!7%1&W$J3MA@  'A6   9
M              " @4JW  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L!
M A0#%     @ C8%<5,ERE(8C!0  _0T  !D              ("!-]   'AL
M+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "-@5Q4,<-5;=H$
M  #_"@  &0              @(&1U0  >&PO=V]R:W-H965T<R]S:&5E=#$X
M+GAM;%!+ 0(4 Q0    ( (V!7%11J<Z3O1T   -@   9              "
M@:+:  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ C8%<
M5)O &I9T @  >P4  !D              ("!EO@  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " "-@5Q4IO1[VV0$   >#   &0
M        @(%!^P  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( (V!7%1)^:?IM@8  )H8   9              " @=S_  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ C8%<5.$C_@4(!@  L \
M !D              ("!R08! 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " "-@5Q4ZVG8.8L"  #M!0  &0              @($(#0$
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( (V!7%0;CX=N
M @,  'X&   9              " @<H/ 0!X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ C8%<5!(3,/6U!   - P  !D
M ("! Q,! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "-
M@5Q4?)78BCP'  "A&0  &0              @('O%P$ >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( (V!7%0B-8PS\ ,  /,)   9
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M970S,BYX;6Q02P$"% ,4    " "-@5Q4+U &VKH%  "S%P  &0
M    @('@. $ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M (V!7%2)K_#Q80(  !T&   9              " @=$^ 0!X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ C8%<5"6?+>1/!   NQ   !D
M             ("!:4$! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " "-@5Q4<I15!EX#  "W#   &0              @('O10$ >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( (V!7%2W<"@+9@8
M #HG   9              " @81) 0!X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ C8%<5$Y+$GG# @  4 <  !D              ("!
M(5 ! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "-@5Q4
MU%BNV)@&  "&)P  &0              @($;4P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( (V!7%2F=1PK6 (  #@%   9
M      " @>I9 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ C8%<5.:(&:S<!@  B"$  !D              ("!>5P! 'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "-@5Q4.77J$6T"  !7!@
M&0              @(&,8P$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( (V!7%1\74K1K@,  -P.   9              " @3!F 0!X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ C8%<5)\9M8&,
M @  T 8  !D              ("!%6H! 'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " "-@5Q4*= K+WP#  !9#   &0
M@('8; $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( (V!
M7%16_TT+B@(  .0&   9              " @8MP 0!X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ C8%<5(_XO++_ @  V@@  !D
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M=#4Q+GAM;%!+ 0(4 Q0    ( (V!7%0!XDT46@(  (\%   9
M  " @8J" 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
MC8%<5&&R#*:# P  U L  !D              ("!&X4! 'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    " "-@5Q4;J>S-6,#  "_"@  &0
M            @('5B $ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    ( (V!7%3&)/_VG 0  "$3   9              " @6^, 0!X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ C8%<5+E5RLY9 P
M<@P  !D              ("!0I$! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6Q02P$"% ,4    " "-@5Q4A\H>Z\H#  "?#   &0              @('2
ME $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( (V!7%1B
MM\D%'0,  $P)   9              " @=.8 0!X;"]W;W)K<VAE971S+W-H
M965T-3@N>&UL4$L! A0#%     @ C8%<5#4_OPF)"P  )#T  !D
M     ("!)YP! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (V!7%3+E3)Y%P0  *,2   9              "
M@1"] 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ C8%<
M5%$V:.3V P  #!   !D              ("!7L$! 'AL+W=O<FMS:&5E=',O
M<VAE970V-2YX;6Q02P$"% ,4    " "-@5Q4 K"&3XH#  #>#   &0
M        @(&+Q0$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0
M   ( (V!7%0L1AZD^0,  -@.   9              " @4S) 0!X;"]W;W)K
M<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ C8%<5)&&3)^@ P  4PX
M !D              ("!?,T! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q0
M2P$"% ,4    " "-@5Q43\$L51$"  ![!   &0              @(%3T0$
M>&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( (V!7%37# F*
M1@,   L+   9              " @9O3 0!X;"]W;W)K<VAE971S+W-H965T
M-S N>&UL4$L! A0#%     @ C8%<5-"D*[Q> P  A@P  !D
M ("!&-<! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " "-
M@5Q4WUPP[SD#  #@$P  #0              @ &MV@$ >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( (V!7%27BKL<P    !,"   +              "  1'>
M 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (V!7%1C,F);- 4  'TO   /
M          "  ?K> 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "-@5Q4
ML 4 O38"   <*@  &@              @ %;Y $ >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " "-@5Q4X<M&R/T!   ]*0  $P
M        @ ')Y@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     3P!/ * 5
(  #WZ $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>303</ContextCount>
  <ElementCount>531</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>118</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations and Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00500 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Business Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitions</Role>
      <ShortName>Business Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Invitae Collaboration Arrangement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangement</Role>
      <ShortName>Invitae Collaboration Arrangement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Termination of Merger with Illumina</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIllumina</Role>
      <ShortName>Termination of Merger with Illumina</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureFinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Convertible Senior Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotes</Role>
      <ShortName>Convertible Senior Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11002 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Net (Loss) Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShare</Role>
      <ShortName>Net (Loss) Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Segment And Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformation</Role>
      <ShortName>Segment And Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>20402 - Disclosure - Summary of Significant Accounting Policies (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy</Role>
      <ShortName>Summary of Significant Accounting Policies (Policy)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30103 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Business Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables</Role>
      <ShortName>Business Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitions</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureFinancialInstruments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Convertible Senior Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesTables</Role>
      <ShortName>Convertible Senior Notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Net Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureNetIncomeLossPerShareTables</Role>
      <ShortName>Net Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Segment And Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationTables</Role>
      <ShortName>Segment And Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40105 - Disclosure - Summary of Significant Accounting Policies (Calculation of Basic and Dilutive Net Income (Loss) per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutiveNetIncomeLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Calculation of Basic and Dilutive Net Income (Loss) per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Business Acquisitions (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails</Role>
      <ShortName>Business Acquisitions (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Business Acquisitions (Schedule by Acquisitions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails</Role>
      <ShortName>Business Acquisitions (Schedule by Acquisitions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Invitae Collaboration Arrangement (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangementNarrativeDetails</Role>
      <ShortName>Invitae Collaboration Arrangement (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangement</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Termination of Merger with Illumina (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails</Role>
      <ShortName>Termination of Merger with Illumina (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIllumina</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Financial Instruments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Financial Instruments (Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Financial Instruments (Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Financial Instruments (Changes in estimated fair value of contingent consideration) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails</Role>
      <ShortName>Financial Instruments (Changes in estimated fair value of contingent consideration) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40504 - Disclosure - Financial Instruments (Summary of Cash, Cash Equivalents and Investments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails</Role>
      <ShortName>Financial Instruments (Summary of Cash, Cash Equivalents and Investments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40505 - Disclosure - Financial Instruments (Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails</Role>
      <ShortName>Financial Instruments (Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Balance Sheet Components (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails</Role>
      <ShortName>Balance Sheet Components (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Balance Sheet Components (Components of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfInventoryDetails</Role>
      <ShortName>Balance Sheet Components (Components of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Balance Sheet Components (Components of Property and Equipment, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components (Components of Property and Equipment, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40604 - Disclosure - Balance Sheet Components (Changes in carrying amount of goodwill) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails</Role>
      <ShortName>Balance Sheet Components (Changes in carrying amount of goodwill) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40605 - Disclosure - Balance Sheet Components (Definite-lived Intangible Assets from Business Acquisitions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails</Role>
      <ShortName>Balance Sheet Components (Definite-lived Intangible Assets from Business Acquisitions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40606 - Disclosure - Balance Sheet Components (Estimated Future Amortization Expense Of Acquisition-Related Intangible Assets With Definite Lives) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails</Role>
      <ShortName>Balance Sheet Components (Estimated Future Amortization Expense Of Acquisition-Related Intangible Assets With Definite Lives) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40607 - Disclosure - Balance Sheet Components (Schedule of Accrued Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Components (Schedule of Accrued Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40608 - Disclosure - Balance Sheet Components (Furture Principal Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails</Role>
      <ShortName>Balance Sheet Components (Furture Principal Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40611 - Disclosure - Balance Sheet Components (Schedule of Other Liabilities, Current) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfOtherLiabilitiesCurrentDetails</Role>
      <ShortName>Balance Sheet Components (Schedule of Other Liabilities, Current) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Convertible Senior Notes (Narrative) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails</Role>
      <ShortName>Convertible Senior Notes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Convertible Senior Notes (Schedule of Net Carrying Amount) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfNetCarryingAmountDetails</Role>
      <ShortName>Convertible Senior Notes (Schedule of Net Carrying Amount) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Convertible Senior Notes (Schedule of Interest Expense) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfInterestExpenseDetails</Role>
      <ShortName>Convertible Senior Notes (Schedule of Interest Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Commitments and Contingencies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Commitments and Contingencies (Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies (Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Income Taxes (Reconciliation of Federal Income Tax Rate) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes (Reconciliation of Federal Income Tax Rate) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Income Taxes (Reconciliation of Deferred Tax Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes (Reconciliation of Deferred Tax Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Income Taxes (Reconciliation of Unrecognized Tax Benefit Accounts) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitAccountsDetails</Role>
      <ShortName>Income Taxes (Reconciliation of Unrecognized Tax Benefit Accounts) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Stockholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Stockholders' Equity (Summary of Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity (Summary of Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Stockholders' Equity (Reconciliation of Outstanding and Exercisable Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails</Role>
      <ShortName>Stockholders' Equity (Reconciliation of Outstanding and Exercisable Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41004 - Disclosure - Stockholders' Equity (Summary of Time-Based RSUs Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails</Role>
      <ShortName>Stockholders' Equity (Summary of Time-Based RSUs Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41005 - Disclosure - Stockholders' Equity (Summary of Performance-Based RSUs Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails</Role>
      <ShortName>Stockholders' Equity (Summary of Performance-Based RSUs Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41006 - Disclosure - Stockholders' Equity (Schedule of Stock-Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity (Schedule of Stock-Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41007 - Disclosure - Stockholders' Equity (Schedule of Fair Value of Employee Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails</Role>
      <ShortName>Stockholders' Equity (Schedule of Fair Value of Employee Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41008 - Disclosure - Stockholders' Equity (Schedule of Fair Value of Employee Stock Purchase Plan) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stockholders' Equity (Schedule of Fair Value of Employee Stock Purchase Plan) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Net (Loss) Income Per Share (Computation Of Basic And Diluted Net Loss Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net (Loss) Income Per Share (Computation Of Basic And Diluted Net Loss Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureNetIncomeLossPerShareTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Net (Loss) Income Per Share (Antidilutive Shares Excluded From Computation Of Diluted Net Loss Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net (Loss) Income Per Share (Antidilutive Shares Excluded From Computation Of Diluted Net Loss Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureNetIncomeLossPerShareTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Segment And Geographic Information (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationNarrativeDetails</Role>
      <ShortName>Segment And Geographic Information (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Segment And Geographic Information (Schedule of Revenue by Geographic Location) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails</Role>
      <ShortName>Segment And Geographic Information (Schedule of Revenue by Geographic Location) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="pacb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Segment And Geographic Information (Summary of Revenue by Category) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails</Role>
      <ShortName>Segment And Geographic Information (Summary of Revenue by Category) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="pacb-20211231x10k.htm">pacb-20211231x10k.htm</File>
    <File>pacb-20211231.xsd</File>
    <File>pacb-20211231_cal.xml</File>
    <File>pacb-20211231_def.xml</File>
    <File>pacb-20211231_lab.xml</File>
    <File>pacb-20211231_pre.xml</File>
    <File>pacb-20211231xex21_1.htm</File>
    <File>pacb-20211231xex23_1.htm</File>
    <File>pacb-20211231xex31_1.htm</File>
    <File>pacb-20211231xex31_2.htm</File>
    <File>pacb-20211231xex32_1.htm</File>
    <File>pacb-20211231xex32_2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pacb-20211231x10kg001.jpg</File>
    <File>pacb-20211231x10kg002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="1049">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pacb-20211231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 33,
   "contextCount": 303,
   "dts": {
    "calculationLink": {
     "local": [
      "pacb-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pacb-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pacb-20211231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pacb-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pacb-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pacb-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd"
     ]
    }
   },
   "elementCount": 712,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 17,
    "http://xbrl.sec.gov/dei/2021q4": 7,
    "total": 24
   },
   "keyCustom": 66,
   "keyStandard": 465,
   "memberCustom": 64,
   "memberStandard": 45,
   "nsprefix": "pacb",
   "nsuri": "http://www.pacificbiosciences.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document And Entity Information",
     "role": "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pacb:MergerTermination",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Termination of Merger with Illumina",
     "role": "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIllumina",
     "shortName": "Termination of Merger with Illumina",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pacb:MergerTermination",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Financial Instruments",
     "role": "http://www.pacificbiosciences.com/role/DisclosureFinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Balance Sheet Components",
     "role": "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Convertible Senior Notes",
     "role": "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotes",
     "shortName": "Convertible Senior Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Commitments and Contingencies",
     "role": "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Income Taxes",
     "role": "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11002 - Disclosure - Stockholders' Equity",
     "role": "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Net (Loss) Income Per Share",
     "role": "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShare",
     "shortName": "Net (Loss) Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Segment And Geographic Information",
     "role": "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformation",
     "shortName": "Segment And Geographic Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20402 - Disclosure - Summary of Significant Accounting Policies (Policy)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy",
     "shortName": "Summary of Significant Accounting Policies (Policy)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "role": "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pacb:EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30103 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pacb:EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pacb:ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Business Acquisition (Tables)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables",
     "shortName": "Business Acquisition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pacb:ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Convertible Senior Notes (Tables)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesTables",
     "shortName": "Convertible Senior Notes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pacb:LesseeOperatingLeaseDescriptionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pacb:LesseeOperatingLeaseDescriptionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Net Income (Loss) Per Share (Tables)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureNetIncomeLossPerShareTables",
     "shortName": "Net Income (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - Segment And Geographic Information (Tables)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationTables",
     "shortName": "Segment And Geographic Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit13",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit13",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "Unit15",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_srt_CounterpartyNameAxis_pacb_ObrienLeaseAgreementMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RestrictedCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "Unit13",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40105 - Disclosure - Summary of Significant Accounting Policies (Calculation of Basic and Dilutive Net Income (Loss) per Share) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutiveNetIncomeLossPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies (Calculation of Basic and Dilutive Net Income (Loss) per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_9_20_2021_To_9_20_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pacb:IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Business Acquisitions (Narrative) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
     "shortName": "Business Acquisitions (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_9_20_2021_To_9_20_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pacb:IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Business Acquisitions (Schedule by Acquisitions) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails",
     "shortName": "Business Acquisitions (Schedule by Acquisitions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_7_20_2021_us-gaap_BusinessAcquisitionAxis_pacb_CirculomicsIncMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Invitae Collaboration Arrangement (Narrative) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangementNarrativeDetails",
     "shortName": "Invitae Collaboration Arrangement (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossOnContractTermination",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Termination of Merger with Illumina (Narrative) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails",
     "shortName": "Termination of Merger with Illumina (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_3_31_2020",
      "decimals": "-6",
      "lang": null,
      "name": "pacb:ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Financial Instruments (Narrative) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit15",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Financial Instruments (Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Financial Instruments (Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40503 - Disclosure - Financial Instruments (Changes in estimated fair value of contingent consideration) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails",
     "shortName": "Financial Instruments (Changes in estimated fair value of contingent consideration) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member",
      "decimals": "-3",
      "lang": null,
      "name": "pacb:ContingentConsiderationIncurredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40504 - Disclosure - Financial Instruments (Summary of Cash, Cash Equivalents and Investments) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails",
     "shortName": "Financial Instruments (Summary of Cash, Cash Equivalents and Investments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_pacb_CashCashEquivalentsAndInvestmentsMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Consolidated Statements of Operations and Comprehensive (Loss) Income",
     "role": "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
     "shortName": "Consolidated Statements of Operations and Comprehensive (Loss) Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSoldAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40505 - Disclosure - Financial Instruments (Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails",
     "shortName": "Financial Instruments (Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "pacb:PercentageOfFeeToPrepayDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit15",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Balance Sheet Components (Narrative) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
     "shortName": "Balance Sheet Components (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "pacb:PercentageOfFeeToPrepayDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit15",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - Balance Sheet Components (Components of Inventory) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfInventoryDetails",
     "shortName": "Balance Sheet Components (Components of Inventory) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40603 - Disclosure - Balance Sheet Components (Components of Property and Equipment, Net) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails",
     "shortName": "Balance Sheet Components (Components of Property and Equipment, Net) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40604 - Disclosure - Balance Sheet Components (Changes in carrying amount of goodwill) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails",
     "shortName": "Balance Sheet Components (Changes in carrying amount of goodwill) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40605 - Disclosure - Balance Sheet Components (Definite-lived Intangible Assets from Business Acquisitions) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
     "shortName": "Balance Sheet Components (Definite-lived Intangible Assets from Business Acquisitions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40606 - Disclosure - Balance Sheet Components (Estimated Future Amortization Expense Of Acquisition-Related Intangible Assets With Definite Lives) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails",
     "shortName": "Balance Sheet Components (Estimated Future Amortization Expense Of Acquisition-Related Intangible Assets With Definite Lives) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40607 - Disclosure - Balance Sheet Components (Schedule of Accrued Expenses) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails",
     "shortName": "Balance Sheet Components (Schedule of Accrued Expenses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40608 - Disclosure - Balance Sheet Components (Furture Principal Payments) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails",
     "shortName": "Balance Sheet Components (Furture Principal Payments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_pacb_OmniomeIncMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40611 - Disclosure - Balance Sheet Components (Schedule of Other Liabilities, Current) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfOtherLiabilitiesCurrentDetails",
     "shortName": "Balance Sheet Components (Schedule of Other Liabilities, Current) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_2_9_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Convertible Senior Notes (Narrative) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails",
     "shortName": "Convertible Senior Notes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_2_16_2021_To_2_16_2021_us-gaap_DebtInstrumentAxis_pacb_ConvertibleSeniorNotesMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentIssuanceDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Convertible Senior Notes (Schedule of Net Carrying Amount) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfNetCarryingAmountDetails",
     "shortName": "Convertible Senior Notes (Schedule of Net Carrying Amount) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "pacb:ContractualInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Convertible Senior Notes (Schedule of Interest Expense) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfInterestExpenseDetails",
     "shortName": "Convertible Senior Notes (Schedule of Interest Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "pacb:ContractualInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Commitments and Contingencies (Narrative) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "pacb:LesseeOperatingLeaseDescriptionTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Commitments and Contingencies (Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails",
     "shortName": "Commitments and Contingencies (Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "pacb:LesseeOperatingLeaseDescriptionTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Income Taxes (Narrative) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Unit15",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Income Taxes (Reconciliation of Federal Income Tax Rate) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails",
     "shortName": "Income Taxes (Reconciliation of Federal Income Tax Rate) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit15",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - Income Taxes (Reconciliation of Deferred Tax Assets and Liabilities) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes (Reconciliation of Deferred Tax Assets and Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40904 - Disclosure - Income Taxes (Reconciliation of Unrecognized Tax Benefit Accounts) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitAccountsDetails",
     "shortName": "Income Taxes (Reconciliation of Unrecognized Tax Benefit Accounts) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit13",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Stockholders' Equity (Narrative) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit13",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00500 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "-3",
      "lang": null,
      "name": "pacb:AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Stockholders' Equity (Summary of Stock Option Activity) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
     "shortName": "Stockholders' Equity (Summary of Stock Option Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - Stockholders' Equity (Reconciliation of Outstanding and Exercisable Stock Options) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails",
     "shortName": "Stockholders' Equity (Reconciliation of Outstanding and Exercisable Stock Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41004 - Disclosure - Stockholders' Equity (Summary of Time-Based RSUs Activity) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails",
     "shortName": "Stockholders' Equity (Summary of Time-Based RSUs Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_TimeBasedRestrictedStockUnitsRsusMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41005 - Disclosure - Stockholders' Equity (Summary of Performance-Based RSUs Activity) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails",
     "shortName": "Stockholders' Equity (Summary of Performance-Based RSUs Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_pacb_PerformanceBasedRestrictedStockUnitsRsusMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41006 - Disclosure - Stockholders' Equity (Schedule of Stock-Based Compensation Expense) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity (Schedule of Stock-Based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "Unit13",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41007 - Disclosure - Stockholders' Equity (Schedule of Fair Value of Employee Stock Options) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails",
     "shortName": "Stockholders' Equity (Schedule of Fair Value of Employee Stock Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit15",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41008 - Disclosure - Stockholders' Equity (Schedule of Fair Value of Employee Stock Purchase Plan) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails",
     "shortName": "Stockholders' Equity (Schedule of Fair Value of Employee Stock Purchase Plan) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_pacb_EmployeeStockPurchasePlanMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit15",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Net (Loss) Income Per Share (Computation Of Basic And Diluted Net Loss Per Share) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Net (Loss) Income Per Share (Computation Of Basic And Diluted Net Loss Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_pacb_OptionsToPurchaseCommonStockMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Net (Loss) Income Per Share (Antidilutive Shares Excluded From Computation Of Diluted Net Loss Per Share) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
     "shortName": "Net (Loss) Income Per Share (Antidilutive Shares Excluded From Computation Of Diluted Net Loss Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit16",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Segment And Geographic Information (Narrative) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationNarrativeDetails",
     "shortName": "Segment And Geographic Information (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit16",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - Segment And Geographic Information (Schedule of Revenue by Geographic Location) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails",
     "shortName": "Segment And Geographic Information (Schedule of Revenue by Geographic Location) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_NorthAmericaMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41203 - Disclosure - Segment And Geographic Information (Summary of Revenue by Category) (Details)",
     "role": "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails",
     "shortName": "Segment And Geographic Information (Summary of Revenue by Category) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_pacb_InstrumentMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Business Acquisitions",
     "role": "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitions",
     "shortName": "Business Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pacb:DevelopmentAndCommercializationAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Invitae Collaboration Arrangement",
     "role": "http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangement",
     "shortName": "Invitae Collaboration Arrangement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pacb:DevelopmentAndCommercializationAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 118,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r725",
      "r726",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm Id"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r725",
      "r726",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r725",
      "r726",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r725",
      "r726",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r725",
      "r726",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfOtherLiabilitiesCurrentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Employee Stock Purchase Plan Liability, Current",
        "label": "Accrued Employee Stock Purchase Plan Liability, Current",
        "terseLabel": "Accrued ESPP"
       }
      }
     },
     "localname": "AccruedEmployeeStockPurchasePlanLiabilityCurrent",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfOtherLiabilitiesCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_AccruedProductDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Product Development Costs, Current",
        "label": "Accrued Product Development Costs, Current",
        "terseLabel": "Accrued product development costs"
       }
      }
     },
     "localname": "AccruedProductDevelopmentCostsCurrent",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_AccruedTenantImprovementsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Tenant Improvements, Current",
        "label": "Accrued Tenant Improvements, Current",
        "terseLabel": "Accrued interest payable"
       }
      }
     },
     "localname": "AccruedTenantImprovementsCurrent",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_AchievementOfMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upon achievement of a milestone.",
        "label": "Achievement Of Milestone [Member]",
        "terseLabel": "Achievement of milestone [Member]"
       }
      }
     },
     "localname": "AchievementOfMilestoneMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Liability Associated With Indemnification Obligations",
        "label": "Additional Liability Associated With Indemnification Obligations",
        "terseLabel": "Additional liability associated with indemnification obligations"
       }
      }
     },
     "localname": "AdditionalLiabilityAssociatedWithIndemnificationObligations",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) and research development expense in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible assets and research development expense",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_AnnualDecreaseInLongTermRestrictedCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Decrease in Long-Term Restricted Cash",
        "label": "Annual Decrease in Long-Term Restricted Cash",
        "terseLabel": "May 1 annual decrease to long-term restricted cash"
       }
      }
     },
     "localname": "AnnualDecreaseInLongTermRestrictedCash",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_AnnualReductionInNonCurrentRestrictedCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual reduction in non-current restricted cash",
        "label": "Annual reduction in non-current restricted cash"
       }
      }
     },
     "localname": "AnnualReductionInNonCurrentRestrictedCash",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated pre-tax unrealized gain before deducting pre-tax unrealized losses on investments in available-for-sale securities impacting investments.",
        "label": "Available For Sale Securities Gross Unrealized Gain Accumulated In Investments",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated pre-tax unrealized loss before deducting pre-tax unrealized gain on investments in available-for-sale securities impacting investments.",
        "label": "Available For Sale Securities Gross Unrealized Loss Accumulated In Investments",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_BalanceSheetClassificationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance Sheet Classification [Abstract]",
        "label": "Balance Sheet Classification [Abstract]",
        "terseLabel": "Balance Sheet Classification"
       }
      }
     },
     "localname": "BalanceSheetClassificationAbstract",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_BalanceSheetComponentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance Sheet Components [Line Items]",
        "label": "Balance Sheet Components [Line Items]"
       }
      }
     },
     "localname": "BalanceSheetComponentsLineItems",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic and Diluted",
        "terseLabel": "Pro forma net (loss) income per share - basic and diluted"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, operating lease right of use assets net recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Operating lease right-of-use assets, net Acquired and Liabilities Assumed Operating Lease Right of use assets Net",
        "terseLabel": "Operating lease right-of-use assets, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_CashAndMoneyMarketFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and money market funds.",
        "label": "Cash And Money Market Funds [Member]",
        "terseLabel": "Cash and money market funds [Member]"
       }
      }
     },
     "localname": "CashAndMoneyMarketFundsMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_CashCashEquivalentsAndInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents and Investments [Member]",
        "label": "Cash Cash Equivalents And Investments [Member]",
        "terseLabel": "Cash, cash equivalents and investments [Member]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndInvestmentsMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in the estimated fair value of contingent consideration liabilities table.",
        "label": "Changes in the estimated fair value of contingent consideration liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ChangesInEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pacb_CirculomicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Circulomics Inc. (\u201cCirculomics\u201d), a Maryland-based biotechnology company focused on delivering highly differentiated sample preparation products that enable genomic workflows.",
        "label": "Circulomics Inc [Member]",
        "terseLabel": "Circulomics, Inc [Member]"
       }
      }
     },
     "localname": "CirculomicsIncMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies [Line Items]",
        "label": "Commitments and Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies [Table]",
        "label": "Commitments and Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Voting Rights, Number Of Votes Per Share Owned",
        "label": "Common Stock, Voting Rights, Number Of Votes Per Share Owned",
        "terseLabel": "Voting right of common stock share holders, number of votes"
       }
      }
     },
     "localname": "CommonStockVotingRightsNumberOfVotesPerShareOwned",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "positiveIntegerItemType"
    },
    "pacb_ConsumableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumable [Member]",
        "label": "Consumable [Member]",
        "terseLabel": "Consumable [Member]"
       }
      }
     },
     "localname": "ConsumableMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ContingentConsiderationIncurredDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Incurred during the period",
        "label": "Contingent Consideration Incurred during period",
        "terseLabel": "Acquisition of Omniome",
        "verboseLabel": "Fair value of contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationIncurredDuringPeriod",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent consideration [Member]"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continuation Advances Payable Per Agreement To Repay Advance If Change In Control Transaction Or Single Equity Or Debt Financing Takes Place",
        "label": "Continuation Advances Payable Per Agreement To Repay Advance If Change In Control Transaction Or Single Equity Or Debt Financing Takes Place",
        "terseLabel": "Possible Continuation Advances payable"
       }
      }
     },
     "localname": "ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Liability, Noncurrent, Recognition Period",
        "label": "Contract with Customer, Liability, Noncurrent, Recognition Period",
        "terseLabel": "Deferred service revenue, noncurrent, recognition period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrentRecognitionPeriod",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pacb_ContractualInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Interest Expense",
        "label": "Contractual Interest Expense",
        "terseLabel": "Contractual interest expense"
       }
      }
     },
     "localname": "ContractualInterestExpense",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_ConvertibleSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes [Member]",
        "label": "Convertible Senior Notes [Member]",
        "terseLabel": "Convertible Senior Notes [Member]"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer B [Member]",
        "label": "Customer B [Member]",
        "terseLabel": "Gene Company Limited [Member]"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_CustomerDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer D [Member]",
        "label": "Customer D [Member]",
        "terseLabel": "Berry Genomics Co., Ltd [Member]"
       }
      }
     },
     "localname": "CustomerDMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_CustomerDepositMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer Deposit [Member]",
        "label": "Customer Deposit [Member]",
        "terseLabel": "Customer Deposit [Member]"
       }
      }
     },
     "localname": "CustomerDepositMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_DebtInstrumentAdditionalInterestInEventOfDefault": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Additional Interest in the Event of Default",
        "label": "Debt Instrument, Additional Interest in the Event of Default",
        "terseLabel": "Additional interest in the event of default"
       }
      }
     },
     "localname": "DebtInstrumentAdditionalInterestInEventOfDefault",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Conversion Rate, Shares Issued Per Stated Amount",
        "label": "Debt Instrument, Conversion Rate, Shares Issued Per Stated Amount",
        "terseLabel": "Shares issued conversion rate per $1,000 principal amount"
       }
      }
     },
     "localname": "DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Price, Consecutive Trading Days",
        "label": "Debt Instrument, Redemption Price, Consecutive Trading Days",
        "terseLabel": "Debt redemption, consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPriceConsecutiveTradingDays",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Price, Percentage of Conversion Price",
        "label": "Debt Instrument, Redemption Price, Percentage of Conversion Price",
        "terseLabel": "Debt redemption, percentage of conversion price"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfConversionPrice",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pacb_DebtInstrumentRedemptionPriceTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Price, Trading Days",
        "label": "Debt Instrument, Redemption Price, Trading Days",
        "terseLabel": "Debt redemption, trading days"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPriceTradingDays",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pacb_DebtInstrumentStatedPrincipalAmountForConversionRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Stated Principal Amount for Conversion Rate",
        "label": "Debt Instrument, Stated Principal Amount for Conversion Rate",
        "terseLabel": "Principal amount for conversion rate"
       }
      }
     },
     "localname": "DebtInstrumentStatedPrincipalAmountForConversionRate",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease Liabilities",
        "label": "Deferred Tax Assets, Operating Lease Liabilities",
        "terseLabel": "ASC842 Operating lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Right-of-use Assets",
        "label": "Deferred Tax Liabilities, Right-of-use Assets",
        "negatedLabel": "ASC842 Operating Lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_DevelopmentAndCommercializationAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and Commercialization Agreement [Abstract]",
        "label": "Invitae Collaboration [Abstract]"
       }
      }
     },
     "localname": "DevelopmentAndCommercializationAgreementAbstract",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "xbrltype": "stringItemType"
    },
    "pacb_DevelopmentAndCommercializationAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and Commercialization Agreement Disclosure [Text Block]",
        "label": "Development and Commercialization Agreement Disclosure [Text Block]",
        "terseLabel": "Invitae Collaboration"
       }
      }
     },
     "localname": "DevelopmentAndCommercializationAgreementDisclosureTextBlock",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and Commercialization Agreement Transactions [Line Items]",
        "label": "Development and Commercialization Agreement Transactions [Line Items]"
       }
      }
     },
     "localname": "DevelopmentAndCommercializationAgreementTransactionsLineItems",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_DomesticCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic Customers [Member]",
        "label": "Domestic Customers [Member]",
        "terseLabel": "Domestic Customers [Member]"
       }
      }
     },
     "localname": "DomesticCustomersMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_EachDayDuringFirst180DaysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Each Day During the First 180 Days [Member]",
        "label": "Each Day During First180 Days [Member]",
        "terseLabel": "Each Day During the First 180 Days [Member]"
       }
      }
     },
     "localname": "EachDayDuringFirst180DaysMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Merger Expense, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Merger Expense, Percent",
        "terseLabel": "Merger Expenses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "pacb_EffectiveIncomeTaxRateReconciliationTaxCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Credit,",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredit",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pacb_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_EquityIncentivePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Equity Incentive Plan [Member]",
        "label": "Equity Incentive Plan2020 [Member]",
        "terseLabel": "2020 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlan2020Member",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated useful lives of the major classes of property and equipment.",
        "label": "Estimated useful lives of major classes of property and equipment [Table Text Block]",
        "terseLabel": "Estimated useful lives of the major classes of property and equipment"
       }
      }
     },
     "localname": "EstimatedUsefulLivesOfMajorClassesOfPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pacb_ExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The relative number of new shares that will be given to existing shareholders of a company that has been acquired or that has merged with another.",
        "label": "Exchange ratio"
       }
      }
     },
     "localname": "ExchangeRatio",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "pacb_ExercisePriceRangeAcqusitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range related to Omniome acqusition.",
        "label": "Exercise Price Range Acqusition [Member]",
        "terseLabel": "$2.05 \u2013 $4.90 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeAcqusitionMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ExercisePriceRangeAcqusitionTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Acqusition two.",
        "label": "Exercise Price Range Acqusition Two [Member]",
        "terseLabel": "$4.71 - $4.90 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeAcqusitionTwoMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ExercisePriceRangeEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price range eight member.",
        "label": "Exercise Price Range Eight [Member]",
        "terseLabel": "$9.27 - 13.91 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeEightMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ExercisePriceRangeElevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Eleven [Member]",
        "label": "Exercise Price Range Eleven [Member]",
        "terseLabel": "$23.19 - 27.82[Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeElevenMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ExercisePriceRangeFifteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Fifteen [Member]",
        "label": "Exercise Price Range Fifteen [Member]",
        "terseLabel": "$41.73 - 46.37 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeFifteenMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ExercisePriceRangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price range five member.",
        "label": "Exercise Price Range Five [Member]",
        "terseLabel": "$1.16 \u2013 46.37 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeFiveMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price range four member.",
        "label": "Exercise Price Range Four [Member]",
        "terseLabel": "$2.54 \u2013 46.37 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeFourMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ExercisePriceRangeFourteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Fourteen [Member]",
        "label": "Exercise Price Range Fourteen [Member]",
        "terseLabel": "$32.46 - 37.10 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeFourteenMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ExercisePriceRangeNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Nine [Member]",
        "label": "Exercise Price Range Nine [Member]",
        "terseLabel": "$13.91 - 18.55 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeNineMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price range one member.",
        "label": "Exercise Price Range One [Member]",
        "terseLabel": "$1.16 \u2013 20.90 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ExercisePriceRangeSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price range seven member.",
        "label": "Exercise Price Range Seven [Member]",
        "terseLabel": "$4.64 - 9.27 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeSevenMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ExercisePriceRangeSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price range six member.",
        "label": "Exercise Price Range Six [Member]",
        "terseLabel": "$0.00 \u2013 4.64 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeSixMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ExercisePriceRangeTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Ten [Member]",
        "label": "Exercise Price Range Ten [Member]",
        "terseLabel": "$18.55 - 23.19 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeTenMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ExercisePriceRangeThirteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Thirteen [Member]",
        "label": "Exercise Price Range Thirteen [Member]",
        "terseLabel": "$27.82 - 32.46 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeThirteenMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price range three member.",
        "label": "Exercise Price Range Three [Member]",
        "terseLabel": "$1.16 \u2013 15.98 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price range two member.",
        "label": "Exercise Price Range Two [Member]",
        "terseLabel": "$23.06 \u2013 46.37 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_FinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments [Line Items]",
        "label": "Financial Instruments [Line Items]"
       }
      }
     },
     "localname": "FinancialInstrumentsLineItems",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_FinancialInstrumentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments [Table]",
        "label": "Financial Instruments [Table]"
       }
      }
     },
     "localname": "FinancialInstrumentsTable",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_GainLossOnReverseTerminationFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Reverse Termination Fee",
        "label": "Gain (Loss) On Reverse Termination Fee",
        "terseLabel": "Gain from Reverse Termination Fee from Illumina"
       }
      }
     },
     "localname": "GainLossOnReverseTerminationFee",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_IlluminaFcOpsCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Illumina, FC Ops Corp [Member]",
        "label": "Illumina Fc Ops Corp [Member]",
        "terseLabel": "Illumina, FC Ops Corp [Member]"
       }
      }
     },
     "localname": "IlluminaFcOpsCorpMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In-process research and development indefinite lived",
        "label": "In Process Research And Development Indefinite Lived [Member]",
        "terseLabel": "In-process research and development indefinite lived [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentIndefiniteLivedMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax benefit from reduction in deferred tax assets valuation allowance.",
        "label": "Income tax benefit from reduction in deferred tax assets valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_InducementEquityIncentivePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Inducement Equity Incentive Plan [Member]",
        "label": "Inducement Equity Incentive Plan2020 [Member]",
        "terseLabel": "2020 Inducement Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "InducementEquityIncentivePlan2020Member",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_InstrumentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument [Member]",
        "label": "Instrument [Member]",
        "terseLabel": "Instrument [Member]"
       }
      }
     },
     "localname": "InstrumentMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_InventoryTransferredFromPropertyAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Transferred From Property And Equipment",
        "label": "Inventory Transferred From Property And Equipment",
        "negatedLabel": "Property and equipment transferred to inventory"
       }
      }
     },
     "localname": "InventoryTransferredFromPropertyAndEquipment",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_InventoryTransferredToFromPropertyAndEquipment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of inventory transferred (from) to the entity's property and equipment in noncash transactions.",
        "label": "Inventory Transferred To (From) Property And Equipment",
        "terseLabel": "Inventory transferred to property and equipment"
       }
      }
     },
     "localname": "InventoryTransferredToFromPropertyAndEquipment",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_InvitaeCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Invitae Corporation [Member]",
        "label": "Invitae Corporation [Member]",
        "terseLabel": "Invitae Corporation [Member]"
       }
      }
     },
     "localname": "InvitaeCorporationMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock in Private Placement, net of issuance costs, number of shares.",
        "label": "Issuance of common stock in Private Placement, net of issuance costs shares"
       }
      }
     },
     "localname": "IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "pacb_LaboratoryEquipmentAndMachineryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment And Machinery [Member]",
        "label": "Laboratory Equipment And Machinery [Member]",
        "terseLabel": "Laboratory Equipment And Machinery [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentAndMachineryMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_LesseeOperatingLeaseDescriptionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Description [Table Text Block]",
        "label": "Lessee, Operating Lease, Description [Table Text Block]",
        "terseLabel": "Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionTableTextBlock",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pacb_LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "label": "Long-Term Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Long-term Restricted Cash"
       }
      }
     },
     "localname": "LongTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pacb_LongTermRestrictedCashFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Restricted Cash Fair Value Disclosure",
        "label": "Long Term Restricted Cash Fair Value Disclosure"
       }
      }
     },
     "localname": "LongTermRestrictedCashFairValueDisclosure",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_LongTermRestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Restricted Cash [Member]",
        "label": "Long Term Restricted Cash [Member]",
        "terseLabel": "Long-term restricted cash [Member]"
       }
      }
     },
     "localname": "LongTermRestrictedCashMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Agreement, Continuation Advances Repayable, Minimum Company must Raise in Equity or Debt Financing in a Single Transaction",
        "label": "Merger Agreement, Continuation Advances Repayable, Minimum Company must Raise in Equity or Debt Financing in a Single Transaction",
        "terseLabel": "Equity or debt financing that must be raised in a single transaction"
       }
      }
     },
     "localname": "MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_MergerRelatedExpensesCashSettledMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger-related expenses - cash-settled",
        "label": "Merger Related Expenses Cash Settled [Member]",
        "terseLabel": "Merger-related expenses - cash-settled [Member]"
       }
      }
     },
     "localname": "MergerRelatedExpensesCashSettledMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_MergerRelatedExpensesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger-related expenses - milestone.",
        "label": "Merger Related Expenses Milestone [Member]",
        "terseLabel": "Merger-related expenses - milestone [Member]"
       }
      }
     },
     "localname": "MergerRelatedExpensesMilestoneMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_MergerRelatedExpensesStockSettledMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger-related expenses - stock-settled.",
        "label": "Merger Related Expenses Stock Settled [Member]",
        "terseLabel": "Merger-related expenses - stock-settled [Member]"
       }
      }
     },
     "localname": "MergerRelatedExpensesStockSettledMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_MergerTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Termination",
        "label": "Merger Termination",
        "terseLabel": "Termination of Merger with Illumina"
       }
      }
     },
     "localname": "MergerTermination",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIllumina"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pacb_MergerTerminationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Termination [Abstract]",
        "label": "Termination of Merger with Illumina [Abstract]"
       }
      }
     },
     "localname": "MergerTerminationAbstract",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "xbrltype": "stringItemType"
    },
    "pacb_MergerTerminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Termination [Line Items]",
        "label": "Merger Termination [Line Items]"
       }
      }
     },
     "localname": "MergerTerminationLineItems",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_MergerTerminationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Termination [Table]",
        "label": "Merger Termination [Table]"
       }
      }
     },
     "localname": "MergerTerminationTable",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_NumberOfOfferings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Offerings",
        "label": "Number of Offerings",
        "terseLabel": "Number of offerings"
       }
      }
     },
     "localname": "NumberOfOfferings",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "positiveIntegerItemType"
    },
    "pacb_NumberOfPurchasePeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of purchase periods.",
        "label": "Number Of Purchase Periods",
        "terseLabel": "Number of purchase periods"
       }
      }
     },
     "localname": "NumberOfPurchasePeriods",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pacb_ObrienLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "O\u2019Brien Lease Agreement [Member]",
        "label": "Obrien Lease Agreement [Member]",
        "terseLabel": "O\u2019Brien Lease Agreement [Member]"
       }
      }
     },
     "localname": "ObrienLeaseAgreementMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_OfferingShareAmountMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering Share Amount Maximum",
        "label": "Offering Share Amount Maximum",
        "terseLabel": "Common stock offering price per share"
       }
      }
     },
     "localname": "OfferingShareAmountMaximum",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pacb_OmniomeIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omniome, Inc. (\u201cOmniome\u201d), a San Diego-based company developing a highly differentiated, proprietary short-read DNA sequencing platform capable of delivering high accuracy.",
        "label": "Omniome Inc [Member]",
        "terseLabel": "Omniome, Inc [Member]"
       }
      }
     },
     "localname": "OmniomeIncMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_OmniomePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omniome Plan.",
        "label": "Omniome Plan [Member]",
        "terseLabel": "Omniome Plan [Member]"
       }
      }
     },
     "localname": "OmniomePlanMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_OmniomeStockAwardsRelatedToAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omniome stock awards in connection with the acquisition.",
        "label": "Omniome Stock Awards Related To Acquisition [Member]",
        "terseLabel": "Omniome stock awards related to acquisition [Member]"
       }
      }
     },
     "localname": "OmniomeStockAwardsRelatedToAcquisitionMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_OneHundredAndEightyFirstDayTo360thDayMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Hundred and Eighty-First Day to 360th Day [Member]",
        "label": "One Hundred And Eighty First Day To360th Day [Member]",
        "terseLabel": "181st Day to 360th Day [Member]"
       }
      }
     },
     "localname": "OneHundredAndEightyFirstDayTo360thDayMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYYformat.",
        "label": "Operating Loss Carryforwards, Expiration Year",
        "terseLabel": "Net operating loss carryforward, expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pacb_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common stock [Member]",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options to purchase common stock [Member]"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_PaymentsForAdvisorFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Advisor Fees",
        "label": "Payments for Advisor Fees",
        "terseLabel": "Advisor fees paid"
       }
      }
     },
     "localname": "PaymentsForAdvisorFees",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering",
        "label": "Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering",
        "terseLabel": "Commissions, percentage of gross proceeds"
       }
      }
     },
     "localname": "PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair market value at which stock can be purchased.",
        "label": "Percentage Of Fair Market Value At Which Stock Can Be Purchased",
        "terseLabel": "Percentage of fair market value at which stock can be purchased"
       }
      }
     },
     "localname": "PercentageOfFairMarketValueAtWhichStockCanBePurchased",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pacb_PercentageOfFeeToPrepayDebt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fee of the outstanding debt to prepay the debt.",
        "label": "Percentage of fee to prepay debt"
       }
      }
     },
     "localname": "PercentageOfFeeToPrepayDebt",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "pacb_PerformanceBasedRestrictedStockUnitsRsusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance-Based Restricted Stock Units (RSUs) [Member]",
        "label": "Performance Based Restricted Stock Units Rsus [Member]",
        "terseLabel": "RSUs with performance-based vesting [Member]"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsRsusMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_PrivatePlacementOfCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Placement of Common Stock",
        "label": "Private Placement Of Common Stock [Member]",
        "terseLabel": "Private Placement of Common Stock [Member]"
       }
      }
     },
     "localname": "PrivatePlacementOfCommonStockMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pro forma adjustment to reflect acquiree's acquisition-related costs.",
        "label": "Pro forma adjustment related to acquiree's acquisition-related costs"
       }
      }
     },
     "localname": "ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_ProceedsFromContractTermination": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Contract Termination",
        "label": "Proceeds from Contract Termination",
        "terseLabel": "Continuation Advances"
       }
      }
     },
     "localname": "ProceedsFromContractTermination",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity, net of issuance costs.",
        "label": "Proceeds from Issuance of Common Stock, Net of Issuance Costs",
        "terseLabel": "Proceeds from issuance of common stock from underwritten public equity offerings, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_ProceedsFromRepaymentsOfContractTermination": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from (Repayments of) Contract Termination",
        "label": "Proceeds from (Repayments of) Contract Termination",
        "terseLabel": "Continuation Advances"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfContractTermination",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering, Option to Purchase Additional Shares, Period",
        "label": "Public Offering, Option to Purchase Additional Shares, Period",
        "terseLabel": "Public offering, option to purchase additional shares, period"
       }
      }
     },
     "localname": "PublicOfferingOptionToPurchaseAdditionalSharesPeriod",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering, Option to Purchase Additional Shares, Shares",
        "label": "Public Offering, Option to Purchase Additional Shares, Shares",
        "terseLabel": "Public offering, option to purchase additional shares, shares"
       }
      }
     },
     "localname": "PublicOfferingOptionToPurchaseAdditionalSharesShares",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pacb_PublicOfferingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering, Shares",
        "label": "Public Offering, Shares",
        "terseLabel": "Public offering"
       }
      }
     },
     "localname": "PublicOfferingShares",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pacb_PurchasePeriodOfEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase period of employee stock purchase plan.",
        "label": "Purchase Period Of Employee Stock Purchase Plan",
        "terseLabel": "Purchase period of ESPP"
       }
      }
     },
     "localname": "PurchasePeriodOfEmployeeStockPurchasePlan",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pacb_RepaymentsOfContractTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments of Contract Termination",
        "label": "Repayments of) Contract Termination",
        "terseLabel": "Continuation Advances paid"
       }
      }
     },
     "localname": "RepaymentsOfContractTermination",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued expenses and other current liabilities.",
        "label": "Schedule Of Accrued Expenses And Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pacb_ScheduleOfBalanceSheetComponentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Balance Sheet Components [Table]",
        "label": "Schedule of Balance Sheet Components [Table]"
       }
      }
     },
     "localname": "ScheduleOfBalanceSheetComponentsTable",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, details of total considerations transferred.",
        "label": "Schedule of Business Acquisitions, by Acquisition Consideration Tranferred [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition Consideration Tranferred"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTranferredTableTextBlock",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Development and Commercialization Agreement Transactions [Table]",
        "label": "Schedule of Development and Commercialization Agreement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_ScheduleOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Earnings Per Share [Line Items]",
        "label": "Schedule of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareLineItems",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_ScheduleOfEarningsPerShareTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Earnings Per Share [Table]",
        "label": "Schedule of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareTable",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_ScheduleOfInterestExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Interest Expense [Table Text Block]",
        "label": "Schedule of Interest Expense [Table Text Block]",
        "terseLabel": "Schedule of Interest Expense"
       }
      }
     },
     "localname": "ScheduleOfInterestExpenseTableTextBlock",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pacb_SecurityDepositMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security Deposit [Member]",
        "label": "Security Deposit [Member]",
        "terseLabel": "Security Deposit [Member]"
       }
      }
     },
     "localname": "SecurityDepositMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ServiceAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service and Other [Member]",
        "label": "Service And Other [Member]",
        "terseLabel": "Service and Other [Member]"
       }
      }
     },
     "localname": "ServiceAndOtherMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ServiceContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service contract",
        "label": "Service Contract [Member]",
        "terseLabel": "Service contract [Member]"
       }
      }
     },
     "localname": "ServiceContractMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Award, Tranche One, Two, Three and Four [Member]",
        "label": "Share Based Compensation Award Tranche One Two Three And Four [Member]",
        "terseLabel": "Share-based Compensation Award, Tranche One, Two, Three and Four [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ShareInstrumentNumberOfSharesConversionRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares into which the share instrument may be converted.",
        "label": "Share Instrument, Number of Shares, Conversion Ratio",
        "terseLabel": "Ratio of number of shares into which the share instrument may be converted"
       }
      }
     },
     "localname": "ShareInstrumentNumberOfSharesConversionRatio",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pacb_SharesIssuableUponConversionOfConvertibleSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issuable upon conversion of convertible senior notes",
        "label": "Shares Issuable Upon Conversion Of Convertible Senior Notes [Member]",
        "terseLabel": "Shares issuable upon conversion of convertible senior notes [Member]"
       }
      }
     },
     "localname": "SharesIssuableUponConversionOfConvertibleSeniorNotesMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "label": "Short-Term Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Short-term Restriced Cash"
       }
      }
     },
     "localname": "ShortTermRestrictedCashAndCashEquivalentsPolicyPolicyTextBlock",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pacb_ShortTermRestrictedCashFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Restricted Cash Fair Value Disclosure",
        "label": "Short-Term Restricted Cash Fair Value Disclosure"
       }
      }
     },
     "localname": "ShortTermRestrictedCashFairValueDisclosure",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_ShortTermRestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Restricted Cash [Member]",
        "label": "Short Term Restricted Cash [Member]",
        "terseLabel": "Short-Term Restricted Cash [Member]"
       }
      }
     },
     "localname": "ShortTermRestrictedCashMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense excluded from consideration transferred.",
        "label": "Stock-based compensation expense excluded from consideration transferred",
        "negatedLabel": "Less: Stock-based compensation expense excluded from consideration transferred"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseExcludedFromConsiderationTransferred",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_StockBasedCompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation.",
        "label": "Stock Based Compensation [Member]",
        "terseLabel": "Stock-based compensation [Member]"
       }
      }
     },
     "localname": "StockBasedCompensationMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in private placement net of issuance costs.",
        "label": "Issuance of common stock in Private Placement, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_StockholdersEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders' Equity [Line Items]",
        "label": "Stockholders' Equity [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityLineItems",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_StockholdersEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders' Equity [Table]",
        "label": "Stockholders' Equity [Table]"
       }
      }
     },
     "localname": "StockholdersEquityTable",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_SupplementalBalanceSheetComponentsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Balance Sheet Components Disclosure [Abstract]",
        "label": "Balance Sheet Components [Abstract]"
       }
      }
     },
     "localname": "SupplementalBalanceSheetComponentsDisclosureAbstract",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "xbrltype": "stringItemType"
    },
    "pacb_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of the tax credit carryforward, in CCYY format.",
        "label": "Tax Credit Carryforward, Expiration Year",
        "terseLabel": "Research and development tax credit carryforward, expiration"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pacb_TenPercentOrGreaterBalanceAccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ten percent or greater balance accounts receivable",
        "label": "Ten Percent Or Greater Balance Accounts Receivable [Member]",
        "terseLabel": "Customers with 10% or greater accounts receivable [Member]"
       }
      }
     },
     "localname": "TenPercentOrGreaterBalanceAccountsReceivableMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_TimeBasedRestrictedStockUnitsRsusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time-Based Restricted Stock Units (RSUs) [Member]",
        "label": "Time Based Restricted Stock Units Rsus [Member]",
        "terseLabel": "RSUs with time-based vesting [Member]"
       }
      }
     },
     "localname": "TimeBasedRestrictedStockUnitsRsusMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_TimeBasedStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time-based stock option",
        "label": "Time Based Stock Option [Member]",
        "terseLabel": "Time-based stock option [Member]"
       }
      }
     },
     "localname": "TimeBasedStockOptionMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_TimeBasedStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time-based stock options.",
        "label": "Time Based Stock Options [Member]",
        "terseLabel": "Time-based stock options [Member]"
       }
      }
     },
     "localname": "TimeBasedStockOptionsMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_TwoThousandTenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Ten Equity Incentive Plan [Member]",
        "label": "Two Thousand Ten Equity Incentive Plan [Member]",
        "terseLabel": "2010 Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTenEquityIncentivePlanMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_UnderwritingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting Agreement [Member]",
        "label": "Underwriting Agreement [Member]",
        "terseLabel": "Underwriting Agreement [Member]"
       }
      }
     },
     "localname": "UnderwritingAgreementMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_UnderwrittenPublicEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten Public Equity Offering [Member]",
        "label": "Underwritten Public Equity Offering [Member]",
        "terseLabel": "Underwritten Public Equity Offering [Member]"
       }
      }
     },
     "localname": "UnderwrittenPublicEquityOfferingMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Government Corporations and Agencies Securities, , Not Included with Cash and Cash Equivalents [Member]",
        "label": "Us Government Corporations And Agencies Securities Not Included With Cash And Cash Equivalents [Member]",
        "terseLabel": "U.S. government &amp; agency securities, not included with cash and cash equivalents [Member]"
       }
      }
     },
     "localname": "UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_WithExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "With Expiration [Member]",
        "label": "With Expiration [Member]",
        "terseLabel": "With Expiration [Member]"
       }
      }
     },
     "localname": "WithExpirationMember",
     "nsuri": "http://www.pacificbiosciences.com/20211231",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AsiaPacificMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region of Asia Pacific.",
        "label": "Asia Pacific [Member]",
        "terseLabel": "Asia Pacific [Member]"
       }
      }
     },
     "localname": "AsiaPacificMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Future Principal Payments , Fiscal Year Maturity"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r65",
      "r67",
      "r132",
      "r133",
      "r323",
      "r361",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continent of Europe.",
        "label": "Europe [Member]",
        "terseLabel": "Europe (including the Middle East and Africa) [Member]"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r210",
      "r384",
      "r389",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangementNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r322",
      "r360",
      "r401",
      "r404",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r629",
      "r683",
      "r687",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r322",
      "r360",
      "r401",
      "r404",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r629",
      "r683",
      "r687",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r210",
      "r384",
      "r389",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Name Of Major Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangementNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NorthAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continent of North America.",
        "label": "North America [Member]",
        "terseLabel": "North America [Member]"
       }
      }
     },
     "localname": "NorthAmericaMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r205",
      "r384",
      "r387",
      "r632",
      "r682",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r205",
      "r384",
      "r387",
      "r632",
      "r682",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r322",
      "r360",
      "r391",
      "r401",
      "r404",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r629",
      "r683",
      "r687",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r322",
      "r360",
      "r391",
      "r401",
      "r404",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r629",
      "r683",
      "r687",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r66",
      "r67",
      "r132",
      "r133",
      "r323",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r146",
      "r148",
      "r149",
      "r151",
      "r152",
      "r167",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Restatement Adjustment [Member]",
        "terseLabel": "Effect of Change Higher/(Lower) [Member]"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r3",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r145",
      "r146",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r167",
      "r239",
      "r240",
      "r452",
      "r489",
      "r538",
      "r542",
      "r543",
      "r544",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r3",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r145",
      "r146",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r167",
      "r239",
      "r240",
      "r452",
      "r489",
      "r538",
      "r542",
      "r543",
      "r544",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Restatement [Domain]",
        "terseLabel": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember": {
     "auth_ref": [
      "r3",
      "r139",
      "r140",
      "r146",
      "r153",
      "r239",
      "r240",
      "r452",
      "r489",
      "r538",
      "r544",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative increase (decrease) to previously issued financial statements for retrospective application of amendment to accounting standards and adjustment for reclassification from amendment to accounting standards.",
        "label": "Revision Of Prior Period Accounting Standards Update Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Accounting Standards Update, Adjustment [Member]"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r147",
      "r153",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r206",
      "r207",
      "r384",
      "r388",
      "r685",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Segment, Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r384",
      "r388",
      "r685",
      "r702",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r738",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r147",
      "r153",
      "r298",
      "r402",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201904Member": {
     "auth_ref": [
      "r234",
      "r532",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-04 Codification Improvements to Topic 326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments.",
        "label": "Accounting Standards Update201904 [Member]",
        "terseLabel": "Accounting Standards Update, Topic 326 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201904Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsAndNotesReceivableNet": {
     "auth_ref": [
      "r29",
      "r212",
      "r667"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss"
       }
      }
     },
     "localname": "AccountsAndNotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r49",
      "r597"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r8",
      "r29",
      "r212",
      "r213"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r52"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional services and legal fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r47",
      "r292"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r70",
      "r71",
      "r72",
      "r672",
      "r695",
      "r699"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r69",
      "r72",
      "r79",
      "r80",
      "r81",
      "r136",
      "r137",
      "r138",
      "r529",
      "r690",
      "r691",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r30",
      "r452",
      "r597"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r449",
      "r450",
      "r451",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r139",
      "r140",
      "r141",
      "r142",
      "r153",
      "r215",
      "r216",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r307",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r486",
      "r487",
      "r488",
      "r489",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r557",
      "r558",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r594",
      "r634",
      "r635",
      "r636",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r405",
      "r407",
      "r455",
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r407",
      "r440",
      "r454"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "positiveLabel": "Stock-based compensation expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r88",
      "r113",
      "r342",
      "r577"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r113",
      "r342",
      "r355",
      "r356",
      "r577"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization Of Financing Costs And Discounts",
        "terseLabel": "Amortization of debt discount and financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r113",
      "r277",
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive securities excluded from the computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r126",
      "r191",
      "r195",
      "r201",
      "r233",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r526",
      "r530",
      "r556",
      "r595",
      "r597",
      "r641",
      "r669"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r64",
      "r126",
      "r233",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r526",
      "r530",
      "r556",
      "r595",
      "r597"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r545"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r220",
      "r258"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r217",
      "r221",
      "r258",
      "r648"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Total investments in debt securities",
        "totalLabel": "Total investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r219",
      "r258"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Available-for-sale Securities, Debt Securities, Current",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r219",
      "r258"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Available-for-sale Securities, Debt Securities, Noncurrent",
        "terseLabel": "Due after one year through 5 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r409",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting",
        "terseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r400",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r400",
      "r403",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Pro Forma Information [Abstract]"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Schedule of Unaudited Pro Forma Financial Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r504",
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Pro Forma Net Income (Loss)"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r504",
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Pro forma total revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r502"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Merger-related expenses",
        "terseLabel": "Acquisition-related costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r514",
      "r515",
      "r518"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "positiveLabel": "Consideration",
        "verboseLabel": "Total consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r514",
      "r515"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Fair value of share consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r112",
      "r521"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "positiveLabel": "Change in fair value of contingent consideration",
        "terseLabel": "Change in the estimated fair value of contingent consideration",
        "verboseLabel": "Change in estimated fair value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails",
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r513",
      "r516",
      "r520"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "positiveLabel": "Fair value of contingent consideration",
        "terseLabel": "Contingent repayment liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r513",
      "r517"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Contingent consideration liability, non-current"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Since the date of acquisition, net loss"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Since the date of acquisition, revenues"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r509"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r509"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt",
        "terseLabel": "Short term debt acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r509"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Deferred income tax liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r509"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "In-process research and development (\"IPR&amp;D\")"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r508",
      "r509"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Allocation of purchase price to intangible assets",
        "verboseLabel": "Intangible assets, finite lived"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r509"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedLabel": "Liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major classes of assets and liabilities allocated to total fair value of consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r509"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt",
        "terseLabel": "Long-term debt acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r509"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r508",
      "r509"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r509"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "verboseLabel": "Total consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business acquisitions [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r44",
      "r115"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents at end of period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents [Member]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r17",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r107",
      "r115",
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r107",
      "r566"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents Period Increase Decrease",
        "totalLabel": "Net increase in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r392",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper Not Included With Cash And Cash Equivalents [Member]",
        "terseLabel": "Commercial paper, not included with cash and cash equivalents [Member]"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r59",
      "r297",
      "r649",
      "r676"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends declared"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r136",
      "r137",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common Stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common Stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common Stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r28",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "terseLabel": "Common Stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r28",
      "r597"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value Authorized 1,000,000 shares; issued and outstanding 220,978 and 192,294 shares at December 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Voting right of common stock share holders"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r74",
      "r76",
      "r77",
      "r86",
      "r652",
      "r678"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r278",
      "r283",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software Intangible Asset [Member]",
        "terseLabel": "Computer software [Member]"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r178",
      "r179",
      "r210",
      "r554",
      "r555",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r210",
      "r554",
      "r555",
      "r701",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r210",
      "r554",
      "r555",
      "r701",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r174",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration and Credit Risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r178",
      "r179",
      "r210",
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r178",
      "r179",
      "r210",
      "r554",
      "r555",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction in Progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r381",
      "r382",
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r381",
      "r382",
      "r385"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r381",
      "r382",
      "r385"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureInvitaeCollaborationArrangementNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Fair value of convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible senior notes, net, non-current"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r392",
      "r399",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r91",
      "r632"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.",
        "label": "Cost Of Goods And Services Sold Amortization",
        "terseLabel": "Amortization of Intangible Assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r92",
      "r126",
      "r233",
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r556"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "totalLabel": "Total cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost Of Revenue [Abstract]",
        "terseLabel": "Cost of revenue:"
       }
      }
     },
     "localname": "CostOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost Of Sales [Member]",
        "terseLabel": "Cost of revenue [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Sales, Policy [Policy Text Block]",
        "terseLabel": "Cost of Revenue"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.",
        "label": "Credit Loss, Financial Instrument [Policy Text Block]",
        "terseLabel": "Credit Losses"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r177",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer Relationships [Member]"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Senior Notes [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r123",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r336",
      "r343",
      "r344",
      "r346",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Senior Notes"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r21",
      "r23",
      "r24",
      "r125",
      "r134",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r353",
      "r354",
      "r355",
      "r356",
      "r578",
      "r642",
      "r644",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r24",
      "r347",
      "r644",
      "r666"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfNetCarryingAmountDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "verboseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfNetCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r321",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price per share"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r319",
      "r353",
      "r354",
      "r576",
      "r578",
      "r579"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument Face Amount",
        "terseLabel": "Principal amount of notes"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r54",
      "r351",
      "r576",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument, effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r54",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Debt instrument, stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentIssuanceDate1": {
     "auth_ref": [
      "r56",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the debt instrument was issued, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Issuance Date",
        "terseLabel": "Issuance date"
       }
      }
     },
     "localname": "DebtInstrumentIssuanceDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r55",
      "r322",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r57",
      "r125",
      "r134",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r353",
      "r354",
      "r355",
      "r356",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r57",
      "r125",
      "r134",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r345",
      "r353",
      "r354",
      "r355",
      "r356",
      "r375",
      "r376",
      "r377",
      "r378",
      "r575",
      "r576",
      "r578",
      "r579",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r332",
      "r348",
      "r353",
      "r354",
      "r577"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfNetCarryingAmountDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfNetCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan.",
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r577"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r113",
      "r127",
      "r483",
      "r492",
      "r493",
      "r494"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r25",
      "r26",
      "r474",
      "r643",
      "r665"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r63",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r475"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "verboseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r481",
      "r482"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r480",
      "r481",
      "r482"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "verboseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpense": {
     "auth_ref": [
      "r481",
      "r482"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.",
        "label": "Deferred Tax Assets, Tax Deferred Expense",
        "verboseLabel": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r481",
      "r482"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r462",
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpense": {
     "auth_ref": [
      "r481",
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r481",
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r481",
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r113",
      "r290"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed Technology [Member]"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net (Loss) Income Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r87",
      "r143",
      "r144",
      "r146",
      "r147",
      "r148",
      "r154",
      "r156",
      "r161",
      "r162",
      "r163",
      "r167",
      "r168",
      "r543",
      "r544",
      "r653",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "positiveLabel": "Net income (loss) per share, basic",
        "terseLabel": "Basic",
        "verboseLabel": "Basic net (loss) income per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutiveNetIncomeLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutiveNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Basic And Diluted [Abstract]",
        "terseLabel": "Net income (loss) per share:",
        "verboseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding used in computing net income (loss) per share",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r87",
      "r143",
      "r144",
      "r146",
      "r147",
      "r148",
      "r156",
      "r161",
      "r162",
      "r163",
      "r167",
      "r168",
      "r543",
      "r544",
      "r653",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted",
        "verboseLabel": "Diluted net (loss) income per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutiveNetIncomeLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutiveNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r464"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate, Continuing Operations",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r129",
      "r464",
      "r496"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate",
        "terseLabel": "Statutory tax rate",
        "verboseLabel": "Statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r464",
      "r496"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance",
        "verboseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r464",
      "r496"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost",
        "negatedLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r464",
      "r496"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r464",
      "r496"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes",
        "verboseLabel": "State tax rate, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "verboseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount",
        "terseLabel": "Stock-based compensation cost capitalized in inventory"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options",
        "verboseLabel": "Unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan.",
        "label": "Equity Based Arrangements Individual Contracts Type Of Deferred Compensation [Domain]",
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]"
       }
      }
     },
     "localname": "EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r79",
      "r80",
      "r81",
      "r136",
      "r137",
      "r138",
      "r140",
      "r149",
      "r152",
      "r171",
      "r238",
      "r374",
      "r379",
      "r449",
      "r450",
      "r451",
      "r488",
      "r489",
      "r542",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r690",
      "r691",
      "r692",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r545",
      "r546",
      "r547",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r545",
      "r546",
      "r547",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r545",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r334",
      "r353",
      "r354",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r546",
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r551",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r334",
      "r392",
      "r393",
      "r398",
      "r399",
      "r546",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r334",
      "r353",
      "r354",
      "r392",
      "r393",
      "r398",
      "r399",
      "r546",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r334",
      "r353",
      "r354",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r546",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value",
        "terseLabel": "Estimated fair value of the liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r334",
      "r353",
      "r354",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsChangesInEstimatedFairValueOfContingentConsiderationDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r582",
      "r586",
      "r593"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r230",
      "r231",
      "r232",
      "r245",
      "r246",
      "r247",
      "r248",
      "r253",
      "r262",
      "r263",
      "r264",
      "r265",
      "r345",
      "r372",
      "r533",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated Useful Life (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "2027 and thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r278",
      "r280",
      "r284",
      "r288",
      "r633",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r284",
      "r637"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r278",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r284",
      "r633"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfAcquisitionRelatedIntangibleAssetsWithDefiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Functional Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnContractTermination": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.",
        "label": "Gain (Loss) on Contract Termination",
        "negatedLabel": "Loss (gain) from Continuation Advances",
        "terseLabel": "(Loss)/Gain from Continuation Advances from Illumina"
       }
      }
     },
     "localname": "GainLossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfDerivatives": {
     "auth_ref": [
      "r113",
      "r654"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.",
        "label": "Gain (Loss) on Sale of Derivatives",
        "negatedLabel": "Loss from derivative"
       }
      }
     },
     "localname": "GainLossOnSaleOfDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposition of equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r271",
      "r272",
      "r597",
      "r640"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisition"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r274",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r90",
      "r126",
      "r191",
      "r194",
      "r197",
      "r200",
      "r203",
      "r233",
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r556"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r289",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Tangible Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research And Development [Member]",
        "terseLabel": "In Process Research and Development [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r128",
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Income (loss) before taxes from U.S. operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r84",
      "r191",
      "r194",
      "r197",
      "r200",
      "r203",
      "r638",
      "r650",
      "r657",
      "r680"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before benefit from income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r128",
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Income before taxes from foreign operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r294",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r129",
      "r465",
      "r472",
      "r479",
      "r490",
      "r497",
      "r499",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r151",
      "r152",
      "r190",
      "r463",
      "r491",
      "r498",
      "r681"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r460",
      "r461",
      "r472",
      "r473",
      "r478",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Deferred Service Revenue",
        "negatedLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase Decrease In Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase Decrease In Other Current Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r163"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Add: weighted average"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r279",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r279",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r276",
      "r282"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r82",
      "r189",
      "r574",
      "r577",
      "r656"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseBorrowings": {
     "auth_ref": [
      "r655"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of interest expense on all borrowings.",
        "label": "Interest Expense, Borrowings",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r94",
      "r340",
      "r352",
      "r355",
      "r356"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "totalLabel": "Total interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r106",
      "r109",
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r36",
      "r268"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory Finished Goods Net Of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r7",
      "r61",
      "r597"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory Net",
        "terseLabel": "Inventory",
        "totalLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfInventoryDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r62",
      "r120",
      "r170",
      "r266",
      "r267",
      "r269",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r38",
      "r268"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory Raw Materials Net Of Reserves",
        "terseLabel": "Purchased materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r37",
      "r268"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory Work In Process Net Of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Amortization (accretion) from investment premium (discount)"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r545"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments Fair Value Disclosure"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held for their financial return, rather than for the entity's operations.",
        "label": "Investments [Member]",
        "terseLabel": "Investments [Member]"
       }
      }
     },
     "localname": "InvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lease, Policy [Policy Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetailsAltCalc": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total undiscounted operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetailsAltCalc": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter Of Credit [Member]",
        "terseLabel": "Letter of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r51",
      "r126",
      "r196",
      "r233",
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r527",
      "r530",
      "r531",
      "r556",
      "r595",
      "r596"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r35",
      "r126",
      "r233",
      "r556",
      "r597",
      "r645",
      "r674"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r53",
      "r126",
      "r233",
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r527",
      "r530",
      "r531",
      "r556",
      "r595",
      "r596",
      "r597"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r545"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities Fair Value Disclosure"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r24",
      "r333",
      "r349",
      "r353",
      "r354",
      "r644",
      "r670"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfNetCarryingAmountDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesScheduleOfNetCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r134",
      "r306",
      "r338"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r134",
      "r306",
      "r338"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r134",
      "r306",
      "r338"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Long Term Notes Payable"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDisclosures": {
     "auth_ref": [
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.",
        "label": "Loss Contingency Disclosures",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "LossContingencyDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Text Block]",
        "terseLabel": "Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash (used in) provided by in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r107",
      "r111",
      "r114"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r73",
      "r75",
      "r81",
      "r85",
      "r114",
      "r126",
      "r139",
      "r143",
      "r144",
      "r146",
      "r147",
      "r151",
      "r152",
      "r160",
      "r191",
      "r194",
      "r197",
      "r200",
      "r203",
      "r233",
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r544",
      "r556",
      "r651",
      "r677"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net (loss) income",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss [Abstract]",
        "verboseLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r24",
      "r644",
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Notes payable, current"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expense"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expense:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r191",
      "r194",
      "r197",
      "r200",
      "r203"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r587",
      "r593"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "terseLabel": "Maturity of Lease Liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r581"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetailsAltCalc": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Present value of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r581"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetailsAltCalc": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r581"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetailsAltCalc": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountTimingAndUncertaintyOfCashFlowsFromOperatingLeasesDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r583",
      "r588"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r580"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r591",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r590",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r480"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r52"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r524",
      "r525",
      "r528"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax",
        "terseLabel": "Unrealized (loss) gain on investments",
        "verboseLabel": "Other comprehensive income loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Liabilities, Current"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r52",
      "r597"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfOtherLiabilitiesCurrentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Current",
        "terseLabel": "Other liabilities, current",
        "totalLabel": "Other liabilities, current"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfOtherLiabilitiesCurrentDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities, non-current"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r52",
      "r304"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfOtherLiabilitiesCurrentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "Other Sundry Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfOtherLiabilitiesCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payments for Rent",
        "terseLabel": "Rent payments"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Estimated issuance costs",
        "negatedLabel": "Proceeds from issuance of common stock under equity offerings, net of issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r98",
      "r519"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "positiveLabel": "Total cash paid"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Cash paid for purchase of business acquisition, net of cash acquired",
        "negatedLabel": "Cash paid for purchase of business acquisition, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments To Acquire Investments",
        "negatedLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-based stock options [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred Stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred Stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r27",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred Stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred Stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r27",
      "r597"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.001 par value: Authorized 50,000 shares; No shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r9",
      "r42",
      "r43"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of Convertible Senior Notes, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromFeesReceived": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for fees during the current period. This element excludes cash proceeds from license fees.",
        "label": "Proceeds from Fees Received",
        "terseLabel": "Termination fee received"
       }
      }
     },
     "localname": "ProceedsFromFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureTerminationOfMergerWithIlluminaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock from equity plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r96",
      "r97",
      "r218"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r103",
      "r105"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r96",
      "r97",
      "r218"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds From Sale Of Available For Sale Securities",
        "terseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r101",
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options",
        "verboseLabel": "Cash received from option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductLiabilityContingencyAccrualPresentValue": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of the accrual for product liability loss contingencies as of the balance sheet date (if the accrual qualifies for discounting).",
        "label": "Product Liability Contingency, Accrual, Present Value",
        "terseLabel": "Inventory accrual"
       }
      }
     },
     "localname": "ProductLiabilityContingencyAccrualPresentValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "auth_ref": [
      "r52",
      "r302",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Warranty"
       }
      }
     },
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r47",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r46",
      "r291"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "verboseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r18",
      "r19",
      "r293",
      "r597",
      "r661",
      "r675"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r45",
      "r293",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r18",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Components of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r18",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Property and equipment estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Notes payable principal payoff"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r458",
      "r631",
      "r720"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r17",
      "r115",
      "r118",
      "r639",
      "r671"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash at end of period"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r11",
      "r20",
      "r115",
      "r118",
      "r704"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Long-term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r6",
      "r17",
      "r118"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Short-term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsCurrent": {
     "auth_ref": [
      "r6",
      "r17",
      "r118",
      "r703",
      "r705"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Current",
        "terseLabel": "Short-term restriced cash"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r11",
      "r20",
      "r118",
      "r703",
      "r704",
      "r705"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Noncurrent",
        "terseLabel": "Long-term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r379",
      "r452",
      "r597",
      "r673",
      "r694",
      "r699"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r136",
      "r137",
      "r138",
      "r140",
      "r149",
      "r152",
      "r238",
      "r449",
      "r450",
      "r451",
      "r488",
      "r489",
      "r542",
      "r690",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r187",
      "r188",
      "r193",
      "r198",
      "r199",
      "r205",
      "r206",
      "r210",
      "r383",
      "r384",
      "r632"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenues",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Geographic Location"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r589",
      "r593"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-use asset and liability additions and modifications"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Price Per Share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r178",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Sales Revenue Net [Member]",
        "terseLabel": "Sales Revenue, Net [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "verboseLabel": "Antidilutive Shares Excluded from Computation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r222",
      "r223",
      "r226",
      "r227",
      "r228",
      "r229",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule Of Available For Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsDefiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsFurturePrincipalPaymentsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsScheduleByAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Schedule Of Cash Cash Equivalents And Short Term Investments Table [Text Block]",
        "terseLabel": "Summary of Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r57",
      "r134",
      "r353",
      "r355",
      "r375",
      "r376",
      "r377",
      "r378",
      "r575",
      "r576",
      "r579",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Net Carrying Amount"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureConvertibleSeniorNotesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Reconciliation of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "verboseLabel": "Computation of Basic and Diluted Net Income (Loss) per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation of Federal Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r407",
      "r439",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r407",
      "r439",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Summary of Revenue by Category"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsChangesInCarryingAmountOfGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Changes to Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of definite-lived intangible assets from business acquisitions"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r16",
      "r39",
      "r40",
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule Of Inventory Current Table [Text Block]",
        "terseLabel": "Components of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r47",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r83",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicLocationDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformationSummaryOfRevenueByCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r409",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]",
        "terseLabel": "Summary of Time-Based RSUs Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]",
        "terseLabel": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r415",
      "r428",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Fair Value of Employee Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r471",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "verboseLabel": "Reconciliation of Unrecognized Tax Benefit Accounts"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Estimated Future Amortization Expense Of Acquisition-Related Intangible Assets With Definite Lives"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment And Geographic Information [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r183",
      "r185",
      "r186",
      "r191",
      "r192",
      "r197",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r209",
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segment And Geographic Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSegmentAndGeographicInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling General And Administrative Expense",
        "terseLabel": "Sales, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling General And Administrative Expenses [Member]",
        "terseLabel": "Sales, general and administrative [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service [Member]"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of shares, Outstanding at December 31, 2021",
        "periodStartLabel": "Number of shares, Outstanding at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average grant date fair value, Outstanding at December 31, 2021",
        "periodStartLabel": "Weighted average grant date fair value, Outstanding at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of shares, Released"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Released"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional common stock reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Common stock remain available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value",
        "verboseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "terseLabel": "Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of shares, Canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period",
        "terseLabel": "Number of shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic value outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r417",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of shares, Outstanding at December 31, 2021",
        "periodStartLabel": "Number of shares, Outstanding at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Outstanding at December 31, 2021",
        "periodStartLabel": "Weighted average exercise price, Outstanding at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Reconciliation of Outstanding and Exercisable Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest, weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of outstanding common stock used to determine annual plan increase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r406",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfPerformanceBasedRsusActivityDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfTimeBasedRsusActivityDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options expired, weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r409",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.",
        "label": "Share-based Compensation, Performance Shares Award Nonvested Activity [Table Text Block]",
        "terseLabel": "Summary of Performance-Based RSUs Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit",
        "terseLabel": "Exercise price, lower range"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options",
        "verboseLabel": "Number vested"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options",
        "verboseLabel": "Number outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit",
        "terseLabel": "Exercise price, upper range"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Stock price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r435",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term 1",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic value exercisable options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted average remaining contractual life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityReconciliationOfOutstandingAndExercisableStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShippingAndHandlingCostPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.",
        "label": "Shipping and Handling Cost, Policy [Policy Text Block]",
        "terseLabel": "Shipping and Handling"
       }
      }
     },
     "localname": "ShippingAndHandlingCostPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r22",
      "r646",
      "r647",
      "r668"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short Term Investments",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r119",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r60",
      "r79",
      "r80",
      "r81",
      "r136",
      "r137",
      "r138",
      "r140",
      "r149",
      "r152",
      "r171",
      "r238",
      "r374",
      "r379",
      "r449",
      "r450",
      "r451",
      "r488",
      "r489",
      "r542",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r690",
      "r691",
      "r692",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables",
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r171",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityTables",
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r27",
      "r28",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Issuance of common stock in acquisition of Omniome, shares",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r27",
      "r28",
      "r374",
      "r379",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan",
        "terseLabel": "Common stock purchased under plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r374",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Shares issued",
        "verboseLabel": "Issuance of common stock from underwritten public equity offering, net of issuance costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r27",
      "r28",
      "r374",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Issuance of common stock in conjunction with equity plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r27",
      "r28",
      "r374",
      "r379",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of shares, Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r60",
      "r374",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Issuance of common stock in acquisition of Omniome"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r374",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock from underwritten public equity offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r27",
      "r28",
      "r379",
      "r408",
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Issuance of common stock in conjunction with equity plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r60",
      "r374",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Stock options issued by PacBio in replacement of Omniome\u2019s unvested options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r28",
      "r33",
      "r34",
      "r126",
      "r214",
      "r233",
      "r556",
      "r597"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r124",
      "r359",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r480"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Research and development credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r224",
      "r225",
      "r230",
      "r231",
      "r232",
      "r345",
      "r372",
      "r533",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Fair Value, Option, Eligible Item or Group [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r139",
      "r140",
      "r141",
      "r142",
      "r153",
      "r215",
      "r216",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r307",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r486",
      "r487",
      "r488",
      "r489",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r557",
      "r558",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r594",
      "r634",
      "r635",
      "r636",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "U S Government Corporations And Agencies Securities [Member]",
        "terseLabel": "U.S. government and agency securities [Member]"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r131",
      "r392",
      "r399",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "U S Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury security [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/DisclosureFinancialInstrumentsSummaryOfCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r459",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefit, Ending balance",
        "periodStartLabel": "Unrecognized tax benefit, Beginning balance",
        "verboseLabel": "Total unrecognized tax benefit"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Decrease in balance related to tax positions taken in prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r466"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "verboseLabel": "Accrued interest or penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r470"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions",
        "verboseLabel": "Increase in balance related to tax positions taken during current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions",
        "verboseLabel": "Increase in balance related to tax positions taken in prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r172",
      "r173",
      "r175",
      "r176",
      "r180",
      "r181",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r155",
      "r163"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "positiveLabel": "Weighted average shares used in computing net income (loss) per share, diluted",
        "terseLabel": "Diluted",
        "totalLabel": "Weighted average shares used in computing diluted net income (loss) per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutiveNetIncomeLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r154",
      "r163"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic",
        "verboseLabel": "Weighted average shares used in computing basic net income (loss) per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutiveNetIncomeLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding Diluted Disclosure Items [Abstract]",
        "verboseLabel": "Computation of basic and diluted net loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacificbiosciences.com/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124256539&loc=SL120269210-210444"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124256539&loc=SL120254536-210444"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124266218&loc=SL120267834-210445"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL120267845-210446"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919260-210447"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL120267966-210447"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL120267969-210447"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 6.M.Q4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122651532&loc=SL122037091-237805"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124268681&loc=SL120267897-210452"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=125515542&loc=SL120267917-210453"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=125515542&loc=SL120269220-210453"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267859-210455"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267862-210455"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q1)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/subtopic&trid=2127163"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "http://asc.fasb.org/subtopic&trid=2127197"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123377177&loc=d3e11281-110244"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12524-110249"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.13(h))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.7,8)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r721": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r722": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r723": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r724": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r725": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r726": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r727": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r728": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r729": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r730": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r731": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r732": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r733": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r734": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r735": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r736": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)"
  },
  "r737": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r738": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r739": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r740": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r741": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r742": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r743": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r744": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r745": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r746": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r747": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r748": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08"
  },
  "r749": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001299130-22-000030-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001299130-22-000030-xbrl.zip
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M!4\L#(>5C;/%9I9LHP)I1]&X8M;Z604'HCK#"3M+N]N+O>5(I6^"6K8RB7%
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MJBI+82=9ZB!9^-<SX/CW_P=02P,$%     @ C8%<5-4FFSJ 5@  (DD& !4
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MZQ#,,G?3KVX4)L2V/ ]848)VYM0M?R<F.O+^\4."4P0"M]R;'!\_Q EVW$2
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M0CW8,4>-[&,R86.\(AHO>UQ#K2X8NT8=;@6! (=U2T/5!G9C-3"6B1J8S6(
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MYXN,A09'(J<HF&5+IHEUER&/81@!-K<T(YL@ JW\S=;R\\G<\K/!+"#I<T?
MYJ\0UA.NOM1D"U"W5:1;GS@_'.U]^ AC35"5.(\!("!\)5TNTZ40AOKOUN=V
M@=ZL0U?KW  1L?,J%W'M=^MG.TTBKG,#SW[YBAR:CX=N52_#YS1IB%T1%K>U
MJ'XVOZ<3BV0<\$EW$9(*$%9E5;5LP@ONCL\@8O6%\N/1WM$^C)7>+(H\-D<
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M7G;Y#I# P324731=&YJN#8WJVE#E^L.^]K60?; K@<EK(?LCV,]6R#W0AO$
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M)HOZ::PVAB$NU8AFP0!W.TH8J,2K5.-2]+$6-03&1=D#^D+AC5<?Q-$[#97
MQ._T@+-V# \H3+_%:)$&5_Y"F*Q)I2J8"'KS^%8%-(93B(L4TPL -]@/7?_9
M"6Z<U3([G= [:/BD?M"0=SE;]SDK.IW.$2#XH*=SA.D< 9X';#I'F,X1>A@I
M3=X):17+7@D5=B9OA%,FR*49>:B[G)@?Q"P[?HA9HG@!\@V5P'@B=+6@21C
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M'ZH+A#'R+OR0[KA/HUB>G$!<W@*8)IQ&0O;! R?R7)XO%LBE2T8'YRZO#0L
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MPT=&>'Y%R7_QO=0)6([I$R=&7G&5\&1U3TADJ=FVFY&]U]AOKY#":166O,'
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M\Y.VL@.N$]5[ZE5E+C:@HCC/YGH6DKH9.%Y0D =P1"LY!JK7<@4XBDI;0,^
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MJ M,EP_]^@*0"[L*,?3M_C&.UI=Q&NCW)#(,ZD^O8+;]RTL F#]\EPWM[RX
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M96]1\O27(-[K0B8W7$0C&"2<;!1.B'A&XLZ>0O,8$N]"P/^0T,EI02H"A%/
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ME[V,01]6A@7-_(;Q%$"9FFL:Y/0N>GHN;C:?6;@)_D<CO!D'T="=A)$MW8B
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MYG#=3W]80=60'5T7T0N-,=>@TS#D#?2"^#:(PJOD/-A%;$.EF74=-.9# [,
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MT6I+F:-28I!?!<["SU$G\-_6=@WWBUYE<+8^\G=*VC-H&0;UFD+!;/M20@+
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M7_5]!)NQ2MOCHPG?V 2DWGBX96:NB4X?HBTM&P[>W7_._0U0;VG&BWTR0^4
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MX-C(0/YOLXA%7CL6_0<<#(P^@2#.&QNX2IC,; ,"]ZO0((>&Y3O$X$EW>3*
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ME >G2<Z7M ^O\*=.CQR1,1_/#!*O]8K&"1/Q.8T[?XH=7X4L](]P="+CDY(
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M>[MC0V;1NJ#<7NQ:-!0;K:/P8 &;QL'.J-C]@8<QJFAY"P1.@ )I2 BWYZ2
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M&:=,I+\$\5ZW_QU(!/>!^ AQ.P_&!U! ?4 ^E$_E^VN^_M14B$2&YQ0#(7A
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M$I%P3-)&/72*@LI)'*\TYGS(@X@THY5?)>MT2Q^"5T-1D!X,E@7KF*WMM0N
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MYNQ:)T6J \%&( &X91TK,A\L&P_O<)54V>B1AZA.6W/N3(^V%NQ(CKB;!B@
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M4#K&ZTKKD>:T3/DN(YN"-;Y*\-U3>D>PT"<3/A )?,;;>RQ]:G$$-C#?/5H
MC7L?C IZ!S".<(F?597LS?G#?R561-"2?SREY#\4-4OQHLC1'QS]U)L)+W)
M;Q5R$,5 I5 *83Z)$/2E2,>S(B;TU)Q],HUFC]8> ^BII<2*GKHU ,Y3=\F0
MI$MQ;2&#X+=K"LW(,OH,!VO*^/:E&7,=O=#?,08:3I,E313]$FVQ=M?G92K
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MP.C4JXT[8J=,M%C^>Y\7+$#X(<V^X*?Y8D&O><G&[CI+$_+C@A=4Z<H7K'!
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MG<.4!V(&A6[0+?H*'!]SR,YW!"[OIJ^7__]$)J<_D_]1/_Q?_PM02P,$%
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M_0?/-,(8^<9^3:@ER+^^9,6^D%]]F<Z^'$___".P?L(83"9_\ST'/:/E).[
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M4'S($LOR3_MY%9!,Z6\WP,2!Q2'5N7(%(+C&O[ ME+P:(L\*TX2OC28&V=\
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M0];.%C0#OQ&?6!+3^M\Q4E?(14L[#)X]Q[GS_.^&SWX[V+U![7DH Q!95\]
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ML6Q%Q+U_,P29/*F4TIP;'-*J?2<-)4I&XD2)?#Z24$IK3A8!J=4^2(:R"F6
MO'C+\+M!0J^7DE%Q48A9=T\()8R!VB?#4.AU%_FN':<S<ZT[^P?YB;W'H5?0
MG$AB@JM]A@N%/=>>:R*2VRSVG;2#/ZX^KY!KKO$I]@_&X;RI&B@F*3J9M\&
M12IXFYVJ?)ETS#-Y4S50U.BD2QY*-,NN[4GJQ7!0D+IC/S;L<VK+CH0I'"K>
M90JWP-K2(YU\,0@FLC_(O,MD"*VXSB01D7DL-PB<=T/_]/S\V0;E2GZW$"@N
M*+B;YY.8%79#\1Z#2[G$CW.Q+,E2NZ%@E@6E:@'=E!4J)!Z\E8 6VAR1J%]D
M ESXO_K(P!],\RYSSODM6P''"3'U5ARRY,@/_**'YMF>HG7%<&8O%RG+?C:;
M'573<8Y)]QS"J36XJU(LA@ %H6WF$R5=P92B>BE:0$C@QO*&D7S3/))O=%0P
MAW *S-0P3G@U1I4&GQ]&#5"TZ,^BR!*?%6\,O#&QT;>'40,4%]HJCT/];(GA
MG0=D<26=,W?P8%^5LFN-@S,-&J_AC+C4^O(&]]P.[PR2H#G\9"TS.P5!L4/5
MZL(E=<:.BS$L*B6)V*M)35%02A?44I-Z]W#9>$ A[M-BF0#1X.:Y6W0$;!!:
M&7AEU)8/7Y%!(A$15Y%[]ST*&\X>M.*@>*%H:1"1/>/+Y0@6B#JYF,L$O0(H
M&K32&Y_:]W#AJ,) HIB1P?1LA.P[Z>:*HV&-T-+23NZQ\(?K$O.:R(M\#';X
M20R$E#OJNF*@.*'@EII7YIP/1T OJI_1>YH38+[R44SWJFS4BVONNJ#8(*2^
MLM8["0QO:J!<9RS>?!NY\5NI7$SZS0:]-#BM=U-?Y=)#3&YXRI>TK[B* MM%
M03 W_Q79@1WWA'[^H)0&Q11%QP\!T7.RL$(Q0CE^U,E%?L1#@GD*::P'BA1M
MM,C'@4:9X4T=M'5CX]K>!MV[)F.UJ)09C9*;U51='S@D'8UJ^:;#ARQU59WF
M!9LHPW4^FYZ?:K,DR,(CI\\8@B52G[A]"] R<A[L936&MT#-L;*%K=[=!:0E
M%$I2,P'<BY3C!Q8#!T8^T1:%8$W5]H5=;7#8C]SQ5&0>/==LQZUMS;VG%QL*
MX!G=*3NFN>M&AO.,2"86W.J]BX5,AU$9A[J]$G=EW:G3'0U9CJ<.U,?MV4,)
MO!N(H[]O'TP\HH9\+O5U=.=4:Q#&]*X].\)>>YLWVXU[<NW%<,5&3S>PL2AI
MSB7C+7:\:+#3"+2T+PR2!(W:%.*G0!A9SG-Q9YAHOB'X4VA'*[XOW!*17VU.
M;I@$NB?7-GCU)]?Q<>YT*WU(:*QH=@3^!O:39**(L+QH 6S,E=#NJQ$F&00P
M/%PT*U;83UHU(<#RM>M.HV,@--IYN[ =6U,*D5A5]H5*HA@P_6T4K860,IM>
M&XX9.?$G%\LK([!-?+RY29.FXW/-O8N;1@]>D*=%%TV!>MHE!6JA>Z1\W,&)
MX5J3K(L3W,=)TLG)SZ2;?YJ\(W\2]U2CM*D#IA:_-7P7]RC7?T(2MB#,.N5A
M>#&;GIP/?X7;K*M2[%]1^7AR94(Q!=0*)Z)HD H65QFGVD75+;*HQ%FG\"P'
M=K-;122>EI$E.#U4:H'D3[<)@D-"GD2&4*:(WY&]6A-Y/I"/=U:/$7%8P3L-
M(FJPB,(@Q&LTEI\U=0BU 9(2;92\2Y7..(QI;:$(FR*W([,8=6BM[!]Y1)"0
M=2$_UK5*;(W2F$L"$O.D/*R=<OHY^M;X8P:/AD^, A^"Y]?9T;1Z?LU:GQ2;
MG_R<?V#H8V?-+5/3P9-99;BCYXNY1E;DH,6R3J-7GX5_Q6Z4%.E$FP$YQGFT
M6HJE+$'H,>TL[FS7#M$#'G]6)1<&%C:)4^88 2MKNT +(!DB1>.[1.H("P^'
MH-C<&:)N!:6^<&S9"D@N=56Z$(UX48'W^D$2[^[=)]_#>YG@&7<%*XGD++]!
M'\CQFO-I<=4=&\>X&;'+L]9X:,NN5'IDO2)S[7J.M_I\)J=&=D*DAEI[Q*@6
M2(PE[T";6^DZ=S6>&*;L>B#YI&A'U0H,'O,PE'T414">Z*;L>B!9TDZ=W+1@
M2P]OU:*];\ (HB2#[F+YU790$'HN(],!J_R8:-"@OBT-6DD-3_UPPT0 X8FB
M144  A[K+92EI*=H$4"X(:)$/@HTR@QO!J$E3;!],W*\C6T&S(@1=>5&H^QF
M=546#%YI1Z/F[D%!=%(OCZ3:'C;GWPW?:CA8ELJ Y(&B];Y1<-9#5FB7-YDW
M';)(7G/D!FEG? -OJ,EF&..T+?-D?)+?Q0AL87 M$N2BT3JOXE,@>==,D)I+
MPY[ &=MJ]!)ZYA^QB,$S<LA+IU>O,&X;5RJN^B!9U!LCZA>^UL#!8UBGF*L!
M>5X70UL?4K=2 B:5Y"Z$G&(/^ A?5+>,N+F5,J#TRZL(JNK&M$Y(&L76/Z,@
MI-[M-I2&K'VN&;Z%?&-A@@P#UP,E+")/%5#<Z-_DR<1AP!S@PK1(=U)!NMW9
M^K2BX%??"VC4:*H&DA[">MRE0ANYE3_2@A+QJ3[L3.&*"F_F@T1@$F0M_,P"
M.P3W01 A"V_@R0\,#UN)7]"5H8HA I[Y6K\H5;HS4Q@*66$7U4VGM(NE>F'O
MDQB3UDWDDT>?"/>C^E9(M+IN#)(A_ZC,U,0:E4S'1;&29W;%+2W-]LQ;OPS4
MY6PZFXZ:*%( 8%ER=%_B:O<)M#A (DWHRK2N&,B*L0C^<$ 9DK\93I18WQ>Q
MY,'M#^2;=D!]+RO<CJ[,DP*$K B-M #\8-AG$*M0#,N3;YLH>WM,(QFEN+9<
M$I"7)T>YJBUT?#)U3=Q7/-]N/#<9 R[N\X<1HB?',&-#[R,*%\NL[+6'S[;)
MRE^WK>[8I&Z,4(4)3^)B*)-%_+ +6<$=!K46"II1M*F>;F3I)'@_&4AI>:/J
M%T\>CM=-(AV:TXT3*O#@RCL(9O9(KPC2]93%'9XJNO&CK<RCRBE6<RHL0)5Z
M&+$8P=^ KOSHAD#.%C7)>:#P;.[$K:<1N';<YVY_D!]IAQR^RKKRJ[WT.;>Z
MIN[I_08BB5_\:ORX0BY:VB'9KQ72%]VDG<<%DL?LQ):0?!^#]9U,S[4GJ,ZM
MZL8QA;#DY.MJG9:?-XI".GPXN//\C;'UOBI[V/H(O? MCEV;TY)FDO'(^=75
M( TV+UG-QB+#\-Y=DO\D.'T@-\*GV!Q$&X_( I D:\3<#"."#.\6KMMW=*-O
MKT#EO%:3BVA<Y,XB<"Y\DLE .<?%/[??5)>#5\YX-6F0H##^5\^SOML.C:'9
MGW5E%$N^G %C,+HS8FJQ')&;JNFJ]S9RY[Z;2BWNTJ+)Y>>CS!W01D'V6[9E
M@ZNNKLQH+7Q.CS&$X<U/UZE Z2&;0@A*:5TI("!NKG3A="##A5C/GOF4'O0$
MHO'69YSQUK.O3=X^2W\YA%_7*?SZ&6;$Y3&<T=]+^/54Z#&%7Z^1LF.\-BB:
MEZ))^I&3 X*Q\T!^O#8HW!!1(A\%&F6&]Q!:=;PVR,IN5E?E6H!7VM&HN7.\
M-JW4RR.IMO':6"<D_FF__E %A27][0:8.(PI6:3 4QSQ<U)32R!))*QMKAN+
M-E",:6O91T@,: SIJMY=XK2!8V_2&0O #BQ2AO[$58R<V@ :T,*I#Q] 8U\)
M*XR0\K@:G;D)*ZZ&OL22 0LKW(:,A\6=5W+6PS":-_CM#].)+&015UX:QM3G
M85T:W2?B*0&K<TR/RX2.+EH1]UFPWE ".I$>U4-?7LJ"1E:P#]JD> J7A<_(
M]%:N_6]DW5NX=_;2-G*'I?2 2';.!8\5_+=H@ZQ'%(I;:V1\#32WY5IT5,$U
M<NMA:UBNC8"D@R7'PP_#(5:0'JB[^U'0#.Z#?FK)SP>X@@NV<1BT6N/ZY'OO
MR \_23*', 4XSJG<PR"B?OLPEI2.)2'<U9K05)TL!>%:O,>;2G?U@/!9*$X$
MO5A^"]*_$FVQ\&RL77=,A=7#PX@KGXOA:T>6!;%^7.JX4=P^W>ACAUCXVF%P
M*5W.&I!6;1P%? O4 5(++>F/GGH9/LP>'(:4XB$EC+[:0,Y0CEYM'L >Z-D$
MS9AR^,A$<1&ND?_H);=\^"C6U^1:^]T#9Y5.J=R8RXH273^1ZGAK4?\(MX=Q
M5/_APT!2.I#X06<%SY9Q#ZWC6.IW !U&35^CAG.HU 4OD3%4H.S?6T*:;5YI
MBI4[5)J^=A@JLH9*&Z29H=1E&)3.@(V5@OM#3?PL3G\1OD9 ,UN"&TA[%%CF
M?JA'Y.(CNDS<-+(@/UNJ-<="$5']<I&&!PRU/A#0K-UUX.").PG*\T!_0,9=
MOPPQ^=_E'O*M$9)>O,\:+OMKT,BB.V8YEJZ,P#;Q:G]C.U%8[S_>OC7]J:(
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M"G-GE"-5!VB,'8'TJ^W:FVA#0KP:[N?7* B?#3O .-:B=>\F4!;0I6^V>NJ
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MMP U)?7C!:>0>FT(-AL[C(-&XNWP-NNAW3H0S45=()K\(Q/#M2:ESP"*1L,
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M@0@7>W-0>EOYLL8ZNS("9%U[&_*;9$S2TVC)_Y!F1.T7J,ZWB'7QOX:;_NH
M^8K\%?+3?]2GEY3>OF:<[ 4?!3$YQS.W+L(U\N?6/Z,@B=/58?:L-J49%V5#
M(>OF<S1'F3H_2R&ZU36P5R3C!4#:+>DV:A!$>_+.R8L8$;9Q*$5-R\>BIN7L
M^[%1.>E!G'JLT =]S<S3TX'-S#O:?T1A@VRL*J.>2%)E\#CY-8BLL<5W!PIA
M'S^!%D#229@,''QJYQ"HZN(3RD.R'9AJW5OPBA8@K+XU+]_8K>P-Y\1A4')O
M,!+>9;]+3\("7*O4W"=^<8BNQ((_3DX5+7YX$Y[YQP@;:55\:H]9*P4KM3F]
M.C]OI!AM&?N42KJ".I,L?VW=V"5!?+4/A,#.BK_Z> /,.Z_%A77CCKBTTDSO
MM>&MP5)%VR>)*DDDYE;1VJK>D%<(+*<PP@)6K[UA#456!19R@#$;"F@4UNQ?
M/<_Z;CM.XJMNN"MR9YJ@5?UW,Z/:M0N2?E*-K?)PZ6RZ4. IH92?3[Z'MYOA
MYY-CN"$&[?9?D?V^V76>:-G*7G%/"(7.!HW^?'+JI7VV5^MPL?P6U$]? C4U
M(TE'R3N; .!/03FV=,L 3Y42>A='T].SHS'SIJW(DKW[7IE^"!!VWP4\!#;B
MY5J:<T= :@5F 7"\X9]G]FJ&X9];I)[P(;HWU3\ZGIMQAF5A[Z834>^FXN=C
M#Z>T Y.L!QK[-ET,[-LD/][#Z&:*"]I,(2"M+&\3?(2R/>LE-/P0TFI"CTK@
MDVL:XA 1.>36AD0Y?2+6J:=8$%SVR0MLE@.NC*;WBW^=H='X:2L%LANDC*A"
M3>\743M# ]%,-,2,FB8.5S.G4AO?+[)* $>6_\IXYM7.V\0!4VT/L4^<2G-9
M23:*M^[0I\J7T#/_6'L.%BH@)O_PLUV2[>G1;I+M8MO_8;Q[P5\GR2< 9=S>
M=GBQ+/JX/2.'+#G$U2WQ@GLC7G!/QF?\2J_I]4BG1@GO9L?GI].3LY/9T=GQ
M].Q88M[N7853TW=3BH)<5^1#7KT4$4"#)Y$TE%" OY',*>Z*D9&V4 *4ZH6U
MLCOS-X@V0CTR\\Z6RH#2):]"J"JDRS2:A'#USM9S\F+EU3=<<XT6+GK][KWB
M5D@4K#LO\NEIX]JW!ID8##57IVNI\L,CD:1I(P$$?X:Q )3*@&*'A"6@43B>
M/.10W/@HI,=[;7<59]X,KCZW9=)=4(S %@;7(BY C\8&,=<2%9\"Q2U^@NR2
MJB]PX$U+U#09L=7EU7N*?'-MQ ^.-B2@(QZZ]#6LN19(QO2F_<J2UPZNT7#H
MU=XDB#WCO8!OF_A8%XOVS;7#X#F( CJ1.*L>V%1,L] >,P5Y#G5(JSXTHSKL
MEH0$Y,FNKFC'-%!V]:$U*Z:>BEI%)%2;3;=S$B;*RO'-Q9W^CK\1(O<I>G-L
M,V'^8HF[C$^5](6#KR8\+@CIM#+QMY=Y-%N)7$1B:UKY*!XW'"S8+:ZIZOD$
M'<LZW]K[EK+C^MT.U_>N97_85F0X.YLOO"$CNZYMV+E2,W0[B^*O@J*J!,O-
M '#QI+>%DM\X 306N7A8V$)"8D22RZ^ C@/3 B3O Z"8.22]=DFN%N1Q;N<6
M&]?V-H@<:1FVHVJALOPGTY/3\^%)IEB]50,1#R9J.=$Y*@+-.$1N<KPH,%SK
M%;D)K/<N">1M?S0PA;/J@3]=D%*P5>R!5;>;=\?[1(F75&959;.IH<J!16T0
MDA5 KV?V[ X07.B(P1U6A0-SQ/%1&Y%.%6\P>I$9 RG,(,ZJ!RYU06H_PM;5
MWSO%OPWF4;C&W?TWLF*+43R3)[>/!#U\]KG]@7S3QM.Z;YOHF>B28?=0\"50
M!)=@Z^@)(A:SQ^'KP@7)+B M7%TZ?0D4/_LFF51ZBR \SJ/MKH0+%S$VD?3B
MNK%.2/?5O:083/"NMF1-H]FU<;(H$1UX;OPV@K%@L^J (IF,I5=46%9,&FFF
M4:F7!+E,'/;^2EE0VFZO,IKAG4-:>#,#91W!,]T'Q@7/G,FY)WXHU>R$R5$-
M) GX%5A9&5H*#'QS(6G":*(,M9PV'!&2$)Z'!/>ST ?;1?=X&JV-C<DH#DK1
M'=;_-G)2(XZI.AF8<6KY9])H_5F@4& ,BF&CN[.%;Y!.UI3LC& VOB%&4N1:
MP1,^)Y'#TPTR'?P?JWF"IE;5B3%=Y59[@0G%::B SF\>\0*,@_[2SH&4TIK3
MIDE4M9>59XK6$HJ CQ'9VBR6^'<H'R>+[^[.O-*N$9VH(@\!M=>6JMRR$E_Q
MS$L\,>#5'BAKRFG' UXAU=XE=@Y.0?/ *\HUWY @KU^-'_8FVM2ZXE%+:Z=V
M,5&E1:_N5?EE:B?F^.V;T[EEV8D4">F3T&O-\P!?.]H11A8(G6-=#Y)[44QZ
MWB6%KYTRBJ?3D]E>48D.@K2,5VJH).W>"X-]'P01LFXB E@RMA)8'M'W^$_T
M"S">RCHQK+OD&:TN8=**-D,AG_B%&:LXF((=!#8)N!^GJ7SR/1,A*UBX+X:#
M2K<$\6WU'"_]_A\HS$9D[<0EKWF=V-8'-KEQ\&A<A$Q%)]%MR6 CZ2U+ #P2
ML;._Q'$/ZV_UA)O1CV!R,,B)I.;F#\J"F;G;9F.JCEK,LCKQ1UC0G"1 [<>4
MV2:S6V7RU<XE.X5TTC2_A+F*@;Y2D>EW&R1;P-AY+C-GLKQGZ\KKQ))6PN:$
M46/G[7Q3T%=00EK\JFS457U!A=RT.WQ'6X*J!BDGMAJK-I0=46<LJS89]12G
M?_% ]LYPY;178\^_T(7V*98?ANT0/ZP[S_\5UZ4E4U#UN0/ANV&5LUW-E0.H
M[6X;2+?F*WQNB,(@-%R+W S&#J.UEZ5]?/+ ^NYXY<Q7<T.BZMXV&^-YR(78
M<L\\T5>*ZD0>43ESI8_L_J(DV6))#;Y1?ZW*65D[8G22/'<5'=G-0F$VO#-L
M/[E"^<UP(C0/?U_;YCJ6_MIPKU &0;UC1YN&]*.0+!1R.NE]O]!Z%4_#WM_^
M>+?]N$YP[]9Z'2G\4EEO9].3(3,C#KVM$H,II[>:FY'1T)L:QI\.Y^^(.!<C
M:_Z!?#S/E)ZTM^6^Y&[LY<#H <-\U*BY;!K-J&E NG"JNW=#WW8#VXR78$5+
M _5[>SD.9(*5$UYJ=F: (1FV64K9J+Y1)Y=XZB#FNS*J4Q;GE7Q06]+WAE;.
M^JXW::-@?>/&1>\M1?-BK^9B"<KCT]S(@OP/C$3]\O+HN1\H(#LE,JB"5R\D
M@2&W?R<>6(]>^-\H?,Z3NB=;K#O/3W]%RM%FPWX[H2.7AT<P'R]=KZ9&,6MV
MV(']EJC M?")!)$,;Z\>^55A8Y98R!7MEGD_K^,H&1*[?'QH_L1'.<3SU<I'
M*R-$O1PN6_?G,'X4@YD/**"7@Z,94"HLFDH[=1A:?2":AU0!>J,*Q/0C#/PS
M(@'OXG<K26C]R'!>D;]192J2U\$R2\ZGQ^<S/<8=6'3S,7BXAF;?[21S67ZS
M$Q]M>]D?\GQ:VW$S &[YB.AZ<ZW,S$ +]DG0N'>#T(\(%F7GWVMBF?')8VMJ
M6$F1^CH13HKP.6O4W-R.WC05_S^R;N7!)9B[$4F?T(FF?>&3,UG5E2R4BXG6
M&[,BD$D@P*U7H.PM-NM;VK*[#Z!RFJMYS0B%Y%S7-G,G[H)-(K%4+V;BV ?7
MQKN--T_DMTGXNR[7;.)?TY'H/4*54_UPT=SJAK*0H(@6&J67;^_M,% !7#XH
M5-TF=W[PU4=(O-(+&!*YV _6]GO-RZ&.K>E(78E0Y&14<W4+988NAN8JCL_,
M5$-[VM%83T=ZM1(Z)U+7*TOHLUHAGELQ.@^%0)32.M)&0-0\('W=_1LTRU-C
M6#^.N:.V7AF9B^GQB(-/=Q(ZIT/=51 T.G2]'8@#8-#>Z<1_O#%"1%YXJKS;
M$>R%CE0% &%.?#5O%0$NF4^&O_#C?)I6C$I#L#^.FCI2LZ78.9WJKH*8\VCY
M-[B[?\3@_:WZV[2O.SAAN>VE;;[97F#:",_YP9]-;Y-P\\8.3,<+(A_M O,2
M;3:&_[E8%O:9<S.T/_#?;E!HV$YN]TCTA7Z$R+6VVZW0#DE73J9'1[/)E\GV
M6_@?Q<_]A_'N!7^=)%^=_)Q^=^(MDU*3Y-.3[-M_FOR<?OY//PT2'#>7(UX\
M\]GI&3F$";$%;L<:'<S?@MCM@C*8.C9:'E2]+KGF&ED1"<Q=/V=7@ZEQIY2/
M\S;25EBE'P4U:\EE76F-[1U$M6ESH:RHDM%DY6:7_R60W!^ J;Q;4NE@L\;(
M.(Y;7)#L L+,1Z_@2S"9WA/)I-);!&&U2X J)[I="1<NJLV)WE1<-]8)Z;[B
M72<(DP+J],66U^^>"%ORX@>VL-C"A$EM#F=5<3MKIG#S7U$0/W\685"UUH%(
M+"+QH*4VTW/G",@M^"0X*=54/+"*CU5<$]6X$D#7S,:XO-">J%#A0"3F.L<&
M2FU:Z?YFICLO\D7XLRU_H ^+/FR<U.:E[F_ZN;,_A&:?;?D#>YCL8>*D(!4U
M#--6?)G\BC_#,+^6RL!D$03#:2-,K*/:.$R>//%@MS"X%L'UT=BTL7EV^Q1(
MEC83I(6#B"1P1F-T>K4WB:R%X4M?#^FE03*D-VU7ED,QF-3:ME5MQ%./J5<O
M2TQ0<'"A$ZBY5AFAR^GQ['A_B=0.+@4V3!BKZ!/REYZ_(0ZHR1:DEF@-I0\$
MJ[CW\L.DP)@)@UA9CFX*^+_;X?K>M>P/VXK2/(]%/6#=$ 4LEK7-T \"BK\*
MD^@0CA8# ,\:.M .*XE'92QR<0;:0I+%@@KH.#"/*/(^ )+C0]!KE^1J01[-
M 6>Q<6UO$R=B8VQ+JX5 \DJQ1JM[3QY,X-$ HH_:0_96H \WM8?ZAPE . QB
M_>\/;^"WM$#>S_453+XA\CF4(=(?.UL82&5 +&O5>$]B)(2&'VH[-LI/$GMY
M.GH8%;)'13.^:OT.P0P&5I03D2 >X@T=2+U#:BD8=K8)7B;$=>,\"A9<ZG:<
M NX\?XGL,/*1ZLF\YDL'\LN>T3E![KS_WY/1 >D$,&!V#BV&!A_&LMQ/DS/
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M0_GP^N+P^N(PG ZO+R"-*/@G)@WOV$$>F::']Q<'3Y<]<D,;<A >WE\ ,6G
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M_$4_6:$SQ<5^\!ER,P_T[]=OLJ<[WJT6)U.?__S&\>*)SZ8?@C" U?[DW7_
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MPYN #][]![@I3".;Q^+CB#.'V 2V\\M__H<&__P$?VJVS^(8>(Z^/@'295Y
MUM;,C;_0W7$R]8%#K3""NW4K3))P_$$+PH!_E-=\[B;5*Q'6 U4O)>'D@Q:'
MON=H?S'H'\T\,B;)QPES'"\8BAN,C[","5A T<]O_"1ZD[W=A57J+AM[_O2#
M]G=L\1YKW_B==A6.6?#WAO;W&!C2_?M'NB_V_LT_:&UXM@\;TT=<K$:\;LRB
MH1?D^S@" 5-<%3LQLH]R&_EG6B+>CLRN,]\;!A\TG"G"(UQW/&%!MN"[$7"0
M#E=L_F$2<?TN8I./VA.W(3[B@Q&FT9CYXM(=S^!,U\0J<;T2I@*>VD_O<66
MWHF"[89A^[>_F%WC8QG [[?(.'=>X(1WI'T7\(ZXI/CGI7"\&3";W3DX&_V_
MSH+9> R$6R\+8=K!0R"V0M]9!N#OW\YO3C]KUS?'-Z?76Y!66P"QL5< OCX]
M^7YU?G,.T#W^]ED[_3\GOQU_^_54.[GX^O7\^OK\XMLVH&[L.=2-9T+]=Q:/
MX$,2!@TA0CX?G1QI3:/3'E3 O5Q7+)'ZC]8>=*$"Y]:1V?:"&6#+BYE2R5:Q
M8;TRSXR;T2O-HV;G907?.FRY4]72WS@'OCR0:1//8<,SN+\*9W"-@"/(G_1L
M+6 8@,#Q%)]#FR+[6)WZAIPR.]&+.W6WU[=:W.[H;F?0U-N.:>L#EYFZTV2M
M0;O/>PYOO]%D+."*N^O$1^H),]/0_Y%3905<=5VQDJA*HKZ 1'WM-LW;KRSZ
MH5T$_%U=#,:CUCS;K0%AN@1B #Y]T'3YE+7 [GCQQ&>P*R^@Q5I^:/^H/L_X
M>.<YR4BLSA /?DCI' =!ROPK/@FC9)'RZ=ANEQG]CFXW.Y;>'AA,'_2</OS5
M;9J=@=5M=SN/4SY 0(#\Y.<WWGWRP0I#G[,@B5+^>.+['>@#:21^-*VM9N;'
MKN-O_TK#Y&.^&O'QS2_W.:TNUFCR<CTY[OC;M^_'7[2KT\N+JQOM\OO5]??C
M;S?:S84&7MT-NFYF2[NXTLS.6^>==G&FW?QVJI4<OMS9.SZYP:_-0:N]>=X=
M'("E.7B^H:DE(ZZY7FPS7YMR%FD<)(*C/61XGJ11!'L[HQ_^#_SN5!PW+9(#
MAL$YMZF#C=/2V\QLZ<RP#;W3;_6=GN%:1K?_##G@8-\D^/'(85,>K"&W+NDD
M;,6"F3,P>D9GH+?['117\%??:/=TWFS:G U8UWR6X"HO&$$.BZ:'>4'*G>/D
M*:O1Y>]I$;I15WK[S&U*ZA F#YY5+A%O,Y_A8WF#3T39+) V"_2MN4;/!7I#
M*X.YO.:'6:7@[S.X$B]B%KO;Z3$V<'3X%VCY;I?K?<8=W;%LH]DQ[&;7,!_K
M8FX#W[7%#^YY.8;F6*/.T<X=Q%J>:ZQ<1/OC%BP';^U\@YN(!:*=R7+_H.7V
M6+/IMO5VBYMZV^BW]<$ Q ?OP=^M0<_H\][S_0.7^?'A.0BH0?L?]]E+N+DZ
M_G9]3NZ \A3VQE-(<K[61$*9YD;A6!,&W?/_K26APM\V\(>%05Z,&=K:F>=S
M#60$YFT_Y.:=4IXB_D+\8)$8[_&V:76,@3ZPVQV][5I-$..&!3Y>S[(&#N\;
M?%"+,X;GPM# %-1V?S!8*F]5(+].@?Q-!>BWD&F@P*; M@[8-GD2U)Q/CWNN
M'C0W!+7F.BEOJT3S3]YXJ,61_?,;3 7748N8S99Y;QH_AD -1W].ACGHI#/3
M/.ITVIT!RD@M X@!USI]T^QXP1N-^>!(_ I+'8%*;+W1WO_R&(*^"@&B8<5B
M;KXD_%=K]"L^]&*TY1*L"%NDU?O]]L"U#$<'W<[U-N_T=,MUNSHWC4[;,'I]
MLVEM6:LO >%SZ.22V9X+\/CDA;'M\< &M@E=[03 !ZYCX+&&=A[81QM*)-C"
M!K8@5#=O'K_H ?%SK;JWI_?,3HA#D!2BG#,T%FOQA"/!<$?S LU+8LT>L0AV
M\^XU)V_,$TQ]M/#F:6>7R1N@H[; G-N"IECMIN%98JX290C"@)TDS )W=@[8
M@GFJG&2'OL\F,:PK^VL=FF4IB/ J0.F2-"-,P_@K0C2)LE<7QH1ABF!IXBP4
M#P64JO45BZ[3FQ=] 3BM7)[E_1R^.7%DGW/JF"EGHGDO-O,S'AQ[CN/S;+\=
MV-9?E\B2$G[P94^+*ZY#\(^7+8^A^F(AF[3D$T<1@B($20CODPA%QE**>&K1
MU0.87X)8N+P.5K=E6SX%B4]Q>L"R+YK>T+@M:HT134]"9[$/Y/8'+6:8NFV#
MY],V>SU]P =-W7 [3L=R,87:>/H!E1YS&PNZ$SZ)PEM<+&6OU-)(_LQ]=L>P
M6'MYY'.5A%/TO 5ZOF'WY[*U@$U4MSQ&SUV@Y;YMZJS;!&_>P;]XNZ_SGN$.
M'+MK TD?1(S>[.IF9V"T6BN#]*]*!O>VXD2\H)?66\NO6.GCD[37PD@+DQ&/
MM#_3R(L=SZ9SS-#=?$Q%P?P7KZQM"?31D 7>O^GSNW5-XY=E0G&CXL.M\>'Y
MT=71]9%V.I[XX91O(?5* ?F7JDV@?0N/YKE-ZKX%(8O^RI#%R[+CRSJ<:Y7<
MOX3#N>DSQ-J(5X5/%4"H[>'4:E_KV'$B'-,G_O,%5F0N3&DU6CV[:YHZY]9
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M5%[*7C927%IS4$"C:C\NNDYO6/0%8*ER>7DM0H;N['..[T=U_AH<F4\K5EC
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MZ9B55,I&*14)\VRS?">9S93)SH1*[^D(&GT-/3N/J,@L*J<&[X2@P?#<2<1
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M3J.C#3;&/N_B^=@8,!LQ1NH04^3>V@G\YYV6M2G-$TI#(5BI\ >@CVG9DFW
MI_+R=H.BK2*=-HP]D8B"P3D'&QEF8?.W7Z\^OVO,9=C)QX5N FIQ&'(1,TS$
M23J=6@B%'&,HCGB&Q3&;YD5S6??3(^U3UKB13G>"HGAZ(;YF8IK50Q"L_* 6
MB[+4/J\[ 28-M&Q:4;CT)#[+SA7L7&I06L2HRY7B,EQ:.7B@Y,/*ODD R"Z6
ML-@TFH2BY :QXU%;D^SH1AA!V)TYM. E\'> R\U", 1RY08\P0VXS/.MC@69
MRZ*2^(/V&_?)?*P4J\9W@)=2;C102[RPRT9$'8WQ>'%91I="U],ZVV;)]R.0
M*R GLC[L:9R)W#P_9Q[T$VZ3H3]S"((622S3=%(/FQ]CJ^5;''<L.VGGAP22
M7:GYMH@"Y:B/T5;$G&P1<LKL$&P57RI,H/ZE\MB:Y&9T2R*MQ-(4[V) R2&=
M"P"Y.72J@0:J:"M"4H$T3^4<.#O!QKZGM;8LUB*F%^JM\U!J[$W)3K@LMZ&Z
MSG(Z:PSH)W/RB_=]^5V66TJ="0R2M]*:L\) 85O4NCAOGX,Y'1D7"+]0^RHS
M\;4KSGP=$X*TM]=?KV[>52T_XLPL=4(Z,ED2/QZ3P&\3_&V='.?<,*AS'Y^9
MHI7<5Q8RM,!KM?-3UKX.&Y07IC):5YEP*U*I"?N47:W:I]4*]^]$-29V[)8,
M1M9W7#)^2]SLAA4,5NGA^P3,7Y^E 3U$C(\ :Q]4>X)>=<45N..Y%T$U;8%?
M=#FD!1!58*E-0'JYU*</Y;F\6%I*)>!#I82E&NY#E/HODGY28\+58N:+0 )F
MHB#!B0OP![;4BE(YSL(>>9-8!I3P,#$IC1D@AQ3T3*7A8Q%MDDV_J+^ '+%#
M'% $"O"Q=UQ:BWD4.V_P5WE1P((05*&SL'VA2A>O8<KPJG3QEDH75^GB!P'T
M+8*M9KIV5Z[LHVO7T)OZ@E9W[;K;KEHVVF$[7?!CX5SR0&I,M?L3%\ 0S/)(
M -;'A[ F[0Y,*XS=)5HZ$;91[<C\ 1E'FRPW<A!M-\J#LM N3<<B5$%)PJ&;
MW+&(RVI?X6,)0Y)2$7C@ ,YU'I2;"*.Q68Q_)$NU]-:J]_5;-;32J!RB974G
M,0V E'EZV*W+%\FH<OH2IDU@!8\_#"-PV,>4? JF;);I$7 ,XN*JL(0'4SRB
M2!Y[  "$F?T>!U"*[%4TIL6$4K".)US&!TKMZ<3B#](]JP6AGN2.2C:)='G/
M^\Q-%QT"*=V].!E90G5E@K\;A3Y?T.2D/+*Z-EKAH9@='2GLFU2JIHY/&U(,
M$PXG(Q;3V46>4E5N98#M ($G@F$RHJP3,8>M2!0IWUO*[LV[$(TY'D^+F%\Y
M8[)H;##V[N&=U">,85H8D,ZM%RWJBE-JAY 5D%2/?\1 1#:A,Q4\0Q(15B"U
M4F%:EMD! B_U$Q9PF0 V%5+NWYE$^^'1_7G#FDGH3\?%WN3TB#@O,,^G)4;<
MRE)X1!T*?%ST?IG+T]''E4(Z+)/YMF<$1F'-[F,CFK58NH1^WFDNB]ODLU$%
MHHBJ\LH?,?"TU!$>%5IY^.GQ)/)\K6DTF[4^P:N3#GNLB4XV3W&L=XA0WM4,
M$B!>$-O15)N!<:4X.;0P")H+>A+@67\KE&M>(CI)RDI>S-_!$S@+,WNBH&A=
MFW6>S-IP90^+^*3H_9'-ZI$M-TCN9D>&W'4]RNZH'J-GCZ/)K;(!2$F.BRZ
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M[DUN&UGVX%=AS.Q,N"-0U2I)?HU^.[&R;'=KNMWR6'9W[/[3 9)@%5HDP '
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M05)(=[? 0(G;[832\L S9B)*H$@(#4XXI62JWT$1058*,_:O]F-T+ ?N4@1
M@;M.E.-F!#QJ%66K%;NQ:S#T@+: 4E7(\@7%3[J!T&_>;*K2B Q?L;R5MOA:
M?<&P"2(D QYAL9/DP&;6+)EWYS$=F]WD,T\LQ6^\:T)$>)X$@F:(#"$9M*:
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MO?# EH3 %BVJ?>+%AZ=7[YPQ2-H/G1ME4IQ3=N'^BWZ%9F5ZJ\_C6^555>.
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M;Q1X>NP1'$:O7MF@Z8TR-/TOKG+IU-R4721 P7%5<4V)^?V26Z27C'9CMV2
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MJGV7?4TOGFZNLMRRL)+H#<P:=/UE;GZO\\:.7Q^Y"?"K1RS#:MIO_OKZ:Z9
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M5?(2D9\%(E_5>;/DZ?VO^JJ:?8MI7B/S7]W#5![KQI F 9Y]>N<DP(1..T&
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M\K.S%7G!DDGF6G;YZE#G'>]X;PK!<M#/-C/ 4-;[2(CK"7>&^YP><>H9"[I
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MUNN]N=45BIZZMV*[=!+ET* #="8/J8#XT$' QCH"L*@6.1,L 5+86U <82P
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M+%_?&.,5[5$#/];H_K3VGIX,@V'*T^5_&"]BJICWU-W '\=(B_W"5Q-@CV[
M+%LWDN3TY..!-4#8C]N:Y<>LD*C[FHNADG"(W5&+)P8QU9 5>\4:<2Z-T93M
M.Y^(^(^/89Y/>I9Y_L7SLCIJGL_//SU@G_RWDA4D_V-V]N3\Z:=TJ0\Q6AI7
M<I3IK<J*7V"^KA?O4E-^N]_01O*@IIP\_I,7-^6RN\*(//WT";_'O__K9Q>?
M/7UVCZS.1U^+XVLK,[U9)=D"V4-D]NN;M2_%.Y79I-U1R<>'A6];NS[ ^O4.
MQLF8'[,Q]QO5^I2*O@*<<M&-H"_&M$WZX(,@$-KW.U],,,(31I(=A1$^FV"$
M$XSP-S'HO^"P/9I#^30CH(\7_D_>^F_)P>ECV**/<IM,$G.):4B;UC*,I6<D
MPI;F(@X$&!9SRTTF@YX,^@,\=F[^M/X;6+6Q.)DG;KKO^4PI^[ER=S0*Y=*
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M.EXY HRQ_N4^448]8#@Q]Y<V/-H1-R#$A >./:I2OC$:YVZGH-!+<%T6FNX
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MW_*5.P.9.O:\*(5JXLER(NIJ\8!3!S$NTUX6UD_E(6,/SDQ?FK-2<1=PB(I
M$^#+DG==(D?B?RJ/N6//V/\X=IL,+R./G5P%4^O$ T1;0I*O^GKX_B:D#H?[
MO79^N9R+-/2E*4B+R/G]=F"FG];GP^!X).I>[!?KPF3%$*E(0@<K9%U4E]W5
M/L)PWM'WRVX<19]4)P18JMZIE&) ((\8BA9N1)=SZATREP-?;M0(IIE_($KQ
M9.[-=S]0%"+34$.@G4]V<9K1?=)EM\G_@>UN&.I(I!PJ-%;)XZ /G3_7**KT
M,,TAYU-4I6BLY](NBR"V; -<0\&F7)&+R=HQ0QHSN(%Q90X2 OIBU1T7^C2.
MQTI+'<6<E:(?,4;US?GL6XEO8W9*QNO69QIN=YIR$ IR''B<"<T-"GZ(,3!P
MK1VB+T';0QCI%Q2+S4.JA,MQM$9+B<QV;2"![Q0'D^3H7\R4J"+TZ*L<%:BJ
M#^KFBA1A*.@EEY?ZKZKP6AK<"]<L]U4.%1$S&1.RT?I$WJ804WE""M]W&M_J
MPP;?P6JW;+ M7LG=7'NTA*S9XGK?%=U[@Q=FYR&LSU*E'9VUD'#6$914BQ9#
M\Q;E49JS%TJN<4GFR%S@175=-C6G.%Z$!T8_?+U@0/\$(CIE',E1$-&G$XAH
M A%-[LP'#BZ',P$K(ILZY DK[3&IPDF4(HMDAZ43C5$B=#I&<J6FX/!1TM'O
MR-<I*"ZM]T6J<-4[81DS%#V#NKG,*\7WO)A!/>@R]"[J03<HAZ]4Z7 HIY3(
MFWAJ@,%!'TJW 6NCM4Z\6QL)B.-9AS.MX<J;ZB4-6#6&<O8OCB:GOU(_,?0O
M>P<H0P@!ATE4XMA50O"'2%\3,>H;M0="0=%6S+F*O 90ZZH84->V:$$PR:9\
MO6]-K_>Z@/:4!.1\[RMR1(NJ32!C FNRZF17+][-;@3J( ]MF??SV?=CB>C4
MOQ-ZB7&GT_HEA%!"DMARZ7 AN3T_T?GL+?R<Y'8,+MH4T'"2D=07',N_-GCV
M^D!P9;V_#A@MCJ^HA(2TF:P**Y%%9#0]'!L^ ^S[[;3!7((.EBF2YA'-0(\G
M+P68FF#1I%5CI#  ->X0EZCF4>8BC2Y_)S(=HI>TH?WD2H6ZZ (=;_RB2X;V
M[_5:V-1&GU <L?AH8BG6*:GC$0!OTH"%C->\Z(%-E&EDY'U4(T2"H[R2IF/@
M[0H*D'814:@= Z$K^[7K.[<'29*[ >#!"+(D4)*=<EY@FY3:5YH/L&2<0!GE
M:S>.$:.*TL)D,WL5_7H9._&"(!)G 14OSW<1*B:?[\/2;#7A)/^IJ<$L@0$%
M')Q_$7.&$1?QI-/^PGC#F*<0O5I).BZPT9BNPKI'M&(X@$#^8QM]!(P$4?%O
M16P%M\I":&P-@&J9;DPS-:3<HT\'G? @I'0\3"-@OO4^CDUO[P^YF&%2.T#O
M,# &E(RXU?B=V%^9UOP.4"M,*9F?GXRSX](W<*<[9\A NP*[<87<H3WR".%#
M@,@-09BBVU1P\,L@!(F5-;BEO:AJ):0ONANX62Q[5;%AO>T8T(SO"Y_)9"4/
MTYV=-PG<B<5.?!) 2A!APE"Z(U/L>I,$;;(X-[.CV"S;&P+2FIE[N)HBO[X[
MA!6)?_*2=]621NU;_I\7'WT0$ZZ7GT5Z-$YO=!NUS\,3(*4-[ 8B69PPM#B4
MQ?H%/ICWH@G&&[\V4!=G9*RIM+K=T$NCRH_YNT7)GJ04]- &#PB]G6I13-.N
M(J%"^JT>%R7S(_S_[+UKD]M&DB[\5QBQE]>.@'HE^39>[Q=9\D6[GI%>29Z)
M$R=.G ")8C=&(, !"+;I7W\JG\RLR@) =K?4MBD--F+'ZFX2J$M65EZ>?)+S
M@T<><I/2FSH.LR*\;0;#FV=-5ZJFVN6M-_9,%'F'[IS+O&UQ;1Y7?\/4L3[)
M]-DL25F0?2LFD_&M]=/B20I!$OSVIHM7*%YI,&I^T(HGHWFT(4$-X8/!S5^D
M7Y XI]_5,RZ/;0KQ7KN5O]F9YZ%O@XV)HY51KM9,A'3(A@M>Y6GDMOO%KCG_
MLWCMMCM6@%[;_2F+T^"^IZ\T^\- BD_HS]+-\^?7;UYI)T^O3/. O@5\3C=J
MO?CJX@M2=@_I?[Y@C??8_U<PA[PNB"O(&DQ5!U-/3(S*GO<ZHK]2H' O=M.H
MS*:+^RZ%U7DI15=2GOPD[#EA6OPS_N)W9&IYGC+OL/,7".D*6FU):'6+;[VJ
MRGN:TW.;&'C-L8I#Z(?Z[?/780&]Y\F5U,214^R1[?&^D\0G@J"UO=]9=G^4
MBZ6I-#(B"^FWGHY3VKA7"",YM28/#N5>,I[_O?P_*=[4;$!>-\L2O_YFT1V\
ME^T(A1I^=<F-WT,>D/[HJ,&T0XOY;P#]<#V*&ZYDTA1P\+/J2B2B*1I"HX\U
MY3(CF:3. "2_:SAC'& *CPBL,L95TE7ITV[;? !%7+R HT^K&W"37.@YI= +
ML9A %Q'V086[#L<:H#;^>"C62(SDB\4/Y5XT$T<9X'UZ-ZPLCN1_XC6E496Q
MV1V.M9_NE<3(()\$;_:+Y+6\42H24Z- WK"=D\PI0V R=C]F_0K*F$CJH6DR
M'(? X;)TJ<;\)6II,[]!VD]7FF"D7-DC?^=GAJOY*&'OR&$_Q5GV@;DG*=/[
MA?"[G^--_8*W&6X*[YSHEKDMX]P<X(ZR! 5$E(F(.E"J(^&M%(V8,H'!AE+4
M'W5;1/E&T#]^+X24<H=4*2L)4)R2 Y+O<G\#--LKNK3V[(FPHR+12(Z/4,0-
MP/.\-F@V4\-'H+=0"UXUTO;9J]"ZHUM":L#EMI$<"9L_@D[@ZVX3RUKD?8@:
M7=$CC.I$L CE%FU^;2PA<"1U80%1UZP>%%W%\XF<3^3=3J3F&D3BK'2E+$ "
MM4G/)LN)MPE9Q#LA+QH8 A%ZLS[B$64FX-77=(PX_]MQ?#\$+"/P)JB+N5?-
M+/SOTZ9)S>&0T8F$PMH/.Z3ERCTE50!?VA*SE^2CI[+]T\[_&:\%@3,_,!OZ
M/.WE9YJR+%4#EH.\N,T4<TIS1X61N> KM?!=J,^"V8&@P(:T-!R\J#W900J6
M!_FNEKV#?6MX>_Q/^CK_:QSDG&&'9X8\.PD[_'*&'<ZPPX]BT7_#99MOLON@
M#TK9N[R)7VXY+T<A<G\G):D\]'=:25XU8!W>Y.5U7E\LGMC:TITV=LL18^)(
MKY:41Z]@!%6(T5-^+&Y5I3%:E>VJWW0HK)#\@8$%"4\6*@L&G6<#R74R331O
M2QF)]$U U<4:_E"1J#!6+J];Y36!I=8EP&-=Z3<MY[R$UZT2D]W'*D7EPI8\
M#J<-8!-(=%1,@[L$2#_0$T%T7*^\7$A9SO]]'>LK_(8C?'(^#%UW10V9R=Q0
M:G1CVY</+@!^GBKO;THFP>Q8 4+"YO)GC[H=$"8/E&ULZ?QYW4M^BE49\#T&
MC*,50<J<8@JA)?K'8/,A@S.R,;:<[7B!7T8*84]P%0PZJ4NCX58'[B65#8KN
M2 -.P!QO*"?,DLC0?=:&$G7 8$7]Q6!*JH+L2Y^VV)_M""V-$+)ME!Z%26Z
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M9<Z+_=Z>S_>Q1RU"Z12SW5E*JR. 6&E^1*[VD.F2\XD;XA)-N[XF+=BD8\'
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M05GG^T9*+JG';,8 8YJAVD12C,M]I=$R9VIKYCJX,RZ%.ED']Z>Y#FZN@_N
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M95]2AG_M_RH'WNXZ-7Z!T:VV-33&2]$,U*107?#%"_0&&IHW=!S-Z,D9=%W
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ME$5:(H*TG*6BJ@W!@+"RLKB0 /1Q2QB3SVO",5N1*GZ5J8_MZU!=L+UJ:$/
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M:=]JT7HOJ H:FAH<;%UI:"#VQ5*_$\P;9$ C8>?-U4N0VZE?Q/PY1T>M#:\
MGC$% 87SRAC&0<O\?QB+KL>UL/E@2L"D=-2DFLI?O/3YT2\:$&YZX8B3M(4%
M7AK%=.*&W5B *_]YUSZ@!9(5F @YP)Y"O5&^,8XO$G0=#>X!6S9LB\(X)&Y,
M3K[Z/1Z%36( 1NQ 'AC,]/_VJTUFMY>&KZ(TY'7=D <D=5"E5A$%PQ?.0I6X
MQ:#L#6OBG06:H%CY84>YX"/8V=A96AA>#.^>R8L0>E7JDFWO%WZ%4]-SCY4&
M5 &6RCJ^&;_-B>8&64]*O/J+][+EP.*07T#=ACQ!;G1-U7/;((+'H)4,$W?O
MS$&7(W.=<UE,Y;AU#FBC./!TJ32G7EC9W(YT,C$\H6@+WBRFNV1*1>K61JH
M-#W4-ZF3PX:>-8TRL%$:"AV53,>VC/8JD/#882,DYVT6A+^DS$<"":N\W;L'
MWDW5&FG=&HG(<EM)H[T(DX:B%0Y!75-/4+,K4;SQE\&RR(3;G.I&K.<B^RW=
M"16L<C%?5?=2:=\-SJ.> %1"*@?W2(=P#"7\,E:RJ6B)&\I9@W+7+5(L(E]%
M3X@2A'UM>]S(JTU;\[0]**#?"EW12*\ V(2Z?1(L*"/J^Y,IWC7TF :!\3
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MP2F"#OQQK-K]HC2'88PS8_YB6C)O)PECG?DKVYC_<['XEHP6OT941N]UB[=
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M[=$PR=M]+=/0;O.RX"!(V P)<XRXC2;W,/VJEIF-MY$8-V-WXU"8BV"-]\M
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M?<5Y=H[Q KVRW7JG VI0@0WMXK(E "KUQFJ*;JQ0NYXP""5H_N!:)*H]>?]
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M-B <I/<3LT"2?/,W@;7.6>K-(9>S'-A:CM!+)I?.@&92Z$)8*M#6P&OATB:
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M 4GT- 2VV92=DWV*CCMO%<KUV#\/>:04?B:9[2'FS-Q8%"CM"8,Z[^\]<0-
M*:)5>DMJM6\[-Z$:G6I<OHI(Z7HU7G<EHJVD8:VG/:G^,PT=;,E)I[>%31[*
M"N=OUZ=+*Z-F#-!81DM3K3H'XHG,HER7T(_V'<-'LX!&3*W@#G!QL">7X*$E
M9-!QW2MN,V=N4XDG.4Y."NM]W1%\0EZ.[+4=$"$S-9HI=6^VZD]]9[CK>B@C
M&[X$35)38#I>(G$'RM5=^7]@U<9!C WI"3"&KYIB&-68BEAHP$%@WH>E:Q\
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MQ:=#)6]TDC(DWI:5E^#*-%FAW^T#H6EBYXM53=<6BM_]FP1;C@?)*#"K@%#
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M[7LOR]FVG/<L>/ 5#=8X=.G-IRV@?0M:E?FPD\S[BM0KJWL*33U*!F,G063
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MK$7]ZR&'X!6P41(\[[3;/^!NYRG\7U!7'I/V7DV 7U/29CDU?%7=Y_3.NB^
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M(F6;C]_"XNO XH=NNWUT5]+82A%B$?"7QA%V&O:VQV]Q[0W*@YZ[?W"\T_+
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MG@!*!.#H=SDAF-X=%''>D;;Q9ASRU6%IH9@*3GXC(A _$Z"E<;;L#&D$5G!
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ME?\FTA&F'5:UP<QNZGI4N61;68GLU&.GMYD+H QP% F8&X;6B3[?%#0%CU4
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M(UPW&I&.."RDT>#8N2N8T?M0C!*C>AN:F49#"(_ZKF%>3(B@,09F<H60:9J
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MJ[$,"C;?HL2UNF9 9?!L-BPB#AB4/UF@9/D\Z8_HO)G)L(,278-[8#GENHE
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M.I?)@U5F&&,>*UIK$6:>JQQB-D,I>94X8869ZQ1>DT=*OEI)-Y8QG[0=>K^
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MU>5J=8HFZ13M6W6*SM%AG4YQ4HQ@DV@((L,/R;46YFVG@)>E-VF8YP*HJ!B
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MQ6@X)+N-> ]F1.+U9PY#TI:"C]UJX*].>$%-G-)^R@R8P(A<+@%/+KG$K"V
MTP"E 6T!@B@EI\^7!#JWG/)$Y>ZC5"V7!;L#W!>T&KIE^,XT%+BG-)G8N08]
M(T$53V6D5#<@1,L##$?4;TB-D"HBJ7/:,')\#-2:(&;@XX)XOS2-\!FCT4K?
MP#1#MN;A"' G_BP""1@XWB I>+]]+TUG^.VU%Q7"V.X%W4FJL&P'P?0""OF>
M(B'!IC"Z3:O+@"9]W+,3-N75%%$##4)$%!!UA0TBFU-AQIE));QD?EB>BMZP
M!"%N>4VVR6)J,+LZT5'Q!)FC8)@AGPE0.@>2(GTE0\(ATJN^[E[EQ^H,Y8_(
M!.<+D\258V02A$=S;5DA<8UAOD 5!5!XBKYEQV,ZA5$9LM(O"#,:W<7YE)12
MTI"^03,).A#K&[!Z3L&2*?[42/>K#*]G9(P3A5\%*]>)#SJ4'-<@YG "9\<3
MKN.1.^? >PP-?I7>\HEY.DA"/QG%+!FW9PL;?.,QV4 *S!("1,%8QHUJ9QXF
M"<@HT++&@00J$)N6U0[4<.4(,G&!A IG&D@<$RWMM-#FEI;*^(-B@D(O>^M<
M*2A$)W*J-]0F1*@OA9?&RB.K"C&@8Q!,:%)REJ!M-OBI8?$O*X.?.C;XR08_
M[<2F;W#;K'!<PXO &BV93Z7?3SHU'3#D82= (MV,1<Q)S2A%/2<2(](#10P_
M] 69;_K'<^ P65]R(&G+X>0RY6=3B#&A=+A-Y&OE)_68")NASU"DK&H6 [8.
MV=KU$_*G*DQ.#JQ_K#*VV;H/R:,PX)18J7AE4@,F[>N_B.7A@FF )-(33=&O
M"5^.$O2IE5X,PBK@57$FBU1(;ZM:=?59C_UR:+_B,E'UCY4OD91QF0*>J448
M<T>G^C?E^QV0PR?,(WYCB*BES&OF6*$$;,V%N6Z3;M[@NW-94>]4@BD<;>EE
MSM#CA,?K#,#.CPB(UL$,DFXQ9 SM*4:G9<"!&M4UW]"D2@G -426)2D!5#A'
M6*_''CBX!A2<IBZF5G1;SHG&SR.,5( -;-*:Y@ZS$GAB'*HZ*8]])TDL8R=E
M/BI: 'S16NBB8'= S?%S+(O)?8',P^LPD#$ABP8(_(, 2C3,0V)(,Z*W(,0,
M.E_50@HS @H\;1,8SM:P.HCDM<2\#5B+"R](F$!-'8[C*ZB-[#<=FJ+!AZ.3
MY9AX%/A?Y++(X&]BCO] -ZJT;"1H5H$=&&&[]L)(%0,R94;+N6P8J91\'1:/
M*&%E_<D<9YAEM*&X"X@$5:\+^Z'+3V@[B24,#"E1!LG\!?3!L4AX[E2%(DGQ
M;J%49@"2)2>_=G'\N0HF+$8\!_VQD:C&!VEGJRD8.6"F,B35QII,(\'>-W+;
M(T4S3X0WU$^:1!]CN;XGX[3DK!&2DV0M[>9ZP8Q:P9S<I=*%Y5OD"_+9%"$]
MM* 1T,K8IY"-.<&SY5B9^!CWXO."OH)D4,?]2(N,HL0G.$0IC(HY+2'#K 18
M.?#"8)D<7Q@A.\Y$%,F(:.3"?P@=4\4T-A!9"9\2PU[R6Z?@B(EK6,UH[CNX
MC-<4*M?I[H$(!P8G!0#<A$$8*V\P5_\!6:FSU= C'2-2DWX5N0GP.Q>L92Z=
MC0H0H[ 2I.0!\G4N&D91XOA97 +#3>*8C6+?@YFF4MS="?#,<(HRT.,P)!;Q
MI,-@W!QN>A1.0HZG<>G@,19GX0C=\I>@,"0C6 XP'PY='''<  8*85B >I=+
MP: I?B53(T%LHR1)!G]R2!%]%/I,!IB[X5=JOI5$ "--B^V"WAO,ROXPK$$%
MN684C+:$-:%<Q=R.;"C#8K5<PJ-;M"3G=;,YI8?"PJZE.U0%N7JK@=YYJYT5
M)X47+]%G@X0(7.8*H1*!V\- <UZDL3:1D?_HF!59E0.]R^2]=BLRU\C,D?5_
M61/POE&5GT@6.$M0<1Q[T1"'&N%J8YP=1M86H"NI*CU;1-"-\"5=R/J3VU5C
MH<&\P-Q0NN8Y1XVQ_S-*;O"Z#F5\1DIW XR:*/POL66*-R"GL#,,TPP7Z<I_
MH3GP&@-GNNVWYQ?GE_3/SMLW'-(@"]7AJ!SBH)U*LKXHWTC@!X*3PS .3IN.
MVKXRE'W4S>%:7E/L/TB.!%5V,\AFT6\MX\@# 1PO<!=EGD;X0/U0A>AB<3,W
M#XR(R(HIUIP$'H.P"*@WK/)X'#M1>8]#L1P+;X+O*79WZ%TG*5N*8R^6.!>\
M\$]F*\![R\@<UXS:*W>.4@CW C!0,Q5$K^+T50R1X4OWM.L;1N/*F8(C>1(5
M2*B#4_"$$AW$M$5A&XW@7;\D28#I(D16%R +XA&5F#CA4)WMV<T'L[-*$\YS
M^L_;YT@OH'"V"C_ DD@ZZ(1*,K-5I5*(AQZ89)+;E<%5LF370I05#2TT/BJ+
M_+'U1'>'V9].AU&!>=6WA"6)J. YOKTZF#YKE.F!0,N( X.Q0"'6\RX3CE0I
M*F7OQ<X$F7^U\*$.1\)?%,QPS3$Q^(V403/UJWH\N$>"K =*<\)]<[*QRE>2
M5<:1$4JP+TL84I(6+E51A-\GQ&HEOD*X=?4LZL;D0SW%&G\@K$IR6J2?N5IN
M>RIT8N'$C>@(MM=Y+E0)UYN"6/#\L:(*K:]*+PH*3A8\7+H09#D!5I)VY&RD
MH \X ')A:JV[$U@C+K=SMGSM10[W$RP>DZ),)J#*\:K;JXP+6-1-/G;U!CL$
MXY H)S4C\RE(5%J]EHT_S4F? W.&N454TKN&55(&&+=Y06Q#IY&RZT99HLQ(
MX/3'X13M.:(8JK[*@' <E/>[M%E14V.]N))05$FL1#U/\8  F1EFB4;AD%&[
M5(R*R$LC3".[#D&GK(3QELF7E*"U<J6<OJ@P0,7\$#WT/4X\&U)$8YA.&)L#
MUO0- Z]D-#F9SKE1KCOCXMQS$<6UB[F6A69)GM9&)J-1C9!2Z;RNK$8N@7!O
MO&V<,F9$<U:"I=6J5%QG7+LP,*I/*M]0GXR;,F6U"K<3+%FH/-L%W@E$+J^]
M1 8,A@(F"NGL4E.O/4 MA5K.%8L,8V8T7Y8_2^<[ <NCH)1M Q^6UHX.!ECQ
MWI)JZ4^=RE!*)!M"U^0HJI4A=%T;0F=#Z'9BTVT(7?.P00U8@* 3*"I(^E,\
M1RFMO#@N9/ (29DF6:290(@-7?1ISOJ: (.)8EK8 *PH'N@\IX22JM(AH\ZX
M&1?GBF#O$Y5&@K*?DZD0K%QF[)$D'@CL3X7!(U7URG #-&'7_@<C&CA17[L-
M&>DD[XDJFT!M/A YG"CB,-JQ@-ZD-2D%*QI 2.E5Q!/"HN6ET["(01\-L=Q7
M;BKNE+6D-$/VPTQ%'L[U3W1U5[2O@DJA9)BG+YLN(F0+5GWIC9$#%92G?X\S
M:(0!] ?2KG$1,X&1.+6T*6OAH3'QEW&XI?>>G.S2^T<$^Q=63%A\#B\,C$\E
M8*B5P1)ZYP10+FH72M]=3:)BQ:DLF8V.%9A3:K/ZL3-2A44P-Q$.02/FQ7Z]
M.6N!J*2B4:OL,W^K>LELMPU_ 1-?;=VR'7\1[WW$>H5P9I]$!MP;@9H8JSF6
M;5Q?7WS\]#=O,GW[_HVKPDFR@B(-J)&1V5^0L+],TO6B2*/8M9SZQU&5*"GC
MI*=*RKD5LD5:^&37A[<N<?[M,C!GR4V%L1_[WM,MD?4@E9O]UOMOI%B:]ZY%
M67Y5B_\.6X!IH-K.G4GFHO#.E=:M+!-FSN">@,3"]#8#2ORNBE66D?Y&NTOX
MF:9?GH!+A;$H+ &M+0XQ)*QG$=/2;48S[MJV?*O=.DC+S(*?@ZI> "?</)LK
MZW(8826U$+76K0Q8VBAWI,-=*L41I#^ 86H"I[,YL-H,JI)Z%ET3Y3X'T5]F
M9DIOF)?&5*46*_^9D62RF"Q=T5B7%."B5,HU++M<E]G3<'DPO@N41=@*WW#@
M9R'LNY<J/P[?:2X<(!F"SB<H*91W'6^JC%[D.F[428>PVY;SOK;J@,R&19<Z
MY;2'7'K#4V4\%E+!94V+TO]NG)4*#C"4W](U6.7I6^0I;_ U^D.4'M=7G8Y1
MLG@>5JY1(U[MM]O52LD&O\6F(?N=N>]'VOI=K/9UGV9,4E_@"F*&ND!UD!R\
MABR #>V;(FB4UE$1Q:-*#(%>@2%R<HP 7JJCP$N[Z*?D LXL$$E/@>_^JK'[
MY$!#M)'&\[,G[0'T#$3&$R4'U788U+]%4J01@2*Z9EE.58%TQ/GV;&.#N<C%
MK;?9O,RK+F]9!EA5#O0J)7]+91DEG8RG94$^!;WP5;==Z8O*7>!D;ZX<*]-B
M]T>R")3J" 8&EA=2\?8>_ARN.X;3DZ):/LD<Q$PJ'9?]OG3\6JE+ZN0>S6$S
MF(;@JOJEHMERKD0)\56J#G:_O)/XSHG!&'>QX* #'%2MU3$7>[_R@D\0#(%:
MR! Y-WF$*;0[KW2FMIQD_8P@Q:JKR4%E$45L4J:-6U![#;3,JPNYH5@<!5&@
M_BM_RA%*,M,+QB&XH03#9)ECY&>&J6J\S*S)6':(KF)W2Y>C% I5!8EB$\I(
M4(I\0@T,6<V\XCX%[7S/7*!>E(SE8IMG>7DYA8A@H V68).MLF6<%MD2:K:4
M*4AK0SZGJUF#]8\VDAX:2(S*Y&"FO K:PQ7YG,+D<Y(Y[;#\*>8;J#$X,559
M<?,A588QGB.$H*T567.]?.M,HT9J9=5@#I(\">8,+"*L2T]*UNF6M#5')$Q#
M"-)@ 3=X62TK[W_1]0<ORB(_.\G*^RVCUJ*QV$:S\J"L0DE5"97Y:=R9+;(X
M&U%;]9/ \)!*9=4TB1.L8/=D#4ZVL5[M:JK]R&D3V3*=L?/E,AT!2RZW7=6S
MW4EF ^8^K==T0UP9P:@U=7V;QH=<JDXCC2=9GD4F^=QVA60"$&7&?P1#RKFX
M<)T+S(@_TH6O3QCR^$0""YF;KH0MRTAH'18C*+V4D$FC:'[*<S#K8%;F\"QL
ML75X"$KK^MKOGASI3L0/,F(:>;"*,*8)#Z+$__HH+KWE;+2JJ[^]"8-\S.MG
MK?WB\]EO7%GD\*15=;>'P<_?(2T<GMQ^\Y\T5.*6U7(B+/P.KOL4M"LL]L A
M%!JSVX;Y$BLRXS[>Z]+*<"G)>?8;YZQ]"K.O35G15L5Y-4+-N2"T*H-C5#9F
MS;$V?R\;# I<RB16CJ6G+*@AR/*$8NB^@2FLFB71MJ>P[=*?5MKLH3HD<MVQ
M;3U*O*B2)*O'IS+/5'8-C=#T6GNBI"_,!;,A&H91I,SV* 1[.T#K,Z8&D.RI
M"PHP@:C;F4[FUX D_0.M=# U=+G7<A)S91EL!'G#@HA71I#W; 2YC2!O-K=O
M"&=7;<G FOW*+/Q;.,%\0AE_8=1'TYQ1%T8C: ;M$3/Y$+D_]8>2?AWZ-7%Z
MV>PKC+EZOB%&%%]>P8XY[1B;50B&&,%>*U(-<F)Q?L=/!8@ Z?*=L8PQ'I.!
M$;6"3'6/B 1'7P0R;:Z,4L(<2EWP3A5+8^@U%:X3%*HB#'9-&\/ >U0$)L8N
MOL(UH_8P WM"Q0T,D2CW#>-7N.!46>EE+ *"M<VG2>K"P"WGO7ZQ^5K9/%A!
MP-4#Y ZL/+AL[B&#5YSQ;(H1-=Q.H=/^0<<Y3Y)KL2C'9>RX[N*JJR[$8L0Z
MM^P[(#UX&NU==A#6B_-8UYH"#+FH;0(;G>84.9*).*0VHN22R"5VKQI1<RRB
MRPF 15Q&U 5BD)>MLV7AJ[H>/Y5NRAA__DXVQ,07\5ME@8YA^(UR40D;J1(W
MT$>GU6__8-*I)C$=6U]_(:B?ZF*#"U9*YUM_W:*?+CHH: 78QO8&^81+H9##
MJ,"**+G@X,JY"Z("JJ1NS(4"Y 7@QN-R$BN\T(?8[TX=X7LXBIT$$@^QV5U)
MJ5=,J?A5XP##.Z!]58RO4M)F*UW6C\+8UC3TJ^TAGQ]X@#.&IV+G3!7QMH##
MXS>!<56?-%F?F@$ 57J%H'*=*"4A U5=A'!!S^<B)-P^+DBBR$NSMR4+]\RB
M+M5:4%PGE_I?\Q!#>>#2H4[%[BIU?%4;._6@+N^NQ%.UP3=V\S:F!6(615OL
MU03E3H"QYXAEW-8#S1PC-*<J0Z4IC\+<"Y9UU<P^F9Q4A7?,9 $>=58ND*6=
M[LRCFV*I,] %P1(@4IX>9L7E851]GI;-;:I);O,1H%10\6C5N2.ES!W+K%0&
M0K/8#(R#8$>JM@9?=U:DH'.>D*J;Y?#K$88W4'X);X5Y/)7%EMU^H\C<95(L
MJDT-U71<U;R<N]YQ=)TL*)X,A[AJ[G*F G#A2!>ZC)HJ-Y.=JLGTJMLZU+%W
M 7:U]S(=[%>?>(9!XUC_@8E*]\6CE3&)4?MB'3'+L?VWMLNK6!$+@^D,M;D&
M9T #-,$X,!NU+YZM>0AHEI3=FCC6CY90&D@,7E+-5BF"C1M.X?JE:89:8J9J
M3\MR5;4_-)+\ZFO.\OY0WSFEL)H9HL;2$>WDG?(CBA4R?YQ[WY N4<-,4?-4
M1=FQT$I9Y0OU35 LRP\6^ ]MUG6"/R+;N'%2ZN!N0JJWWQPA555'+$K<0*!P
M)4J\;U%BBQ+OQ*9O<-LV)1SZ]]L(?'SK0D3Z[?D0D:/6$Q?%6&F^7GPX^7!Z
M<?*K<_7Y!*9X]N'SE7/RX;US]?O'C[_2W_#=^Y//)XMA+3J^M&SE?><8E\;H
M',=S.L=]A-RF#^?CR>G%^<6I\^[B\NKTXNS#Z=F5<WGNG)[\>G%^^>G#Q8GK
M7'PX;2""]'"]8?-Q(H'XAEK^K5WIF[BKSRT(4'4Q+S@?,)\OS"TGO]C"3@TP
M.R.5+(#_V,-^ MXT@RFI?]U%4'H%;')UB^@CR6T[[?8/N$=Y"O\75%\OQRTW
MHIP+CEWW.;VA[@LXC<K'<L.,4U6?J&-5?^MS51_(@R7$&\P_=64F81!$0JWK
MN-TZI(75D*%Q#OBR.^&OS5!2'EFURX,=._16SY[Y'<[\1[KMRV_\XK'7'/C"
M4=]ZR/;B/L'%?=:SL_=O"^\?/[B1^]< \_ZIH<S&7,VY8UU^-9_M$)MJ\"#.
M^3I[LT2+?Y0C)3O*N0GC(+G!;7 Z+9QUY4CYHUTZLXTBE,UCK/#Q\W'5A<2S
MSFV)9^V%#+..S##3454G11!B*: OR32,PR1N0$#5?8EG94"5RC4<.@AZJ)(K
MG\0HS+BRR\=B$(6^F==X'J:3NV.335JL\_KCZ<GE.^?B_4^.&2D6?OL)3N]#
M,1$I+#7V)K":0(0_R</'!5\$WQ&<Z>=[Y:-[O4X@>F+8VSON>F)O?^@=[WF]
MP^.]H"..#P9!Y_ P@-]A4@E,ZQ,2U/N")_:E _\/O?1?/B=?.MTO/?YKZ^AG
MOZS!7]G%;5O'&ZO2;!5\NUI:'APTW +9&4'9A-.^%:6W=_MI[_:&M%Y[C3>O
M[[Z[VC4-=T76B:D#6MZP"W+_V#*,)V88%[O-, Q7/]9%->*!L<YQ,H$EC$5,
MC;=?_YIDV1NPHS$?UK*6'6,MAVW+6IZ8M5R=O2#6<H4IGN,DPBJ>LDNE<T:E
MD"TKV356TK&LY(E9R>GY"V(EIY@9=XX)@99U[!KKZ%K6\<2L@^H*[!KWH$7=
M*<+9LI!=8R&]>A;R(P5FJ^""!VSC\T<^;21^S>Z$35IM:-[BRJ35ODU:??S+
MU:##MTFKNY6TVM38T$]G'R\_?<:4PHL/[\\^GL%_??CL?#K[Y>+J\]FGL_?.
MQ]_?_7IQZIR<GE[^_N'SQ8=?G/.+3[\M9H+>/Y2ND5TG&A.*_9EK.9K H2XB
M]R[QT@"Q@/=A*KB7(?SQT?.Q^*;S+DPR/Q34OY?P@B@<)FD<>BYZ+YZDY(=E
M%N5>'#26 %?QA4N^Q:I@YVUQ-]M)2)NNO<G%*I$QBD!V0N/6PE2!R3>-\X$,
M7<@H=.$>U]EYC0.?\K!O9&>LQ6I1R#K@'VU7]D7EMLN5*605F#&I.D/]JC,T
M(F=H6'&&/C_1ND\[E5N82U;C\Y'M+W7A>2[L5O9C&\J.G*D0SDQX99-:;F[F
M8 1WL'B\KA8-ZF2YQNIKS*S&AC;7(IK!=T.1IES$S:,&;JJ]384.:LJFJOXV
M;UI <[(Z'O$'5_5K6_USW40.2ZE&,VJ3@_72=)U@^'H*\\Q<V>!3#:%JH*F=
MD71>7Q&MI/%R-[ P&K?LQ?^ITC1^]+BGP-V4L; G-4?$$G!4.&XDP$KBWH:^
M+Z;4WMMLXT.%=R/Q-"U\K'#>%?E")=M-(<,7R\=>F"1-= =@N(IQ $JC[LDI
M$S_4?3(20"ZQT#=.0*J9KW^/0^V% J;/619O7/,^_LV#B_HV4V7RHK+3!@QF
M7.>R6>,2.>4:50'3D)@#]L[T8+(@&:G X85ZQRF_@UAKYRU^/.*:CN>I-Q$W
M2?J52E67S2EALG O<T'U+:^FR+2HN)[9MTQOT.=4>,&--^-?<4/"U]UVI^<,
MU?!O=+%!7I<C<78Q2 LLT=D]HD5UL0@A<**,ZEP[14R%Z:F8O.2B^,)4)+&]
M_E8WOX.:\\[+0A974DO??K+9="_C3-3K)5CW4RH*R _"LG5M#7>;>+''W<^Y
MFNC<CT)RN<F[CC<]J=I0:C16!;/Z"6GV1S5,D:MGU T")^HY4^;:ANXP#-,)
MU@%5"7V:XW,NG.Q+H?H0D^HWP&*P938@_4+J7ZJ#A!(+2Z0)Z31#@6UY([.S
M1N3=E""%V;FPB(2J4%I6+)6;?%7^'I_01;0-OJN&I#59)FEUI/OTO]"%N\L;
M=7<MB0C.^4P%DLMO55=O*K9] V8!V.[<#5RDJ/PS_>.K\$(E VIT@V68DYCN
M S;,2>G5'K4?O!D+69-[!9L:IJRX:)L);X=ZQ-5CR 8T8.B!?, F&"E,A/F5
M7CQ6+!9ZMFR")+X(J# Y&8<9LC!BC%0)>=EKU3[53?J6*;GFALU/ ?>5N6O
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M7HCFOA*;W1#M[*9K*71UY4K.'-:K%U(^R'U<IG3^,>VOMK+Y"X7*M6Z?LWS
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MS4,@3^(A*#D13*"#L,_>5700>@B'PS6QHH/0?W2@@S R!\%GX0B7 8*GC9?
M&)C$RS^=B#80)VQ*AW80J+WJ()1_/86#H/5$"[;EV9,W"A*]W^A8?+C_H9$M
M*MOS71:KD[3<J@S1YT[F3BJB!.N='SD@#*![,'3W@#/**2E. 16>@*!1@?=4
M0TY*&\<\SUIWI\)0GJ#_</Z->7S3V.6]EAGTA!!SKR1"[UT#K"B@H4>R1PP@
MV0^>[ /3*CK%"[M+#R)&"<YH!5$Z0X/4-'C3G6+!P<F>3T1S2OB8R!ZK VCH
MNU$20+)'LD>R/R#9RQQEB,Q#)C*!(#J"E3Q"\L390',4@74G\?\(9$_%%F2/
M[0B/3 -RGVTJ!]US[Q<K-^M4,\*H>Z65[IW_,'!<H$\Q=)^"<2$9=1Q25@R$
MHAQ\9A&B53S%8#5QXK&K!?OR#\A$4H[ZP8Z4 _;J%J!U1]9'7"#K(^OOUF/@
M?-":6;!*4A F-EV(1$(@H1 P%XE'^MAE@SUI LW$6"3]KI0%D/2[9MR[42I
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MG)!-"._WQN#=F>5,)I;<;Y!#__<RYNE':\8Q)S_:I4<&'SJ#6^,DS5J!TXZ
M$(Z!9]0TIS80$YB*5NZK\-ZA <UT(L46U7<4Z?>9WP^ZM8Y.%^6!_D^+[R9!
M/YVOW/SCU,]2Y>HZK>J'%&M[/N\?0_X#%?%[C@OT)H;N3>1LLHDA@N1&@" N
M@!.>@K4QYD@=T2IL[TU<M;%/,*:9$X4"/4S=HS%'DD=<(,D?CN3_^)UAE'T_
M.F[!I#+:$,PX(RZ06QZ?6U!??$#+L:_9\F$Q6RQ?G._6[P\/E\VQ<^%,='Q?
MB?'>K0N>/G,@$ W@"%L<1M\7"NI9#M-1XR7E#GBV"41F'KQ/#JR)C&C+E9+N
M[ASFV>CN)TA5:CI1<F22I(YD)@_)]6BFD<(1&TCA3\V:?:-PX;+*7!B0G@80
MP1LP.3)@*M(8@I$FD =0^$&.AQ-JPID>%X5W) &,%-Y%,]V-)#!2>!>Q@10^
M= IGQF1&/ =J% &1O 5ON8',M9"<JI3T%^:";$/AASGLK9GF227*BCN7C[?[
MK.0==&?\^W)1U\WD[SQ==6+>TXCC]W*K9' 5X)[C HE_Z,2O&$F)BPC2LD+\
MWA-P@1D(DK/D3;#:W(K=6ZOYMC6:3Y!\EV92?!24"G<D(;]7LD>CC62.N$ R
M1S+?;3Z(%HGSI$!YYT$0K\#8$LIK;BR)EBA+^<YD?I T/&<3J;#OIRNI>23S
MKAGM+J3ED<R[APLD\Z&3.3>2>JHUD) 5".<R.!4%^$ALS%D0ZF\U]VY+YH=)
MR',QD7H+,D<Q_.-MT6[FW=]\2@T>YQ^KE[]]2O,ZO1BX\*(#(3F>T]RS)JHQ
MGM,\I*7O1H(6-SS:>EQZM/5HZX>?O\,-/\K)"6CKT=9WW-:C!K//4W8.F@OZ
M)=7)+<-)>]A:3)_3;/'I-,V[H<<<8^@PP$$\_80#UGB&7N,)U/.L709#DP>A
M4@1KN0"E//&\+$_0[&:-Y]Q>'LWCCY?6\BR/_@1Z3$K9Q-C[';$VR/W:C7S?
M$.?K]1(.R.8(!V3S,;%Y]*I1: 303F004EDP07NP.AK*N9>)Y#VR^4$$F4I,
MJ&1(YMU(Z"*9=P8.G<CT(IEW! Y(YD,G\ZR$BU)G8$%0$#8'<%)%B,Y+*I@C
M2MR:B+ [F1]H0H*=*+Y%JR0*,OM"X0?=%>\*;NI)]3'-T]+-VGR\BZ?3^;1>
M-6#]O/UHXEX"!@-VK.8BGP^5S[F@*;JD(6JN0213@G-J$N3(6&8^L.1OI=K?
MI5E9V8__OC&(A=6/KIG#)\RYLQ*FLRV.5!W2)L7\^GCM,U+S:)<>J7GHU.R8
M%2E:"5Y+!H+[5*@Y>@A:$9HDH5'?FD&T#VH^2 )=LXF^9S6\_WL4D^6C-<^8
M&!_MTB,S#YV9>0F*DPD&.'4<A' *O%49E!2%H*7E^?9 H3TP\V&RX5I.A*4X
M+Q@SY#MOF?],RX_-"J:96Z58I0V6Z_'5/S$>QW(X>@(C\@2((D&[P("R2$%0
M3\$96?X2+ 0MRX_(K7+X#^NZ+&Q='R]._73>$OQ1^-=Z6D^;+W_9&-'F%('Z
M"5+HG$XH0]4Z9M71E".S(QR0V0]^!OS@L8)98#0=F!E&.""3')A)4*_;%_XX
M*#Z.3]S\8ZJF\RJ[Z;+Z[&;K5"UR&TN7%S4S-,J7]32F33S]9,=68@33"]X9
M$ :0;(:>D#0^4!L-;P9F>!")&[!<1A#"<,<XB\+?*DW>D9 \OK"5QU=-Y=%R
MV=C6IGVGWIC95_.CT^*3K=[D+_S*SU/GI[/IZG?Z%(+@"15\7*(C3%RBG4>N
M1PP@UQ\D1=E[?L!T)-H&S$$B!I ?#IMX'&2VNBO)2+G/T=X'Q<S[Q<K-JL7%
MP4YGVLA.%#I&?! S>:YT[\AGX+A 0AIZ<I*'*(2-%@QW$422$9RE 43@V0O+
MO>"WU)(79^*==4@\A2B2*3MA5J(JLB/)Q;W2/]INY'3$!7(Z<OINL_H5Y3:K
M!#1*#X)Q#4;J %HPJ@C5-GG]0$X_R$ "RM7$RBWZ'H?.Z1U)"".G=\UV=R-)
MC)S>-5P@IP^=T[,53C(E0 5N0$2FP-AFW*]6)FNJN9#Q89Q^F%$&E,L)93O.
M,N@]D7<D.=^/O/P%7*O9HJX'/I&F&]$YGL>*5=X^D/6?>\;6B1H:9":0,TV%
MK44"STR&X!6S0I,2F)LOLO6K>5B<II^+#7S\O'I5E]4O+W_V=T;)1/ O)]B[
ML!)_&;2AZ$9F'^D!/0-<>O0,T#/8BV?@B4^!4P\T) <B)P4V$0+!$DVBD,&E
M\&#/X!#9^4O/@!(QX08]@['7!Y >1BD11\\ /0/T# Z@Q#,Q*Z,8L.R;YN#(
MP :I@03.*5%1A_AE)=Z6GL%!<OQ7/0,RD:)OG@&V"O2YT>R@8/EWUXPL62Y.
MJU]2>;9UJMZGY>E90W[U4TJ;'[Z:S=;-=[M0@<9D12]<DF'" =T4G,&(V6VT
M&D@B" <D$12S?2'495QDRI0':C,'P:4 GPP!SJR,4NM@Q85 O5R_?]'XX4UP
M^V9^YH=?<<.+%_X$6G5K)H1L<6#]X'<KIJ+1;F-Z&N& -/ZXPTQZ#Q#,1MX7
M'W]N7*"__/4R*;F9[[G>9"./XF<W#ZG>/B79>PAAY(@54:27P59$B50FV&1!
M::I!9)/!I*# >!.9SXQI=:OGZ3)2;(QC\TY70L6GU%-+]M6 L0M+,FS1%":<
M1\D3Z"*,=NG111AZ(CDK0[3(! PC%H0-"9S,#JR*U'/MF4[[]! .DDGFXMZ9
MY/YO3<P:C]$@8X9XM$N/7#QT+C;)Y!BT EW"<A!1._ R$-"$,)>SI4+>FCJV
M.Q<?:%K)EE5=E QCDOX+.^55@>PRU:M.C14?8\C=PZ,LA@D'I/[!9^JME5DD
MR<"(2$"X',!9EL'QQ"5Q3$>F;G+_N:$\&T[V%$<1LHGD/4[)#])<="--W\?#
ML 8)!W0F$ [H3(S*F0B"N2RS!RE2!D&E!.NL*<Z$X9%KIAC+#W(F#I+&9TJC
M)]$M6]&)(@-Z$IV!0R>J#^A)= 0.Z$D,WI,@SG+/=6X.0A$@DG-@$M5@/?%!
M"NN9NR4/N(\G<9@B!)LH^N6!Z5UX]-O-4.F]B<#BQ[U'N*].TK*:ML.()M4\
MK<9R<C-F*?:@;.@Y!M"A&+K$00;#"$L$L@H>A.<4K(L:#)6>,Q9(U+='M#4F
M\?5BOK@^JNWIJAZ6CTMKB 4%M,W(SX@!Y.?!\[,*CG(6$U A2KPO)0<730#+
MB O2>ZF$W"<_'Z:0,"'R?N>:]YZB,5./YAG3\X@!I.C!4[0/V7N23*%HSYJ.
MO0B6:@Z6DV;L&T\N[Y.B#]0F,"&,89= UQ+E_<B1;Z;XG"7)*Y\*XIK_S%.>
MKC:S>\Y^M'*_I;H+==FG.NR\$S%[#[L%!XX+=!(&7[@W)IJ4!8&8A0/AG 83
MFT/3E.(R9D7Y[43[Y1$H/Q4C>C8:K7SHV1DIBWG]0VMK-Z][WQC7E[^MEJ[
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M@NYVBF3O/8*.U$?Z41HY_K).=ONY07&Q+EB_( 3V7#Z,$,;<<ML/V/QA=.!
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M8&>I%*)@0"C K!&BX $2*$3!@%"PSYF]B(+^H@"S1HB"W65,"(,AP0"- :(
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ME9OMT]<P$RDPGX&]$<@]6#/!-<>>AT[Y&SA<&@W!,-<<D]FC6W.4@Z/U1TN
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M^<R1YR '/(GXNAU":>85J/C%+'X)*#^X63L[V*VJ'U-H\_05IY.JV2RC:P7
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M).+@@X\4(\+$C"AIN%9)$NILBQ)XCI$_#'.?3N)HA^"[T6]>)/11M2/)CX*
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M1'Y&A(D#DC#AI[Y6@NV2!O(D>W\(9\@J!C.>^&DX:,IB]+H&/25HB=![@H*
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MAO$DC1XN$WTTF[LG3.WP3_\CD0[D\5$2D-M'"-!! *,2NUY,0[ =(U1+1;)
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MR:WQ630YE]887>GIK+GA/*_G31JFM"L!%*57Z5KS2E[IJH;7Y?1&>Y>ZT([
MG#:CFNK?H4^4F.IK>PSW+A85_%,M9'NQM8=P?$,W7E=)L[86SS-5>>W-O]JQ
MV"FS5U6Y,;J" 3D+:6W$VE18%6_712YJ^TD)D6/2:FAY._'^M>!-1BD\@!O7
M7#L)M6LKH5&[G"Z4]DH[/OU[WO1L_Z_\?>Y-2_O*GA0WYFAMU'!!]RNK5R[=
M_%V5U;SYQ>?5+\2M]RXO8&F][SZ_>[<[[M@@LM^[_W[HF*'(_;?)#/WYM+)P
MP1V >%&3[5,0.XE?'L=2+V9_^],?@Y3^8)]D,7ME'/6-[/.UY3EY0O3/8S.]
M6QCD'@:_N4&4JD!&5UN2RZJT;W!/5*43R3E$1/+9;-KE1;>B#()VM;"[W>[(
MZAITYYK\3KS9U,(C)[N\@)"=3JG4$_M[HR%&9V'52%Y#5F&C.')[:Y&[69W8
MO27;5T[^YU8'K'; ^G">L@!O,ME.6X#.M.K"3OQ-[J8.=K1]W]H54&Y?\_G5
MO;IR0^^X;X&2LG,QO[*"='DU6S23G%_#I>UOOY;5;V9:?JT;5?U5>T)/<ZOR
M[*^G4T\7X)KP5,6O[?3)[IX-[,\+SUYT#DMYI?ET?B6M<>CU_.XO]&Y/B[U:
MTD[A<\F5M:W2+=.E7:.J@-E>LV[VJ]8<S)L-.''!R;IR1S)[8)MW=K4&G&.-
M\I0+.+2450Y[R5I#>[OV>&K_/5L(NS/:Y8/OVO>NRGJ6VQL^8%R7M]?NYL4<
M(NA6GY9PE,K_W>[][\X^7=1_L?>YXG8JI%XX4]S" Y!1M^,O+0!>3"T$6/_H
MI'='_ ?1F7O/&E,[J]]#R+N?%WU!;/94"-C$*E+8KO.K')#1# "!!5-_^B,+
M0_^'CUR^R\N)^U?P0_?N5WWWG46]? >\'.V[9PW46WX$*]I^9)56]VX%XX![
MVIO!8=B"C[)3\6 QSNR4FK(J<C[QS@MYTF@IJV0V?"GU0M16'_+JM>1COQ#^
M,9;@':_S^L*L&(+[" &(PU6Q[Q.61AFA@FO"96"(-DK1-&()]=7^"(%=[M9'
M0L!-)0C51]!*5G>Z(_S+COO/FXN1JJTWP47?=*IZ5_P&X(L&W*1G'-H=6)UG
M?P>!X7#6:F#3<H?9KUFKF]NC5^V.B94[)-K/]6S>_!;4',2:VW\YNM-:O++R
M?CGY?.+]_?3THP6;M8.\]@;SJ^X'*XITM9GAYX7BE:J]=Z7]RUWG_>GG=Y/[
MOW2V5EG(???T\]F)]V47W_(22<!8VH=M=L,]FK<[+'Z]*N'9RZ_%72WKG5H8
MF -<6)[IH099$S7?7$#P*7=76RV Q9#7=FQVC'=<W7=VVA@T]R^UOC _V:]>
M<\?P;RL/;96&D:DB- HXH3Y3A%/*B1:2*:9]ILT>>=Q=[M9'M6WG$<1T.9,O
MU-C/FX9AB&,?D"4HHT;/\BX1\@%UM*6"07=:1/BO16X-M+=PQ-XU_TU[>KGV
M[EQ0UXOK64O]P>F4&V "&L5VW>BU!LRNM/6]0W 76X^1*CK?UD,_.?$N"OLS
M>P:_+!U;!I!B L=C?<.G5EX:9JY>N7;6QKXD/":>L.=M>S,/U.'<M=^9N'LV
M%VFG;=F0I_E,::MLG?9L/Z_!+%@I*!UG,IVVIDLZ:K&R4V!_OM#V;UG:X30F
MPST8SRMWIS:)U1D9H#'!AN1*5WSUW8T!N?S6QGS:6U_F0 &X:GCUO1?6%02C
MN(9#0&A^!0O6?'%1:[.8VJ>_@26M8;J:'D1 8A)X6VU<&)9H,5^.P]$?M5M_
M>% [KW!XG?/?=?M]>[2MRJ\P'Q4LB6-90=[XU)XG714J][6RJTGE31U]U(3/
MKI?Y:RWAG>]U=?_R[GY '"]+ =9U*1O*UPGUC;67CBR9\=M&[!K^V&Z0N<46
M]54^V^"2[:E7-\+6<%8;JP""/>6-Q#3<3UFX2%RX@<6TN9T.)\0GWO]<Y=/&
MV%M= 1>V$P?_RJVTR^6_SB[^^_Q'$F1V.$7#+\ 4VPN+SC-B(7-+:"^*=DF=
MP'?"HM7&99M?KV]1UW1JN0G<6MC!=]+<#-'N=WO07]NV[3ZW&&KMV;G#*S]J
MJ:^%G<$HF'A@]2P6D?-%0T6XJUAL,U4M_^[!;8%IM@_0,/17%ORO!O16..2@
M4/TQ6/*^K.RPBK-%!>?_IG)LB]I."^7^.6WFV_FB;Q_U1$NI(C\5*6$9CPAE
MDI&,Z80$]OBCC9]RK<S^$,PN=^LC@GEO=PX,QXIH-^TOPS#/FXA!BG)?((T[
MW"E[&N(5J$1G[E;+*MME!?T$^L\=C!I+;3]M[8?S,GC_ ]KNVMJ11:7!?,%F
MW#A:>=?6H,]Y=;MN@M9,3H=/UD<$7P$[7RG/_M:[M$JZAN/AM+27J!O%M[RK
M,S/6'#;>D,9Z3N!WDPXM;9)K'?IQ#[=\E*6'LM)7VIH">\3[#F[WE_:*)T>F
M5\]X?645*/P%-;>MV0(;OH,.S51*,R,E,31*"54R)#R*.,EH$BM?"Q8$>SP%
M[G*W/NI0F->)!W]Z:]/;0"0H@U[/[\2</4NQ/F=V]CO;AXS>&;VB_I\5+/4L
MXNN ZS2W$J/<>:H3D]FBDE>\[D Z'.GL+.2@K2TL7%2 Y*VZRWQ/\=M&E0(8
MMJI7V'N %.J5%+Y.0.[XJ )8+DA?L$-JK>9J@:PE4EK,[:%&PFHXGZ#]_QN>
M3^$T1>#@5_.I;DU?X[J"<\C:-?A\_4@*!T!GIN>M83T!6[QQ;M^X/'&7OS.F
M15%I.YG_MH(#QLZ;E?5:X7>XK@O5T?/&N:ZW?F"Q@[1GIGQ.'K>/][R#Z4#]
MR@AY-!THPG2@HTX'.D2D\+[CM,,__*W1)(< 1AB&_!1I:FD]>S[\964PFF.<
M._XUY[B&[;;G1N".6S/2$8+P=DOU_KNA.R&H]'K1?-J<]1XYKL$/7"'#*PO"
M=55#@$:0_M"RMR?>IX<&-?'T[S,M78BK&]'R?6NOOVJ+PGC=G(>M'5V>-B'F
M==O8KAM[B">>UN4&D[]U8NU\G_;*'<E[+U6^-9- GZ]N9@^["BRSX&T\+ERD
MMD_E'*,Y0-VEV]6[ML:]5&MWMM>RJ_J;=NGZZY?-(3(2! U<LF75.2BJ>1L'
MU7#9^CI?7#>#4WG=^F4MT%Q.:P=(3R!P ;Z\\=W-*[HX'N !'IPPQ*K/#C58
M84$/9-+8LWT)(!.\W[,R;UB5>7[M3B%S)W)WX*,[.2CM4*/=(<#TW+;" W22
MVHS;F_&9KN"=:E8Z1\86(K9R\,OGM7# -F[.45%KWUM&?'9;M'%G- C8>>?M
M(*WTYO45['![6-*PQ"!+E[QR@:;63EBML-H%38S^O+M#ZZ[J'M7=T+E8Q#\A
M2/>F^<HUS]V\N/!S;G0;Y]Z<SZR$3\#"VSUTS7_/K_-_P]=N<SU5;\0EO5ZL
M@$5J ((;6N=37O]VYM8)7MT;[\5\E1EJB @2:^J9\$F6TH"8P*=!P&@8A'ND
MW7>Y6R\IH_5)=8+6S*H'T_I2IN@YD[+?24: ]13]O8J^@CCE:M'H*0>H9N7<
M9>F B[!>.(75!A]TVM+*2T,L66O?!H>Y;SNMUR ;(C1WJ4H;! 3X;RM[% .C
MK/,;  B-TNTTH;,(DRU&J0ESO:M0P94,Z0[7_)\639B-)^H"OSM<LH!Q@8]Y
MS6.P<BTW;F3G!R_O4"_K=J-[9ON<F_?N3%(3:G[_2*QY6Q2YFZJ5M5HW56"F
M6MNQ;IM<6(,=VHEW.M]V]H+1;$;DW-\P;U]YW=G4CL]SOI&')LC;LN7 T:^%
M^L%ZVCTYK]="2EQ$0S- "\Q*Y[VQ<P>F'^(O<BAJ6[G)K^!?5AJ;X(YN[JTE
M!V5D'[ISO:\@A)/":WX+W&(G& U^VP"34#87\K.6SI\OE7/H-$:TB3Y<3>]I
M.[TN3+#!@6M7,PMX4,@D:JYI4<3R:O;[?]]>IA56@,,'@-/*!0NJC6B7C2-
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MTW/B?2D]Y2KW=IVABG*^NB3TE]RN/?E&M6U?S[[\;!=%:Y=UL8L9":,X\M-
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M +DCO.MYO1$5V=RO,_8.('33_""B:ZZB&IRP48VZ\W5?Z368N"I2_5_E5^U
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MP\A+,Y!SH(-799$N6U*#DA&V0[*HW_BJF)N&A-/.;4HHIU8UBZ?WIIZT"F;
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M("L;$&=\B991Y\LYOS'/H#IA7X!_#W:UU#?4/'N&W')G(MHP@MS68;''L]8
M@ 6R5ENEWT8S#P%.Y-OH;0,;97UV=*=(-I:'.?"> 49GA3D8+JW$-.C=;/[8
MO::A!J? V<)LK_8GM^!<7V\<Q5JNR^O:Y&O@:S8#*OI=62A&+W&(.X ( ,.$
ME:SC^<P'I33!%,:*/;87@,X\@P[=VO*MM&$O#<I6CC..ST[:LX]/Q54NG)"&
MDWM$N=_W[;7DFN;B/F__L9:]1LJ>U--0V1<]:7SZ>QSQ_=>+5WT:36,JK!BX
MK<K:;.*:;VU9G?K4R5"\M<)@2QM$RY)U)ITY)VJ?:\W<I8^D\XOIFA=83^^6
MP4B+UH'5>55#[U9N98DH1,Y4\%VERB\YR,S.FZU(3?-"R EWI27;8"@3;]^K
MW0R8LA03+(N&8X$2[M,HNW:6/2O-9RUMY78W:]":F#70$S6E-KY1X)V5_KL"
M]T<G5KU/[V=8<B,EKJ8<]F9[]FPRZNR9[RW1!(RKCIXK-"^9U\D<J[L<9J#V
MEBF]JW]K!)/E/_#M3:FDF=("0@^7ON\V5Z0.H 0QT;K@SQ>YU<]Z55H]NW*J
M;XX;^;D"@]598JX)*VB?W;QTU3%GCISC66/%P^T6,S.V5KZN&^72[-"WSDNT
M;W>#TV,]T8V,6.]Y!#1!E++59[+Q(YL04:&-L\74@-2<]-3?U?MX H%NI*[H
MJ-?<2*'?]$,@3-GQ71LVL_1#=E;[BE_;Z-+U8QI@5I-,N$RC(":!E)PP-U8D
MI6Y (NIY$9383&_'F#?L\5]Z6S;4L4E.O%X6RUP7:KX,TOM<E?//-I2\89_+
M9*<V8+&-'-IE$+GG'P7#""+_'GHGS7F)7A*3!&TP_XI/C9 \NU!JC@)I)TMB
MSG.7#HC.\>M:)E^?>*X_X:S]:2"I2JN29I7-FVSNW_@?OBJC,R%QS5A\((,*
M/:>-OT\KWVPQS?)IY[Y&&]HAWK1,5LYF6YVL%;9-F+'ZN/.LHZ<U8.\*?W7N
M'4O_G+A>8MAG]\+PL ),'ABT?C- G7W^I,K+(OM=E>>J!)">3J<+<&H_/E;=
MWO/3TD>^+@*=9U&04)Z2+(U#PB3+2!J*B,2IKU(6R2A*Z.XBT+=Y6F\CT)D6
M3:\__G[ZSL:=OW_C_/[ZX]]??W3^=?KI'\[IV[=_P'>/BT%_R 3M=L+W&8.^
MATR/YP\Z?U=\L?39L&<WGMR..N]&DH/N@V:QP)CM#G5^U.I/;ULX+9\XG4#S
M1A0TUVT*-J\O@Y@O<;2,,Z\_;B^&)[\Y<=Y?528N_0@.;[Y>%&!#%%\A2 #\
M9+G,N8WW:)]^\X;-<,X6Z?+,OQ-];X/O*<S#9'D7<]#<_*-/C'/Y-I,^#>L6
MA'@+(: W*\?T-_&QDJ[040"W$73T'7*!H>P]BV:^,Y3=PU!V#&7?!\G8-:OS
MQ@*.P[%<GHR$W?]\]Z0+]V,;JU.'M3:, R?V0:[HRH0:-?$B:YE$A^*9J*%%
M96LEM/[BACZN7:66G [0?^QQ7_@L8X0*);38\P,29Y$@+O-$2/T@9''PHFN0
M?R@+B+VNWFAD-H[D%?-\O9E-C9WM)ET[6_]+JOSS6W7.IZ_UO,ZO.Q[D>CW>
M"$WU@>EOXT .MZU"$@^E"DGGW!V"W;6A]&]MGI@$B P,M<28)$,#G8I]X051
M2-Q,*U7F^U3K6H^1A&O\B<@3;B9W 3KKVZ& .;]V[=!G@IS/A@@YDS^Q@CB/
MMC4!37TON&QH\*-1$#-H'>,':498D,4DC81+W(1*3]*4IVYR\\RL:20'@37F
ML/K4E.!Y;9W_6P"P=2[N&H';GIH-!X%#%&E)XKE4^8Q$;JC-!]_5YD,2NB3P
M>>A*2K51<:LGT2,PM6=%NG4YK\$H4EZ9<]=VJIL26OF:\]>SN?X_R_NTS'M_
M55=8K9H"&_H%+O0*Y5^4\^/;HJI^<NS"M;7M;$J:S1RZ&9A S5U@S28FIQ*R
M5+^HZ?73G/..C][_<=66"EM,IX.3&X)F:1I[DL0!TW(C2.$O&A*5A)%*,TJS
M.%ZA0ET+I#% /O!K*$GR096M1?.I^*BT]5)?<9J=F-2>TYEA3\7T$W0%L$-X
M7Y[I 4_5ZW\OM.!X7_ZFTOD;+3!,Y91/_$]]>X@S6Q<-TI*JW7"DP!N*--%B
M8;V]OLPYL6?_D%QIUJ;-HLJ-1[RR8<:-T9EGD[9*W=>BEA]PMF+B#QK)<>M0
MQL3O0IS=XO+22"[NV'5N!JA7VNDL-5Q>\MP$*\R=J8*TZZ%MF#B3BB=!1%RN
M(. I2PG/DH D$65>%(@@4?S%[1/D=F.LVS\?FU7ZW69F@HSGL^O?M:3["--U
M.EN[.4YG=N=T9OB>I\P[,6;I0#8-9&@XE9DQ1YGY=$Q^8CK7AD8]I;TZ5/NQ
MS7,S<81M>C44Q=,753_UZZQM6534!%YV9(]45\I$M#3A9LT55A:DUUI>(?]X
MV+1_5!7@0D-WF8M102DTH>JBY--!!I8F;I(DKJN@=YC0Q$3Z)*62$E=J"R=+
M9:S8K7+Y(!U/9]6\7("D?:/?ZM@ ;1UW\#Y[\6K1XM5?=RKG%S/3RD4C^4S-
M\J*$F*.MJA)O*T*3H8A0C:,^C6L+&$6Q2!7U(B*XEQ F P_LXH1XF2MXE%*?
MJUOQR:M .*T)TT?-<(QE)C7/A8-O."Y^,F %76"=OGNS#;+@A- ]"OJ-K?]V
M.M/@V'EPS$0X<K%,05H7H+=^O7[G4*)H?OV;7JIUP7II0*F7BI D<9C!B4-&
MTBB,B0R5D' (R[)P XWR.C1J5\O<748P_TW)(<FO@8.K64^4S!N5EK8H:&!,
M@7A3@%X?!CL9G*Z+J"?=U ])JDT);5,D&J612@AG/$YY[/M*1K=:P_!\!LZ?
M][-['TCLPPPPZ?/Z\E%8T<9T-J;TW5;SS&DWAJF4"WQKV<;HAL.OCM/?G\=O
M@\///>J5SOX 9C\X)C+(!R[:L7'GH@0(_@#2T?W\OCS7[[[,H/^@YTJ8/J[?
MB^C^_DMV6\)M62#_,;$5MT9J<J'!5(&@:/VVCEXB\[Y-R618];-..8I.(8%F
M'EH!S/NQK"T2^7*L\U)QTTVAB7U8N]N>I#A%W^V^A]5C**O5>)(W2F'$SK-%
M[/#!\8XXE-H@HHQX0>H1EL1<L^-$DM!+ BZ]B&:<W^0=W5 (C;?J8YW)NH%R
ML+HWD#F#;O^QF]._9#"G?]T:6YG>I-W0\@T;N0GJFM@=71>@K&D)%$NK?99\
M"I6U\@J*<"USZ_5#JB%Z?>+0BY7KA<1WW8BP4)MIL8@]$J6NC.+4C9.,KD;F
MU!%R;XKRV$X#@/(9P!@.!8N:?QY?E?FT#J;ITQAO-G'8('EK!@WYS'.3AFK2
MF M3M;,PI/),7<UK$DPWG%UI<2U59BH 0*W0-NMCV19"+_O- Z[)]TZX3.K1
M#)[5NNWKYJ9U?SE3.>^*VY*,FW3XCS?-CI]NVAWKZDNWXZQM&U.M[L[1FN(%
M^4Q".2I;Z^#X[,1A >U7Z2E+&\^AEX;J54TG@,,YK\M5VA'"48:MY%?74.I4
M?ZAQNQ3<U=+LLP4&Z_(P4*1)7VQE/E18%-T9:)+#B^F7NF"%*6T"XS#E=$WK
ME72JS.H"" SVVSH [<7M><%65+(S0E/BN"E<TM4ZW6F8\JL*$M'?SYSW8EZT
MN7VP%9OBP,VU8@JE/:OZ-[8<X\!C_(02 :5I2I3O"\)2&I&41Y($829BF;FI
MG]XZOGA8/!9=&^2WHX.)P3 LR/YL6?M=D5;KPIBU'GR>\@"[M9WVD;3D]<0F
M&U9OO67B4U.C(/C\IA'[RS."+;Q96QQ_K+OQEJWS8NDSQERFI934=-M7/L3
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MX]:7$>]@#6^N=8_.ZXK.?6M\^^W>G86H_HP[$U\]GT'^S>C'.=BOV>9=6'(
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M'C]C[L[NN1NKN;5]1BV/V<S]YIMX9<1T<P1?@\.'-]22='3TR2':LPUV7\$
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MV!TV-Y X/D:2@6;)XUMS$!9'$A-FN5!!I'"P*QSBRN3(4.&1*[B0.B\<$^%
MR=]]Q8+E<@T!7:X=M^^[W%V_G;X_S3Z5\7Z.$F:S;_1%_%C]R8_L559?[X*G
ME IU;9 PI(]W7%?8-4" CC@2':$D-X8;C8+$''&F'5+,%\AP[ZD+0C/+6Y);
M_NW]/ZZ-]LNRNBPKG;Y"?39R9\EXQ\^^N8IMJ@U*5U :?1<8D(D&6H T-0 "
M= +T+4%>&^P&)+T!$$ D0"20QP0B:1$D(,EYY(  (CF2R&51%+9PA4>*BH X
M=Q*94!2H$#GCQF@2&#EP!O2 $4L./;&'' )-Q!:'0.]RHWTHQWHX/=_PH8,.
M]UX? \<:=D0W='GQ02,<B4;0D@LLO4.<D/C#48JTHQ@Q4Y B8&5),"W);LZF
M9:0_?KRQO]L4!;S )X(1:*!MT=YN9Y"@R[8=4I1'O/A [+N,(O> #"#U>%3V
M -*,1[SX0 8;0Z)C3;:L8%X9XY%WUB">TP)IK!EBC%#!5&Z8,NUMLMVYXP>]
MMI"C!L4!)Y2"X@#%T5;%T2)&6B6N[!36.C!D"J80)SC]31GDC:%$4&WRD!^Z
M^W8_\>156F.@";>;]OYIF\R40[=LB]U2T<^/L&X1DLUP;$?_] $@ 9*4@ 3(
M5P(.@!L "9"S!"1 ^A)P -P 2(#L$B !$DV  ^"&]G #=+^UWP[ B9"0<^A5
M(0)P =0?;*/^(,\+ZS652$JG$/>2(>F)02'5/@HF*,]=6_K:%J> ORW';T9V
M.''>_6LP/M^X2@&O.BE<BA.!UYO?V<&=#_FD8[3WD#LZOC4'CM\8"=#B=G \
M@.F'U!"L.9A^:&A[U+^33A,J D<J:(HX5Q@I[1TJ&.:Y+@PV3+6WH>VP'I]@
MT.X&"4E0'Y!\!/4!ZJ,--K]CP65-?$&4M(A)(A"G7"/E#4-:1!UBE0S4MNQH
MR4,$E0M&H?,-$L^;))ZG@X!]!)X9WSIP\ABJ52 K#55+(":.2$PP8G4PN$ ^
M,!/%A+5(%RX@JXP7TCI*2'LRU3/#O/AYVVR9ER>J6&$R>__V.^2GP?)#SAIP
M  K@Z!2 \+D3.B^0*!1#7&B)I.<<,2FLH+G%A=AP.-\_]&"T\US&SC6! CT
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M <@ ;0#:8!JEH"17E%+$N%>(Y](@;5/?*/&X$)0[B8O6E5SL6"T0#$(!:BB
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MK5Q(L4@/KIS$?71MSNEIWDE^Z%75Q"YA].>C@P9(A[Y*!X<95=H21(5VB/O
MD:1,(Q^51,XM]:0=PRE2%>:=2LRSD=N1JF!$G@@*LR;:M,?;&57HI;7O58D$
M" $0 B $OBX$M+!8>YHC6GB-N+8:&9PZ.63P. @I.::MJY'8OS18MVRB![(
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M?Q?FINM#_$XOAJ7]_=D#WB?F/AA,-"+4%(A+0E-^4R/&%+7:>64,62_O,@U
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M8\:0Q"I'Q!-/E3%8R?5"15!U?Z"HT>((_1R?XBX6T&YX\ (46*^)#[GI(1P
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M</*48S=7S[=B"=E6L,?]L\? PI!M!1_NJ!@Y+VQ!I)((YXHCGCN/C(P$+8S
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MFS!J2E<LUK$P4:U)!:O3_?20D_-\"HCL"E2X34F;NNR>V\$28.0U,%I>9-4
MZ@B*[8;!,'A8,9<?OF9C53D?U25L\S'/?Q@X/U2 $OW#O??[3@K][*S^[M%
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M]:!%4JM,&] 8OTUK=X-P4B-5SGPF"PNX !  J6K0/QM)$S::#PRD?+%L=**
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M 4E3X1(J81$2S%((>1!3F;) TF1_MO:G7/T=ZZ4I>9;+=S@%5V:#P^[^6@"
M:MSXV][F=/UMOO<^YTUM<UT6XZ4>&B_Q8-/W-[QA^4NN-,NW>.5!R0 ,8K:.
M)6DFIR7$,S;[8NA\RMM7Q4F9O^'R1SS/="^2=7\NE2%Q[]$F&+)Q]EX;]BS]
MRXQB-K07_:B;85QHA?8BO M$_ZYW7R#A2TZ<8SV!__P/!_[WWZ:T /SCB!&O
M*N3G, 1,,$%B"%MSWZL*/+P9XA[5".@F7]1_5QS,M/=F$3ZCZ^\U6^RH:-;K
MHNR^,8%KWI2*_SY;F_8)7C*I'1R8 RH(KR(I7O82,_G5*V?^"3&;XB48?Y=
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MJ]E+P97J#U6*CFRW6ZK(.^J=F4@BT->\&,.6TF =%F5U2(U4]F2;F8B7J:"
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MM20\" 316BN?1XE,=+!IS;TA*ST:!$%LP]Y'(:2WN@V^U(7XG:0<BQYC/6,
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M-7XV+DKEC++?8?:=^@(&GQ<U_M#2B1(,E[%R)D5I;@?BO+Y0<WJ1F0#; LN
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M:K_[8Z+R2KUIIF%1K[R=-I/WJ_=KHUA^_5IL6LTX%8A$N/S9:Q8,][OJP(R
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M!GH8E/_9^IT[$/:22PY;?%(6"9&RB"@A*/I#).&<*:+C1'/ETH *;V.9!7O
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M>FCXS,M/I>'$\A]\-%6?56D <C]4!'U8K(P7O4;1Y.TW&":\-&Y)$"QFHF!
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MDYR?W&2XWB8WFJI1WN3;EX^<^X-//=YFWAG?:=YOQ_J$\5N(;[<$3#L*D:.
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M#VP?[@H^:(\ /  >&W-)!. #\ 'B ^ !\ !X'$&[ #D%?(#X 'CLE_>^L2
MP /@070/ SX>@X\OM(7I"E#V]Y'MZ>IN-2BZC86]*0= H6M0V-_W!5CH&A9
M+  4  H A4/YKP +7<,"B 6 PF/]4@"%SD%A;Q_4*6(!_$T[@X+O#8JC593D
M("6>CSN<#A[<:) /_OU%^6)+;+2MX_ J2/!F3?),VQK6%/3995/8(7+N[6C@
M-Z&F2I\NYOG3Q5+E&M [CY<SJGER1H'>>3Z] W@X#AZ>JM?"]J&/%BN;)V\R
MUCE@/" Q !> "\ %X&+K" D XX2! 0+C$1X/NJW'H]T8 8_'CAZ/1:TI<'"
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M?89--*$L*>+46L25L$@)&I"BIF3*.E'J\"3^YJ4&EZ?L;\8/:BIV)K "577
M9%5056U557<M],-! BST#L'D7A1B(\L%1M,)1B.\$U0(C&10$G'/.=*$:^2T
ML;K$-#AKCFJAWV<R#UGH8)'O;9&O2Z?O +>!U/F=N4T+9QVRXX]"7UJ(!$B
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MT(1PW9SNVH0PF96Y!]V/\YYS166S%A]F8W>>C-FZ-]TC^XIUXKWNOE9>5_T
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M9*9I7?K^Q.5FBL7T/%&O3^?%I;D>CP:#-$]^5KWI2>%GX^PV\2'V<WO-44S
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M?Q]_-8.PH5TZ7>F9Q;:I4,Y>O))GA,HOMT[O.J, C\?CHK:=4 ' %( I %,
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M4!SA@$EZ/9+T#<0))N2W1LEG2=-$%I/;5 SBME7YH#WI;($7BKZSHL< WG/
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M^EUS*JLMX.AL$EX3)G0)EBW)!X/\1MFYVA+6C*549H^S 1\/ZI4 %O>>D7_
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MUO18QM^$F/8/66KM5V])E0<<+FQ?O3@Z5'_ ,$S+J,^0C($*$D4,[Q[2-NG
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M=VD>PQ!$H;<SB6$H$(Z(JW8KA_NT6"=OQC* 8\ =09QJ$=9(&I8G#7^W2 !
M!;-@L"\Q:- LXT%4A"[[S(Z[X!B.PW;<P+8\8SQ ?N-)MQ"+@R3)@2LO!+(\
M YX]@><"+3>^F%YSH0 [ ^:#^ZZ6>#/DYT*ISZ#)S7&\)5Z=I<CX,@E2U<&>
MRX4L*M$"_QQ;YLD$SL QPF-0*$$^SWF +\L.9:H#B6<9L3T"I@.!2R1?9Y^3
MH%9T;GX\IE[SY/J[[>VB!3-,?*$(U]%L>G3JT%Z$Q34[P]?<10*N42#2(<YP
M\'2!]^&MK/?@$%[H?M9\GL#K3"HE=$<4$6BX -_X6B1"&3W2)PX2#ZRYZQQC
MUD.*S>BJ@D2U&9ES!IEIIG'X'!]^:"JV:>:)K=W]*9Y]?YOBOR&/\OXHWK>O
MYUY>W8W5=#NU-X6S:UY5AO]\]3D3[?KN<-IEL).X<:Q??1SQY7[^B<'/!^/6
MH7L?Q%QK?*44V.BHA[(JS:V>CA:+1OT"@2F5Z92\1;L ](D?9)\$"+4Z,2!@
MCNC5QWJ],>J'1ZI_20=..@13^N8>G-XCZJ#D&8Z,!=D&GK71Q-/>@^&=BWWV
M<&3#*([WC,=WO*MA,)M##!&9$;G$$*ZA_R@/8  >$5$+M4_E(?5QBO_SU?$W
M5M^ML9.SBV^%O7#Y^[=O!Q=_VFFBUAMPWW*MU.JS%J<P=]1HYK!8=XR?.;9I
MYJ"9PPNB5T@V*V;6^951U1/M)8R(9SDXBD,>'KH>#U]-[7XL_WWLP[ZPJH:C
M/U:9 ><#&T5A? 'C]%*9!)")@?0VCRJ2AO5M#$;4W[P.?[W?26J6Z 9><"&N
MI<X4[R4'PCSN,A/Y#"<&C8K(C@;.A)/A&VG"IA&/6QCAP9N; $UQ@GF:$CE&
M>\Q#>)Y%J0*ZA<L)_%?.)]6HT('R@$=EGS R4]0R2K\B^3]<"1"D<<P[&@;4
M_VN>"09 3.\KE;:V3*&2-<O2VC(,8]$?WDZC[U&544%KS0SMZQ*'8? :C7>U
M/4+/-?0(+J?@ZBORW=H.R9JCX*&F?$OH38.>78OHR5KQ2@;)6G$./8++*;C(
M6G$?/+)6YK)6[.H(,K!*N52S96?Y<(X?W&(0V[PU.$)*("X$HK4R.E[GEA)K
M?\D*@:J36%,6HTY(8931HL&/'+#EDUF5;KC?F%HQ<97KRA%@3CMS!)_;[IS?
M^-D[!U;ET-D :*75.[_Q#*X[$4V5<]5EC;UUUMAJ-.P47?+Q/''4ES=W5MZ9
MI1(I/>R^GQ[,R4U7'@;R".2GO@!*#!U^'O ^2?N?[VE*GGYEG+&I-PMA'_W-
MCB(E=29AD&<U]DDDJEM:H>U;,\>6H:3&_[8\ TYQ9)^GIW*3XH0IV8T$HGUV
M(T%: J3/V)P+=A)=R!HL3!27S,'IC*IQF9_G+3XRH$BHR8 B3,F 6FD0R8#R
M"M*7-Y?L6+=>AJ4D18L=_Q!!;OJ;G;5:,A#*]('#_<Y,Q\0R&K'/6?,Y#YT7
M7?=;;L:0"./Z>NC52/'2]$5F97EU%XL#-O5^35:(8F-GMU;WJMQB)>MGJ(;4
MAYHV LPQP*B&U ?XJ(9T;H^0B..(@4 %ME1@ZYA#MLI>-1785EY@^\N6^:'J
M6EO+*2JNKKVTJICV]\N#TY=MHSO!MOE7C7V1;:MH-$W!,94=TZ2][) J5<WX
M@RF!Z &(5#7C%:149+Q0Z<QEKF$,P_8=&4HDO&0H$:9D**TTB&0H>04IE1<O
M5EY\(A.>!+BO>K^\V)V*8JH>7CX1G*D47KZJHKT(O"JGH;T(G$./X'(*+MJ+
MP'WP:"^"N2KK;(.1K!7'99"L%>?0([B<@HNL%??!(VME+FME-=8!4)2?LF_N
M@FBMC-+2-"^T+BW/]L$.(L < XR69_L '\V!7LR!M )Y3I"+%<BT!-DJ7/UW
M*6D),BU!IB7(E2Y!_B:#2,2"G7#5%LJYM;:6)VDIU.GSO$2+1SS"E$#T $1:
M/.(5I"^_>,0BPV_Q%21/VW9D*I'XDJE$F)*IM-(@DJGD%:0O;RKYLL[V#QF(
MA_UZS.X]Q=+;@R!(\R2#$VGM[:R)P-F)\&X:(KR937'TK,B%F>Q=!:JC(C9Q
ML%S5IB#^LA/H*TZ+#TW%-D%8]AI;N_LS)B,JJFA G?[S3PQ^/ACUC@OJ@YAK
MC<BD,(T=P9TYT%]-,=FN7<FVT.Q4W &2;9ZLK;,U+91LK=F=HYI":\[P:@O!
MTR=^D'T2'(RF$P/".;\6KS[6ZSLCV'V(5/^2#IQTJ 2_N0>G]X@ZN*8,1\:"
M; //VFCB:6 HJUSLLX<C&[R586<$'M_QKH;!; XQ1&1&Y!)#N(;^$\(Y*J)>
M$-W!268F$Q5E;JDY\W$^P?G9]^,+=G;"#JZNSBY.C_^TCWX[QO%9;&_*2JL.
MOIR>?6<'7[^R\^.+R[/32W;X)[OZ='QYS,XOX/?IU>4ZRR*>,<&#B'6$TFD"
MJB;5@FE@")[E2C#>Z0BN-&N*.+UCD5"BV65!FNA,9GD&0HSN&IR4RB33;'3O
M^G4VV&IRG8'ZSS)VD-W(I+AV.$:^;HZ9 :4M&)V 2[AFD=0L5?AX,R.8DV)^
MU\ICQ@$ZE8@N@ #D# K_$>:+)%MG=S*+&)P4LTYZ!]?"+77>+(8NX67Q5/ [
M!PZM RZJ>#Z *F]EF/,8_H13N\6=X68!!RQE)H4& J:&6$/?\[9(0O@?" )?
M9SCX@R3!&UV(3JHR!H\^ >@ Y(TOQ1O#>2T)5( W9AJN[XT=[R9^1+(I\5Y(
M?3@1ST_Q PO3("^> R,$4!(1F/<R9^(->K?!NUZ*(%=FT.8&QS^"B"?7@AVE
M[;;4VKS[M>*%NPU>-[P7E^$]>?4H??538 U0VYR89U$*C^WB&X;%V('36OCV
MYD)SAUNA@'J]>P.]8 1*_)5+#8)CCL&+":VQ\!%NTQ1PIT0\_\[ ,#B,KL$2
M20B\::ADGIZK#K"X-FPED*LT_--&@<(/09K'(8X4[EZ(Q'J?ZQ7/9*N+@\/[
MP*-;4K7-1WB$$:0I*(8C E:YIQ=\1G0>F UM[_K;??W J< ,;=[M\3N\%0P.
M!\IS$-0!<L (;Z7*0#IPO&FK1BIS9I5YGBN=@PP4<BL*+E2BD+$"LT%!NA>B
M T 9OJZ_V]XQ[&<T@ C7"^%7A=1''-6H2(S"$"$"AO=KI3&H5N2C@M\TJH>F
MB'C<ZC_R0ER#6D7A1+;$(P\JJ% 'Q=&0HT9&7@K@K[!&#%!!Z[;"3'J)YFVF
M6=LP.<VA)W9WWK:ANO_1BINW6[6WU!/%G14WPQF,/>IGXQ!VCU=+-4CT7()O
M6/3>$7+.(/=HSFN .4."-_\JQ16P8YZPJM_4_(AKVB.6%=HRA)_S]@Q!Z+)-
M0^@Y;]?X#J&]MLVP5$ZP;2; N#<=BB]6) &43M7[_HKJ_2E&OTB*\K*?([-3
M@*NS@*:$O3+A+1]F?ZJ.Q]I)),YCQ/E*9K$3HER>)46";"O&$^PM$N0Q@HRM
MDAPRR%XZ:;9T":\T(&Q7N[-'48SM>JU!V'J);;WQKN+ O\?8VJN<G_>6!VI#
M9FOKM=!P2^NX518W6=USB\VX@*72\8R6QHX6TE>'K4? 3B"DI1:]?RFH2D&V
MV54;ZJKA86*JVD:V4HD@2]5Z;XWW\0\1Y)F\%?TEWA-J5JLBJ:OTQ.K?A[7S
MK\^53 +9X?$H87^U4YK\3A.NK)*<*7](!NP3Z$[N]6VOWT1!K8J6B1*M' X2
M40#07VPG! "7!V6929M5# '25+8J(DSJV5]L23U[JIX'.VE2>J94[];FWC=6
M$*CR_-5@ZQ3*%LU%QF=):$VDC/)$GH9 *4^T4)87LT,G,N%)('G\9 -@2@]-
M).- 0FB$EI00\DUH;-:&E!"BA!!%T2@A1+2RCU8N1/ H.NLOMA2=]30Z2]/^
MJH@PJ6=_L27U[*EZIN09)<^\#)5@\FS,YKN4/IN6D!-V,+8BLD@)-$]#QI1
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M>GH&%D;&"TQL+&QLK"RLK.P<W!?9.;@X6%DO\E[DNL0# H'8./GX>7GXN7E
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MY'@@R:]3SU+;I/X8G;RV[&LB\&VK7*:[[Z:-;)>LPY0MN)$8=^QS_KE5@6A
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M@\;LAC@6HJO8\A5*3&>[.=6$22A2TJ>-\G/&GLN0V-KLT"?Z&'>8N^IR@&Z
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MI"9/"N2CC*"_B6#YIAI\W'$S!4C-(,11 ,=7X'>H-O#2>PJP[]%  8YOV5&
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M% #D "(^(D^>07N36%"1(?). 1S9-X955E?W2Y6S.2RX:#2A;(;J2VQ6C!2
MS1T?38[D))7,4%OHK=76 !PGEK';&+Q+%L=]_Q[Y]EF%7XJ!Y@-3X^^"M^SR
MU/M5^G59PR+UI(S5QLU#)BW>>57R"9C4\W$)8$SG'<;D';+D%E\$'UL3H,%X
M<2SYK5@,NL:O[.T1ZPS.OU2_,]UWZQMMV)ZIZ[D>ZAL%F D_3F@BR&$9QNN
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MDF;EY^BZIH05S[-"D)]G^YQS7E$ MZ<8;MN!9$E1&@Q6/&P;DB3"&6)& 9C
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M^]O_O[_]?V>M\[SXO Y@OY>1EP%@8&  ]Y<7\+P!Z$B[6YH!@)(2P @  #*
M  <#(+P<P;S@/1S</WS^!<!'['\\_LO;1QP _A^_QW7^B/M/QW_I!\"$9@-
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MB#G\^9!UJX"9@? OAZS_#@S6%"4[)XC.T[:L65FV(K9;6V:&Z:9^YY"\/J2
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MC?Y>=J'66[IDI- 2\Z:TRD>(I2.5(IHKG=4G;%7TIP5L4NRCLK>N6PD%R'G
MFM1.YMOZZ#,0BH^4H_E2#)18DICHB,:#BGI'1V!!K"OZK764CO+TRW.0?^<(
MRO2M"#1X+U7</.S@V0'3!&W8\L]G?*]FSE_"KHE2Y3YM.@="#*%JK6L(.KZ=
M0)=13WXU.&"/C%'GG2'Q!ML/WPU'@6R*MD:PW3;GQ3^PBR!G(_VU&FAF/;X_
M"ZW:+'%NF#&: <=3?W$_.M=;&G[DE#F<D^AA8'=CO/RUC_<!":/T3M-@_MI$
MMZT,F7E3/H=P?F!@]$SXC7<)=G0SYL!E>Z"ZW </8OL[./W7D"</YXT2K6?
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M2]89\YH_4ROW/E:NU:U>T!^&ZBT/PC7?IY=P>;1JD49);8]7',8%?HF3X&N
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M]^&*P<%VY!@Y<\5- GEEWW!;-:0LRNLD&T.'B>)FK5]MI6NQ041P?B8ZY\C
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MIQ\R6.J?YJ',68A*\3*6\E-?!D4NSOK]62R2H,';0[=C9+I".&@AFMN.;X#
M]]'C)3KD.&VC$=8I@I@(5#RQ.PGAMS2B"ACU\O,YK] %]9#S_"'AJC51J</.
MUY]^YO<9OA3G+V7M?N%7"OTB2%,U#^& F9GMV>FY!>7FNI2-*NAM_0EV\79
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M0ZV4>N]@:Q\5$*)_N'SDRD0]X"^M*G746^JQ'VS#:4:@\'+24EG<!AN"<R3
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MJR"@JG:6!QQ!X<L#G*R=B^RNBRH:M#VJ)6#[[!VY*S^I%*'T3R,-3HCKI4H
M/'YG;XA@'B8*LS[ISB?:N1P)\,;T[8(L0&(-?S![600=I<^B$FCS-TCU_'#U
MK.9KE@CQSN1:ZD(T23^'(/V)DG#$.1G\F6! '#M8(97CS]8^4JI_;_JXH,S]
MT<\)9ZIX&?\R%Q5)5+/)$$AHDROT4QUW<_U'<V(23\@;8$LW^\ N_^1)]S65
M@_#,'U(D1?;%NW31*-$V,]+3!0>XX\G3,X'E[CN$]A.J<^=DL4#DTSW&&4'R
M[124R(?YG::2AO)G\#COM_FD5]R0_&^E%DX'^-SU%6:X>6C%X@Z<ZMCBF,"M
M1!).QQ(;);ZO!K QK8_I.,!!<T_\4$Y2I=NUI>N!:=L;Z8HU#RUQ7FEA(P((
MH GCV62"O"=EFTD8^_#6-:9_>G&5T'JWICFLXC0K4EQ'FKZ>"FI*;$+1ORPI
MA39489CC+[BL=>]1M%81KC3N13>C(LO&)"X0&;@4X+-"8HS.*M_.8"1Y_MJ1
M<XA_&R/]NSW:JTC>!W0I&+(!RG6 4 #%,-*$KP;.=UN(Z&"'K%]QUL5SA=-=
M$.(]F<I ]75QIY>7JK\X_2$#;6HKN(KIJ96+U*<;)_O\(F&MU/E]%K ##KC]
M9=@#IE<CKO7<GP&#<=79W?[@%0  >/5^PD\"X+#&<9[_!@BMTV4^G-8VEI'1
MWC=^SP'S]?S! @+;*>33;-JTW!'"W[8*8?5I'N?^T9.H99D^WKFR/$H#!\%8
MC<LRJ_@0?L-/!\LCS3\3\6/>:&:3<7LP9&Q--BP@?9I5MS?M6K7SYDA+Y3]&
M#9R"J>N6,DDTR6W9FI1'8*BM<8 6>$#$)73PT--SSN]>TAEHYV++*<0SU&)_
MQ_82)U3#R@??SSH@^&>^# >XY^G6(Q/QUVD8>64GSMB^3M9(Y/Q,_IFX2N G
M&*S#!X#OWK075M3U>Z;F!S0T-Q"1I?Y9;?3Z]3I$MO2+)'";P"C#T4HM'%!D
MEW]P&R=%4Q=9RBX!:(C,#5;)$_U#06&?=7N@I[OE]STEJJG@J,+.PP*AP*58
MVL6"TNV=02P6&9^P'D>#(.QPM'*TSE\1'ZG<N_A5'.I1M,RZN#;(+'^NK N9
ME=P>5!T'L4N"1[\W#$HM\/8*TYT+MVQEHFM80!-^![@YX<9 5EMK))CJQ@'L
M_9MRU[Q#G_!CV.7M9/[:,,[Y0CAGF9=Z^PRQ;-N33W!=\827&\B1NA?R6U(U
M+,BXWJ'1^6A,O>'>PC4)JL)2.H2>G'>@_ZW>RCDR/TYJR\PDD4<5%4! */S:
M'OG7B'<S-\K<ODX_"X#4N3D.4X I:T 0I&I%JV,8]Q<EW>8G1]P0=5(T[7.Y
MH"T!-#?M66^%VP7\I,IER7BM>L./!"Y=<!_7QW<?/CWWV/+!-OY=WP2&N2_-
M^5QP1H Q5"5%M32/YO@2;,:*K?WM.YWNMH";QZ_.\;4YL5:4XM0BSC> \,03
MD:S7D_F*1_1M=-LN0;W-\MT;(-IM]97D2B_X[P(3P\Z/U&>LO87@%K@9H;9)
M7F9L4HZ$NQ1%.A44;N/"(34VK4Q;/BRZ53/'-C:T<>1(D?S:R5"5^BO!;MX8
MRB$2TCP8J0*MFT<ZV!&I'B:M$?!L+0/*")_SB];T]-KN[F:ZB7]W!/%/422?
MX2Q_3=?X%=43JT[/](5(JOG:(B9&$(8ML4+@H?DI$4[_O4D$&LGPLCKBQTG8
M&+[K+W2P8\YG "M^UX1-NM9E0K.I"N:=1GV^*3V^T4R'^O>-B"280(JKM5+W
M#YWX&<3M-5;KU:,ISMC+RSH1R\G&L9J-5!^$=:C-"571XB<A3OLJ_['Z5.$2
MP@#/)W+-.;<P7&#1LKG8QAU/Z-@B$G8^%[_@ *---EG0#AH<5A?OO:3KFJ(%
M: .'.5T&NWJ L5U458+B&R9S+DMU&C:U,F',%!K&NNKRVIF,Y:[-)(&\O R3
M&\Y[0G_=6O!F!9+Y&EYU")-P][1 PG<))JAVGN/82B(]HO(XOVKB^7C@8\%M
MZGZ*E26P-].*.S;9#3VR@W"BW4HI''!UAO,LV'A!VU*BGQKZ[:J40H90S(X=
MI3 ]7?\WX,%_8P_N0I6SXX?6M%\W!_QI&6E9^X^"5O"\@"YT<YQ@2R/\>*D3
M9 :Z/COXJ8"8UK/AHX4!U[49D6J#KU'9T)R@1GP DO0RU.C]7)C9DN 4%$Q-
MBE3H' WK'M$ST#VC-?*M4"9/\Z_+25)W_"SBV96@^%WN2Q:QI.@&.J+8/V9,
M%>E9-3QPOB_GXK69NO&H*Y,X\?C&1]X,#LI64^4=<AB?=,B(^]"SJL3$HUH9
MK1PBVURKU1_O8)]5/8[DAIU#3Z>T\3(^*L?;Y\F$ ^RR:/X007L?AE"W!32<
MQ[M=P%K*3]N5]!]4V/HTF!J"X_]I[[>/G&G%^9UBRYRWLF,*RP^63'6^VM:V
M]'DK\1TX.$,\BA#B=C5R!:M9NBP,CEEADL.KPQ+?E#3\]]"N F(/6\T['7G+
MG; DP(:P9Z"<G,, QR$9_#P7*;E.HK2UT5R=K"3T;E!3IXNH6X'>(Y4'6Y5=
MV^#/-HEI&UXXX/)!F'!MS3*IP^J)05-?OS[KU 4EQ\#U*RY8I=2ZZQ&\WM.E
M]ZO=FVFK)!.PZJZT>6U^LCVMUCT/_I.0HJZ  _Y3B%4^*:Q \N?EE-4'X:]@
M=94W3RN\"O4G<,=BHC9KJ[/SO*-KV%@RD]I]]1=P3?U@+.WL2IIUH!')@N)D
M#8:E9SOIJ:QQ#K'IWTG,2,@\U;.F1,E,7,[W5.=<E(O6=31[N-9R[GCLNQBJ
M^_"7(.^JJA0T*\5 P21/3H8]G8\M4@5])2/F%-.<'LXM^I6#8S2#+BIK7=W?
M!11]=2J'1%AA_K')\Q?8K[-UBD16*1([]9E&FY+3QLM&]L:FC.&-:A \[X\@
M21)FX(K3@-_Y!'B6LP-1G+NRM+D^F[*E!9UU>!2@2EV%5,BV&*0;^5]U ^7_
MIG]! GYYTIAQ'CHQ:&\+7-/^S0 #WL"G+A<*D1+Z&Q&+U<@8I[@$'H[+[&1D
M 8[+F^Y3@9@DN=7!]NQ-]&!"LISR]0,USU3MNA59RH88&3R0"72[ \YI>5_#
MV1"#>'.,7"&ZMSF-??]J<7\Z67C&RHE?WH8C)O4K15R7[QN 0 (0T$#]#C@E
MO<V$($2VKHK?;R60Y+[AY0[Z-:SLNE4<KA%0%;7!%I"V]=L.Q[Q'I6$F>-\J
M(E@2DF<]E;[Q$T&4&Z9+6@'\H=Z1(2[B\P)G&X-T4\27N,O=:9O/TF8D%R6X
MZ:NQU:,XT2VQ:?X#@9+T[9F;:%9?;43 3_03MC0S'Q)?3/296:K[PX]J8QZ,
M,/MQHC/CV$3)HI@Q5[DJ-07[Q"AI:9<"P03>-A^"8M"EX*(D3<IA^X1QV^=;
M]9C1 G4.RE,\9=IFK$J=1J<_*CE*+NA #(*B/' S$0-=S&ULRJAJH@2L2B(B
M&/8CRK%[3F0YW0'7EW=9BC/C!UU9&/+%T^O+XCYV)J!L6UM5*-VY8Q=;XROQ
MCST]7;L-&Q7Y$J:YQ%Q0$N;J@.#%JM:G)/.SGZI4'-3I;;\IU0EV9-6B.YLW
MZW\<0P75U%'0<^'+.C'[:#I2<0P_N$0N&=%\#[H31%NN+S+-PC JAOIF6Q5K
M#'B9L*3:T;H*3S=U49R+"HE5,%>?FYRTU3*^DK9FRD0]T&9*-L?U>FQ\&FDS
M"@4)"E ^I#+5@& 0W)1[4HJ?&6JGH*.IA7F1IXQ:FQH3V..DF^SO@]K8FSX@
M\O+"32)ZJ=3I:O6(3Y]R,<D="F@+N*R"JLD UZ1#0@"2.%&2A5\Z[@BWKP)3
MM $XKC8%A_I+M^R"4L=.X"D/>H!AX9(F 2Z-NINB;D.XLU6ZT>;+C7^==KIL
M[0,VD%*IVS0LGC+57VZ7<$)2<&,2?GD"UWP>_\#,R?F ^E>7@QVU9(CX=PP*
MI5"-;6"H8+2BXMI]C_C,*2AP]U3T FST,[^VO H3)^ZX^!/+> <'9IND.^_X
M/$*)1S'48GI?_<I\DL#$@RFOH??R(RKL68*FT2<@Q4=F25X%\9U#3^Z:#T'J
M7XDXK];7&9.49- .*1I:8I,O6!GA8C_Z!KE3LM409*$O/.G+ORX3L;9 #B57
M5E[22"I#V8N,]MD[46_V"+OZW)^E<T><C*R3II+/H!)U$7"<&7HG?U#-S*$>
M@F2L'H2]L]>12NN]^E"HR4^E%32\4]K8=Y(T+:9!IJ=.@Q$5O.\0LXJ(>\@-
MYP3IK&UB<V8BI)Q$ADL5M =#M5N\Q\[NPFZRT'P$>CW52GR8TM-[I#G%HL=0
M<AK5H'V$_IH 6V0E49!981D2,_8F8:PQ4#=7V/CK#WHP+RJ"% E6%TF@A ,9
M\F3=&+Y"R-J.G5%U?;7Y!ZN(+DYU]A_Z3)NRO?W9L,8V7T\)426M,F<%X8OU
MI<I:H5^=ODY:1AKH@8<T=YHM*$V&'K0M!FW?_8% 8D7)FE3+*D[LF)DW&GX)
MUCN&FBE@#.[@=MX]:,J3U0T\?SJ_F6_)UV#4LF[^7O\T&$I RI, \ AC4QCV
M($Z86^!3'NK'OA=0_*'0FG+6XZ ''2KJ<7.QPHEE7V=9@B&_B>(Y3G7:4N)(
M[XP7)2M3=5Z57%"?L:DC)O1>UO[56R5=6[Y#3;'A+[6MYY7CKJTT<T,J=",$
M^_3)?7I16P^ECWQI$+*\O2)WY>])1WE5%PK+E7N^T-.<&7(]6S=7>F5O0]&W
MS,_Q&_-C XB\&8*"UO$179ZIL1+135&:7X*3C7U0R_!30EBR)%"$#19EIJA?
MGE36@W,-<=ZL+A%^JK4D/9KT91U*_08(R^6:=60X7Q)0U-FY35BM<V0HO&@(
M*:^H/4(1PNMF0ZMK^R.#(T&MT0.5(0(@ ]!&<Z.2C^E@Z_^7L6K2[/QLMT;7
M5+U-&%*C=Z<@RUI(&=F(*!'HVC''6C4?$2J](]*QP=3^C?DERK4&WA1]JFI%
M\J1IB$+-6 ]VH>9W:@3*]LZG(NOZ.^[DJO@3=@$.:?H69M5M@:T1TN]8W9.(
M-2KR_#2]"KCQW@'AL>]Q"?H=.[_)"\)(>O3;6X5.ES+7DNI=:;1.DUKG23V1
M8+6:U.ZL\4@B')-S;LG'\U+;F11XBY_?EI1[B"S5]QLVN_P!A:DB>0B6!<7Q
MG]AZ&?H+%)=8%$+793QP:UO6QOUJQKECJV6+[_\X73:G1?%5\+:>J]2GI%]*
M;8;>8&#X-.7]D [>_"Q01BW/IKBD8B@1XQ24M +,%N3;0F&2T]Z9RE"D&>O$
M''"/&J[67.XG]H:@T+G_PO8U@ISP96& VV:9G&\"RO,O>Z] 6,]YIZZ\BIVG
M7M=%3.78AU"!T'D):1SV,$/S1=C#4MB/MQ1$E^D<72E]9?WQMVU($QYHX^DL
MMZ$9+-?N5"&@.-@K6UYGU^[  M?C/X;)V?>(:K75,WM-TXHN#)K.,7')U"S8
MGU5TX U6T)K@,%IY]\(!-X<,@Z\D$4;;Q.9E)R=KAR-?FJ*5.NH;PTV:T_="
MPPCZQT)\HGR]>>",4-3J]&'U)M!ZWP!+992IVAF[APP.UI<KRS%;+#<;_5V:
M0=:^:;$A?0!/2[EH!T:@\3J!4F]OEYP3A(W :(#B?10')#RQ-6>ALSFM(<7;
M,^37S&)I(JWYZ2E5*C*)FUA")0[W.C=7IXY30 QRB999X(V5\70I=$ZI?^/[
M'.9PP4C4FEOB"@"#,@B.PED!N)V%^'O.K*-.5HZ4+Q_FU%S/.1J1!C.G:D(L
MB.KF*(.?Z#(5 W@XM7RHN+9XJ"S/U3+@1J^S)-DP:JJVXB^I]4E5XPV0AQ79
MAX'>JQ;?Z3EC,=+0,\74-7U6NF4^RB;X=;I_*A'F4Z$&LAR5@,J@/0X; !9*
M5\'<>H[VAW]LKC^BH,=PI#B,L=S01)\*KXJMA1E=E(-,=">:5\@R(V&#X<($
MK?918EIT08W)#7ZV/D.GA1!22AVLPMK594:S8J\>($I6:'<2DM?L\=.G+)LC
M]-QW@U)Z0BY/97HXYM/E<)>1!..H%W"(:Z\=^SQA+6(KPJOIVGT[A)?%(,J$
MC9R&Z" #=^,/2Z(]@,29M[BA'7W6CFMD/EY2FB;N\-3"A0\$B2BQH#".6H8[
M$]#,?=" (U/;< H'7,MR*-?-<^[;'4/*;-A/(_.#MQB%7!L1$:L&J&/[..3F
M&>M,UHTO90B5NL51BDDX*(&A@!C%:H[8KGTQP82[D'+\;C*\*GYVO66+L??Z
M!W2&, :4)M2HG[B7"/7A-D[&G2 ;!QEH"Z79VG,SW'H:4#&F-'E'B);Y:;EN
MSFI&&<ZR&YF(QT+0W[W'YZ[( #1Y^G&JV%B5T[91)0DN!N&V(=M4N3,W*+I*
M0RR,^5<&CL,5M>5?JI2[ #<(K3VOF#9RTY<?F3D3YJQ5H#(^YA5X+'G(3KOI
MY5UR-,G&/3$8152%F<"C,;Q?'RK;A56;9)P;FFI7C5B@QCXGC,7'36J0LU"\
M!SY2.MBEXEJBX+*^F[F?2J>-=4M[M-/<IX1Z#D&Q!WI&+AM"NHF7/L+C KJ2
MISXZTL[5Q34#'#6?"'_N66P$C$\[^5O6[04RE^=T>/DARQM9SO0PU6=$F]&7
M,#)_KV5<4Z;=_8.HMF=/&=:)6*FHF0*C)Y:C =77>L#'U.J.LXX9#.Y&Z]+\
MU02 F#0)%Y193/Z_U3]'I-QF$E=KF',68&+7E9"8D=_]G5;?K_;.'T(<4 GP
MO"M=SL0_Y$=9%:?)R/:=O]"JG?#>AV^,-37U\!U#L8$=>0=&;1/>'Q+J??3Y
M>U)EQU6VC77K?]JWN$\);#F"8H]4[%K9\@YY'%<GX$I<6!*UW&U-0L0J>75+
M(>\NJ(,"V0F"4@"CT\^:/J5KW?7\G(Y+Q:*VN_C[8RC@U%?1K+SPK'(-WO%3
M8)_!T 7ZY>,K,8.Y01!/H@2S3;[%=@;AA\M%!/<$>1(3E"@Y8JKFO'.S']N-
MM1D":"%SU. ITQC)SQZ+6D++NDD?4#MCCQ2UW#%Z7)4^G6N B6#)?^H=FBU2
M&UP4K@R\*V7'S]J#C8]!M,R@]>%0?QWG)C..>\D\+J492#/^F9?9,Y (<%J@
MF!=.O\"J(Z^3?8FYO65 C5M>6TG^YG]BD#L6NX444!.CF+?!XPT[M;K?87-!
MFUD\1D]P3!TCAAFQB\T+'=47XKYH@(U/RP 4>F-LSMRF+;)I?W<VX<%.@ C8
M.1"LAE9WOJ^QHR";!4;D/HNVSMO96&=/83$;MZ2LZ7-O@>?92!S &HC!.CLF
M!/#XL?M.ZBX5Q-+Y]]%/M N2+>V7<1^9]9!^NTK$_D++X4V7!DH++"%F"VXK
MRY]G1.2OE>WDET;8D_ZY(MN21G;]+&G4%"6M,0.Z=,C(2_'-W_0A5^N065Y6
MBW-!*K >CZ JL56-50T<A'6$#420+\I"UWT%3=CA).'S$^"--V0:L^G9>NBM
M?<-24_*G,+5%UR;M4VJ^&*_)LX0VS3%U;(^.46F)V?]FJEI"KG\(H1A%@1W'
M"?0*"#_6[R9"K3^RH\V(^U3BF$VZ%,),[-TF+Y"::;M8_ 8X#[BW'^ ?,N'\
MO0&F]:B@C?VSCO]SR=1QX./ES78=P&1@._*+KIAS0+9VI)9T@E'H>N:'$?.O
M+5!Y!@I_)"CF513XCW2)>]SMU>8*T5A8_-?FYL8ZB)%Q-)+7KVV[UGQIZ$ 5
MKIWNN351#/8B)UY2B$IL.>A]#5JHHBO!;F3,B2$[<0R88BY5'NE@RIU_H8='
MV*0O#9DH$7VRAIW5OC,;7FX#J6L;!SAQ2$8W*TA>O'+0H+QRE&%M+VTZW8VG
MZD$XF^N!15).S?BN7_L,W;WO2)[0,B5BN<=LLTEVX:=I2^"N:8.Q&$LBJB&X
MRV?1E/B[-S#M?4!A._H4?'I?C?;$ATPJ&=#TFBSH:>84BX,OUO6V!]5XNVC4
MT9V\I[K+#D6C(PG@$.!$Q_[#X)B&LH:.D5W\=&C<,P6PM[YE559>Y-D,O[P(
M%7=@5#Y.5I,'Q8AS?*;67>2%GLVDD=%K9Y):)MXEX:GS@[A/<"=KXLS/O+NC
MSCVF*I4)5O<[8X-F[,N:_JKE4LKQB,%H@P6CHZ0MS6*.<C(W\TE5HF"<_WNU
M4V^N/-T56<';U#\ISDVQK0.$L4:7L^=>+ 0']Y.(I(B]$2-"M -/4F 6'R\K
M.Z%?(6H_=9#9V;=X(ZA1;>F+MV. @MM6TA<^MV7%BXMHR"=ZYJ",C57P!<$<
MZ/)5PKQ'^#A$MXM7<.-"+?O\PP^F$Z)Y!F0X$T,)(Y>/[HG4OWIMM9V_28-L
MJ./D/=M^WSM)3YM&63'H,VMLN0<ED_XJ:;]=T4@?U8X; &5< V-+5P\?]<.N
MFZ"O=L<C+7T-[JV_6D/G8HJ+!(=-+-@"6?U)L/JU!D+J2-7.-"_0RDM <%"=
MWI@!F.>JDD_1#1\217@8'3+%)G7C>_B_-G<?5ECO'AB_-YJ(^6R,4@DV7*UL
MU$'K<^K<"U!3!U?+1#1M1X%W6A/YS)R39ULH%-HP8-]E!701(O)Q CW_"RZ=
M_U<BC+>E_P%02P,$%     @ C8%<5-Z[<I,6!0  RT4  !@   !P86-B+3(P
M,C$Q,C,Q>&5X,C%?,2YH=&WM7&MOXC@4_=R1YC]X4LVJ(Y5'TBG3AA1I2Q_#
M%':J@7Y>F=@EUCAVY)A2]M>O\T)0H 62#J^TJAKBY-KWW'-\X@"Q/A4*WSNM
M)D#<[KN826 +#"5&8$"D ^I8R&#G%?%MROV^P* %&>SA\%##*.K%<M$H%&H?
M/U@J4CT^ES,3&"7CK&24#0/HAGE:,?4S<-^*CG2D2]7_ \O!$ 4;!Y8DDN)P
M\^#ZV2%=HJ+K1?W?#GSFC+M#%4@/#RR-CK1*R>E6EZ-AS4+D"?AR2/&%YD+1
M(ZQ \:,TOQF>K,8[!.DY\1XMZMB;/,4LJR:)GV4!4M)C9GA"M<L%PJ+0Y5)R
MU]0]"1AG&!Q>G0>_H$H)PP4'A\'U<OES]9$S67B$+J%#LT-<[(-_\ #\XBYD
M49M/_L,FT%5OT3@.K&!W,A9$?(_"H0D("T)'IPRB^%U.T5B,((3*)0'-*@5-
MM931 NBSB?07Z_I>-8X5%=!;"'A;$0R+!'G)O8V$O=EH=\#/&]!^N&PWKAI_
M_VI<MQ=)]FOQ5&53COZBM E#*F73")M63\U8(K4X7%TAWA4DJ-;A\\WUS<W,
M>HVI:T"0=,)A:35+PB[%P,:4>A APGH76ED+7_L>M)/785$OM*BJ6A(HKJ[-
M*86>C\UDHQKUH I5+@;)C\NY/-*NFC5$M*&V$'B*^XA4JDT.]O1K&.A5.L6-
M82]S6^?. 7%[-,-,-R>U5,-0"<10C2<S1Q)+$6&R$_Z$Q2/E ],A2'%K@B8C
MEBQ$E(CRD: G*9+0(YR9T:+5."FON1IC^"<J!&?%BLIP L(UE&:"$0?)]+D*
MR'HE!SDER&I+K#K5+"SQ$39*%2<O,]9//T_80WS,\D:7WNO:_:Y/$(%B"!AT
M<183P'R&+$&* *)UX/&C+XB/B"T)9ZG B(6Z(ABC8V=<.+QDC[XN[G2&WFN$
M>4MGKA(PQ;-U%N=:6=)8-TAU$]?+2]KK3&1B=:V(S'+J&DVR(!LKFYE0K)"T
MI<Y"(1GD^Q;;E57OCJ6,D_M>K0<>B0TN"?=M@IFM.FD$"P(&@TD44M!LUA=E
M_C1*TZ:R($J5XK>9Q/@#D%QA"@=0+.RFTUE/N\=V^,4$"ER%E<1.81$[*YIE
M'6&#=&&,9[W@_+_!!%\PG;UEZJSIO0X91! TB4LD1EO(X11XQ+D?!8$O19_Y
M V+__K+?,_T-%VH$KZV7,E@+Z$:^&)BS&%@=FE6$M(;%P>H)YJN#S;./6RQ4
M#T-PZW:_[Y=Y))D?M?J,V$YN&REM8ZYL]MPSYJIE)PQCKAKVWBUVC/:SS.,'
M]" #MW?;*86,@(E ..KPWT.>WD0V0C:YI^2>DGO*!GK*MO-\EHD<M1W(>@XD
M7T"=%X]!4Z+B?JU$Z@YA< R'?"7R3JZQ[?+)WZG8%'Z_]SL5.W9]H^9]->6#
MMLH!>DK?X+YS?9S9>Q;;O'H809*O''(/R#T@]X!=]H"I:_^'N]P$U/ >6  !
MN%,#1MP%1TW.$&?YS:3\9M):'2*_F;33-Y-VC/8_74:XBX]!@]GI;R!MLYUD
M]I'7C9!(5J"\XR=@=TQ)N8%LCSIR \GN-CP1=I]RE]A^;B*U%A1#"EF*A=DF
MR60-)J(V@B_NJX,0>8KVI/[Z[>S;#Z_F\/HS!UZ.Z'P,]\))\-7(-3PZX8TA
M)T_,4#$O-%VK@;%J6(Z(&TY&;+0YY<(\/ ]_-!"24YT8/%SAQ5,35 @G+%Y4
M,ZL4/O;DXP>U.WB@RO]02P,$%     @ C8%<5,(@+_95!0  Q!H  !@   !P
M86-B+3(P,C$Q,C,Q>&5X,C-?,2YH=&WM6>MOVD@0_YQ*_1_FJ*YJI !^\#0D
M4DN@19<01%*=^JE:["6L:N^ZZW42[J^_V;4)3D-:&M*&D\X18;R/>?W&,^.E
M^T>Y_.'B] 0"X:<1Y0I\28FB 5PS-8<>E4H/'K/$#T622@JGA)-+:I8Z3L6N
M6!6G7#YZ^:*+G'KY7L$]<*I.J^I8C@.VX]4;GM. \6FV<JZB$+_WNG-* DWL
M=153(37D7O]FSJ8,N;L5^_,%N1%<1 MD9)N%U=N5W>IR>W<J@L51-V!7D*A%
M2 ]+$9&7C)=#.E->TXE5)Q^0['*>CY0RP?'=+5X]5F#AM*(WJDQ"=LD]LZD3
M,D[+<VH8V);U9V<FN"K/2,3"A7?!(IK B%[#1$2$9W,)^X=Z8".W3-9>5P\O
MY04LB4.R\(!QS3K;<IWQGXHP*/#0+%#?HF.@6]7SF0W5>+TM>EM1;2YD1,*B
M:3["2.7&IC@K4PAP$J&HSQ_"+^UZTVTTFJW24;=*CGYL92ZI_VFHI2<*8P9.
MC)/O.<$7H9#>*\M<Z(/>V>B\/[J LP$,1\?]<1__X>VD_WYX?M&?](]A_/'=
MR; ';WN]LX^CB^'H/0R&D]/G=M?W?%(Z>LVG2=S90L='Q&(10+MFVTZKMCU^
M=^&Z%\%_4_ %3W3N4 +4G");7\A82**8X#!=@*0S*BGW]919,1-A**X9OX0)
MO62)RI>>:ZDZ"R7>[_7;8Y$L9*=K%JBY22+H<46F(;T_TP$S44;V(E4>S-@-
M#3HE\&D8QB0(T"&')2N[3V+BY_?(3^(G^(9AR[A_Y97"\,K,#".M,&;9P'"Y
M,G%_6%(B+D%.ZZ1:NLL([%;%LFZ3:L']:WP^%3*@LCP52HG(LS'?<L$IO#IN
MZS]8%T,Y0CW48"K9M\AT"ACG"MR%J3#_@_C]:76_'_&H#KRQ]POAL(J'I8OO
M.-):BY,>75'?!>P.1D7T=@287YA<'D@/\&: YB5P7F[!2"05<%VW;#>QG[ /
M<KK=LJV<;C6L1CVGVV[-;6:T8]E8WY9TVZXOQY&J-7+:<1KMG,;6J.TVEAM<
M9)H+<VIVH]4\^"U*/*A#W;;K[I+&RMU>TG6WYBSI=J-I ^%!=MNP<=<^Q-@/
M$L9U-LX3^!A3SXSY\(Z)Q&<Z<2<@9J C8B8D9^0 AMRO "IO0?]KRM1"#R R
M[ IWAX0?/()/%(=B02G"+/PO,$ZE/R?)H]F=I2IA <4N5U)?"?DT>CI/9"_R
M&?(@];.>^P&6&BC-]BSB3$1T_3(M8$.YAF.>MU8)IJJ+2]44)OS&BO9@L87E
MQVVLK[QYLL'4M";3_"@3;9![_B_73UNNUP.UF[5ZG:X;%&KG/U:H?QTDSUFE
MW565=MRVU;PMG&V\5H7*J14*E;4J5/K6V3?WDH;F-&(L11)C8D^3+-=MF ([
M6Z2_9W[7>!Z-M@L,1$"D$D'#MT&,A\! -Z!3F1*Y  ?[&'V8=)"=2TEJ$%TV
M(?JE4H0LVS-CG'"?D1"257AM#OMM*:6S&8K VLEI8E8R;1%'OBA.21&"N**R
M("Y37?=&/R$-7X##-$"US>LN2^ MYRDRFQAFV6.!")3_VO\9KGAC;%A0(H%R
MS?^88@<Q185=V[C2KNQ.Y.Q>+.^>1ML]7=6D"GW)$P6O211WX)-(,4Y/3L:[
M8^#S'X-EYYB_X1QL0H-K(0+H88]^4'AZ=P>,[>R[E[8W->S^6>M3'+M/)52W
M/Y9>&?CMH?3S6O?KCMOOX?KZU<V@/QBL?T27'L;UAR4;&^IB_S27^81[^RZ2
MRVJ;JP2F;\:-^C5KV1UG7M(.GLOL)Q_=='6KYO>>ER]P6/^2]"]02P,$%
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MS#$9D'D:5);D.X&BR&IMZ;B!)F@ $S5;L,3C "H2)Y@#( !3UVW<TQ#T=)Z
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M9: !>IQZ7/!LCDELV[((>X,)$VZ+V)6AE>K(D.]#85":JQ3@IDW2]7V(H5'
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M%5)+"D!,[)%N-VJJI7H4"JM,*KU(<:8!9,8QSS+&OD2SGH0LB@,"#AH:*<>
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M1KABGC@Y/CD9?AMXOX.M<=/6^V.&9]L:(Z+^HP?L"!-# B=LHF=$SR'>]W>
M>%/\JM1YW?3>(-C_2M-O5GKK$L57.&'3]-LUW>L7[QO.N6E3='NQ993@%+9#
M_UDU?&V%^^U)<"TU/AS?%RZ _6#O3A1PO\']*W8_!G(_4*1_B<0_P7\,X'_'
MD^VV7P]< 7"*%0!W==0&9]T2Z^!E_U$;O'.J.58[)98[-ZS>W20>L.$J!)R$
M%<3M]<[Z\N5.EY$O47GUFK5:@1W4PJCS52MJ'4##M%&NZX'>DMI8N"B=; _\
MIP6>Z2CH2B*H@Z'"#2ND;JZKURO. :.N?[?R] EVN[<V_P!02P,$%     @
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M     '!A8V(M,C R,3$R,S$N>'-D4$L! A0#%     @ C8%<5+8>7,'(&
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M8BTR,#(Q,3(S,7@Q,&MG,# Q+FIP9U!+ 0(4 Q0    ( (V!7%3N;E_'>'H
M )Z7   9              "  7,H!@!P86-B+3(P,C$Q,C,Q>#$P:V<P,#(N
M:G!G4$L! A0#%     @ C8%<5-Z[<I,6!0  RT4  !@              ( !
M(J,& '!A8V(M,C R,3$R,S%X97@R,5\Q+FAT;5!+ 0(4 Q0    ( (V!7%3"
M("_V504  ,0:   8              "  6ZH!@!P86-B+3(P,C$Q,C,Q>&5X
M,C-?,2YH=&U02P$"% ,4    " "-@5Q4A"$R7)L(  !\+0  &
M    @ 'YK08 <&%C8BTR,#(Q,3(S,7AE>#,Q7S$N:'1M4$L! A0#%     @
MC8%<5 B?C-V>"   32\  !@              ( !RK8& '!A8V(M,C R,3$R
M,S%X97@S,5\R+FAT;5!+ 0(4 Q0    ( (V!7%0;%NG6*04  # :   8
M          "  9Z_!@!P86-B+3(P,C$Q,C,Q>&5X,S)?,2YH=&U02P$"% ,4
M    " "-@5Q4*$AT<TH%  #H'@  &               @ ']Q 8 <&%C8BTR
H,#(Q,3(S,7AE>#,R7S(N:'1M4$L%!@     .  X P ,  'W*!@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
